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Edward Pulling
(1898-1991)
Edward Pulling, who died on April 17, 1991 at the age of 92, was a truly re-
markable man whose career embodied the virtues of education, family life, and
devotion to service for the public good. In his dual roles, as a trustee of this Lab
and as Chairman of the Long Island Biological Association, he played an in-
valuable role in the Laboratory's achievements over the past two decades. My
wife and I will always remember the gracious way Ed and his wife Lucy brought
us into their world when we first arrived in this community in the summer of
1968. By then, he had retired as the founding headmaster of the Millbrook
School and they had moved to Oyster Bay to live in "Redcote," their home on
Yellowcote Road which Lucy had inherited upon the death of her father.
To this charming extended farmhouse, sited on its accompanying estate, we
were first invited by Ed on a late June evening to meet Lucy and several of their
neighbors. There, below the terrace off the drawing rooms, I first appreciated
the ha ha, the sunken fence of stone that the English have long used to keep
their horses at proper distance from their living quarters. Later, Liz and I came
often to Redcote and its book-lined rooms to hear Ed and Lucy speak of their
lives and of the events that formed their aspirations, and soon we felt at ease as
denizens of their fabled world of Long Island's Oyster Bay. In particular, I still
remember our flying down from Cambridge during an interterm break at Har-
vard and soon becoming so delightfully snowbound that we missed the open-
ing days of the spring academic term.
Ed's erect 6'3" body with its strong-featured warm face and voice gave in-
stantly the impression of a leader toward goodness and responsibility, first
tested in battle conditions when he served as a destroyer officer in the British
Navy toward the end of the First World War. He was born on June 10, 1898, in
the London suburb of Ealing. His father, of Devonshire yeoman stock, was then
the British agent for the New York Life Insurance Company. As a youth, he had
emigrated to the United States and there had married Elizabeth Douglass,
whose Ohio-based family had come several generations before from Scotland.
After their marriage, Ed's parents moved to England, where his father estab-
lished a thriving business that lasted over a decade. Then a change in Amer-
ican insurance company regulations forced New York Life to close down its
English office, and at the age of ten, Ed and his parents returned to the states,
first to Pittsburgh and then to Baltimore. In the latter city, Ed prepared at the
Gilman School for Princeton, where his college education was interrupted by
his service in the British Royal Navy.
Upon leaving the Royal Navy he was offered a position at the Bethlehem
Steel Company but happily, when stopping at Princeton on his way home from
England, he was persuaded by Professor Charles Kennedy to give a try to
teaching. After an interview at Groton, then headed by the renowned Endicott
Peabody, Ed became spellbound by the Rector's wonderful personality and
quickly signed on to be a Master of History. For six subsequent happy years,
he learned the art of teaching under Mr. Peabody's aegis. Interrupting this very
formative period were two years spent in Trinity College at Cambridge, where
he read English and displayed his mastery of golf through his membership on
the Cambridge University team. It was while at Groton that he first became
befriended by Franklin Roosevelt, whose son James was one of his students
and whom he tutored at Hyde Park over the Christmas 1920 vacation period. It
was Franklin Roosevelt who first suggested that Ed start his own school. Ed re-
membered being counseled "You ought to start a school someday. Promise to
let me know when you do, because I want to help."
On a trip to Europe during the summer of 1926, he first met Lucy Leffingwell,
the only daughter of the banker Russell Leffingwell, a partner of J.P. Morgan,
who subsequently was to become Chairman of the Board of J.P. Morgan and
Company. Ed and Lucy both were passengers on the Cunard Liner Aquitania
and saw each other first as partners in a game of deck tennis. Their marriage
occurred two years later in St. John's Church here in Cold Spring Harbor, with
their departing from their reception at the Beach Club aboard the yacht Corsair
which J.P. Morgan had put at their disposal.
In 1929, while searching a site for their proposed school, Franklin Roosevelt,
by then governor of New York State, offered them property on Cream Street ad-
jacent to his Hyde Park estate. This most generous proposal, however, was
declined both because they feared Hyde Park would soon be less rural than
they wanted and also because they feared that the parents of many prospec-
tive students might hesitate to favor a school founded under the aegis of such a
famous Democrat. Years later, after President Roosevelt's death, Eleanor
Roosevelt made her home on the Cream Street site. To this site, Ed and Lucy
made many visits during and after the Roosevelt's grandson Haven was a
Millbrook student.
The site Ed and Lucy finally chose was near the town of Millbrook in the roil-
ing countryside of Duchess County. Even today it is totally unspoilt. Their first
class of 21 boys came together in the fall of 1931, and over subsequent years
they presided over an ever-expanding school of great beauty which purpose-
fully offered a less traditional curriculum than Groton. Rather than putting faith
in grades or admission tests, Ed hired teachers and accepted students on a
hunch. Always paramount was a close relationship between the faculty and the
students. Equally important was the participation of all its students, through
community service, in the school's daily functioning. The 34-year partnership of
Ed and Lucy was extraordinarily productive, being from its start to their leaving
a joint venture. Much later Ed was to write that while he believed his students
respected him, he knew they loved Lucy. During their Milbrook years, they
raised and educated their four children-Joan, Patricia, Lucy, and Tom, with
whom they would go each summer to their house at West Chop on Martha's
Vineyard.
Ed was an early beneficiary of the surgical procedures for hip replacements
developed in the 1950s in England. In 1963, a severe attack of osteoarthritis
threatened to confine him to a wheelchair for the rest of his life. To his rescue
came Dr. Otto Aufranc of the Massachusetts General Hospital (MGH), who
through two operations performed nine days apart gave Ed two steel hips. He
was the first person operated upon at MGH to have both hips replaced during
one hospitalization. Happily, the surgery was amazingly successful, as within
10 months Ed was again riding and playing golf.
It was Walter Page who sensed the great opportunity offered to the Cold
Spring Harbor Laboratory by Ed and Lucy's movement into our community fol-
lowing his retirement in 1965. Sensing Ed's vast experience in public relations
and fund raising gained while he was a headmaster, Walter, then the President
of LIBA, persuaded Ed in 1968 to become a LIBA director. In so joining the
LIBA board, Ed followed in the tradition of his late father-in-law Russell Leffing-
well, who in 1924 became a founding director of LIBA. A year later, in 1969, Ed
assumed the chairmanship, a position he was to hold for 17 highly effective
years. Soon the LIBA membership was doubled to nearly 500 families, and
conditions were created for the subsequent holding of major fund drives. The
first, conducted during 1972-1973, raised $250,000 toward (I) construction of
the west addition to James Lab for cancer virus research, (2) winterization of
Blackford Hall, and (3) purchase and renovation of the Takami residence as a
dormitory, now called Olney House. In 1977, Ed mounted his second fund
drive, which raised $220,000 to allow Williams House to be completely rebuilt
as a year-round residence with five apartments.
Just as this project was finished, Ed received the devastating news that Lucy
was striken with a potentially fatal disease. Fortunately, the initial therapy sent
her disease into complete remission, and Lucy could actively participate in the
celebrations held at the Piping Rock Club to mark their 50th wedding anniver-
sary. Unfortunately, Lucy's disease reoccurred the following year, culminating
in her death on February 15, 1979. With her passing, Ed grieved for his gentle
companion who so well personified loyalty and open-minded intelligence.
At no time, however, did Ed's ability to work for this institution falter. Over the
following years, he led his third fund drive, which raised $200,000 to purchase
20 acres of land from the Carnegie Institution of Washington. Its purchase
made possible the 1982 completion of the Harris Building, as well as the sub-
sequent siting of the Oliver and Lorraine Grace Auditorium. Funds for the con-
struction of this later building were the objective of Ed's last major fund-raising
effort. Through his efforts, $600,000 was raised from individuals who previously
had expressed interest in the Lab. In addition, it was he who attracted the
Graces to make their seven figure gift which allowed us to proceed with the
project. Ed, as chairman of the Building Committee of our Board of Trustees,
also played a very active role in the design process, drawing upon his many
years of experience in the building projects of the Millbrook School.
A mere chronicling of the LIRA fund drives does not adequately reflect the
many important gifts to the Lab itself that came in large measure through his
actions. I particularly remember Ed tracking me down in California in late June
of 1982 to arrange a date when Charles S. Robertson would make his first visit
to the Lab and have lunch at Osterhout Cottage where Liz and I were then
living. This was the most important lunch ever held at the Lab, initiating the sub-
sequent measures which led to the creation of the Robertson Research Fund
and the Banbury Center. Ed's enormous enthusiasm for the Lab was also the
major factor leading the Doubleday Trust to give us the Doubleday shares that
made possible the creation of the Doubleday professorship for advanced can-
cer research.
To honor Ed's enormous contributions to this institution as well as those of
Walter Page, Liz and I hosted a party on the Airs lie lawn in June 1983 to mark
their combined 40 years of service (25 by Walter and 15 by Ed). To it came
some 200 guests who took much pleasure in our good fortune of being served
by two such illustrious neighbors. By then, we feared that Ed was considering
passing on his mantle, wishing to retire while he still had complete command of
his LIBA role. This moment formally came in January 1986 when Ed transferred
his responsibilities to George Cutting, Jr. In this his final major act of help, Ed's
instincts were again right on mark, with George knowing from the start how to
carry on the responsibilities so ably handled before. Later, Ed took delight in
continuing to manage the dinner parties hosted by LIBA members for
Symposium participants. Much pleasure also came to him from the books he
put together that recorded the earlier years of his life. Happily, he was to
remain in good health almost to the very end of his life. Up until he was stricken
with a bad cold that affected his heart, he maintained an active social life and
greatly enriched the many occasions when he went to neighboring homes for
drinks or dinner.
His final days were peaceful and serene. He knew that his time had come
and his heart ceased to beat after he was read to by his daughter Lucy. Two
days later, T. Carleton Lee conducted the funeral services at St. John's, the
very church in which Ed was married 63 years before and to which he regularly
came to hear Carleton give the Sunday service. Afterwards, the assembled set
of bereaved friends went back to Redcote to convey their condolences to the
family over which he presided with such love and dignity.
In his passing, we have lost an extraordinary force for enlightenment and
decency. We will continue to cherish his accomplishments for the remainder of
our lives.
April 29, 1991 James D. Watson
DIRECTOR'S
REPORT
Cold Spring Harbor Laboratory has now just passed its 100th birthday. Our
centenary celebrations are over; so instead of looking backward to take pride
in our past achievements, we must again be oriented toward the future. In look-
ing ahead, we must ask not only what science we should be doing, but also,
equally important, what sort of institution do we want to be-what are our roles
and what do we really cherish? We must ask these questions because our
reputation owes as much to the way we do science as it does to the sterling re-
search accomplished here over the past century. Now there are many other
universities and research institutions with stellar track records, and they also
are justifiably proud of what they have become. Each has had its own recipe for
success, and if asked what lies behind these triumphs, each would have its
own unique story to tell. Here, I will try to evaluate the ingredients that have
made us what we are. In so doing, I can call on a direct involvement that goes
back more than 40 years.
When I first came here for the summer of 1948, I heard much local gossip
about what Cold Spring Harbor was like from my two most important mentors,
Salvador Luria and Max DelbrOck. They were first invited here for the summer
of 1941, only a few months after the Yugoslav-born, Cornell-trained geneticist
Milislav Demerec (1895-1966) became the Director. Until then, Cold Spring
Harbor Laboratory was very much a Yankee institution, with both the strength of
an ethic for hard work and the limitation of prejudice against newly arrived im-
migrants. Suddenly, it was a truly international laboratory playing host to many
superb scientists who came to the United States as refugees and then
remained here after the war ended. I still remember my first day at Cold Spring
Harbor eating in the Blackford Hall where French was spoken by many, and I
felt acutely the cultural limitations of my Midwestern background.
Cold Spring Harbor's Main Intellectual Goal Has Been the Gene
What most made Cold Spring Harbor Laboratory then an extraordinary institu-
tion was its commitment to understanding the gene. Then, as now, the most im-
portant ingredient for greatness was the setting up of an important goal that
would make one leap into the unknown as opposed to following others along a
well-worn path toward predictable success. Milislav Demerec's goal for Cold
Spring Harbor in 1941 was to find out what the gene was and how it functioned.
Although for several years more he kept Drosophila as his major research tool,
by the end of the war he had become committed to the genetically then much
more exploitable bacteria and their viruses-the bacteriophages. Demerec thus
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chose not only the right goal for his era, but also the right system to move
toward it.
Equally important was his commitment to the first class in selecting his
scientific colleagues. It is impossible to imagine two better appointments than
his of Barbara McClintock in 1941 and Alfred Hershey in 1950. Also crucial was
his choice of Max DelbrOck to refocus (with his bacteriophage course) the sum-
mer teaching program away from the prewar emphasis on physiology and ecol-
ogy toward genetics. And by having the likes of Theodosius Dobzhansky, Ernst
Mayr, Leonor Michaelis, Salvador Luria, Rollin Hotchkiss, and Ephraim Racker
as summer guests in the unheated whaling-era tenements along Bungtown
Road, Demerec gave to Cold Spring Harbor summers an air of intellectual bril-
liance and integrity unmatched anywhere else in the biological world.
We Have Been Led by Scientific Entrepreneurs
To direct a scientific institution inspiringly, one must not only have a feel for
where science can go and who should do it, but also be in a real sense an en-
trepreneur, scientific-style. Monies must be found both for new equipment and
buildings. Successful leaders of science must accept the fact that they are
managers as well as doers of science. Demerec, for example, knew that
postwar Cold Spring Harbor had to be more than a plant and animal- breeding
institution and had to have research facilities for studying genetics at the
molecular level. As soon as the war ended, he began planning for the 1953
building now known as Demerec Laboratory. At the same time, he knew that
the Symposium could only continue to thrive if a lecture hall became available,
and he successfully sought out the Carnegie Foundation funds needed for the
construction of what we now call the Vannevar Bush Lecture Hall. And to make
the one-storied 1930 James Biophysics Laboratory suitable for molecular
genetics, he planned for a second-story addition.
Even more the scientific entrepreneur was Charles B. Davenport (1866-
1944), who in 1898 became our third Director, At that time, we were still a
small, marine-oriented biology station at the head of the inner harbor of Cold
Spring Harbor, founded in 1890, two years after the Marine Biological
Laboratory at Woods Hole was started. Immediately after his appointment,
Davenport dreamed of expanding Cold Spring Harbor into a year-round re-
search and teaching center. In this way, he would have a much greater impact
on biology than if he were to remain a member of the zoology faculty of the Uni-
versity of Chicago.
He labored mightily to persuade the newly established Carnegie Institution of
Washington to establish a year-round research "Station for the Study of Experi-
mental Evolution" (the name was changed in 1918 to the Department of
Genetics) adjacent to the summer-oriented Biological Laboratory. Davenport
had the great foresight to concentrate his Carnegie monies on extending the
1900s rediscovery in Europe of Mendel's laws independently by Hugo de Vries,
Carl Correns, and T. Tschermak. In this way, he quickly made Cold Spring Har-
bor one of the world's leading sites for genetics, with its earliest great triumph
being the 1908 discovery by George Shull of the increased yield of hybrid corn
over that produced by highly inbred corn strains. Davenport's crusading per-
sonality also led him to persuade Mrs. E.M. Harriman, the widow of the powerful
railroad founder and the mother of one of his earlier students, to support (1910)
and later richly endow (1918) his much more poorly thought out eugenics pro-
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gram aimed at first identifying and then, through sterilization, eliminating
deleterious genes from the human population.
Davenport brought in the best architects of this area to design the new build-
ings for his year-round research program. To proclaim the standards he hoped
to reach, he had his friend Julian Peabody copy features of the Zoological Sta-
tion at Naples for the design of the 1914 Animal House (now McClintock
Laboratory). Davenport's first building for Carnegie, a new (1905) laboratory
(now Carnegie Library), was also in the Italianate style, and the 1906 Blackford
Hall dining hall and dormitory had classical Grecian features overlaying its ad-
vanced reinforced concrete construction.
Davenport's entrepreneurial zeal was passed on in the mid-1920s to his son-
in-law, Reginald Harris (1898-1936), who took on the task of reinvigorating the
Biological Laboratory. At that time, its summer courses and research compared
very poorly to those of the Marine Biological Laboratory at Woods Hole. As-
sistance was thus sought from the major estate owners of the North Shore,
such as Marshall Field and William Kissan Vanderbilt, to create a year-round re-
search program at the Biological Laboratory aimed at understanding cells at
the chemical level. Harris was as equally successful as Davenport had been in
finding the right long-term goals for his era, focusing research at the Biological
Laboratory on hormones and on the electrical properties of cell membranes.
For the new buildings to house these research programs and the more
research-oriented summer courses, Harris utilized the highly talented architect
Henry Saylor. He designed Nichols and Davenport Laboratories in the colonial
revival style, and for the more hidden James Biophysics Laboratory, he
adapted the idiom of early modernism.
Harris, however, was soon faced with the impact of the Great Depression,
which greatly lessened financial support from the estate owners for year-round
research. To combat his growing frustration over his inability to maintain a thriv-
ing experimental effort, Harris initiated in 1933 the Cold Spring Harbor
Symposia-comprehensive meetings that initially extended over a month-long
interval. These meetings proclaimed our difference from Woods Hole in our
partiality to quantitative, as opposed to descriptive, approaches to science.
Central to Harris's vision was the need for physicists and chemists to join forces
with biologists in attacking until then unsolvable problems such as the structure
and function of proteins and the propagation of signals along nerve fibers. Sup-
port for the Symposium and the summer research that went along with it came
from the Rockefeller Foundation, which continued its assistance even after
Harris's untimely and premature death from pneumonia early in 1936. Only
through this Rockefeller help did the Biological Laboratory's program on cells
manage to survive through the Laboratory's 50th anniversary in 1940. The year
following, Demerec, who had joined the Carnegie staff in 1924, was appointed
the Director of the Biological Laboratory as well as Director of the Department
of Genetics of the Carnegie Institution. In effect, the two institutions were
merged, thereby creating an institution where both the summer and year-round
research programs focused on genetics.
Max Delbriick Created Our Tradition of Intellectual Fearlessness
and Honesty
While Demerec was the manager who skillfully moved Cold Spring Harbor into
the modern world, the spirit that dominated the transition was that of Max Del-
3
bruck (1906-1981), German-born and a product of the Protestant intellectual
elite of Berlin. DelbrOck was an extraordinary mixture of arrogance and
decency. He despised all forms of pretense and had equally little use for
tortoise-like minds that remained anchored to the past and could not share his
love affair with the little phages of Escherichia colt. But he could also relax from
being deadly serious and took pleasure in tennis, canoeing, camping, and the
fun that came from practical jokes on those who took themselves too seriously.
Giving a seminar before DelbrOck was for most scientists a frightening experi-
ence-he actually wanted to learn if you had a "take home message." Unclear
talks could provoke his scorn, as did unreadable scientific papers. Any form of
secrecy or hint of intellectual dishonesty also upset him, and those who
seemed to be in science for personal gain as opposed to intellectual excite-
ment never became accepted into the inner circle of the "Phage Group" that he
was to lead with Luria and Hershey.
Delbruck's approach to science pervaded the early postwar Cold Spring Har-
bor Symposia, particularly those that had genetics themes and at which the
speakers had to face front rows occupied by sharp minds that would not
hesitate to interrupt when the message was unclear or patently erroneous. Oc-
casionally, an unschooled mind would present an outrageous talk, but for the
most part, everyone respected each other, and no one was accorded special
privileges to speak because of either age or past accomplishment. Postwar
Cold Spring Harbor thus became the site to which the best and brightest of the
gene-dominated scientific world came to meet for the exchange of ideas or to
which their brightest proteges were sent for one of its expanding list of summer
courses. In coming here, there was the expectation that everyone would
benefit, with the giving of ideas to be as important as the receiving of them.
small number of scientists
then occupying the DNA world. Those who behaved badly and who were self-
ish with their ideas soon found themselves not wanted and chose to spend their
summers elsewhere.
This Delbruck-dominated style continued through the five years that John
Cairns was the Director (1963-1968). His was a very tough assignment indeed,
since substantial Carnegie Institution of Washington funds were no longer com-
ing to Cold Spring Harbor. The year previous to his appointment, the Carnegie
Institution decided to close down their Department of Genetics, providing
monies only to allow Barbara McClintock and Alfred Hershey to remain working
in Demerec Laboratory. Suddenly, there was no endowment to provide funds to
attract younger scientists or to provide them with permanency if their experi-
ments succeeded. Cairns worried that unless the newly created Cold Spring
Harbor Laboratory (the name given to the new body formed to take over the
facilities of the Biological Laboratory and the Department of Genetics) acquired
a substantial endowment of its own, it could not survive in a world where it was
facing increasing competition from many other institutions that began to follow
its lead in making the pursuit of the gene their major research objective.
Opting for Scientific Achievements as Opposed to Tenured Stability
I thus decided when I became the Director in 1968 that our survival depended
on a radical shift in our main goal so that we would once again be perceived as
a leader in science. My choice was to push research on the small DNA tumor
viruses like SV40 and the adenoviruses. In so moving, I took the gamble that
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their cancer-inducing properties would reflect the presence along their
chromosomes of one or more cancer-causing genes (oncogenes). If my hunch
was correct, then the pursuit of these viruses could provide the best way to get
at the essence of cancer at the molecular level. In turning to tumor virus re-
search, I also solved, at least temporarily, the Laboratory's financial crisis.
Then, there was much more money voted by Congress for cancer research
than could be used effectively. Joe Sambrook took virtually no financial risk in
deciding to move here in the summer of 1969 from Renato Dulbecco's
laboratory at The Salk Institute. The grant application we submitted to the Na-
tional Institutes of Health was quickly funded, as was a much larger request for
$1,000,000 per year that we submitted in 1971.
Moreover, no difficulty existed in recruiting many other first-class younger
scientists to collaborate with Joe, despite the fact that the total endowment of
the Laboratory was then only $20,000. Fortunately for us, it soon became clear
that accomplished postdocs were more concerned with moving to positions
that would allow them to do important science, rather than to less-exciting op-
portunities that carried potential long-term job security. We thus made the deci-
sion to use Robertson Research funds created by Mr. Charles S. Robertson's
1973 gift of $8,000,000 to support the careers of young scientists, rather than to
create tenured research professorships to guarantee the salaries of more
senior scientists.
Our belief was that those who already had been here for several years would
have by then built up highly productive research groups that would allow them
to compete well for outside research grants. In the 1970s, before it became
possible to clone oncogenes, there was still more money for cancer research
than good proposals to use it. So worrying about money over the short term
was not then a serious concern. Nonetheless, we wanted to provide some um-
brella of help for those more-senior scientists whose grant support might not
come through immediately. To provide such support, we began in 1978 to give
them Rolling 5 appointments. When they were promoted to this position,
generally around the age of 35 after they had been here some five years, their
salaries were guaranteed for a period of five years and this guarantee would
continually roll forward if they continued as successful scientists. In retrospect,
we put ourselves at little risk with this sort of salary guarantee. During the 13
years that it has been in existence, only twice have we had to provide such
salary support, and both times only for very limited periods. In each case, the
science involved was connected not to the DNA tumor viruses, but to the in-
tellectually very important movable genetic elements. Unfortunately, support
through the National Institute of General Medical Sciences has proved in-
creasingly inadequate to fund all of the new, high-powered, pure genetics done
in the United States.
Although the Rolling 5 position has allowed us to maintain an energetically
charged group of productive scientists in their thirties, for the most part it has
not allowed us to keep them through their forties. By the time this age ap-
proaches, most scientists have families, and the prospects of educating their
children makes them more security conscious than they were in their early
thirties. The result has been a steady flow of these still highly productive
scientists away from Cold Spring Harbor to tenured university positions. Al-
though such departures have caused me great anguish, both because of
friendships formed and because of the fear that we might not be able to recruit
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an equivalent younger scientist whose career will blossom equally well here, we
have taken pride in the high quality of the universities and medical schools to
which they have moved. The net result, however, is that as we have grown in
size, we have spent more and more of our time in recruiting young scientists.
So we have found ourselves ever more frequently asking whether we should
move gradually to establish a number of truly tenured positions.
A cadre of high-powered tenure appointments would immeasurably help me
to appoint outstanding young scientists fresh from their postdoctoral positions.
On the other hand, it very likely would create more long-term problems than it
would solve. Conceivably, our greatest advantage now is the relatively young
age of even our more senior scientists. In recent national ratings of major uni-
versities and research institutions that measure the number of citations to pub-
lished research papers, we ranked at the top or very close to it. So why change
from a system that has served us so well to one that is bound to make usmore
aged and conservative? The unknown will always be scary, and those individu-
als we may need the most may very well be those who worry about how to do
their science as opposed to whether they will go on being successful.
Continuing to Emphasize the Young and the Underdogs
We must thus remain an institution where young scientists join our staff with the
expectation that they will be treated fairly. Toward this objective, our own
resources should continue to be directed predominantly toward them, provid-
ing the funds to attract the graduate students and postdocs on which their
careers will depend and to secure the special pieces of equipment needed to
allow them to be competitive with their peers elsewhere. Furthermore, we
should continue to have flexible terms of appointment and never permit
talented minds to seek jobs elsewhere below their abilities. We must also avoid
the danger of excessive preoccupation with the judging of whether a junior staff
member is worthy of promotion. While a member of the Harvard faculty, I partic-
ipated in all too many such actions and seldom saw anyone who was the better
for it. In reality, most scientists, like members of virtually all other occupations,
seldom live up to their inherent talents. Our highest objective must be to
maintain an environment, moral as well as physical, where our scientific abilities
can be maximally expressed.
Our concerns should always embrace the well-being of all scientists, not only
those here, but also those who strive to achieve scientific enlightenment else-
where. We are rightfully admired for the selflessness shown in the ways we
organize and finance our advanced teaching courses, as well as for the in-
herently democratic way we host our now very wide variety of meetings both
large and small. Through our meetings, with their packed schedules from early
morning to late evening, we try to extend recognition to all who do good
science as opposed to providing still another forum where old-boy networks
dominate the lecture platforms. Nothing could cause more harm to our reputa-
tion than to be regarded as an instrument of a senior establishment concerned
with the maintenance of its power over the fate of others. If we are ever to be
accused of favoritism, it should be that directed toward the talented underdogs
as opposed to those well entrenched in science.
If we can continue to so act and dream, we shall move into our next century
with our heads high and our eyes level to those who need our help.
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HIGHLIGHTS OF THE YEAR
The Laboratory's Hundredth Birthday Party
The Centennial celebration held on July 14th was a splendid day of festivities for
the Laboratory and all of its guests. From the gathering of sailing ships to the
endless variety of music, food, and fireworks, all went remarkably well. I, for one,
had a grand time. It was on July 7, 1890 that eight students and seven teachers
gathered for three weeks to participate in the Laboratory's first biology class. On
the Centennial day, members of that original class were portrayed by Rob
Gensel, from our Purchasing Department, and a group of Laboratory friends, who
set forth on the small launch Rotifer to reach our shore while storyteller Heather
Forest narrated the occasion. Four majestic sailing vessels also took part in the
gala. On Blackford lawn, more than 1500 people enjoyed a delicious feast, which
included a giant birthday cake, as the Old Bethpage Village Restoration Brass
Band paraded through the crowd playing music from a century ago. Throughout
the day, we received a number of proclamations in honor of the Centennial, in-
cluding a letter from President George Bush commending the Laboratory and its
staff. "Your devotion to the pursuit of knowledge has led to some of the most im-
portant scientific discoveries of our time," the President's letter stated.
In the evening, Liz and I hosted a gala dinner party for our corporate friends
who helped support the celebration. Our guests were greeted with sea chanteys
by Stephen Sanfilipo, and they danced to the big
Fireworks by the famed Grucci family lit up the misty skies, and the Clan Gordon
Highlander's Pipe Band of Locust Valley marched across the fog-enshrouded
campus. No finer day of revelry could have been planned.
In September, as part of our Centennial celebration, the Laboratory offered a
very special concert. Opera virtuoso Frederica von Stade performed a selection
of music ranging from Mozart to Gershwin that filled Grace Auditorium. Her
breathtaking performance raised more than $70,000 for the Laboratory, most of
which will go toward endowing a Frederica von Stade Undergraduate Research
Internship. With her voice, "Flicka" brought joy to all who heard her.
Skillfully orchestrating all of the centennial year events was Susan Cooper,
who energized her Public Affairs and Library staffs to heights of imagination and
hard work that virtually exceeded the capabilities of the human mind and body.
In pursuing her multifold objectives, Susan was most ably assisted by her admin-
istrative aide Emily Eryou, her valuable Library co-worker Laura Hyman, her very
imaginative designer Margot Bennett, and her writer Dan Schechter.
All the funds needed to host the centennial events, as well as for two more
specialized scientific meetings (on cancer and evolution), were raised by the
centennial committee headed by Robert McMillan and Tom Doherty. Ably assist-
ing them in their solicitations was Judith Carlson. Through their Partners for the
Future campaign, specifically aimed at the Long Island business community,
they raised almost $200,000. To immortalize these events, a highly attractive
Partners for the Future booklet, over 200 pages in length, was prepared by Susan
Cooper and her staff. In it is a very informative "time line," prepared by Elizabeth
Watson, which recalls key events in each of our 100 years of existence.
Barbara McClintock and
Susan Cooper being
interviewed by
Cablevision at the
Centennial
Frederica von Stade
Neuroscience Center,
nearing completion
F Crick and J.D. Watson
on the porch of
Airs lie during the
1990 Symposium
on The Brain
The Neuroscience Center
With the Neuroscience Center on the upper campus nearing completion, the
stage is now set for a major new effort at Cold Spring Harbor Laboratory in
molecular neurobiology. Our hope is to open new pathways in the fight against
neurological disease and to unlock the mysteries of learning and memory. Over
the next few years during the "decade of the brain" (so named by President
Bush), up to 75 additional researchers will join us, most of them setting up shop
in the Center's Arnold and Mabel Beckman Laboratory. The new facility en-
compasses the W.M. Keck Structural Biology Laboratory; the Hughes Teaching
Laboratories; Dolan Hall, a 60-room guest lodge for visiting scientists; and a 150 -
car garage. In Hazen Tower, a unique symbol of biology's quest, a helical stair-
case winds its way upward to a bell almost within one's reach. Charming in its
blend of styles and materials, the Neuroscience Center fits beautifully into the
Laboratory's eclectic 19th and 20th century architecture.
Symposium-The Brain
The Brain was the subject of our 55th Symposium on Quantitative Biology, held in
late May and early June. Eric Kandel, Terrence Sejnowski, Charles Stevens, and I
endeavored to bring together the top researchers in all aspects of neuroscience.
Among them was my early cohort Francis Crick, who presented his latest findings
on memory and the way the brain processes vision. Francis spoke to an overflow
crowd at the LIBA-sponsored Dorcas Cummings Memorial Lecture. During his
visit, Francis and I were persuaded to pose beside a model of the double helix in
the DNA Learning Center, in a reenactment of a photograph made more than 35
years ago at the Cavendish Laboratory. While we were at the Learning Center,
we encountered a high school biology class from Dobbs Ferry, New York, and its
avid teacher, Carl Shiavo. Both Francis and I enjoyed meeting some of the
younger DNA science enthusiasts.
Centennial Meetings
In addition to our Symposium on The Brain, two other meetings commemorated
the Laboratory's first hundred years. In early September, some of the world's best
minds in cancer research were brought together by Joan Brugge, Tom Curran,
Ed Harlow, and Frank McCormick. In the fifteen years since our first Origins of
Human Cancer meeting, enormous progress has been made here and elsewhere
in identifying the genetic mechanisms of that dreaded disease. Fighting cancer
remains as much our priority today as it was in 1975. Our second hundred years
will surely see a successful solution to this struggle. Saturday evening during the
Cancer meeting, our guests were treated to a special centennial performance by
world-class saxophonist Christopher Hollyday. Christopher entertained scientists
and staff on Grace Terrace with his 1950s-style jazz. The crisp fall air, cold beer,
and bebop proved most enjoyable.
In late September, a meeting entitled Evolution: Molecules to Culture em-
braced a variety of fields, ranging from molecular biology to anthropology and
linguistics. Attendees came away from that gathering with new insights into how
the evolution of living things compares with those of culture and language.
Richard Dawkins, who organized the meeting with Jared Diamond, presented his
own intriguing views on Darwinian theory during a LIBA-sponsored lecture for the
general public.
Assistant Director Bruce Stillman
With my commitment to the human genome initiative taking up much of my time,
finding a capable second at the Laboratory became essential. On September 1,
the appointment of Bruce Stillman as Assistant Director of Cold Spring Harbor
Laboratory was announced. A gifted researcher and organizer with endless ener-
gy, his help will be invaluable in the recruitment of new scientists during this criti-
cal period. Bruce first came to us in 1979 as a postdoc from the Australian Na-
tional University and has held the position of Senior Staff Scientist since 1985. His
work over the last decade in identifying the key cellular proteins involved in DNA
replication has elevated him to the highest ranks of his field. I am certain that he
will continue to make such strides while ensuring that our research staff maintains
its vitality and diversity.
David Mick los Honored
For his pioneering achievements as founder and Director of the Laboratory's
DNA Learning Center (the first such facility in the world), David Mick los received
the Charles A. Dana Foundation award, given each year to outstanding individu-
als in health-related education. Amazingly, in the few years since the Learning
Center's inception, its instructors have taught over 10,000 high school students
and have trained nearly 2000 teachers to conduct experiments using some of the
latest techniques in biotechnology. Some of the experiments developed by Dave
and his colleagues for the Learning Center have been incorporated into the Ad-
vanced Placement Biology curriculum, reaching more than 50,000 students
across the country every year. In May 1990, Dave and DNA Learning Center As-
sistant Director Mark Bloom journeyed to Moscow to set up a similar center there.
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Mark made a second trip to the Soviet Union in January 1991 to inaugurate the
new center and conduct its first training sessions in DNA technology.
A Good Year for CSHL Press
Our publications continued making strides in 1990. The second edition of
Molecular Cloning: A Laboratory Manual by Joe Sambrook, Ed Fritsch, and Tom
Maniatis surpassed the 50,000 mark in sales. Another manual destined to be-
come a standard, Antibodies, by Ed Harlow and David Lane, has already sold
more than 20,000 copies. The first printing of the high school/college text DNA
Science: A First Course in Recombinant DNA Technology, written by David Mick-
los and Greg Freyer, sold out in short order. Among our journals, Cancer Cells
successfully completed its first full year in a highly competitive field. A study of
citation frequency found Genes & Development, now in its fourth year of publica-
tion, to have the greatest impact of any journal in either genetics or developmen-
tal biology. "G&D" also won a Gold Award in the 1990 Neographic competition for
excellence in cover and graphic design.
Daniel Marshak Receives Prize
For his work in tracking down the protein sloop, a major factor in Down's
syndrome, Senior Staff Investigator Daniel Marshak was presented with a
Science Scholar Award from the National Down's Syndrome Society. Dan is
among those at the Laboratory pursuing a greater understanding of the brain. His
research has come far in elucidating the protein chemistry and molecular biology
of neurites (the physical circuits between nerve cells). Soon his group will occupy
a space in the Neuroscience Center.
Banbury Meetings Cover a Wide Range
Last year, a remarkable variety of topics were discussed at the Laboratory's Ban-
bury Center, located on the beautiful estate donated by the late Charles S.
Robertson. Each year, Banbury Director Jan Witkowski outdoes himself in focus-
ing on topics in biology that are of concern to scientists and to the public at
large. This year was no exception, with meetings ranging from basic research,
such as Computational Aspects of Protein Folding, to topics of broader interest,
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including The Impact of Human Molecular Genetics on Society. A workshop for
science journalists on Women and Cancer surveyed the latest research on can-
cers unique to women and explained diagnostic tests and treatments in develop-
ment. At a meeting on Addiction, congressional staffers learned about the
physiological and psychological components of a disorder that has become
epidemic in this country. In January 1991, another congressional workshop dealt
with the numerous scientific aspects of aging.
Baring Brothers Executive Conference
Last October, the investment firm Baring Brothers & Co., Inc., and Cold Spring
Harbor Laboratory cohosted the fifth annual weekend meeting at Banbury Center
for executives interested in biotechnology. The subject this time was Genetic
Pathways to Cancer. Attendees included Laboratory Trustee William Miller, Vice
Chairman of the Board of Bristol-Myers Squibb, and Henry Wendt, Chairman of
SmithKline Beecham. Top scientists in all areas of cancer research presented the
current status of work on oncogenes, cell-cycle control, genetic prognosis, the
prospects for gene-specific therapies, and related topics. The executives, who
spent much of one day at the Laboratory's main campus, learned the way the
work of our scientists fits with other frontline research around the world.
Major Gifts/Second Century Campaign
Through the efforts of the seven committees of the Second Century Campaign
and the help of numerous staff members and volunteers, the Laboratory is near-
ing its goal of $44 million set in 1986. Over $40 million has been raised to date,
helping to ensure the Laboratory's financial health, providing support for our
scientists, and propelling our expansion. The completion of the Neuroscience
Center, the renovation of Blackford Hall, much-needed improvements in our infra-
structure, and the addition of new cabins for visiting scientists have all become a
reality because of the generosity of our many individual, corporate, and founda-
tion donors. In 1990, major corporate support totaling more than $2 million came
from Boehringer Mannheim Corporation, Burroughs Wellcome Co., E.I. du Pont
de Nemours & Company, Hoffman-La Roche Inc., Merck & Company, Pall Corpo-
ration, Rorer Group, Schering Plough Corporation, and SmithKline Beecham
Pharmaceuticals.
The largest foundation gift announced in 1990 was from the Lucille P. Markey
Charitable Trust, which donated $4 million toward the Neuroscience Center. The
Markey Charitable Trust, established by the will of Mrs. Markey in 1983, supports
and encourages basic medical research. The Trust's generous donation will
benefit our new scientists in their fight against disorders and disabilities of the
brain.
Other foundation grants received in 1990 include a $500,000 challenge grant
from an anonymous donor, to be awarded if we can raise an additional $1 million
in unrestricted funds; a $300,000 grant from the Ira W. De Camp Foundation; and
$75,000 from the Nichols Foundation. George Garfield, a gentleman who as a
teenager was taught and inspired by Laboratory Director Charles Davenport in
1914, graciously contributed $70,000 from the Garfield Foundation. In 1990 and
early 1991, the William and Maude Pritchard Charitable Trust gave the
Laboratory a total of $75,000.
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A Vibrant Board of Trustees
Our Board continues to exemplify the knowledge, expertise, and generosity that
are needed to run an institution such as ours. In November, President George
Bush awarded Laboratory Trustee Dr. David Pall the National Medal of Technol-
ogy, the highest honor for technology in the United States, if not the world. David
was recognized for his vast contributions as founder and Chairman of Pall Corpo-
ration, through which he has developed filters for use in industry, medicine, air
travel, and numerous aspects of life. One of his latest inventions is a biomedical
device that removes leukocytes from blood and platelet concentrate during trans-
fusions, bringing the benefits of such to patients in several thousand hospitals.
Last year, Trustee Helen Ann Dolan left the Board after serving six years, hav-
ing been a great help to the Building, Education, and Robertson House Com-
mittees. At the same time that Helen departs, her husband Charles F. Dolan joins
us. Charles is the Chairman and CEO of Cablevision Systems Corporation and
the founder of a number of premium cable services, such as Home Box Office,
with tens of millions of subscribers. His years of experience and acumen in busi-
ness will be an invaluable asset to the Finance and Investment Committee.
Wendy Hatch, a good friend and tireless champion of the Laboratory, has
worked on the Development, Executive, Finance and Investment, Building, LIBA,
and Banbury Committees. Having served two consecutive terms on the board,
Wendy is required to take a two-year leave, but she will continue to act as Chair
of the Major Gifts Committee of the Second Century Campaign and will work with
many of her other committees as well. Her energy and talents have proved vital
to the Laboratory and will continue to be a treasured resource.
Departing Trustee Thomas J. Silhavy, a gifted professor of molecular biology
at Princeton University, has for many years taught a course in advanced bacterial
genetics at Cold Spring Harbor Laboratory. Also from Princeton, new trustee Shir-
ley M.C. Tilghman is a leader in mouse genetics research and an investigator of
the Howard Hughes Medical Institute. As a member of the Tenure and Appoint-
ments Committee, Dr. Tilghman will help in the tenure and approval process for
staff promotions.
Owen T. Smith, an accomplished environmental lawyer and expert on taxation
and real estate, joins the Board as a caring neighbor, having lived in nearby
Oyster Bay for 40 years and, more recently, in Laurel Hollow. As a member of the
DNA Learning Center Committee, Owen will be a high-profile advocate for that vi-
tal conduit of biology education.
Mary D. Lindsay returns to us after a two-year absence during which she ac-
companied her husband to England while he was there on business. Mary has
served three previous terms as a Laboratory Trustee and has been a Director
and Vice Chairman of LIBA. We are fortunate to have her back, working on the
Nominating and Building Committees.
Sadly, 1990 marked the passing of a dear friend and wonderful advocate of
the Laboratory, Elizabeth B. Schneider. Betty served on the board for six years
and on the LIBA board for 25 years. Among the many activities to which her
enthusiasm extended were sailing, flying, and especially her work here. She will
be sorely missed.
Robertson Research Fund
Our largest endowment, the Robertson Research Fund, has maintained its in-
tegrity amidst the volatile markets of the last year, allowing the continued support
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of younger scientists at the Laboratory who have yet to secure their own grants.
In some instances, the Fund also bolsters the research of more senior scientists
and provides other miscellaneous support. In 1990, the Robertson Fund contrib-
uted housing and supplemental stipends for postdoctoral fellows, aided our plant
genetics program, and provided relocation expenses for 24 scientists and salary
support for visiting scientists.
Blackford Renovation
The renovation of Blackford Hall, the Laboratory's dining facility, proceeds
apace. The basement is now completed, including the Blackford lounge and new
restrooms. The original foundation, part of the first poured concrete structure built
on Long Island in 1907, was reinforced in preparation for the addition, which will
bring Blackford's one-sitting dining capacity to 400 from the present 150. After
this year's meeting season has ended, workers will begin the second phase of
this project. We anticipate completion by spring 1992.
New Cabins Begun
Five new cabins, slightly larger than the six completed in 1989, are now under
construction. Like the others, each new cabin will comfortably house eight, but in
addition, each will have a full basement containing heating equipment and
storage space. Thus, the living areas will have more room, without sacrificing any
of the home-like charm of the original design. The two connecting cabin com-
plexes, located above the Neuroscience Center, provide a relaxing retreat for
scientists attending our meetings and courses. Toward the cost of these cabins,
Renovation of Blackford Hall One of five new cabins under construction
as toward those built earlier, we have specifically sought the help of scientific
alumni, in particular those who have helped create the increasingly successful
biotechnology industry. Most pleasing this last year was a major gift received
from our Trustee Tom Maniatis, who with Mark Ptashne founded Genetics In-
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stitute. Earlier on, Mark made a gift toward the first set of cabins. This support
from my former colleagues in the Harvard Department of Biochemistry and
Molecular Biology pleases me deeply.
LIBA and Associates
Since its founding in 1924, the Long Island Biological Association has been an in-
valuable source of support for the Laboratory. In 1990, LIBA provided funds for
six postdoctoral fellows and granted a New Investigator Start-up Fund to Senior
Staff Investigator Nicholas Tonks. Nick comes to us with an impressive body of
work on tyrosine phosphatases and their relation to cell growth.
Last year, Jim Eisenman retired as Treasurer of LIBA, after serving for 27
years. Arthur Crocker, Penny Chenery, and Lon Chaiken also retired. Succeeding
them were Jack Evans, Missy Geddes, Alan Kisner, and Alec Thayer.
The LIBA Annual Meeting in January of 1990 included an interesting panel
discussion on science in the Soviet Union. Four of our visiting scientists and their
wives spoke of differences in our cultures, disparities in education, the funding of
science, and the slow exchange of information from abroad. Joint efforts like the
establishment of the Moscow DNA Learning Center provide some hope of
greater communication in the future.
There were 139 Cold Spring Harbor Associates (contributors of $1000 or
more) in 1990, thanks to the efforts of the LIBA Directors, the Development Of-
fice and our volunteers. An Associates lecture, held on November 30, dealt with
new technologies and opportunities in the life sciences industry. Laboratory
Trustee John Reese moderated an informative discussion on the problems and
prospects for fledgling biotechnology firms. Panelists included David Bonagura,
partner at Ernst and Young; John R. Drexel IV, president of Concord Manage-
ment International, and Douglas E. Rogers, a Director at Baring Brothers & Co.,
Inc.
Undergraduate Research Program
Since 1959, up to 20 undergraduates from the United States and overseas have
come each summer to the Laboratory to work with our scientists. In 1990, 18 stu-
dents participated in the Undergraduate Research Program, coming from as far
away as Tartu University in Estonia and the University of Glasgow in the United
Kingdom. In addition, two students came from Cambridge University. Each stu-
dent was able to complete a ten-week project on topics such as telomere length
(with Bruce Futcher and Carol Greider) and the use of computer software to as-
sist in restriction mapping (with Kim Arndt). Although National Science Founda-
tion support was unavailable for the program in 1990, funds were provided by a
number of corporations, primarily Burroughs Wellcome and Baring Brothers.
Partners for the Future
We inaugurated a program in 1990 that enables a select group of high school
students to conduct research at the Laboratory, naming it Partners for the Future
after the centennial year's cooperative program involving Long Island
businesses. From the more than 150 high schools on Long Island, five excep-
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tional students were chosen to assist some of our researchers. Along with a
stipend, the interns receive an unforgettable initiation into the world of science.
As funding permits, more high school students will join us each year, opening the
path toward constructive and rewarding careers. The following is a list of the
1990 interns, their high schools, and their Laboratory mentors: David Adelman,
Commack High School (Dr. Jeffrey Kuret); Cathy Andorfer, East Islip High School
(Dr. Venkatesan Sundaresan); Eugene Choi, Garden City High School (Dr.
Richard Roberts); Susie Hong, Syosset High School (Dr. Robert Franza and Dr.
Yuchi Li); and Jennifer Munneyyirci, Plainview High School (Dr. Nouria
Hernandez).
Changes in Scientific Staff
With keen regret we say goodbye to Senior Scientist Ed Harlow, who is establish-
ing a new base at the Massachusetts General Hospital Cancer Center in Charles-
town, Massachusetts. Ed's invaluable work in the study of cancer-suppressing
genes and the retinoblastoma anti-oncogene-E1A protein interaction signified a
great breakthrough in the quest to demystify cancer's origins in cells. Several
major honors attest to the significance of his findings, namely, two awards of
$50,000 each, one from the Milken Foundation and the other from Bristol-Myers
Squibb, both for distinguished achievement in cancer research.
Senior Staff Scientist Yakov Gluzman, who first arrived here in 1977 to work
with Joe Sambrook, has also ended his direct affiliation with the Laboratory. For
the past several years, Yasha has served as the Director of the molecular biology
research section of the American Cyanamid Company, Medical Research Divi-
sion, Lederle Laboratories, in Pearl River, New York. He continues to probe the
molecular biology of viruses and the mechanism of antibiotic ac-
tivity and resistance.
Senior Staff Investigators Guilio Draetta, Loren Field, and Andrew Rice ac-
cepted new positions elsewhere. Guilio, who was appointed Robertson Fellow at
Cold Spring Harbor in 1986, collaborated with David Beach on cell-cycle control
in yeast and vertebrates. He is now at the European Molecular Biology
Laboratory in Heidelberg, Germany. Loren has taken up new duties as associate
professor in the Department of Medicine, Division of Cardiology, Krannert In-
stitute of Cardiology in Indianapolis, Indiana. His field of study is the molecular
biology of the cardiovascular system. Also assuming new responsibilities as as-
sociate professor is Andrew Rice, who continues his research at the Division of
Molecular Virology, Baylor College of Medicine in Houston, Texas. Andy came to
us from the Imperial Cancer Research Fund and focused his work on the regula-
tion of human immunodeficiency virus (HIV) gene expression.
In the fall of 1990, Staff Investigator Eileen White left us to join the staff of Rut-
gers' Center for Advanced Biotechnology and Medicine in Piscataway, New Jer-
sey. After receiving her PhD from the State University of New York, Stony Brook,
in 1983, she joined Bruce Stillman's laboratory as a postdoc studying the function
of adenovirus E1B tumor antigens in transformation and lytic infections. She was
appointed Staff Investigator in 1986.
Staff Associates John Collicelli, Nicholas Dyson, Ken Ferguson, and Toshiki
Tsurimoto also departed in 1990. John became assistant professor at the School
of Medicine in the Department of Biological Chemistry at the University of Califor-
nia, Los Angeles. Nick is an assistant professor at the Cancer Center of the
Massachusetts General Hospital in Charlestown, Massachusetts, and Ken has
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become director of the program in signal transduction at ICOS Corporation in
Seattle, Washington. Toshiki has returned to Japan, where he is assistant profes-
sor at the Institute for Molecular and Cellular Biology at Osaka University.
New Staff Members
We welcome to our ranks Nicholas Tonks, who joins us as Senior Staff Investi-
gator in James Laboratory, and Hong Ma, who joins us as Staff Investigator in
Delbruck Laboratory. Nick examines signal transduction mechanisms. Before
coming to us, he was at the University of Washington's Department of
Biochemistry in Seattle. One of David Botstein's doctoral students, Hong Ma left
the biology division of the California Institute of Technology in Pasadena to pur-
sue further research here. He focuses on plant signal transduction, plant flower
development, and transcription factors.
New visiting scientists in 1990 include Igor Garkavtsev, Catherine Jessus,
Janos Posfai, and Natalia Yenikolopov. Igor and Natalia add to the numbers of
our Russian scientific contingent. Working out of Demerec and James
laboratories, respectively, Igor comes to us from the Medical Genetics Center in
Moscow and Natalia comes from the Institute of Molecular Biology at the Acad-
emy of Science, also located in Moscow. Catherine Jessus, from the Centre Na-
tionale de la Recherche Scientifique in Paris, is in David Beach's laboratory re-
searching cell-cycle regulation, particularly the M-phase or mitosis stage. Janos
Postal from Hungary has made two previous visits to Rich Roberts' laboratory,
first in 1987 and again in 1989. He is here for a third time, continuing his explora-
tion of biological sequence analysis using mathematical methods. Another addi-
tion to David Beach's laboratory is Japanese scientist Toru Mizukami, who comes
to us from the Tokyo Research Laboratories, where he was researching amino
acid fermentation and enzyme production.
Several visiting scientists completed their studies at Cold Spring Harbor, in-
cluding Robin Allshire who returned to Scotland to take up responsibilities as
staff associate at the MRC Human Genetics Unit in Edinburgh's Western General
Hospital. Clement Echetebu accepted a position as research associate in the
division of molecular biology, AIDS wing, Baylor College of Medicine in Houston,
Texas, and Valentin Shick returned to the Institute of Molecular Biology at Mos-
cow's Academy of Science.
Staff Promotions
Former Staff Investigator Jeff Kuret has moved up to the position of Senior Staff
Investigator. In 1984, he received his PhD in pharmacology from Stanford Univer-
sity in California and then joined the Department of Biochemistry at the Medical
Sciences Institute in Dundee, Scotland. His postdoctoral interest involved the
structure and mechanism of enzymes in signal transduction. Jeff, whose current
work focuses on protein kinases, first came to Cold Spring Harbor in 1987 as a
postdoc in Mark Zoller's laboratory.
Rob Martienssen has also been promoted to Senior Staff Investigator. A na-
tive of England, he completed his doctorate in plant molecular genetics at Cam-
bridge University. As a postdoc at Berkeley in California, he worked with Michael
Free ling and William Taylor. Rob works out of DelbrOck Laboratory in plant devel-
opmental genetics, specifically investigating the high mutation rate in the maize
transposable elements system.
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Former visiting scientist Yan Wang, from Beijing, China, has been made Staff
Associate. After completing his MD and before coming to us, he completed post-
doctoral studies at Stony Brook, Department of Biotechnology. Postdocs Graeme
Bolger and Tamar Michaeli, who both work in Mike Wigler's laboratory in
Demerec, have also been advanced to Staff Associates. Graeme arrived here in
1985 and has worked in phosphodiesterases and human neurological diseases,
and Tamar has pursued her research in the functions of RAS in Saccharomyces
cerevisiae and the characterization of phosphodiesterase enzymes in the human
brain.
Postdoctoral Fellows
The following scientists have departed after having completed their postdoctoral
studies at Cold Spring Harbor Laboratory: Young-Seuk Bae to Kyung-Pook Na-
tional University in Daegu, Korea; Jennifer Brown to Miami Beach, Florida; Karen
Cochrane to the Krannert Institute of Cardiology, Indianapolis, Indiana; Greg
Conway to Harvard University Biological Laboratories, Cambridge, Massachu-
setts; John Diffley to the Imperial Cancer Research Fund, Herts, England;
Bernard Ducommon to the European Molecular Biology Laboratory in Heidel-
berg, Germany; and Christine Hermann to the Department of Molecular Pathol-
ogy, Anderson Cancer Center at the University of Texas in Houston.
Also departed are Emma Lees and Jackie Lees, both to continue their work at
the Massachusetts General Hospital Cancer Center in Charlestown, Massachu-
setts, and William Ryan, to join the firm of Smith, Barney in New York City as an
associate in corporate finance. Mark Steinhelper departed to the Krannert In-
stitute of Cardiology in Indianapolis; Li Lhui Tsai to Massachusetts General Hos-
pital Cancer Center in Charlestown, Massachusetts; Ilse Weiland to the Institute
for Cell Biology, University of Essen, Germany; Zhang Ming to Emery University
Medical School in Atlanta, Georgia; and Zuo Zhao to Pioneer Hi-Bred Internation-
al, Plant Breeding Division, Johnston, Iowa.
Several graduate students completed their doctorates and moved on, name-
ly: Karen Buchkovich-Sass to the Department of Biochemistry, New York Univer-
sity Medical Center, New York City; Duncan McVey who returned to Falcon
Heights, Minnesota, to pursue an entrepreneurial career, and Susan Smith to the
Cell Biology Laboratory at Rockefeller University in New York City.
Employees Recognized for Long-term Service
In 1990, three employees reached the milestone of 20 years' service to the
Laboratory: Jack Richards, Director, Buildings and Grounds; Barbara Ward,
Course Registrar; and Madeline Wisnewski, Scientific Secretary. Two others, Vin-
cent Carey, Grounds Foreman, and Robert McGuirk, Senior Lab Technician,
have completed 15 years' service.
I particularly wish to mention here the extraordinary role Jack Richards has
played in the physical rebuilding of the Laboratory. Jack first came to my atten-
tion when he was an independent contractor. In April 1970, he was one of three
contractors asked to make bids for the construction of the annex to James
Laboratory in which my office is located. After the bids were in and Jack the ob-
vious choice to do the job, he asked us whether instead of acting as the outside
contractor, he could become the head of our Buildings and Grounds Depart-
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ment. In that capacity, he would find subcontractors to do the job. We immediate-
ly accepted, and ever since then Jack, in effect, has been our contractor in
residence. His extraordinary devotion to the Laboratory, coupled with his innate
good taste, has already left a mark on the Laboratory equal to that of our most
distinguished scientists.
My NIH Position Continues to be Both Time-
and Emotion-consuming
Effectively, I have spent almost half my time during the past year in my capacity
as the Director of the National Center for Human Genome Research in Bethesda,
Maryland. But because of the FAX, much of the time occurred while I was in my
office here at the Laboratory. Initially, I thought I would regularly spend the first
part of the week in Bethesda, but my visits there have evolved into a process
where I try to overlap my time there with essential meetings and conferences.
That I have been able to direct the Genome Office owes much to the high quality
of my staff at the National Institutes of Health, in particular to Dr. Elke Jordan, the
Deputy Director of the Center, and to Dr. Mark Guyer, the Assistant Director for
Program Affairs. In addition, we now have our own study section to handle our
major grants, and I was very pleased when we were able to persuade Eric
Lander of the Whitehead Institute of the Massachusetts Institute of Technology to
chair this most important body. I was also greatly assisted by the help that Norton
Zinder of Rockefeller University gave to me as Chairman of our Program Advisory
Board during its first two years of operation. In fiscal 1990, we had a budget of
$58 million, a sum that has increased to $88 million for fiscal 1991. Already I take
great pleasure in the establishment of our first genome centers at six major aca-
demic institutions (Washington University School of Medicine; University of
Michigan Medical School; University of Utah Medical School; University of Cali-
fornia, San Francisco, Medical School; Massachusetts Institute of Technology;
and Baylor University Medical School) as well as the awarding of the four large
grants to commence megabase sequencing of selected regions of the genomes
of the model organisms Escherichia coli, Mycoplasma capricolum, Sac-
charomyces cerevisiae, and Caenorhabditis elegans.
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Our Nation Needs Its Scientists More Than Ever
The recent congressional hearings on abuses in the way federal research funds
have been spent has created in many scientists' minds the fear that we are wit-
nessing the start of an anti-intellectual phase in Congress that could badly
damage our nation's capacity for high -class intellectual pursuits. In my dealings
with Congress, however, I sense no such mood, only a bipartisan sense of sor-
row and indignation over individual acts of misbehavior, sometimes by scientists
and at other times by university administrators, that badly discredit the image of
science as an endeavor devoted to the pursuit of truth. Science, however, is no
longer a small elite enterprise; rather, it is a major aspect of our nation's fabric
populated by far more individuals than can occupy the largest of athletic arenas.
So it is not surprising that misdeeds, some very black, have been done in the
past, and we must expect more in the future. After all, scientists like everyone
else are human, and we have never expected any other occupation to be a
paragon of virtue.
At the same time, however, we must never forget that in the past, our nation
has treated us very well. It has valued us for our objective analyses of the natural
world, not for bending the facts to suit our own personal needs and prejudices. If
our charlatans are not treated for what they are, our nation's scientists risk being
perceived as just another lobby group more interested in their own private gain
than in the perpetuation of our nation's greatness. Drawing the wagons around us
to protect our sinners from punishment is not the way to ensure that the voices of
scientists are heard more, not less, in the Washington corridors of power.
In our past as in the present, we as scientists have much to be proud about.
We thus must not falter in seeing that we continue to be known for our integrity as
well as our brains.
April 19, 1991 James D. Watson
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ADMINISTRATION
Cold Spring Harbor Laboratory completed 100 years at the forefront.of biological
science in 1990. Across a broad spectrum, the Laboratory's research and education
programs continue to be outstandingly productive. Not surprisingly, this has resulted
in satisfactory operating results and an overall strong financial condition.
The year ended with a small surplus of revenues over expenditures after fully
providing for $1.5 million of depreciation and raising the reserve for future start-up
expenses of the Neuroscience Center to $650,000. The positive operating numbers
at the Laboratory reflect the continued success of our remarkable young scientific
staff in commanding a good share of the now very competitive Federal funding avail-
able for science. Foundations, corporations, and private individuals continue to sup-
port the Laboratory's programs at a high level.
Cold Spring Harbor Laboratory Press had another excellent year, with sustained
demand for its best-selling books and good sales of new 1990 titles. The Journal De-
partment contributed to the good results, and it is particularly noteworthy that Genes
& Development achieved its first surplus after four years of existence. The Meetings
Department held two fewer major scientific meetings during 1990 than is ordinary,
and this resulted in lower revenues. Several meetings planned especially for the
Centennial, particularly the Symposium on "The Brain" and the fall meetings on "The
Origins of Human Cancer" and "Evolution: Molecules to Culture," were outstanding
scientific events.
Banbury Center and the DNA Learning Center had memorable years as well. Ban-
bury, strongly supported by the thriving Corporate Sponsor Program, held 17 meet-
ings at the Robertson Estate in Lloyd Harbor, with a fall meeting on "Impact of Hu-
man Molecular Genetics on Society" being particularly noteworthy. The DNA Learn-
ing Center's year was highlighted by Dave Micjclos' receipt of the Charles A. Dana
Foundation Award for Pioneering Achievement in Education and by the opening of a
DNA Learning Center in Moscow.
The Laboratory's endowment, consisting of the Robertson and Cold Spring Harbor
Funds, reached a new high level of just over $44 million by the end of the year. This
was the result of the reinvestment of a substantial portion of the income from the
Funds to provide for inflation and future growth of the Laboratory, some new gifts,
and very good investment results accomplished by our investment advisers, Miller
Anderson and Sherrerd. They succeeded in achieving a positive investment return in
a year when many popular market averages declined by as much as 15-20%.
The Second Century Fund capital campaign completed the second year of its
planned three-year fund-raising effort with more than $40 million of its $44 million
goal already in hand. One cannot overstate the contribution to the Laboratory's future
made by David Luke Ill, Chairman of the Fund, the Campaign Committee Chairs,
Oliver Grace, Wendy Hatch, George Cutting, Taggart Whipple, Bill Miller, and
Townsend Knight, and the many campaign volunteers. The effectiveness of their ef-
forts is clearly demonstrated by the impressive dollar totals already accomplished.
They have been ably supported by Konrad Matthaei and the Cold Spring Harbor
Laboratory Development Office. The marvelous facilities and growing endowment
made possible by the Second Century Fund will be treasured by the next genera-
tions of scientists here as the Laboratory's second century of science unfolds.
1990 might well be termed the year of the Laboratory's Buildings and Grounds
Department, so very ably led by Jack Richards. They have managed, refurbished, or
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largely constructed no less than five major projects, including the Neuroscience
Center, Blackford Hall (Phase I), five new guest cabins, and the Frame House and
Northview House. In addition to attending to innumerable Laboratory alterations,
renovations, and general repairs, all of the above-mentioned work was accomplished
with skill, on budget, and within reasonable time frames. The cost savings have been
substantial, and the high quality of the work is a great tribute to the professional
abilities of Russ Allen, Lou Jagoda, John Meyer, Lane Smith, and others too
numerous to mention. The Laboratory's 30 separate buildings have been well
maintained under the leadership of Peter Stahl, Danny Jusino, and Dorothy Youngs.
As in the past, but particularly this Centennial year, the beauty of the entire
Laboratory grounds has reflected the care and pride of such men as Buck Trede,
Vinny Carey, Chris McEvoy, Danny Miller, and Tim Mulligan.
Now as we look ahead to the great promise of the next 100 years, we must first
deal with the realities of 1991. Cold Spring Harbor Laboratory Press book sales in the
early months of 1991 have been adversely affected by the Gulf War, the national
recession, and severe constraints on grants at academic institutions. Federal grants
for the Laboratory's research programs are being arbitrarily reduced on renewal by
as much as 20% instead of being adjusted upwards as expected to compensate for
inflation. This seriously affects the direct research funding available to the scientific
staff and also reduces indirect cost recovery, which is the major source of funds
available to pay for overhead. The cost of major overhead components such as
maintenance, depreciation, and hazardous waste disposal continues to increase.
Postponing or ignoring them is only a form of mortgaging the future. Other overhead
components such as utilities and administrative expenses can be controlled and
every effort is being made to do so.
Recent instances of improper practices at some institutions regarding indirect
cost recovery promise to bring about across-the-board limitations on overhead reim-
bursement that could seriously threaten the infrastructure of much of the nation's
basic research establishment. We shall have to live with whatever Federal decisions
result from the current reevaluation of the whole subject of indirect costs, but in all
likelihood, new non-Federal sources of funding will have to be found. Such costs are
a very real part of doing research and cannot be legislated away.
Despite the immediate challenges created by the recent explosive growth of the
Laboratory and the unusual number of uncertainties for the year immediately ahead,
we view the future with much optimism and anticipation. I feel most fortunate in being
able to rely on an administrative staff of extraordinary motivation and skill to guide
the Laboratory soundly into its second century of science.
G. Morgan Browne
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BUILDINGS AND GROUNDS
The Annual Report for the Buildings and Grounds Department is again one
neverending story of construction, renovation, and repair. Every nook and
cranny of the Laboratory has been touched by us, and in fact, we are probably
the only department that knows every square inch of the campus, both indoors
and outdoors.
Centennial Celebration
Most, if not all, of the Buildings and Grounds staff were involved in the prepara-
tion of the Laboratory for the celebration of its 100th birthday. The carpenters
built a stairway and bridge between Demerec Laboratory and Grace Auditorium,
as well as a bandstand on the back lawn of Davenport House. Where needed,
the painters painted and the groundskeepers landscaped, manicured, and in
general cleaned up, all contributing to making the Laboratory look its best. The
electricians supplied all of the extra lighting needed for the celebration, which
went on into the late evening. All of the special events were manned by the
custodial staff, with other segments of the department lending a hand in setting
up chairs and tents on the lawns of Blackford and Airs lie, parking cars, acting as
guides, helping to prepare the fireworks display, and cleaning up after the
celebration was over.
Neuroscience Center
Our highest priority for the year was the construction of the new Neuroscience
Center, which is located on the site of the now-defunct Page Motel. One of our
responsibilities when we entered the construction in progress during the year
was to help the contractor keep on schedule. Our in-house architect, Leslie Al-
len, spent much time solving problems inherent in coordinating our crew and the
construction site crew. Job report meetings were held every week to review the
work and to keep to the schedule, and by the end of the year, more than 90% of
the construction was completed. Two new housekeepers have been hired so far,
and we will need at least three more staff for maintenance.
Log Cabins
By the end of the year, four of the planned five new cabins were erected and en-
closed. We discovered after the first six cabins were built that more room was
needed for the utilities and the hot water heaters. Full basements were thus in-
cluded in the design of this second complex of cabins, providing additional
space in the living areas plus increased storage areas and better insulation for
the heating systems.
Blackford Dining Hall
Phase I of the Blackford expansion began after the summer meetings season,
The 3-foot-deep concrete piers originally supporting the building were rein-
forced and extended down another 10 feet to prepare for the new addition. In
the basement below the dining area, we demolished the bar, restrooms, and of-
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fices to make room for the Blackford lounge and new restrooms. Phase II will be-
gin after the 1991 meetings season.
Landscaping and Paving
It is becoming abundantly clear that parking is inadequate to meet the needs of
our ever-increasing staff. Additional parking spots furnished by the large parking
area for the Neuroscience Center may alleviate some of the problem, but we are
always on the lookout for other areas. This year, the parking lot above the pond
was made larger to accommodate about 25 more cars.
We also added a waterfall to the pond this year. About a ten-foot-wide area
on the north end of the pond was excavated and lined with concrete, and large
flat rocks were set in tiers to form the waterfall. A pump was added to recirculate
the water from the pond to the pool above the waterfall. A little further up from
the pond, the sculpture "Transform" had begun to sink because it had been
placed in the pond meadow which retains a lot of water. To prevent it from sink-
ing further, we provided better drainage, fashioned a concrete base, and bolted
the sculpture to this base. In the early summer, two of the older cabins near the
Neuroscience Center were demolished, and this area was also graded and
landscaped.
Wastewater Treatment Facilities
The Laboratory provides many utilities, and perhaps the least popular is
wastewater treatment plant. To accommodate the increased flow from the new
buildings, the wastewater treatment plant was renovated to improve its capacity
and reliability. Our own plumbers and mechanics re-piped the underground sys-
tems, which now include an additional equalization tank, a new distribution box,
and a relocated sludge tank. After the pumps were relocated, the sludge
removal area was landscaped. All of this work was done before the Centennial
celebration, and our staff did an excellent job of completing this project on
schedule.
Alterations and Renovations
Cairns Laboratory: The north microscope room at Cairns was renovated to make
room for a laser microscope and to provide additional space for nitrogen
storage for Dr. Spector.
Demerec Laboratory: We rebuilt an entire office complex for Dr. Wig ler by gut-
ting the original area and building new offices for the postdocs, a secretary, and
Dr. Wig ler. A new entrance was also created to allow more light to enter the nar-
rower foyer area caused by the enlargement of this office complex.
Harris Research Facility: We completed the remodeling of the kitchen and
repainted the entire building. We also installed door guards and chair rails to
prevent further damage by lab carts.
Hershey Building: The offices for Dr. Beach's postdocs were renovated to ac-
commodate 12 postdocs and a secretary. We also installed new built-in furni-
ture, which included new desks, and new telephone lines.
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McClintock Laboratory: On the south end of the second floor of McClintock we
completed Dr. Beach's laboratory. The library seminar room was gutted and
rebuilt into a laboratory, which included new utilities, cabinets, and exhaust
hoods.
Bonn House: After two years of debate, the Historical Society gave us permis-
sion to install a new asphalt roof on Bonn House. This historical Huntington
house on Route 108 is owned by New York State and is maintained for the State
by the Laboratory.
Davenport House: Like all exterior porches on older houses, Davenport's porch
showed signs of structural deterioration. We replaced all of the old porch
columns and repaired the hand rail.
Frame House: All interior walls, piping, and electrical wiring were removed from
this house, which is situated in Cold Spring Harbor on Route 25A. The gutted in-
terior was reworked into five bedrooms, four bathrooms, a living room, dining
room, kitchen, and library. The project was completed by the summer.
Northview House: We renovated this entire house purchased from the U.S. Gov-
ernment to provide accommodations for Laboratory personnel. All of the window
glass had to be replaced, and since the heater had not been drained properly,
there was much damage to the pipes over the winter and the whole system had
to be replaced, including the radiators.
Nichols Building: The installation of another built-in desk allowed one more per-
son to work in the Grants Department office. After making the computer room
smaller, we were able to build another office for the Personnel Department.
Banbury Center: To conform with the requirements of the Board of Health, we
renovated the kitchen in Robertson House to create a more efficient facility. This
included the installation of a heavy-duty commercial dishwasher and a large
refrigerator-freezer.
Uplands Farm: We refurbished the Basset house and the Superintendent's cot-
tage with a coat of bright white paint.
I would like to take this opportunity to thank all of the people in the department
for another year of a job well done!
Jack Richards
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DEVELOPMENT
Second Century Campaign
1990 was a year of challenge and growth for the Development Department.
Reductions in government funding and new urgent social and environmental is-
sues meant increased competition for the philanthropic dollar. Despite these is-
sues, the Laboratory was able to add over $4 million to its Second Century
Campaign. Initiated in 1986, this $44 million capital drive, which was the
Laboratory's first broad, public-funding campaign, has now raised $40.4 million
or 92% of its goal. National and local foundations, those new to the Laboratory
and those familiar with it, have accounted for slightly more than 50% of this
amount. Laboratory Trustees and other individuals have accounted for approxi-
mately 38%, and an ever-widening group of corporations have contributed nearly
10%. Campaign Chairman David L. Luke III and Steering Committee members
Oliver R. Grace, George W. Cutting, Jr., Mrs. Sinclair Hatch, Townsend J. Knight,
and Taggart Whipple continue to provide dynamic leadership for the Campaign.
Other diligent and persistent volunteers ably man the six different Campaign
Committees and are listed later in this report. Through their efforts, three founda-
tion challenge grants have been matched or are well on their way to being
matched: the Fannie E. Rippel Foundation, the Kresge Foundation, and an
anonymous foundation.
The Second Century Campaign was designed to raise money for new and
renovated facilities and for staff endowment. It is this latter area that we must
emphasize in the remainder of the Campaign. The Neuroscience Center, which
will be inhabited in March and dedicated in May, is powerful proof of the
Campaign's success in realizing the first of these goals.
Several areas in the Neuroscience Center have been named as a result of
significant campaign gifts: Dolan Hall (The Dolan Family Foundation), Hazen
Tower (Lita Annenberg Hazen), Keck Structural Biology Laboratory (The W.M.
Keck Foundation), The Plimpton Seminar Room (Mrs. Pauline A. Plimpton and Mr.
Amyas Ames), The Gardner Neuroscience Library (Mr. and Mrs. Robert B.
Gardner, Jr.), The Lucy and Edward Pulling Seminar Room (Mr. and Mrs. George
W. Cutting, Jr.), and The F. Thomas Powers Room (Elaine E. and Frank T.
Powers, Jr., Foundation).
Another remarkable Campaign gift was a benefit concert performed in the
Laboratory's Oliver and Lorraine Grace Auditorium in September by world
renowned Metropolitan Opera mezzo-soprano Frederica von Stade. In a pro-
gram entitled From Mozart to Broadway, Miss von Stade enthralled the sold-out
auditorium with selections that ranged from Mozart's Don Giovanni to Gershwin's
Porgy and Bess. The benefit raised more than $70,000, which will help match the
Kresge Foundation challenge and will endow the Frederica von Stade Un-
dergraduate Research Internship. Patrons who played such an important part in
the success of this event are listed later in this Annual Report.
Annual Giving
Unrestricted annual giving provides strong underpinning for the Laboratory's fis-
cal needs. It is money that can be used at the Trustee's discretion for specific un-
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expected, and sometimes pressing, needs. Almost 80% of the Laboratory's an-
nual unrestricted income comes from Cold Spring Harbor Laboratory Associates,
and the remainder comes from the Long Island Biological Association. Early in
the year, at George Cutting's behest, John Reese agreed to Chair a new com-
mittee to expand and strengthen the Associates membership. Through the efforts
of Associate Committee members Jack Evans, Charles Gay, Missy Geddes,
Harry Lee, and Jordan Saunders, the Laboratory has the highest number of As-
sociates it has ever had and the number is growing steadily. These programs are
enthusiastically and effectively guided by George W. Cutting, Jr., and 28 direc-
tors. (A complete report of their 1990 activities may be found in Financial Support
of the Laboratory, which appears later in this Annual Report).
Planned Giving
In addition to making outright gifts to the Laboratory that take effect immediately
(cash, securities, insurance policies, and real estate), gifts may also be made to
take effect in the future. These gifts can be made in trust or by will. The mechan-
ism for one of these "planned gifts" has just been established by the Laboratory
with the U.S. Trust Company. The Cold Spring Harbor Laboratory Pooled
Income Fund allows an individual to give cash or stock to the Laboratory which
will be pooled with other such gifts. These funds are then invested, and the donor
or the person the donor designates will receive the net income from his or her
share of the Fund for life. Afterward, the principal amount of the gift is paid to the
Laboratory. There are several significant benefits of making such a gift: It pro-
vides long-term stability for Cold Spring Harbor Laboratory, it increases income
for the donor or the donor's relative, capital gains tax is avoided, and it provides
an immediate charitable deduction for income tax purposes. With a low-cost-
based stock, for instance, it is now possible to make a gift to the
Laboratory (and the Campaign) and increase your income!
Staff
The Development Department staff (Claire Fairman, Joan Pesek, and Debra Mul-
len) has become a cohesive, effective fund- and friend-raising team. I wish to
acknowledge their skill, dedication, and diligence and the fact that they always
approach their tasks with creativity and a sense of humor. Trustee George Cut-
ting wears many hats at the Laboratory and has put in long and productive
volunteer hours. Without him, the Development Department would not be nearly
as effective as it is.
We continue to be grateful to all of those who have helped us make such
progress toward our development goals. Second Century Campaign contributors
are listed under Financial Support of the Laboratory. We invite those who have
not yet participated in the Campaign to do so before the end of 1991. What bet-
ter way to help secure the future of Cold Spring Harbor Laboratory!
Konrad Matthaei
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LIBRARY SERVICES
Active Archives in Centennial Year
The Laboratory archives was an extraordinarily busy place in 1990, our Centen-
nial year. The news media needed to know a great deal about our early years
and the accomplishments and growth from 1890 to the present. The archives, a
true working archives in constant use under the dedicated supervision of Lynn
Kasso, contains a well-preserved wealth of information and photographs. In De-
cember, a New York State archives examiner came for a routine half-hour visit;
he was so impressed with the organization and content of the archives that he
stayed the entire day and was totally engrossed.
In addition to the media and book publishers who constantly access our pic-
ture collection, the archives was used extensively for the following: the centen-
nial commemorative book; research on a new CSHL Press book in progress by
Elizabeth Watson; a 1990 book from our press, The Emergence of Bacterial
Genetics by Thomas Brock; Jan Witkowski's articles in Current Contents and
Cancer Cells; DNA Science by David Micklos and Greg Freyer; and by Judy
Cuddihy for Genes & Development.
The archives also played an important part in the Centennial exhibit of paint-
ings and prints by Jane Davenport Harris DeTomasi, which opened in January in
Bush Lecture Hall. This was the Laboratory's first indoor art show and was most
successful. The exhibit was critically acclaimed, and several paintings and
prints were sold. Since then, an abbreviated version of the exhibit has traveled
to the Union Savings Bank of Huntington and the Cold Spring Harbor Public Li-
brary. Matted works and wood blocks were also sold as part of the Laboratory's
third annual arts and crafts fair, What began as a great idea by two scientific
secretaries, the arts and crafts fair has grown in size, popularity, and profit and
is managed by Laura Hyman, whose undaunted energy and talent contribute to
so much at the Laboratory beyond her job description. Without her support, both
in the Library and in the Public Affairs Department, my work on the Centennial
would not have been possible.
Automated Reference Center
Our automated reference center has exceeded expectations in meeting the
needs of individual Laboratory scientists. This system is capable of down-
loading machine-readable searches from library equipment to their personal
databases lab-wide. The Medline database on compact disk provides key word
searches by end users for citations and abstracts published from 1966 to the
present. Current Contents on diskette allows "current awareness" scanning of
journals. In 1990, 540 different queries were done by scientists and staff on
Medline CD and 68 on Current Contents. Genemary Falvey, Head of Library Ser-
vices, gives excellent, personalized instruction in the use of the new tech-
nologies, and she reports that most Laboratory scientists like this direct involve-
ment in literature searching. The library subscribes to these services just as they
do to journals; therefore, no additional telecommunication costs are passed on
to the user. Comprehensive online searching of other databases is still available
from the librarian.
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Our computerized interlibrary loan service continues to provide fast access
to articles requested by staff scientists. Photocopies of 70 tables of contents
from journals received are sent to 44 scientists.
New Storage Facility in Plainview
Our storage facility was moved from West Side School to a warehouse in Plain-
view this summer. Approximately 5800 volumes and 1500 linear feet of shelving
were relocated. Although the distance is greater, a two-day retrieval time is still
possible.
A Special Staff
I want to thank the entire library staff: Genemary Falvey, Head of Library Ser-
vices; Laura Hyman, Administrative/Business Manager; Helena Johnson, Library
Assistant; Lynn Kasso, Archives Assistant; Wanda Stolen, Senior Library As-
sistant; and our newest member, Clare Bunce, Library Clerk, for all of their as-
sistance and support during 1990. I would not have been able to concentrate so
much of my time and energy on the Centennial had I not known that the library
was in extremely capable hands.
Future
The future of library and information services at the Laboratory depends in large
measure on three factors: the availability of funds for an ever-inflating subscrip-
tion budget, the unknown advances in information technology, and sufficient
space for quality library service.
Susan Cooper
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PUBLIC AFFAIRS
The Centennial Celebration
By the end of 1991, more than three years filled with a variety of events will stand as
a reminder of the Laboratory's first 100 years. Add to that two years of planning
preceding the dedication of the DNA Learning Center in 1988 and a total of five
years will have been spent focusing on this scientifically and historically important
event. It was a unique privilege to work with Emily Eryou, Dan Schechter, Margot
Bennett, Herb Parsons, and Ed Campodonico. Their grit and dedication created the
events of the Centennial.
July 14, 1990 marked the 100th birthday of Cold Spring Harbor Laboratory. On
July 7, 1890, 100 years and 7 days earlier, the first biology class was held on the
shore of Cold Spring Harbor. That first class was immortalized by Rob Gensel and
his "Rotifer" cast members (see back cover illustration). This tiny launch was joined
by four magnificent, sailing vessels, Black Pearl, Zarefah, Emestina, and Little Jen-
nie. At 2:00 p.m. that afternoon, staff members and guests were gently propelled
back in time for a grand celebration. Storyteller Heather Forest narrated the arrival
of the historic launch and later told related stories to children and adults alike. A
hearty meal, adeptly prepared by Jim Hope and his food service staff, complete
with ale on tap, was served on Blackford lawn. There, the Old Bethpage Village
Restoration Brass Band played "Happy Birthday" and marched through the crowd to
traditional turn-of-the-century music. "Sparkles the Clown" kept the little ones en-
chanted with her balloon art and magic.
The evening's festivities were divided between the gala dinner party held at
Airs lie for our corporate friends who supported the Centennial and a concert on
Davenport lawn. The latter featured the highly acclaimed sea chanteymen, The
Forebitter, from Mystic Seaport, and starred Kim Strongin, a superb folk-rock singer-
songwriter. Although mother nature threatened to rain on our festivities, all agreed
that the misty fireworks by Grucci provided the evening's crescendo. Then out of
the mist came the noble sound of bagpipes; the Clan Gordon Highlanders Pipe
Band of Locust Valley marched majestically from Airs lie to Grace Auditorium. Our
guests, who waited patiently for the buses at day's end, were joyously entertained
by Synergy, a Barbershop Quartet.
A general sense of well-being dominated the day-people were relaxed and joy-
ous and basked in the sense of history surrounding this great institution.
Two Very Special Concerts
On September 8, jazz musician Christopher Hollyday, the 20-year-old alto
saxophone sensation, performed on the Grace Auditorium terrace for the attendees
of the "Origins of Human Cancer" meeting. A month later, Hollyday was pictured in
Time magazine and extolled as "a veteran who began performing at age 13." Then
on September 16, mezzo-soprano Frederica von Stade graciously performed a
benefit, "From Mozart to Broadway," in Grace Auditorium. It was one of the most en-
chanting evenings that was ever experienced at the Laboratory.
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Centennial Materials Expand Library of Lab Information
"Cold Spring Harbor Laboratory & Long Island: Partners for the Future," our com-
memorative book, was compiled to document the Laboratory's past, present,
and future. A specially designed section called "Partners for the Future," con-
tained congratulatory messages from Long Island business. Special thanks go
to Judith Carlson who was commissioned to coordinate this important aspect of
the book. Together with her cochairmen, Robert McMillan of Rivkin, Radler,
Bayh, Hart, & Kremer, and Thomas Doherty of Norstar Bank, she encourageda
group of prominent business figures to contribute nearly $215,000 in support of
the Laboratory and its Centennial. Born out of this program were the new in-
ternships for qualified Long Island high school seniors. Appropriately named for
the initial contributors, the "Partners for the Future" program allowed five gifted
seniors to work with five laboratory scientists after regular school hours from Oc-
tober to March.
In addition to the Centennial literature, which included an art catalog, special
commemorative meetings posters, and a variety of programs, flyers, tickets, and
invitations, 1990 saw the complete redesign and revision of FYI, the little flyer
that packs a lot of information about Cold Spring Harbor Laboratory into a num-
ber 10 envelope. Three Harbor Transcripts were completed, and the second
and third issues were combined to make way for the Centennial. Photographs of
new staff members hired in 1990 were completed for inclusion in the 1990
F.A.C.E.S., which is being published in February 1991. FA.C.E.S., the staff
directory, contains 435 photos; just 5% of the staff were camera shy. In 1989,
10% were not represented. We look forward to a time when all will be pictured.
A Banner Year for Press Coverage
As expected, the Centennial provided the perfect focus for press attention. The
Laboratory was featured in a dozen television programs and appeared in more
than 200 magazine and newspaper articles. It has been gratifying to see that
Cold Spring Harbor Laboratory is no longer the best kept secret on Long Island.
Especially noteworthy was Cablevision's special documentary, A Century of Dis-
covery, which aired to all of the company's affiliates. Of the numerous and
wonderful articles that appeared in print, the following were of particular interest:
The Scientist, "Cold Spring Harbor Tops Among Independent Labs:" Newsday,
The Land of DNA," a major article on the Lab and its history; and Innovations in
Oncology,"At the Cold Spring Harbor Laboratory," which is a comprehensive lay
report featuring lab scientists involved in cancer research.
Staff Changes
After two and one-half years, we said goodbye to the multitalented Dan
Schechter, who in September joined Darby & Darby, a law firm in Manhattan, as
a patent agent. As the Laboratory's first science writer, Dan established a stan-
dard for multitasking in Public Affairs. To this day, it is hard to figure out just how
he did what he did with a computer. His cancer brochure, The Good Fight, be-
came the mainstay of our effort to reach the Laboratory's lay audience.
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Ed Campodonico joined the staff in April 1990 to assist both Herb Parsons,
Director of Audiovisual, and Margot Bennett, Artist/Photographer. Ed's back-
ground includes a BFA from Long Island University, C.W. Post campus, and ex-
tensive work in audiovisual and photography both in school and in the private
sector.
Our new science writer, David Siegel, joined the staff in October. Dave has
an eclectic background. He received his BS in physics and astronomy from the
State University of New York at Stony Brook in 1984; an MS in astronomy from
Yale; and an MA in journalism, science, and environmental reporting from New
York University in 1990. David worked as a news intern at CBS, as a research in-
tern at WNET Innovations, and was a feature writer for Yale Science Magazine.
Rounding out the staff, Clare Bunce joined us in early 1990 as a part-time as-
sistant. Clare does a great job with all the office tasks that filter down from an
overworked and crowded staff. She was that extra edge we needed during the
final stages of Centennial planning.
Extra Effort Appreciated
I have received appreciation in abundance for my part in planning the Centen-
nial-there are always so many who need to be thanked, and a list would not be-
gin to express my gratitude. Those people know just how hard they worked, and
I want them to know that the Laboratory will always be thankful for their extra ef-
fort on its behalf. This was a special time at a very special place.
Susan Cooper
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TUMOR VIRUSES
At the close of 1990, the Tumor Virus Section was preparing to apply for renewal
of the large program project grant that has supported research in this area since
1972. As can be seen from the reports of the nine constituent groups, the ground
covered by this section has expanded considerably over the years. It now in-
cludes two new viruses, bovine papillomavirus and human immunodeficiency
virus, in addition to the time-honored adenovirus and simian virus 40, and it en-
compasses the cellular processes with which these viruses come into contact.
These processes include DNA replication, transcription, mRNA splicing, transla-
tion, and posttranslational modification, all of which are potential sites of dis-
turbance in malignancy as well as fundamental aspects of gene regulation in the
cells of humans and other animals. Also at the end of 1990, we prepared to bid
farewell to Ed Harlow, a member of this section for more than 8 years. His work
on protein-protein interactions, and particularly his discovery of the complex be-
tween adenovirus E1A proteins and the product of the cellular retinoblastoma
susceptibility gene, epitomized the power of the tumor viruses as probes of cel-
lular function and have made an indelible mark in fields as diverse as the cell
cycle, transformation, and transcription.
DNA SYNTHESIS
B. Stillman E. White
T. Tsurimoto
G. Bauer
S.P. Bell
S. Brill
J.F.X. Diffley F. Bunz
S.-U. Din K. Fien
A. Dutta Y. Marahrens
T. Melendy S. Smith
J.M. Ruppert
In dividing cells, the duplication of the genetic
material is a key event that is normally precise and
tightly controlled. There is a growing appreciation of
the notion that a breakdown in the control of cell
division increases the chance of damage to the
genome, including accumulation of mutations that
contribute to cancer progression. For this reason,
studies on DNA and chromosome replication may
provide valuable insight into the mechanisms of car-
cinogenesis. We continue to investigate both the me-
chanism and regulation of DNA replication using
both human cells and the yeast, Saccharomyces
cerevisiae. As in previous years, these two systems
are wonderfully complementary, resulting in substan-
tial progress.
T. Macdougall
N. Kessler
P. Sabbatini
L. Mellon
Mechanism of DNA Replication
G. Bauer, S. Brill, F. Bunz, K. Fien, N. Kessler,
T. Melendy, J.M. Ruppert, T. Tsurimoto, B. Stillman
The best system currently available to study the me-
chanism of DNA replication in eukaryotic cells is
simian virus 40 (SV40). SV40 contains a small cir-
cular genome that harbors a single unique origin of
DNA replication. The viral genome encodes a
protein, the SV40 large tumor antigen (T antigen),
that plays a number of essential roles in the replica-
tion of SV40 DNA. T antigen recognizes, binds to,
and locally unwinds the origin of DNA replication
and also functions as a DNA helicase (DNA unwind-
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ing enzyme) during DNA synthesis. The remaining
replication machinery is provided by the host cell,
and it is the identity and functions of these cellular
proteins that have been the focus of our attention dur-
ing the past 5 years. In the past year, we have
reconstituted the essential, core DNA replication ma-
chinery with highly purified proteins and have
determined the general mechanism of initiation and
elongation. In addition, we continue to identify func-
tional homologs of the human cellular DNA replica-
tion proteins from yeast cells to allow a genetic anal-
ysis of the replication apparatus.
REPLICATION FACTORS
In last year's Annual Report, we described in detail
the cellular proteins required for SV40 DNA replica-
tion in vitro. These proteins are: replication factor A
(RF-A), a multisubunit single-stranded DNA-binding
protein and polymerase a and S auxiliary protein;
replication factor C (RF-C), a DNA-dependent
ATPase that is also a primer/template-binding protein
and DNA polymerase a and S auxiliary protein;
proliferating cell nuclear antigen (PCNA), a
polymerase S auxiliary protein that stimulates RF-C
ATPase activity; DNA polymerase a and its associa-
ted primase subunits; DNA polymerase 8; and topo-
isomerases I and II. Although polymerase S had been
implicated in DNA replication by the requirement for
RF-C and PCNA, its participation in DNA replication
had not been directly shown. In the past year, we
have purified an essential DNA replication factor
(replication factor D, RF-D) and subsequently identi-
fied it as DNA polymerase S. Together with the pre-
viously described replication factors and im-
munopurified polymerase a/primase complex, we
have used this highly purified polymerase S to
reconstitute DNA replication in vitro.
MECHANISM FOR BIDIRECTIONAL DNA
REPLICATION
With the seven purified cellular replication factors
and SV40 T antigen, a series of detailed biochemical
analyses were conducted to determine their role in
DNA replication. The principle used was to omit in-
dividual factors or combinations of factors from the
reaction and characterize the resulting "phenotype"
by studying replication products. It was found that in
the absence of either T antigen, RF-A, or polymerase
a/primase complex, no DNA replication was ob-
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served, suggesting that polymerase a/primase was
responsible for the synthesis of the first strand at the
replication origin. It had been demonstrated that T
antigen and RF-A cooperate to unwind the replication
origin, and recent studies have demonstrated that ad-
dition of the polymerase a/primase complex is suffi-
cient for synthesis of the first nascent DNA at the
origin. In contrast, omission of either RF-C, PCNA,
or polymerase 8, or combinations of these, yielded
some DNA replication, but the products were ab-
normal. Short nascent DNA strands that correspond
to products from only one DNA strand (lagging
strand) were observed. DNA replication of the oppo-
site strand (leading strand) did not occur. These
results concur with observations made in previous
years when PCNA and RF-C were omitted from
replication reactions with crude extracts. Moreover,
they clearly demonstrate that the polymerase a/pri-
mase complex is responsible, at least in part, for
replication of the lagging strand and that polymerase
S synthesizes the leading strand at a replication fork.
Last year, we noted a striking similarity between
the replication factors RF-C and PCNA and the bac-
teriophage T4 proteins encoded by genes 44/62 and
45, respectively. These phage-encoded proteins func-
tion with the T4 DNA polymerase (gene 43) to
synthesize the leading strand at a replication fork. We
have now demonstrated that the phage T4 proteins
can substitute for RF-C, PCNA, and polymerase S in
a hybrid replication system. The phage proteins func-
tion with T antigen, human RF-A, and polymerase
a/primase to replicate DNA. These observations sug-
gest an extraordinary evolutionary conservation of
the replication functions. More importantly, because
mutations in the genes encoding the phage proteins
debilitate phage DNA replication in vivo, we suggest
that our biochemical studies using the SV40 system
have identified homologous proteins that function in
the replication of human cell DNA.
A MODEL FOR DNA REPLICATION
The studies described above suggested a novel me-
chanism for the initiation of SV40 DNA replication
that might be generalized for initiation of bidirec-
tional DNA replication in eukaryotic chromosomes.
The novel feature of this model, shown in Figure 1,
involves the switching of DNA polymerases at the
replication origin during initiation of leading-strand
DNA replication. We propose that polymerase
a/primase synthesizes the first nascent strand at the
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FIGURE 1 Initiation of bidirectional DNA replication by two
DNA polymerases.
replication origin. Because RF-C is a primer/template
recognition protein, it recognizes the 3 ' end of this
nascent strand and then binds PCNA. The RF-C/
PCNA complex displaces polymerase a and recruits
polymerase S. The RF-C/PCNA/polymerase S com-
plex functions as a processive replication complex
and continuously synthesizes the leading strand (see
Fig. 1).
Detailed biochemical analysis of the function of
RF-C and PCNA, as well as their effect on the func-
tion of polymerase a and 8, provides strong support
for this mechanism of initiation of DNA replication.
These studies include nuclease protection footprint-
ing and native gel electrophoresis of RF-C and RF-
C/PCNA complexes with DNA. RF-C is an unusual
DNA-binding protein that recognizes a specific struc-
ture (a primer/template junction) in a sequence-
independent manner. Once RF-C is bound to the
DNA, PCNA recognizes the RF-C/DNA complex
and binds adjacent to RF-C. This is an interesting
complex because PCNA does not, by itself, recognize
DNA. We have shown that formation of the RF-
C/PCNA complex at a primer/template junction, in
cooperation with RF-A, functions in the polymerase
switching step, thereby preventing polymerase
from copying the leading-strand template.
Our studies to date have reconstituted the rudi-
mentary core of the eukaryotic DNA replication ap-
paratus in vitro with purified proteins. We still need
to identify factors that are required for formation of
complete, covalently closed daughter DNA.
REPLICATION FACTORS FROM YEAST
To investigate the role of these replication factors
during cell chromosomal DNA replication, we have
searched for functional homologs of the human fac-
tors in the yeast, S. cerevisiae. This organism offers
the ability to combine biochemical and genetic meth-
ods to the problem of DNA replication. We have pre-
viously described the purification of yeast RF-A
(yRF-A) as a complex
ecular weights of 69K, 36K, and 13K. In the past
year, the genes encoding the three subunits of yRF-A
have been cloned and sequenced. All three genes are
essential; mutants lacking any one of them fail to
grow. The production of conditionally defective
mutations in these genes will enable us to determine
if they have a defect consistent with a block in
chromosomal DNA replication.
The gene encoding the 69K subunit is identical to
a gene, RPA1, that was isolated by R. Kolodner's
group at Harvard because it encodes a protein impli-
cated in genetic recombination. The gene encoding
the 36K subunit has previously not been identified,
and curiously, it is one of the few genes in S.
cerevisiae, other than ribosomal protein genes, that is
spliced. The predicted sequence of the yeast 36K sub-
unit shows 29% identity and 40% similarity with the
human 34K RF-A subunit, the sequence of which
was determined in T. Kelly's laboratory (Johns Hop-
kins). The gene encoding the RF-A 13K subunit is
also a novel gene, and the protein is unrelated to
others present in sequence databases.
In addition to the yRF-A replication factor, we
have identified and purified the S. cerevisiae RF-C
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replication factor, yRF-C. This factor cooperates with
yRF-A and yPCNA to stimulate the activity of yeast
DNA polymerase S in much the same way as RF-C,
RF-A, and PCNA cooperatively stimulate human cel-
lular DNA polymerase b. Isolation of the genes en-
coding the yRF-C subunits will allow a genetic anal-
ysis of the function of this replication factor in cel-
lular DNA replication.
Regulation of DNA Replication
S. Brill, S.-U. Din, A. Dutta, B. Stillman
In the past year, we reported that RF-A from human
and yeast cells was phosphorylated on serine residues
and that this posttranslational modification was cell-
cycle-regulated. The 34K subunit was not phosphory-
lated in the G., phase, but it was phosphorylated later
in the cell cycle. We have more precisely timed the
onset of the phosphorylation event to just prior to the
onset of DNA replication in S phase. This places the
onset of RF-A phosphorylation at an interesting and
critical regulatory stage in the cell cycle.
We have pursued a two-pronged approach to
determine whether the phosphorylation of RF-A
plays a role in the control of DNA replication. The
first, which is currently under way, is to make
mutants in both the human and yeast genes encoding
the 34K subunit that affect phosphorylation and study
the phenotype. A second approach is to identify the
RF-A kinases and determine if they perform a
regulatory function and influence RF-A activity.
Considerable progress has been made toward this
goal.
An RF-A kinase was found in an extract from hu-
man cells that phosphorylated RF-A on a subset of
the serines phosphorylated in vivo. Importantly, this
kinase activity was absent in extract prepared from
cells in the G1 phase of the cell cycle but was present
at later stages. This kinase was purified to
homogeneity. The kinase activity cofractionated with
a multisubunit protein complex consisting of a 62K
subunit and a doublet at 34K, with a 45K protein that
may associate with the other proteins. This subunit
structure suggested that the protein kinase was identi-
cal to the p34cdc2 kinase associated with a cyclin sub-
unit (62K), and subsequent studies with antibodies
confirmed this identification of the enzyme as the
cyclin B/p34cde2 kinase complex. The cdc2 protein
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kinase has been shown both genetically and bio-
chemically to be a major regulator of cell cycle pro-
gression by its association with a number of cyclins,
proteins that are synthesized and degraded in a
temporally controlled manner through the cell cycle
(see D. Beach's report in the Genetics Section). We
have demonstrated, in collaboration with D. Beach
and G. Draetta, that both the cyclin A and cyclin B
forms of cdc2 kinase will phosphorylate RF-A. The
challenge now is to determine what form of
cyclin/cdc2 kinase phosphorylates RF-A and at what
time in the cell cycle, in addition to identifying the
function of the phosphorylation.
Along these lines, we have shown a modest in-
crease in RF-A single-stranded DNA binding follow-
ing phosphorylation in vitro by purified cdc2 kinase.
Furthermore, a stimulation of origin unwinding by
RF-A and T antigen was also attributable to RF-A
phosphorylation in vitro by the p34cd.2 kinase, proba-
bly reflecting increased DNA binding. Current
studies are directed toward determining whether
these effects occur in SV40-infected cells during
SV40 DNA replication and in uninfected cells at S
phase.
Initiation of Chromosomal
DNA replication
S.P. Bell, J.F.X. Diffley, Y. Marahrens, B. Stillman
The SV40 system for studing DNA replication has
been invaluable for examining the mechanism of
DNA synthesis. These studies have relied on the
SV40 T antigen and are therefore of limited value for
understanding initiation of DNA replication in
eukaryotic chromosomes. To complement our studies
on yeast replication proteins, we have studied the
structure and function of a chromosomal origin of
replication in S. cerevisiae called ARS1. ARS1 was
selected because it confers on plasmid DNAs the
ability to replicate as a circular, minichromosome in
synchrony with the 16 cellular chromosomes and has
been shown by other investigators to function as a
chromosomal origin of DNA replication.
Comparison of the sequences of a number of ARS
elements revealed a highly conserved 11-bp "ARS
consensus sequence" that is essential, but not suffi-
cient, for ARS function. Several laboratories per-
formed deletion analyses on various ARS elements
including ARS1 to identify additional functional
domains. These studies, however, managed to define
only vaguely broad regions next to the ARS con-
sensus sequence as important.
To define this origin further, we substituted 8-bp
ARS sequences with the sequence 5 ' -CCTCGAGG-
3 ' that can be cut with the restriction enzyme Xhol.
Thirty-four such mutations were constructed to cover
179 by of a 185-bp ARS1 clone. Two substitutions,
both disrupting the ARS consensus sequence, abolish
origin function entirely. We tested origin efficiency
of the remaining 32 mutants by measuring plasmid
levels in yeast cultures after 14 generations of cell
growth. Clusters of mutants with reduced plasmid
levels defined three additional short sequences that
contribute to origin function. We named these addi-
tional domains Bl, B2, and B3 in descending order of
importance. Disrupting combinations of domains ei-
ther greatly reduces or abolishes ARS1 function.
DNA was synthesized that contained the four im-
portant domains, all correctly spaced, but with all
other DNAs scrambled. This "synthetic ARS" func-
tioned nearly as well as the natural origin, proving
that the four domains are sufficient for efficient ARS
function. Moreover, none of the domains (B1, B2, or
B3) successfully substituted for each other, suggest-
ing that they are functionally distinct.
Domain B3 overlapped with the footprint for
ARS-binding factor 1 (ABF1), a protein purified in
our laboratory and discussed in previous Annual
Reports. Point mutations that abolished ABF1 bind-
ing also abolished B3 activity, demonstrating that
ABF1 binding at ARS1 was responsible for this ac-
tivity. Because ABFI also has a known role as a tran-
scription factor, we replaced the ABF1-binding se-
quence with a sequence that binds a homologous
transcription factor called RAP1. Interestingly, the
binding of RAP1 restored domain B3 function. These'
results suggest that transcription factors that are
capable of binding to DNA may influence initiation
of DNA replication at chromosomal origins in a man-
ner similar to activation of a number viral origins.
We have continued to study the function of the
ABFI protein, particularly its role in DNA replica-
tion and transcriptional regulation. A clone of the
ABF1 gene has been used for defining a functional
domain structure for the ABFI protein. An initial sur-
prising result was that ABF1 contained two distinct
regions of the protein for site-specific DNA binding.
One region, when expressed alone, bound specifical-
ly to the ABF1-binding site, but with greatly reduced
affinity. Another region, when expressed alone,
bound nonspecifically to DNA in a zinc-dependent
manner. The two regions, when coexpressed on the
same polypeptide, recognized the ABF1-binding site
with the same specificity and affinity as the intact
ABF1 protein. These results suggest a novel bipartite
DNA recognition structure containing two different,
cooperating, DNA-binding domains. Further charac-
terization of this structure is under way.
Chromatin Assembly
G. Bauer, S. Smith, B. Stillman
In previous years, we had described a cell-free sys-
tem for assembly of correctly spaced chromatin dur-
ing DNA replication. In addition to the essential
DNA replication factors, novel chromatin assembly
factors are required to assemble the histones onto the
DNA. Last year, we described the purification and
characterization of one such factor, CAF-1. This mul-
tisubunit protein is required for the assembly of
histones onto the replicating DNA.
Biochemical fractionation of the remaining cell
extract has allowed separation of the chromatin as-
sembly reaction into two steps. During the first step,
CAF-1 targets the deposition of newly synthesized
histones H3 and H4 to the replicating DNA. This
reaction is dependent on and coupled with DNA
replication and utilizes the newly synthesized forms
of histones H3 and H4, which, unlike bulk histone
found in chromatin, do not bind to DNA by them-
selves. The H3/H4-replicated DNA complex is a
stable intermediate that exhibits a micrococcal-
nuclease-resistant structure and can be isolated by
sucrose gradient sedimentation. In the second step,
this replicated precursor is converted to mature
chromatin by the addition of histones H2A and H2B
in a reaction that can occur after DNA replication. On
the basis of these results, we have suggested a model
for the DNA-replication-dependent assembly of
chromatin and a role for CAF-1 in this process (Fig.
2). The requirement for CAF-1 in at least the first
step of the reaction suggests a level of cellular control
for this fundamental process. It is of particular inter-
est that CAF-1 is modified by phosphorylation, and
we are currently determining whether this modifica-
tion plays a regulatory role during chromatin assemb-
ly.
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FIGURE 2 A model for a two-step mechanism for chromatin assembly by CAF-1.
Functions of Adenovirus
El B Protein
E. White, P. Sabbatini
The adenovirus EIB gene is required for regulation
of viral gene expression in productively infected cells
and for oncogenic transformation. Last year, we
made some interesting discoveries that have greatly
enhanced our understanding of E1B protein fuction.
The E1B gene of adenovirus encodes two major
tumor antigens, the 19K and 55K proteins. The
coding regions for these proteins have been placed
under the control of heterologous promoters to as-
certain the role of individual EIB proteins in trans-
formation and their primary biological function.
These E1B plasmid expression vectors have led to
two significant findings: (1) Both E1B proteins pos-
sess transforming activity when cotransfected with a
plasmid encoding E1A, but it is the 19K protein that
confers anchorage-independent growth, and (2) the
42
E1B 19K protein has the unique and unusual ability
to associate with and disrupt the organization of two
distinct classes of intermediate filaments, cytoplas-
mic vimentin filaments and nuclear lamin filaments.
We propose and are preparing to test the hypothesis
that the biological function of the 19K protein in
transformation and productive infection is a direct
consequence of the perturbation of intermediate fila-
ments.
This year, we have expanded upon these results in
three areas. First, we have been identifying cellular
proteins, most likely intermediate filament proteins,
that directly interact with the 19K protein. Second,
we have continued our investigation of the role of
El B proteins in transformation, establishing whether
or not El gene products are capable of cooperating
with oncogenes other than E1A. Third, a mutational
analysis of the 19K coding region was performed to
identify important funtional domains responsible for
the activity of the protein in transformation and pro-
ductive infection.
We have begun to test the ability of E1B proteins
to cooperate with the products of other viral on-
cogenes. In a collaborative effort with Peter Howley
at the National Cancer Institute, we have discovered
that the E1B 19K protein can enhance the transform-
ing activity of the human papillomavirus type-16 E6
and E7 transforming genes. This finding establishes
that the transforming activity of the El B 19K protein
is not restricted to cooperation with the adenovirus
E1A gene and may represent a more universal func-
tion related to the development of human cancer.
Finally, mutational analysis has so far identified
an important region of the 19K protein required for
both transforming activity and intermediate filament
disruption. With one exception, mutations within a
conserved central region of the 19K protein eliminate
transforming activity of the protein. Therefore, a
single domain in the 19K protein may encode the
transforming function. Furthermore, a single substitu-
tion of an acidic glutamic acid residue for the basic
lysine at position 44 of the 19K coding region results
in simultaneous loss of transforming activity and the
ability to associate with and disrupt intermediate fila-
ments. This is readily apparent in double-label in-
direct immunofluorescence of transfected cells
transiently expressing either the wild-type 19K
protein or the mutant protein. Whereas the wild-type
protein localizes to the nuclear envelope and
cytoplasm and disrupts intermediate filaments, the
mutant protein is defective for nuclear localization
and the organization of intermediate filaments is.
completely unaffected. Whether this sequence of the
19K protein is a bone fide nuclear localization signal
is being explored.
In summary, the E1B 19K protein represents a
transforming protein with a novel function that will
be useful both for understanding a unique mechanism
of oncogenic transformation and for determining the
function of those cellular structures with which it in-
teracts, intermediate filaments.
PUBLICATIONS
Diffley, J.F.X. and B. Stillman. 1990. The initiation of
chromosomal DNA replication in eukaryotes. Trends
Genet. 6: 427-432.
Din, S., S.J. Brill, M.P. Fairman, and B. Stillman. 1990. Cell-
cycle-regulated phosphorylation of DNA replication fac-
tor A from human and yeast cells. Genes Dev. 4:
968-977.
Ng, L., G. Prelich, C.W. Anderson, B. Stillman, and P.A.
Fisher. 1990. Drosophila PCNA: Structural and func-
tional homology with its mammalian counterpart. J. Biol.
Chem. 265: 11948-11954.
Tsurimoto, T. and B. Stillman. 1990. Functions of replication
factor C and proliferating cell nuclear antigen: Func-
tional similarities of DNA polymerase accessory proteins
from human cells and bacteriophage T4. Proc. Natl.
Acad. Sci. 87: 1023-1027.
Tsurimoto, T., T. Melendy, and B. Stillman. 1990. Sequential
initiation Of lagging and leading strand synthesis by two
DNA polymerase complexes at the SV40 DNA replica-
tion origin. Nature 346: 534-539
White, E. and R. Cipriani. 1990. The role of adenovirus E1B
proteins in transformation: Altered organization of inter-
mediate filaments in transformed cells that express the
19-kilodalton protein. Mol. Cell. Biol. 10: 120-130.
In Press, Submitted, and In Preparation
Diffley, J.F.X. and B. Stillman. 1991. A close relative of HMG
1 in yeast mitochondria. (Submitted.)
Din, S. and B. Stillman. 1991. Immunological characteriza-
tion of RF-A, a human cell factor required for DNA
.replication. (In preparation.)
Dutta, A., T. Melendy, G. Draetta, D. Beach, and B. Stillman.
1991. cdc2 kinase directly activates a human cell DNA
replication factor, RF-A. (Submitted.)
Melendy, T.M. and B. Stillman. 1991. Purification of DNA
polymerase 5 as an essential SV40 DNA replication fac-
tor. J. Biol. Chem. 266: 1942-1949.
Smith, S. and B. Stillman. 1991. Stepwise assembly of
chromatin during DNA replication in vitro. EMBO J. 10:
971-980.
Smith, S. and B. Stillman. 1991. Immunological characteriza-
tion of CAF-1, a human cell factor required for chromatin
assembly during DNA replication in vitro. J. Biol. Chem.
266: (in press).
Stillman, B., S. Brill, K. Fien, T. Melendy, S. Din, and T.
Tsurimoto. 1991. Studies on eukaryotic DNA replication
using simian virus 40 as a model system. In Eukaryotic
DNA polymerases (ed. J. Engler and T. Wang). Sprin-
ger-Verlag. (In press.)
Tsurimoto, T. and B. Stillman. 1991. Replication factors re-
quired for SV40 DNA replication in vitro. I. DNA struc-
ture specific recognition of a primer-template junction
by eukaryotic DNA polymerases and their accessory
factors. J. Biol. Chem. 266: 1950-1960.
Tsurimoto, T. and B. Stillman. 1991. Replication factors re-
quired for SV40 DNA replication in vitro. II. Switching of
DNA polymerase a and 8 during initiation of leading and
lagging strand synthesis. J. Biol. Chem. 266: 1961-
1968.
White, E., R. Cipriani, P. Sabbatini, and A. Denton. 1991.
The adenovirus E1B 19K protein overcomes cytotoxicity
of the E1A proteins. J. Virol. 65: (in press).
43
MOLECULAR BIOLOGY OF BOVINE PAPILLOMAVIRUS
A. Stenlund M. Ustav
P. Szymanski
J. Alexander
E. Ustav
The papillomaviruses are a family of viruses that
have been isolated from a large variety of mammals.
Initially believed to be related to the polyomaviruses,
it is now clear that they form their own distantly re-
lated group. The group as a whole has some distinc-
tive characteristics. All of the papillomaviruses have
what appears to be a very high degree of tissue
specificity; a given virus type very frequently infects
only one tissue type. None of the papillomaviruses
give rise to a full productive (or lytic) cycle in tissue
culture cells. In some virus types, however, a part of
the viral life cycle can be studied. Bovine papil-
lomavirus type 1 (BPV-1) has become the prototype
virus for the papillomavirus group, since the BPV
genome can transform mouse C127 cells in culture.
In these transformed cells, the viral DNA is
maintained and replicates, as an episome, providing
model systems for gene expression, replication, and
transformation.
Apart from its importance as a prototype virus for
the pathogenic human viruses that cannot be readily
studied at the molecular level, BPV has attracted con-
siderable attention for its replication properties in tis-
sue culture cells. BPV shares with one other virus,
Epstein-Barr virus, the property that the viral DNA
can replicate as an episome with a stable copy num-
ber in transformed cells. The study of BPV DNA
replication offers several unique and interesting
aspects fundamentally different from replication in
the lytic viral systems which have been studied in
detail. These include questions about the control of
copy number and segregation and the involvement of
cellular mechanisms in regulation of viral replication.
Development of a Transient Assay
for BPV Replication In Vivo and
Determination of Viral Gene
Requirement for Replication
M. Ustav, A. Stenlund
One of the essential tools required for studies of BPV
DNA replication is an efficient short-term replication
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assay. The main problem in detecting short-term
replication of BPV in C127 cells is the low copy
number compared to that of lytic viruses. Therefore,
to detect replicating DNA, a large number of cells
must take up and replicate the DNA. Conventional
procedures for transfection of C127 cells yielded very
low transfection efficiencies. We therefore developed
an electroporation procedure that could be used to
deliver DNA into C127 cells with very high ef-
ficiency. In fact, 10-20% of the cells expressed trans-
fected markers. Using this procedure, we developed a
short-term replication assay for BPV that consisted of
transfecting BPV DNA by electroporation, followed
by harvest of low-molecular-weight DNA at time
points ranging from 2 to 6 days after transfection and
analysis of the DNA by gel electrophoresis and
Southern blotting. Replicated DNA was scored after
digestion with Dpnl, which will cleave nonreplicated
DNA. Using this assay, we have reexamined some of
the properties of BPV replication. Interestingly, the
accumulation of replicated DNA is biphasic. Initially,
replication during the first 48-72 hours proceeds at a
faster rate than at later times, when accumulation of
replicated DNA appears to increase at the same rate
as the cellular DNA. This result is consistent with the
results expected from a two-stage model in which ini-
tial amplification of the viral DNA is followed by
stable maintenance.
We determined which viral gene products were
required for replication by assaying a series of
mutants located throughout the early region of BPV
in the short-term replication assay. Frameshift muta-
tions in the E6, E7, and E5 open reading frames had
no effect on replication, whereas mutations in the El
and E2 open reading frames abolished replication
completely (Fig. 1, top). Using complementation ex-
periments, we showed that the mutations affected
trans-acting factors and mapped to two different
complementation groups. The same mutants were
tested in stable replication assays with similar results.
The E2 open reading frame encodes three related
polypeptides that all share the carboxy-terminal part
of the open reading frame. To determine which of
these polypeptides were important for replication, we
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FIGURE 1 (Top) Schematic figure showing the organization of the early region of
the BPV genome. (Open bars) Early open reading frames El-ES. Arrows labeled
P1 through P5 represent the five known promoters that transcribe the early region.
(Closed boxes) Location of mapped binding sites for the gene products from the
E2 open reading frame. (Bottom) Short-term replication assay using El and E2 ex-
pression vectors as the only source of viral trans-acting factors. A 3.2-kb on frag-
ment from BPV, lacking the coding sequence, was transfected either alone or to-
gether with either El or E2 expression vectors or together with both El and E2 ex-
pression vectors. The arrow marks the position of the replicating on fragment.
generated expression vectors encoding these three
polypeptides. To determine that the expression vec-
tors produced the predicted polypeptides, we ana-
lyzed the protein products produced in transient ex-
pression assays by in vivo labeling and immunopre-
cipitation with polyclonal antiserum raised against
E2. When tested for complementation of an E2
mutant in a short-term replication assay, only the ex-
pression vector expressing the full-size trans-
activator form of E2 could complement the defect, in-
dicating that this form, a 48-kD polypeptide, was re-
quired for replication.
The results of assaying mutations throughout El
indicated that the replication function was encoded
by the entire open reading frame. We therefore con-
structed several expression vectors and assayed them
for their ability to complement mutations in the El
open reading frame. Several of the vectors could
complement the El defect, and we could identify by
immunoprecipitation the complementing polypeptide
as a 72-kD protein that was encoded by the entire El
open reading frame. A polypeptide of similar
molecular mass, 69-72 kD, has recently been identi-
fied in BPV-transformed cells. To determine whether
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FIGURE 2 Comparison of the sequences at the BPV on with the corresponding region from four other papil-
lomaviruses. The boxed sequences represent the region with the highest degree of homology.
any other viral gene products were required for
replication, we deleted all of the early coding se-
quences from the viral genome and assayed the
resulting fragment for its ability to replicate in the
presence of the El and E2 expression vectors (Fig. 1,
bottom). This 3.5-kb fragment replicated to wild-type
levels. Replication was completely dependent on both
El and E2, showing that the two proteins were neces-
sary and sufficient for replication of BPV in C127
cells.
cis-Acting Sequences Required
for BPV Replication
M. Ustav, E. Ustav, A. Stenlund
In conjunction with the determination of which viral
factors are required in trans for replication, we have
also conducted a search for the cis-acting viral ele-
ments that are involved in replication. Our approach
has been very simple. We have cotransfected C127
cells with El and E2 expression vectors to provide
trans-acting factors (see above), together with sub-
genomic restriction fragment mixtures of the BPV
genome. Replication was then assayed in the short-
term replication assay, and fragments that were
capable of replication under these conditions could
easily be identified. We found that for any given
digest, only one fragment was replicated, indicating,
that a single region was required for replication. In
addition, all fragments capable of replication had
some sequences in common. For technical reasons,
detection of replication of very small fragments is
difficult, i.e., small fragments are obscured by the
Dpnl cleavage products. With this approach, there-
fore, the smallest replicating fragment that we could
detect was 1.5 kb.
Deletions in the 1.5-kb region in the context of a
larger fragment showed that the sequences required
for replication were confined to a small region
around a unique Hpal site. That this region was both
46
necessary and sufficient for replication was shown by
the fact that a cloned 105-nucleotide-long Alul frag-
ment, which included the unique Hpal site, replicated
in an El- and E2-dependent manner in C127 cells.
Replication of this construct was destroyed by inser-
tion of an Xbal linker into the Hpal restriction site,
confirming the importance of the sequence at the
conserved Hpal site (Fig. 2). To confirm the impor-
tance of the putative on region in the context of the
whole viral genome, we inserted an Xbal linker into
the Hpal site of the viral DNA and assayed the
mutated construct for replication in C127 cells. The
construct failed to replicate even when cotransfected
with the wild-type BPV genome as a source of trans-
acting factors. The mutant also failed to replicate in
stable transformation assays when cotransfected with
the wild-type BPV genome, indicating that this
region plays an important role at all stages of the
viral life cycle.
The sequences surrounding the minimally re-
quired Alul fragment in BPV have quantitative ef-
fects on replication even though these sequences are
not essential for replication. This is especially true for
the sequences located on the upstream side of the
Hpal site, in the so-called upstream regulatory region
(URR) that serves as an E2-dependent enhancer for
transcription. The relatively small effects on replica-
tion of deletions in this region are enhanced consider-
ably when the wild-type genome is present as a com-
petitor for replication. Our preliminary results thus
indicate that the sequences within the URR can aug-
ment replication and that in addition to its role in
transcription, the URR region can serve as an auxil-
iary sequence for replication.
Host Range for BPV Replication
M. Ustav, A. Stenlund
A characteristic of the papillomaviruses is the very
limited host and cell-type range that they exhibit.
Very little is known about what determines this
restriction, since only a few types of papilloma-
viruses will reproduce any part of their life cycle in
tissue culture cells. BPV has the widest host range
and has been shown to replicate in, and transform,
mouse C127 and NIH-3T3 cells, Rat 2 cells, hamster
embryo fibroblasts (HEFs), and primary bovine con-
junctival cells. For SV40 and polyomavirus, the
restriction on host range is at least partly due to
restrictions directly on viral DNA replication. It has
been shown that the interaction between T antigen
and DNA polymerase/primase appears to be species-
specific. To determine whether this was the also case
for BPV, we tested several established primate cell
lines for their ability to support BPV replication in a
short-term replication assay. None of these cell lines
(CV-1, COS-7, 293, He La) replicated the viral DNA
to detectable levels. To test if this restriction was due
to limitations in gene expression, we utilized the El
and E2 expression vectors that are driven by the
cytomegalovirus (CMV) immediate-early promoter
(which is active in most cell types) and cotransfected
these with a BPV restriction fragment containing the
on elements. In these cases, we could detect replica-
tion in all tested primate cells, including He La, 293,
CV-1, and COS-7 cells. The efficiency of replication
was similar to the efficiency seen in C127 cells, as-
suming that the transfection efficiency for these dif-
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ferent cell lines was not widely different. This result
indicated that some aspect of expression of the viral
factors El and E2 are limiting for replication. When
these two viral factors are provided, the cellular ma-
chinery for replication is capable of replicating BPV
DNA. Further analysis using mutants in the BPV
genome has shown that the expression of both El and
E2 from the viral genome appears to be restricted in
primate cells, since both of these gene products must
be supplied from heterologous expression vectors to
allow for replication.
Role of the E2 Enhancer
in Viral Gene Expression
P. Szymanski, A. Stenlund
Analysis of viral gene expression has been performed
mainly in BPV-transformed cells or with isolated
subgenomic fragments linked to the chloramphenicol
acetyltransferase (CAT) gene. This means that even
though viral gene expression in transformed cells has
been extensively studied, very little is known about
immediate-early gene expression from the intact viral
genome. With the aid of the highly efficient elec-
for the first time been
able to analyze transient gene expression from the in-
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FIGURE 3 Response of the P2-P5 promoters to the trans-activator E2. The BPV genome
was cotransfected with varying amounts of E2 expi"ession vector, and transcription was
measured from each promoter using an RNase protection assay. The RNA levels in ar-
bitrary units are plotted against the quantity (micrograms) of cotransfected E2 expression
vector.
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tact viral genome in mouse C127 cells. We have de-
veloped specific RNA probes to detect transcripts in-
itiated at four of the early promoters, which allows us
to analyze expression from these promoters simulta-
neously. Using this procedure, we have shown that
the transient expression pattern from the viral
genome is similar to the expression pattern that is
seen in stably transformed cells. Furthermore, we
have shown that the E2 inducible enhancer present in
the upstream regulatory region of BPV is responsible
for activating the four early promoters in an E2-
dependent fashion (Fig. 3). In addition, by analyzing
a large number of deletion mutants in the URR for
their effect on the four promoters, we have
determined that the enhancer is functionally
redundant. Our studies have also shown that none of
the other known gene products from the viral genome
have any effect on transcription from the viral
promoters. This establishes, that the E2 system func-
Lions as the master regulator for viral gene expres-
sion.
PUBLICATIONS
Stenlund, A. and M. Botchan. 1990. The E2 trans-activator
can act as a repressor by interfering with a cellular tran-
scription factor. Genes Dev. 3: 510.
In Press, Submitted, and In Preparation
Szymanski, P. and A. Stenlund. 1991. The bovine papil-
lomavirus E2-dependent enhancer is redundant and
regulates transcription from all early promoters in their
natural context. (In preparation.)
Ustav, M. and A. Stenlund. 1991. Transient replication of
BPV-1 requires two viral polypeptides encoded by the
El and E2 open reading frames. (in press).
Ustav, M., E. Ustav, and A. Stenlund. 1991. BPV replication
is directed from a 105 by minimal sequence element.
(In preparation.)
ADENOVIRUS TRANSFORMING FUNCTIONS
T. G rodzicker S. Abraham P. Yaciuk
E. Moran Y. Rikitake M. Carter
H.-G.H. Wang
For the past several years, our primary goal has been
to understand the genetic and biological mechanisms
that are the basis of adenovirus ElA transforming
functions. In previous years, we have demonstrated
that the ElA protein products encode two autono-
mous transforming functions localized in separate
regions of the E1A proteins (see Fig. 1). The trans-
forming function associated with domain 2 is linked
with the ability of domain-2 residues to bind the pro-
duct of the cellular retinoblastoma (RB) tumor sup-
pressor gene. The transforming function localizing to
the ElA amino terminus is linked with the ability of
the ElA products to bind an unidentified cellular pro-
duct of 300 kD. The extraordinary degree of indepen-
dence that exists between the two functional domains
is emphasized by the ability of domain-2 and amino-
terminal deletion mutants to cooperate in trans, in a
translation-dependent manner, to induce cellular
transformation.
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T-antigen Complementation
of the E1A Amino-terminal
Function
P. Yaciuk, M. Carter, E. Moran
In previous years, we have shown that E1A domain 2
constitutes a discrete genetic element that is common
to the transforming proteins of other classes of DNA
tumor viruses. We demonstrated this relationship spe-
cifically in SV40 T antigen, and it was subsequently
shown by other investigators to exist in the human
papillomavirus E7 gene products as well. As the
autonomous nature of the El A amino-terminal trans-
forming function became clearer, it became of inter-
est to determine whether other transforming products
such as SV40 T antigen encode a functional analog of
the E1A amino-terminal function. In last year's An-
nual Report, we described preliminary evidence in-
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FIGURE 1 Summary of E1A protein structure. The E1A
proteins contain three domains of highly conserved amino
acid sequence (indicated in the upper bar) alternating
with less-conserved regions. Conserved domain 3 is
unique to the largest (13S) E1A splice product. Large
segments of the E1A proteins can be deleted without im-
pairing transformation function severely. Three such dele-
tions are indicated by the black areas in the lower bar.
The numbers above the bars indicate the positions of
amino acid residues. The boundaries of the E1A se-
quences required for p300 and pRB binding are indicated
below the bars. Various other E1A-associated proteins re-
quire similar sequences as pRB, but no associated
proteins other than p300 appear to require the extreme
amino-terminal sequences.
dicating that SV40 T antigen does, indeed, encode a
function complementary to the biological activity en-
coded by the amino-terminal region of the E1A pro-
ducts. During the past year, we have confirmed and
extended these results.
We have found that an El A amino-terminal
mutant can be complemented in trans for transform-
ing activity by a T antigen mutant that lacks the
entire domain-2 homology, shows no pRB-binding
activity, and, by itself, cannot transform primary
cells. Neither the pRB nor the p53-binding activity of
T antigen is sufficient to substitute for the E1A
amino-terminal function. The complementing T-
antigen function can, however, be inactivated by a
deletion near the T-antigen amino terminus (construct
obtained from Dr. J.M. Pipas at the University of
Pittsburgh) . The trans-cooperating activity shown by
the heterologous combination of E1A and T-antigen
mutants is as efficient as the trans-cooperating ac-
tivity shown by the combination of individual El A
domain mutants. The demonstration that SV40 T
antigen encodes a biological activity that is func-
tionally equivalent to the transforming activity lost by
deletion of the E1A p300-binding region significantly
extends the known relationships between the DNA
tumor-virus-transforming proteins and supports the
prediction that p300 plays an important role in the
regulation of cell growth.
E1A-dependent Cell Cycle Effects
Correlated with Induction of
cdc2 Expression
H. -G.H. Wang, E. Moran
The recognition that El A encodes two separate func-
tions with specific cell cycle effects provides impor-
tant genetic tools that will now allow us to separate
and analyze the biochemical steps by which the ElA
products control the expression of cellular products in
such a way as to activate resting cells.
A major goal for us now is to identify and charac-
terize the specific cellular targets with which E1A in-
teracts to mediate cell cycle activity. Several years
ago, our laboratory and others showed that the cell-
growth-regulating activities of the El A gene are in-
dependent of the major E1A transcriptional trans-
activation activity that localizes to domain 3. Thus, it
is likely that study of cellular products whose expres-
sion is induced independently of domain-3 function
will lead to a better understanding of the E1A-
mediated activities underlying the transition from
quiescence to active proliferation. In recent years, we
have identified two cellular products, intimately asso-
ciated with cell growth, whose expression is induced
by E1A independently of the well-characterized E1A
trans-activation function. One of these is the DNA
replication factor known as proliferating cell nuclear
antigen (PCNA). The other is the mammalian
homolog of the yeast cell-cycle-regulating gene,
cdc2, which is believed to play a central role in mam-
malian cell cycle regulation.
Because the p34cdc2 serine/threonine kinase is
believed to play such a central role in cell cycle con-
trol, the regulation of expression and activity of this
product in response to E1A transforming domains is
now a particular focus of this project. Of special in-
terest is the recent evidence from several laboratories
suggesting that p34cdc2 is the pRB kinase: The RB
protein sequence includes several consensus p34cdc2
substrate recognition sites, pRB can be phosphory-
lated by p34cdc2 in vitro, and cell extracts can be
depleted of pRB kinase activity by addition of a-
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p34cdc2 antibodies. Current models of pRB function
propose that phosphorylation inactivates the cell-
growth-suppressing effect of pRB. The link between
3 cd c 2 and pRB phosphorylation suggests the pos-
sibility that, in addition to any direct effects the E1A
products may exert through actual physical associa-
tion with the RB products, the El A products may be
able to release pRB-mediated growth suppression in-
directly by inducing cdc2 activity. It has long seemed
likely that the E1A products have the capacity to
mediate cell cycle activity in the absence of the pRB-
binding function; even before the principal E1A
A
9S 12S.WTrii
r%
B
a - Histone HI
sessig -pRB
1 2 3 4 5
12S.928
ct ON n
11114 - Histone HI
- pRB
100
90
80
70
60
rf)
O
x50
40
domain-2-associated cellular protein was identified as
the pRB product, we had shown that E1A domain 2,
although absolutely required for transforming activity
and pRB binding, is largely dispensable for E1A-
mediated induction of DNA synthesis in quiescent
cells. E1A-mediated induction of PCNA expression
is independent of both domain-2 and domain-3 func-
tion. If E1A-mediated induction of cdc2 is similarly
independent of domain-2 and domain-3 function, this
might represent an alternative mechanism by which
ElA could mediate entry into the cell cycle.
To explore this possibility, and to elucidate the
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FIGURE 2 Induction of cdc2 activity and pRB phosphorylation mediated by a domain-2 negative
mutant. At various times after infection of primary BRK cells with 12S.VVT or 12S.928 (a domain-2
mutant, non-RB-binding virus), cdc2 kinase activity was assayed by immunoprecipitation of the
cdc2 protein from specific cell extracts, followed by reaction with histone H1 substrate in the
presence of [y- 32P]ATP. The phosphorylation state of pRB was monitored in a duplicate set of in-
fections by in vivo 32P-pulse-labeling, followed by specific immunoprecipitation. Induction of cdc2
kinase activity correlates closely with pRB phosphorylation in both sets of infections. Clearly,
though, induction of cdc2 activity and pRB phosphorylation occur several hours later in the
12S.928 infection compared with the 12S.VVT infection. A third set of infected cells was labeled for
2-hr pulses with [3H]thymidine to monitor the induction of DNA synthesis. The slower induction of
cdc2 kinase activity and pRB phosphorylation in the 125.928-infection correlate closely with a
slower onset of DNA synthesis in 12S.928-infected cells. The level of DNA synthesis in 12S.928-
infected cells eventually reaches the same level as that in 12S.VVT-infected cells, and at this point,
the degree of pRB phosphorylation is similar in either infection. The cdc2 histone kinase activity in
12S.928-infected cells does not increase to the same levels reached in 12S.VVT infection,
presumably because beyond 24 hr postinfection, the 12S.VVT levels of cdc2 kinase activity reflect
a contribution from mitotic cdc2 activity, which represents a dramatic increase.
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mechanisms underlying the biological events directed
by E1A, we have monitored the expression of cdc2
and the RB products in primary cells stimulated by
wild-type ElA and by selected ElA mutants that in-
duce abortive cell cycle progression. (Some of these
experiments were done in collaboration with Dr. G.
Draetta at the EMBL Institute in Heidelberg.) We
have found that, in addition to binding the RB pro-
duct, the 12S E1A products can actually induce
phosphorylation of pRB in normal quiescent cells.
The induction of pRB phosphorylation correlates
with E1A-mediated induction of p34cdc2 expression
and kinase activity, consistent with the possibility
that p34cdc2 is an RB kinase. Expression of SV40 T
antigen induces similar effects. Induction of pRB
phosphorylation is independent of the pRB-binding
activity of the E1A products: E1A domain-2 mutants,
which do not bind detectable levels of pRB, remain
competent to induce pRB phosphorylation and to ac-
tivate cdc2 protein kinase expression and activity (see
Fig. 2). Domain-2 mutants induce wild-type levels of
pRB phosphorylation and host-cell DNA synthesis,
yet fail to induce cell division. These results imply
that direct physical interaction with pRB is not re-
quired in the early stages (pre-S phase) of E1A-
mediated cell division. Significantly, these results
also imply that pRB phosphorylation occurring dur-
ing S phase is not, of itself, sufficient to allow quies-
cent cells to divide. We infer from these results that
the E1A products do not need to bind pRB in order to
stimulate resting cells to enter the cell cycle. Indeed,
a more important role of the pRB-binding activity of
the E1A products may be to prevent dividing cells
from returning to Go.
The demonstration that the E1A products can in-
duce expression of Gi products independently of
domain 2 (and domain 3) suggests that this activity
can be expressed by the amino-terminal active site,
which is linked with p300 binding. It is possible that
induction of GI genes is a property of the amino-
terminal active site, whereas pRB binding and the
ability to induce progression from S phase through
mitosis are properties of domain 2. However, we
have found that deletion of either the amino-terminal
region or domain 2 leaves the ability to induce cdc2
expression and activity and to induce pRB phos-
phorylation intact, albeit with slower kinetics. Only a
double mutant, combining mutations in both the
amino terminus and domain 2, is devoid of these ac-
tivities. These results imply that the ability to induce
G, gene expression and pRB phosphorylation is a
redundant function, a property of either the amino-
terminal or the domain-2 active sites, whereas the
mitogenic activity of E1A requires that both sites be
functionally intact. These results suggest that p300
binding, like pRB binding, is linked both with induc-
tion of Gi gene expression and with some function
required for progression from S phase through
mitosis. Our plans now are to identify and delineate
the role of the p300 product. Preliminary progress
toward that goal is described further below.
Use of E1A to Analyze Steps
in the TGFp-I-induced
Signaling Pathway
S. Abraham, M. Carter, E. Moran
Separation of the amino-terminal and domain-2 trans-
forming functions has also provided compelling ge-
netic evidence for a role of the retinoblastoma tumor
suppressor gene in the pathway of growth inhibition
induced by transforming growth factor 131 (TGF(31).
During the past year, we have found, in collaboration
with Drs. Peter Howley and Hal Moses, that expres-
sion of the wild-type E1A products completely
blocks the growth-suppressing effects of TGF[31 in
epithelial cells, including the ability of TGFP1 to
repress expression from the myc promoter. The
ability to block TGE131-mediated repression of myc
promoter activity is lost if the domain-2 pRB-binding
function is inactivated in ElA. The ability to block
the myc-suppressing effects of TG931 appears to be a
specific effect of domain 2, because this ability is not
lost in an E1A amino-terminal deletion, even though
this mutant has lost all ability to induce cell growth
or transformation. These results imply that TGF131
may function by activating pRB, presumably by pre-
venting pRB phosphorylation (possibly by decreasing
cdc2 kinase activity), and that E1A binding to pRB
negates the effects of dephosphorylation. Suppression
of pRB phosphorylation in the presence of TGFI31
was demonstrated subsequently in Dr. J. Massague's
laboratory, and supression of cdc2 kinase activity in
the presence of TGF131 has been reported recently
from Dr. E. Leof's laboratory.
We are continuing to study the relationship be-
tween the TGFI31-blocking activity of ElA and the
ability of the ElA products to induce DNA synthesis.
Our results suggest that E1A-mediated induction of
p34cdc2 kinase activity may play a role in the ability
of E1A to counteract the effects of TGFI31. In partial
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contrast to the myc-CAT (chloramphenicol acetyl-
transferase) transient expression results, we have
found that infection with domain-2 mutant viruses is
sufficient to protect DNA synthesis activity substan-
tially in TGF[31-treated cells, implying indirectly that
physical binding of pRB by El A is not absolutely re-
quired for El A to block pRB function. On the basis
of the studies described immediately above, we
postulated that El A induction of cdc2 kinase activity
may be a means by which E1A can abrogate the ef-
fects of TGF(31. We have found that E1A does in-
deed induce cdc2 kinase activity in TGF(31-sensitive
cells. In the presence of E 1 A, high levels of kinase
activity are maintained even in the presence of
TGF(31, whereas in the absence of El A, cdc2 kinase
activity is sharply reduced by treatment with TGF(31.
To explore the mechanism of TGF(31-mediated sup-
pression of cdc2 activity, we assayed cdc2 expression
levels. These results show that TGF(31 suppresses
cdc2 expression as well as cdc2 kinase activity; cdc2
expression levels are maintained, however, if El A is
present during TGF(31 treatment.
Expression of both wild-type and domain-2
mutant (non-RB-binding) El A resulted in the
maintenance of p34cdc2 histone H1 kinase activity, as
well as the maintenance of phosphorylation and
synthesis of p34cdc2, in the presence of TGF(31. In
addition, the domain-2 mutant virus was also capable
of maintaining pRB in a phosphorylated state even in
the presence of TGF(31. These results suggest that
adenovirus E1A may function both directly by se-
questering pRB, preventing pRB activity, and by in-
tervening in the natural cellular pathway by which
TGF(31 activates pRB. Either mechanism of interven-
tion may be sufficient to overcome TGF(31- mediated
growth inhibition.
p300: Purification and Antibodies
P. Yaciuk, E. Moran
The results of our cell cycle studies imply strongly
that the unidentified p300 cellular product plays a
major role in the biological mechanisms by which
E1A induces cell-cycle-specific gene expression and
cell growth. The indication that other DNA tumor
virus proteins, such as SV40 T antigen, encode a
function biologically analogous to p300 binding sup-
ports the evidence that p300 is involved in a central
control pathway. The identification and characteriza-
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tion of the E1A-associated p300 product are now a
major goal of our laboratory.
Our goal of identifying and characterizing p300
has focused largely on obtaining specific antibodies
that recognize this product. We have recently suc-
ceeded in raising high-affinity p300-specific rabbit
polyclonal antiserum. The antiserum, raised against
human p300, recognizes p300 in both human and ro-
dent cells. Peptide digest analysis confirms that the
300-kD protein species recognized by the antiserum
is authentic E1A-associated p300 (see Fig. 3). Com-
parison of antibody-bound p300 with E1A-associated
p300 indicates that the majority of detectable p300 is
associated with E1A in both newly infected cells and
stably transformed cells. p300 is synthesized in both
quiescent and proliferating cells and appears to be a
fairly stable cellular protein with a half-life greater
than 10 hours in either the presence or absence of
E1A.
p300 is a phosphoprotein, and we find that it is
actively phosphorylated in both quiescent and grow-
ing cells. However, in partially purified mitotic cell
populations, we detect a form of p300 with decreased
electrophoretic mobility, suggesting that there is an
additional modification specific to mitotic cells. We
have found a similar slower-migrating species
coprecipitating from 32P-labeled infected mitotic
cells isolated either by nocodazole treatment, by
mitotic shake off, or by elutriation, so this effect does
not appear to be an artifact of drug treatment. We
have also seen this form in all cell lines examined
and in both the presence and absence of ElA expres-
sion. Analysis by silver-staining indicates that at least
half of E1A-associated p300 is in the higher-
molecular-weight form in mitotic cells. The mitotic-
specific form of p300 is greatly reduced by treatment
with potato acid phosphatase, implying that a
phosphorylation event is involved in the generation
of the mitotic-specific form. The mitotic-specific
form of p300 shows a near-identical partial
proteolytic digest pattern to p300 from un-
synchronized cells. Significantly, however, we ob-
serve two additional peptide fragments that appear to
be specific for the mitotic form of p300. The specific
appearance of these peptide fragments in digests of
the mitotic p300 form is reproducible, and we are
continuing to investigate the nature of these peptides.
We also plan to determine whether any biological or
biochemical properties of p300 vary with its phos-
phorylation state.
The availability of specific antiserum represents
an important tool that we can now use to probe ex-
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FIGURE 3 Analysis of p300-specific rabbit immune serum. (A) An immune bleed
was withdrawn from a rabbit 2 weeks after a second injection of p300. 32P-labeled
293 cell extracts were immunoprecipitated with preimmune serum (lane 1), serum
from the test bleed (lanes 2-4), or E1A-specific monoclonal antibody supernatant
(lanes 5-?). An immunoprecipitate with control monoclonal antibody supernatant
(pAb419) is shown in lane 8. The positions of the E1A products, and the predomi-
nant E1A-associated products including p300, are shown on the right. Reactions
were done in triplicate to provide material for V8 peptide digests. The immune
serum specifically immunoprecipitates a phosphoprotein species migrating in-
distinguishably from the E1A-associated p300 phosphoprotein. (B) The 300-kD
bands (lanes 2-7) were cut out of the gel shown in A and subjected to V8
protease digestion. As a control, p107 and an E1A band were also excised and
subjected to V8 digestion. (Lanes 1-3) Digests of the immune-serum-precipitated
bands; (lanes 4-6) E1A-affinity-precipitated p300 bands. The amounts of V8
protease used in the reactions are indicated. The peptide pattern generated from
the immune-serum-precipitated p300 species exactly matches that generated
from E1A-affinity-precipitated p300. The control digests generate very different
patterns.
pression libraries in order to obtain a cDNA clone
corresponding to p300. Obtaining this clone will
enable us to identify and sequence p300 and to probe
its molecular function with a variety of approaches.
p300: DNA-binding Activity
Y. Rikitake, E. Moran
With the availability of purified p300, we have al-
ready begun to characterize the in vitro biochemical
properties of this product. A variety of approaches to
this question are possible, but the genetic evidence
suggesting that p300 plays a basic role in the regula-
tion of gene expression prompted us to concentrate
on the possibility that p300 is a DNA-binding
protein. We have now obtained a great deal of
preliminary biochemical evidence suggesting that
p300 does, indeed, bind to DNA with at least some
degree of specificity. We have found that p300 binds
double-stranded DNA in a nitrocellulose-binding as-
say. Gel-shift assays have confirmed the ability of
p300 preparations to bind DNA, even in the presence
of high levels of competing nucleic acid.
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Analysis of total cellular protein extracts on
DNA-cellulose columns indicates that a significant
portion of p300 -is- 'retained specifically on the
columns until the high-salt elution fractions, confirm-
ing that p300 has DNA-binding activity. Purified
p300 shows similar salt-stable binding affinity on
DNA-cellulose. p300 binds both single- and double-
stranded DNA with similar efficiency. We are
engaged in additional studies to determine whether
there is a specific nucleotide recognition sequence in-
volved in the interaction of p300 with DNA. To ex-
amine the sequence specificity of p300 binding to
DNA, we selected possible binding sites for p300
using a polymerase chain reaction (PCR)-amplified
oligonucleotide selection method. We synthesized a
50-bp oligonucleotide encoding terminal restriction
enzyme recognition sites bracketing random se-
quences. This double-stranded oligonucleotide was
chromatographed through a cyanogen bromide
(CNBr)-linked p300-Sepharose column. p300 affin-
ity-selected oligonucleotides were cloned and se-
quenced. Of 17 sequenced clones, 16 contained a se-
quence closely related to a 5-bp consensus sequence.
p300 shows stronger DNA-binding activity with the
affinity-selected oligonucleotides than with random
sequence oligonucleotides in a nitrocellulose-filter-
assay.
Although these results indicate that p300 DNA-
binding activity is relatively nonspecific under less-
stringent conditions, preferential binding to specific
sequences can be detected under more-stringent bind-
ing conditions. We are continuing to explore the
biological significance of the DNA-binding activity
we observe in p300.
Fine-structure Analysis of the
Amino-terminal Active Site
and Conserved Region 1
M. Carter, E. Moran
One goal of our laboratory is to define the functional
boundaries of the ElA amino-terminal active site by
constructing and analyzing deletion mutations. Our
deletion analysis, combined with others, has now
restricted the boundaries of this active site to two
regions, residues 1-25, and a noncontiguous segment
from residue 36 to 76 that coincides with conserved
region 1 (see Fig. 1). The surprising finding that the
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extreme amino terminus of E1A (outside the highly
conserved sequences) is essential for transforming
function has interesting implications. The localization
of the amino-terminal active site allowed us to
demonstrate, in agreement with other studies, that the
amino-terminal function is independent of the RB-
product-binding function and correlates with binding
of the unidentified p300 product. The required region
from residue 1 to 25 is linked with binding only
p300, whereas the region from residue 36 to 76 ap-
pears to be involved in the binding of almost all E1A-
associated proteins, including p300 and pRB.
The observation that the E1A region extending
from residue 36 to 76 is involved in binding both the
amino-terminal-binding protein, p300, and the
domain-2-binding proteins that include pRB raises
several interesting questions. One important question
is whether p300 and pRB bind to the same, or dif-
ferent, residues within the region from 36 to 76. The
deletion mutants that have been examined to date are
not sufficiently specific to address this question. We
have approached this question by constructing and
analyzing smaller deletions and specific single mis-
sense mutations within the area of interest. This anal-
ysis is still in progress; however, substantial
preliminary results indicate that p300 and pRB asso-
ciate with distinctly different subregions of conserved
region 1. Although we have not formally ruled out
the possibility of some overlap in required binding
sequences, it appears that the required pRB-binding
region is limited to residues between 36 and 55,
whereas the required p300-binding region is limited
to residues between 55 and 73. Deletions or missense
mutations that are confined to either of these sub-
regions abrogate the binding of only one or the other
of these two E1A-associated proteins. This conclu-
sion is supported by analysis of the ability of specific
monoclonal antibodies that bind to E1A within con-
served region 1 to block the binding of p300 or pRB.
A monoclonal antibody whose binding site lies
within E1A residues 15-50 blocks E1A association
with pRB but not with p300. Conversely, a
monoclonal antibody whose binding site lies within
E1A residues 68-85 blocks the binding of p300 but
not pRB.
A second important question that arises from the
observation that p300- and pRB-binding sites within
conserved region 1 can be separated is whether con-
served region 1 is required in ElA transforming func-
tions for its p300-related binding activity or its pRB-
related binding activity or both. Experiments
designed to answer this question are now in progress.
Influence of El A on E2F
Cellular Transcription
Factor Complexes
M. Carter, E. Moran [in collaboration with
P. Raychaudhuri, S. Bagchi, and J.R. Nevins,
Duke University Medical Center]
The generation of new and more-specific E1A muta-
tions has also proved useful in a collaborative study
done with Dr. Joseph Nevins aimed at understanding
the significance of the ability of the E1A products to
dissociate, or inhibit formation of, transcription com-
plexes involving the E2F cellular transcription factor.
The ability of El A to activate E2F is independent of
domain 3, raising the possibility that activation of this
transcription factor may be related to E1A-mediated
gene activation involved in cell cycle activation. We
have examined the ability of a panel of ElA con-
structs expressing mutations covering the entire
region upstream of domain 3 to influence the forma-
tion of E2F transcription complexes. We have found
that E1A mutants with defects in conserved region 1
or conserved region 2 are inactive for E2F complex
dissociation, whereas deletions within the amino-
terminal region have no effect on the activity, nor do
mutations localized between the two conserved
domains.
Isolation and partial purification in the Nevins
laboratory of a cellular factor designated E2F-BP,
which associates with E2F to generate the E2F com-
plex, have permitted a more-detailed analysis of the
mechanism of E1A action. Mutations within both
conserved region 1 and domain 2 impair the ability of
E1A to dissociate the reconstituted E2F/E2F-BP
complex. In contrast, if the E1A protein is added at
the same time that E2F and E2F-BP are combined,
only mutations within conserved region 1 block
formation of the complex. In addition to E2F-BP, the
Nevins laboratory has also found an activity desig-
nated E2F-I that inhibits E2F binding to DNA, again
apparently through the formation of a complex with
E2F. This inhibitory activity is also blocked by E1A,
dependent on the same elements of the E1A protein
that disrupt the interaction with E2F-BP. These
results thus suggest a complexity of E2F interactions,
at least one of which inhibits E2F function. More-
over, since the E1A sequences that are important for
releasing E2F from these complexes are also se-
quences necessary for mitogenic activity, this activity
may be a critical component of the cell-cycle-
regulating activity of El A.
SUMMARY
This year, we have made significant progress in our
goal of analyzing the mechanisms of regulation of
cellular products controlled in response to E1A ex-
pression. Elucidation of the pathways activated by
E1A is giving us valuable insight into the mechan-
isms of cell growth control. A particular advantage of
the E1A system is that the good genetics permit us to
correlate the gene control pathways with specific
functional domains of E1A. These functional do-
mains, in turn, have already been linked by direct
physical association with specific cellular products.
At least in the case of pRB, these E1A-associated
products have been implicated as important cell-
growth control proteins. The availability of E1A
mutants that induce S phase without progressing
through cell division provides a special advantage in
studying the cellular events that control progression
through these later phases of the cell cycle. For ex-
ample, these mutants have shown that pRB phos-
phorylation can be dissociated from progression
through mitosis, and that a Gt level of cdc2 kinase
activity can be detected in cells that do not enter
mitosis or activate mitotic levels of cdc2 kinase ac-
tivity. The El A mutants will facilitate more detailed
study of the role of p34cdc2 kinase, pRB, and other
cell-growth-regulating proteins involved in the
S/G2/M transitions. This information is basic to our
long-term goal of understanding the mechanism of
carcinogenesis.
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The Protein Immunochemistry Laboratory is divided
into two different sections. One section is a basic re-
search group that has been studying the interaction of
the transforming proteins of small DNA tumor
viruses with the products of tumor suppressor genes,
such as the retinoblastoma protein. The other section
of the Protein Immunochemistry Laboratory is the
Monoclonal Antibody Facility.
MONOCLONAL ANTIBODY FACILITY
The Monoclonal Antibody Facility is a service group
that prepares and characterizes monoclonal anti-
bodies for Cold Spring Harbor Laboratory scientists.
The facility provides all of the reagents as well as the
expertise for the production and characterization of
hybridomas. When needed, the facility personnel can
handle all of the steps in this process. Typically,
antigens are prepared by scientists and then the facil-
ity staff does immunizations, test bleeds, fusions,
screening, and single-cell cloning of the resultant
hybridomas. Where appropriate, the Monoclonal
Antibody Facility can be used as a central site for the
production of hybridomas, e.g., when Cold Spring
Harbor scientists who are skilled in the hybridoma
fusions lack a suitable place for this work in their
own laboratory. The facility is managed by Carmelita
Bautista and staffed by Margaret Falkowski and
Susan Allan. In the last year, they have prepared
more than 100 different hybridoma lines, secreting
antibodies specific for over 15 different antigens. The
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use of the various antibodies is discussed within the
individual research reports in this volume.
PROTEIN IMMUNOCHEMISTRY LABORATORY
For the past several years, we have been studying
transformation by the small DNA tumor viruses.
Small viruses face a number of unique problems fol-
lowing infection of cells. One of the most challenging
is how to use a limited amount of genetic information
to reprogram the host-cell metabolism into an en-
vironment more suited for virus replication. To help
initiate these changes, small DNA tumor viruses such
as the adenoviruses, polyomaviruses, and papil-
lomaviruses have evolved potent cell-cycle-modify-
ing proteins. An analysis of the viral proteins that
promote cell cycle changes indicates that they all
share properties of potent oncogenes. During the last
several years, some of the mechanisms used by these
viruses to immortalize cells in culture have begun to
be understood. It appears that one key mechanism
used by these viral proteins to manipulate host cells is
to bind to cellular proteins and alter their function.
Perhaps not surprisingly, several of these cellular
proteins are key players in the control of the
eukaryotic cell cycle. The fact that these complexes
exist and are relatively stable provides an experimen-
tal avenue to their study. Antibodies that are specific
for members of these complexes can be used to iso-
late the associated proteins and to investigate their
function.
Perhaps the best characterized of these viral/host
protein complexes involves the adenovirus El A
proteins. The El A polypeptides bind to a number of
cellular proteins, known originally by their molecular
weights of 300K, 130K, 107K, 105K, 90K, 80K,
60K, 50K, 40K, 33K, and 28K. Some of these
proteins are known to interact directly with E1A,
whereas others may bind indirectly. In many cases,
identical or similar interactions have been detected
with the large T antigens of the polyomaviruses as
well as with the E7 proteins of the papillomaviruses.
Genetically, the same regions of El A that are
needed to bind to the cellular proteins are also those
that are required for E1A to act as an oncogene. This
suggests that these cellular proteins, either individual-
ly or collectively, are the cellular targets for the role
of E1A in transformation. Although the functional
significance of all of these interactions is not known,
several lines of evidence suggest that these proteins
are closely connected with the cell-cycle-controlling
pathways of a cell.
Two of the cellular proteins are now known by
name. p105 is the product of the retinoblastoma
tumor suppressor gene, and p60 is the human cyclin
A. The retinoblastoma gene is the best characterized
of the tumor suppressor genes or anti-oncogenes. The
protein products of these genes are thought to act as
negative regulators of cell proliferation. Their loss
during tumorigenesis removes a block to cell division
and thereby indirectly contributes to the loss of
growth control. Because El A functions as a potent
oncogene when introduced into primary cells and ap-
pears to act by association with proteins like pRB, it
has been suggested that E1A inactivates the function
of pRB by binding. The interaction and inhibition of
pRB function would then mimic the loss of pRB in
human tumors.
Another view of the role of El A in transforma-
tion comes from consideration of the function of
cyclin A. Cyclins are proteins whose levels oscillate
dramatically through the cell cycle. They appear to
play an important regulatory role in the cell cycle,
mediated at least in part by physical association with
cdc2. This interaction appears to modulate the ac-
tivity of the cdc2 kinase in a cell-cycle-dependent
manner. Cyclin A is one of the originally identified
proteins of this class. It interacts with cdc2 to pro-
duce a kinase that is active in interphase cells. Why
cyclin A appears in E1A-immune complexes is un-
known at present.
It is convenient to divide our work into the fol-
lowing two major divisions: (1) the analysis of the
retinoblastoma and related proteins and (2) the study
of the control of the mammalian cell cycle. Our entry
into both of these areas was the association of key
proteins in these fields with the El A proteins of
adenovirus. An underlying goal of all our work is to
learn how interactions with E1A affect the function
of these cellular proteins.
The Retinoblastoma Protein Is
Targeted by the Large T Antigens
of Many Polyoma-Type Viruses
N. Dyson, P. Guida, E. Harlow [in collaboration with
R Bernards and S. Friend, Massachusetts General
Hospital Cancer Center; L. Gooding, Emery University;
J. Hassel, McMaster University; E. Major, National Institutes
of Health; J. Pipas and T. Van Dyke, University of Pittsburgh;
A. Larose, M. Sullivan, and M. Bastin, Sherbourg]
The El A proteins of adenovirus type 5, the large T
antigen of SV40, and the E7 protein of human papil-
lomavirus type 16 (HPV-16) all form stable com-
plexes with the protein product of the retinoblastoma
susceptibility gene. In each case, genetic studies have
shown that regions of the viral protein that are neces-
sary for association with the retinoblastoma protein
(pRB) also contribute to transformation by the viral
oncoproteins. The correlation between the loss of
pRB binding and the loss of transforming ability sug-
gests that the association with pRB is an important
component in virus-mediated transformation.
Similar sequences can also be found in the large T
antigens of other polyomaviruses. The large T
antigens of all polyomaviruses are thought to perform
similar roles during virus infections, and each has
potent transforming or immortalizing properties when
introduced into appropriate host cells. However, the
oncogenic properties of these proteins vary consider-
ably, both in tissue culture assays and in their associ-
ation with naturally occurring malignancies. We were
interested in determining the pRB-binding abilities of
these viral proteins. Stable protein complexes be-
tween the large T antigens of mouse, monkey, ba-
boon, or human polyomaviruses and the retino-
blastoma protein were detected using an in vitro
coprecipitation assay. All of the large T antigens
tested were able to bind to both human and mouse
retinoblastoma polypeptides, showing that these in-
teractions have been conserved during evolution.
In collaboration with M. Bastin and his col-
leagues, we have investigated further the function of
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the pRB-binding region of polyomavirus large T
antigen. A series of mutants with small deletion or
single amino acid substitutions were prepared in the
two regions of the protein that show sequence
similarity to conserved regions 1 and 2 of adenovirus
E1A. The pRB-binding properties of the large T
mutants were assessed with an in vitro copre-
cipitation assay. pRB binding was readily detected
with wild-type large T antigen, but coprecipitation
was completely abolished by a number of single
amino acid substitutions (Asp-141 to Glu or Glu-146
to Asp) in region 2 of the polyomavirus large T
antigen. Mutants defective in pRB binding were un-
able to immortalize primary rat embryo fibroblasts,
suggesting that association with pRB is an important
component of immortalization mediated by poly-
omavirus large T. The mutations in region 1 affected
pRB binding only marginally, yet some of them
severely impaired immortalization, indicating that for
polyomavirus large T antigen, like other viral on-
coproteins, pRB binding may be essential but not suf-
ficient for deregulated growth.
A Short Region of Adenovirus
E1 A Provides Interaction with
a Family of Cellular Proteins
N. Dyson, P. Guida
Adenovirus E1A will readily bind in vitro to cellular
proteins isolated in detergent lysates. We have ex-
ploited this observation to investigate the physical pa-
rameters of the association of ElA with several host
proteins and to compare the binding properties of
homologous sequences from several viral on-
coproteins. Synthetic peptides (prepared in Dan Mar-
shak's laboratory at Cold Spring Harbor Laboratory)
were designed to contain sequences that are predicted
by genetic studies to be important for binding to
pRB. Using ElA peptides, we have shown ElA con-
tains at least two regions that make direct and distinct
contact with pRB.
Peptides comprising the pRB-binding regions of
E1A were assayed for their ability to compete with
E1A for binding to cellular proteins. An E1A peptide
containing amino acids 37-49 and 117-132 efficient-
ly blocks binding between ElA and pRB. This same
peptide inhibits the binding of several other cellular
polypeptides in addition to pRB. This group of
proteins includes p130, p107, and cyclin A. In a com-
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plementary assay, peptides representing regions of
E1A were covalently bound to Sepharose beads.
These peptide beads also were shown to interact with
the same set of cellular proteins. Together, these data
show that small regions of ElA are sufficient for
protein association with the pRB, p107, p130, and
p300 proteins.
We have performed similar experiments using
peptides comprising SV40 large T antigen or HPV-16
E7 protein sequences that show homologies with the
pRB-binding regions of E1A. The peptides from
large T antigen or E7 generally behaved in manner
similar to that of the E1A peptides, suggesting that
the physical parameters that allow these viral on-
coproteins to bind to cellular proteins, such as pRB,
are conserved between these viruses. Nevertheless,
these peptides did show several intriguing differences
in their binding properties that are being investigated
further: T-antigen peptides were able to bind to the
E1A-associated protein p300, both E7 and T-antigen
peptides showed a reduced affinity for cyclin A, and
the T peptide, like the full-length protein, binds pref-
erentially to the unphosphorylated forms of pRB.
The Adenovirus E1A-associated
p300 Protein Binds to the
Transformation-controlling
Region of SV40 Large T Antigen
N. Dyson, E. Harlow [in collaboration with Jeff Morgan,
John Ludlow, Nazanine Modjtahedi, and
David Livingston, Dana-Farber Cancer Center]
Recent experiments carried out in collaboration with
David Livingston's group suggest that the E1A-
associated p300 proteins also interact with SV40
large T antigen. This interaction has been shown for
protein complexes formed both in vivo and in vitro.
Both biochemical and genetic means have been
used to identify the regions of large T antigen in-
volved in complex formation. In the first, a synthetic
peptide, containing amino acids 6-19 and 98-113
joined together through a glutamine (T;6- 19 -Q -98-
113), was coupled covalently to beads and incubated
in a lysate prepared from cells labeled with
radioisotopes. The beads were washed, and the
proteins that remained bound were analyzed on SDS-
polyacrylamide gels; 300-kD proteins were observed
that comigrated with the heterogeneous E1A-
associated p300 bands. These proteins were not seen
when beads carrying control peptides were used. A
comparison was made of the partial digestion patterns
generated by these bands after proteolytic digestion
with Staphylococcus aureus V8 protease. These pat-
terns matched, indicating that this small portion of T
antigen is sufficient for stable binding to p300. In
complementary experiments, T-antigen peptides were
used to compete the interaction of 32P-labeled p300
proteins from human cell lysates with ElA provided
from a cold cell lysate. Large T antigen peptides con-
taining as little as 102-115 amino acids of wild-type
sequence were able to block the E1A-p300 binding
completely. Amino acids 121-134 of E1A are highly
homologous to amino acids 102-115 of T antigen, but
we have been unable to show that these ElA se-
quences interact with p300, even though both regions
efficiently bind to pRB and p107.
Genetic data support the idea that the region of
SV40 large T antigen that interacts with pRB is also
essential for the association of large T antigen with
p300. Stably expressed mutants of T antigen that
delete this region of T fail to bind to p300. These data
suggest that in addition to its association with
adenovirus ElA, p300 is also able to bind to SV40
large T antigen. In both cases, p300 binds to regions
of the viral proteins that are essential for transforma-
tion activity. Thus, binding to p300 may be a further
common mechanism used by these viral oncogenes to
transform cells. An unexplained feature of these
results is that ElA and SV40 large T antigen seem to
be using different structures to bind to p300.
Monoclonal Antibodies Specific
for the Retinoblastoma Protein
Identify a Family of Related Proteins
Q. Hu, C. Bautista [in collaboration with Gwynneth Edwards,
Deborah Defeo-Jones, and Raymond Jones; Merck,
Sharp, and Dohme Research Laboratories]
To help in the analysis of the retinoblastoma protein
(pRB), we have prepared a new set of anti-human
pRB monoclonal antibodies. Previously, we mapped
the regions of pRB that allow binding to adenovirus
E1A or SV40 large T antigen. The sequences needed
for binding consist of two distinct regions of pRB,
the first from amino acid 393 to 573 and the second
from 646 to 772. These regions appear to form an in-
dependent structural domain, as even small deletions
across any of the boundaries destroy the ability of
ElA or large T antigen to bind. More importantly,
this region also appears to be important in pRB func-
tion as 23 of the 25 naturally occurring pRB muta-
tions identified to date alter sequences in these
regions, This is true even for missense or short in-
frame deletions, all of which map to these regions.
A carboxy-terminal fragment of pRB that con-
tains the binding regions was cloned and over-
expressed in bacteria. This pRB fragment was
purified and used to immunize BALB/c mice. Ap-
proximately 30 hybridomas that secrete antibodies
specific for this region of pRB were isolated and
characterized. In addition to being useful reagents for
the study of human pRB, these antibodies display
several unexpected properties. All of the antibodies
were able to recognize the native forms of pRB, al-
though some had preference for the status of pRB
phosphorylation. Antibodies, such as XZ77 and
XZ91, precipitated all the forms of pRB, whereas
others, such as XZ19 and XZ55, preferred the un-
derphosphorylated forms of pRB. In contrast,
antibodies, such as XZ121, were only able to recog-
nize unphosphorylated pRB. These preferences were
also seen in immunoblot analysis.
Some of the antibodies were able to recognize
pRB homologs in other species, including mouse, rat,
chicken, and Xenopus. The identity of pRB in these
other species was confirmed by several methods. In
several cases, cDNAs for pRB are available. When a
cloned gene for the homolog was not available, we
identified pRB candidates by mixing with E1A or
large T antigen. Such a high degree of structural con-
servation between pRB from these species suggests
that pRB is likely to play a similar role in many ver-
tebrate species. Since pRB function appears to be
critical for the control of division in many human
cells, similar key roles can be expected in all verte-
brates.
Genetic studies have indicated that ElA uses
similar regions to target several cellular proteins, in-
cluding p300, p130, p107, and pRB. Therefore, it is
possible that these cellular proteins share some struc-
tural similarities, at least in the E1A-targeted regions.
Using the XZ antibodies, we have shown that at least
one antibody, XZ37, can directly recognize both pRB
and p107. More surprisingly, a second antibody,
XZ77, can directly recognize both pRB and p300. Al-
though the properties of p107 and pRB had suggested
that they might be structurally related, there was little
indication that p300 and pRB also shared homology.
These results suggest that pRB may be one member
of a family of cellular proteins that show at least
limited homology, particularly in the El A/large T
antigen interaction domains.
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The Retinoblastoma Protein
Binds to Human cdc2
O. Hu, J. Lees, K. Buchkovich
Using a new panel of antibodies specific for the
retinoblastoma protein (pRB), we have investigated
the biochemical properties of pRB and its counter-
parts in human cells. Immune complexes prepared
with some of these antibodies contained a potent
kinase activity. The kinase was able to phosphorylate
pRB itself as well as histone Hi when it was added as
an exogenous substrate. Since this kinase was
detected by immunoprecipitation with anti-pRB
antibodies, there were three possible ways to account
for pRB phosphorylation. First, pRB itself might be
the kinase. This seemed unlikely as the pRB se-
quence did not show any of the characteristic
hallmarks of a kinase. Second, the anti-pRB anti-
bodies might cross-react to another cellular protein
that either was a kinase itself or was bound to a
kinase. Third, the kinase might be bound to pRB and
precipitated by virtue of this association. To dis-
tinguish between the second and third possibilities,
we tested whether the kinase activity copurified with
pRB. Using glycerol gradients, we found that the
pRB kinase activity could not be separated from pRB
itself, supporting the notion that pRB was bound to
the active kinase. This was further tested by analyz-
ing cell lines that carry a homozygous deletion of the
retinoblastoma gene. In these cells, no histone HI
kinase activity could be immunoprecipitated with the
pRB antibodies. Again, these experiments suggest
that the kinase activity is closely linked with the
presence of pRB. Finally, we tested whether the asso-
ciated phosphorylating activity had any character-
istics of known kinases. Immunoblot analysis showed
that pRB immunoprecipitations contained the human
cdc2 kinase or a closely related kinase. In addition, in
vitro kinase assays performed with anti-cdc2 anti-
bodies contained a phosphorylated band of pRB. To-
gether, these results indicate that the pRB forms a
complex with a subset of the cdc2 kinase from human
cells.
When the in-vitro-phosphorylated pRB sites were
compared by two-dimensional tryptic peptide map-
ping, it was found that the sites that are phosphory-
lated in vitro were a subset of the sites that were
phosphorylated in vivo. This suggests that the associ-
ated kinase activity represents an authentic pRB in
vivo event and a potential regulatory step. In
preliminary experiments, we have tested the cell
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cycle regulation of the associated activity and have
shown that the associated kinase is found in all stages
of the cell cycle in which pRB is naturally
phosphorylated. These data in conjunction with the
data of Lees et al. (see the following report) strongly
implicate the cell-cycle-controlling kinase, cdc2, as a
major regulator of pRB function.
The Retinoblastoma Protein Is
Phosphorylated by cdc2
J. Lees, K. Buchkovich [in collaboration with
Carl Anderson, Brookhaven National Laboratory, and
G. Binns and D. Marshak, Cold Spring Harbor Laboratory]
Although the retinoblastoma tumor suppressor gene
product is postulated to inhibit cellular proliferation,
it continues to be expressed in actively dividing cells.
When the levels of pRB are analyzed throughout the
cell cycle, little change is seen at the various stages.
However, a number of studies have shown that pRB
becomes phosphorylated on transition from the GI to
S phase of the cell cycle, suggesting that the tumor
suppressor function of the retinoblastoma protein is
regulated by phosphorylation and that the un-
phosphorylated form is the active repressor. To un-
derstand the significance of these phosphorylation
events better, we have begun to study the kinases that
are responsible for these phosphorylations and to
determine the exact amino acids that are phosphory-
lated. One of the first kinases that was tested for its
ability to phosphorylate pRB in vitro was the human
cdc2 kinase. cdc2 kinase was purified from human
cells arrested at mitosis with nocodozole and was
kindly provided by Jim Bischoff, Leonardo Brizuela,
and David Beach (Cold Spring Harbor Laboratory).
This preparation of purified cdc2 was able to
phosphorylate pRB in vitro, and two-dimensional
tryptic maps showed that the pattern of phosphoryla-
tion is very similar to that found in vivo. To
determine which residues were phosphorylated in
vivo, a strategy that compares potential sites in vivo
with sites phosphorylated in vitro was employed.
Synthetic peptides representing all serine or threonine
residues followed by a proline (representing the
weakest cdc2 consensus phosphorylation sequence)
were prepared and phosphorylated by the purified
cdc2 kinase. These peptides were then digested with
trypsin and compared to the authentic in vivo
proteolytic fragments. Comigration of the spots in
two dimensions was taken as strong evidence that the
site phosphorylated in vitro corresponded to the same
site in vivo. To identify the correct residue in the
digested peptides, the phosphorylated trypsin digest-
ion products were purified, their mass was
determined by spectroscopy, and the position of the
labeled phosphate group was located by sequencing.
From this type of analysis, five sites on pRB that are
phosphorylated in vivo have been identified. All are
surrounded by sequences that fit well with the cdc2
consensus phosphorylation sequence. These results,
together with those of Hu et al. (see above) showing
that pRB is physically associated with cdc2, suggest
that either cdc2 or a cdc2-like kinase acts to regulate
pRB in vivo.
Adenovirus E1A Associates with
a Serine/Threonine Kinase
C. Herrmann, L.-K. Su, E. Harlow
Many proteins are regulated during physiological
changes by phosphorylation. The addition or removal
of a phosphate group is a common mechanism used
in all cells to regulate key proteins. Many of the
proteins that bind to E1A, as well as E1A itself, are
phosphorylated when isolated from cells metabolical-
ly labeled with 32P orthophosphate. Several years
ago, we noticed that immunoprecipitations prepared
with antibodies to E1A contained an active protein
kinase activity. In these experiments, anti-E1A
antibodies are used to isolate E1A and its associated
proteins from lysates of cells. The immune com-
plexes are then incubated with appropriate buffers
containing y-labeled ATP. Associated kinases are
scored by the transfer of the labeled phosphate group
to any of the E1A-bound polypeptides or to an ex-
ogenously added substrate. The target of these
phosphorylations are the E1A-associated 107K and
130K proteins.
Our initial experiments have been directed at
determining which of the proteins in the immune
complexes might be the active kinase. Although we
do not yet know which kinase is responsible for the
phosphorylation, its association with El A has pro-
vided us with an easy assay to characterize the kinase
activity. The optimal conditions for the kinase reac-
tion have been established, and we have begun to
determine whether the kinase activity can be at-
tributed to any of the well-characterized E1A-
associated proteins. This has been done by studying
El A mutants that can interact with only a subset of
the cellular proteins. By choosing mutants that fail to
bind to a particular cellular protein and assaying for
associated kinase activity, we can eliminate various
El A-bound proteins as candidates for the kinase. In
addition, we have been able to prepare specific
antibodies for some of the cellular proteins that bind
to E1A. These antibodies can be used to preclear
lysates of all immunoreactive proteins prior to the
kinase assay. This also has been used to eliminate
certain proteins as candidates for the kinase. Togeth-
er, these experimental approaches have shown that
the kinase cannot be the retinoblastoma protein or the
E1A-associated p300 polypeptide. These assays also
indicate that the p130 or p107 proteins are unlikely to
be responsible for the kinase activity.
Using E1A as a molecular handle to purify and
study this kinase, we have also examined the cell
cycle control of the associated kinase. The levels of
the substrate 107K and 130K proteins do not change
throughout the cell cycle, whereas the kinase activity
shows dramatic changes. The associated kinase ac-
tivity appears to be maximally activated during the
transition between the 01 and S phase. With some
protocols, we have seen a low level of kinase activity
in GI, but with other protocols, the activity is specifi-
cally activated when cells cross the Gt /S boundary.
Further work will be needed to characterize this
kinase fully, but recently, A. Giordano et al.
(Molecular Genetics of Eukaryotic Cells Section)
have shown that E1A associates with a member of
the cdc2 kinase family. This protein then would be-
come an excellent candidate for the E1A-associated
kinase activity characterized here. Giordano et al.
have also seen similar properties of this kinase, fur-
ther indicating that both groups have been studying
the same kinase activity. Although it is still not
certain, this kinase is probably one of the kinases de-
scribed by B. Faha (see below).
Structure/Function Studies
of Human Cyclin A
E. Lees
One of the cellular proteins that is found in im-
munoprecipitations with anti-El A antibodies is hu-
man cyclin A. Originally, this protein was known
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only by its molecular weight of 60,000. Two sets of
results have helped this protein gain an identity. First,
A. Giordano and others at Cold Spring Harbor
Laboratory were able to show that the E1A-
associated p60 protein was associated with a cdc2 or
cdc2-like kinase in cells that do not have adenovirus
E1A. Then, Pines and Hunter (Nature 346: 760
[1990]) cloned the human cyclin A and went on to
demonstrate that it was identical to the E1A-
associated p60 protein. We have begun to study the
structure/function relationships of human cyclin A in
some detail. Using an in vitro mixing technique, we
have begun to map the binding site on cyclin A for
cdc2. These experiments have been done in two
ways. In the first approach, wild-type cyclin A or
mutated cyclin A is prepared in vitro by translation in
rabbit reticulocyte lysates and then mixed with a cold
cell lysate as a source of cdc2. Any complexes that
form are recovered with anti-cdc2 antibodies or with
a cdc2 adsorbent, p13 beads. Using these reagents,
we have shown that it is possible to remove the
amino-terminal 173 amino acids without affecting the
ability of cyclin A to bind to cdc2. Analysis of
carboxy-terminal deletions showed that only 12
amino acids could be removed and still retain bind-
ing. However, internal deletions that removed amino
acids 241-275 allowed good binding. Somewhat sur-
prisingly, we have shown that in the presence of this
internal deletion, it is possible to remove further
amino- and carboxy-terminal sequences without
abolishing binding. This study suggests that two
small regions, 173-241 and 275-320, are sufficient
to bind to cdc2. We are not yet certain why this inter-
nal deletion allows further deletions at the amino and
carboxyl termini to bind more efficiently. In the sec-
ond experimental approach, we have tested the same
cyclin A mutants for their ability to interact with a
bacterially expressed fusion protein between glu-
tathione-S-transferase (GST) and the human cdc2 -
coding region. This fusion protein binds tightly to
cyclin A mutations. We are currently analyzing
which mutants can bind the GST-cdc2 fusion con-
struct.
To compare the structural characteristics of these
interactions with their biological functions, we have
shown that human cyclin A can cause maturation of
the Xenopus oocytes when RNA for cyclin A is mi-
croinjected. In preliminary experiments, any mutant
that can bind tightly to cdc2 retains the ability to
stimulate maturation of the oocytes. As the binding
characteristics of the cyclin A mutants become more
clear, we will continue to examine this correlation.
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Cyclin A Forms Complexes with
Several Cellular Proteins
B. Faha
We have investigated the cellular proteins that
coprecipitate with cyclin A in the absence of
adenovirus El A using a new panel of monoclonal
antibodies specific for cyclin A. One of the proteins
that is bound to cyclin A is the E1A-associated p107
protein. The complex between cyclin A and p107 oc-
curs in cells whether or not E1A or the retino-
blastoma protein is present. The association between
E1A and p107 has been shown to be important for
oncogenic transformation by adenoviruses. In addi-
tion, p107 has been shown to associate with the large
T antigen of SV40 and JC viruses. The significance
of the association of cyclin A with p107 has yet to be
determined. However, the identification of p107 in
anti-cyclin A immune complexes suggests that it may
play a role in the regulation of the cell cycle.
We have also shown that cyclin A associates with
the human cdc2 protein and p33, a protein originally
described by Pines and Hunter (Nature 346: 760
[1990]) and Giordano et al. (Molecular Genetics of
Eukaryotic Cells Section). Comparison of these
bands with authentic human cdc2 (either precipitated
by anti-cdc2 antibodies or translated in vitro from the
human cdc2 cDNA) by V8 partial proteolysis has
shown that the two slower-migrating bands are
authentic cdc2. The retarded migration of these bands
has been shown to be due to phosphorylation. The
fastest-migrating band, p33, has a V8 partial
proteolytic pattern distinct from that of cdc2. The p33
proteins associated with cyclin A are phosphorylated
on threonine and tyrosine. The p33 band is also found
in anti-El A immune complexes, as first described by
Giordano et al. However, we have not been able to
detect any cdc2 in the E1A immune complexes. It is
unknown whether these proteins, p107, cdc2, and
p33, are part of one complex or whether they con-
stitute separate interactions with cyclin A.
Cloning of Multiple cDNAs That
Encode Human cdc2-like Kinases
L.-H. Tsai [in collaboration with Matthew Meyerson,
Massachusetts General Hospital Cancer Center]
Recently, several cdc2-related genes have been
cloned from Schizosaccharomyces pombe, Droso-
phila, Xenopus, and mammalian cells. Although these
genes encode proteins that share close sequence
homology with cdc2, most fail to rescue null mutants
of cdc2 in S. pombe or CDC28 in Saccharomyces
cerevisiae and thus are postulated to perform a dis-
tinct function during the cell cycle. One cdc2-related
kinase in which we have become particularly inter-
ested is known as p33 (see report by B. Faha above).
p33 is bound to cyclin A and is structurally related to
cdc2, but represents a distinct family member. In an
attempt to isolate a cDNA for p33, we performed
polymerase chain reaction amplification of human
cDNA, using degenerate oligonucleotides derived
from conserved regions of cdc2 genes. Using this
strategy, we have cloned a number of unique cdc2 -
like DNA sequences from the human cell lines HeLa,
NALM-6, T84, and RAC. All of these clones encode
protein sequences that are characteristic of protein
kinases. A computer search of GenBank reveals that
these genes are more similar to the cdc2ICDC28 class
of genes than to other kinases. Some of them contain
cdc2-specific motifs such as the PSTAIR region. We
are currently characterizing these clones and are par-
ticularly interested in determining whether any of
them are capable of encoding the cyclin-A-associated
p33 kinase.
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PROTEIN CHEMISTRY
D.R. Marshak W.B. Benjamin
G.E. Binns
H. Mehmet
M.R. Meneilly
G.L. Russo
M.T. Vandenberg
I.J. Yu
The Protein Chemistry Laboratory is engaged in re-
search pertaining to the structure and function of
proteins involved in fundamental mechanisms of
normal and abnormal growth of cells. We use ad-
vanced instrumentation such as protein sequencers,
mass spectrometers, and peptide synthesizers to take
a biochemical approach to the analysis of proteins
and, particularly, in the analysis of modifications on
proteins. One class of modifications, the phosphory-
lation of serine, threonine, and tyrosine residues, and
the enzymes that catalyze them, protein kinases, ap-
pears to modulate many of the regulatory mechan-
isms in cellular growth.
Mapping Phosphorylation
Sites on Nuclear Oncoproteins
D.R. Marshak, M.T. Vandenberg, G.E. Binns
During the past year, our work on mapping
phosphorylation sites has concentrated on the human
recessive oncogene products p53 and RB (retino-
blastoma). As part of this work, we have assembled a
spectrum of protein kinases to use for in vitro
phosphorylation of the overexpressed proteins. These
kinases include casein kinases I and II (CK-I and CK-
10; protein kinase C (PK-C); cAMP-dependent
protein kinase (PK-A); myosin-light-chain kinase
(MLCK); calcium-calmodulin kinase II (CaM K-I0;
raf kinase (raf); p34cdc2; glycogen synthase kinase 3
(GSK-3); phosphorylase b kinase; and pp60c-src and
pp60c-s"(+). These protein kinases are enzymes that
catalyze the transfer of phosphate from adenosine
triphosphate to the hydroxyl moiety of serine,
threonine, or tyrosine residues. The recessive on-
cogenes refer to human cellular genes that give rise to
tumors in which both alleles of the gene are mutated,
usually by partial deletion. Normally, such genes are
thought to play a role in suppressing and regulating
nuclear processes that would lead to abnormal cell
growth and tumorigenesis. The recessive oncogene
products p53 and RB are phosphoproteins with ap-
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parent molecular weights of 53K and 105K, respec-
tively. It has been only in the last few years that the
concept of recessive oncogenes has changed the para-
digm under which research in the biology of cancer is
performed. Understanding the mechanisms by which
these recessive oncogene products control cell proli-
feration and are themselves regulated by phosphor-
ylation is the central goal of this research.
The focus of the phosphorylation work has been
to uncover the sites of modification by p34cdc2, the
cell-division-cycle-regulated protein kinase that is
critical to the 051S transition and the onset of mitosis
in eukaryotic cells. The phosphorylation site on p53
was determined by isolating the peptide from the
phosphorylated protein and subjecting it to automated
Edman degradation on an Applied Biosystems 473A
protein sequencer. By collecting the reaction products
of each cycle, the amino acid residue containing the
radioactive phosphate was determined. Figure 1
shows a plot of the radioactivity recovered from each
cycle of the analysis. The site of phosphorylation
turned out to be the serine residue 315 in the se-
quence Lys-Arg-Ala-Leu-Pro-Asn-Asn-Thr-Ser-Ser-
Ser-Pro-Gln-Pro-Lys-Lys. To confirm this assign-
ment further, a synthetic peptide containing the na-
tive sequence of the p53 site was synthesized by
solid-phase methods, phosphorylated with p34cdc2,
and subjected to two-dimensional peptide maps. The
phosphorylated synthetic peptide migrated to exactly
the same position as that of the protein phosphory-
lated in vivo. These studies demonstrated that this
cell-cycle-regulated protein kinase, p34.1c2, phos-
phorylates the recessive oncogene product, p53, on
serine both in vivo and in vitro. However, it is not yet
clear what the physiological consequences of this
modification are. One intriguing possibility is based
on the observation that the p34cdc2 site in p53 is ad-
jacent to the nuclear localization sequence in the
protein, exactly as in the case of the SV40 large T
antigen protein. Last year, similar biochemical ana-
lyses demonstrated the phosphorylation of T antigen
by p34cdc2 and the effects of this phosphorylation to
stimulate DNA replication in vitro. We suspect that
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FIGURE 1 Radioactive phosphate recovered from automated Edman degradation of a synthetic
peptide substrate for p34cdc2 based on the recessive oncogene p53 sequence. Data taken from
Bischoff et al. (1990).
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the role of p53 in DNA replication might be affected
by the analogous phosphorylation by p34cdc2. Further
effort in this area is in progress in collaboration with
C. Prives (Columbia University) and D. Beach (Cold
Spring Harbor Laboratory).
Phosphorylation of the retinoblastoma gene pro-
duct, RB, by the cell-cycle-regulated protein kinase,
p34cdc2, has been studied in collaboration with Ed
Harlow, Jackie Lees, and Karen Buchkovich (Cold
Spring Harbor Laboratory). The approach to this pro-
ject has been somewhat different. RB is a very large
protein that has a molecular mass of more than
100,000 daltons and dozens of potential phosphoryla-
tion sites. We chemically synthesized peptides cor-
responding to sites in the carboxy-terminal domain of
RB that contain several potential targets for the
kinase. The consensus phosphorylation sites contain
either serine or threonine, followed by a proline, two
neutral residues, and one or more basic residues. Al-
though it is not a strict requirement, this consensus
Ser/Thr-Pro-Xxx-Xxx-Lys/Arg is very often fol-
lowed in nuclear oncogene products. We have used
advanced instrumentation, including mass spec-
trometry, to analyze the synthetic peptides and to
compare their phosphorylations with those of the
protein in vivo. Mass spectrometry measures the pre-
cise molecular weight of the peptide fragment con-
taining the phosphate modification, calculated as a
mass-to-charge ratio (m/z). Compared to the un-
modified peptide, the phosphorylated peptide is 80
atomic mass units (amu) larger for each phosphate
group attached. Because the resolution of the spec-
trometer is about 2 amu, the addition of phosphate is
very easy to identify. With one charge (z = 1), the
difference in mass should be 80, whereas charges of
2 or 3 should produce differences of 40 and 27,
respectively. Figure 2 shows one of these RB
synthetic peptides following phosphorylation with
p34cdc2. The peaks at m/z = 3997, 1999, and 1222
correlate well with the expected peaks for the singly,
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FIGURE 2 Partial mass spectrum of a peptide based on the
RB sequence after phosphorylation with p34.0c2 in vitro.
doubly, and triply charged (z = 1, 2, or 3) species of
the phosphorylated peptide. In each case, the peak
below represents the unphosphorylated peptide. This
project exemplifies our application of state-of-the-art
biochemical approaches to questions of paramount
biological interest.
Phosphorylation of
Transcription Factors
D.R. Marshak, G.E. Binns, G.L. Russo,
M. Vandenberg, I.J. Yu
Transcription factors are multiple families of proteins
that either bind to regulatory elements of genes or in-
teract with protein complexes, which, in turn, pro-
mote gene transcription. Many of these transcription
factors appear to be phosphorylated, mainly by at-
tachment of phosphate to sense and threonine
residues, catalyzed by several candidate nuclear
protein kinases. Of these, we have studied casein
kinase II, p34cdc2, glycogen synthase kinase 3,
protein kinase C, and cAMP-dependent protein
kinase. Using this panel of enzymes, our strategy has
been to phosphorylate transcription factors in vitro
and to test how individual phosphorylation events
might alter the ability to bind to the appropriate DNA
element or to direct transcription. To this end, we re-
quire purified proteins produced in relatively large
amounts, unlike the vanishingly small quantities of
natural products. Expression of the cDNAs for these
proteins in bacteria or in insect cells is necessary to
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obtain sufficient quantities of protein for our bio-
chemical analyses.
We have continued to study regulatory proteins
involved in the control of transcription of the c-fos
gene. Two regulatory elements have been defined by
M. Gilman and his colleagues (Cold Spring Harbor
Laboratory) as the serum response element and the
cAMP responsive element, and the corresponding
proteins that bind to these elements have been termed
the serum response factor (SRF) and the cAMP ele-
ment binding protein (CREB). The phosphorylation
of SRF by CK-II appears to increase the binding af-
finity of the factor to its cognate DNA sequence. This
result has been slightly confusing, since the time
course of CK-II induction on serum stimulation fol-
lows that of induction of the c-fos gene transcription.
Thus, the physiological role for CK-II phosphoryla-
tion ought to be in the turn-off of c-fos transcription.
However, increased binding affinity for DNA has
been generally assumed to be associated with a turn-
on of gene transcription. Therefore, further studies of
the exact mechanism of SRF action at the c-fos serum
response element are necessary to sort out this
quandry.
In another project related to gene transcription,
we have collaborated with J. Kadonaga at the Univer-
sity of California, San Diego, on the structural analy-
sis of a transcriptional repressor. This repressor ac-
tivity was identified in the supernatant of an am-
monium sulfate precipitation of the basal transcrip-
tion mixture. In this fractionated in vitro transcription
mixture, basal rates of transcription are high, but
sequence-specific factors do not activate the rate of
transcription. The repressor lowers the basal rate of
transcription and restores the abilities of several
sequence-specific DNA-binding proteins to activate
the system. Because the repressor activity possessed
the ability to rejuvenate previously inactive mixtures
of transcriptional activators, the factor was given the
operational nickname Elvis, to commemorate the
deceased singer who is reported to reappear in odd
places by the popular press. The goal of this project
has been to determine the structure of Elvis. Follow-
ing purification, the protein was digested with
proteases, and the fragments were isolated by
chromatography. Each fragment was analyzed by se-
quencing, amino acid analysis, and mass spec-
trometry. Upon collating all the data, Elvis was found
to have a primary structure identical to that of histone
H1, as shown in Figure 3.
This was an exciting finding because it suggested
that the mechanism of transcriptional activation, in
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FIGURE 3 Sequence analysis of the basal transcriptional
repressor, histone H1. The heavy lines represent portions
sequenced by chemical means, and the light lines indicate
sequences confirmed by mass spectrometry. Data taken
from Croston et al. (1991).
many cases, is not by true activation of a basal ac-
tivity, but by antirepression. By analogy, one can
think of it in the same way as we turn on lights, either
from an on/off switch or from a dimmer switch. True
activation in the absence of Elvis would be analogous
to turning up the lights in a room with a dimmer
switch, progressing from low levels to high levels of
light. On the other hand, antirepression, mediated by
Elvis, is analogous to turning on the lights in a room
that is initially dark because the switch is off. In other
words, Elvis keeps the system off, just as the switch
keeps the lights completely off, and a sequence-
specific transcription factor turns the system on by
antagonizing Elvis, just as the new occupant of a
room would "antirepress" (i.e., turn on) the light
switch. It is clear from this analogy that the
antirepression mechanism in theory allows the me-
chanism of transcriptional activation to be an on/off
proposition, rather than having continuously interme-
diate levels of action.
Role of Casein Kinase II
in Cell Growth
I.J. Yu, H. Mehmet, D.R. Marshak
We are continuing our studies of CK-II in cell growth
and viral transformation of cells. In two different cell
systems, a human lung fibroblast cell line (WI38) and
a human epithelial carcinoma cell line (HeLa), in-
creases in CK-II activity appear to be correlated with
cell growth phenomena. Initial studies on cell cycle
control of CK -lI in HeLa cells indicate that CK-II ac-
tivity is high in the Gt phase of the cell cycle and
decreases during S phase to very low levels. In
mitosis, CK-II is reactivated to approximately 30% of
the Gi levels. These cyclic patterns of CK-II activity
are consistent with our previous observations of CK-
II stimulation early in serum activation of fibroblasts.
H. Mehmet worked as a visiting scientist in our
laboratory for 3 months, introducing the Swiss 3T3
fibroblast cell line to these studies. The signal trans-
duction pathways in these cells have been dissected
by Drs. Mehmet and Rozengurt in London, and the
role of CK-II in those systems was investigated. No
clear results have been obtained, but the response ap-
pears to be different from earlier work in epithelial
cells, suggesting that protein kinase C activation was
positively linked to CK-II, and the cAMP pathway
was negatively linked. These studies point to the pos-
sibility that fibroblasts and epithelial cells may utilize
CK-II in different parts of their signaling mechan-
isms.
To investigate the cell cycle regulation of CK-II
further, II Je Yu has raised polyclonal antibodies that
recognize specific epitopes on various subunits of the
enzyme. The structure of CK-II is highly conserved
among eukaryotes, and we had trouble developing
high-titer useful antibodies to the intact purified
holoenzyme. Polyclonal antibodies to holo-CK-II
reacted poorly on Western blots, and all attempts to
produce mouse monoclonal antibodies to the bovine
protein failed. Therefore, we synthesized peptides
representing epitopes on each of the a, a ' , and
subunits. These were coupled to either keyhole
limpet hemocyanin or ovalbumin with maleimido-
benzoyl-N-hydroxysuccinimide. Antisera were raised
in rabbits that react with the individual subunits of
CK-II. This has been demonstrated on immunoblots
of whole-cell extracts of purified CK-II. In summary,
we have antibodies-specific for a (the catalytic sub-
unit) and specific for a' (an alternate form of the
catalytic subunit)-that react with both a and a' at
different epitopes and that react exclusively with p
(the regulatory subunit). The antibodies were used to
localize CK-II subunits in asynchronous HeLa cells.
The a and 13 subunits stain cytoplasm, with little or
no staining of the nucleus. However, antibodies that
react with a' as well as a stain the nucleus and
cytoplasm. In addition, the antibodies that recognize
a' fail to stain 18% of the asynchronous cells'
nuclei. After treatment of cells with hydroxyurea to
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arrest at the Gi/S transition, 5% of the cells are nega-
tive for a' in their nuclei. Upon release of the
hydroxyurea block, there is an increase of a ' -
negative nuclei during the first 4 hours, followed by
diffuse staining for all of the subunits when the
nuclear envelope breaks down in prophase of mitosis.
Following mitosis, the original Gt distribution of
CK-II subunits is reestablished. To localize CK-II in
HeLa cells during mitosis, we have used immuno-
electron microscopy because the immunofluor-
escence patterns were not interpretable due to diffuse
staining patterns. At the electron microscopic level, it
is clear that the a subunit decorates the spindle fibers
of the mitotic apparatus as well as other nuclear
structures in metaphase and anaphase. Figure 4
shows a representative photograph of HeLa cells in
metaphase and anaphase, indicating immunoreact-
ivity of CK-II a on spindle fibers. The chromosomes
are clearly negative, and there is diffuse staining in
other parts of the cells.
FIGURE 4 Electron micrographs of HeLa cells in mitosis immunostained using an
antibody to casein kinase II a subunit. (Panel a) Cell in metaphase; (panel b) cell
in anaphase. Arrowheads point to spindle fibers. (Photos courtesy of I.J. Yu and D.
Spector.)
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Our working hypothesis is that the a' subunit is
the major nuclear form of the enzyme during G1 and
that it must exit the nucleus at the onset of S phase to
allow DNA replication. The change in localization of
a' during S phase is concomitant with the decrease
in activity found in extracts of elutriated cells from S
phase. We are continuing to investigate the role of
CK -ll in DNA replication, possibly as an antagonistic
activity. The activity of CK-II is to a large extent
reciprocal in level to p34cdc2; i.e., CK-II is high in Gi
and undergoes a large decrease at the Gi/S transition,
whereas p34cdc2 kinase activity is low in GI and un-
dergoes a large increase during the progression of the
cell through S and into G2 and M phase. During the
past year, in collaboration with J. Roberts (Fred
Hutchinson Cancer Center, Seattle), we found that
p34cdc2/cyclin complexes can induce replication in
extracts of GI cells. Previously, we showed (with D.
Beach, Cold Spring Harbor Laboratory) that p34cdc2
phosphorylates SV40 T antigen and stimulates viral
DNA replication. The control of DNA replication by
p34cdc2 and potentially by CK-II is a continuing in-
terest of the members of our laboratory.
Synthetic Peptide Substrates
for Protein Kinases
D.R. Marshak, M.T. Vandenberg, G.E. Binns,
M.R. Meneilly
We have been actively pursuing the design and
synthesis of peptides that are phosphate acceptors on
serine or threonine residues for CK-II and p34cdc2
kinases. Peptides are synthesized by chemical meth-
ods on the basis of the original Merrifield approach
using N-a-Boc-protected amino acids on poly-
styrene supports. Synthesis is done using automated
instruments, and they are extensively characterized
by mass spectrometry, sequence analysis, and amino
acid analysis to ensure purity. Peptides are analyzed
as kinase substrates by carrying out a phosphoryla-
tion reaction with radioactively labeled ATP and then
separating the radioactivity incorporated into the pep-
tide by immobilization on phosphocellulose paper.
Synthetic peptide substrates for the cell-division-
cycle-regulated protein kinase, p34cdc2, have been
developed and characterized. These peptides are
based on the sequences of two known substrates of
the enzyme, SV40 large T antigen and the human cel-
lular recessive oncogene product, p53. The peptide
sequences are H-A-D-A-Q-H-A-T-P-P-K-K-K-R-K-
V-E-D-P-K D F OH (T antigen) and H-K-R A L P-
N-N-T-S-S-S-P-Q-P-K-K-K P L D-G-E-Y-NH2
(p53), and they have been employed in a rapid assay
of phosphorylation in vitro. Both peptides show
linear kinetics and an apparent K. of 74 and 120 p.m,
respectively, for the purified human enzyme. The T-
antigen peptide is specifically phosphorylated by
p34cdc2 and not by seven other protein serine/
threonine kinases, chosen because they represent
major classes of such enzymes. The peptides have
been used in whole-cell lysates to detect protein
kinase activity, and the cell cycle variation of this ac-
tivity is comparable to that measured with specific
immune and affinity complexes of p34cdc2. In addi-
tion, the peptide phosphorylation detected in mitotic
cells is depleted by affinity adsorption of p34cdc2
using antibodies to either p34cdc2 or immobilized
p13, a p34cdc2-binding protein. Purification of pep-
tide kinase activity from mitotic HeLa cells yields an
enzyme indistinguishable from p34cdc2. These pep-
tides should be useful in the investigation of p34cdc2
protein kinases and their regulation throughout the
cell division cycle. Table 1 shows the utility of these
peptides in their abilities to detect p34cdc2 activity in
whole-cell extracts, and it compares the activities of
the peptides and histone H1 with enzyme prepared by
three preciptation methods.
Protein Chemistry
Core Facilities
G.E. Binns, M.R. Meneilly, D.R. Marshak
During the last 5 years, the growth of the protein
chemistry core services has increased dramatically.
The major areas of chemistry required are the struc-
tural analysis of proteins and the synthesis of pep-
tides. We are now seeing the number of these proce-
dures performed per year begin to plateau as we
reach the physical capacity of the instruments and the
limited personnel. At present, scientists must wait
weeks to months for their analyses because of these
limitations in resources. Figure 5 demonstrates
graphically the plateau effect in sequencing and
synthesis, due to limited resources. In the coming
year, we will move to the Keck Foundation Labor-
atory of Structural Biology in the new Neuroscience
Center. This will allow more space, personnel, and
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TABLE 1 Peptide Kinase Activity in Elutriated He La Cell Extracts
Sample
Cell cycle
stage
Phosphate incorporated (pmole/10 min/107 cells)
CSH103 CSH133 histone H1
Cell lysate G1 138 204
S 536 586 n.d.
32/M 890 [6.5]. 822 [4.0] n.d.
Immunoprecipitate G1 29.0 13.2 36.9
p34c..2 antibody S 117 87.4 169
G2/M 155 [5.4] 155 [11.7] 258 [7.0]
Immunoprecipitate GI 0.19 0.15 0.09
p60 antibody S 0.65 0.55 0.50
G2/M 0.96 [5.1] 0.72 [4.8] 0.92 [10.2]
Precipitate with G1 120 59.3 55.3
p13-Sepharose S 493 407 370
G2/M 646 [5.4] 552 [9.3] 578 [10.5]
From Marshak et al. (J. Cell. Biochem. [1991] in press).
a The value shown in brackets is the relative increase in phosphate incorporation, calculated as the ratio between
the values for the G2/M and Gr cell extracts.
b n.d. indicates not determined.
the possibility of new equipment for the constantly
increasing demands for protein chemistry. In addi-
tion, we have instituted several new methods, such as
mass spectrometry, high-performance electrophor-
esis, and quantitative chemical analyses to maintain
the facility on the leading edge of new technology.
The growth of the use of protein chemistry is il-
lustrated in Table 2.
As part of the core protein chemistry support fa-
cility, peptide synthesis is performed to assist re-
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'Year
FIGURE 5 Growth of protein sequencing and peptide
synthesis procedures at Cold Spring Harbor Laboratory,
1986-1990. Data based on the calendar years.
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searchers throughout the programs at Cold Spring
Harbor Laboratory in their work. In general, there are
three uses of peptides: (1) as antigens for antibody
production, (2) as enzyme substrates, and (3) for
biological studies. Approximately half the peptides
synthesized are used as antigens by coupling to car-
rier proteins or by direct injection into animals. The
antibodies produced in this way allow an investigator
to prepare a reagent that reacts very specifically with
a site on the protein of interest. Such "site-directed"
antibodies are of tremendous value in structure-
function studies of proteins. To facilitate the rapid
synthesis of these peptides, we have employed small-
scale (0.1 mmole) rapid-cycle chemistry using an
automated synthesis instrument. By optimizing our
procedures, we have been able to synthesize, purify,
characterize, and deliver 79 peptides during the 1990
calendar year. This rate is constantly increasing, and
our annual production with the single instrument now
available is 100 peptides per year (two per working
TABLE 2 Growth of Protein Chemistry
Procedure 1986 1987 1988 1989 1990
Protein sequences
Peptide synthesis
Amino acid analysis
Chromatography
Mass spectrometry
47
6
87
18
357
61
162
46
389
68
256
225
71
400
75
666
205
79
339
67
1064
week). This is in addition to the other procedures
carried out in the facility.
One of the recent developments has been the se-
quence analysis of peptides using mass spectrometry.
This has resulted in fewer peptides requiring chemi-
cal sequencing, which makes the sequencer available
for other projects. Sequence analysis of peptides by
plasma desorption mass spectrometry (PDMS) has
been accomplished for an assortment of peptides.
Peptides ranging in molecular weight from 1100 to
3600 amu displayed useful sequence ions under
PDMS. Acidic, basic, and neutral peptides all showed
sequence fragment ions, and carboxy-terminal se-
quence information was readily obtained on all pep-
tides (A, B, or C' ions). The A ion series was most
abundant for the basic peptides, whereas the C' ion
series was most abundant for the acidic peptides.
Sequence-specific fragment ion patterns appear to oc-
cur. For example, peptide CSH084 showed dehydra-
tion (-18 amu) of all the Y' ions in the internal
basic region (residues 10-16). Subsequent examples
of peptides containing aromatic side chains indicate
that loss of the indole moiety from the side chain is
common under PDMS. Similar generation of these
w' ions from histidine residues through loss of im-
idazole has also been detected. We suggest that
PDMS is generally useful for sequence analysis of
peptides of various compositions. In particular,
PDMS is useful as a complementary tool to classical
methods of protein chemistry, and PDMS should be
considered an important part of a multidisciplinary
approach to the structural analysis of peptides and
proteins. It is clear from Table 2 that there has been a
huge increase in the use of mass spectrometry,
reflecting the growing capability of the instrument to
analyze samples, both natural and synthetic.
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R. Packer
Studies have continued on the regulation of gene ex-
pression in three systems: translational control by
small viral RNAs, the regulation of a cellular growth-
related replication factor, and transcription of the hu-
man immunodeficiency virus (HIV) genome. With
T. Pe'ery
A.P. Rice
M. Sullivan
P. Wendel
the departure in the fall of Andrew Rice and Odi
Echetebu for Baylor College of Medicine, we have
discontinued work on the structure of the Tat protein,
but studies of its function are still being actively
pursued.
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Adenovirus VA RNA and
Translational Control
T. Pe'ery, Y. Ma, L. Manche, K.H. Mel lits,
M.B. Mathews
The interferons are products of a multigene family
that can affect a wide range of cellular functions in-
cluding cell growth, the immune response, and viral
infectivity. Exposure of cells to interferon can induce
an antiviral state in which the cells become refractory
to infection by a variety of viruses. This induction in-
volves the transcriptional activation of a number of
genes whose protein products interfere with viral
replication at stages ranging from uncoating to as-
sembly. One of the most studied interferon-induced
proteins is the protein kinase DAI, an acronym for
the double-stranded (ds) RNA-activated inhibitor of
protein synthesis. This enzyme is present in most
cells at a basal level and in an inactive (latent) form;
it is activated in a process that is accompanied by
autophosphorylation and requires dsRNA. Once ac-
tivated, the enzyme becomes able to phosphorylate
eukaryotic initiation factor elF-2 on its a-subunit.
Phosphorylation of elF-2 hampers its function and
brings protein synthesis to a halt.
It appears that DAI activation is mediated by
dsRNA generated as a consequence of viral metabo-
lism. No requirement for specific dsRNA sequences
is apparent, but the length and concentration of the
dsRNA are critical. Duplexes of more than 50 by ac-
tivate the enzyme, whereas shorter duplexes block
activation. Activation requires very low concentra-
tions of dsRNA, and high concentrations prevent
DAI activation, giving rise to a bell-shaped activation
curve. Two hypotheses have been advanced to ex-
plain the paradoxical inhibitory action of high con-
centrations of dsRNA (Fig. 1). These hypotheses
make different predictions about the number of sites
for the dsRNA ligand (one or two), the molecularity
of the autophosphorylation reaction (uni- or bi-
molecular), and whether phosphorylation is inter- or
intramolecular. Our binding assays detected only a
single site for dsRNA, and kinetic measurements in-
dicate that the activation reaction is second order
with respect to DAI. These data are consistent with
the one-site/bimolecular model (model 1), although
they do not prove it, and some data in the literature
are more compatible with the two-site/unimolecular
model (model 2). Further support for model 1 comes
from the finding that adenovirus VA RNAt competes
with dsRNA for binding to DAI and vice versa. This
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EXPLANATIONS for the BELL-SHAPED DAI ACTIVATION
CURVE
DAI
ACTIVATION
MODEL 1
[ ds RNA ]
Inactive Active
O
- 1 site for dsRNA
DAI dimer
- intermolecular
autophosphorylation
VARIATION 1a.
MODEL 2
- 2 sites for dsRNA
- DAI monomer
- intramolecular
autophosphorylation
Or
Inactive
Activation site,
High affinity
site, Low affinity
FIGURE 1 Models for the binding of dsRNA to DAI and its
consequences for enzyme activation (from Mathews at al.
1990). See text for explanation.
result implies that the sites for these two RNA
ligands are probably one and the same; alternatively,
if they are different, they must communicate with one
another in such a way as to ensure mutually exclusive
occupancy. Additionally, mixing experiments indi-
cated that the activated form of the enzyme, which
phosphorylates eIF-2, is not capable of activating
latent DAI. Thus, activation results in a change in
substrate preference, probably brought about by an
alteration in enzyme conformation. Presumably, this
switch guards against runaway autocatalytic activa-
tion of the enzyme that could block protein synthesis
inopportunely.
Uninfected cells possess detoxification mechan-
isms to dispose of dsRNA that accumulates as a
result of normal metabolism. Presumably, these
safety mechanisms are saturated or otherwise in-
capacitated during viral infection, allowing dsRNA to
accumulate and trigger the activation of DAI and
other dsRNA-dependent enzymes. For their part,
several viruses have acquired the means to evade this
antiviral defense. In the case of adenovirus, an
abundant small RNA, VA RNA1, blocks activation of
the kinase and the resultant inhibition of translation.
As described in last year's Annual Report, this RNA
is highly structured, comprising a central domain
flanked by two stems. One of these stems, the apical
stem, is required for efficient binding of VA RNA to
DAI, and because of its extensive predicted sec-
ondary structure, it was thought that VA RNA might
function as a short RNA duplex to prevent DAI ac-
tivation. Surprisingly, the molecule's function is
preserved in mutants that contain alterations in the
apical stem, but mutations that perturb the structure
of the central domain abrogate this function whether
or not the site of mutation is in the central domain.
Foreign sequences inserted into the apical stem are
tolerated provided the central domain and the base of
the apical stem remain intact, although the sequence
in the stem can be varied. Consideration of other
mutational data argues that the terminal stem is also
nonessential for function, emphasizing that the cen-
tral domain plays the determinative role in blocking
DAI activation.
We have begun to explore the functional con-
in the central domain using an
in vitro kinase assay. Our data are still preliminary,
but some conclusions can already be drawn. First,
mutations in the central domain are permitted, even
some that delete or substitute relatively large
stretches of sequence. Second, some of the mutants
that retain functionality cannot adopt the conforma-
tion depicted in last year's report, so it is possible that
alternative structures for the central domain are (or
can be) active. Third, there are signs of tertiary inter-
actions within the central domain, and these may also
be important for function. We expect that more light
will be shed on the structure-function relationships
within this important region when our current series
of mutagenic and phylogenetic analyses are com-
pleted.
Regulation of PCNA
G.F. Morris, C. Kannabiran, C. Labrie, R. Packer,
M.B. Mathews
Activation of the cellular DNA replication machinery
is central to the process of neoplastic transformation.
The proliferating cell nuclear antigen (PCNA) func-
tions in conjunction with DNA polymerase .5 as an
essential DNA replication factor in leading-strand
DNA synthesis (see DNA Synthesis section). In ac-
cord with this function, the cellular PCNA level in-
creases in response to mitogenic agents such as
growth factors and viral oncogenes, including the
adenovirus E1A oncogene. From this pattern of
synthesis and its critical role in DNA replication, it
seems likely that activation of PCNA gene expression
is a necessary component of the transition from the
quiescent state to the proliferating state. The goal of
this project is to explore the induction of PCNA gene
expression by the El A oncogene product and thereby
to elucidate the relationship between PCNA induc-
tion and oncogenic transformation. Initially, we
focused on identification of the cis-acting E1A-
responsive elements of the PCNA promoter by use of
cotransfection assays in HeLa cells. We have in-
itiated experiments to determine if the findings with
HeLa cells also apply to other cell types.
Alternative splicing generates five different
mRNAs from the primary El A transcript, with the
two largest mRNAs, 13S and 12S, as the major pro-
ducts. Comparison of the predicted amino acid se-
quences for the El A proteins of several adenovirus
serotypes reveals three regions of relatively high se-
quence conservation. Two of the conserved regions,
CR1 and CR2, occur in both the 12S and 13S prod-
ucts, whereas CR3 is unique to the 13S transcript.
Under most circumstances, the 13S product is a much
more efficient trans-activator of gene expression than
the 12S product, and 13S is responsible for the ac-
tivation of other early viral genes during infection.
Nevertheless, the E1A 12S product can activate ex-
pression of a number of cellular growth-regulated
genes, including the gene encoding PCNA. Just as
CR3 is dispensable for induction of the PCNA gene,
functions of the first and second conserved domains
are largely dispensable for the viral gene trans-
activation function. This observation implies that the
PCNA gene represents a different class of targets, ac-
tivated in response to an El A function different from
that of the viral early genes.
We determined that cotransfection of a plasmid
that expresses the El region of adenovirus trans-
activates a chimeric gene consisting of the PCNA
promoter fused to the bacterial chloramphenicol
acetyltransferase (CAT) reporter gene. Because the
products of both El genes can influence gene expres-
sion (including their own), it was necessary to ex-
press the products of the El region independently and
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efficiently in order to address their role in the
stimulation of the PCNA promoter. We obtained
from E. White (DNA Synthesis section) vectors in
which the highly active cytomegalovirus (CMV)
immediate-early promoter drives expression of the
products of the E1B region individually or together
(CMV19K, CMV55K, and CMVEIB) and prepared
similar clones to express El A gene products
(CMV13S, CMV12S, and CMVE1A). We found that
the CMV55K plasmid has no effect on the PCNA
promoter upon cotransfection with PCNA-CAT into
He La cells. The CMV19K plasmid stimulates the ex-
pression of PCNA-CAT and of two control plasmids,
E3CAT and SV2CAT. Furthermore, cotransfection
with CMV19K stimulates CAT expression from each
of the PCNA promoter deletion mutants. These ob-
servations are consistent with our previous observa-
tions that 19K stabilizes transfected plasmid DNAs.
The 13S and 12S expression clones both stimulate
expression of the PCNA promoter at all concentra-
tions tested, but they have different effects on the
E3CAT and SV2CAT constructs. Low amounts of
the CMV13S plasmid stimulate expression from
E3CAT or SV2CAT, whereas higher amounts stimu-
late little or give a negative response, presumably be-
cause of the E1A repression function. The CMV12S
plasmid represses CAT expression from the E3 or
SV40 promoters at all concentrations tested.
These results demonstrate that the El A 12S pro-
duct can activate transcription from the PCNA
promoter in the absence of other adenovirus genes.
Examination of the promoter sequence revealed a
number of potential E1A-responsive elements. To
distinguish elements in the PCNA promoter that
respond to 13S, 12S, or both, deletion constructs of
the PCNA promoter were cotransfected with the 13S
and 12S expression plasmids. As a control, we
employed a construct containing a frameshift muta-
tion just downstream from the translation initiation
site of the El A protein (CMV12S.FS). The analysis
suggests that an element(s) responsive to both El A
12S and 13S resides within the region located 87-46
nucleotides upstream of the transcription initiation
site. This region includes a sequence (TGACGTCG)
that has homology with an ATF site (TGACGTCA)
centered about 50 nucleotides upstream of the start of
transcription. Additional mutations that eliminate the
ATF site from the full-length promoter reduce the
basal level of PCNA-CAT mRNA about fivefold and
abolish trans-activation by 12S, suggesting that the
ATF site plays a role in the basal level of transcrip-
tion and in the response to El A.
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To confirm this result, we mutated the ATF se-
quence in the background of a shortened PCNA
promoter, the -87 to +60 PCNA-CAT construct that
contains only 147 nucleotides of PCNA gene se-
quence. This construct is trans-activated to a greater
degree by cotransfection of pCMV12S, but its basal
activity is low. We therefore included the CMV19K
plasmid in the transfections to boost basal levels of
transcription from the -87 to +60 constructs. The
results allow us to conclude (1) that the principal
target for the 13S product in the PCNA promoter is
the ATF site at -50, but another element in the region
from -46 to +60 or possibly within the vector se-
quences can also respond to the trans-activating ef-
fect of the El A 13S protein, and (2) that the sole
responsive element in the -87 to +60 region that
responds to trans-activation by the El A 12S product
is the ATF site at -50. ATF elements are widespread
in promoters, but only the PCNA ATF site and pos-
sibly an AP-1 site in the c-jun promoter have been
shown to be 12S-responsive. The selective response
of the PCNA promoter to 12S may be conferred by
some contextual feature of the PCNA promoter, by a
complex involving specific members of the ATF
family, or by a combination of these two possibilities.
Our present work is aimed at addressing these issues.
were conducted in
HeLa cells and may not reveal all the mechanisms by
which the PCNA gene can be stimulated by E1A. It is
possible that there are other pathways for ElA to ac-
tivate PCNA gene expression that predominate in
other cell types. We have begun experiments to
evaluate the generality of the ATF-mediated stimula-
tion, to explore the roles of other possible E1A-
responsive elements in the PCNA promoter that
might not be addressed in the HeLa cell assay, and to
extend our findings to cell types with more normal
growth properties. In preliminary studies of the
response of the human PCNA promoter in primary
cells, we cotransfected baby rat kidney (BRK) cells
with the PCNA-CAT and El A constructs employed
previously. We found that the activity of the human
PCNA promoter is reduced by cotransfection of any
CMV El A expression plasmid (12S, 13S, or E1A).
This repression seems to require PCNA promoter se-
quences located between 249 and 172 nucleotides up-
stream of the cap site. It is unclear at present how to
reconcile these observations with prior transforma-
tion assays and our HeLa cell results. Perhaps species
differences or differences in the state of cell growth
or other cell-type-specific factors can account for the
disparate results in the two cell types. It is also pos-
sible that other adenovirus genes participate, since
adenovirus early gene products other than E1A can
elicit transcriptional effects. In the case of viral infec-
tion of BRK cells, the requirement for El A se-
quences could be due to the trans-activating effects
of the E1A protein on other viral genes or possibly to
a requirement for El A sequences in cis for the ex-
pression of other viral early gene products. In the
context of a viral infection, it is difficult to determine
whether the effect on the cellular PCNA gene is
directly attributable to the 12S product or is mediated
through effects of 12S on other viral genes.
The demonstration that the 12S E1A product can
activate transcription of a growth-related gene direct-
ly could provide important clues to its transforming
functions. The adenovirus El-responsive human
DNA polymerase -(1 promoter possesses an ATF site
centered 45 nucleotides upstream of the transcription
initiation point, and this site displays homology
(12/13 nucleotides) with the ATF site in the PCNA
promoter. It is possible that recognition of this ex-
tended ATF site by an E1A-responsive factor as-
sumes a key role in the induction by E1A of the com-
ponents of the DNA replication machinery. Indeed,
the PCNA gene could serve as a paradigm for the in-
duction of a large number of coordinately controlled
cellular proteins (see Quest Protein Database in the
Molecular Genetics of Eukaryotic Cells Section).
Mechanism of trans-Activation
by the HIV-1 Tat Protein
M.F. Laspia, M. Kessler, P. Wendel, M.B. Mathews
The human immunodeficiency viruses (HIVs) appear
to be the etiologic agents of acquired immuno-
deficiency syndrome (AIDS). HIV infects and kills
CD4+ helper T cells, which are an essential com-
ponent of the immune system required for fighting
microbial and viral infections. This produces an im-
munocompromised state in infected individuals,
rendering them susceptible to infection by op-
portunistic pathogens. HIV also infects nervous sys-
tem cells, and, as a result, patients often manifest
neurological disorders. An important pathogenic
component of HIV infection is the establishment of a
state of viral latency, lasting several years, between
infection and the onset of clinical symptoms.
An area of intense interest in HIV research and
one that continues to be a primary focus of our re-
search is elucidation of the molecular basis of regula-
tion of HIV gene expression by the virus-encoded
trans-activator protein Tat. In addition to the struc-
tural proteins Gag, Pol, and Env, the genome of HIV
encodes several structural and regulatory proteins not
found in other retroviruses. One of these, Tat, is an
essential protein that greatly increases the expression
of genes linked to the long terminal repeat (LTR) of
the virus. Tat is a novel activator that binds to a struc-
tured RNA, known as TAR, present in the 5 ' -
untranslated region of all HIV mRNAs. As discussed
in previous Annual Reports, we have utilized a
recombinant adenovirus model system to explore the
nature of trans-activation by Tat. This system
employs a recombinant adenovirus vector (HIV-
1CATad) containing the HIV-1 LTR, including TAR
sequences required for trans-activation by Tat, fused
to a reporter gene (CAT) to infect HeLa cells that
stably express Tat. For comparative purposes, we
have also analyzed regulation of HIV-1 gene expres-
sion by the adenovirus El A trans-activator protein.
Earlier work led us to propose that Tat stimulates
HIV-1 transcription bimodally, by increasing tran-
scriptional initiation and stabilizing transcriptional
elongation. We discovered that in the absence of Tat,
the basal rate of initiation of HIV-1 transcription by
RNA polymerase II is low and elongation is unstable
such that the number of transcriptional complexes
declines with increasing distance from the transcrip-
tional start site (polarity). Tat interacts with TAR and
stimulates transcription by increasing the frequency
of transcriptional initiation and also by suppressing
elongational polarity, resulting in a greater fraction of
initiating RNA polymerases reaching the 3' end of
the transcription unit. E1A, on the other hand, stimu-
lates initiation with little effect on elongation and
does not require TAR. On the basis of these findings,
our working model, shown in Figure 2, is that TAR
RNA functions much like a DNA enhancer element,
providing a binding site for Tat at the HIV-1
promoter. Tat causes the efficient formation of an in-
itiation complex at the HIV-1 promoter that is
capable of stable elongation.
The polarity of HIV-directed transcription in the
absence of Tat suggests that elongation away from
the promoter is impaired. We have mapped the distri-
bution of transcription complexes by sizing the run-
on transcripts to determine if the impairment of tran-
scription is due to a specific elongation block within
the promoter proximal sequences or to poor pro-
cessivity on the part of complexes formed at the HIV
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FIGURE 2 Model for trans-activation of HIV-1 gene expression by Tat. The basal
level of transcription (-Tat) is influenced by cellular and viral transcriptional ac-
tivators (such as NF-KB, Sp1, and E1A) as well as the position of an origin of
DNA replication. In HeLa cells, for example, the basal level of transcriptional in-
itiation is low, but it can be increased by adenovirus E1A or PMA. In the ab-
sence of Tat, elongating transcriptional complexes are unstable, and the density
of transcribing RNA polymerases declines with increasing distance from the
promoter. The RNA products of prematurely terminated RNA polymerases may
be trimmed back to the base of the TAR stem. Tat elevates the frequency of
transcriptional initiation and also stabilizes elongation, leading to a large relative
increase in transcription in the 3' end of the gene. We propose that Tat bound to
the HIV-1 leader via TAR causes the efficient formation of a unique RNA
polymerase complex at the HIV-1 promoter that is capable of efficient elonga-
tion.
promoter. This was accomplished by isolating pulse-
labeled HIV-I-specific run-on transcripts from trans-
fected cells by hybrid selection, followed by analysis
in sequencing gels. Pulse labeling of the nascent
RNA in the absence of Tat led to the detection of
several RNA transcripts of 40-80 nucleotides. In the
presence of Tat, the same short transcripts accumu-
lated as well as longer RNAs. When pulse labeling
was followed by 30 minutes of chase transcription in
the presence of unlabeled precursors, the 40-80 -
nucleotide transcripts elongated, implying that their
accumulation during the pulse is due to the transcrip-
tional complexes pausing, but not terminating, tran-
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scription. The accumulation of transcripts of several
different sizes suggests that polarity is due not to an
elongation block at a specific site but to a propensity
of the complexes formed at the HIV promoter to stop
within the promoter proximal sequences. Interesting-
ly, RNase protection analysis of cytoplasmic RNA in
transient assays has revealed that in the absence of
Tat, the predominant HIV-directed products are short
transcripts of 55-60 nucleotides. We are now study-
ing the processes involved in the accumulation of the
short cytoplasmic transcripts and the relationship of
these transcripts to those produced in the run-on reac-
tions.
To investigate the discrepancy between our find-
ings-that Tat both stimulates transcriptional initia-
tion and suppresses polarity, and the observation
from other laboratories that Tat acts solely on elonga-
tion-we turned to transient expression experiments.
Plasmids containing an HIV-1 LTR-directed reporter
gene and an SV40 replication origin region were
transfected into COS cells, monkey cells that express
SV40 T antigen and permit plasmid amplification as
a result of DNA replication. Surprisingly, we found
that the mode of action of Tat depends on the struc-
ture of the plasmid containing the HIV LTR-CAT
cassette. The position and orientation of the origin
region, the source of the LTR (LTRs from two dif-
ferent viral isolates were tested), the presence of ad-
ditional R and U5 sequences downstream from TAR,
and the nature of the plasmid vector were all consid-
ered. We found that the determinative feature is the
position of the SV40 DNA replication origin relative
to the LTR, but not its orientation. Nuclear run-on
analysis indicated that, in the absence of Tat, place-
ment of the origin region downstream from the HIV
LTR-CAT cassette results in tenfold more promoter
proximal transcription than when the origin is placed
upstream of the LTR. When the origin is in the up-
stream location, Tat increases both the number of in-
itiation events and the efficiency of elongation; on
the other hand, when the origin is downstream, and
the initiation rate is already high, Tat functions
primarily to increase the efficiency of transcriptional
elongation. These observations are compatible with
results obtained by analysis of accumulated cytoplas-
mic RNA using an RNase protection assay. Thus, the
effect of Tat on initiation is diminished when the
basal transcription level is high.
Analysis of plasmid DNA levels indicated that
these transcriptional differences were not due to dif-
ferences in copy number related to the position of the
origin. Moreover, although the origin region contains
portions of both the early and late SV40 promoters,
RNase protection analysis indicated that transcription
from the origin region does not occur to any sig-
nificant extent and cannot explain its effect on ex-
pression from the HIV LTR. Nevertheless, it is pos-
sible that sequences in the 200-bp origin region exert
a transcriptional effect on the HIV LTR from a dis-
tance. Alternatively, the origin could influence tran-
scription from the LTR or the effect of Tat by alter-
ing template structure through replication. Data from
experiments in CV-1 cells (monkey cells lacking
SV40 T antigen) favor the idea that replication is in-
volved. In the presence of T antigen, supplied by
cotransfection, the position effect is observed as in
COS cells; in the absence of T antigen, no such effect
is seen. These findings suggest that T antigen is re-
quired, most likely to allow replication, although
other interpretations are not yet excluded. Replication
has been reported to activate transcription in several
systems; if confirmed in the case of HIV-1, this me-
chanism of transcriptional activation could contribute
in an important way to the transition from latency to
active infection when resting T cells are induced to
proliferate.
Viral latency may result in part from transcrip-
tional quiescence of HIV provirus in infected resting
T cells. We and other investigators have found that
Tat cooperates with general viral trans-activators and
T-cell activators to elevate HIV gene expression
synergistically. Since the interaction between Tat and
other transcriptional activators may be involved in
the transition from low levels of transcription early in
infection or during viral latency to high levels of ex-
pression during active viral growth, we examined the
basis of synergy. As described in last year's Annual
Report, Tat and adenovirus El A or phorbol esters
elevate LTR-directed RNA levels to a greater extent
than expected for an additive action. Analysis of tran-
scription rates indicated, unexpectedly, that synergy
is not due to elevated levels of transcriptional initia-
tion which appeared to saturate. To determine
whether transcriptional synergy results from suppres-
sion of elongational polarity, we constructed DNA
probes that enabled us to measure transcription rates
across the entire LTR-directed transcription unit by
nuclear run-on assay. This analysis indicated that
synergy can be accounted for by increased levels of
transcription in the 3 ' portions of the HIV-1-directed
transcription unit, suggesting that synergy is due
principally to stabilization of transcriptional elonga-
tion.
An important focus of our efforts is to establish a
cell-free system for trans-activation by Tat that
mimics the effects we have observed in vivo. Recent-
ly, Phil Sharp and his colleagues at the Massachusetts
Institute of Technology reported that Tat protein is
capable of stimulating HIV-1 transcription in vitro.
Such a system provides a powerful means to identify
and characterize cellular factors involved in trans-
activation by Tat. To this end, we purified Tat to ap-
proximately 80% homogeneity from Escherichia coli
using a bacterial expression system. To test the
biological activity of Tat preparations, we utilized the
technique of scrape loading to introduce Tat into cells
infected with the recombinant adenovirus. Uptake of
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Tat protein resulted in a large stimulation of HIV -1-
directed gene expression: Analysis of reporter gene
activity and cytoplasmic RNA levels demonstrated
that the bacterially expressed Tat stimulated LTR-
directed transcription levels in a fashion similar to
that produced by Tat stably expressed in an HIV-
1CATad-infected He La/tat cell line. Thus, our
purified preparations of bacterially expressed Tat
protein display the same biological properties as Tat
expressed in mammalian cells.
In agreement with results obtained in Phil
Sharp's laboratory, we have also found that partially
purified Tat is capable of stimulating transcription
from the HIV-1 promoter in vitro in a nuclear extract
prepared from He La cells. We have optimized condi-
tions for transcription by Tat in vitro and have found
that Tat stimulates transcription up to 25-fold from an
HIV-1 DNA template digested with a restriction en-
zyme so as to produce a correctly initiated 747 -
nucleotide runoff transcript. Tat stimulated transcrip-
tion in a dose-responsive manner from a wild-type
HIV-1 LTR template but not from a TAR mutant
template or an adenovirus major late promoter (MLP)
template. Tat produced a smaller, fourfold stimula-
tion of transcription when the HIV-1 template was
digested with a restriction enzyme so as to produce a
shorter 333-nucleotide runoff transcript.
that the magnitude of stimulation of transcription by
Tat increases for longer runoff transcripts is con-
sistent with Tat acting to stimulate transcriptional
elongation. We are currently attempting to determine
if Tat stimulates transcriptional initiation in the cell-
free system: Future efforts will be directed toward
fractionating nuclear extracts and attempting to iden-
tify cellular factors involved in stimulation of tran-
scription by Tat.
Translational Effects of
HIV-1 TAR RNA
S. Gunnery, S. Green, M.B. Mathews
The 5' LTR of human immunodeficiency virus type
1 (HIV-1) contains a cis-acting element called TAR
that confers responsivity to the trans-acting protein
Tat. A transcript of the TAR sequence (TAR RNA) is
present in the 5' -untranslated region of all HIV-1
mRNAs and adopts a stable stem-loop structure. It is
also present as a free cytoplasmic form of about 60
nucleotides. It has been reported that TAR RNA can
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exert an inhibitory effect on protein synthesis both in
trans and in cis: As a result, mRNA with a TAR
leader is translated poorly in vitro compared with that
without the TAR structure. The stem of the TAR
RNA is also reported to inhibit initiation of transla-
tion in vitro by activating the dsRNA-activated in-
hibitor, DAI, which phosphorylates initiation factor
eIF -2.
As mentioned above, the protein kinase DAI re-
quires 30-50 by of perfect dsRNA for activation:
Shorter duplexes or imperfect duplexes do not ac-
tivate the kinase. Secondary structure analysis of
TAR RNA indicates that the stem region has only 11
by of continuous duplex, so it would not be expected
to activate DAI. On the contrary, it is more likely to
inhibit the activation of DAI as other short duplexes
do. On the basis of our experience with VA RNA, we
thought that the reported activation of DAI by TAR
RNA might be due to dsRNA that often contaminates
RNA transcribed in vitro using bacteriophage RNA
polymerase. To test this idea, we synthesized TAR
RNA (+1 to +82 of HIV-1 LTR) in vitro using T7
RNA polymerase. In agreement with earlier results,
we observed that partially purified TAR RNA, frac-
tionated through a denaturing polyacrylamide gel,
does activate DAI. Although TAR RNA is sensitive
to single-strand-specific RNase T1 and insensitive to
the double-strand-specific RNase III, the DAI activa-
tion capability of partially pure TAR RNA exhibits
the opposite sensitivities. This suggests that the ac-
tivation of DAI is not due to TAR RNA per se, but is
due instead to a contaminant whose nuclease
sensitivity is like that of dsRNA. Moreover, the DAI
activation capacity is eliminated by further purifica-
tion through a nondenaturing gel and chromatog-
raphy on cellulose CF-11.
At high concentrations, purified TAR RNA in-
hibits the activation of DAI by dsRNA in a manner
similar to that of adenovirus VA RNA. This result
was observed in an in vitro kinase assay, where ac-
tivation was monitored by autophosphorylation of the
enzyme. The nuclease sensitivity of the inhibition
matches that of TAR RNA, and the antisense comple-
ment of TAR RNA does not affect DAI activation ex-
cept at extremely high concentrations, suggesting that
the effect is specific. We have also tested the in-
hibitory property of TAR RNA in a translation assay
using a rabbit reticulocyte lysate. This cell-free
protein-synthesizing system affords a reasonable ap-
proximation to the in vivo situation as DAI is
ribosome-associated and is activatable by dsRNA,
leading to inhibition of protein synthesis. In this sys-
tern, the dsRNA-mediated inhibition of translation is
blocked by both TAR RNA and VA RNA. We are
now testing a variety of mutants of TAR RNA in or-
der to correlate the structure of the molecule with its
functions.
Structural Analysis of HIV-1
and HIV-2 Tat Proteins
A.P. Rice, C.O. Echetebu, M. Sullivan, R. Packer
Last year, we reported the use of the wheat-germ
cell-free system to analyze structural features of wild-
type and mutant HIV-1 Tat proteins. The wild-type
protein consisting of 86 residues was found to form a
highly fold, protease-resistant structure consisting of
the first 72 residues contained in the first coding
exon. This structure is likely to be relevant to Tat
function, as all mutant proteins unable to form this
structure are defective for trans-activation activity in
vivo. In the past year, we have continued to exploit
the wheat-germ system to investigate the structures of
Tat proteins. We have shown that an HIV-1 Tat
protein consisting of only the first 57 residues is able
to form a protease-resistant structure. However, a Tat
protein consisting of the first 48 residues is unable to
form such a protease-resistant structure. In addition,
we have used the techniques of gel filtration, velocity
sedimentation, and glutaraldehyde cross-linking to
demonstrate that wheat-germ Tat exists predominant-
ly, if not exclusively, as a monomer. This finding
contrasts with initial publications which presented
evidence that the HIV-1 Tat protein expressed and
purified from E. coli existed as a dimer. Recent
modified purification procedures, however, have
demonstrated that E. coli- expressed Tat can exist as a
monomer.
We have also continued our analysis of the Tat
protein from HIV-2, a human immunodeficiency
virus thus far found largely only in western Africa.
The HIV-2 Tat protein that we have analyzed con-
tains 99 residues and is structurally related to the
HIV-1 Tat protein; the proteins are 64% identical and
90% homologous in the centers of the molecules,
which include cysteine-rich and basic regions. To
determine how much of the carboxyl terminus can be
deleted before trans-activation activity is lost, we
used site-directed mutagenesis to construct a series of
truncation mutants. We found that an HIV-2 Tat
protein truncated immediately after the basic region
(residue 90) possesses approximately 30% of the
trans-activation activity of full-length HIV-2 Tat.
Further deletion of five basic residues results in al-
most complete loss of trans-activation activity. Final-
ly, we have initiated structural studies of the HIV-2
Tat protein expressed in the wheat-germ system. Un-
der conditions of limiting trypsin digestion, the HIV-
2 Tat protein appears to be significantly more sensi-
tive to proteolysis than the HIV-1 Tat protein. We
also found that the HIV-2 Tat protein elutes in gel-
filtration columns with a Stokes' radius significantly
greater than that of HIV-1 Tat; because these proteins
differ by only 13 residues, this large difference in
Stokes' radii cannot be explained simply by the addi-
tional residues contained in the Tat HIV-2 protein.
These preliminary results therefore indicate that the
closely related HIV-1 and HIV-2 Tat proteins possess
significantly different structures.
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NUCLEIC ACID CHEMISTRY
R.J. Roberts
A.R. Krainer
G. Conway
B. Dong
D. Kozak
A. Mayeda
C. Marcincuk
M. Myatt
M. Wallace
The long-term aim of our research is to obtain a
detailed understanding of the mechanism of pre-
mRNA splicing in mammalian cells. In particular, we
are interested in determining how the RNA cleavage-
ligation reactions are catalyzed, and how the
specificity of splice site selection is achieved. As part
of this effort, we are purifying several of the
nucleoprotein and protein factors that are necessary
for cleavage of the pre-mRNA at the 5 ' splice site
and for lariat formation. Our general strategy is to de-
velop complementation assays for individual ac-
tivities, such that one or both cleavage-ligation reac-
tions are strictly dependent on the presence of the ac-
tive component in question. The factors responsible
for these activities are purified and then characterized
to determine their mode of action. More recently, we
have begun to characterize activities that modulate
the selection of alternative splice sites in vitro. The
identification and detailed characterization of splicing
factors should provide crucial insights into the me-
chanism of pre-mRNA splicing, the specificity of
splice site selection, and the origin and evolution of
the splicing machinery and of pre-mRNA introns.
SF2 PURIFICATION
Previously, we purified a protein factor called SF2
from HeLa cells and showed that it was an essential
splicing factor. SF2 was purified on the basis of a
biochemical complementation assay, taking ad-
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vantage of our observation that cytoplasmic fractions
prepared in hypotonic buffers are inactive in splicing
because they lack only this activity. SF2 can be ex-
tracted from nuclei at higher salt concentrations,
probably due to its association with large hetero-
geneous nuclear ribonucleoprotein (hnRNP) com-
plexes. The most purified fractions of SF2 contain a
doublet of 33-kD polypeptides that have very similar
amino acid compositions. In addition, a 32-kD
polypeptide is also present, but it is not sufficient for
activity because it peaks in an adjacent
chromatographic fraction that is both inactive and
devoid of the 33-kD polypeptides. This smaller
polypeptide may nevertheless represent a subunit of
SF2 that may or may not be limiting in the 5100 ex-
tract.
ROLE OF SF2 IN SPLICEOSOME ASSEMBLY
The complementation assay employed for the
purification of SF2 indicates that this activity is re-
quired for cleavage of the pre-mRNA at the 5 ' splice
site and for lariat formation. This reaction is normally
preceded by the assembly of specific pre-spliceosome
and spliceosome complexes, in which pre-mRNA in-
teracts in a stable manner with multiple components
of the splicing apparatus, such as the U small nuclear
ribonucleoproteins (snRNPs). To determine the re-
quirement for SF2 in this assembly pathway, RNP
complexes were analyzed by a gel-retardation assay.
These experiments showed that SF2 is required for
the assembly or the stabilization of the earliest
specific complex in the spliceosome assembly path-
way, which is thought to be the A complex.
SF2 HAS AN RNA ANNEALING ACTIVITY
To determine whether SF2 has unwinding or anneal-
ing activities, we incubated the purified protein with
complementary RNAs and digested the RNA with
ribonuclease T1, which is specific for single-stranded
RNA. We found that SF2 promoted annealing of
complementary RNAs in an ATP-independent man-
ner. No unwinding or ATP-dependent helicase ac-
tivities were detected under these conditions. Thus,
SF2 lowers the activation energy for intermolecular
RNA duplex formation and thus behaves as an RNA
annealing activity. To assess the significance of this
RNA annealing activity, we tested other proteins
known to promote intermolecular RNA annealing,
such as the 35-kD hnRNP Al protein (S. Munroe,
pers. comm.). We found that concentrations of Al
that were active in RNA annealing did not substitute
for SF2 in the splicing complementation and splice
site selection assays. These observations suggest that
if RNA annealing activity is integral to SF2 and
necessary for splicing, it is not sufficient, implying
that specific protein-protein or protein-RNA interac-
tions are involved in mediating the role of SF2 in
splicing and splice site selection.
Further experiments are necessary to elucidate the
precise substrate specificity, if any, of the SF2 RNA
annealing activity. However, we can envisage three
types of complementary RNA targets upon which the
SF2 RNA annealing activity could act to mediate its
effects on splicing and splice site selection. First, at
least two snRNA-pre-mRNA helices are known to be
formed during splicing and to contribute to splice site
selection; these involve base-pairing interactions be-
tween the 5 ' terminus of U1 snRNA and pre-mRNA
5 ' splice sites and between an internal region of U2
snRNA and pre-mRNA branchpoint sequences. Sec-
ond, U4 and U6 snRNAs coexist in a single snRNP
particle held together by intermolecular base pairs,
and there is some evidence that the U4 subunit may
be released from the spliceosome during the course
of splicing, possibly to be recycled. Third, pre-
mRNA may be recognized as a proper splicing sub-
strate when it adopts a defined secondary and tertiary
structure. Some of the intramolecular RNA helices
may preferentially expose the splice sites and branch-
point.
RNA-BINDING PROPERTIES OF SF2
To determine whether purified SF2 binds RNA,
several types of analyses were carried out. UV cross-
linking demonstrated binding to pre-mRNA and to
mRNA (Fig. 1). In this type of analysis, when the
cross-linked material is extensively digested with
ribonuclease A, the protein-oligoribonucleotide ad-
ducts usually comigrate or migrate slightly behind the
untreated polypeptides on SDS-PAGE. In the case of
SF2, the labeled adducts comigrate with the 33-kD
doublet, as expected if both polypeptides bind RNA.
No RNA binding was detected by Northwestern blot-
ting, but this could be due to poor renaturation after
SDS-PAGE. We have not been able to separate the
two polypeptides by nondenaturing techniques, and
thus we cannot presently determine whether only one
or both are responsible for the observed activities.
However, amino acid analysis of the individual elec-
trophoretically separated polypeptides suggests that
they are highly related.
The RNA-binding properties of SF2 were studied
further by RNase H protection experiments (Fig. 2).
Pre-mRNA was incubated in the presence of SF2 and
then briefly digested in the presence of a large
amount of RNase H and one of several com-
plementary deoxyoligonucleotides. RNase H specifi-
cally cleaves the RNA strand in RNA-DNA hybrids.
Bound protein may protect the pre-mRNA from di-
gestion by interfering with oligonucleotide and/or
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FIGURE 1 UV cross-linking assay. Purified SF2 was incu-
bated with the indicated radioactively labeled RNAs under
splicing reaction conditions, irradiated at 254 nm, digested
with RNase A, and analyzed by SDS-PAGE and auto-
radiography. The indicated amount of rRNA was present as
competitor.
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FIGURE 2 RNase H protection assay. Pre-mRNA was mixed
with purified HeLa SF2 in splicing buffer and kept on ice (-)
or incubated at 30°C (+) for 30 min. The indicated
oligonucleotide (1-11) was added in excess together with
RNase H, and the reactions were incubated for 5 min at
30°C. Under these hybridization and digestion conditions,
complete cleavage is observed in the absence of SF2.
RNase H binding. In the absence of SF2, all of the
oligonucleotides resulted in complete pre-mRNA
cleavage (not shown). In the presence of SF2 but
without preincubation, several regions were substan-
tially protected from digestion. When the pre-mRNA
was preincubated with SF2, the cleavage pattern was
different, and several protections and enhancements
were observed. For example, the branch site is more
susceptible to cleavage after incubation with SF2
(oligo 7). In contrast, a region in exon 2 becomes
more resistant to cleavage (oligo 11). These experi-
ments suggest that binding may occur at multiple
sites in the pre-mRNA and that there may be sites of
preferred binding. The observed results may also
reflect conformational rearrangements of the pre-
mRNA induced by SF2.
SF2 INFLUENCES 5' SPLICE SITE SELECTION
UI and U2 snRNAs play important roles in splice site
selection by virtue of their ability to interact by inter-
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molecular RNA-RNA base pairing with 5 ' splice
sites and branchpoint sequences, respectively. How-
ever, these interactions are not sufficient to account
for the specificity of splice site selection. Splice sites
are often surrounded by cryptic splice sites that are
only activated upon mutation of the natural splice
sites. It is not known whether the same set of factors
that recognize natural splice sites are also capable of
recognizing the cryptic sites when the natural sites
are mutated. Furthermore, although 5 ' and 3 ' splice
sites from different introns are usually compatible,
the splicing machinery normally avoids exon skip-
ping by an unknown mechanism. Many genes are
capable of expressing multiple protein isoforms by
using alternative 5' and/or 3' splice sites, often in a
regulated manner. Again, it is not known how this
type of mechanism is controlled. Finally, it appears
that in addition to the conserved 5 ' , 3 ' , and branch-
point sequence elements, additional, poorly defined,
sequences in exons and introns can also influence
splice site selection and splicing efficiency. It is not
known how these context elements exert their effects.
We previously showed that not only is SF2 an es-
sential general splicing factor, but it is also capable of
influencing splice site selection in vitro in a
concentration-dependent manner. Thus, when multi-
ple 5 ' splice sites are present in cis-competition, high
concentrations of SF2 promote the use of the
downstream, or proximal, 5 ' splice site. We have ex-
tended our initial observations to a large number of
substrates and have consistently observed a polarity
toward proximal 5 ' splice sites. So far, the splice site
selection effect appears to be restricted to 5 ' splice
sites. Interestingly, even high levels of SF2 result in
proper discrimination between authentic and cryptic
5 ' splice sites. These properties are consistent with a
role of SF2 in ensuring the specificity of splice site
selection during constitutive splicing in vivo, by
helping to avoid aberrant exon skipping. Further-
more, SF2 may play a role in the tissue-specific or
developmental regulation of certain alternatively
spliced genes. In collaboration with D. Helfman
(Molecular Genetics of Eukaryotic Cells Section),
SF2 was shown to be able to modulate the pattern of
splicing of a natural alternatively spliced pre-mRNA
in vitro. High levels of SF2 led to the preferential
utilization of the proximal skeletal-muscle-specific
tropomyosin 5' splice site at the expense of the
fibroblast-specific 5 ' splice site. Thus, high levels of
SF2 can overcome tissue-specific differences be-
tween 5 ' splice sites at least in some cases. In addi-
tion, these studies showed that SF2 can prevent aber-
rant exon skipping in vitro. In collaboration with J.
Manley (Columbia University), we showed that SF2
is identical with ASF, a factor isolated independently
in Dr. Manley's laboratory, which can modulate
alternative splicing of the SV40 tumor antigens.
Current experiments are aimed at determining
whether the in vivo levels or activity of SF2 vary
among different cell lines and whether posttransla-
tional modification can play a role in regulating SF2
activity.
MOLECULAR CLONING OF SF2
To study the structure, function, and in vivo expres-
sion of SF2, we have cloned the corresponding
cDNAs, expressed them in functional form, and ob-
tained antibodies against this factor. The most
abundant polypeptides present in purified SF2 prepa-
rations from He La cells have been analyzed in detail.
The overall amino acid composition of a highly
purified fraction was determined, as well as the indi-
vidual composition of each of the two major 33-kD
bands following SDS-PAGE and electroblotting to a
polyvinylidene difluoride (PVDF) membrane. Both
bands have a similar amino acid composition, charac-
terized by an extremely high content of arginine
(-20%). The same fraction was subjected to auto-
mated sequencing and yielded a single sequence. Our
preparations of SF2 contain variable amounts of a 32-
kD polypeptide, which peaks in an adjacent fraction
that is free of the 33-kD polypeptides, and is by itself
inactive in the complementation assay for splicing.
This smaller polypeptide, which is not arginine-rich,
yielded the same amino-terminal sequence as the ac-
tive fraction, and since larger quantities were avail-
able, we were able to obtain a reliable sequence for
the first 31 amino acids. These observations indicate
that the two 33-kD polypeptides either share the same
amino terminus with the 32-kD polypeptide or are
both blocked at the amino terminus. Although we
could not exclude the possibility that the 32-kD
polypeptide is unrelated to SF2, we set out to obtain
cDNAs and antibodies for this protein to allow prob-
ing of its function.
32-kD Putative Subunit. Degenerate oligonucleotides
were designed on the basis of the most reliable and
least degenerate portions near the ends of the 31-
amino -acid sequence. The carboxy-terminal antisense
oligonucleotides were used to prime cDNA synthesis
on He La poly(A)+ mRNA, and polymerase chain
reaction (PCR) products of the expected length were
obtained after 30 rounds of amplification. The pro-
ducts were subcloned and sequenced. The unique se-
quence bridging the degenerate primers matched the
experimentally determined amino acid sequence, and
an oligonucleotide corresponding to this unique se-
quence was used to screen a X1149 He La cDNA li-
brary. A single clone was obtained from a screen of
3 x 105 recombinants, and the cDNA was sequenced.
The sequence has no significant homologies with cur-
rent entries in the protein and DNA databases. It ap-
pears to be full-length and encodes a highly acidic
protein of 21.4 kD that initiates with a leucine CTG
codon, which corresponds to the amino terminus of
the purified He La protein, an unusual but not un-
precedented finding. Following mutagenesis of this
codon to ATG, the protein has now been over-
produced in soluble form in Escherichia coli, using
the T7 expression system (Fig. 3). This recombinant
product has the correct electrophoretic mobility, i.e.,
32 kD. We have also obtained antisera to a fusion
protein containing the PCR amplified portion and,
more recently, to the complete protein. These anti-
bodies will be used in immunofluorescence studies
and in inhibition and immunodepletion studies to
investigate whether this polypeptide may represent
an essential subunit of SF2 or an associated protein.
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FIGURE 3 Bacterial expression of the 32-kD putative sub-
unit. The full-length cDNA was expressed as an authentic
protein in E. coli with a T7 gene-10 promoter/ribosome-
binding site vector. Crude proteins are analyzed by SDS-
PAGE and Coomassie blue staining before induction (-) and
after addition of IPTG to induce the T7 RNA polymerase (+).
The soluble fraction (SOL) is also shown.
83
33-kD Subunit(s). More recently, we obtained a par-
tial amino acid sequence of several peptides genera-
ted by V8 protease digestion of highly purified 33-kD
polypeptides. Appropriate degenerate oligonucleo-
tides were designed and then tested in each of the two
possible relative positions for each pair of peptides.
One particular combination generated a PCR product
from He La poly(A)+ mRNA. Its sequence matched
the experimentally determined amino acid sequence
immediately adjacent to the primers and provided an
additional unique sequence between the two peptides.
An oligonucleotide corresponding to the unique
nucleic acid sequence was synthesized and used to
probe a X1149 He La cDNA library. Two independent
clones were obtained from a screen of 3 x 105 recom-
binants. They contain the same apparently complete
coding sequence but different lengths of 5 ' -and 3 ' -
untranslated sequences. They encode a basic 27.7-kD
protein with the expected high content of arginine
residues and no sequence relationship to the acidic
32-kD polypeptide (Fig. 4). Several clusters of
alternating arginine and serine residues constitute
regions of high homology with the Drosophila
proteins tra, tra2, and suppressor of white apricot, all
of which are involved in the regulation of specific
alternative splicing pathways. A similar region is
present in the Ul snRNP-specific 70-kD protein from
several species and in a phylogenetically conserved
region of the trans-activating domain of the papil-
lomavirus E2 protein. This cDNA clone also contains
a region that has strong homology with the 80-amino-
acid RNA recognition motif, including the two inter-
nal RNP1 and RNP2 consensus elements, which is
common to a large family of RNA-binding proteins.
These include several hnRNP and snRNP proteins,
the Drosophila alternative splicing regulators sxl and
tra2, and many other prokaryotic and eukaryotic
RNP-2 RNP-1 70 K G domain
proteins. This putative RNA-binding domain near the
amino terminus is followed by a stretch of multiple
glycines, which separates it from the carboxy-
terminal R/S-rich region. The Ul snRNP 70-kD
protein exhibits similar organization, despite its
larger size and lack of strong global homology. There
is, in addition, a stretch of eight identical amino acids
present in SF2 and in the 70-kD protein, located in
different positions in the two proteins relative to the
RNA recognition motif, which in the case of the 70-
kD protein corresponds to a true RNA-binding do-
main.
The fact that this extremely basic protein
copurified through ion exchange columns with the
acidic 32-kD protein suggests an interaction between
these polypeptides, although its physiological rele-
vance is uncertain. We are presently trying to express
the R/S-rich polypeptide in E. coli and to generate the
corresponding polyclonal and monoclonal antibodies.
One or both of the 33-kD bands are the most likely to
be SF2 because UV cross-linking experiments show
that they can bind RNA (see Fig. 1). Independent
studies on ASF have yielded a very similar polypep-
tide profile, including the arginine-rich polypeptides,
using a different purification protocol. As mentioned
above, the two 33-kD polypeptides have similar or
identical amino acid compositions, and thus they
probably differ by posttranslational modification, or
they may represent two different isoforms generated
by gene duplication or alternative splicing. Consistent
with the possibility that the heterogeneity is due to
posttranslational modification, the above cDNAs
generate doublets of the expected electrophoretic
mobility upon in vitro transcription, followed by
translation in reticulocyte or wheat-germ extracts
(Fig. 5).
The conserved sequence motifs identified in the
171123 54A67 93 1106 204
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RNA recognition motif R/S domain
FIGURE 4 Structure of SF2 subunit. The 248-amino-acid SF2 polypeptide (33 kD
apparent molecular mass) is drawn to scale. The RNA recognition motif, glycine-
rich domain, and arginine plus serine-rich domain are indicated. Within the RNA
recognition motif, the smaller boxes denote the RNP1 and RNP2 consensus ele-
ments and an eight-amino-acid identity to a region in the U1 snRNP-specific 70K
polypeptide.
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FIGURE 5 In vitro translation of recombinant SF2. SF2
mRNA was generated by in vitro transcription with T7 RNA
polymerase from the cloned full-length SF2 cDNA (33-kD
polypeptide). The mRNA was translated in wheat-germ or
rabbit reticulocyte extracts in the presence of P'Sj-
methionine. The proteins were detected by SDS-PAGE and
fluorography.
SF2 cDNAs can account in theory for some of the
observed biochemical properties. For example, the
RNA-binding properties of SF2 are fully consistent
with the presence of an RNA recognition motif. Fur-
thermore, this element is probably responsible for the
ATP-independent RNA annealing activity of SF2,
since a homologous element is found in several
proteins with comparable activities, e.g., hnRNP Al,
Drosophila helix destabilizing protein, and T4 gene-
32 protein. The R/S domain is especially intriguing
because it is found in several known regulators of
alternative splicing, although its precise function
remains unknown. We plan to examine the roles of
these domains in splicing, splice site selection, RNA
binding, and RNA annealing by mutagenesis and
biochemical analysis of the recombinant protein.
PURIFICATION OF HELA SF5 AND OTHER
BIOCHEMICAL STUDIES
We have recently identified an activity in HeLa cell
nuclear extracts, termed SF5, that specifically
counteracts the effects of SF2 on splice site selection.
SF5 is not a general inhibitor of SF2, because the lat-
ter activity is essential for splicing and a large excess
of SF5 still results in efficient splicing. However, the
ratios of these two activities precisely determine
which splice site is used in vitro (Fig. 6). Thus, high
levels of SF5 result in utilization of distal 5 ' splice
sites, whereas high levels of SF2 favor use of
proximal 5 ' splice sites.
An assay was designed for the purification of this
activity. An alternatively spliced pre-mRNA is used
as the substrate, and S100 and partially purified SF2
are added in precisely titrated amounts to result in
equal utilization of each of the two 5 ' splice sites.
Chromatographic fractions are added, and SF5 ac-
tivity is located by the resulting switch to the distal
5 ' splice site. On the basis of this activity assay, SF5
has been partially purified from sonicated HeLa
nucleoplasm through three chromatographic steps,
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FIGURE 6 SF5 activates distal 5' splice sites. Synthetic pre-
mRNAs containing alternative 5' splice sites (a distal
authentic p-globin 5' splice site, and either a proximal con-
sensus 5' splice site or a proximal SV40 small T antigen
5' splice site) were spliced in vitro in the presence of
nuclear extract (NE), S100 extract, partially purified SF2,
and/or partially purified SF5, as indicated. The elec-
trophoretic mobilities of the pre-mRNA and of the alternative
mRNA5 are indicated.
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with good recovery of activity. It has been separated
from SF2 activity and from snRNAs, and it does not
require RNA for its activity. Partially purified SF5 is
active in assays employing several different alterna-
tively spliced pre-mRNAs. Thus, this activity does
not operate in a substrate-specific manner, but rather
it has a general effect on the polarity of 5 ' splice site
selection. We believe that the intracellular ratios of
SF2 and SF5 may control the specificity of splice site
selection. Furthermore, in vivo regulation of one or
both of these activities may play an important role in
the tissue-specific or developmental regulation of
alternative splicing.
Another ongoing project concerns the analysis of
spliceosome assembly in nuclear extracts from which
large endogenous RNP complexes have been selec-
tively removed. Although a number of essential fac-
tors are associated with these endogenous complexes,
they can be released in an ATP-dependent manner.
The resulting extracts are competent for splicing, but
they display very different properties in the assembly
of spliceosomes. In contrast to crude extracts, the
RNP-depleted extracts do not form nonspecific com-
plexes that are largely due to hnRNP proteins, and
they form a single spliceosome complex that contains
the pre-mRNA and the intermediates of splicing.
These experiments suggest that hnRNP proteins are
dispensable for splicing and that the kinetics of
spliceosome assembly in standard extracts may
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Transcriptional regulation in eukaryotes is complex.
A large variety of cis-acting promoter elements are
recognized by an even larger number of transcrip-
tional activators. Commonly, families of transcrip-
tional activators recognize the same cis-acting ele-
ment. This phenomenon is no better exemplified than
in the regulation of development by homeodomain
proteins. One of the current challenges in the study of
transcriptional regulation in development is to under-
stand how transcription factors such as homeodomain
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reflect the binding of nonessential factors that delay
the formation of an active complex.
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proteins that recognize the same DNA sequence can
differentially activate transcription.
Homeodomain proteins were first discovered as
regulators of development in Drosophila. Subse-
quently, the 60-amino-acid homeodomain was shown
to be a DNA binding structure similar to the helix-
turn-helix motif found in prokaryotic transcriptional
regulators. In Drosophila, homeodomain proteins that
elicit very different developmental pathways can
share very similar DNA binding properties. Thus, it
is likely that in some instances, it is the different in-
teractions between proteins that are responsible for
the differences in transcriptional regulation observed
in vivo. Some of these types of interactions have
been the focus of our studies of the human
homeodomain proteins Oct-1 and Oct-2, which re-
cognize the same octamer motif ATGCAAAT found
in a variety of cellular and viral promoters.
VIRAL PROMOTERS AS PROBES FOR
TRANSCRIPTIONAL REGULATION IN
MAMMALIAN CELLS
As probes to study transcriptional regulation in mam-
malian cells, we use three primate viruses, the simian
DNA tumor virus SV40 and the human pathogens
herpes simplex virus (HSV) and human immuno-
deficiency virus (HIV). Our past studies of the enhan-
cer within the SV40 early promoter, which can ac-
tivate transcription over large distances, showed that
the restricted or unrestricted cell-specific activity of
enhancers results from interactions between multiple
enhancer modules; seldom is a single element re-
sponsible for the full activity of the enhancer. The
SV40 enhancer is typical of broadly active promoter
elements. It contains many individual elements that
can be categorized into two different types of organi-
zational units called enhansons and proto-enhancers.
Enhansons are the fundamental structural unit of en-
hancers and correlate with protein-binding sites. As
structural units, enhansons are not always active on
their own, but instead, they need to be intimately as-
sociated with a second enhanson to be active. Active
enhancer elements, composed of either one or more
enhansons, are called proto-enhancers. Proto-en-
hancers, however, can still only create an effective
enhancer (i.e., activate transcription at a distance)
when present in multiple copies, but, unlike en-
hansons, here there is no strict spacing requirement
between proto-enhancers.
Our past genetic dissections of the SV40 enhancer
revealed that it contains three proto-enhancers called
A, B, and C, all of which are active in the permissive
simian cell line CV-1. Currently, we are using
strategies similar to those that allowed us to dissect
the SV40 enhancer to analyze the structure of the
HIV-1 promoter, including the characterization of
HIV-1 promoter sequence rearrangements in HIV-1
variants. To study general aspects of transcriptional
regulation in mammalian cells, we have focused on
the transcriptional activation properties of Oct-1 and
Oct-2, which recognize an octamer motif within the
B proto-enhancer. The SV40 B proto-enhancer con-
sists of two overlapping sets of motifs, a tandemly
repeated 9-bp "sph" motif and an octamer motif
formed by the junction of the two sph motifs. The
SV40 octamer motif does not normally activate tran-
scription in cells permissive for SV40 infection (in-
deed, it may repress transcription), but instead, it dis-
plays activity in B cells, which express the Oct-2 ac-
tivator. We are studying how Oct-1, which is ubiqui-
tously expressed, and Oct-2, which is expressed
primarily in B cells, differentially activate transcrip-
tion. It turns out that a major player in this story is an
activator of HSV immediate-early gene expression
called VP16 (also referred to as Vmw65) that
modifies the activity of Oct-1, but not Oct-2, by dis-
criminating between the homeodomains of these two
activators. VP16 associates with Oct-1 to form a
multiprotein-DNA complex that alters the activation
potential of Oct-1 and that can alter the regulatory
specificity of Oct-1 by recruiting it to new DNA
binding sites.
Oct-1 Recognizes a Diverse Set
of Regulatory Sites through
Interdependent Interactions
by Multiple Regions of the
POU Domain
R. Aurora
The octamer motif-binding proteins Oct-1 and Oct-2
are POU proteins. The POU proteins are a unique
subfamily of homeodomain proteins that are dis-
tinguished by a 150-160-amino-acid bipartite DNA
binding domain, called the POU domain. The 60-
amino -acid homeodomain lies in the carboxy-
terminal portion of the POU domain; the amino-
terminal region contains a 75-amino-acid motif par-
ticular to the POU proteins called the POU-specific
region. Linking these two conserved motifs together
is a 15-27-amino-acid hypervariable segment. Al-
though the POU homeodomain can bind DNA weak-
ly on its own, the entire POU domain is required for
high-affinity and sequence-specific DNA binding.
Oct-1, along with many eukaryotic transcriptional
regulators, possesses the ability to recognize a
diverse set of DNA sequences. The ability of site-
specific transcriptional regulators to recognize
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diverse sequences has important consequences on the
flexibility with which promoters can be assembled
with overlapping binding sites and potentially on how
transcription factor activity can be modified by the
sequence of the binding site. Oct-1 recognizes and
activates transcription through two regulatory ele-
ments of very different sequence, the octamer motif
ATGCAAAT, through which both Oct-1 and Oct-2
can activate transcription of cellular promoters, and
the TAATGARAT motif, through which Oct-1 ac-
tivates HSV immediate-early transcription in associa-
tion with VP16. We showed previously that Oct-1 is
able to bind to these two very different sequences be-
cause it can recognize DNA through flexible interac-
tions with DNA. Few if any Oct-1/DNA contacts are
essential for Oct-1 binding. Instead, it is the sum of
many individual Oct-1/DNA contacts that result in
effective and sequence-specific DNA recognition.
To understand the mechanism of divergent DNA
sequence recognition by Oct-1, we have assayed the
relative contribution of the different regions of the
Oct-1 POU domain for binding to a series of different
octamer- and TAATGARAT-related DNA binding
sites. We took advantage of the fact that the related
pituitary-specific POU protein Pit-1 also recognizes
the octamer and TAATGARAT motifs; but whereas
preferentially to the octamer motif, Pit-1
displays the opposite binding site preference. To as-
say the relative contribution of different segments of
the POU domain-the POU-specific region (which
can be subdivided into A and B segments), the hyper-
variable linker, and the homeodomain-to binding to
these two different types of sites, we prepared a large
series of Oct-1/Pit-1 POU-domain chimeras (in the
context of the Oct-1 protein) by reciprocally ex-
changing Oct-1 and Pit-1 POU segments. All of the
chimeras can bind DNA well and in fact frequently
bind better than either parent on particular sites. This
analysis has furthermore shown that the contribution
of a particular subsegment to sequence recognition,
including even the nonconserved linker between the
POU-specific and POU-homeodomain regions, is de-
pendent on the origin of the other segments in the
POU domain. These results suggest that the POU
domain is a dynamic structure in which DNA binding
specificity is generated by multiple interdependent
POU domain-DNA contacts as well as intraprotein-
protein contacts within the POU domain. Such flexi-
ble interactions may influence the structure of Oct-1
on different binding sites, affecting its ability to inter-
act with other proteins involved in transcriptional
regulation.
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Although Oct-1 and Oct-2 bind DNA with very
similar, if not identical, sequence specificity, they are
implicated in the regulation of different promoters.
Consistent with expectation, the DNA binding
domains of these two proteins, the POU domain, are
very similar in sequence. Outside of the POU
domains, Oct-1 and Oct-2 also display sequence
similarity within the amino-terminal region, which
are both rich in glutamine residues, a feature shared
with the ubiquitous activator Spl, where such regions
constitute transcriptional activation domains. The
carboxyl termini of Oct-1 and Oct-2 display minimal
sequence similarity, but B cells express a variant
form of Oct-2, called Oct-2B, that through alternative
splicing of the primary Oct-2 mRNA transcript ac-
quires a carboxy-terminal extension of 135 amino
acids that is closely related to the carboxyl terminus
of Oct-1.
The DNA target of transcriptional regulation by
Oct-1 and Oct-2, the octamer motif, is unusual in that
it is found in a large variety of promoters, either ubiq-
uitously or cell-specifically expressed cellular pro-
moters, as well as viral regulatory regions. The oc-
tamer motif is implicated in cell cycle regulation of
the ubiquitously expressed histone H2B gene, where
it is located close to the transcriptional start site, and
it also functions as an enhancer of small nuclear RNA
(snRNA) genes. snRNAs are short, nonpolyadeny-
lated structural RNAs involved in RNA processing
and can be synthesized either by RNA polymerase II,
as in the case of the U2 snRNA, or by RNA
polymerase III, as in the case of the U6 snRNA (see
N. Hernandez in the Genetics Section). Curiously, in
these promoters, a TATA box, which is usually asso-
ciated with RNA polymerase II transcription, is
responsible for directing RNA polymerase III tran-
scription. Among cell-specific cellular promoters, the
octamer motif functions as an enhancer and
promoter-proximal element in immunoglobulin pro-
moters, and it functions as a B-cell regulatory ele-
ment in the SV40 enhancer. It is also associated with
some of the TAATGARAT motifs that serve as the
target of VP16 activation in HSV immediate-early
promoters.
A series of experiments we performed some years
ago in collaboration with N. Hernandez (Cold Spring
Harbor Laboratory) showed that the octamer motif
displays either cell-specific or ubiquitous enhancer
activities, depending on the structure of the elements
proximal to the transcriptional start site. Thus, in the
context of mRNA transcription units such as the 13-
globin promoter, the octamer motif displays B-cell-
specific activity, suggesting that the B-cell Oct-2
protein is responsible for this activity. In the context
of an snRNA promoter, however, the octamer motif
is able to activate transcription in all cell types tested,
suggesting that the ubiquitous Oct-1 protein is
responsible for this activity. During the past year, we
have established in transfection studies that indeed
Oct-1 and Oct-2 possess different intrinsic abilities to
activate snRNA and mRNA promoters: Oct-1 can ac-
tivate the U2 snRNA promoter, whereas Oct-2 can
readily activate the p-globin mRNA promoter.
We have shown previously that Oct-2, after intro-
duction into the non-B-cell He La cell line, can readi-
ly activate transcription from an mRNA promoter. In
contrast, Oct-1 does not readily activate such
promoters, but instead its activation potential is de-
pendent on promoter context. For example, in
preliminary experiments, we have found that whereas
in other promoter contexts Oct-1 fails to activate
mRNA transcription, in the context of the human
histone H2B promoter, where the octamer motif is lo-
cated near the TATA box, overexpression of either
Oct-1 or Oct-2 leads to equivalent further activation
of this promoter. We plan to dissect this promoter in
detail to understand how Oct-1 is able to activate
transcription in this promoter context.
A major success in the past year has been our fur-
ther understanding of how Oct-1 is able to activate
the U2 snRNA promoter. It proved difficult to assay
transcriptional activation by Oct-1 because of the
ubiquitous endogenous Oct-1 activity already present
in mammalian cells. To circumvent the endogenous
activity, we reprogrammed the DNA binding speci-
ficity of Oct-1 (and Oct-2) without changing the
gross structure of the protein by replacing the Oct
POU domains with the Pit-1 POU domain, thus creat-
ing the chimeras Oct-1.P.1 and Oct-2.P.2 with dif-
ferent DNA binding specificities to Oct-1 and Oct-2.
Using a multimerized Pit-l-binding site from the pro-
lactin gene promoter in place of the octamer motif in
the P-globin and U2 snRNA promoters, we assayed
the ability of Oct-1.P.1 and Oct-2.P.2 to stimulate
transcription from these promoters. Consistent with
the differential ability of Oct-1 and Oct-2 to activate
the P-globin mRNA promoter, these Oct/Pit-1
chimeras also showed that Oct-2 possesses an in-
trinsic ability, lacking in Oct-1, to activate an mRNA
promoter. In striking contrast, however, in the con-
text of the U2 snRNA promoter, the activities of Oct-
1.P.1 and Oct-2.P.2 are reversed. Now, the Oct-1.P.1
protein can activate transcription more than tenfold,
whereas the Oct-2.P.2 protein does not detectably ac-
tivate the U2 promoter. Although Oct-2 does not ac-
tivate the U2 snRNA promoter, the Oct-2 variant,
Oct-2B, which carries an Oct-l-related carboxyl
terminus, is able to activate the U2 snRNA promoter.
Thus, here it is promoter-selective activation
domains, separate from the DNA binding domain,
that confer the transcriptional specificity of the ac-
tivator, and an alternative splice can alter the
promoter selectivity of a transcriptional activator
without affecting the DNA binding domain.
The major determinants for Oct-1 activation of
the U2 promoter lie in the carboxy-terminal region,
although the Oct-1 amino-terminal region can also in-
dependently activate U2 transcription. This result dif-
fers from the analysis of Oct-2 activation of mRNA
transcription, where two interdependent activation
domains, the glutamine-rich amino terminus and a
serine/threonine/proline-rich carboxy-terminal seg-
ment, cooperate to stimulate transcription. Oct-1 fails
to activate transcription of the P-globin promoter
readily because it lacks a domain equivalent to the
carboxy-terminal Oct-2 activation domain. It does,
however, possess a glutamine-rich activation domain
that can cooperate with the carboxyl terminus of Oct-
2 in an Oct-1/Oct-2 chimera to activate P-globin tran-
scription. We hypothesize that Oct-1 can activate
mRNA transcription in particular mRNA promoter
contexts, where the requirement for the carboxyl
terminus of Oct-2 is relieved. This activity has proba-
bly been conserved for activation of mRNA tran-
scription, because although the Oct-1 amino terminus
can functionally replace the Oct-2 amino terminus for
activation of an mRNA promoter, unexpectedly, the
Oct-2 amino terminus cannot substitute for the Oct-1
amino terminus to activate the U2 promoter. This
result suggests that the amino terminus of Oct-1 has
conserved two different types of activation surfaces:
one for mRNA promoters and the other for snRNA
promoters.
Analysis of the activation of the U6 RNA poly-
merase III promoter by the Oct/Pit-1 chimeras has
revealed unexpectedly that both Oct-1 and Oct-2 are
able to activate this promoter. Thus, these two ac-
tivators, which display different abilities to activate
two different types of RNA polymerase II promoters,
can both activate the same RNA polymerase III
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promoter. Possibly, this is due to the fact that the U6
promoter contains elements in common with both
snRNA and mRNA RNA polymerase II promoters.
The U6 promoter contains both an snRNA-specific
proximal element in common with the U2 snRNA
promoter and a TATA box in common with mRNA
promoters.
Transcriptional Modification of
Oct-1 through Association
with VP16
S. Stern, M. Cleary, W. Herr, M. Tanaka
We continue to dissect in molecular detail the inter-
actions between Oct-1 and VP16. On its own, VP16
does not bind to DNA well, but instead, in associa-
tion with Oct-1 and a second less well-characterized
host-cell factor we refer to as HCF, VP16 can direct
formation of a multiprotein-DNA complex. Because
VP16 contains a very effective acidic mRNA activa-
tion domain, the association of Oct-1 and VP16
results in activation of mRNA promoters that would
otherwise not be activated by Oct-1 alone. Thus,
VP16 effectively serves as an adaptor to convert Oct-
1 into an activator of mRNA promoters. Last year,
we showed that the Oct-1 homeodomain is re-
sponsible for directing formation of the VP16-
induced multiprotein-DNA complex. Oct-2 fails to
complex with VP16 because of seven amino acid dif-
ferences between the Oct-1 and Oct-2 homeo-
domains. We are now dissecting the different associ-
ations between Oct-1, VP16, and HCF in the VP16-
induced complex. Although Oct-1 and VP16-like ac-
tivities are not present in invertebrate cells, the HCF
activity is highly conserved because it is also present
in Drosophila cell extracts. VP16 can form a stable
heteromeric complex with either human or Drosoph-
ila HCF in the absence of Oct-1. We have analyzed
the ability of VP16 mutants that fail to form the
VP16-induced complex to bind to HCF. Surprisingly,
three of the four mutants analyzed still retain the
ability to bind to HCF. This result suggests that the
other three mutants are defective in other aspects of
the formation of the VP16-induced complex.
To study the influence of the VP16 mutations on
associations with DNA and Oct-1, we have assayed
VP16-induced complex formation in the absence of
HCF by using higher concentrations of VP16 in gel-
retardation assays. At the highest VP16 concentra-
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tions, VP16 can bind to DNA in the absence of either
HCF or Oct-1. At intermediate concentrations, VP16
only forms a gel-retardation complex in the presence
of the Oct-1 POU domain. Under these conditions,
Oct-2 still fails to associate with VP16, thus showing
that VP16 directly discriminates between the Oct-1
and Oct-2 homeodomains. At lower VP16 concentra-
tions, VP16 only forms the VP16-induced complex in
the presence of HCF. Two of the VP16 mutants that
can bind HCF but fail to form the VP16-induced
complex are defective for binding DNA at the high
concentrations of VP16. The remaining mutant, how-
ever, binds DNA as well as the wild-type VP16
protein; instead, it has only lost the ability to interact
with the Oct-1 homeodomain. Thus, we apparently
have uncovered the region of VP16 responsible for
interacting with the Oct-1 homeodomain. Consistent
with this conclusion, a synthetic peptide representing
the region of VP16 affected by this particular mutant
can associate itself with Oct-1 bound to DNA.
The DNA binding specificity of the VP16-
induced complex differs from the binding specificity
of Oct-1 itself. VP16 can readily form complexes on
certain DNA sequences, called TAATGARAT, that
themselves are poor binding sites for Oct-1. Although
we do not detect differences in the bases contacted by
Oct-1 alone and the VP16-induced complex on such
sites, VP16 stabilizes Oct-1 on these otherwise weak
Oct -i- binding sites. Thus, VP16 effectively recruits
Oct-1 to new targets; Oct-2 is not recruited because it
does not interact with VP16. In vivo activity assays
also reveal that Oct-1 is not active on the TAAT-
GARAT motif unless VP16 is present, presumably
because of the low Oct-1 affinity for these sites.
These results demonstrate that VP16 alters not only
the transcriptional activation properties of Oct-1, but
also its DNA binding properties. The association of
VP16 with Oct-1 serves as a model system to study
the reprogramming of the transcriptional activity of a
homeodomain protein by a cell-specific adaptor
protein.
Genetic Dissection of
the HIV-1 Promoter
W Phares
Our earlier studies focused on the similarities be-
tween the transcriptional control elements in HIV-1
and SV40, in particular, on the relationship between
the KB motif sequence GGGACTTTCC found twice
in the HIV-1 promoter and once in the SV40 C proto-
enhancer. Both transcriptional activation studies and
DNA binding studies showed that the HIV-1 and
SV40 KB motifs are functionally indistinguishable.
During the past year, we studied the proteins that
bind to the HIV-1 and SV40 KB motifs by using gel-
retardation analysis. The protein-binding patterns in
all cell lines we have tested (i.e., He La cells and the
human T-cell lines Jurkat and H9) were complicated
and included many complexes in addition to the one
formed by the previously described KB-binding
protein NF-KB. The patterns of complex formation
also varied considerably between Jurkat and H9 T
cells. Of particular interest was that in H9 cells, there
was no evident NF-KB DNA binding activity even
though the KB motif is very active in these cells, sug-
gesting that other KB-binding activities can activate
expression by this motif.
In our more recent studies, we have focused on
the analysis of sequence variation in the HIV-1 long
terminal repeat (LTR) in infected individuals. Char-
acterization of retroviral pathogenicity in other
retroviruses has shown that rearrangements within
regulatory sequences can alter the progression of
retrovirus-induced disease. To understand how such
alterations may affect the progression of AIDS in
persons infected with HIV-1, we are characterizing
the LTR sequences present in infected individuals.
When viruses isolated in vivo are passaged in cell
culture, there is a strong selection for those viruses
that can grow in tissue culture. To avoid this bias, we
are collaborating with Dr. J. Gold (Bronx-Lebanon
Hospital) to analyze LTR sequences isolated directly
from blood samples by first amplifying the LTR se-
quences with the polymerase chain reaction (PCR).
In addition to being direct, this strategy has the ad-
vantage that we can also study the regulatory se-
quences from defective viruses that would not grow
in culture but may be important in the progression of
AIDS.
To date, we have analyzed samples from five
HIV-1 seropositive individuals of which two had
AIDS. Sequence analysis of the amplified LTR se-
quences isolated from one of these patients has
revealed a 16-bp sequence duplication just upstream
of the KB elements. This sequence duplication is
reminiscent of duplications that arise in SV40 to im-
prove both enhancer potential and viral growth. In
SV40, such sequence duplications permitted us to
identify functional SV40 enhancer elements. Con-
sistent with the significance of the HIV-1 duplication
we have identified, three other HIV-1 isolates grown
in culture have been shown to contain duplications in
the same region of the HIV LTR, and analysis of one
of these showed it resulted in improved growth in
culture. We plan to continue the analysis of HIV-1
LTR sequences from infected individuals and to dis-
sect the regulatory function of the HIV-LTR duplica-
tion.
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MOLECULAR GENETICS OF EUKARYOTIC CELLS
Research in this section is generally directed at questions of signal transduction
or cell regulation, the mechanisms by which cells respond to external change.
This encompasses the subject of cell growth and differentiation, processes that
are aberrant in cancer, diseases of the immune system, and in neurological dis-
eases.
The laboratory of Nicholas Tonks (Structure, Function, and Regulation of
Protein Tyrosine Phosphatases) studies the newly discovered superfamily of
protein tyrosine phosphatases (PTPases). This family is diverse in structure and
function and contains proteins with all of the hallmarks of extracellular receptors.
The laboratory of Dafna Bar-Sagi (RAS Oncogenes and Signal Transduction)
studies the role of RAS proteins and phospholipase A2 in signal transduction. The
involvement of RAS in lymphocyte activation is being studied, and the physiologi-
cal role of phospholipases in membrane signaling is being probed with newly de-
veloped monoclonal antibodies.
The laboratory of Michael Wig ler (Genetics of Cell Proliferation) studies the
mechanisms by which oncoproteins transmit growth proliferation signals and
uses yeast systems to discover and characterize components of mammalian sig-
nal transduction pathways.
The laboratory of Michael Gilman (Nuclear Signal Transduction) is directed at
the problem of how multiple, independent pathways converge on the control of a
single genetic element, the "serum response element." This is representative of
the more general problem of how signals are transduced from the cytoplasm to
nucleus.
The laboratory of David Spector (Cell Biology of The Nucleus) uses advanced
microscopic techniques to observe the structure of the cell nucleus during gene
activation. Recently, the pathways of nascent RNA molecules have been followed
from their sites of transcription to the cytoplasm using confocal laser scanning
microscopy. The functional interaction between the nucleus and the cytoskeleton
has long been a focus at Cold Spring Harbor Laboratory.
The laboratory of David Helfman (Molecular Biology of The Cytoskeleton)
studies the multiple forms of cytoskeletal components and how isoforms become
specifically expressed. Recently, a protein has been identified that may
determine the pattern of alternative splicing of a tropomyosin isoform. One gener-
al approach to the study of cell regulation depends on the tools of two-
dimensional gel electrophoresis, a method that has the power to discern
changes in the population of protein species expressed in cells. The develop-
ment of these tools and the building of a comprehensive protein data base are
the objects of Quest Protein Database Center, directed by Jim Garrels. Robert
Franza (Cellular trans-Activators of Gene Expression) uses this approach to study
the early changes in gene expression. Many complex cellular interactions can
best be studied in the intact animal.
Methods for the germ-line manipulation of Transgenic Mice are applied by
Jacek Skowronski and co-workers to study problems in the pathogenicity of the
human immunodeficiency virus and the function of the central nervous system.
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TRANSGENIC MICE
J. Skowronski R. Mariani L. Usher
N. Peunova G. Yenikolopov
The recently developed technology of gene transfer
into the mouse germ line has provided a powerful
way to address diverse biological problems. Develop-
mental and regulatory processes that involve complex
interactions between different cell types can now be
probed in transgenic animals that carry new, defined
genetic traits. Transgenic mice also provide one of
the most comprehensive assays to assess the path-
ogenic potential of viral genes and to generate animal
models where complex disease processes are
reproduced and accessible to study. Our studies have
focused on two separate problems. First, we are as-
sessing the disease-inducing potential of the human
immunodeficiency virus (HIV) regulatory genes and
characterizing their effects on development and func-
tion of the immune system. Second, Grisha Yen-
ikolopov is now developing strategies to perturb sig-
naling pathways in the central nervous system (CNS)
of transgenic animals and consequently deregulating
of the CNS that are involved in learn-
ing and memory processes.
HIV-1 Genes in Transgenic Mice
R. Mariani, L. Usher, J. Skowronski
HIV-1 infection of humans is associated with a com-
plex disease most frequently manifested by multiple
immunologic defects and an increased risk of devel-
oping neoplastic lesions. T cells and antigen-pre-
senting cells are the major targets of HIV-1, and it is
conceivable that infection of these cells results in dis-
ease development. In addition to the gag, pol, and
env genes found in all retroviruses, HIV-1 contains at
least seven accessory genes (tat, rev, tev, vif, nef, vpr,
and vpu). tat, rev, tev, and perhaps nef are important
for regulation of expression and replication of the
viral genome, and vif plays a role in viral assembly.
The function of the other HIV-1 gene products is not
clear, as are the consequences of HIV-1 nef and other
regulatory gene expression on the infected cell and
the biological effects of these genes on host-cell
function.
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Recent evidence has implicated three of the HIV-
1 genes, env, tat and nef, as potentially important for
HIV-1 pathogenicity. The nef gene is found in all
members of the lentivirus family and is well con-
served between different viral isolates (64% invari-
able amino acid residues; tat and rev show 48% and
54%, respectively). Accumulating evidence indicates
that the HIV-1 nef gene can perturb cellular signaling
when expressed in cultured cells. Results of in vitro
experiments suggest that at least some variant nef
genes (e.g., SF2, NL43, and HxB3) may down-
regulate transcriptional activity of the viral long ter-
minal repeat (LTR) and viral replication in estab-
lished cells. In T-cell lines, these effects are relatively
subtle; however, they may reflect defects that have a
profound effect on T-cell function in vivo. To test
these possibilities, several lines of transgenic mice
that express the HIV-1 nef gene in lymphoid and non-
lymphoid cell types have been recently generated.
Our data suggest that the HIV-1 nef gene can perturb
T-cell development/function when expressed in trans-
genic animals.
TARGETED EXPRESSION OF THE HIV-1 NEF
GENE TO LYMPHOCYTES
When the experiments described here were initiated,
T-cell-specific expression vectors characterized in
transgenic mice were not available. Therefore, in ini-
tial experiments, transcription control elements
derived from the murine immunoglobulin g heavy-
chain gene (IgHR) were used to direct expression of
the HIV-1 nef gene to lymphoid cells. IgHg control
elements were chosen because previous studies had
demonstrated their transcriptional activity not only in
the B cell, but also in the T-cell lineage including
adult and fetal thymocytes. Although the IgH
promoter is not absolutely lymphoid-specific and
may direct low-level transgene expression into non-
lymphoid cells types, this promoter was the best
choice at that time. A hybrid transcriptional control
region composed of the IgH enhancer placed up-
stream of the SV40 early promoter is much more ac-
tive in T cells than the IgH enhancer/promoter con-
structs (R. Grosschedl, pers. comm.). Two hybrid
genes composed of the HIV-1 nef gene (isolate
HxB3) placed under the control of the IgH enhan-
cer/SV40 early promoter (11SV Nef) or the IgH en-
hancer/promoter (RI Nef) were used to construct
transgenic mice.
Fifty-three mice were born as a result of micro-
injection experiments with Rp. Nef and RSV Nef in-
sert DNA, but no transgenic mice were identified by
analysis of DNA from tail biopsies (yield less than
2%). This was a highly unusual phenomenon because
in our hands, on average, 10-40% of the pups that
develop from microinjected embryos are transgenic
when other constructs are used. To exclude the pos-
sibility of a technical error, three independent prepa-
rations of insert DNA were used in these experi-
ments. At the same time, we also also generated H-
2K Nef transgenic mice without any difficulty (see
below). The unusually low efficiency of generating
transgenic mice with the !A!..t Nef and !ASV Nef con-
structs suggested that expression of the HIV-1 nef
gene directed by the IgH enhancer may have a
deleterious developmental effect on transgenic mice
that prevents their normal development to term. This
is a valid possibility since it is known that the IgH.t
gene is expressed in the fetal hematopoietic tissue
from day 11 of embryonic development.
LETHALITY AND THYMIC ALTERATIONS
IN pµµ NEF MICE
The lethal effects of the µµ Nef may have resulted
from a high level of transgene expression. We there-
fore attempted to attenuate expression of the 1.41, Nef
vector. It was anticipated that this would result in at-
tenuation of the lethal phenotype and would allow us
to construct viable transgenic mice and observe their
phenotypes. It has been observed that the presence of
plasmid sequences in microinjected hybrid gene con-
structs frequently results in significantly lower levels
of transgene expression (10-100-fold lower) than
when plasmid sequences are removed from the
hybrid expression constructs prior to microinjection.
Therefore, the complete 1.4i, Nef construct, including
the plasmid sequences, was used to generate trans-
genic mice. Embryos microinjected with the Rill Nef
construct gave rise to a total of 82 animals. Analysis
of DNA isolated from tail biopsies identified four of
them as transgenic. It appears that the attenuation
strategy was partially successful; however, the yield
of transgenic animals was still remarkably low (5%
yield). We believe that this low frequency of trans-
genic animals reflects transgene integration at partic-
ular chromosomal loci where transgene expression
and its consequences are further attenuated.
The conditions of two of the four pRi Nef trans-
genic mice deteriorated rapidly within the first 3 days
of life (mice 3 and 4), and these animals were col-
lected for analysis when moribund. Perinatal death
was observed only at a low frequency among non-
transgenic littermates (3 of 78) when compared to
transgenic animals generated in this experiment
(50%; 2 of 4). Histologic analysis performed on tis-
sues of transgenic animals 3 and 4 and two non-
transgenic controls (which died in the same period)
identified characteristic alterations in the thymuses of
both transgenic pups and in the bone marrow and
spleen of animal 3, but not in the nontransgenic con-
trols. Hematoxylin/eosin-stained sections showed dis-
ruption of normal thymic architecture. The T-cell
content in thymuses of both transgenic animals was
low (pp,p, Nef animal 3, -10-20% of that in the
thymus collected from the control animal). The bone
marrow cell count of animal 3 was also low. No ab-
normalities were observed in other tissues of these
transgenic mice.
Two lines of transgenic mice were established
with the remaining two founder mice (pmi Nef
animals 1 and 2). These animals carry approximately
5 and 20 copies of the Rill Nef transgene in an appar-
ently nonrearranged conformation. Transgene expres-
sion analysis was performed with the RNase pro-
tection assay and total RNA isolated from major
organs of 6-week-old animals. Correctly initiated
transgenic transcripts were detected in RNA isolated
from the heart and brain of NIA Nef animal 1. In RIR
Nef animal 2, a high level of Nef transcripts was ob-
served in the spleen and lymph node. Nef transcripts
were also detected in the thymus and other tissues,
but at a lower level. Transgene expression was also
high in Peyer's patches, which are specialized in-
testinal lymphoid organs that contain large numbers
of B cells. This pattern is consistent with predomi-
nantly B-cell-specific expression of the pgt Nef
animal 2 transgene. RNase protection experiments
and polymerase chain reaction (PCR) amplification
of cDNA prepared to RNA isolated from tissues of
animals 1 and 2 indicated that Rip. Nef transcripts
were processed correctly. We are currently character-
izing the B-cell, T-cell, and immune functions of the
Ni[i Nef transgenic mice.
Low yield of the [iSV/mA./pmi Nef animals is
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likely to reflect perturbations elicited by these trans-
genes during prenatal development. This conclusion
is supported by a limited success of experiments with
an attenuated pl.tp. Nef transgene. The known speci-
ficity of the Ig fItt enhancer suggests that thymic T-
cell depletion of the pnt Nef 3 and 4 mice resulted
from transgene expression in T cells, or perhaps their
precursors. It is possible that the nef gene expression
affected normal progression of the thymic T-cell
maturation process, generation of bone marrow
precursors, and/or their migration to the thymic tis-
sue. These possibilities have been addressed in addi-
tional transgenic experiments with T-cell-specific ex-
pression vectors and attenuated titt Nef constructs.
CD2 NEF AND H-2K NEF TRANSGENIC MICE TO
DIRECT NEF GENE EXPRESSION TOT CELLS
AND TO A WIDE VARIETY OF CELL TYPES
To exclude technical reasons for our inability to gen-
erate transgenic mice with the Rt. Nef vector, and to
define consequences of nef gene expression in
selected cell types of transgenic mice, additional
transgenic animals were generated. First, the H-2K
histocompatibility class I gene promoter was used to
direct expression of the HIV-1 nef gene into a broad
variety of cell types in transgenic mice. Second, the
CD2 expression vector was used to direct high-level
nef gene expression to T cells, a cell type that appar-
ently was affected in the milt Nef 3 and 4 transgenic
animals. These experiments were performed in paral-
lel with the pull Nef experiments.
The H-2K gene is one of the class I genes of the
major histocompatibility complex of the mouse and
encodes the heavy chain of the cell-surface H-2K
antigen. It is constitutively expressed on thymic
medullary T cells and stromal structures but not on
cortical lymphocytes or epithelial cells. In addition,
the H-2K promoter directs low-level constitutive ex-
pression in keratinocytes and several cell types in
spleen and lymph nodes. The H-2K enhan-
cer/promoter fragment sufficient to direct expression
in transgenic mice is contained within the 2-kb 5 ' -
flanking region of the H-2K gene. A fusion gene
composed of the HIV-1 Nef protein-coding region
placed under control of the H-2K gene enhan-
cer/promoter and followed by the SV40 small T
antigen intron and polyadenylation signal (H-2K Nef)
was microinjected into one cell embryos. Four lines
of transgenic mice (H-2K Nef 1 to 4) were estab-
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lished without any unusual difficulties. Analysis of
transgene expression by an RNase protection assay
detected correctly initiated transgenic transcripts in
total RNA isolated from thymuses, spleens, and
lymph nodes of all four lines of transgenic mice.
The murine CD2 antigen (T11, or erythrocyte
receptor) is one of the earliest developmental markers
expressed on all T cells following migration of the
bone marrow T-cell precursors to the thymus. The
CD2 expression vector comprises 22 kb of the native
CD2 gene, including approximately 5 kb of 5 ' -
flanking sequences and 5 kb of the 3 ' -flanking se-
quence. The precise location of transcription
regulatory elements is not known. Therefore, in order
to preserve the native structure of the CD2 gene, the
CD2 initiator ATG located in the second exon was
disrupted by site-specific mutagenesis and replaced
with a small polylinker containing a unique CIaI
cloning site (vector provided by D. Littman, Univer-
sity of California, San Francisco), into which the
HxB3 HIV-1 nef gene was cloned. Four transgenic
founder animals were generated with the CD2 Nef
construct. Recently, the CD2 Nef 1 and 2 mice be-
came available for analysis. Relatively high levels of
correctly initiated and processed fusion CD2 Nef
transcripts were detected in RNA isolated from
thymuses isolated from mice of both transgenic lines.
Currently, we are characterizing phenotypes of trans-
genic animals and of transgenic T cells in particular.
In conclusion, it appears that the HIV-1 HxB3 nef
gene, when placed under control of the IgHµ enhan-
cer, elicits several specific effects in transgenic mice.
First, transgenic animals are generated at a very low
frequency. Second, T cells are depleted in thymuses
of transgenic mice that die in early postnatal life. It
appears that these consequences of the HIV-1 nef
gene are specifically associated with the IgHtt Nef
transgene, but not with the H-2K Nef or CD2 Nef
transgenes. It is conceivable that this promoter
specificity of perturbations elicited by the nef gene
reflects its expression in specific cell types, e.g.,
lymphocytes or perhaps their bone marrow precur-
sors. Specific alterations in the T-cell compartments
may be relevant to the mechanisms of the T-cell
depletion that invariably ensues in HIV-1-infected
humans. Our observations suggest that the HIV-1 nef
gene may be an important determinant of the HIV -1-
induced disease and that specific defects conferred by
the nef gene and their biological consequences can be
analyzed in transgenic mice. Experiments to address
these issues are currently under way.
Recombinant Pseudosubstrate
Inhibitors of the Protein Kinases
G. Yenikolopov, N. Peunova
The aim of our study is to obtain dominant interfering
mutations, by reverse genetics techniques, that would
affect specific structures involved in memory and
learning processes in mice. Currently, genetic analy-
sis of memory and learning in higher animals is pre-
vented by the lack of appropriate single-gene muta-
tions. Our general approach is to use transgenic tech-
nology to introduce into the mouse germ line recom-
binant genes that would impose a dominant pheno-
type in the neuronal cells of the hippocampus and the
cortex of the brain by perturbing the relevant signal
transduction pathways. Transgenic animals will be
tested for neurophysiological changes in these areas
of the brain, in particular, the long-term potentiation
in the hippocampus, and for the behavioral correlates
of the introduced molecular changes. The rationale
for this strategy is based on the neurophysiological
studies on Aplysia, genetic data from Drosophila, and
studies of long-term potentiation in mammals, which
together suggest that secondary messenger systems
are crucially involved in synaptic plasticity and thus
in the acquisition and storage of new information. It
appears that the memory deficit that occurs in these
systems is induced by defects in the adequate
response to the incoming signal, rather than a change
in the overall amount of second messenger per se,
and that various types of perturbations introduced
into the signaling machinery of a neuronal network
may lead to similar effects on learning and memory
processes.
Of the numerous potential points of interference
with the signaling pathways in neurons, we have
chosen the protein kinase level of signal transduction
because protein kinases are located downstream from
many signaling events, and in some cases, they have
been shown to interact directly with the last targets in
the pathway. It is known that several protein kinases,
including cAMP-dependent protein kinase (PKA),
protein kinase C (PKC), and Ca"/calmodulin-
dependent protein kinase II (CaMKII), are regulated
by an autoinhibitory mechanism. This suggests a way
of altering the activity of these enzymes by introduc-
ing into the cells either the gene(s) coding for the in-
hibitory ("pseudosubstrate") sequences or the gene(s)
coding for the truncated catalytic domain (subunit) of
the kinase, devoid of the autoinhibitory sequences.
These protein kinases are especially challenging op-
tions for manipulation because of their known direct
involvement in the modulation of the synaptic
plasticity in the brain. To date, our efforts have con-
centrated on the construction of recombinant pseudo-
substrate inhibitors of protein kinases and on the
analysis of the disruption of specific signaling path-
ways in cultured cells by these inhibitors.
We have made a series of recombinant genes con-
taining peptide sequences that are known to act as
protein kinase inhibitors. The recombinant PKA in-
hibitors involve two types of agents: one containing
the active part of a natural PKA inhibitor from skele-
tal muscle (PKI) and the second containing a mutated
murine PKA regulatory subunit (RIa) that is unable
to release the catalytical subunit in the presence of
cAMP. We have matched the structures of the recom-
binant PKC and CaMKII inhibitors to the sequences
of the short conserved peptides located at positions
19-36 in various forms of PKC and positions
273-309 of CaMKII, respectively. Such peptides act
as powerful pseudosubstrate inhibitors of these en-
zymes in vitro. We have based the selection of the
most potent recombinant inhibitors on their ability to
antagonize activation of the c-fos gene promoter in
cultured cells by various stimuli (cAMP, TPA, Ca++,
depolarization); activation by these agents is
mediated by the corresponding protein kinases.
Mutant forms of the c-fos promoter that no longer
respond to particular signals were used as experimen-
tal controls. A series of reporter constructs with the
chloramphenicol acetyltransferase (CAT) gene under
the control of the c-fos promoter (from M. Gilman,
Cold Spring Harbor Laboratory) were cotransfected
along with the recombinant protein kinase inhibitors,
and CAT activity was monitored. Comparison of
CAT activities in control cells and cells stimulated by
forskolin, TPA, or K+-induced depolarization has
shown that the recombinant inhibitors of PKA, PKC,
and CaMKII, respectively, were very efficient in
blocking the induction of transcription. Quantitative
comparison permitted us to select particulary strong
inhibitors of PKA and PKC from a series of prepared
fusion genes and point mutants. For instance, we
have found particular substitutions of the Arg-27
residue in the PKC inhibitor that greatly augmented
the inhibitory activity of the construct. Likewise, we
have shown that some recombinant PKA inhibitors
(e.g., RIa/PKI and influenza virus hemagglutinin
epitope/PKI chimeras) were 10-100 times more
potent in blocking PKA activity than the fragments of
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the natural PKI gene. At present, we do not know
whether this observed enhancement is due to the
lower Ki or to the increased stability of the peptides.
These results have demonstrated the feasibility of our
approach in cultured cells and have proven directly
the potential of the pseudosubstrate-coding genes to
block the action of PKC and CaMKII in vivo.
Recombinant inhibitors show a remarkable degree
of specificity. Our experiments demonstrate that the
PKA inhibitors do not block the activation of the c-
fos promoter by TPA and, reciprocally, that the PKC
inhibitors do not block the induction of c-fos by
forskolin. Furthermore, in vitro tests by other investi-
gators with the synthetic peptide inhibitors and
purified enzymes show a very high degree of
specificity of each inhibitor for its cognate kinase.
Taken together, these data suggest that the recom-
binant inhibitors provide a powerful approach to dis-
sect points of overlap and divergence among the sig-
nal transduction pathways.
Recombinant pseudosubstrate inhibitors represent
a new generation of in vivo protein kinase inhibitors
that, in contrast to the low-molecular-weight syn-
thetic compounds and peptides, can be introduced
into the genome of the cell and can act in a transgenic
organism. We have constructed and tested the recom-
binants designed to target the expression of the in-
hibitors for PKA, PKC, and CaMKII to the neuronal
cells of transgenic mice, using neuron-specific tran-
scriptional control elements of neurofilament H and
L, 13-amyloid, and SCG10 genes. We now plan to
generate transgenic lines of mice using the most
potent and specific recombinant reagents.
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GENETICS OF CELL PROLIFERATION
M. Wig ler J. Field
D. Young
J. Colicelli
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G. Bolger
Y. Wang
R. Ballester
E. Chang
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G. Heisermann V. Jung
M. Kawamukai J. Camonis
I. Wieland C. Nicolette
A. Vojtek N. Chester
H.-P. Xu G. Asouline
The focus of our group remains largely on the signal
transduction pathways involved in growth control,
with a special emphasis on pathways involving RAS
proteins. The RAS proteins were first discovered as
the products of retroviral oncogenes. They are low-
molecular-weight GTP- and GDP-binding proteins.
We and other investigators have found mutant RAS
proteins in a large number of human tumor cells.
Closely related proteins are found in yeast, and we
have attempted to explore the function of these
proteins both in the budding yeast Saccharomyces
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L. Rodgers
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J. Douglas
cerevisiae and in the fission yeast Schizosac-
charomyces pombe. RAS function is best understood
in S. cerevisiae, where we identified its major effec-
tor as adenylyl cyclase. However, the mechanism by
which RAS activates adenylyl cyclase remains large-
ly unknown. A new component of the RAS/adenylyl
cyclase system has been discovered, called CAP,
which may integrate this signaling system with
remodeling of the cellular cytoskeleton. In S. pombe,
where little is understood about RAS function, we
have identified several genes that appear to encode
components of the RAS signaling system. We use
both yeasts to explore the function of mammalian
RAS and putative RAS-related proteins, such as the
product of the neurofibromatosis locus, NF1, and we
have developed genetic screens to clone novel mam-
malian cDNAs which encode proteins that function in
signal transduction pathways. Among these proteins
are candidates for mammalian RAS effectors. This
work has also led to the cloning of genes encoding
cAMP phosphodiesterases, enzymes of considerable
physiological importance. Finally, we continue work
aimed at developing methods for genomic difference
cloning that will enable us to discover recessive on-
cogenes and novel pathogens.
S. cerevisiae Adenylyl
Cyclase
J. Field, J. Colicelli, T. Michaeli, K. Ferguson,
R. Ballester, D. Young, N. Chester, H.-P. Xu,
G. Heisermann, M. Wig ler
The CYR1 gene encodes adenylyl cyclase, the one
known target for RAS protein action (Kataoka et al.,
Cell 43: 493 [1985]; Toda et al., Cell 40: 27 [1985]).
This large (220-kD) protein has two distinct domains:
a 40-kD carboxy-terminal catalytic domain and a 60-
kD leucine-rich domain with a repeating motif, lo-
cated in the center of the molecule. In the past year,
we completed two related studies of adenylyl
cyclase/RAS interactions. In the first study, a series
of in-frame deletion and insertion mutations were
made in CYR1, and the encoded product was tested
for RAS responsiveness (Colicelli et al., Mol.
Biol. 10: 2539 [1990]). Most of the amino-terminal
region, to within 100 amino acids of the leucine-rich
repeat domain, is not required for retention of RAS
responsiveness. Large deletions or small insertions
within the repeat domain destroy RAS responsive-
ness. Large deletions in the region between the repeat
and the catalytic domain also destroy RAS respon-
siveness, but small insertions are tolerated throughout
this region. We conclude from these data that the
structure of the leucine-rich repeat domain is very
sensitive to perturbation and is critical for RAS
responsiveness. The latter conclusion is confirmed by
the second study. We discovered that overexpression
of catalytically defective adenylyl cyclase molecules
inhibits RAS function in yeast (Field et al., Science
247: 464 [1990]). Truncated genes encoding frag-
ments of adenylyl cyclase were tested for this effect.
The smallest fragment capable of inhibiting RAS
function was precisely the leucine-rich repeat
domain. These studies further emphasize the impor-
tance of this domain in RAS responsiveness. Future
studies will focus on determining what other proteins
bind to the leucine-rich repeat.
S. cerevisiae CAP
J. Field, A. Vojtek, J. Gerst, K. Ferguson,
M. Kawamunkai, M. Riggs, L. Rodgers, M. Wigler
To explore the mechanism by which RAS stimulates
adenylyl cyclase, we designed an epitope fusion-
immunoaffinity protocol to purify the adenylyl
cyclase complex from yeast (Field et al., Mol. Cell.
Biol. 8: 2159 [1988]; Ce1151: 219 [1990]). The com-
plex is RAS-responsive and contains at least one
other protein, with an apparent mobility of 70 kD,
which we have called CAP. Antibodies raised to CAP
were used to screen expression libraries, resulting in
the cloning of CAP. Sequence and restriction
endonuclease analysis indicates that CAP is identical
to the gene we prevously called SUPC. We had pre-
viously identified an allele of SUPC as a suppressor
of the activated RAS2va119 allele. Gene disruption in-
dicates that CAP function is required by cells to be
fully responsive to RAS. However, cap- cells have
other phenotypic defects. They are round, often en-
larged and multinucleated, sensitive to nitrogen
deprivation, and fail to grow in rich medium or in the
presence of an excess of certain amino acids, such as
valine (Gerst et al., Mol. Cell. Biol. 11: 1248 [1991]).
CAP is in fact a bifunctional protein; the amino
terminus is required for full RAS responsiveness and
the carboxyl terminus is required for the diverse
growth and morphological effects.
To gain insight into the nature of the carboxyl
terminus, we have sought genes on multicopy plas-
mids that suppress the phenotype that results from the
loss of CAP. One strong suppressor has been found
so far: PFY, the gene encoding profilin (A. Vojtek et
al., in prep.). Profilins are low-molecular-weight
proteins that can block actin polymerization by bind-
ing the actin monomer (Lassing and Lindberg, Na-
ture 314: 472 [1985]). This binding is released by in-
teraction with lipid micelles containing phosphatidyl
inositol phosphates.
The surprising connection between profilin and
CAP led us to examine the phenotypes of pfy- and
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cap cells more closely. These studies were per-
formed in collaboration with Susan Brown and Brian
Haare at the University of Michigan. pfy- cells look
like cap cells. They are round and enlarged. They
also grow less well in rich medium. cap cells, like
pfy- cells, have no discernible actin cables and bud
randomly from their surface. Overexpression of PFY
in cap cells restores most of cap phenotypic
defects, save one: Such cells grow in rich medium,
survive a nitrogen starvation, are smaller, bud asym-
metrically from one pole, and have actin cables, but
they are not RAS-responsive. These results suggest
that the carboxyl terminus of CAP is required for
proper profilin function and that the phenotype which
results from its loss is mainly due to loss of profilin
function.
Some biochemical insight into CAP emerges
from these experiments. In our collaboration with the
group at the University of Michigan, we have found
mutant PFY genes that can suppress a pfy- cell but
not a cap- cell. These mutant genes encode proteins
that apparently bind actin with affinities equal to
those of wild-type profilins, so some function beside
actin binding is required for suppression of cap
cells, perhaps phospholipid binding. To test this, we
expressed form I and form II Acanthamoeba profilins
in pfy and cap yeasts. Form II profilin binds
phosphatidyl inositol phosphates with high affinity
and suppresses both cap and pfy- cells. However,
form I profilin, which binds phospholipids with lower
affinity, suppresses pfy cells but not cap cells.
These results suggest that CAP effects profilin func-
tion, and hence the cellular cytoskeleton, by effecting
the metabolism of phosphatidyl inositol phosphates.
We do not yet know if CAP is a regulatory
molecule, and if so, what regulates it. However, it
physically connects two major pathways: (1) the
cAMP pathway, presumably involved in growth sig-
naling, and (2) a pathway in phospholipid metabo-
lism effecting the remodeling of the cell. CAP is
therefore a prime candidate for integrating these path-
ways. Its proximity to adenylyl cyclase means it is
proximal to RAS, and although we have no evidence
yet that CAP is controlled by RAS, we note that the
types of changes in mammalian cells induced by on-
cogenic RAS, namely, morphological transformation
with its dissolution of actin cables and alterations in
phospholipid metabolism, resemble the effects of
altered CAP function in yeast.
Future studies will be directed to finding CAP
homologs in other organisms, exploring the precise
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biochemical function of CAP, and looking for further
genetic clues into its interactions with other proteins.
Mammalian cDNAs Selected for
Interfering with RAS Function
in S. cerevisiae
J. Colicelli, C. Nicolette, E. Chang, L. Rodgers,
M. Riggs, M. Wigler
The observation that dysfunctional forms of adenylyl
cyclase interfere with RAS function inspired the de-
sign of a genetic screen for mammalian cDNAs that
encode products which can interact with yeast RAS
proteins. Cells expressing the RAS2va119 gene are
heat-shock-sensitive, one of the phenotypic hall-
marks of a constitutively activated RAS pathway.
The same phenotype results from overexpressing
adenylyl cyclase or the catalytic subunits of the
cAMP-dependent protein kinase, encoded by the TPK
genes, or from the disruption of the cAMP
phosphodiesterases, encoded by the PDEI and PDE2
genes. We designed a high-copy yeast shuttle vector
that can express mammalian cDNA inserts from a
strong yeast promoter. cDNA libraries constructed in
this vector were screened for clones that could sup-
press the heat-shock-sensitive phenotype of
RAS2va1l9 strains. Several clones were so isolated,
and these fell into two sets (Colicelli et al., Proc.
Nati. Acad. Sci. 86: 3599 [1989]; Proc. Nati. Acad.
Sci. 88: 2913 [1991]). The first set of clones could
also suppress the heat-shock-sensitive phenotype of
pde strains. These cDNAs encode cAMP phos-
phodiesterases (see below). The second set failed to
suppress pde- phenotypes and hence contained candi-
dates encoding proteins that interact with RAS
proteins.
Three genes were represented among this second
set: JC99, JC265, and JC310. Sequence analysis
revealed no relationship between these genes and
genes in the known data banks; however, JC99 and
JC265 encode proteins that are clearly related to each
other and presumably are members of a family. Fur-
ther genetic analysis in S. cerevisiae indicates that all
three genes can interfere with the activity of RASI
and RAS2 and the mammalian Ha-ras genes ex-
pressed in S. cerevisiae. The mechanism of action is
not known.
Future studies will aim at expressing products of
the genes in mammalian cells, Xenopus oocytes, and
the yeast S. pombe in an attempt to understand
whether they interact with RAS proteins directly and whether NF1 shares other functions with the IRA
to determine if they are effectors of RAS action. proteins.
Function of the Von Recklinghausen
Neurofibromatosis Gene
Product, NF1
R. Ballester, M. Wig ler
The gene for the Von Recklinghausen neurofibro-
matosis locus NF1 was recently identified (Cawthon
et al., Cell 62: 193 [1990]; Viskochil et al., Cell 62:
187 [1990]; Wallace et al., Science 249: 181 [1990]).
People afflicted with this disease have widespread
disorders of the proliferation and differentiation of
tissue of neuroectodermal origin. The partial se-
quence of the NF1 cDNA was determined and found
to encode a protein with sequence similarities to the
mammalian GAP and yeast IRA proteins (Buchberg
et al., Nature 347: 291 [1990]; Xu et al., Cell 62: 599
[1990]). GAP (GTPase activation protein) is a factor
that accelerates GTP hydrolysis by RAS and is
capable of down-regulating wild-type RAS proteins
(Trahey and McCormick, Science 238: 542 [1987];
Ballester et al., Cell 29: 681 [1989]; Zhang et al., Na-
ture 246: 754 [1990]). Oncogenic RAS proteins are
generally resistant to GAP. The IRA proteins are
structurally related proteins with similar functions
(Tanaka et al., Cell 60: 803 [1990]). They are en-
coded by the IRA] and IRA2 loci, and disruption of
either loci leads to a heat-shock-sensitive phenotype,
the result of activation of the RAS pathway. The NF1
protein bears about the same relatedness to GAP as
do the IRA proteins, but NFI shows a greater global
similarity to the IRA proteins. In collaboration with
F. Collins and D. Marchuk at the University of
Michigan, we have begun to examine the function of
the human NF1 protein when expressed in yeast (Bal-
lester et al., Cell 63: 851 [1990]). Expression of NF1
can restore heat-shock resistance to yeast defective in
IRA function, as we have previously demonstrated
for GAP, and can down-regulate mammalian Ha-ras
when they are co-expressed in yeast. Unlike GAP,
NF1 appears to be capable of interfering with the
function of the activated Ha-rasva112 mutant protein in
yeast. These results indicate that NF1 can interact
with a wide range of RAS proteins. We directly
demonstrated that NF1 possesses GAP-like activity:
Extracts of yeast cells expressing NF1 accelerate the
GTP hydrolysis of purified Ha-ras, but not of Ha-
rasvall2, proteins. In the future, we intend to examine
S. pombe Adenylyl Cyclase
D. Young, M. Kawamukai, K. Ferguson, M. Wig ler
We have begun studying S. pombe as an experimental
system to explore RAS function. S. pombe contains a
single rasl gene encoding a RAS homolog (Fukui
and Kaziro, EMBO J. 4: 687 [1985]). rasl does not
regulate S. pombe adenylyl cyclase (Fukui et al., Cell
44: 239 [1986]). In search of clues to RAS function,
we have begun to explore the difference between the
regulation of adenylyl cyclase in the two organisms.
First, we cloned and sequenced the S. pombe cyrl
gene (Young et al., Proc. NatL Acad. Sci. 86: 7989
[1989]). It encodes a large protein with about 30%
sequence identity to S. cerevisiae CYR1 overall. The
homology between the catalytic domains is stronger.
Like S. cerevisiae CYR1, the S. pombe gene encodes
a leucine-rich repeat domain, and the catalytic
domain is carboxy-terminal. Thus, the overall struc-
tures of the two yeast cyclases are very similar and
differ radically from the structures of the mammalian
adenylyl cyclases that have been discovered recently
(Krupinski et al., Science 244: 1558 [1989]).
Disruption of S. pombe cyrl produces a pheno-
type we call hypersexed (Kawamukai et al., Cell
Regul. 2: 155 [1991]). cyrl- cells are perfectly vi-
able, but mate prematurely in rich medium, unlike
wild-type cells that mate upon starvation. Over-
expression of cyrl leads to a partial sterile phenotype.
Overexpression of the repeat domain encoded by
cyrl also leads to a hypersexed phenotype, suggest-
ing that expression of this fragment of adenylyl
cyclase interferes with the function of the wild-type
protein, much as we have found in our studies of the
S. cerevisiae cyclase. This study suggests that both
molecules share a conserved regulatory mechanism.
Other evidence points to the conclusion that S. pombe
cyrl is regulated.
Full-length cyrl molecules can be purified from
S. pombe, using the epitope addition immunoaffinity
method, and these preparations have high levels of
enzymatic activity when assayed in the presence of
Mn'' + ion. The ratio of Mn" to Mg++ activities is
much higher for S. pombe cyrl than it is for S.
cerevisiae CYR1. We see no stimulation of activity
in the presence of guanine nucleotides. We have clear
evidence that a protein antigenically related to S.
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cerevisiae CAP is associated with S. pombe cyrl, and
we are in the midst of characterizing this molecule.
An S. pombe Kinase in the
rasl Pathway
Y. Wang, H.-P. Xu, M. Riggs, L. Rodgers,
M. Wig ler
We have sought genes in S. pombe that encode com-
ponents of the rasl signaling pathway. rasl- cells are
viable but fail to sporulate or conjugate and are round
in shape rather than cylindrically elongated (Fukui et
al., Cell 44: 329 [1986]). We selected for S. pombe
genes present on high-copy shuttle vectors that could
restore conjugation to cells expressing a dominant in-
terfering S. cerevisiae RAS2atal5 gene. In this way,
we isolated byr2 (bypass of ras, no. 2, also known as
sirl) (Wang et al., Cell Biol. [1991] in press). byr2
can also suppress the sporulation defects of rasa -1
rasl- cells but not the cell-shape abnormalities or the
conjugation defects of a rasl- cell. byr2 has the
potential to encode a serine/threonine kinase, with a
carboxy-terminal catalytic domain. In size and struc-
ture, byr2 resembles the protein kinases C, the raf
kinases, and the cGMP-dependent protein kinases,
but it has no particularly close relationship to any in-
dividual kinases. In its genetic properties, byr2 most
closely resembles byrl, an S. pombe gene encoding
another protein kinase that was identified previously
(Nadin-Davis and Nasim, EMBO J. 7: 985 [1988]).
Expression of byrl can likewise suppress the sporula-
tion defects of rasl-lrasl- diploids. Like byrl- cells,
byr2- cells are perfectly viable and of normal shape
but are absolutely defective in conjugation and
sporulation. byrl and byr2 are thus both good candi-
dates for genes encoding downstream components of
the rasl signaling pathways. Since overexpression of
byrl can complement the sporulation defects of byr2 -
cells, but not vice versa, we can place the site of ac-
tion of byrl downstream from byr2.
A Putative Nucleic-acid-binding
Protein in the rasl Pathway
H.-P. Xu, Y. Wang, M. Riggs, L. Rodgers,
M. Wig ler
We directly selected for S. pombe genes that on high-
copy shuttle vectors are capable of suppressing the
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sporulation defects of rasl-lrasl- diploids. One of
these genes, called byr3 (also known as prs and
HP18), was found to encode a protein comprised al-
most in its entirety of a zinc finger repeat motif
(H.-P. Xu, Ph.D. Thesis [1990]). This metal-binding
motif is commonly found in proteins that bind
double- or single-stranded DNA, or RNA. The motif
structure of byr3 resembles most closely the metal-
binding motif of CNBP, a putative sterol regulatory
element that binds single-stranded DNA (Raja-
vashisth et al., Science 245: 640 [1989]). On the basis
of its structure, we imagine that byr3 encodes an in-
hibitor of gene transcription.
The genetic characterization of byr3 is as follows.
High-copy expression of byr3 suppresses the sporula-
tion defects of rasl-lrasl- diploids, but not the shape
abnormalities or conjugation defects of rasl- cells,
and none of the phenotypic defects of byr2- or byrl-
cells. byr3- cells are perfectly viable and normally
shaped, but they are partially sterile. This defect is
restored by high-copy wild-type rasl or byr2, but not
by byrl. This result indicates again that the byr2
kinase lies closer to the root of the rasl signaling
pathway than does the byrl kinase. This result further
suggests that byr2 and byrl have common but per-
haps parallel functions and that byrl acts at least part-
ly through byr3. Further studies will focus on resolv-
ing this model and delineating the role, if any, that
byr3 plays in transcriptional regulation.
GAP-like Molecules in S. pombe
Y. Wang, H.-P. Xu, M. Riggs, L. Rodgers,
M. Wig ler
We have sought genes that on high-copy shuttle vec-
tors are capable of inhibiting the phenotype of S.
pombe cells expressing ras/val17, the activated allele
of rasl. Such cells are partially sterile, highly ag-
glutinable, and develop long exaggerated conjugation
tubes. One gene was isolated that we called sari
(suppressor of activated ras) (Wang et al., Mol. Cell.
Biol. [1991] in press). Upon DNA sequencing, it
eventually became clear that sari encoded another
member of the family of proteins that included the
GAP, IRA, and NF1 proteins. The homology with
other members of this family resides strictly in the
"catalytic" domain, and sari is closest in sequence to
NFl.
Genetic evidence indicates that sari down-
regulates rasl in S. pombe. sari - cells have the same
phenotype as ras/va117 cells, and rasl- mutations are
epistatic to sari -; i.e., rasl- sari- double mutants
have the same phenotype as rasl- cells. Expression
of sari, like expression of GAP and NF1, can com-
plement yeast defective in the IRA genes.
Many investigators have speculated that GAP-like
molecules encode RAS effectors. There is some evi-
dence for this in mammalian cells (Tatani et al., Cell
61: 769 [1990]), but no evidence of this for the S.
cerevisiae IRA proteins. There is also no support for
this hypothesis from studies of sari function in S.
pombe.
An RNase in the Regulation of
S. pombe Sexual Function
H.P. Xu, Y. Wang, M. Riggs, L. Rodgers,
M. Wig ler
Disruption of rasl function leads to failure to con-
jugate and sporulate. We therefore selected for genes
on high-copy plasmids that caused failure to sporu-
late. One such gene was isolated and called hcs (high
copy sterile) (Xu et al., Nucleic Acids Res. 18: 5304
[1990]). Disruption of hcs causes lethality. Over-
expression causes no diminution in growth rate or
change in shape, but it renders cells unable to sporu-
late or conjugate. Sequence analysis reveals the hcs
can encode 363 amino acids with 24% sequence
identity to Escherichia coli RNase III. RNase III is a
double-strand-specific RNase involved in processing
of ribosomal RNA and mRNAs in E. coli (Nashimoto
and Uchida, Mol. Gen. Genet. 201: 25 [1985]; Portier
et al., EMBO J. 6: 2165 [1987]; Takiff et al., J. Bac-
terial. 171: 2581 [1989]). This work suggests that
some control of the pathways regulating sexual dif-
ferentiation may be exerted at the level of RNA
stability or availability and implicates regulation of
RNases in the control of gene expression in
eukaryotes.
Mammalian cDNAs Selected for
RAS Function in S. pombe
H.-P. Xu, M. Riggs, L. Rodgers, M. Wig ler
It is altogether possible that the function of rasl in S.
pombe resembles its function in mammalian cells. To
explore this possibility, we screened mammalian
cDNA libraries cloned into S. pombe expression vec-
tors for genes capable of inducing sporulation in
rasl-lrasl- diploids. Many classes of candidates
were obtained. The first class comprised mammalian
RAS genes, which was expected (Xu et al., Cell
ReguL 1: 763 [1990]). The second class comprised
mammalian RAP genes, which was unexpected, in-
cluding RAP1A, RAPIB, and RAP2 (Xu et al., Cell
Regul. 1: 763 [1990]). The RAP genes encode mem-
bers of the RAS superfamily (Pizon et al., Oncogene
3: 201 [1990]). RAP proteins show approximately
50% identity with RAS proteins. RAP1A is also
known as Ki-rev-1, which was discovered as a weak
inhibitor of the morphologic transformation induced
by oncogenic RAS (Kitayama et al., Cell 56: 77
[1989]). These mammalian RAP genes can induce
sporulation in rasl-lrasl- diploid S. pombe and can
restore normal cell shape to rasl- haploid cells, but
they fail to restore conjugal competence to rasl-
cells. We next explored the function of mammalian
RAP1A in S. cerevisiae. In that yeast, expression of
RAP1A was not able to provide RAS-like functions.
Indeed, expression of RAP1A weakly antagonized the
phenotype of the activated RAS2vall9 allele. These
studies indicate that mammalian RAP can interact
with RAS targets, sometimes productively and some-
times nonproductively.
The third class of cDNAs comprise two genes
known as ATG16 and ATG29 (H.-P. Xu, Ph.D. Thesis
[1990]). In virtually all its genetic aspects, ATG29
resembles a weaker form of ATG16. In high copy,
both genes can induce sporulation in rasl-lrasl-
diploid yeast. They fail to correct shape and conjuga-
tion defects of rasl- cells, but both can correct the
conjugation defects of byr3- yeast. Neither can cor-
rect the phenotypic defects of byrl- or byr2- yeast.
These results suggest that ATG16 and ATG19 can
each carry out a portion of rasl function lying up-
stream of the byrl and byr2 kinases and also suggest
that they operate on the same pathway. Strikingly,
both ATG16 and ATG29 can induce haploid sporula-
tion in cells containing the activated ras/vall7 allele.
Haploid sporulation is a very rare event in wild-type
yeast. This result again strongly suggests the related-
ness of the function of these gene products, which
can evidently act synergistically with ras/val 17. Final-
ly, coexpression of ATG16 and ATG29 can induce
haploid sporulation in wild-type S. pombe. Thus,
their gene products can cooperate. Future studies will
focus on the characterization of the ATG16 and
ATG29 gene products and their function in mam-
malian cells.
103
Mammalian cAMP
Phosphodiesterase Genes
J. Colicelli, T. Michaeli, G. Bolger, M. Riggs,
L. Rodgers, M. Wig ler
In the course of selecting for mammalian cDNAs that
could suppress the phenotype of RAS2vall9 cells, a rat
cAMP phosphodiesterase (PDE) gene was cloned
(Colicelli et al., Proc. Nati Acad. Sci. 86: 3599
[1989]) and named rat DPD because it was homo-
logous to the Drosophila melanogaster dunce phos-
phodiesterase. A great variety of cAMP phos-
phodiesterases are expressed in mammalian tissues
and are of considerable importance, since cAMP
regulates many physiological processes. A better un-
derstanding of this complex family of enzymes will
emerge once the genes encoding them are cloned and
characterized. Approaching this problem through
biochemical purification and sequencing has been a
slow process, and yeast selection for cDNAs encod-
ing PDEs provides a way to accelerate this discovery.
By screening a cDNA library made from a human
cell line, we have discovered three different human
PDE genes. Two of these are closely related and en-
code rolipram-inhibitable, high affinity, cAMP-
specific PDEs. These two genes are homologous to
the rat DPD. We discovered other members of this
family by using the rat DPD as a probe. Using
degenerate oligonucleotide probes to conserved
regions as primers in polymerase chain reactions, we
have concluded that there are probably only four
genes that comprise this family. The third human
PDE cDNA cloned by complementation in yeast has
biochemical properties that suggest it represents a
previously undiscovered family of PDEs. We plan to
characterize the human PDE families further.
Genomic Difference Cloning
I. Wieland, G. Asouline, K. O'Neill, M. Wig ler
We have been in the process of developing a method
of "genomic difference cloning." This method allows
the identification by cloning a DNA sequence present
in one genome that is absent in an otherwise similar
or identical genome (Wieland et al., Proc. Natl. Acad.
Sci. 87: 2720 [1990]). Such differences arise in im-
portant situations: when an individual or a tissue is
infected with a DNA-based pathogen or when a neo-
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plastic cell has lost sequences from both alleles of a
recessive oncogene. The outline of one method for
difference cloning was described in last year's An-
nual Report and was published this past year. This
method is not yet powerful enough to be used
routinely for our purposes. We have concentrated this
year on the incremental improvement of our meth-
odologies.
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RAS ONCOGENES AND SIGNAL TRANSDUCTION
D. Bar-Sagi N. Gale S. Palmer
L. Graziadei J. Yates
K. Degenhardt Y. Yeh
S. Kaplan
Our major interest is in transmembrane signals that
control cell proliferation. Our research focuses on
two components of the signal transduction machinery
in mammalian cells: (1) ras proteins and (2) phos-
pholipase A2 (PLA2). ras proteins are small guanine-
nucleotide-binding proteins that reside on the inner
surface of the plasma membrane. They have been
highly conserved in evolution and play a critical role
in mediating signals that control cell growth. PLA2 is
a calcium-dependent esterase that catalyzes the
hydrolysis of fatty acid ester bond specifically at the
sn-2 position of glycerophospholipids (hence, the
designation A2). Our interest in the action of PLA2
derives from its implication in mediating signal trans-
duction through the release of arachidonic acid from
phospholipids in the plasma membrane. Arachidonate
is the precursor for a number of intracellular mes-
sengers involved in growth control, including
leukotrienes, thromboxanes, and prostaglandins. In
addition, earlier studies from our laboratory indicate
a possible functional link between PLA2 activation
and ras-induced cell transformation. During the past
year, we have continued to analyze the molecular
properties of PLA2. A particularly useful develop-
ment in this area has been the generation of
monoclonal antibodies against PLA2. These anti-
bodies are being extensively used to characterize the
involvement of PLA2 in signal transduction. We have
also continued to study the mechanisms of signal
transduction by ras proteins. Through the use of sig-
naling events in the immune system, we have ob-
tained some new insights into the possible function of
these proteins.
Participation of ras Proteins in
T-cell Activation
N. Gale, D. Bar-Sagi
To understand the regulatory function of ras proteins,
it is essential to identify both upstream and down-
stream components in the ras signaling pathway. To
this end, we have been investigating the role of ras
proteins in T-cell activation. Activation of T cells by
interaction of antigen with the T-cell receptor (TCR)
proceeds via a well-documented sequence of trans-
duction events that leads to cellular differentiation
and proliferation. The interleukin-2 (IL-2) gene is ex-
pressed in T cells in a strictly regulated manner. In
resting T cells, IL-2 transcripts are not detectable;
however, triggering of the TCR by lectins or
antibodies in combination with protein kinase C
stimulation leads to the activation of the IL-2 gene.
We reasoned that if ras proteins are involved in these
signaling events, then their overexpression may have
an effect on IL-2 gene activation. To test this pos-
sibility, Jurkat cells were transfected with a plasmid
expressing the proto-oncogenic form of ras (Fig. 1,
pNV-WT) and control plasmid (Fig. 1, pNV-
VECTOR). To monitor ras effects on the level of IL-
2 mRNA, a quantitative polymerase chain reaction
(PCR)-based assay was employed. To visualize and
quantitate the amplified products, 32P-end-labeled
primers were used. In these experiments, mRNA
levels of three genes were evaluated using specific
primer sets for each. IL-2 mRNA was evaluated for
inducibility under the various stimulatory conditions.
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FIGURE 1 Effects of ras overexpression on IL-2 gene inducibility. Jurkat cells were transfected with
vector alone (pNV-VECTOR) or with a wild-type c-Ha-ras (pNV-WT). Twenty hours after transfection,
cells were stimulated with PHA, PMA, PHA +PMA, or none for 8 hr. Cells were then harvested, and RNA
was prepared and processed for PCR. To visualize and quantitate the PCR products,32P-end-labeled
primers were used in the reaction. Equal aliquots of the reactions were electrophoresed on TBE-PAGE
gels and exposed to XAR film (inset) or phosphorimaging screen. To correct for any differences in in-
put cDNA among the various conditions, results were normalized according to f2MG expression.
Numbers under bar graphs correspond to lane numbers on the autoradiogram. Note that overexpres-
sion of ras induces a fourfold stimulation of the induction of IL-2 by PMA+PHA (compare IL-2, lane 4,
and IL-2, lane 8).
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ras mRNA levels were assayed to verify the expres-
sion of the exogenous construct. [32 microglobulin
((32MG) mRNA levels were used as internal controls
for the quantity and quality of RNA used in each as-
say. As shown in Figure 1, in cells transfected with
control plasmid, a very low level of ras expression
was detected (Ras, lanes 1-4). In contrast, a high
level of ras expression was detected in cells trans-
fected with the ras expression plasmid (Ras, lanes
5-8). As expected, IL-2 transcription was induced
when cells were stimulated with both PHA (a
mitogenic lectin) and PMA (a protein kinase C ac-
tivator) (IL-2, lane 4). We found that ras overexpres-
sion had no effect on IL-2 transcription in unstimu-
lated cells or in cells stimulated with PHA or PMA
alone (IL-2, lanes' 5-7). However, in Jurkat cells
treated with both PHA and PMA, the induction of IL-
2 expression was potentiated by ras overexpression
(compare IL-2, lanes 4 and 8). Quantitative analysis
of the results (Fig. 1, bar graphs) indicates that ras
overexpression results in a fourfold stimulation of IL-
2 induction. These observations provide evidence for
the involvement of ras in signaling events relevant to
IL-2 induction. The signaling pathways that contrib-
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ute to the induction of the IL-2 gene have been ex-
tensively characterized. Therefore, we anticipate that
the effects of ras on IL-2 expression will constitute a
useful experimental system to elucidate the ras path-
way.
Posttranslational Processing of
ras Proteins: Role of Carboxyl
Methylation
K. Degenhardt, D. Bar-Sagi
Protein carboxyl methylation is a posttranslational
modification found in both prokaryotic and eukary-
otic cells. In mammalian cells, this methylation reac-
tion is part of a series of posttranslational modifica-
tions of proteins originally synthesized with a -Cys-
AAX carboxy-terminal sequence, which involve the
proteolytic removal of the last three amino acids, the
lipidation of the cysteine sulfhydryl group with an
isoprenyl moiety, and the methyl esterification of the
newly exposed a-carboxyl group. The protein sub-
strates for these reactions include molecules involved
in sensory transduction (the a-subunit of retinal
cGMP phosphodiesterase), in nuclear membrane
structure (lamin B), and in transmembrane signaling
(small [21-24 kD] G proteins).
One of these G proteins has been clearly identi-
fied as ras. We have developed an in vitro assay sys-
tem for the methyl esterification of the a-carboxyl
group of the carboxy-terminal cysteine residue of ras
proteins. In this assay system, membrane prepara-
tions are incubated with the methyl donor [3H]S-
adenosyl-methionine for various intervals. ras
polypeptides are isolated by immunoprecipitation
using anti-ras monoclonal antibody (Y13-259). The
immunoprecipitates are resolved on polyacrylamide
gels. The ras band is then cut from the gel, and the
radioactively labeled methyl group is hydrolytically
released by the addition of 1 N NaOH and counted by
scintillation counting. Using this assay system, we
have found that more than 90% of the incorporation
of 3H-methyl group onto ras was inhibited by S-
adenosylhomocysteine, a specific inhibitor of meth-
yltransferase enzyme. This result demonstrates that
the methylation of ras in vitro is specifically
catalyzed by protein carboxyl methyltransferase. In
addition, we have found by pulse-chase experiments
that the carboxyl methyl group on ras turns over with
a half-life of approximately 60 minutes. These results
document, for the first time, the turnover of the car-
boxyl methyl group on ras and are consistent with a
dynamic methylation-demethylation cycle catalyzed
by methyl transferase and methyl esterase, respec-
tively. We plan to use this in vitro assay system to in-
vestigate the functional significance of the carboxyl
methylation of ras proteins. Our current hypothesis is
that methyl esterification of ras proteins leads to a
tighter association of these proteins with the plasma
membrane.
Establishment of a Method for the
Introduction of ras or Other
Proteins into a Large Number
of Cells and the Isolation of
Protein-loaded Cells
L. Graziadei, D. Bar-Sagi
We have recently shown that ras proteins co-cap with
surface immunoglobulins (slg) in mitogenically
stimulated B lymphocytes. The functional sig-
nificance of this redistribution event is being studied
in our laboratory. To assess the possible role of ras in
the clustering of slg, we plan to introduce mutational-
ly activated ras proteins into B cells and then monitor
slg distribution. These experiments require that cells
which contain introduced protein can be dis-
tinguished from those which do not. B cells grow in
suspension and are very small, with large nuclei and
relatively little cytoplasm. This makes them un-
suitable for microinjection. In addition, the redis-
tribution phenomenon observed in stimulated B cells
persists for only minutes, thus making the DNA
transfection approach not applicable. Therefore, we
have established a method for introducing proteins
into B cells. This method involves the use of elec-
troporation to load purified proteins into a large num-
ber of cells with high efficiency. A unique feature of
this method is that dextran-FITC is included in the
electroporation medium and is thus cointroduced
with the protein of interest. This enables the purifica-
tion of cells containing dextran-FITC using fluor-
escence-activated cell sorting (FACS) and yields a
population that is composed almost entirely of cells
containing the protein of interest. The features of the
method can be summarized as follows: (1) Subjecting
cells to electroporation in the presence of fluorescent-
ly labeled dextran leads to the efficient uptake of dex-
tran into the cytoplasm. (2) Electrical parameters of
the electroporation can be adjusted to optimize for
uptake and cell viability. (3) Dextrans with molecular
masses of 19-150 kD display equivalent capacity to
enter cells by this technique, as measured by the fluo-
rescence intensity of loaded cells. (4) Using FACS, it
is possible to separate the live loaded cells from the
nonloaded cells. (5) After electroporation, cells
remain capable of capping slg upon proper stimula-
tion.
To establish that dextran-FITC can be used as a
reliable indicator of protein entry into electroporated
cells, we co-loaded dextran-FITC with a fluorescent
protein and directly monitored by FACS the coin-
cidence of the two molecules on a per cell basis. The
protein we used for this analysis is B-phycoerythrin
(PE), a 240-kD member of the family of plant
Phycobiliproteins which has an intrinsic fluores-
cence. As indicated by the two-color flow cytometric
analyses shown in Figure 2, there is a linear correla-
tion between the amount of dextran-FITC and the
amount of PE loaded per cell. Thus, dextran-FITC
uptake can be used as a quantitative indicator of
protein loading. This method has been used on vari-
ous cell types in our laboratory and should prove ap-
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FIGURE 2 Use of dextran-FITC as a marker for the loading of proteins by electroporation. (A) Three-dimensional
biparameter histogram of cells that have been co-loaded with dextran-FITC and PE. The peak height along the z-axis
represents cell number. Population I is composed of nonloaded cells. Population II represents the double-loaded cells
and constitutes 70% of total cells. Population III is composed mostly of dead cells and debris to which PE tends to stick
nonspecifically. (B). Fluorescence intensities of PE versus FITC measured at positions of maximum peak height on the
histogram shown in A. Numerical values on the axes are derived from the channel number on the log fluorescence scale
and represent equivalent units of fluorescence intensity on each axis. Nonloaded and coloaded populations are indi-
cated. The plot yields a straight line indicating a linear correlation between the amount of dextran-FITC and that of PE
loaded per cell.
plicable for the introduction of proteins into many
cell types. It is especially useful in situations where a
large number or pure population of protein-loaded
cells are required.
Tissue-specific Expression of
Phospholipase A2 Enzymes
N. Gale, S. Palmer, J. Yates, D. Bar-Sagi
Phospholipases A, (PLA2) are a growing family of
enzymes implicated in the biosynthesis of the prosta-
glandins, leukotrienes, and related eicosanoids. PLA,
hydrolyze membrane phospholipids to liberate
arachidonic acid, which is the rate-limiting factor in
the synthesis of these important regulators of cell
growth and proliferation. All of the structural in-
formation available to date about PLA, is derived
from secreted forms of the enzyme. The two most
abundant forms of secreted PLA, identified in mam-
malian cells have been termed pancreatic (type I) and
splenic (type II) PLA2. Catalytically, these two forms
appear indistinguishable despite significant sequence
differences primarily in the noncatalytic domains of
the enzyme. In the past year, we have searched for
novel forms of cellular PLA, using PCR amplifica-
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tion. To this end, we have synthesized several
degenerate primer pairs, the sequence of which cor-
responded to two conserved domains found in both
the pancreatic and splenic enzymes. cDNAs made
from total RNA from various rat tissue sources were
then used as targets in low-stringency PCRs to hunt
for novel PLA, clones. Sequence analysis of a large
number of amplified products revealed that all of
them were identical to either the pancreatic enzymes
or the splenic enzymes. However, we found that we
were able to amplify these two types of PLA, clones
with different apparent frequencies, depending on the
tissue source examined, and in several instances were
able to observe transcription of PLA, in tissues
where they had been heretofore unseen. In light of
these observations, we have undertaken the quantita-
tive analysis of the expression of the pancreatic and
the splenic enzymes in various rat tissues. For these
experiments, pairs of primers that match exactly one
or the other type of PLA, were synthesized. These
primer pairs were used in high-stringency PCRs,
using the cDNAs from 14 rat tissues as templates.
Because there were significant differences in the
qualities of RNA that we were able to prepare from
different tissues, we incorporated an internal control
for quality and quantity of input RNA into the assay.
For this control, we employed exact match primer
pairs to I32MG, a gene whose transcription is thought
to be ubiquitous and nearly equal in all cell types. As
shown in Figure 3, the levels of PLA2 expression
vary significantly among various tissues. As ex-
pected, pancreatic PLA2 (type I) is expressed highly
in the pancreas, greater than two orders of magnitude
higher than in any other tissue examined. In other tis-
sues, pancreatic PLA2 expression is relatively high or
low, with no true instances of intermediate levels of
expression. There are notably high levels of pan-
creatic PLA2 expression in ovary, lung, testis, and
spleen that had not been previously observed; in fact,
this PLA2 was thought to be restricted in expression
to only the pancreas and the lung. As has been pre-
viously reported, the levels of splenic PLA2 (type II)
expression are high in spleen and even more
abundant in the intestine. Splenic PLA2 is also ex-
pressed at intermediate levels in many of the tissues
surveyed, including liver, heart, lung, and pancreas.
Note that in contrast to the expression of pancreatic
PLA2, splenic PLA2 was expressed at low levels in
nearly all tissues examined, with the exception of
muscle tissue and adrenal glands where its expression
is absent or extremely low. Previously, splenic PLA2
was thought to be restricted in expression to spleen,
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intestine, and platelets. We have found that splenic
PLA2 expression occurs at comparable levels in pan-
creas and liver as well. Overall, the pattern of expres-
sion of the PLA2 enzymes indicates that in a given
tissue, one form of the enzyme is preferentially ex-
pressed. In addition, the abundance of PLA2 appears
to be correlated with the proliferative capacity of the
tissue. Thus, brain and muscle tissues exhibit low
levels of expression, whereas spleen, pancreas, and
intestine display high levels of expression. It is our
hope that these new findings will be of value in our
ongoing research concerning the role of PLA2 in
transducing intracellular signals, as well as in re-
search in other laboratories concerning the structure
and function of this enzyme.
Identification of a Novel Form of
Cellular Phospholipase A2
S. Kaplan, Y. Yeh, D. Bar-Sagi
In the past year, we have succeeded in generating a
monoclonal anti-phospholipase A2 (PLA2) antibody
using the pancreatic secreted enzyme as an antigen.
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FIGURE 3 Expression of pancreatic and splenic PLA2 enzymes in various rat tissues. The relative abundance of PLA2 tran-
scripts was determined in a variety of tissues using PCR. Three separate reactions were performed on cDNA from each tis-
sue using different primer pairs in each reaction. Primer pairs were to I32MG, pancreatic PLA2, and splenic PLA2. Results of
these reactions are shown in panel A, and the quantitative phosphorimager analysis of these results, corrected for dif-
ferences in p2mG expression, is shown in panel B. (Gray bars) Pancreatic PLA2; (black bars) splenic PLA2.
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FIGURE 4 Immunoprecipitation of a novel polypeptide by a
monoclonal anti-PLA2 antibody. (A). [35S]Methionine-label-
ed HeLa cells were fractionated to S-100 and P-100.
Detergent lysates were prepared from each fraction and im-
munoprecipitated with anti-PLA2 antibody (-) or with anti-
PLA2 antibody blocked with an excess of purified antigen
(+). Under normal conditions (panel A, control), the antibody
specifically immunoprecipitates a 39-kD protein (arrowhead)
present in both the soluble and particulate fractions. In cells
treated with the calcium ionophore A23187 prior to frac-
tionation, the proportion of the 39-WD protein associated with
the P-100 fraction is significantly increased. (B) Im-
munoprecipitation from 32P-labeled HeLa cells. The 39-kD
protein is a phosphoprotein (control), and the stimulation of
PKC by PMA treatment results in the significant enhance-
ment of its phosphorylation.
This antibody specifically immunoprecipitates a 39-
kD protein from metabolically labeled cells. This 39-
kD protein has been detected in a variety of cell lines.
Cell fractionation experiments show that this protein
is found in both the soluble (S-100) and the particu-
late (P-I00) fractions (Fig. 4A). The association with
the particulate fraction is enhanced by an increase in
the intracellular calcium concentration (Fig. 4A) and
is abolished by calcium removal. These results indi-
cate that the 39-kD protein is most likely a PLA2,
since it has been long recognized that the association
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of PLA2 with the cell membrane is calcium-de-
pendent. Indirect immunofluorescence staining with
this antibody shows that the protein is located in both
the membrane and the cytoplasm. Specific enrich-
ment of staining is found in membrane ruffles and in
perinuclear regions. This staining pattern is consistent
with the biochemical fractionation data published by
other investigators. The 39-kD protein has a pI of ap-
proximately 5.0 and appears to consist of multiple
forms. In addition, the 39-kD protein is a phos-
phoprotein, and its phosphorylation is significantly
enhanced by treatment of cells with the phorbol ester
PMA. These results indicate that the 39-kD protein is
a protein kinase C substrate. Immunoaffinity purifica-
tion experiments are under way to test whether the
protein exhibits a PLA2 activity. Purification of the
protein will be the focus of our effort in the coming
year.
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NUCLEAR SIGNAL TRANSDUCTION
M. Gilman R. Attar
L. Berkowitz
D. Girgenti
R. Graham
D. Grueneberg
G. Lee
R. Raje
K. R i abowo I
H. Sadowski
We are interested in how extracellular signals are
communicated to the nucleus, resulting in stable and
specific changes in the pattern of cellular gene ex-
pression. The major focus of our work is the proto-
oncogene c-fos, which plays a critical role in cellular
signaling. The c-fos gene is rapidly activated in cells
within minutes of receiving a signal. Activation does
not require new protein synthesis and therefore pro-
ceeds by posttranslational modification of preexisting
proteins. A major goal of our work is to define the
proteins and other molecular messengers through
which these signals travel from the cell surface to the
c-fos gene. In particular, we are interested in how the
specificity of signaling is achieved. Since a cell will
respond in a distinct fashion to a given growth factor,
how is the message delivered by one factor different
from another? Thus, we wish to know how signals
from discrete individual signal transduction pathways
reach the c-fos gene and how the function of the Fos
protein depending on the
activating signal.
We are taking several approaches to this problem,
as described in the sections below. We are perform-
ing mutagenesis on the c-fos promoter and other
regulatory sequences to identify the elements that
respond to individual signal transduction pathways.
We are using these sequences to identify cellular
DNA-binding proteins that mediate the activities of
these elements. We are also developing genetic ap-
proaches that we hope will accelerate our efforts to
isolate intracellular mediators along these signaling
pathways. Finally, we are using high-resolution two-
dimensional gel electrophoresis to study the composi-
tion of the Fos protein complex induced in cells by
different stimuli, and we are actively isolating novel
components of the complex.
Functional Analysis of the SRE
R. Graham, M. Gilman
The serum response element (SRE) is a major target
through which growth factors activate c-fos transcrip-
tion. We and other investigators have shown that the
SRE is the target for at least two distinct signaling
pathways, one dependent on protein kinase C (PKC)
and one independent of PKC. In addition, the SRE
appears to be a major target for the active repression
of c-fos transcription that begins approximately 30
minutes after induction. Not surprisingly, the SRE is
a binding site for several different cellular proteins.
We have undertaken a detailed mutagenesis of the
SRE in an effort to correlate the binding of these
proteins with individual regulatory activities of the
SRE.
We isolated one important class of SRE mutants.
These mutants bind one of the SRE-binding proteins,
SRF, with wild-type affinity, but they fail to form a
ternary protein-DNA complex, consisting of SRE,
SRF, and a second protein termed TCF (ternary com-
plex factor). We found that these mutants were spe-
cifically defective in response to one of the signals
that act on c-fos through the SRE, the PKC pathway.
Response to PKC-independent signals was unaffected
in these mutants (Fig. 1). Thus, we conclude that the
ternary complex, SRF and TCF bound to the SRE,
comprises the target for the PKC signal, whereas
PKC-independent signals are able to target SRF alone
or in conjunction with proteins we have not yet iden-
tified.
Our observations suggest a model to account for
the specificity of action of growth factors on genes
regulated by SRE sequences. It is clear that an SRF-
binding site alone is not sufficient for response to the
PKC pathway. Only when the site is situated within a
sequence context that permits the recruitment of TCF
is it responsive to this signal. We generalize this ob-
servation to suggest that all signals require accessory
proteins that interact with SRF. An important
ramification of this model is that virtually any spec-
trum of signal response can be generated in an SRE-
containing promoter simply by varying the sequence
context near, or perhaps distant from, the SRE. A
critical prediction of this model is that we will find
additional sequences in the c-fos promoter required
for response to PKC-independent signals. We are
now seeking such sequences.
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FIGURE 1 Binding properties in vitro and inducibility in vivo of a c-fos promoter carrying a single nucleotide
substitution, pm18, that abolishes ternary complex formation. (A) Mobility-shift assay. DNA probes carried c-
fos sequences from -356 to -275, either wild-type (WT) or mutant (pm18). Assays were performed with no
added protein (lanes 1 and 2), partially purified p62DBF (lanes 3 and 4), and partially purified TCF and SRF
(lanes 5 and 6). (B) Transient expression assay of c-fos promoters. BALB/c 3T3 cells were transfected with
plasmids carrying a wild-type (lanes 1-4) or pm18 (lanes 5-8) promoter and starved for serum for 48 hr. The
cells were treated for 45 min with nothing (lanes 1 and 5), 10% calf serum (lanes 2 and 6), 50 ng/ml phorbol
myristate acetate (lanes 3 and 7), or 40 ng/ml c-sis protein (lanes 4 and 8). T, E, and a indicate the positions
of probe fragments protected by RNA from the transfected gene, the endogenous c-fos gene, and a human
a-globin gene internal control, respectively. (C) Identical to B, except that cells were treated for 48 hr with
200 ng/ml phorbol dibutyrate to remove active PKC.
Regulation of c-fos Transcription
by cAMP
L. Berkowitz
Among the many second-messenger systems that ac-
tivate c-fos is the well-studied cAMP pathway. Pre-
viously, we identified three elements in the c-fos
promoter required for induction by cAMP. These
three cAMP response elements (CRE) all contain the
CRE consensus core sequence, TGACG, yet they dif-
fer in transcriptional strength. The hierarchy of
strength correlates with the elements' affinity for cel-
lular binding protein(s), thus reflecting their intrinsic
activities and not their relative positions within the
promoter.
A likely candidate for the transcription factor ac-
ting through these CREs is the CRE-binding protein
(CREB). This protein is phosphorylated in vitro by
the cAMP-dependent protein kinase, the biological
effector of cAMP, and can activate transcription of a
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CRE-containing gene in vitro. Using sequences from
a published CREB clone, we isolated two classes of
CREB cDNA clones by the polymerase chain reac-
tion (PCR). The two types of CREB proteins differed
by the insertion of 14 amino acids, presumably the
result of alternative splicing. The two CREB proteins,
produced by in vitro transcription/translation, showed
no difference in their binding affinities to the
strongest c-fos CRE. Both forms are expressed in all
tissue-culture cell lines examined and in several
mouse tissues. Studying the in vivo function of the
cloned CREB proteins is complicated by the presence
of endogenous CREB and related proteins. Therefore,
we reprogrammed the DNA-binding specificity of
CREB by attaching the DNA-binding domain of the
yeast transcription factor GAL4. Correspondingly, the
CRE in the reporter plasmid was changed to a GAL4-
binding site. Cotransfection of the GAL4-CREB fu-
sion expression plasmid and the GAL4 reporter
showed that both forms of CREB are able to confer
cAMP responsiveness on the reporter. This re-
sponsiveness required CREB proteins in trans and
the GAL4-binding site in cis. Thus, both forms of
CREB are capable of transcriptionally activating a
gene in response to cAMP.
Although CREB can confer cAMP responsive-
ness on a heterologous promoter and can bind to the
c-fos promoter, it is not known if it plays a direct role
in c-fos induction by cAMP in vivo. To determine
this, we are attempting to block CREB activity by
microinjecting specific CREB antibodies into cells
and measuring their effect on c-fos expression.
Several monoclonal antibodies against CREB have
been generated. Alternatively, mutations made in the
basic region create a dominant interfering CREB,
which should interact with the endogenous CREB but
create a nonfunctional complex. This construct will
be transfected and microinjected into cells, and c-fos
response will be assessed. We will also explore the
basis of the growth inhibitory effect of CREB over-
expression in cells.
The Synergistic Action of Protein
Kinase C and Calcium on c-fos
Transcription in T Lymphocytes
G. Lee
A fourth pathway that regulates c-fos transcription
(after PKC, PKC-independent, and cAMP) is cal-
cium. Calcium is a particularly important second
messenger in the response of T lymphocytes to
antigen. In fact, treatment with phorbol esters (which
activate PKC) and calcium ionophores (which elevate
intracellular calcium concentrations) is sufficient to
mimic the effect of antigen. A key feature of this
response is the synergistic interaction between these
two signals. Together, they elicit a substantially
stronger response than either does separately. We are
interested in investigating the mechanism of this
synergistic interaction.
Transfected c-fos genes are strongly activated by
the combination of PMA and ionomycin at con-
centrations at which each has little effect. Thus, we
observe this synergistic interaction on genes trans-
iently expressed in T cells. We are currently consid-
ering two general molecular models that account for
the synergistic response. First, the two signals may
converge prior to reaching the c-fos gene, perhaps by
synergistically activating a protein kinase, which in
turn acts on a single element in the promoter. In this
case, we would expect the induction to be abolished
by mutation of one element, probably the SRE, which
we already know to be a target for the PKC pathway.
Alternatively, the two signals may act independently
on the c-fos gene but be integrated in a synergistic
fashion at the level of transcription. In this scenario,
we anticipate that mutation at any of two unrelated
sites would block induction. Our preliminary data
suggest that induction is indeed blocked by mutations
in two different sites-the SRE and an as yet un-
characterized element in the first intron of the gene.
We are planning to map this intron element and
determine if it is the target for the calcium signal.
Biochemical Characterization of
Multiprotein Complexes at the
Serum Response Element
H. Sadowski
Transcription of the c-fos gene is stimulated by the
activation of a large number of cellular signal trans-
duction pathways (i.e., protein tyrosine kinases,
protein kinase C, protein kinase A, and calcium). Dis-
section of regulatory sequences within the c-fos
promoter has led to the identification of sequence ele-
ments that confer responsiveness to specific stimuli
through specific signal transduction pathways. The
SRE is required for the large stimulation of c-fos
transcription by serum in quiescent cultured cells.
Several proteins are capable of binding specifically to
the SRE sequence in vitro. Serum response factor
(SRF) is a 67-kD phosphoprotein that binds to the
SRE as a dimer. Mutational analysis indicates that the
binding of SRF is required for c-fos induction by
serum. In vitro, a 62-kD protein (TCF) can also bind
to this site in the presence of bound SRF, forming a
ternary complex. In vivo DNA footprinting assays
suggest that these proteins are bound to the SRE in
the presence or absence of stimulation, and no new
complexes can be detected in gel-shift assays using
extracts from stimulated cells versus unstimulated
cells. Although SRF is phosphorylated by casein
kinase II in vitro (and possibly in vivo as well), SRF
is constitutively phosphorylated in cells (its phos-
phorylation state does not change after serum
stimulation).
Serum is a complex mixture of growth factors,
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hormones, and bioactive components that activate
several signal transduction pathways in cells. Serum
activation of c-fos transcription occurs through both
PKC-dependent and -independent pathways, and
maximal activation requires an intact SRE. Recent
experiments from this laboratory have demonstrated
that TCF is the target for PKC-dependent activation
of c-fos transcription, as mutants that bind SRF but
not TCF lose response to phorbol esters while retain-
ing a PKC-independent response.
In the simplest model, serum stimulates TCF
phosphorylation/dephosphorylation through PKC ac-
tivation, leading to altered activity of the ternary
complex in the absence of new binding activities.
Using both wild-type and mutant SREs, DNA affinity
precipitation (DNAP) assays of [32P]orthophosphate-
labeled nuclear extracts from phorbol-ester-stim-
ulated and unstimulated cells are being performed to
determine whether TCF phosphorylation is altered. If
this is the case, biochemical fractionation of nuclear
and cytoplasmic proteins from stimulated cells will
be performed to purify the kinase/phosphatase
responsible. Furthermore, these types of DNAP ex-
periments, as well as gel-shift assays, will be per-
fomed with nuclear extracts from cells overexpress-
ing epitope-tagged SRF to faciliate the detection of
potential "quaternary" complex formation. In addi-
tion, these complexes can be subjected to chemical
cross-linking in vitro (in the DNAP assays), and sub-
sequent immunoprecipitation with anti-epitope
monoclonal antibodies should allow the identification
of nearest neighbors of SRF bound to the DNA
template.
Cloning of a Novel
SRE-binding Protein
R. Attar
As described above, the SRE is a target for multiple
signals that activate and repress c-fos transcription.
The SRE is a binding site for at least three cellular
DNA-binding proteins. Until now, only one of these
proteins (SRF) has been cloned. To achieve a better
understanding of the complex mechanism by which
the SRE regulates c-fos transcription, we have at-
tempted to clone other SRE-binding proteins. We
screened a He La cell cDNA expression library for
phage expressing proteins that specifically bound an
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SRE oligonucleotide. For this study, a variant SRE
sequence was used that binds a protein previously
characterized in this laboratory, p62 DBF, with high
affinity and SRF with low affinity. We isolated a
phage that encoded a lacZ fusion protein that specifi-
cally bound this SRE oligonucleotide but not a
mutant site that does not bind the human protein in
vitro. The fusion protein binds specifically to the
SRE in both a Southwestern blot and a mobility-shift
assay.
Analysis of the partial DNA sequence of this
clone revealed that it was a previously unidentified
gene that belongs to the family of zinc-finger-
containing proteins related to the Drosophila Kruppel
gene. The clone contains seven tandem repeats in the
carboxyl terminus that match the zinc finger con-
sensus for this gene family. In the zinc finger region,
the clone shares 65% sequence identity with several
human and mouse Kruppel-related genes. This gene
is expressed in a variety of human cell lines at a very
low level. Expression is induced by serum in HeLa
cells with a maximum level at 6 hours of stimulation.
Antibodies raised against this cloned protein do not
recognize p62DBF in Western blot or mobility-shift
assays. These observations, together with the
methylation interference pattern obtained with the
cloned protein, suggest that this clone does not en-
code p62DBF, but instead identifies a novel SRE-
binding protein. Immunofluorescence assays on
transfected COS cells show that this protein is local-
ized to the nucleus (Fig. 2). Preliminary results sug-
gest that the cellular counterpart has an apparent
molecular mass of 70 kD. The presence of zinc fin-
gers in this clone strongly suggests that it is a DNA-
binding protein and probably a transcription factor.
After preliminary characterization of the protein, we
will address the role of this protein in the regulation
of the c-fos transcription.
Isolation of Human Genes Encoding
SRE Complex Proteins by
Functional Complementation in
Saccharomyces cerevisiae
D. Grueneberg
We are studying the intracellular pathways by which
signals travel from cellular receptors to the SRE of
the c-fos proto-oncogene. There are multiple proteins
+A2
A2cDNA Carrier
FIGURE 2 Indirect immunofluorescence demonstrating the nuclear localization of the zinc finger SRE-
binding protein. All panels show COS cells fixed and stained with a rabbit polyclonal antiserum raised
against E. coli-expressed protein. In the upper panels, the antiserum was blocked with antigen prior touse,
demonstrating the specificity of staining. The panel on the lower left shows COS cells transfected with a vec-
tor expressing the cDNA. Note the strong staining in the nuclei of two transfected cells in the field. The panel
on the lower right shows untransfected cells photographed with a longer exposure time, revealing nuclear
fluorescence due to endogenous immunoreactive protein.
that bind to the SRE in order to both positively and
negatively regulate the expression of c-fos. One
DNA-binding protein, SRF, has been cloned and
characterized. Recently, an SRF homolog, termed
MCMI, has been cloned in the yeast Saccharomyces
cerevisiae. Like SRF, MCMI acts in conjunction with
accessory proteins encoded by MATal and MATa2.
The complex formed by the MCMI and MATal
proteins is highly similar to the SRF-TCF ternary
complex. And like the SRF-TCF complex, the
MCM1-MATal complex constitutes the target for
activation by an extracellular signal, the a-factor
mating pheromone. Therefore, we are attempting to
clone a cDNA encoding TCF by complementation of
a MA Tcd mutation.
We have constructed a yeast strain in which the
expression of a selectable marker (HIS3) is under the
control of a yeast upstream activating sequence
(UAS) that binds the MCM1-MATa1 complex.
These cells are His+. We have deleted the active
MATal gene in this strain, which extinguishes ex-
pression of the 111S3 marker gene, making the cells
His-. Finally, we have transformed this strain with a
human cDNA library contained within a yeast ex-
pression vector and selected colonies that restored
HIS3 function. We obtained 60 His+ colonies, of
which approximately 70% were plasmid-dependent
(Fig. 3). Sequence analysis revealed that almost all of
these clones contained cDNAs derived from the same
human gene. The gene, called phoxl , encodes a
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FIGURE 3 Activation of a MATc, 1-dependent UAS by a hu-
man cDNA. Three independent yeast transformants (labeled
1.5, 1.8, and 2.2-all derived from the same human gene)
were streaked on minimal plates lacking histidine. The
parental strain, labeled matal::TRP1, does not grow on
these plates, whereas the three transformants all grow.
homeodomain protein. The phoxl homeodomain
shares 70% homology with the homeodomain of the
Drosophila paired gene. However, phoxl does not
share homology with MATcd . It appears to be more
similar to MATcc2, which is a homeodomain protein.
DNA-binding assays were performed using ex-
tracts prepared from yeast cells. Control cells contain
the yeast transcriptional activator, MCMI, which
binds the SRE, forming an MCM1-SRE complex.
When extracts are prepared from yeast cells express-
ing phoxl, we observed a new complex of lower
mobility. We are testing whether the phox 1 protein
interacts with MCMI and SRF. We hope that corn-
plementation in yeast will prove to be a fruitful ap-
proach for isolating human signal transduction genes.
Changes in the Fos/AP-1 Complex
during Human Fibroblast Aging
K. Riabowol, J. Schiff
Human diploid fibroblasts (HDFs) undergo a finite
number of population doublings in vitro that are in-
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versely proportional to the in vivo age of the donor.
In addition, fibroblasts explanted from individuals
with premature aging syndromes such as Werners
and Progeria show decreased abilities to divide in
culture. These and other observations have led to the
fibroblast being used as a model for cellular aging.
After isolation from a donor, HDFs undergo a period
of exponential growth followed by a gradual decline
in growth rate that culminates in cells entering a state
of cellular senescence. Senescent HDFs are unable to
proliferate in response to a variety of normally
mitogenic extracellular stimuli, even though recep-
tors for growth factors and initial ligand-receptor
events such as receptor autophosphorylation are not
markedly altered. In addition, the majority of senes-
cent HDFs contain a 2 N complement of DNA, and
serum-stimulated senescent HDFs show a DNA-
staining pattern similar to that shown by proli-
feration-competent cells in late G1. Thus, it appears
that the major block to cell cycle progression occurs
during mid to late Gt of the cell cycle, which is also
the period of the cell cycle during which activity of
Fos is required for entry into DNA synthesis
(Riabowol et al., MoL Cell Biol. 8: 1670 [1988]). The
results of several different experiments suggest that
this loss of proliferative potential with increased age
is a result of a genetic program that may involve ex-
pression of "anti-proliferative" genes and/or de-
creased expression of genes whose functions are re-
quired for proliferation. Several genes, including
those encoding c-fos, c-Ha-ras, c-myc, and c-myb,
have been identified whose expression or active
protein products are necessary for cells to progress
through the Gt phase of the cell cycle and enter into
DNA synthesis. Transcription of these and a variety
of other genes is not appreciably reduced in senescent
cells with the exception of c-fos.
Since Fos binds DNA and affects transcription of
genes containing AP-1 sites only upon formation of
heterodimers with members of the Jun protein family,
we investigated the ability of young (Y), old (0), and
senescent (S) fibroblasts to express Fos in response to
several stimuli, and asked if the Fos expressed in
young and old fibroblasts formed heterodimers with
Jun. Fibroblasts were deprived of serum for 48 hours
and refed with medium containing [35S]methionine
and agents known to induce Fos expression through
different signal transduction pathways. Cells were
harvested 1 hour later, and lysates containing identi-
cal numbers of input counts were immunopre-
cipitated under nondenaturing conditions in antibody
excess. Figure 4 shows that in the absence of stimula-
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FIGURE 4 Reduced induction of Fos and Jun proteins in old
and senescent human fibroblasts. Cultures of young (40
mean population doublings [MPD]), old (76 MPD), and
senescent (80 MPD) were serum-deprived for 48 hr and
then stimulated with isobutyl methylxanthine and forskolin
(IF), phorbol myristate acetate (PMA), fetal calf serum (Ser),
or c-sis protein (PDGF) in the presence of [35S]methionine.
Lysates were prepared, and immunoprecipitations were
performed using affinity-purified polyclonal antibodies
against Fos. Immunoprecipitales were analyzed by SDS-
PAGE and visualized by fluorography.
tion (-Stim), young fibroblasts expressed a basal
level of Fos greater than the amounts expressed by
old and senescent cells. Stimulation with cAMP (IF),
the phorbol ester PMA, platelet-derived growth factor
(PDGF), and 10% serum (Ser) all induced expression
of Fos to much higher levels in young fibroblasts
than in old or senescent fibroblasts. Since Jun
(recovered due to heterodimer formation with Fos),
actin (a nonspecific contaminant), and FRA1 (recog-
nized by virtue of shared epitopes with Fos) show
similar electrophoretic mobilities, the proportion of
Fos forming heterodimers with Jun was tested by im-
munoprecipitation of nondenatured lysates from
young and old cells using Jun antibodies. We ob-
served that a considerable proportion of the Fos
protein expressed in response to 1 hour of serum
stimulation in young fibroblasts is recovered in com-
plex with Jun. In contrast, little, if any, Fos is
recovered from old fibroblasts at this time point. This
difference is not due to different kinetics of Fos in-
duction or of heterodimer formation, since no Fos is
recovered in complex with Jun at time points up to 8
hours following serum stimulation. We are now in
the process of examining the AP-1 binding and tran-
scriptional activity in young and old fibroblasts
directly to better understand the consequences of
decreased Fos expression during cellular aging.
Isolation, Cloning, and
Characterization of Fos-related
and Fos-associated Proteins
K. Riabowol, D. Girgenti
Fos is one member of a family of proteins consisting
of c-fos, FosB, and the Fos-related antigens FRA1
and FRA2 that form heterodimers with members of
the Jun protein family (c-Jun, JunB, and JunD). By it-
self, Fos is unable to bind DNA efficiently, but upon
heterodimer formation, Fos-Jun complexes avidly
bind AP-1 and related sites, affecting transcription of
genes containing these sequence motifs.
Fos expression is rapidly and transiently elevated
by a wide variety of mitogenic and nonmitogenic
stimuli to varying degrees in different cell types. One
possible explanation for the different cellular effects
seen upon stimulation of cells with agents that all in-
crease Fos expression is that the activity of the AP-1
complex is regulated by varying the ratios of the
seven known members of the complex and by addi-
tional cell-type-specific and stimulus-specific pro-
teins. To address this possibility, we have taken an
immunological approach to purify proteins on the
basis of their being directly recognized by Fos
antibodies or by virtue of being complexed with Fos
or Fos-related proteins through leucine zippers or
other regions of protein-protein association. One such
protein with an apparent molecular mass of 45 kD'
was present in relatively high levels in human T and
B lymphocytes, but was not detected in 15 other cell
types examined. This protein was not recovered in
immunoprecipitations from denatured cell extracts,
suggesting that p45 associates with Fos or another
protein directly recognized by the affinity-purified
Fos antibody. When run under nondenaturing condi-
tions, p45 sediments in glycerol gradients with a rela-
tive molecular mass of approximately 250 kD.
We have now isolated sufficient amounts of the
p45 protein from the human H9 T lymphoblast line to
obtain partial protein sequences from several peptides
generated by V8 proteolysis. Degenerate oligonu-
cleotide primers were synthesized and used to prime
the polymerase chain reaction using double-stranded
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cDNA from H9 cells as substrate. Several clones
representing approximately 40% of a 45-kD protein
were-isolated and sequenced. Initial sequence com-
parison of this portion of p45 to available databases
shows limited homology with an enzyme of
nucleotide metabolism and with histone H2A. Exper-
iments are under way to isolate a full-length clone of
p45 as well as to isolate other proteins recognized
directly or indirectly by Fos antibodies.
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STRUCTURE, FUNCTION, AND REGULATION OF PROTEIN
TYROSINE PHOSPHATASES
N.K. Tonks Q. Yang
P. Guida
It is now well established that the phosphorylation of
proteins on tyrosyl residues is an essential feature of
many cellular processes, including the control of both
normal and neoplastic cell growth. In the 10 years
since protein tyrosine phosphorylation was first ob-
served, considerable progress has been made in the
characterization of the structure, function, and mode
of regulation of the protein tyrosine kinases (PTKs).
The PTKs exist as low relative molecular weight
(low-Mr) enzymes, as typified by the src gene pro-
duct, and as transmembrane molecules, such as the
receptors for a variety of hormones and growth fac-
tors. Nevertheless, one should not lose sight of the
fact that protein tyrosine phosphorylation is a revers-
ible, dynamic process. The net level of phosphate in a
target substrate depends on the balance between the
activity of the kinase that phosphorylates it and the
activity of the phosphatase that catalyzes the
dephosphorylation reaction. The main theme of the
research in this laboratory is the elucidation of the
structure, properties, and mode of regulation of mem-
bers of the protein tyrosine phosphatase (PTPase)
family of enzymes. A complete understanding of the
physiological role of tyrosine phosphorylation and its
potential as a mechanism for the reversible modula-
tion of enzyme activity must necessarily encompass
the characterization of the PTPases.
It is becoming apparent that the family of
PTPases will rival that of PTKs in terms of the struc-
tural diversity of its members. The PTPases represent
a rapidly expanding family of enzymes found in a
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diverse array of tissues and cell lines, which includes
both nontransmembrane low-M, forms and integral
membrane proteins with the hallmarks of receptor
molecules. The occurrence of receptor-like PTPases
raises the exciting possibility of a novel mechanism
of signal transduction, in which the early events in-
volve the ligand-modulated dephosphorylation of
tyrosyl residues in proteins. However, such ligands
remain to be identified and their effect on activity as-
certained.
I joined Cold Spring Harbor Laboratory in mid-
October 1990. Consequently, rather than presenting a
description of work carried out in 1990, I will use this
Annual Report to discuss briefly some of the direc-
tions my laboratory will follow in the coming years.
REGULATION OF PTPASE ACTIVITY
When assayed in an in vitro reaction, the PTPases
display a very high Vmax (one to three orders of mag-
nitude higher than the PTKs) and a high affinity for
substrate (Km values in the submicromolar range).
Consequently, one would expect them to control ef-
fectively the level of phosphotyrosine in the cell; fur-
thermore, they must be tightly regulated so as to
permit the normal function of the PTKs.
The structure of the low-M, PTPases, PTP1B and
TCPTP (see Fig. 1), can be described in terms of two
segments. In these -50-kD molecules, the amino-
terminal approximately 300 residues contain the
catalytic domain, whereas the carboxy-terminal -11-
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FIGURE 1 Schematic diagram illustrating the structure of PTPH1 and its relationship to other proteins. PTPH1 com-
prises three segments: an amino-terminal segment (shaded bars) that has homology with the membrane localization
domains in band 4.1, ezrin and talin, a putative regulatory segment in the middle of the protein (open bars), and a
carboxy-terminal PTPase related segment (closed bars). TM denotes the transmembrane domain in C045. The
length of each protein is shown in proportion to the number of amino acid residues. The homology among domains
is indicated by percentage identity. (Reproduced from Yang and Tonks, Proc. Natl. Acad. Sci. [19911 in press.)
kD segment appears to serve a regulatory function.
This latter segment is involved in controlling the in-
tracellular localization of the enzymes and modulat-
ing their activity. It appears to direct the association
of the -50-kD PTPases into a very high-molecular-
weight complex that elutes from FPLC gel-filtration
columns with an apparent relative molecular weight
in excess of 700K. We are attempting to identify the
binding proteins with which the PTPases associate in
these high-Mr complexes and to characterize the ef-
fects of such putative regulatory proteins on activity.
In addition, the PTPases are themselves phos-
phorylated. Both the low-Mr enzymes and CD45, the
first receptor PTPase to be identified, are phosphory-
lated on tyrosyl residues in vitro. In addition,
phosphotyrosine has been detected in CD45 in vivo
(D.R. Stover, H. Charbonneau, N.K. Tonks, and K.A.
Walsh, unpubl.). Furthermore, many of the PTPases
display canonical sequence determinants for phos-
phorylation by a variety of protein serine/ threonine
kinases. Thus, CD45 is known to be phosphorylated
by protein kinase C in vitro and in vivo and is also a
substrate for casein kinase II in vitro. We have shown
that the low-Mr PTPases are phosphorylated on
serine/threonine residues in vivo and are currently in-
vestigating the possibility that the kinase involved is
the cell cycle control element p34cdc2.
An appreciation of the mechanisms for control of
PTPase activity will be essential for understanding
how the level of cellular phosphotyrosine is regu-
lated. The characterization of regulators of the
PTPase will illustrate a new tier of control, in addi-
tion to the direct effects of kinases and phosphatases,
through which the amount of phosphotyrosine in the
cell can be modulated.
PTPASES AND THE CYTOSKELETON
We have isolated cDNA for a novel PTPase, which
we term PTPH1, from a He La cell library. Its struc-
ture is summarized in Figure 1. It is a member of the
family of proteins that includes band 4.1, talin and
ezrin, proteins that participate in the interaction be-
tween the plasma membrane and the cytoskeleton.
They possess a homologous amino-terminal domain
of approximately 340 residues that appears to associ-
ate with protein components in the plasma membrane
(Rees et al., Nature 347: 685 [1990]). In band 4.1,
which promotes the association of actin and spectrin
in erythrocytes, this domain interacts with the trans-
membrane protein, glycophorin. A similar model has
been proposed for the interaction of talin with the in-
tegrin family of extracellular matrix receptors. In the
case of ezrin, which displays a submembranous
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localization in brush border cells, the details of its in-
teraction with other proteins remain to be established.
The structure of PTPH1 can be described in terms
of three segments (Fig. 1): (1) the amino-terminal
segment displays homology with the membrane
localization domains of band 4.1, talin and ezrin; (2)
there is a central segment bearing putative phos-
phorylation sites for protein serine/threonine kinases,
including p34cdc2 and casein kinase II; and (3) a seg-
ment that is homologous to members of the PTPase
family is located at the carboxyl terminus. The
protein has been expressed, and intrinsic phosphatase
activity has been demonstrated. In view of the struc-
tural homology with the band-4.1 family, we propose
that PTPH1 will also display a submembranous
localization at interfaces between the cytoskeleton
and the plasma membrane, such as focal adhesion
plaques.
Focal adhesion plaques are specialized regions of
the plasma membrane through which cells in culture
adhere to their external substrate (Burridge et al.,
Ann. Rev. Cell Biol. 4: 487 [1988]). On their internal
face, these structures anchor actin stress fibers, which
are important in determining cell shape. Within focal
adhesions, the integrins provide the transmembrane
link between components of the extracellular matrix,
such as fibronectin, and the cytoskeleton. Their in-
tracellular segments interact indirectly with actin
cables through a multiprotein complex that comprises
talin, vinculin, and a-actinin; however, this picture is
undoubtedly incomplete, and additional focal adhe-
sion proteins remain to be identified and their func-
tion established. Similar but less well characterized
structures have also been implicated in attachment
between neighboring cells and adherence to the ex-
tracellular matrix in vivo.
Oncogenic transformation is frequently associated
with a less-adherent, rounded morphology, which
results from a disruption of cytoskeletal integrity and
a reduction in the number of focal adhesions (Kellie,
Bio-Essays 8: 25 [1988]). Furthermore, residual ad-
hesion plaques are invariably associated with the
transforming PTK, such as src. In cells transformed
by Rous sarcoma virus, for example, it has been
postulated that a contributing factor to the generation
of the transformed phenotype is the aberrant
phosphorylation by pp60v-src of tyrosyl residues in
key focal adhesion proteins, including vinculin, talin,
ezrin, paxillin, and the I3-subunit of the integrins. The
exact role of the tyrosine phosphorylation in this pro-
cess is unclear as yet; however, recent studies have
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implicated the phosphorylation of the integrins as a
crucial step (Horvath et al., Oncogene 5: 1349
[1990]). The adherens junctions also represent a
major target for pp60'src, and the protein connexin43
has been shown recently to be an important substrate
for tyrosine phosphorylation in these structures
(Swenson et al., Cell. Reg. 1: 989 [1990]; Volberg et
al., Cell. Reg. 2: 105 [1991]). Immunocytochemical
staining with antibodies to phosphotyrosine has indi-
cated that tyrosine phosphorylation of focal adhesion
and apical junction proteins also occurs in non-
transformed cells, suggesting that PTKs act at these
sites during normal cell function. However, the
kinases involved have yet to be identified. In view of
the potentially disastrous effects of aberrant tyrosine
phosphorylation, it is expected that the activity of
these tyrosine kinases will be tightly controlled. The
localization of a PTPase to these structures is one
means by which such regulation may be achieved.
We are currently investigating the possibility that
PTPH1 may play such a role.
Antibodies to PTPH1 are being generated to look
at intracellular localization and also to identify
proteins with which this phosphatase interacts in
vivo. We will also be pursuing the question of
whether, in view of the fact that its structure suggests
that PTPH1 will localize to expected sites of action
src, overexpression of this PTPase will reverse the
transformed phenotype induced by src. If so, PTPH1
should prove to be a powerful probe with which to
ascertain the precise role of tyrosine phosphorylation
in the transformation process.
Clearly, the elevated levels of intracellular
phosphotyrosine associated with transformation can
be generated through either the activation of a PTK
or the inactivation of a PTPase. Thus, the question
arises as to whether the genes for PTPases function as
growth suppressor genes or anti-oncogenes; i.e., will
deletion of the PTPH1 gene lead to transformation?
We will be addressing this issue and also trying to as-
certain the chromosomal localization of the PTPH1
gene in an attempt to correlate its position with
chromosomal abnormalities that characterize some of
the known malignancies.
PTPASES AND NONINSULIN-DEPENDENT
DIABETES MELLITIS
This work will be performed as a collaboration with
Dr. J. Sommercorn, National Institutes of Health,
Phoenix, Arizona. Noninsulin-dependent diabetes
mellitis (NIDDM) is a life-threatening disease that af-
fects about 10% of the general population over the
age of 40, and it is particularly prevalent in the Pima
Indians of Arizona, in which 50% of adults over the
age of 35 are diabetic. Because NIDDM is associated
with aging and the population as a whole is getting
older, the prevalence of NIDDM is likely to increase.
Longitudinal studies of the development of NIDDM
have demonstrated that subjects with normal glucose
tolerance, who subsequently become diabetic, first
develop impaired glucose tolerance, a condition that
is characterized by reduced capacity of skeletal mus-
cle to respond to insulin. This condition of insulin
resistance may be an early manifestation of a genetic
lesion that causes NIDDM in Pima Indians and in
other racial groups. Understanding the biochemical
basis of insulin resistance should therefore help to
elucidate the cause and to suggest potential treat-
ments of NIDDM.
Although mutations in the insulin receptor gene
are associated with insulin resistance and NIDDM in
rare disease syndromes, the predicted primary struc-
ture of the receptor is normal in subjects with the
more common form of NIDDM. Furthermore, studies
conducted by the Phoenix group show that properties
of insulin binding and regulation of the PTK activity
of the receptor from muscle of insulin-resistant hu-
mans do not account for insulin resistance. Neverthe-
less, insulin resistance limits the ability of the
hormone to influence activities of various muscle en-
zymes, including S6 kinase, S6 peptide kinase, kemp-
tide kinase, myelin basic protein kinase, and type-1
protein phosphatase, which are thought to mediate in-
sulin action intracellularly. Because numerous
responses are affected, the cause of insulin resistance
likely involves an early postreceptor step in the me-
chanism of insulin action.
Recently, we have shown that insulin infusion in
vivo produced a rapid 25% inhibition of soluble
PTPase activity in skeletal muscle of insulin-sensitive
subjects. This response was severely impaired in sub-
jects who were insulin-resistant. Insulin did not affect
the particulate PTPase activity; however, the basal
level of activity was 33% higher in resistant subjects
than in sensitive subjects. Given that signal transduc-
tion in response to insulin absolutely requires the
phosphorylation of proteins on tyrosyl residues by the
insulin receptor kinase, we anticipate that either or
both of these effects on skeletal muscle PTPase, high-
er basal particulate activity, and the lack of insulin-
induced suppression of soluble activity may
antagonize the action of insulin in resistant subjects.
Although the observed effects of insulin on
PTPase activity are small, it is possible that we are
looking at a modification of one isoform in a back-
ground of several PTPases. We will expand on these
observations by using both molecular biology and
protein chemistry approaches to characterizing the
PTPases involved. It is possible that the defect that
causes insulin resistance will not be in the PTPase it-
self, but rather in its mode of regulation by insulin,
for instance, either through interaction with
regulatory proteins or via covalent modifications
such as phosphorylation. Again, this highlights the
importance of understanding the mechanisms through
which the activity of these enzymes is controlled in
vivo.
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CELL BIOLOGY OF THE NUCLEUS
D.L. Spector S. Huang A. Ryan
S. Henderson G. Lark
R. O'Keefe R. Derby
Our research program has continued to focus on the
structural and functional organization of the mam-
malian cell nucleus. We have continued to evaluate
the localization and nuclear associations of factors in-
volved in pre-mRNA processing, and we have begun
to study the intranuclear organization of specific pre-
mRNA molecules. The use of the electron micro-
scopy core facility has continued to expand, and a
large number of collaborations are under way with
the excellent technical expertise of Robert Derby.
Differential Distribution and Nuclear
Associations of Spliceosomal Factors
during lnterphase and Mitosis
D.L. Spector, G. Lark in collaboration with
X.-D. Fu and T. Maniatis, Harvard University]
We have examined the intranuclear distribution and
nuclear associations of SC-35, a non-snRNP (small
nuclear ribonucleoprotein particle) factor that is asso-
ciated with spliceosomes (Fu and Maniatis, Nature
343: 437 [1990]). Our studies have shown that al-
though these factors colocalize within a specific
nuclear domain (nuclear network) during interphase,
they appear to be associated with nuclear components
by different molecular interactions. Using confocal
FIGURE 1 Immunoelectron microscopic distribution of SC-
35. (a) Low-magnification view showing several immuno-
stained cells. The protein distribution is observed by im-
munoperoxidase staining (arrowheads). SC-35 appears in
clusters within the nucleoplasm (N); it is not present in the
nucleoli (No) or in the cytoplasm (C) (b). Regions of SC-35
immunostaining extend out to the nuclear lamina envelope
(c, arrowheads) and come into direct contact with the
nucleolus (No) (d, arrowheads).
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microscopy and immunoelectron microscopy (Fig. 1),
we found that, similar to snRNPs, the SC-35 protein
appears to be organized in a nuclear network that
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contacts the nucleolar surface and the nuclear en-
velope at several locations (Fig. 1). However, the ad-
ditional diffuse nuclear staining .observed with anti-
snRNP antibodies is not observed with antibodies
directed against SC-35. The associations of the SC-
35 protein with nuclear components were investi-
gated further by in situ nuclease digestions. The dis-
tribution of the SC-35 antigen in a speckled pattern is
not changed by prior treatment of cells with DNase I
or RNase A, in contrast to the distribution of snRNPs
that become diffusely distributed after RNase A di-
gestion. Furthermore, although snRNPs become dif-
fusely distributed after cells are heat-shocked, this
treatment does not disrupt the speckled distribution of
SC-35 but causes minor changes in its localization
sop. 2a
e
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FIGURE 2 Redistribution of SC-35, snRNPs, and DNA during mitosis. As cells enter prophase (a-d), most of the
speckles break up; SC-35 (b) and snRNPs (c) are more uniformly distributed between the condensing chromo-
somes (seen by immunofluorescence in d). In addition, some diffuse immunoreactivity appears to be present in the
cytoplasm of prophase cells. During metaphase (e-h), both SC-35 (f) and snRNPs (g) are uniformly distributed
throughout the cytoplasm. However, these antigens are not associated with the interior of the chromosomes in the
metaphase plate (arrowheads). During anaphase (i-f), SC-35 begins to reassociate into speckles (arrowheads j),
whereas snRNPs are still uniformly distributed throughout the cytoplasm (k). During telophase (m-p), the nuclear en-
velope is re-formed, and although all of the snRNP immunoreactivity is contained within the nucleus (o), in many
cells, several SC-35 speckles (arrowheads in n) appear in the cytoplasm in addition to the typical nuclear im-
munostaining.
SC-35
pattern. Studies on cells undergoing mitosis (Fig. 2)
show that the speckled staining pattern breaks up in
prophase, and speckles containing SC-35 re-form in
the cytoplasm of anaphase cells. However, snRNPs
do not organize into a speckled staining pattern until
late in telophase. Thus, although both types of
antigens, snRNPs and SC-35, are integral com-
ponents of the spliceosome, and they colocalize to the
same nuclear domains, their molecular interactions
with nuclear components appear to be fundamentally
different. We interpret the interphase localization of
pre-mRNA processing factors to specific nuclear
domains to mean that spliceosome assembly and/or
RNA processing events take place within these nu-
clear regions.
snRNPs DAP I
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Localization of c-fos mRNA in
the Cell Nucleus
S. Huang, D.L. Spector
Although much biochemical information is currently
available with regard to the events associated with
pre-mRNA processing, little to no information is
available as to where these events occur within the
cell nucleus. We have been interested in the localiza-
tion of specific pre-mRNAs and their association
with nuclear domains and factors. We have chosen to
study a cellular mRNA, the mouse c-fos message,
since this message can be induced to high levels upon
serum stimulation of quiescent NIH-3T3 cells. This
system allows us to trace the message from its site of
transcription through the nucleus.
c-fos mRNA has been localized in the interphase
nucleus by in situ hybridization using a biotinylated
genomic probe and streptavidin fluorescein. Conven-
tional fluorescence microscopy indicates that the
FIGURE 3 In situ hybridization using a 3.4-kb biotinylated c-
fos probe. c-fos mRNA localizes to two dots in the nuclei of
NIH-3T3 cells that have been stimulated with 20% fetal calf
serum for 15 min (a). Cells that have not been serum stimu-
lated do not exhibit any hybridization signal (b).
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message localizes to two dots in the interphase
nucleus of cells that have been stimulated with 20%
fetal calf serum (Fig. 3a). However, upon further
analysis by confocal laser scanning microscopy, we
have determined that the dots extend in the z-axis of
the nuclei forming "tracks" (Fig. 4). This signal is not
observed in cells that have been serum starved for 24
hours (Fig. 3b). Upon serum stimulation, the c-fos
message can be detected within 5 minutes. To con-
firm that the signal we have observed represents
mRNA, we have evaluated the effect of nuclease di-
gestion upon the localization of the signal. We have
found that the signal is sensitive to RNase A but is
resistant to DNase I digestion. These data support the
idea that we are indeed observing the localization of
RNA molecules. Ongoing studies are evaluating the
association of the c-fos message with other cellular
components, such as factors involved in pre-mRNA
splicing and the nuclear envelope. In addition, we are
evaluating the localization of other mRNAs, some of
which lack introns, in order to determine how mRNA
is organized in the nucleus.
FIGURE 4 Transverse view of a three-dimensional re-
construction of the localization of the c-fos message (a) pro-
vides data identical to that obtained by standard fluores-
cence microscopy. However, if this model is rotated 90°, it
is apparent that the dot forms a "path" that extends in the z-
axis of the cell nucleus (b).
Organization of DNA Replication
Sites in the Interphase Nucleus
R. O'Keefe, D.L. Spector
The sites of DNA replication were identified in non-
synchronous and synchronous cultures of He La cells
by incorporation, for 10 minutes, of 10 ttrA 5-
bromodeoxyuridine (BrdU). BrdU is a thymidine
analog that is incorporated into DNA at active
replication sites by the cell's replication machinery.
The incorporated BrdU was then detected by
monoclonal antibodies that are either directly or in-
directly conjugated to FITC. The sites of DNA
replication were visualized by standard fluorescence
microscopy and confocal laser scanning microscopy.
Five distinct patterns of DNA replication have been
identified during S phase (Fig. 5). The five patterns
correspond to different sites of DNA replicating at
different times. During early S phase, replicating
chromatin appears to be diffusely distributed
throughout the nucleoplasm, excluding the nucleolus
(Fig. 5a). As replication continues, the more
peripheral regions of heterochromatin appear to repli-
cate (Fig. 5b), followed by perinucleolar chromatin
(Fig. 5c) and more internal patches of hetero-
chromatin (Fig. 5d,e). Similar or identical patterns
have been identified in a variety of mammalian cell
types. These results are consistent with the idea that
euchromatin replicates early in S phase and that
heterochromatin replicates late in S phase. Laser
scanning confocal microscopy has allowed us to
elucidate the three-dimensional spatial organization
of the sites of DNA replication throughout S phase.
Quantitation of the different patterns of DNA replica-
tion during S phase in synchronous cells and the
ultrastructural localization of these sites by electron
microscopy are now in progress. These studies will
provide information on the timing of each pattern in
S phase and the exact nuclear localization of these
patterns. Future studies will attempt to identify
specific single-copy genes replicating within the con-
text of the BrdU-staining patterns.
Immunolocalization of Nuclear
Antigens in Cryofixed Cells
Prepared by Freeze-Substitution
R. Derby, D.L. Spector
Studies in our laboratory are involved in evaluating
the structural and functional organization of the
4
FIGURE 5 Localization of DNA replication sites in HeLa
cells. Observations of nonsynchronous HeLa cells indicate
that five patterns of replication are present as the cells prog-
ress through S phase.
mammalian cell nucleus. Since several major classes
(UL U2, U4/U6, and U5) of snRNPs and another
non-snRNP factor, SC-35 (Fu and Maniatis, Nature
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FIGURE 6 Cryofixed and freeze-substituted CHOC 400 cell section immunolabeled with anti-SC-35 monoclonal
antibody followed by 15 nm colloidal-gold-conjugated goat anti-mouse IgG (a). SC-35-conjugated particles are pres-
ent in clusters within the nucleoplasm (a, arrowheads). In addition, smaller concentrations of this protein are found
within the nucleoplasm and come into direct contact with the nucleolus (No) or the nuclear lamina envelope (NE).
Cryofixed and substituted (0.5% 0s04 in acetone) CHOC 400 cell sections were immunolabeled with a monoclonal
antibody against a 62-kD nuclear pore complex protein followed by 15 nm colloidal-gold-conjugated goat anti-
mouse IgG (b-c). Nuclear pores in which an antigenic epitope was accessible in the plane of section are each
labeled with a colloidal gold particle (b-c, arrowheads).
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343: 437 [1990]), play a crucial role in the processing
of pre-mRNA molecules, we have been interested in
the localization of these factors within the cell
nucleus. Using preembedding immunoperoxidase
labeling combined with three-dimensional recon-
struction, we have recently shown that nuclear
regions enriched in snRNPs form a reticular network
within the nucleoplasm that extends between the
nucleolar surface and the nuclear envelope (Spector,
Proc. Natl. Acad. Sci. 87: 147 [1990]). In the present
study, we were interested in extending these nuclear
localizations using cell preparation techniques that
avoid slow penetration of fixatives, chemical cross-
linking of potential antigens, and solvent extraction.
CHOC 400 cells were cryofixed using a CF 100
ultrarapid cooling device. After cryofixation, cells
were substituted in 0.5% 0504 in acetone for 72
hours at -80°C and embedded in Epon-Araldite. Thin
sections (70 nm) were etched with 5% H202 for 3
minutes and immunolabeled with an anti-SC-35
monoclonal antibody that recognizes a 35-kD non-
snRNP protein associated with spliceosomes (Fu and
Maniatis, Nature 343: 437 [1990]). Antibody-antigen
complexes were identified by labeling with 15 nm
colloidal-gold-conjugated secondary antibody. Clus-
ters of SC-35-conjugated colloidal gold are found
within the nucleoplasm, and some clusters are ob-
served to attach to the nucleolar surface or the
nuclear lamina envelope (Fig. 6a). This immuno-
localization appears to be identical to that which we
reported using preembedding immunoperoxidase
staining. However, with the present procedure,
preservation of cellular structure is significantly in-
creased due to rapid cryofixation and elimination of
routine dehydration protocols. In addition, detergents
were not needed to permeabilize cells, and resins
such as Lowicryl K4M or LR White, which extract
membrane lipids, were not needed in order to achieve
antibody labeling.
A 62-kD protein associated with nuclear pores
(Davis and Blobel, Cell 45: 699 [1990]) was local-
ized on sections of cryofixed cells which were sub-
stituted in 0.5% 0504 in acetone for 72 hours at
-80°C. Cell sections were immunolabeled with anti-
p62 followed by 15 nm colloidal-gold-conjugated
secondary antibody. A grazing section of the nuclear
envelope showed numerous pores in cross-section
(Fig. 6b-c). Pores in which an antigenic epitope was
accessible in the plane of section were each labeled
by a single colloidal gold particle (Fig. 6b-c). Little
to no background labeling was observed. In sum-
mary, cryofixation followed by freeze-substitution
provides conditions for immunolabeling of several
nuclear antigens such that cellular preservation does
not have to be sacrificed in order to maintain
antigenicity. We hope to use this technique in high-
resolution studies to elucidate the functional organi-
zation of the cell nucleus.
In Situ Localization of the
Adenovirus Genome in
Infected He La Cells
A. Ryan, D.L. Spector
The adenovirus genome is a linear molecule of
double-stranded DNA (35 kb) that codes for 20-30
polypeptides. The adenovirus genome is particularly
interesting since the E1A region is capable of im-
mortalizing cells and, with the EIB region, complete
oncogenic transformation can occur. We have been
interested in evaluating the subcellular localization of
the adenovirus-5 (Ad5) genome in infected He La
cells using a biotinylated probe prepared from the
entire Ad5 genome. The probe is visualized in the
fluorescence microscope after conjugation with
streptavidin-FITC. The goals of this study are to
elucidate the pathway by which the virus enters the
nucleus, the localization of the viral DNA within the
nucleus, and the pathways by which specific viral
RNAs move from their sites of transcription through
the nucleus and into the cytoplasm.
Uninfected He La cells that were hybridized with
the Ad5 probe show no hybridization signal (Fig. 7b).
Cells infected with wild-type Ad5 at a multiplicity of
infection of 60 pfu/cell were examined by in situ
hybridization at various times postinfection. At 7
hours postinfection, hybridization signal was ob-
served as several fine dots within the cytoplasm (Fig.
7d); 8-10 hours postinfection, viral DNA is localized
as dots throughout the nucleoplasm (Fig. 7f,h). The
viral signal moves to the nuclear periphery and forms
doughnut-shaped inclusions at 14 hours postinfection
(Fig. 7j). Since the hybridization signal is significant-
ly increased at this time point, we assume that viral
DNA replication is occurring. At 26 hours postinfec-
tion, the nucleus appears to be filled with viral DNA
(Fig. 71). Electron and confocal microscopic studies
are currently under way to identify the precise path-
way of the Ad5 genome into the cell nucleus and the
cellular components with which it interacts.
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FIGURE 7 In situ hybridization localizing the adenovirus-5 genome in infected HeLa cells. See text for details.
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CELLULAR TRANS-ACTIVATORS OF GENE EXPRESSION
B.R. Franza A. Giordano
J.-H. Lee
Y. Li
G. Mak
J. Ross
J.A. Scheppler
We study cellular proteins involved in the growth
control of mammalian cells. The mammalian cell we
study most comprehensively is the human T lympho-
blast. When an interesting event is observed in the T
lymphoblast, we then compare other mammalian
cells, including lymphoblasts and fibroblasts from
different species, to determine the generality or
specificity of the proteins involved in the change. The
QUEST protein database system is the tool that
permits such comparative qualitative and quantitative
observations.
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During the past several years, we have focused on
three systems. One is the effect that expression of on-
cogenes has on the entire complement of proteins
present in a particular cell type. The second is the in-
duction of protein alterations when quiescent cells are
stimulated to proliferate. These studies are directed at
determining the molecules involved in conveying sig-
nals to the genome and the earliest responses of the
genome to these signals. The third is the control of
gene expression at the level of regulation of tran-
scription of mRNA encoding genes.
The goal, implicit in all of our studies, is to con-
struct a molecular map of the networks involved in
regulating transcription as well as other genome
responses to a change in the cell's growth status. This
project is in its infancy. The results of the initial
studies appear to justify a comprehensive application
of the strategy we have used during our early investi-
gations. The strategy employs several tools, including
recombinant or synthetic fragments of DNA contain-
ing genetically defined transcription control ele-
ments; antibodies to proteins identified either to asso-
ciate with the control elements or to respond to
stimuli that activate quiescent cells; enrichment of
cells at different stages of the cell division cycle;
high-resolution two-dimensional protein gels, a
computer-accessible protein database; and in vitro as-
says of transcriptional activation/repression and
kinase activity in order to determine the biological
function of identified proteins. Because of the for-
midable complexity of a living cell, the strategy is
designed to enable multiple investigators to make ob-
servations that ultimately can be linked.
Several projects, utilizing the strategy, were in-
itiated or further developed during 1990. These
projects are directed at the elucidation of the
molecular mechanisms of the following processes:
(1) the immediate-early responses of cells to different
extracellular stimuli, (2) the regulation of transcrip-
tion of human immunodeficiency virus type 1 (HIV-
1), and (3) the activities of adenovirus early region
1A (E1A) protein that result from association with
cellular proteins implicated in the regulation of the
cell division cycle. We work as a group and everyone
listed above contributes to each of the projects. Those
individuals contributing substantially to one project
more than another are recognized by being first au-
thor of published papers (see Publication list).
IMMEDIATE-EARLY CELLULAR RESPONSES
Our past investigation (in collaboration principally
with T. Curran's group at the Roche Institute, Nutley,
New Jersey) revealed that the products of two
immediate-early genes, Fos and Jun, formed protein
complexes with each other and cooperatively bound
two different DNA transcription control elements, the
activator protein-1 (AP-1) and cAMP response ele-
ment (CRE) sites. The term immediate-early gene
designates mammalian genes whose transcription
(and the induction thereof) is not apparently depen-
dent on de novo cellular protein synthesis. This pro-
vides the cell with a mechanism for rapid response to
signals generated when the cell encounters other cells
or soluble factors that interact with various receptors
on the cell surface or alter the membrane potential of
the cell.
The initial two-dimensional gel characterization
of Fos was accomplished using an anti-Fos peptide
rabbit antisera to isolate Fos from different rat cell
lines. The Fos immune complex was indeed complex.
Numerous cellular peptides, apparently not the pro-
duct of the fos gene, were reproducibly found in the
Fos immune complex. Subsequently, one set of
isoforms (different migratory behavior in the two-
dimensional gel because of chemical alteration of the
primary gene product) was shown to be the product
of jun. Another set was found to share a region of pri-
mary structure with Fos but to be the product of a dis-
tinct gene, fral . FRA stands for Fos-related antigen
and the peptide region of Fos to which the rabbit
antisera reacted fortuitously was the region of FRA3
common to Fos. FRA1 is therefore one of the many
non-Fos spots in the two-dimensional gel pattern of
the Fos immune complex.
At the time we were studying the Fos immune
complex, we were interested in pursuing mechanisms
involved in the transcriptional regulation of inducible
genes like the c-fos gene. We wanted to apply the
rigorous analytic power of QUEST analysis of
proteins separated on two-dimensional gels. We
speculated that the protein interaction with control
elements just beginning, at that time, to be defined in
promoter regions for genes like c-fos might be com-
plex enough to justify such analysis. We therefore de-
veloped a sensitive and specific DNA affinity precip-
itation (DNAP) assay using biotin-labeled DNA and
streptavidin-agarose to capture proteins that interact
with specific nucleic acid control elements.The assay
is designed for a small scale, rapid, and flexible iden-
tification and analysis of cellular proteins bound to
the nucleic acid sequence being studied. Use of this
assay has led to the identification of several proteins
that interact with x13 sites in several promoters, in-
cluding the AIDS virus, HIV-1. In addition, using
this assay, the transcription factor AP-1 was shown to
interact with AP-1 sites in numerous cellular and
viral promoters, including the HIV-1 long terminal
repeat (LTR), and to be composed of both Fos and
Jun and related oncoproteins. We have not been dis-
appointed by the lack of complexity of DNA-protein
interactions of transcription control elements.
We are extending our analysis of the Fos immune
complex and the members of the complex that are
found to associate with AP-1 and CRE sites in dif-
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ferent promoters. Although much has been learned
regarding the interaction of Fos, Jun, and DNA
through the work of numerous investigators, we con-
tinue to find evidence for relatively interesting and
unexplored aspects of the Fos immune complex and
the AP-1 and CRE DNAP complexes. In all of the
two-dimensional gel analyses of the Fos complex that
we have published, several proteins other than Fos,
FRA, and Jun are detected. Because of the rapid tran-
scriptional activation of the fos gene and the equally
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rapid and transient synthesis of Fos itself, most ex-
periments were confined to a single time point for
labeling and measuring the Fos protein, thereby
yielding the equivalent of a snapshot of a moment in
a very dynamic protein. That snapshot of Fos and the
proteins associated with it or immunologically related
to it is obviously complicated and has been very in-
formative. However, we knew that, ultimately, a
detailed time-course analysis of cells being stimu-
lated by agents that induce Fos would have to be
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FIGURE 1 Two-dimensional gel analysis of inducible proteins in two different human T- lymphocyte cell lines that are
members of the Fos immune complex. Cells were labeled with [35S]methionine for the times indicated in each
panel. A23187 is a calcium ionophore. See text for further details.
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done not only to complete the characterization of Fos
and the proteins associated with it, but also to ob-
serve what else the cell was doing. Another fact that
we knew we would have to experimentally pursue is
whether the response of cells in one stage of the cell
division cycle was the same or different at other
stages. Typically, examination of the Fos complex
has been performed in serum-deprived, growth-
arrested cells or asynchronously dividing cells. So
much remains to be studied.
We are now pursuing a more comprehensive anal-
ysis of the regulation of Fos and the other members
of the Fos immune complex and comparing those
results with proteins interacting with AP-1 and CRE
sites isolated from the same cellular extracts. We
have chosen to compare two different human T-
lymphoblast lines and a fibroblast line. The fibroblast
line was chosen because it exhibits serum depen-
dence and minimal, if any, spontaneous transforma-
tion from contact inhibition growth in culture. For
each cell line, we are establishing conditions for
centrifugal elutriation. This procedure permits the
considerable enrichment of cells at the G1 and G2/M
stages of the cell division cycle. A simple comparison
of the Fos complex isolated from one of the CD4+
lymphoblast lines labeled at two time points after in-
duction of fos reveals significant differences in the
extent not only of Fos synthesis, but also of the
synthesis of several of the other proteins in the Fos
immune complex. Comparison of the two CD4+
lymphoblast lines at one time point after induction of
fos has already revealed proteins unique to the Fos
complex from one of the cell lines. Figure 1 presents
two-dimensional gel images of these comparisons.
The labeling of spots has been generalized to convey
three points: (1) The difference in extents of Fos and
Jun synthesis (encircled areas); (2) the complexity of
the associated or antigenically related proteins
(marked simply by an X); and (3) the induced spots
unique to the Jurkat cell Fos immune complex com-
pared to the 119 (HuT78) complex (spots marked by a
U). What should be conveyed by this simple com-
parison is that the investigation of something as
restricted as a single immune complex, isolated from
cells at different time points, contains multiple gene
products each of which is being processed at some
unique rate. In all of our studies, we are pursuing me-
chanisms that coordinate transcription of cellular
genes as cells traverse the nonproliferative state to
the point of initiation of replication of DNA (GO-Gi
to S phase). The combinatorial possibilities of dif-
ferent gene products apparent in the comparison of
the Fos immune complex isolated at different mo-
ments during this period may reveal some molecular
aspects of this timing mechanism. In any case, the ex-
tent of change and the number of molecules changing
evident in this one type of immune complex suggest
that definitive statements as to the regulatory func-
tion(s) for any of these proteins must account for how
the fluctuating combinations of multiple proteins
modulate the function of each of them. Perhaps it is
better to discern what is actually happening before
claiming either the function or mechanism of regula-
tion of macromolecules like Fos.
REGULATION OF TRANSCRIPTION OF HIV-1
HIVEN86A, a Member of the Set of KB-binding
Proteins, Is a Product of the Human c-rel Proto-
oncogene. Several years ago, using the DNAP assay
system we developed to study protein interaction
with transcriptional control DNA elements, we iden-
tified HIVEN86A as an inducible member of a set of
cellular proteins that specifically bind to the KB en-
hancer. This enhancer motif has been detected in
numerous cellular and viral transcriptional control
domains. Recently, cDNAs have been cloned that en-
code the 50-kD DNA-binding subunit of murine NF-
KB and the closely related human K-binding factor
(KBF-1). A 350-amino-acid domain at the amino
terminus of these proteins was found to be homo-
logous to the v-rel oncogene from the avian re-
ticuloendotheliosis virus, strain T (REV-T), as well
as a maternal effect gene, dorsal. dorsal is known to
activate transcription of certain Drosophila genes.
The v-Rd oncoprotein has been identified as a tran-
scriptional activator in certain assay systems and has
been shown to be induced by the tumor promoter,
phorbol-12-myristate-13-acetate (PMA) in avian
cells. HIVEN86A is also inducible by PMA. It was
therefore logical to determine if HIVEN86A was en-
coded by the human c-rel proto-oncogene. To do so,
in collaboration with W. Greene's group at Duke
University, we transcribed mRNA in vitro from a
full-length human rel cDNA and translated the Rel
protein product in vitro. We demonstrated its ability
to bind the HIV-1 KB sites by DNAP assay. We
resolved the in-vitro-translated Rel on two-di-
mensional gels and showed that it comigrated with
cellular HIVEN86A. We excised the Rel and
HIVEN86A proteins from the gel (see Fig. 2) and, by
chemical cleavage with N-chlorosuccinimide (NCS),
proved that the two proteins were indistinguishable
structurally at this level of resolution. We will dis-
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FIGURE 2 Microscale DNA-affinity precipitation assays of
Jurkat cells and in-vitro-translated human c-rel as resolved
on two-dimensional gels. (A) Unstimulated Jurkat cell ex-
tract plus HIVEN86A probe that contains a duplication of the
KB sites in the HIV-1 LTR. (8) Extract from PHA+PMA-
stimulated Jurkat cells plus HIVEN86A probe. (C) In-vitro-
translated he -Rel plus HIVEN86A probe. (D) Mixture of one-
half of the volume of samples B and of C that were loaded
on the two-dimensional gels represented in panels B and C.
Jurkat cells were extracted after treatment with PHA and
PMA and metabolic labeling with [35]Smethionine. Prior to
metabolic labeling for 30 min, 4 x 108 cells were treated with
PMA (100 ng/ml) and PHA (1 vg/m1) for 3.5 hr.
cuss, a bit further on in this report, that an anti-
carboxy-terminal Rel peptide antibody reacts with
HIVEN86A. In collaboration with P. Enreitto's group
at Stony Brook, we showed that v-Rel binds the HIV-
1 xB site using the DNAP procedure.
At least two different cellular genes have now
been identified that encode KB-specific binding
proteins: NF-KB/KBF-1 and human Rel. NF-KB/
KBF-1 encodes a 105-kD product that in its full-
length form appears to lack DNA-binding activity.
However, a truncated form of this protein, with a
molecular size of approximately 50-kD, does indeed
interact specifically with the KB enhancer. In addi-
tion, this 50-kD protein appears to interact with at
least two other proteins, including a p65 polypeptide
and a cytoplasmic inhibitory factor termed I-KB. It
will be interesting to examine whether immunologic
reagents specific for NF-KB/KBF-1 will also react
with QJ11 or one of the other 40-50-kD proteins we
have identified by DNAP analysis to interact with the
KB enhancer. Whether all of the members of the set
of NF-KB-binding proteins identified by DNAP anal-
ysis are to some extent homologous to c-rel remains
to be .determined. However, it is interesting that
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genes involved in transcription (HIVEN86A/lic-re/,
NF-KB/KBF-1), oncogenesis (v-Rel), and patterned
development (dorsal) are structurally related and that
their binding specificity for DNA has been con-
served.
Development of Immunologic Reagents That React
with KB-binding Proteins. One disadvantage of the
DNAP assay is that it only permits analysis of
proteins that bind DNA or that complex with DNA-
binding proteins. We need to be able to study KB-
binding proteins that may at some stage not bind
DNA because of posttranslational modification or the
lack thereof. Given the Baeuerle and Baltimore I-KB
model of inhibition of NF-KB (i.e., a cytoplasmic an-
chor of a transcriptional regulator that upon the cell
receiving certain signals releases the regulator), we
also need immunologic reagents to study proteins as-
sociated with KB-binding proteins when they are not
in a DNA-binding state. Furthermore, we need im-
munologic reagents to perform subcellular localiza-
tion studies, to screen cDNA expression libraries, and
to use for affinity purification of the KB-binding
proteins. We have begun preparing both polyclonal
and monoclonal antibodies to proteins identified to
interact with the KB site.
While we were determining whether HIVEN86A
was the product of the rel gene, we had a peptide
synthesized (CSHL protein chemistry) based on the
sequence of the carboxyl terminus of human Rel. N.
Rice and colleagues had already demonstrated that
antisera to this region of Rel immunoprecipitated a
cellular protein with with an apparent molecular size
of 82 kD. Our antipeptide serum has been partially
characterized thus far and has already revealed that it
can (1) immunoprecipitate both HIVEN86A and in-
vitro-translated c-Rel, (2) immunoblot both HIVEN
86A/Rel isolated by DNAP assay and several cellular
proteins that are not present in the DNAP assays, and
(3) immunoprecipitate proteins other than Rel. We
are currently investigating if the coimmuno-
precipitated proteins are Rd-related (antigenically) or
Rd-associated proteins. This peptide antiserum has
already revealed that total levels of Rel in unstimu-
lated cell extracts are significantly larger than the
amount of Rel that binds to the KB site in the DNAP
assays when either whole-cell or nuclear extracts are
used. Upon stimulation, the total levels of Rel in-
crease somewhat in 4 hours, but the amount of Rel
that associates with the xB site increases substantial-
ly. This suggests that the ability of Rel to associate
with the KB site is controlled by some posttransla-
tional process perhaps by mechanisms similar to the
association of NF-KB with I-KB.
Having identified multiple cellular proteins that
associate with KB sites in in vitro DNAP assays, we
decided to use the DNAP procedure to prepare a
complex immunogen analogous to the approach our
colleague Ed Harlow used to prepare antibodies to
E1A-associated protein. Upon completion of a KB
DNAP assay, we rinsed the beads and then injected
the avidin agarose-biotin KB-protein suspension into
the peritoneum of mice. After five injections, at inter-
vals of 14 days, the antiserum immunoprecipitated
HIVEN86A, and cells stimulated with PMA showed
increased nuclear immunofluorescence. A fusion to
murine NS1 cells was accomplished, and 1 hybrid-
oma from 187 screened was positive by immuno-
precipitation and immunoblot analysis for reaction to
HIVEN86A. It was subsequently single-cell-cloned,
and ascites was generated by injection of the cloned
cells into mice. This antibody (139.6) reveals a distri-
bution of immunofluorescence in the cytoplasm and
occasional nuclei in the human osteosarcoma (Hos)
cell line ATCC CRL1543. Upon stimulation of these
cells with PMA for 2 hours or more, there is a clear
increase in the number of positive nuclei and in the
intensity of signal from both the nuclei and
cytoplasm. Under similar conditions, HOS cells pro-
duce Rel as determined by immunoprecipitation with
139.6 antibody and KB DNAP assays.
Immunoblot comparisons of cellular extracts and
DNAP-enriched id3 complexes reveal a startling set
of results with monoclonal antibody 139.6. In addi-
tion to the detection of Rel, two cellular proteins are
readily detected by the antibody in crude extracts of
Jurkat cells. These proteins exhibit no obvious fluc-
tuation in extracts from PMA-stimulated Jurkat cells
and they also bind DNA. However, the association of
these proteins with DNA is relatively nonspecific;
e.g., it is easily competed by increasing the amount of
competitor DNA and therefore they behave opposite
to HIVEN86A/Rel under the same conditions. These
proteins migrate with apparent molecular sizes of 70
kD and 40 kD, respectively. Another protein recog-
nized by the monoclonal antibody is significantly in-
duced by phytohemagglutinin (PHA) and PMA in
Jurkat extracts and binds DNA with considerable af-
finity; however, it binds the mutant KB site
CTCACTTTCC significantly better than the wild-
type site GGGACTTFCC and migrates with an ap-
parent molecular size of 60 kD. We have previously
reported the fact that certain proteins bind the mutant
site better than the wild type. This may indicate that
the KB motif is really a composite of different bind-
ing sites and that the mutation actually enhances the
interaction with one member of the set of potential
KB-binding proteins. It therefore appears that the
antibody recognizes an epitope that is conserved
among several cellular proteins that exhibit different
site-specific interactions within the 10-bp KB site as
well as relatively nonspecific interactions with the
site.
An In Vitro Transcription Analysis of Early Respon-
ses of the HIV -1 LTR to Different Transcriptional
Activators. We have developed a simple, fast, and
reliable method to prepare whole-cell or nuclear ex-
tracts from small numbers of cells to study in vitro
transcriptional activation of promoters such as the
HIV-1 LTR. Our results reveal that the time course of
activation of extracts derived from cells stimulated
with the mitogenic lectin PHA or the tumor promoter
PMA is different. PMA induces a rapid (20-30 min)
onset of increased in vitro transcription from the
HIV-1 LTR, whereas PHA causes a slow (4-6 hr)
and sustained response. The biochemical relevance of
protein synthesis inhibition by cycloheximide treat-
ment of cells has been investigated using this ap-
proach. Cycloheximide has been used by several in-
vestigators to dissect cellular responses that appar-
ently occur in the absence of de novo protein
synthesis; e.g., if transcription of a gene can be in-
duced in the presence of cycloheximide, the gene
falls in the class of the immediate-early gene as dis-
cussed above. In these studies, PMA induction of a
change in in vitro transcriptional activity was not de-
pendent on de novo protein synthesis. Cycloheximide
alone was insufficient to induce activation. Oligo-
nucleotide-mediated site-directed mutagenesis de-
monstrated that mutation of the TATA box in the
HIV-1 LTR ablated initiation of both basal level tran-
scription and activation by PMA. Surprisingly, muta-
tion of both KB sites in the LTR was shown to reduce
but not extinguish the in vitro response to extracts
from either PHA- or PMA-stimulated cells. The
reduction was greater in extracts derived from cells
treated with PMA. However, in both cases, other
regions of the LTR clearly must be contributing to
the in vitro transcriptional activity induced by each
agent. Deletion analysis of the HIV-1 LTR reveals at
least one region (-464 to -252) capable of suppress-
ing in vitro transcription in extracts from Jurkat cells
stimulated by PMA. This result is consistent with ear-
ly studies of the HIV-1 LTR in transient transfection
assays of mammalian cells with HIV-1 LTR reporter
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gene constructs. We therefore have been able to ob-
serve distinct regulatory events at early time points
after cells are exposed to agents known to induce
transcription of both the HIV-1 LTR reporter gene
constructs and the HIV-1 provirus itself.
ADENOVIRUS E1A PROTEIN INTERACTION WITH
CELLULAR PROTEINS
We are interested in understanding the molecular me-
chanisms by which an oncogene alters the growth
status of human cells. The adenovirus early region
lA (E1A) gene products have been very useful in the
search for the cellular processes and the actual
proteins involved in growth regulation. The identi-
fication of the product of the retinoblastoma-linked
gene and a cyclin A gene as members of the set of
proteins complexed with ElA indicates the power of
E1A-affinity precipitation to isolate cellular growth
regulatory proteins. The fact that numerous mutants
of EIA exist that are deficient in one or more of the
biological activities ascribed to E1A contributes to
the ability to probe experimentally the function of
each associated cellular protein. We are now focusing
on a detailed definition of the cell-division-cycle-
modulated association of ElA with cellular proteins
and of the biochemical
isolated from cells throughout the cell cycle. As part
of these studies, we will extend the analysis of the
E1A-associated protein, p130. We look to an under-
standing of the interaction of ElA with these cellular
proteins to reveal mechanisms not only of E1A-
induced oncogenesis, but also of the normal growth
regulatory properties of these proteins. For some of
the studies reported below, we have continued to en-
joy the productive collaboration with David Beach,
Ed Harlow, and members of their respective research
groups.
Human Cyclin A and the Retinoblastoma Protein In-
teract with Similar but Distinguishable Sequences in
the Adenovirus EIA Gene Product. The adenovirus
ElA proteins associate with several cellular proteins
in adenovirus-infected or -transformed cells. Recent-
ly, two of the cellular proteins that bind to E1A have
been identified. p105 has been shown to be the pro-
duct of retinoblastoma tumor suppressing gene. p60
has been shown to be a human cyclin A. Previously,
studies have shown that E1A protein sequences en-
coded by conserved domains 1 and 2 are required for
134
interactions with the retinoblastoma protein (pRB).
We have now demonstrated that amino acids 30-60
and 121-127 within EIA are required for interaction
with p60/cyclin A. These are the same sites within
conserved domains 1 and 2 that are required for E1A
to associate with pRB. However, the association of
p60/cyclin A does not appear to require pRB. We
also demonstrated that another cellular protein, p130,
interacts with E1A at essentially the same sites. It is
interesting that mutations in these regions destroy the
ability of E1A to function as an oncogene, thereby
raising the possibility that interaction with several
different cellular proteins may be needed for trans-
formation by E1A.
The strategy we employed to determine the physi-
cal requirements for complex formation with
p60/cyclin A and 130K was to use adenovirus
mutants to identify the regions of E1A required to
bind these proteins. This strategy has been used suc-
cessfully to map the sites of protein-protein interac-
tions such as E1A with pRB. Such knowledge
permits correlation with existing data on those
regions of ElA that exert specific activities, such as
morphogenic transformation and altered growth con-
trol of mammalian cells. HeLa cells were infected
with recombinant mutants of adenovirus type 5, and
analysis of E1A-cellular protein complexes was ac-
complished by immunoprecipitation and subsequent
separation of the proteins by gel electrophoresis (for
summary of results, see Fig. 3). The anti -E1A
monoclonal antibodies, M73 and M58, were used in
each study. Two-dimensional gel electrophoresis was
used to investigate the p60/cyclin A interaction with
El A. The results obtained in this study indicate that
there is a close relationship between the specific
biological activities of E1A and the interaction with
p60/cyclin A and p130. Previous mutagenesis studies
had indicated that three regions of ElA, amino acids
1-25,36-76, and 121-129, are required for efficient
transformation. The region from 1 to 25 is correlated
with binding of p300 but does not appear to be re-
quired for binding p130, p107, pRB, or p60/cyclin A.
Binding of this set plus p300 is also dependent on se-
quences in conserved domain 1 within residues 30 to
60. They also interact with sequences in conserved
domain 2. The fact that p60/cyclin A and p130 re-
quire a subset of the E1A-transforming regions (i.e.,
amino acids 30-60 and 121-127) for binding sug-
gests that interaction with these cellular proteins may
contribute to the role of E1A as an oncogene. One is-
sue is whether p60/cyclin A or p130 require expres-
sion of pRB for association with E1A. We answered
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FIGURE 3 Two-dimensional gel electrophoretic analysis of p60 interactions with different
recombinant Ad5 E1A mutants. This figure presents a schematic diagram of the genetic
structure of the wild-type Ad5 E1A region and the structure of different recombinant Ad5
E1A mutants and a summary of data regarding the interaction of pRB (derived by P. Whyte
and E. Harlow) and p130 with each mutant. The region from individual two-dimensional gels
in which the p60 isoforms migrate is shown for each M73 or M58 immunoprecipitation of the
respective Ad5-infected HeLa cell lysate.
this by determining ElA association with p60/cyclin
A and p130 in adenovirus-infected cells in which
pRB is not expressed. Both alleles of the retino-
blastoma gene have been deleted from the genomes
of these cells.
p60 has been found to associate with the p34
protein product of the human homolog of the yeast
cdc2 gene. Expression of cdc2 is required in yeast for
cell cycle progression from Gt to S phase (DNA
synthesis) and for transition from G2 to mitosis (M
phase). It has now been demonstrated that mam-
malian cdc2 expression is required not only for the
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G2 to M transition, but also for the G, to S transition.
The interaction of p60 with cdc2 may play a role in
regulating the activity of this protein. This specula-
tion is strengthened by the identification of p60 as a
human cyclin A. Cyclins are a family of proteins,
rapidly degraded at mitosis. The association of
p60/cyclin A with cdc2, coupled with the demonstra-
tion that the region of El A to which p60/cyclin A
binds is required for its transformation function, sug-
gests a direct link between regulation of the cell divi-
sion cycle and acquisition of malignant growth
properties when mammalian cells express El A.
Biochemical elucidation of the actual function of
E1A may thereby reside, at least partially, in under-
standing its interaction(s) with p60/cyclin A and
p34cdc2 (or related gene products).
Cell Cycle Regulation of an Adenovirus E1A-as-
sociated Histone H1 Kinase Activity. As stated
above, several cellular proteins have been shown to
form stable protein-protein complexes with El A in
extracts derived from adenovirus-infected or -trans-
formed cells. We have extended an analysis of the in-
teraction of E1A with cellular proteins by demon-
strating that two members of the E1A immune com-
plex are very related to, if not actual products of, the
gene encoding p34cdc2. We have determined that this
E1A complex displays histone Hl-specific kinase ac-
tivity, that this activity is modulated throughout the
cell division cycle, and that there is apparently no re-
quirement for pRB association with E1A for this ac-
tivity.
To attempt to prove that the E1A-associated p34
isoforms were products of the human cdc2 gene, we
performed the following analyses. Adenovirus-
infected HeLa cells were labeled with [32Plortho-
phosphate, and extracts were prepared. The extracts
were immunoprecipitated with an anti-p34cdc2 pep-
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FIGURE 4 Two-dimensional gel analysis of the different p34cdc2 isoforms. (A)
Precipitates of p34cdc2 from HeLa cells infected with wild-type Ad5 using an anti-
cdc2 serum (G6); (B) precipitates of p34cd52 from HeLa cells infected with wild-
type Ad5 using p13-Sepharose beads; (C) mixture of proteins from precipitates
shown in A and E; (D) mixture of proteins from precipitates shown in B and E; (E)
HeLa cells infected with wild-type Ad5 and immunoprecipitated with the M73
monoclonal antibody; (F) anti-cdc2 immunoprecipitation of HeLa cells infected
with wild-type Ad5, performed in the presence of 100 nmoles of the antigenic
carboxy-terminal cdc2 peptide.
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tide antibody (G6, carboxy-terminal peptide) or were
exposed to p13-Sepharose beads. Figure 4A,
represents the region of the two-dimensional gel in
which the immunoprecipitated p34cdc2 isoforms are
resolved. Comparison with the p13-Sepharose-
precipitated p34cdc2 isoforms (see Fig. 4B) reveals a
strikingly similar pattern with two exceptions (spots
in boxes 2 and 3 in panel B). These same two spots
are seen in p13-Sepharose precipitates of uninfected
He La cells. Clearly, G6 does not immunoprecipitate
these forms of p34. The spot in box 1 corresponds ex-
actly to the spot in the box in Figure 4A. Mixture of
the M73 immunoprecipitate from adenovirus-infected
cells with either the G6 immunoprecipitate (Fig. 4C)
or the p13-Sepharose precipitate (Fig. 4D) reveals
that the two p13-Sepharose unique spots precisely
comigrate with the p34 spots in the E1A immune
complex. Figure 4E represents the two spots in the
M73 immunoprecipitate of infected He La cells and
Figure 4F represents the complete loss of all of the
G6 p34cdc2 isoforms when the immunizing peptide
was included in the lysate prior to immunoprecipita-
tion.
The structures of the unique p13-Sepharose and
E1A-immune-complexed p34 isoforms were com-
pared to the p34cdc2 structure. The results of peptide
analysis using N-chlorosuccinamide (NCS) are pre-
sented in Figure 5. NCS chemically cleaves proteins
at tryptophan residues. Spots from the G6 im-
munoprecipitation (Fig. 4B, spot in box), the M73
immunoprecipitation (Fig. 4E, spot in box), and the
p13-Sepharose precipitation (see Fig. 4B, spots in
boxes 1 and 2) were excised from the two-dimen-
sional gel and digested with NCS. The resultant pat-
tern for each spot is identical to the 04"i° pattern.
This is the pattern for NCS cleavage of mammalian
and Schizosaccharomyces pombe p34cdc2 previously
reported. In all cases, the spots represent phos-
phoproteins. The reason for the difference in two-
dimensional gel migration of the p13-Sepharose/E1A
unique isoforms of p34cdc2 remains to be determined,
but the NCS results demonstrate that the primary
structure of the ElA immune-complex-putative
p34cdc2 isoforms are virtually indistinguishable from
the forms immunoprecipitated by the G6 antibody.
However, as noted above, these isoforms are not
recognized by a p34cdc2 carboxy-terminal peptide
polyclonal antisera, G6, but they do bind p13-
Sepharose. It may be that they represent products of a
gene highly related to the human cdc2 gene, such as
the Egl cDNA from Xenopus laevis. Perhaps the
unique isoforms contain different phosphorylated
amino acids or some other modification that affects
their migration in the two-dimensional gels and
blocks their recognition by the G6 antibody. The ap-
parent size difference between these two forms is no
greater than that between each of the other "layers" of
p34cdc2 isoforms, so it is possible that they all are
structurally identical but modified differently, and it
is the modification that prevents access of G6 to the
forms that associate with El A. Another explanation
for the inability of G6 to recognize these forms is that
one or two amino acid carboxy-terminal truncations
of these isoforms have occurred. The size of the NCS
products is such that one or two amino acid deletions
might not be detected. A protein sequence com-
parison between the two isoforms and other isoforms
of p34cdc2 is required to establish the primary struc-
tural difference if one exists.
Histone 111 Kinase Activity of the E1A Immune Com-
plex Is Modulated through the Cell Division Cycle.
The histone H1 kinase activity precipitated with the
NCS Digests of Spots from 2D Gels
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FIGURE 5 NCS digest of p34 spots from two-dimensional
gels. (1) p13-Sepharose spot 1, see Fig. 2A, panel B, box 1;
(2) p13-Sepharose spot 2, see Fig. 2A, panel B, box 2; (3)
anti -p34cdc2 spot, see Fig. 2A, panel A, spot in box; (4) p34
spot in anti-E1A precipitate, Fig. 2A, panel E, spot in box.
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anti-cdc2 (G6) and the anti-p60/cyclin (C160) anti-
bodies displays a distinctive pattern of cell cycle
regulation in mammalian cells. The cdc2-p60/cyclin
complex has properties distinct from the cdc2-
p62/cyclin B complex in He La cells. We therefore
compared the ElA immune complex histone H1
kinase activity with the activities of the C160 and the
G6 immune complexes from populations of 293 en-
riched at different stages of the cell division cycle by
centrifugal elutriation. Cell lysates were prepared
from equivalent numbers of elutriated cells. Lysate
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FIGURE 6 Centrifugal elutriation and E1A-immune complex
histone H1 kinase activity of 293 cells. Cell fractions, col-
lected by centrifugal elutriation, were fixed and stained with
propidium iodide and analyzed by flow cyto-metry (top). The
remaining cells in each fraction were extracted and im-
munoprecipitated with either M73, anti-cdc2 (G6), anti-
p60/cyclin A (C160), or Pab416 antibodies, and histone H1
kinase was performed for each immune complex (bottom).
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protein concentrations were determined, and equi-
valent amounts of extract were immunoprecipitated
with either Pab416, M73, G6, or C160 antibodies.
The results of the elutriation and kinase assays are
graphically represented in Figure 6. As shown in Fig-
ure 6 (top), a substantial enrichment of cells at Gt
and G2/M phases was achieved. At the transition
from Gt to S between fractions 3 and 4, we see an in-
crease in histone H1 kinase activity in the E1A im-
mune complex that peaks between fractions 6 and 7.
The histone H1 kinase activity patterns for the C160,
anti-p60/cyclin A, and G6 anti-p34cdc2 immune com-
plexes are consistent with what we previously ob-
served in cell division cycle phase-enriched HeLa
cell extracts.
The pattern of cell division cycle modulation of
the E1A immune complex histone H1 kinase activity
suggests that one mechanism for E1A-induced trans-
formation may reside in its ability to associate with
cell cycle regulatory proteins at specific moments
during the transition of cells from G1 to S phase. In-
terestingly, the d1922/947 deletion mutant (deletion in
domain 2, see Fig. 3) is defective for oncogenic ac-
tivity and binds significantly less p34cdc2 and
p60/cyclin A. Consistent with decreased protein-
protein interaction is a significant 80% reduction in
the d1922/947 ElA immune complex H1 kinase ac-
tivity. It remains to be determined if p34cdc2 and
p60/cyclin A association with E1A can occur inde-
pendently. All E1A mutants examined thus far that
affect the binding of p34cdc2 and p60/cyclin A do so
equivalently.
At least three other E1A-associated proteins, the
130-kD, 107-kD, and pRB proteins, require se-
quences within domain 1 and/or domain 2 of E1A for
complex formation, and each of these proteins is
phosphorylated. It has been demonstrated that pRB is
phosphorylated at serine and threonine residues. It is
possible that p34cdc2 is the kinase responsible for
pRB phosphorylation in cells. Interestingly, the d1928
mutant that does not bind pRB maintains full histone
H1 kinase activity and binds the isoforms of p34cdc2
and p60/cyclin A. This raises the possibility that the
association of the d1928 product with p34cdc2 contrib-
utes to the induction of viral and cellular DNA
synthesis that has been observed when this mutant
E1A protein is expressed. We would hypothesize that
mechanistically, the d1928 E1A-p34cdc2 complex
phosphorylates pRB sometime during the Gt to S
phase transition and thereby is able to contribute to
induction of DNA synthesis because the phos-
phorylation of pRB results in release of suppression
of DNA synthesis. Of course, other activities of the
E1A-p34cdc2-p60/cyclin A complex may contribute
to the mitogenic activity of El A. The physical asso-
ciation of El A with pRB would represent an addi-
tional component of the transformation phenotype
resultant from expression of E1A. Such a model
would be consistent with El A having pRB-binding-
independent and pRB-binding-dependent effects on
cellular growth control.
Much remains to be learned regarding the regula-
tion of the modifications of the cellular proteins asso-
ciated with E1A and of the E1A gene products, as
well. For instance, the extensive, rapid posttransla-
tional modification of El A may be due at least partly
to the presence of p34cdc2 in the E1A complex. The
resolution of the same two specific forms of p34cdc2
in both the HA and p60/cyclin A immune complex
focuses our effort on determining what is special
about these two proteins and if one of their activities
is to modify El A itself. Because it is now known that
p34cdc2 is required for G1 to S transition as well as
G2 to M transition in mammalian cells, it is important
to determine if these two isoforms contribute to the
effects of E1A on the regulation of DNA synthesis.
We hypothesize that these two isoforms are involved
in the regulation of the mammalian equivalent of
"START" in yeast. An extension of this hypothesis is
to determine not only if these two isoforms partici-
pate in the regulation of initiation of DNA synthesis,
but also if they contribute to the posttranslational
modification of RNA polymerase II, resulting in
modulation of transcription initiation. We will there-
fore be studying the activity of extracts from cells ei-
ther expressing El A or not at different stages of the
cell cycle to determine if in vitro transcription of
promoters known to be E1A-sensitive is growth-
regulated. We will simultaneously identify the
proteins associated with the promoters during the
time course analysis of transcriptional activity. Fur-
ther study of the activity of different E1A-cellular
protein complexes may therefore uncover mechan-
isms for the coordination of activation of transcrip-
tion and initiation of DNA synthesis when resting
mammalian cells are propelled into the cell division
cycle.
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MOLECULAR BIOLOGY OF THE CYTOSKELETON
D.M. Helfman W. Guo
G. Henry
J. Kazzaz
A. Kistler
M. Leonard
J. Lees-Miller
G. Mulligan
M. Pittenger
R. Roscigno
T. Tsukahara
S. Worms ley
The molecular and biochemical bases for related cel-
lular processes such as cell motility and contractility,
organelle movement, chromosome movement, cyto-
kinesis, and the generation of cell shape are important
problems in biology. These processes are all depen-
dent on a complex macromolecular set of protein
fibers found in the cytoplasm, termed the cyto-
skeleton. The cytoskeleton of vertebrate cells is com-
posed of three major filamentous systems: actin fila-
ments, intermediate filaments, and microtubules.
Each of these filamentous systems contains a number
of different protein components, although different
cell types and tissues express specific protein
isoforms that comprise these structures. The research
in our laboratory is focused on two related problems
in molecular and cell biology: (1) the mechanisms
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responsible for tissue-specific and developmentally
regulated patterns of gene expression and (2) the
functional significance of cell-type-specific protein
isoform expression. Specifically, our laboratory has
been interested in understanding the regulation and
function of tropomyosin gene expression in muscle
and nonmuscle cells. Tropomyosins are a diverse
group of actin-binding proteins with distinct isoforms
present in striated muscle (skeletal and cardiac),
smooth muscle, and nonmuscle cells. We now know
that at least 12 different tropomyosin isoforms are ex-
pressed from three separate genes in rat. The cc-
tropomyosin (a-TM) gene encodes nine isoforms
(Fig. 1), the 11-tropomyosin ((3-TM) gene encodes two
isoforms (Fig. 2), and the tropomyosin-4 (TM-4)
gene encodes a single isoform. We have been study-
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FIGURE 1 Schematic diagram of the rat a-tropomyosin gene and nine different isoforms ex-
pressed from this gene. Boxes represent exons and horizontal lines represent introns; they
are not drawn to scale. The gene contains two alternative promoters which result in expres-
sion of two different amino-terminal coding regions (exons is and 1 b), two internal mutually
exclusive exon cassettes (exons 2a and 2b and 6a and 6b), and four alternatively spliced
3' exons that encode four different carboxy-terminal coding regions (exons 9a, 9b, 9c, and
9d). The different polyadenylation signals are also indicated (A).
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ing the expression of these genes with particular at-
tention to understanding the mechanisms of their
regulation at the posttranscriptional level, i.e., tissue-
specific alternative RNA splicing. In addition, the ex-
pression of a diverse group of tropomyosin isoforms
in a highly tissue-specific manner via alternative
RNA processing strongly suggests that each isoform
is required to carry out specific functions in conjunc-
tion with the actin-based filaments of various muscle
and nonmuscle cells. The function of these different
isoforms is not known and is under study. We have
also recently cloned a gene from the fission yeast
Schizosaccharomyces pombe that encodes a distantly
related member of the actin family and have begun to
study the function of this actin-like protein. Below is
a summary of our present studies.
Identification of cis-Elements and
Cellular Factors Involved in
Regulated Alternative Splice
Site Selection
W. Guo, G. Mulligan, S. Worms ley, R. Roscigno,
D. Heitman
The generation of protein isoform diversity by
alternative RNA processing is a fundamental process
which contributes to tissue-specific and developmen-
tally regulated patterns of gene expression. In addi-
tion, alternative splicing pathways have also been
demonstrated for a number of viral genes. At present,
the molecular basis for tissue-specific alternative
splicing is poorly understood. We are using the rat (3-
TM gene as a model system to investigate the mole-
cular basis for developmental and tissue-specific
RNA splicing (Fig. 2). The I3-TM gene expresses
both skeletal muscle (3 -TM and fibroblast TM-1 by
an alternative RNA splicing mechanism. The gene
contains 11 exons. Exons 1 through 5 and exons 8
and 9 are common to all mRNAs expressed from this
gene. Exons 6 and 11 are used in fibroblasts, as well
as smooth muscle cells, whereas exons 7 and 10 are
used exclusively in skeletal muscle. Furthermore, the
alternative RNA splicing patterns of the 3 -TM gene
are regulated during myogenesis. Myoblasts express
the fibroblast-type tropomyosin isoform (TM-1).
During differentiation, the pattern of pre-mRNA
splicing changes such that there is repression of the
fibroblast-type splice products and induction of the
muscle-specific splice products, i.e., skeletal muscle
(3 -TM.
During the past year, we have focused most of
our efforts on understanding why exon 7 is not
normally used in nonmuscle cells. There are at least
two models to explain why exon 7 (skeletal-muscle-
type splice) is not used in He La cells. One is that
there is an RNA secondary structure, which is predic-
ted by computer modeling, formed between intron se-
quences upstream and downstream from exon 7. This
structure would sequester this exon from the splicing
machinery in He La cells and thereby prevent its use.
A second model is that cellular factors interact with
specific sequences in the pre-mRNA and block the
use of exon 7 in nonmuscle cells. On the basis of our
experiments described below, we are in favor of the
second model.
Using both in vitro and in vivo systems, we have
identified a number of cis elements involved in
alternative splice site selection. We recently identi-
fied two distinct elements in the intron upstream of
exon 7 involved in splice site selection (Helfman et
al., Genes Dev. 4: 98 [1990]). The first element is a
polypyrimidine tract located 89-143 nucleotides up-
stream of the 3 ' splice site, which specifies the loca-
tion of the lariat branchpoints located an unusually
long distance (144-153 nucleotides) upstream of
exon 7. The second element is composed of intron se-
quences located between the polypyrimidine tract and
E Ex -5 AL,E -6 410111116
El ..i MM NM IMM.V
-38 39 - 80 8 125 126 164 165 188
A
89 213 14 234 235 - 257 'W
mp
58
N T4 AN ATE D
189 - 213 258 - 284
I I == I I
V I A
Skeletal muscle 13 -TM
Fibroblast TM I (smooth muscle)
FIGURE 2 Schematic diagram of the rat f- tropomyosin gene and the two different isoforms expressed
from this gene. The amino acids encoded by each exon are indicated. The cap site and polyadenyla-
tion sites are also indicated.
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3' splice site of exon 7. This element contains an im-
portant determinant in alternative splice site selec-
tion, because deletion of these sequences resulted in
the use of the skeletal-muscle-specific exon in non-
muscle cells.
To analyze further the role of specific nucleotides
within this region that are required for inhibiting the
use of exon 7 in nonmuscle cells, we have introduced
a series of clustered point mutations in the 3 ' end of
intron 6 and within exon 7. For example, it was im-
portant to determine if the deletion mutants in our
previous studies resulted in activation of the skeletal-
muscle-type splice in nonmuscle cells due to simply
altering the distance between the 3' splice site and
upstream branchpoint or removal of an inhibitory se-
quence. These experiments have identified a number
of specific sequences in the intron and exon that,
when mutated, lead to the use of exon 7 in nonmuscle
cells. These mutations appear to act by disrupting the
interaction of cellular factors with the pre-mRNA that
normally prevent the use of exon 7 (see below). We
have also found that transfection of tropomyosin min-
igenes containing mutations in the 5 ' or 3' splice
sites of exon 6 (fibroblast-type splice) does not result
in the increased use of exon 7 (skeletal-muscle-type
splice) in nonmuscle cell systems. These results sug-
gest that splice site selection in vivo is not regulated
by a simple cis-competition mechanism, but rather by
a mechanism that inhibits the use of the skeletal mus-
cle exon in nonmuscle cells. As mentioned above, we
believe that nonmuscle cells express factors that
block the use of exon 7. We then reasoned that it
should be possible to overcome the effects of these
putative blocking factors by expressing large
amounts of the pre-mRNA. Accordingly, transfecting
increasing amounts of plasmid containing a wild-type
minigene into HeLa cells resulted in use of exon 7.
As described above, we have identified a number
of critical regions in the intron upstream of exon 7
(skeletal-muscle-specific exon) and exon that, when
mutated, led to the use of exon 7 in nonmuscle cells.
These results strongly suggested that these sequences
in the pre-mRNA interact with cellular factors in
nonmuscle cells and thereby inhibit the use of the
skeletal muscle exon. Using UV photochemical
cross-linking, native gel electrophoresis, and binding
competition experiments, we have identified RNA-
binding proteins that interact with the pre-mRNA,
which likely influence the use of exon 7 in non-
muscle cells. HeLa nuclear extracts were fractionated
using a variety of chromatographic techniques, and
the fractions were analyzed by an RNA-protein gel
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mobility shift assay to determine if there are any
proteins that bind to the intron sequences upstream of
the 3 ' splice site of exon 7. We have identified an ac-
tivity that binds specifically to the 3 ' splice site of
exon 7, but not to similar regions of exon 6 or exon 8.
Furthermore, competition studies demonstrate that
this activity does not bind strongly to the mutants that
exhibit activation of exon 7 in vivo. We propose that
the interaction of this factor with the pre-mRNA pre-
vents the use of exon 7 and is therefore involved in
suppressing the use of the skeletal muscle exon in
nonmuscle cells.
Purification and Characterization
of a Protein That Binds to
Regulatory Sequences in the
(3-TM Pre-mRNA
G. Mulligan, W. Guo, S. Wormsley, D. Helfman
As described above, we have identified a number of
cis elements critical to regulated splicing of the 3 -TM
pre-mRNA. Specifically, there is a polypyrimidine
stretch upstream of the muscle-specific exon 7 that is
required for use of the adjacent branchpoints by the
5 ' splice site of exon 5 (the muscle-specific-splicing
pattern). We and other investigators have used UV
cross-linking to detect a 62-kD polypeptide that binds
specifically to long stretches of pyrimidines. This
protein is expressed in muscle and nonmuscle cell
types, and its role in splicing remains unclear. Ad-
jacent to this region of the transcript is another cis
element that appears to represent a binding site for
cellular factors in HeLa cells (see above). Deletion
of, or substitutions within, this element allows the
cellular machinery of a nonmuscle cell (HeLa) to
splice the muscle-specific exon 7. We propose that
the binding of a protein to these sequences between
the polypyrimidine stretch and the muscle-specific
exon inhibits the use of this exon in nonmuscle cells.
The use of UV cross-linking and gel mobility shift
techniques has allowed identification of a cellular
factor that binds to this inhibitory element with high
specificity. Separation techniques have allowed the
isolation of this protein to at least 90% purity. Work
is currently under way to develop in vitro biochemi-
cal assays to study the function of this protein. We
are also developing antibodies and cDNA clones that
will be valuable tools in studying the role of this fac-
tor in alternative splicing systems.
Development of In Vitro Splicing
Systems from Myogenic cells
T. Tsukahara, D. Helfman
To identify cellular factors and mechanisms involyed
in muscle-specific alternative RNA splicing, it will
be necessary to develop an in vitro system from
myogenic cells. We have begun studies to establish
such a system using the mouse myogenic cell line,
BC3H1. The undifferentiated cells express the non-
muscle (fibroblast-type) tropomyosin isoforms from
the a-TM and R -TM genes, e.g., TM-1 and TM-2.
Upon differentiation, the pattern of pre-mRNA splic-
ing changes such that there is repression of the
fibroblast-type splice products and induction of the
muscle-specific splice products, i.e., skeletal muscle
a-TM and R -TM. We have prepared nuclear extracts
from undifferentiated BC3H1 cells that are able to
splice 13-TM pre-mRNAs in the appropriate cell-type
pattern. Experiments are in progress to prepare
nuclear extracts from differentiated cells.
Alterations in Transcription and
Alternative RNA Splicing Are
Involved in the Changes in
Tropomyosin Expression in
Transformed cells
J. Lees-Miller, M. Leonard, D. Helfman
One of our aims is to study the effects of different
nuclear and cytoplasmic oncogenes on tropomyosin
expression. We have found that rat fibroblasts trans-
formed with Kirsten virus and Rous sarcoma virus
have undetectable levels of TM-2 and TM-3 mRNAs
but elevated levels of TM-5a and TM-5b mRNAs
(Goodwin et al., J. Bio. Chem. [1991] in press). Anal-
ysis of the genetic basis for the expression of the four
isoforms (TM-2, TM-3, TM-5a, and TM-5b) revealed
that all are expressed from the a-TM gene via the use
of alternative promoters and alternative RNA splicing
(Fig. 1). Interestingly, mRNAs for TM-2 and TM-3
are transcribed from a 5' proximal promoter, whereas
mRNAs for TM-5a and TM-5b are transcribed from
an internal promoter. The lack of mRNAs for TM-2
and TM-3 in cells transformed by the Kirsten and
Rous sarcoma viruses correlates with the absence of
proteins for these isoforms. Thus, the absence of
mRNAs for these two isoforms is likely due to the in-
hibition of transcription from the upstream promoter
of this gene. In addition, we have determined that
cells transformed by adenovirus and SV40 have in-
creased levels of mRNA encoding TM-3 and TM-5b,
relative to TM-2 and TM-5a, which correspond to
changes in the relative use of alternative exons 6a and
6b (Goodwin et al., J. Bio. Chem. [1991] in press). At
present, it is not known if these changes in exon
usage are due to alterations in the concentration or
activity of splicing factors or due to differences in the
stability of the respective mRNAs. Experiments are
under way to determine the precise mechanism(s)
responsible for these alterations in tropomyosin ex-
pression. Understanding these mechanism(s) will
provide new insights into the pleiotropic action of the
oncogenes associated with these various RNA and
DNA tumor viruses.
Transcriptional Control of
Tropomyosin Gene Expression
J. Kazzaz, D. Helfman
The rat R -TM gene expresses two distinct isoforms
via an alternative splicing mechanism (Fig. 2). Al-
though the gene is expressed in muscle (skeletal, car-
diac, and smooth) and nonmuscle cells, a single tran-
scription initiation site is used in the various cell
types that express the gene. We now wish to
determine if the same cis-acting elements are used in
muscle (skeletal, cardiac, and smooth) and non-
muscle cells (e.g., fibroblasts) and if the same or dif-
ferent trans-acting factors are involved in transcrip-
tional control of the gene in different cell types. Se-
quence analysis of the 5 ' end of the (3-TM gene has
already revealed a number of potentially important
elements involved in transcriptional control in skele-
tal muscle cells. The gene contains three copies of a
skeletal-muscle-specific enhancer element (MRE) lo-
cated approximately 300, 350, and 400 by upstream
of the transcriptional start site. The consensus se-
quence of this 14-nucleotide-long element .(C/GNG/
AG/ACAC/GC/GTGC/TC/TNC/G) has been found
in a number of genes expressed in skeletal muscle in-
cluding the muscle creatine kinase, 6-subunit of the
acetylcholine receptor, myosin light chain 1/3, des-
min, and vimentin (Buskin and Hauschka, Mol. Cell.
Biol. 9: 2627 [1989]). This element is believed to be
the site of action of the myogenic regulatory factors
such as MyoD and myogenin. Since these myogenic
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regulatory factors are expressed in skeletal muscle,
but not in cardiac and smooth muscle or nonmuscle
cells, it is likely that expression of the [3-TM gene in
cells other than skeletal muscle will require a dif-
ferent set of transcriptional regulatory proteins.
For the initial characterization of the promoter,
we have cloned 300-1800 by of the upstream
promoter region into a chloramphenicol acetyltrans-
ferase (CAT) expression vector. We used this vector
to transfect a variety of cell lines and tested for CAT
activity in transient assays. Results from transfections
into a rat fibroblast cell line (REF52) and a mouse
fibroblast cell line (NIH-3T3) indicate that 1800 by
of the upstream promoter region are not sufficient to
drive transcription of CAT in fibroblasts. To deter-
mine if the muscle-specific regulatory elements
(MRE) identified by DNA sequence analysis are
functional, REF52 and NIH-3T3 cells were cotrans-
fected with a plasmid that contains a copy of the
MyoD cDNA clone (Davis et al., Cell 51: 987
[1987]; courtesy of A. Lassar) and the CAT-promoter
constructs described above. These experiments
demonstrated that the MyoD binding sites between
positions -300 and -400 are functionally active. Fur-
FIGURE 3 Localization of tropomyosin isoforms in fibroblasts. Bacterially pro-
duced fibroblast isoforms TM-5A and TM-5B were fluorescently tagged with
rhodamine and microinjected into rat fibroblasts (REF52). Three hours after
injection, the cells were fixed and visualized by fluorescence microscopy.
Both isoforms localized to actin filaments.
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ther deletion analysis confirmed that this region is
sufficient to confer responsiveness to MyoD. To
determine if these sequences can activate transcrip-
tion in a muscle cell line, C2C12 myotubes were
transfected with the various CAT-promoter con-
structs. This cell line upon induction with low serum
differentiates into myocytes and fuses to form
myotubes. Transfection into differentiated myotubes
indicates that the 3 -TM MRE is sufficient for activa-
tion of CAT in differentiated muscle cell lines. Ex-
periments are in progress to determine if all three ele-
ments are required for muscle-specific gene expres-
sion and if the four different myogenic regulatory
factors, i.e., myoD and myogenin, mrf4, and myf5,
interact with these sequences in distinct ways.
In addition to the myogenic regulatory region, se-
quence analysis has also revealed a 124-bp direct
repeat within the first intron of the 13-TM gene. This
repeat has a 45-nucleotide purine/pyrimidine (dA-dC)
stretch. A poly(dA-dC) repeat has been shown to
have enhancer properties in SV40 (Berg et al., Mol.
Cell. Biol. 9: 5248 [1989]). To determine if this ele-
ment has enhancer-like activity, we have cloned both
copies of this element upstream of the 5 ' promoter
proximal elements in the tropomyosin-CAT con-
structs indicated above. Preliminary evidence sug-
gests that this element does function as an enhancer
in both fibroblast and muscle cell lines. Cotransfec-
tion with MyoD indicates that the effect of the inter-
nal enhancer is additive to that of the muscle regu-
latory region. Further investigation will determine
whether the enhancer activity resides in the poly(dA-
dC) repeat, in the flanking regions, or a combination
of both.
Tropomyosin Isoform Diversity
and Cellular Function:
Microinjection of Fluorescently
Labeled Tropomyosins
M. Pittenger, A. Kistler, D. Helfman
Rat fibroblasts express at least six distinct forms of
TMs. As a step toward understanding the function of
this TM isoform diversity, we have utilized the
cDNA clones generated in our laboratory to produce
homogeneous preparations of the individual isoforms
in a bacterial expression system. The purified pro-
teins were labeled with fluorescent reagents and then
microinjected into cultured rat fibroblasts. Five of the
isoforms we injected could be readily detected to
bind actin filaments; e.g., TM-5A and TM-5B both
localized to actin filaments (Fig. 3). In the coming
year, we plan to study the individual isoforms during
such events as mitosis, cell spreading, and migration
into a monolayer wound. We will attempt to inject
transformed rat cells to reintroduce those isoforms
that are missing to see if there are any effects on cell
morphology and microfilament structure.
Are There Specific Tropomyosin-
binding Proteins in Tissues?
M. Pittenger, D. Helfman
At present, it is not known whether TMs in non-
muscle cells bind to proteins other than actin. Using
125I-labeled Bolton-Hunter reagent, we labeled
purified TM-5a and TM-5b, which differ in only a
24-amino-acid internal sequence (see Fig. 1). The
125I-labeled proteins were used to probe a nitrocel-
lulose blot of proteins from various rat tissues sepa-
rated by SDS-PAGE. We have detected distinct
bands in most tissues that bind to the labeled TM
probes. Interestingly, some bands exhibit preferential
binding to each TM probe. We are in the process of
identifying these proteins, some of which are proba-
bly known cellular proteins, whereas
prove as yet unidentified. This approach will also be
used to identify and map the regions in the TM
isoforms that are involved in binding to specific cel-
lular proteins in this type of assay. In addition, exper-
iments are in progress to determine whether these
putative TM-binding proteins are effected in trans-
formed cells.
Why Do Transformed Cells Alter
Tropomyosin Expression?
M Pittenger, D. Helfman
Dramatic shifts in TM isoform expression occur in
cells transformed by such diverse agents as DNA and
RNA tumor viruses and chemical carcinogens. More-
over, there are two recent reports of spontaneous
revertants from a transformed phenotype to a non-
transformed cell type which then express the normal
complement of TMs. The underlying reasons for
these alterations in TM expression are not un-
derstood, but these findings suggest a role for TM in
maintaining normal cell phenotype. Morphological
alterations are the most obvious and immediate char-
145
acteristics of transformed cells in culture. It is not
known whether these gross abnormalities are directly
related to transformation (e.g., by interfering with
cell-cell communication and/or signal transduction
pathways) or whether they occur only as an indirect
consequence. We are interested in determining if
morphological alterations are directly related to
changes in TM isoform expression. This also requires
an understanding of the normal regulation of TM ex-
pression.
We have used a pulse-chase experiment, high-
resolution gel electrophoresis, and quantitative analy-
sis to look at the half-life of TM proteins in normal
rat embryo fibroblasts (REF52). All TM isoforms
were found to have long half-lives, but the curves ap-
peared to be biphasic, with a initial high slope and a
more gradual slope after approximately 8 hours. We
are testing the possibility that the initial rate reflects
unbound TMs, whereas the slower degradation rate
reflects that of TMs that have bound (reversibly) to
actin filaments and are therefore not degraded. Trans-
formed rat cell lines will then be analyzed in a similar
way to see if alterations in half-life of particular
isoforms can account for the alteration in their
abundance.
Transformed cells generally have a more rapid
transit through the cell cycle than normal cells. To
analyze TM expression through the cell cycle, we
have synchronized populations of cells by thymidine
block and mitotic shake-off. The newly synthesized
proteins in each population were pulse-labeled and
resolved by two-dimensional gel electrophoresis.
Only a modest change was detectable in the newly
synthesized TMs. This alone would not account for
the changes seen in transformed cells. However, it
will now be interesting to see if there is any change in
the degradation rate of isoforms through the cell
cycle.
To address the question of whether morphological
alterations are directly related to changes in TM ex-
pression, we have plated normal rat fibroblasts on a
substrate that has been treated with polyHEMA to
prevent cell attachment. This treatment can be varied
to alter the extent of cell spreading. Newly
synthesized TM isoforms were then analyzed after
two-dimensional gel electrophoresis. We found that
cells that cannot attach and spread properly show
synthetic patterns more similar to those of trans-
formed cells than to the patterns of well-spread cells.
We will now test transformed cells on the
polyHEMA substrate to test whether this produces
any further changes in TM protein synthesis.
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Identification and Characterization
of an Actin-like Protein from
Schizosaccharomyces pombe
J. Lees-Miller, G. Henry, D. Helfman
Actins are a family of highly conserved proteins that
are ubiquitously distributed in all eukaryotic cells.
They form the structural core of thin filaments in
muscle and microfilaments in nonmuscle cells.
Through the interaction with a host of cellular
proteins, they participate in several essential cellular
functions such as muscle contractility, cell motility,
cytokinesis, cell structure, and organelle movement.
We have recently cloned a gene from the fission
yeast S. pombe that encodes a distantly related mem-
ber of the actin family. Unlike all other known actins
from a broad range of phyla, including vertebrates
(human), yeast, plants, and protozoa, that have be-
tween 60% and 90% amino acid sequence identity
and are 374-376 amino acids in length, this actin-like
protein is only 30-35% identical to other actins, in-
cluding that of S. pombe, and is 427 amino acids in
length. Because it is not more similar to S. pombe ac-
tin than to actins from a variety of other organisms,
including mammals, there is a strong possibility that
this protein diverged from actin early in eukaryotic
evolution and will be found in other species.
Our present goal is to determine the function of
this actin-like protein and in so doing to better under-
stand the complex set of interactions that underlie the
cellular roles of conventional actins. Experiments are
in progress to determine the phenotypes resulting
from both knock-out and overexpression of the actin-
like protein gene in S. pombe. On the basis of the
results of this analysis, we will attempt to generate a
selectable phenotype that can be used to identify
potential homologs encoded within a mammalian
cDNA expression library and to identify interacting
proteins within fission yeast. In addition, we plan to
purify the actin-like protein. It will be functionally
characterized in regard to homotypic and heterotypic
protein-protein interactions, and antibodies will be
made for the purpose of cellular localization and as
an additional tool in the search for a mammalian
homolog.
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QUEST PROTEIN DATABASE CENTER
J.I. Garrels G. Latter
B.R. Franza C. Chang
H. Sacco
P. Myers C. Blanchford J. LaMarca
P. Monardo S. Fang J. Slott
J. Kos K. Duhamel
The QUEST Protein Database Center began an ex-
pansion in 1990 with renewed support from the
Biomedical Research Technology Program of the Na-
tional Institutes of Health. Our computer facility has
been expanded with the hiring of Gerald Latter and
Pat Monardo. Their immediate mission is to develop
an enhanced version of the QUEST software for
quantitative two-dimensional gel analysis that can be
distributed to other scientists. Further expansion be-
gan in 1990 with the hiring of Scott Patterson to head
a new laboratory for the identification and character-
ization of proteins from two-dimensional gels.
A major upgrade to the QUEST computer facility
began in 1990. Since the present QUEST facility was
established in 1985, computer hardware has improv-
ed tremendously, and so have the system software
and database tools now available to all users of mod-
ern workstations. Jerry Latter, who comes to us from
the Linus Pau ling Institute where he had a great deal
of experience in two-dimensional gel analysis, now
leads our effort to produce an updated software pack-
age that can be used by investigators anywhere who
have Sun or compatible workstations. Pat Monardo,
who joined Jerry's team early in the year, brings a
tremendous knowledge of modern software tools. He
and Jerry have designed and partially implemented a
new structure for the QUEST system, as described
below.
Jerry Latter has also taken charge of the daily op-
erations of the QUEST Center. Some of the functions
of the QUEST Center are to perform routine two-di-
mensional gel analysis for investigators at Cold
Spring Harbor Laboratory and elsewhere and to train
and assist users in the analysis of their data. Cecile
Chang continues to interact heavily with the users,
helping to analyze, manage, and interpret their data.
Phyllis Myers tirelessly carries out the routine aspects
of pattern matching and editing for virtually all data
passing through the system. Jim Kos has maintained
the user software and has begun a relational database
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to manage the records on every gel run in the QUEST
system. The sections below describe much of the
work that has passed through the QUEST center in
1990.
A new scientist, Scott Patterson, was hired in late
1990. In January, 1991, he will join the QUEST team
as the protein chemist in charge of protein identifica-
tion and characterization from two-dimensional gels.
Scott is a young researcher from Australia with expe-
rience in many forms of electrophoresis and in
protein characterization. New laboratory space being
prepared for Scott will include both his protein
chemistry facility and an upgraded two-dimensional
gel electrophoresis laboratory. To train him in the
latest methods of protein sequencing from two-
dimensional gels, plans were made for Scott to work
in the laboratory of Dr. Ruedi Aebersold in Van-
couver during the first 2 months of 1991.
The two-dimensional gel laboratory in the Mc-
Clintock building continues under the supervision of
Heidi Sacco, with assistance from Shuling Fang and
Kris Duhamel. Kris replaces Christy Blanchford, who
departed for medical school.
Our scientific aims continue to be the construc-
tion and analysis of protein databases for mammalian
cells and for yeast. The yeast database, carried out
largely by Dr. Calvin McLaughlin of the University
of California at Irvine, was described fully in last
year's Annual Report and is being readied for publi-
cation and dissemination in 1991. In the following
sections, we report in detail on recent developments
in the rat REF52 database and the mouse embryo
database. Dr. Robert Franza has continued to add
new information on regulatory proteins to the data-
bases, as described briefly below. His work is cov-
ered more fully in a separate report entitled "Cellular
trans-Activators of Gene Expression."
QUEST Software for Two-
dimensional Gel Analysis
J. Garrels, G. Latter, P. Monardo, J. Kos
The QUEST software package is a very complex
entity that includes such diverse functions as film
scanning, conversion of film density to units of
radioactivity, combining image data from separate
film exposures, spot detection and quantitation, pat-
tern matching, interactive editing, selection of
quantitative or qualitative changes, statistical analysis
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of data, graphic display of data, annotation of data,
and comparison of data from experiments performed
at different times and by different investigators. In
the 1980s, we developed strategies for each of these
tasks, we developed and tested algorithms for each
phase of analysis, and we wrote a large software
package for use on Unix-based (Masscomp) worksta-
tions. This software package was used to build our
REF52 database, which was published in 1989.
The QUEST software package for the 1990s must
be different in several major respects. It must in-
corporate software standards for graphics and for the
user interface that did not exist a few years ago. It
must take advantage of fast modern workstations that
often are interconnected on networks. Finally, it must
be a robust, easy-to-use, documented package that
can be distributed widely to other scientific users.
The software upgrade has proceeded in two
stages. First, the old body of code was converted to
run on Sun workstations using the X windows
graphics system. This conversion has involved (1)
recoding complex algorithms for spot fitting and for
image displays that formerly were designed to run in
an array processor, (2) simplification of the older
code that had become overly complex due to a pro-
liferation of features and tricks that were then neces-
sary to increase performance, and (3) adding new al-
gorithms that were impractical in the slower environ-
ment of the older workstations. At the same time, the
main algorithms for pattern matching and spot fitting
have been significantly improved. Finally, an entirely
new body of code, the Cluster Analysis functions, has
been developed for database analysis (see below).
Jim Garrels, who developed most of the original soft-
ware package, has been primarily focused on this
stage of the upgrade.
The second stage of software upgrade has pro-
ceeded simultaneously. Jerry Latter and Pat Monardo
have taken the converted software and reimple-
mented it as small independent modules that commu-
nicate in a distributed (networked) environment. This
structure ensures that the software can be easily
maintained because each module is independent of
the others, and this design is efficient because all
users can take advantage of data and processing
power anywhere on their network. Jerry, Pat, and Jim
Kos further enhance the software by adding data
management tools, utility functions, and, most of all,
a standardized user interface. Finally, they develop
the documentation and training materials that all
users will require. The design and much of the coding
of the final system were completed in 1990. The new
system is targeted for release to off-site users by Au-
gust, 1991.
The REF52 Database Analyzed
by Cluster Analysis
J.I. Garrels, R. Franza, C. Chang, G. Latter
The REF52 database contains a wealth of information
about the patterns of protein synthesis and modifica-
tion in the REF52 rat cell line as it responds to
growth regulators and transforming agents. This large
body of data consists of 12 major experiments, each
containing 6-10 different gels, each of which has
been quantitatively analyzed at the level of 1600
protein spots. Finding the biologically important pat-
terns in this data set has been both rewarding and
challenging. During 1990, we implemented a new
tool, Cluster Analysis, in the QUEST system in order
to find the patterns of coordinate regulation more
easily.
Figure 1 presents one of the REF52 gel images,
and the inset shows an enlarged region containing
two proteins of interest. The expression profiles of
these two proteins, caldesmon and a nuclear protein
of 85 kD, are elaborated in Figure 2. For this experi-
ment, cells were labeled at various times after plat-
ing, and some cultures were refed with fresh medium
and serum before labeling. The expression profile for
85K is typical of proteins that are repressed at con-
fluence (day 6) and at quiescence (day 12) and that
FIGURE 1 A two-dimensional gel, displayed on the Sun workstation, is shown as a whole-gel image in the large window,
and the region in the box is enlarged in the smaller window. The expression profiles for two spots of interest, caldesmon
and 135K," are shown. Each bar of the graphs shows the relative protein intensity from one sample, and the samples are
identified in Fig. 2.
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are induced to higher rates of synthesis as confluent
cells re-enter S phase. The expression profile for
caldesmon is typical of proteins that are induced as
cells reach confluence and that have repressed rates
of synthesis after refeeding.
Cluster analysis is a method used to find proteins
with similar expression profiles in a given experi-
ment. The algorithm compares the expression profile
of every protein to that of every other protein, gener-
ating a matrix of similarity scores. Clustering is then
the process of grouping the spots with high similarity
scores. In the QUEST system, cluster analysis can be
used either to find those proteins with expression pro-
files most similar to a given protein or to find all of
the inherent expression profiles (clusters) ranked by
the number of proteins they contain. The latter meth-
od was used to analyze the experiment depicted in
Figure 2, and the most common expression profiles
are shown in Figure 3.
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FIGURE 2 These expression profiles are taken from an ex-
periment in the REF52 database. This experiment is design-
ed to reveal changes in the relative rates of protein
synthesis as REF52 cells proliferate, reach quiescence, and
respond to refeeding. Each bar represents quantitation of
one protein from one gel, and the vertical axis is normalized
to the highest bar. The labels in the center apply to both
graphs. These graphs show some of the highly character-
istic protein expression profiles that exist in the database.
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168 Total
PCNA-LIKE 23% Nuclear
1% Glycoproteins
(PCNA, "85K", Lamin-B)
CONSTANT
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0% Glycoproteins
(6-F1-ATPase, TM5, calpactin
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QUIESCENCE 1% Glycoproteins
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FIGURE 3 Cluster analysis of the protein expression pro-
files. The eight-sample experiment described in Fig. 2 was
fully analyzed by cluster analysis, as described in the text.
Each cluster is a group of proteins with similar expression
profiles, and the graphs shown are the average expression
profiles for the proteins in each cluster. Some known mem-
bers and some biological properties of each cluster are
given. Each cluster is discussed further in the text.
The largest cluster in Figure 3 is called "PCNA-
like" because it has an expression profile similar to
that of PCNA. The 85K protein is a member of this
cluster, as was PCNA and lamin-B. The rate of
synthesis of proteins in this cluster correlates well
with the number of cells in S phase, and interestingly,
this cluster has a high content of nuclear proteins.
The next largest cluster (116 proteins) is the set with
constant expression. The synthesis of these proteins,
which comprise about 13% of all proteins analyzed,
was not significantly regulated as REF52 cells enter-
ed quiescence and after cells were stimulated by
refeeding.
The next two clusters shown in Figure 3 are char-
acterized by high or low expression in confluent (day
12) cells, but with little change noted during growth
to confluence. These patterns of expression, which
were not recognized before the application of cluster
analysis, show that many proteins are specifically in-
duced or repressed as REF52 cells enter the Go state,
and that these changes are not substantially reversed
at 5 or 15 hours after refeeding. The "growth-
regulated" cluster has the caldesmon-like pattern, and
it includes several of the tropomyosin isoforms.
These proteins are synthesized at elevated rates in
both confluent (day 6) and quiescent (day 12) cells,
and their synthesis is rapidly reduced after refeeding.
Glycoproteins make up 23% of the proteins in this
cluster, in contrast to a glycoprotein content of only
1-2% in other clusters.
The final cluster in Figure 3 contains 26 proteins
that are induced early (5 hr) but not late (15 hr) after
refeeding. Many of these proteins are undetectable in
nonstimulated cells, and therefore could not be easily
scored as nuclear or cytoplasmic. They are not sig-
nificantly growth-regulated (during days 2-6), but
appear to belong specifically to the early response to
growth factors.
The application of cluster analysis to this relative-
ly simple experiment has led to the identification of
six fundamental patterns of regulation for the proteins
of REF52 cells. The other key experiments in the
REF52 database have likewise been subjected to
cluster analysis, and the results are published else-
where (Garrels et al., Electrophoresis 11: 1114
[1990]). Cluster analysis is now applied as a standard
method in the QUEST system to recognize the major
patterns of coordinate regulation in any quantitative
experiment.
Mouse Embryo Database
J. I. Garrels, C. Chang, P. Myers [in collaboration
with K. Latham and D. Solter, Wistar Institute]
The mouse embryo database is a quantitative study of
synchronized embryos labeled every 3 hours from
fertilization through the blastocyst stage. Additional
samples from 6.5- and 7.5-day embryos separated
into germ layers are now being processed. This
baseline study of normal embryos serves as the con-
trol against which other studies are being compared.
The database of normal development through the
four-cell stage has been completed and analyzed
using cluster analysis. The number of changes that
occur during either the one-cell stage or the two-cell
stage is much greater than the number of differences
(quantitative and qualitative) that were found be-
tween proliferating and quiescent REF52 cells.
The clusters for the two-cell stage are most
revealing. A large cluster of proteins was discovered
for which the expression profile shows a steady rise
in rate of synthesis between 6 and 18 hours of the
two-cell stage. Many of these proteins were not
detected at earlier times. On average, these proteins
are induced by fivefold, although for proteins not
detected at early times, this number reflects only the
induction above the level of sensitivity. Members of
this cluster correspond to the proteins encoded by
embryonic mRNA, which is known to be first
synthesized during the two-cell stage.
The next two clusters, in order of size, have ex-
pression profiles that decrease rapidly between 3 and
6 hours into the two-cell stage. One cluster (20% of
all proteins analyzed) continues to decrease through-
out the two-cell stage. The other cluster (16% of
proteins analyzed) decreases sharply (fivefold) be-
tween 3 and 6 hours, but then returns to somewhat
higher rates of synthesis by the end of the two-cell
stage. The members of these two clusters are thought
to be proteins encoded by maternal mRNAs that are
inactivated or degraded in the two-cell stage. Some of
these proteins are apparently not encoded by em-
bryonic mRNA, whereas the synthesis of others is
probably restored by the activation of embryonic
transcription.
Two other clusters of proteins reveal transient
changes peaking at 6-9 hours into the two-cell stage.
Six percent of the proteins analyzed have sharply
elevated levels of synthesis (tenfold on average) at 9
hours relative to 0 hour, but by the end of the two-
cell stage, these proteins have fallen fivefold on aver-
age from their peak rate of synthesis. Conversely, 4%
of the proteins have sharply lower rates of synthesis
(sixfold on average) at 6 hours relative to 0 hour. The
meaning of these two clusters is not clear, but it is in-
teresting that many transient events occur coincident
with embryonic gene activation.
To summarize the findings from the two-cell
stage, 37% of the proteins belong to the cluster of in-
duced proteins, 36% of the proteins belong to the two
clusters of repressed proteins, and 10% of proteins
show coordinate but transient changes. No cluster of
proteins with constant synthesis during the two-cell
stage was found. At the four-cell stage, in contrast,
the largest cluster (63% of proteins analyzed) has a
constant expression profile, and the other clusters
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show inductions or repressions of twofold or less.
Further experiments are in progress to analyze the
protein patterns of androgenones and gynogenones,
which are embryos possessing either two male or two
female pronuclei, respectively. The two-dimensional
gel patterns reveal a block in the progression of
changes in protein synthesis of androgenones that ac-
companies an observed morphological block. Other
experiments in progress include the analysis of em-
bryos exposed to protein kinase (PK-A and PK-C) in-
hibitors that are known to interfere with develop-
ment.
Regulatory Protein Database
B.R. Franza
Proteins involved in regulation of cell growth and
cell division are being studied in human cells. A vari-
ety of techniques have been used to identify, clone,
and characterize these genes and their protein prod-
ucts (see Cellular trans-Activators of Gene Expres-
sion). The maps of these regulatory proteins, their ex-
pression profiles, and their patterns of modification
are important contributions to the mammalian, and
especially human, databases that now exist and to
those that are planned for the future.
In recent work, the E1A-associated protein
p60/cyclin A was shown to be associated with
p34cdc2. The p60/cyclin A complex also appears in
immunoprecipitates complexed with significant
amounts of the major protein kinase C substrate,
MARCKS. In another line of research, it was shown
that the DNA-binding protein, HIVEN86A, originally
discovered using the DNA precipitation assay
(DNAP) followed by two-dimensional gel analysis, is
actually the product of the c-rel proto-oncogene.
These and other regulatory proteins have been char-
acterized on two-dimensional gels with respect to
their patterns of induction, modification, and associa-
tion with other regulatory proteins in several different
human cell lines.
Service Projects
C. Chang, P. Myers, G. Latter, J. Garrets
During 1990, the QUEST center has engaged in 11
collaborative and service projects as part of its mis-
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sion as a resource facility. A few of the these projects
are summarized here. Studies of the human HOS cell
line and several transformed derivatives were carried
out with Dr. C. Kumar from Schering Research.
HOS, K-HOS (Ki-ras-transformed), MNNG-HOS
(containing the met oncogene), and HOS 312 (K-
HOS revertant) were analyzed at days 2, 4, 7, and 11
after plating. We had known that transformation
shuts off the synthesis of a myosin light-chain
isoform, but it was important to understand the
regulation of this protein in normal and transformed
HOS cells at all stages of proliferation and at con-
fluence. Contrary to our expectation, we found that in
normal cells, this cytoskeletal protein is synthesized
most rapidly in proliferating cells and is repressed at
confluence. Knowing the stage of maximum expres-
sion helped us to evaluate meaningfully the altered
patterns of expression in transformed cells (Kumar et
al., EMBO J. [1991 ] submitted).
Another study of human cells was carried out by
Dr. J. Quigley and S. Nielson of SUNY, Stony
Brook. They have examined HEp3 epidermoid car-
cinoma cells that can be reversibly cycled between
metastatic and nonmetastatic states depending on
growth conditions. Protein differences between
metastatic and nonmetastatic cells have been identi-
fied with the QUEST system. More detailed studies
are in progress to determine the timing of these
changes and the cellular fractions in which they oc-
cur, prior to biochemical analysis of the most inter-
esting proteins.
A mouse project, which interfaces with the mouse
embryo database base (see above), is a study of
normal, androgenetic, and gynogenetic ES cell lines.
This study is carried out with Dr. Colin Stewart of the
Roche Institute and Dr. K. Latham of the Wistar In-
stitute. Although the developmental potential of these
cell lines is markedly different, the protein synthesis
differences are subtle. No qualitative differences
were found, but about 20 proteins were found to ex-
hibit quantitative differences of 1.5-2-fold. These
studies may help to locate differences in regulatory
pathways in stem cells that ultimately affect the
course of development.
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GENETICS
The most interesting proteins are not found by biochemistry: Genetics is a much
more powerful approach." "Genetics without biochemistry is sterile." This discus-
sion occurs in many guises. The protagonists are those on one side who ap-
proach a biological problem by grinding up a cell or tissue and taking the result-
ing extract to the cold room, and on the other are those who begin by exposing a
living cell to a mutagen. Curiously, each side now chases its own tail. Having
identified a mutant phenotype of interest, the geneticist hopes to isolate the
relevant gene, obtain its nucleotide sequence, and express its protein product in
a suitable host for biochemical investigation. The biochemist goes the other way.
Having purified a factor or enzyme, a small amount of protein sequence is ob-
tained and used to design an oligonucleotide to isolate the respective gene. The
biochemist becomes a geneticist and vice versa. This will not stop the argument
that is as much about temperament as it is about scientific method. This section
describes the work of those researches with a primarily genetic outlook.
EUKARYOTIC CELL CYCLE CONTROL
D. Beach S. Allan S. Davey
J. Bischoff U. Deuschle
M. Caligiuri H. Feilotter
D. Casso K. Galaktionov
T. Connolly I. Garkavtsev
G. Cottarel C. Gawel
C. Jessus
D. Lombardi
K. Lundgren
T. Matsumoto
T. Mizukami
1988 and 1989 were extraordinary years for the cell
cycle field and for our laboratory in particular. A
group consisting primarily of Robert Booher,
Leonardo Brizeula, Giulio Draetta, and David Beach
(with outside collaborators, especially John Newport
and Joan Ruderman) uncovered the connection be-
tween the cdc2 protein kinase and a class of proteins
called cyclins. Each cyclin was found to act as a sub-
unit of the protein kinase resulting in a family of en-
zymes, each of which has a particular role in regulat-
ing progression through the cell division cycle. This
discovery has triggered an explosive growth in the
field, as more cyclins are discovered and efforts are
made to piece each new cell cycle kinase into the
overall picture.
In 1990, this work continued apace in our
laboratory (two new classes of cyclin are described
below). We were most fortunate in having our efforts
recognized by the Howard Hughes Medical Institute
of which David Beach is now an Investigator. This
has allowed our work to branch out in new directions,
L. Molz
B. Nefsky
A. Tesoro
N. Walworth
Y. Xiong
some of which are described below. During the
course of the year, Suzie Dembski left to take a posi-
tion with Ed Harlow in Boston, and Joanne Lamonica
entered medical school. We were joined by Catherine
Jessus (visiting scientist), Adrienne Tesoro (lab man-
ager), Craig Gawel (technician), Susan Allan (tech-
nician), David Casso (graduate student), Dianne
Lombardi (computer programmer), and several post-
doctoral fellows, Maureen Caligiuri, Harriet Feilotter,
Igor Garavtsev, Toru Mizukami, Brad Nefsky, Nancy
Walworth, and Yue Xiong.
Human D-type Cyclin
Y. Xiong, T. Connolly, D. Beach
[in collaboration with B. Futcher, Cold
Spring Harbor Laboratory]
Two classes of cyclins, A type and B type, have been
previously identified from various eukaryotic species.
The B-type cyclin has been shown to act in mitosis
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by serving as an integral subunit of the cdc2 protein
kinase. The A-type cyclin also independently associa-
tes with the cdc2 kinase, forming an enzyme that ap-
pears to act earlier in the division cycle than mitosis.
A third class of cyclin, named CLN type, was identi-
fied in budding yeast and was shown to be essential
for progression through the Gi/S phase transition of
the cell cycle. In Saccharomyces cerevisiae, there are
three Cln proteins. Disruption of any one CLN gene
function alone has little effect on growth; however, if
all three genes are disrupted, the cells arrest in Gl.
To pursue our continuing study of the mammalian
cell cycle, a general strategy was developed to isolate
previously unidentified human cyclin genes. A yeast
strain was constructed that contained insertional
mutations in the CLN1 and CLN2 genes to render
them inactive. The remaining CLN3 gene was further
altered to allow for conditional expression from a
glucose repressible promoter GALL. A cDNA library
prepared from a human glioblastoma cell line was
then introduced into the budding yeast strain. A pre-
viously unidentified human cyclin gene was rescued
that we have termed cyclin Dl. Compared to the
other three classes, CYCD1 encodes the shortest
cyclin (34 kD). A comprehensive amino acid se-
quence comparison of 17 cyclin genes was carried
an evolutionary tree of the cyclin
family. This analysis established that human CYCD1
represents a new class of cyclin. The expression of
both the cyclin Dl gene transcript and its 34-kD pro-
duct appears to be present at very low levels in
several cell lines examined, but they are both
abundant in a glioblastoma cell line. The role of
cyclin D in the cell cycle of human cells is presently
being investigated.
A New Fission Yeast Cyclin
L. Molz, D. Beach
In fission yeast, the cdc2 protein kinase is required in
GI, prior to DNA synthesis, and in G2, prior to
mitosis. Recessive mutations that abolish cdc2 gene
function result in cell-cycle-arrest cells at either the
Gt or the G2 control points. There exist dominant al-
leles of cdc2 (the so-called wee alleles) that shorten
G2 and result in a small cell size. The combination of
a particular wee allele of cdc2 (cdc2-3w) and a loss of
function allele of the weel gene (a mitotic inhibitor)
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results in cells that divide at a very small cell size and
undergo aberrant cellular and nuclear divisions, lead-
ing to cell death. This phenotype has been termed
mitotic catastrophe.
To identify new genes interacting with the cdc2
protein kinase, we have isolated extragenic mutations
that suppress mitotic catastrophe (mcs mutations:
mitotic catastrophe suppressors). Subsequent genetic
analysis revealed that two of the mcs mutations
(mcs2-75 and mcs6 -13) interacted in an allele-
specific manner with the various wee alleles of cdc2.
This suggests that the mcs2 or mcs6 genes may be
substrates or subunits of the cdc2 protein kinase. Two
genes were cloned by complementation of the mcs2 -
75 defect. One was demonstrated by linkage analysis
to be the authentic mcs2 gene, whereas the second
was a high-copy suppressor of the mcs2-75 defect.
The mcs2 gene was shown to encode a 37.5-kD
protein that displays limited homology with cyclins
(known subunits of the cdc2 protein kinase). The
high-copy suppressor of the mcs2-75 mutation was
shown to encode a putative 34.5-kD serine/threonine
protein kinase. Null alleles of these genes created by
gene disruption display a mid-mitotic arrest. In par-
ticular, the mcs2 gene disruption was demonstrated to
arrest with compact nuclei and condensed chro-
mosomes. We are currently raising antibodies against
these proteins for a molecular analysis of their gene
products.
cdc2 Tyrosine Kinase
K. Lundgren, S. Dembski, N. Walworth, D. Beach
cdc2 activity is required for the entry of cells into
mitosis. Dephosphorylation of the Tyr-15 residue of
the protein kinase is at least one step that is required
for activation of the enzyme. Genetic analysis has
shown that the weel protein kinase acts antagonisti-
cally to a mitotic inducer, cdc25, in the regulation of
cdc2 activity. cdc25 is required for entry into mitosis
and has been shown to be involved in the tyrosine
dephosphorylation of cdc2. weel acts as a mitotic in-
hibitor, yet its substrate has previously been obscure.
In a genetic screen designed to isolate inhibitors
of mitosis, we identified mikl, a new protein kinase
that is closely related to weel itself. The loss of mikl
function does not confer a phenotype, but a mutant in
which mikl and weel functions are both lost is lethal.
Microscopic examination of the cells reveals a great
range of mitotic abnormalities (Fig. 1). The cells are
literally dividing themselves to death.
We have found that not only do mikl weel cells
enter mitosis prematurely, but, in doing so, they can
bypass the normal requirements for "START," S-
phase, and the cdc25 function. In addition, we have
found that cdc2 is tyrosine-dephosphorylated in these
cells (Fig. 2)
We have shown that mikl acts redundantly with
weel in the negative regulation of cdc2. The simplest
hypothesis is that weel and mikl comprise the in-
hibitory cdc2 tyrosine kinase. This model is now
being tested.
100
80
60
40
20
0
mikl.ura wee 1-50 25°C
FIGURE 1 Lethal mitosis in the mikl weel double mutant.
(Top) Viability plot of wild-type (circles) and mik1:ure
weel -50 (triangles) strains after intervals of incubation at
36°C. Viability was assayed by the ability to form colonies at
25°C. (Middle) DAPI-stained wee-1-50 mikl::ura4+ strain at
25°C. (Bottom) DAPI-stained cells 3 hr after transfer to 36°C.
Bar, 5 pm.
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FIGURE 2 Phosphotyrosine content of cdc2. Lysates from
wild-type (top), mik1::ura+weel-50 (middle), and cdc25-22
mikl::ura+weel-50 (bottom) cells, transferred from 25°C to
36°C for the indicated times, were immunoprecipitated with
anti-cdc2 (G8) antibody, separated on SDS-PAGE gels,
transferred to nitrocellulose, and probed with either anti-
cdc2 or antiphosphotyrosine antibodies.
Involvement of a Novel GTPase
in Cell Cycle Dependency
T. Matsumoto, D. Beach
In fission yeast, abnormalities of nuclear morphology
are readily detectable under a fluorescence micro-
scope. To find new mutants defective in cell cycle
regulators, we constructed a temperature-sensitive
mutant library that consists of more than 700 individ-
ual mutants and then screened each mutant micro-
scopically. We have concentrated on one particular
mutant piml . piml mutants display hyper-condensed
chromosomes under restrictive conditions. Even
when cells prearrested at the Gi/S boundary by hy-
droxyurea, they show hyper-condensed chromo-
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somes. The phenotype suggests that piml mutants
can bypass DNA synthesis and enter mitosis directly.
We cloned the piml+ gene and a multicopy sup-
pressor gene (spil+) by complementation. Sequence
analysis of piml+ revealed that the gene product has
significant homology with human Reel. Mammalian
cells deficient in Reel have a phenotype very similar
to that of the fission yeast piml mutants. Interesting-
ly, the spil+ gene product has 80% amino acid
identity with the human TC4 gene. TC4 and spil
comprise the only presently known members of a
new class of GTPase signaling protein. These results
suggest that a GTPase is involved in maintaining a
coordinated cell cycle.
Control of Meiosis in Fission Yeast
S. Davey, D. Beach
Fission yeast respond to starvation by leaving the
mitotic cell cycle and undergoing meiosis and
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sporulation. We are currently investigating the
molecular controls that constitute the switch from the
mitotic cell cycle to the meiotic cell cycle.
A number of genes involved in the control path-
way are known, and of primary importance to our
current work are the meiotic inhibitor rani and the
meiotic activators mei2 and mei3. The rani gene pro-
duct (p52.111) is a protein kinase that is required for
maintenance of the mitotic cell cycle; loss of rani
function causes cells to enter meiosis immediately.
Starvation initiates a molecular cascade that leads to
the production of the mei3 gene product, which binds
and inactivates p52ran1 . The role of mei2 is not un-
derstood, but it is required for the switch from the
mitotic to the meiotic cell cycle.
Research is proceeding on two fronts. We are cur-
rently undertaking genetic screens to identify novel
suppressors of rani and mei2. In addition, we are
screening mammalian expression libraries for genes
that can functionally replace the meiotic control
genes in Schizosaccharomyces pombe. This work will
further our understanding of meiotic control in fission
+ ne - Thiamine
10
1
8
8
$ " 7
6
24 36 48 60 72
Time(hours)
FIGURE 3 Expression of human p53 in S. pombe inhibits growth. (A) Western blot of wild-type (wt)
p53, p53 with an arginine to histidine mutation at amino acid residue 273 (His-273), and p53 with an
arginine to histidine mutation at amino acid residue 175 (His-175). (B) Immunofluorescence of S.
pombe. (1) Control strain; (2) strain expressing wild-type p53; (3) strain expressing His-273; (4)
strain expressing His-175 (arrow denotes extracellular staining). (C) Strains expressing wild-type
p53, His-273, and His-175 struck on plates containing thiamine (no p53 expression) and plates with
no thiamine (p53 expression). Growth curve of wt p53 (circles), His-273 (triangles), and His-175
(squares) in the presence (open symbols) or absence of (closed symbols) thiamine .
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yeast and determine whether a similar cascade opera-
tes in mammalian cells.
A Yeast System to Study
Human p53
J. Bischoff, D. Casso, D. Beach
p53 is a tumor suppressor gene that is involved in
many types of human cancer. It is thought that p53
may normally act as a negative regulator of cell divi-
sion. To investigate the possible role of p53 in the
cell cycle, we have introduced human p53 into S.
pombe. The overexpression of human wild-type p53
inhibits growth in S. pombe as it does in mammalian
cells. Two mutant alleles of p53 also inhibit growth,
but less severely (Fig. 3). Using a strain in which
wild-type human p53 is integrated into the genome of
S. pombe, we have identified a mutant allele of p53.
It is a point mutation at amino acid residue 175, a
mutation frequently found in tumor biopsies. This is
direct evidence for a dominant mutant allele of a
tumor suppressor gene. This implies that certain point
mutations in a single allele of p53 could inactivate
the wild-type allele, which could be important in the
process of cellular transformation.
We are now using two approaches to identify
genes that might interact with p53. One approach is
to transform the p53-expressing S. pombe strain with
cDNA libraries and look for cDNAs that relieve the
negative effect of p53 on growth. Such cDNAs have
been found and are being investigated. The other ap-
proach is to mutagenize chemically the p53-express-
ing strain to isolate extragenic suppressors of p53.
We hope that by identifying genes that interact with
p53, we will be able to understand the mechanism of
action of this protein.
Fission Yeast Genome Mapping
I. Garkavtsev, T. Mizukami, D. Lombardi, D. Beach
[in collaboration with T. Marr, Cold Spring
Harbor Laboratory].
A stage has been reached in the genetic analysis of
model organisms such as the fission yeast that it is
now appropriate to undertake a comprehensive ap-
proach toward the genome. Ideally, one would
determine the nucleotide sequence of the entire
genome, and efforts could then refocus on trying to
understand what genes are doing, rather than analyz-
ing their structure.
In an effort that aims toward this eventual goal,
we have begun to make a systematic high-resolution
map of the fission yeast genome. This involves creat-
ing an ordered set of cosmid clones that can then be
used to map the genomic location of any gene of in-
terest very rapidly. The genome mapping work also
involves development of computational tools for
record keeping and display of the many clones used
in mapping.
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PRE -MRNA PROCESSING AND sNRNA SYNTHESIS IN
SCHIZOSACCHAROMYCES POMBE
D. Frendewey D. Kim
M. Gillespie
M. Ghee
Our research interests are split between two related
areas: the processing of messenger RNA precursors
(pre-mRNAs) and the synthesis of small nuclear
RNAs (snRNAs). These two lines of research over-
lap, in general, by the fact that snRNAs participate in
the catalysis of a wide variety of RNA-processing
reactions. Most notably, the Ul, U2, U4, U5, and U6
RNAs are required for pre-mRNA splicing and are
components of the spliceosome, the large ribo-
nucleoprotein structure that catalyzes the splicing of
pre-mRNAs. The system in which we investigate
these phenomena is the fission yeast Schizosaccharo-
myces pombe. Pre-mRNA splicing and snRNA
synthesis are even more closely associated in S.
pombe than in most other organisms, because the fis-
sion yeast U6 RNA is produced by the splicing of a
precursor (pre-U6 RNA) that contains an intron
whose structure is typical of those found in pre-
mRNAs. This peculiarity of the fission yeast system
presents some novel and interesting problems in
snRNA synthesis and pre-mRNA splicing and, in ad-
dition, affords certain analytical advantages that will
be explained below.
Four years ago, we began a three-stage approach
to the study of pre-mRNA splicing in S. pombe that
also led us into an investigation of snRNA synthesis.
The first step was to identify genes required for pre-
mRNA splicing or snRNA synthesis by isolating
mutants that are defective in these processes. The iso-
lation and characterization of our original pre-mRNA
splicing and snRNA synthesis mutants were de-
scribed in previous Annual Reports. These projects
are an ongoing part of our research. Some new
mutants isolated in the last year will be described in
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this report. Our second objective was to isolate and
characterize the genes effected in the mutants by
cloning and sequencing them. Progress on the clon-
ing of three genes is presented below. Finally, our
long-term goal is to dissect the biochemical mechan-
isms of pre-mRNA splicing and snRNA synthesis
and to determine the functions of individual gene
products in these processes. In this year's report, we
summarize our efforts to biochemically characterize
pre-mRNA splicing components and analyze directly
U6 RNA transcription in S. pombe.
Pre-mRNA Splicing Mutants
D. Kim, D. Frendewey
The isolation of our first three pre-mRNA splicing
mutants, prpl, prp2, and prp3 (Potashkin et al.,
EMBO J. 8: 551 [1989]), was accomplished by
screening a bank of temperature-sensitive (ts-) S.
pombe strains for mutants that accumulate unspliced
pre-mRNAs. This procedure involved the isolation of
whole-cell RNA from each ts- mutant, fractionation
of the RNA by gel electrophoresis, blotting to nylon
membranes, and probing with oligodeoxynucleotides
(oligos) directed against a pre-mRNA intron. Besides
being slow and laborious, there are several draw-
backs to this method of screening. mRNAs, and espe-
cially pre-mRNAs, are very susceptible to nude-
olytic degradation during isolation, and most mRNAs
are not very abundant, making detection of pre-
mRNAs by Northern blotting of whole-cell RNA dif-
ficult. Since pre-mRNAs are large, they must be frac-
tionated on formaldehyde agarose gels, which run
slowly and have poor resolution, and subsequently
blotted by diffusion, usually requiring 12-16 hours.
To overcome these difficulties, we have taken ad-
vantage of our observation (Potashkin and Fren-
dewey, Nucleic Acids Res. 17: 7821 [19891) that
splicing of pre-U6 RNA is impaired in the prp
mutants. We produced approximately 200 new ts-
strains and screened them by the Northern assay for
accumulation of pre-U6 RNA. Since pre-U6 RNA is
small (150 nucleotides), the whole-cell RNA was
rapidly electrophoresed on short polyacrylamide gels
and transferred to nylon membranes by electroblot-
ting, which can be completed in 4 hours. The
abundance and stability of the U6 RNA made detec-
tion of the precursor very much simpler and im-
proved the sensitivity.
Six new splicing mutants were identified in a
screen of 180 ts- strains (Fig. 1). Three different
molecular phenotypes were observed among the new
mutants: (1) four mutants (ts363, ts377, ts426, and
ts481) accumulated pre-U6 RNA at 37°C (restrictive)
but not 23°C (permissive); (2) one mutant (ts370) ex-
hibited an equal accumulation of pre-U6 RNA at both
37°C and 23°C; and (3) one mutant (ts369) accumu-
lated pre-U6 RNA and two other intron-containing
U6 RNAs at 37°C but not at 23°C. The latter two
phenotypes were not observed in our previous search-
es for pre-mRNA splicing mutants. As expected from
our previous results with prpl, prp2, and prp3, all of
the new mutants also accumulate I3-tubulin pre-
mRNA at 37°C; ts370 shows a pre-mRNA splicing
defect at 23°C as well. The pre-mRNA signal on
Northern blots of ts369 RNA appeared to be a smear
of poorly resolved bands, some running slower than
pre-mRNA by comparison with the other mutants.
This result could be evidence for the accumulation of
other intron-containing RNAs as was seen for the
pre-U6 RNA analysis. Thus, the pre-U6 RNA and
pre-mRNA splicing defects are equivalent in the six
new mutants.
The ts369 mutant is particularly interesting be-
cause it is the first S. pombe mutant that accumulates
possible intermediates of the splicing reaction. In ad-
dition to pre-U6 RNA, two other RNAs of about 120
and 50 nucleotides are detected on Northern blots of
ts369 RNA when probed with two different U6 intron
probes (Fig. 2). The 120-nucleotide RNA hybridizes
to probes against the intron and exon 2, whereas the
50-nucleotide RNA is recognized by intron probes
but not those to exon 2. Both RNAs exhibit slightly
retarded mobilities relative to the pre-U6 and mature
U6 RNAs on higher percentage acrylamide gels.
These results suggest that the 120-nucleotide RNA is
the intron-exon 2 lariat intermediate product and the
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FIGURE 1 Northern blot analysis of pre-U6 RNA splicing in the wild-type (wt) and
six ts- mutants (indicated by their numbers above the lanes). RNA was prepared
from wild-type and mutant cells grown to mid-log stage at 23°C and after a shift to
37°C for 5 hr. The RNA was fractionated by polyacrylamide gel electrophoresis
and electroblotted to a nylon membrane. The blot was probed with an oligo-
nucleotide that hybridizes to the intron of the pre-U6 RNA. The position of the pre-
U6 RNA is indicated on the right (precursor). The asterisk and plus symbols identi-
fy intron-containing RNAs that accumulate in ts369. Lane M contains pBR322
Mspl fragments (sizes in nucleotides given at left).
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50-nucleotide RNA is the intron lariat final product
(theoretical size = 50 nucleotides). Further analysis is
required to confirm these assignments.
In vitro studies in the human and Saccharomyces
cerevisiae systems have shown that after the comple-
tion of a normal splicing reaction, the spliceosome
disassembles, releasing the mature RNA product. The
intron is released as a short-lived complex with some
of the spliceosomal components that include the U2,
U5, and U6 RNAs. When this association breaks up,
the free intron is linearized by a debranching enzyme
and degraded. The mutation in ts369 might affect the
disassociation of the spliceosome and release of the
spliced products required for the recycling of the
spliceosome. In many enzymatic reactions, a block in
the release of products reduces the overall rate of
catalysis. Such a mechanism could explain the ac-
cumulation of the intermediate and the precursor sub-
strate in ts369. We are continuing our analysis of the
splicing defect in ts369 by investigating the splicing
of pre-mRNAs in this mutant in greater detail.
Genetic characterization of the new mutants is un-
der way and is nearly complete for ts426 and ts481.
Linkage analysis indicates that ts426 is an allele of
prp3, and we have tentatively assigned it the name
prp3-2. (The original prp3 allele will be prp3 -1.) Ex-
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periments supporting this result are presented below.
ts481 is not linked to prpl, prp2, or prp3 or to a new
mutant, prp4, isolated in Norbert Kaufer's laboratory
at Drexel University. We have therefore given ts481
the formal name prp5. When the genetic analysis is
complete, we will attempt to clone the wild-type
genes that are affected in one or more of the mutants
by complementation with an S. pombe genomic DNA
library.
Cloning of the prp3+ Gene
D. Frendewey
Our original splicing mutants, prpl, prp2, and prp3,
were isolated by Judy Potashkin, a former postdoc-
toral fellow in the laboratory. Judy started her own
laboratory at the Chicago Medical School in January
1990, where she plans to characterize the prpl+ and
prp2+ genes. This year, I attempted to clone the
prp3+ gene. The prp3 mutant accumulates pre-
mRNA at 37°C, but unlike prpl and prp2, it produces
some mRNA at the restrictive temperature. Con-
sistent with this molecular phenotype, prp3 continues
to grow slowly at 37°C. However, the difference be-
tween the growth rate of prp3 and that of the wild
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FIGURE 2 Northern blot analysis of U6 RNA transcripts that accumulate at 37°C in
ts369. RNA from 37°C cultures of wild type, ts363, and ts369 was prepared, frac-
tionated, and blotted as described in Fig. 1. The same blot was sequentially
hybridized with two different intron probes (1-1 and 1-2) and one exon 2 probe (E2-1),
as indicated above the lane groupings. The position of spliced U6 RNA (mature) is
shown to the right of the E2-1 panel. All other symbols and designations are the
same as those in Fig. 1.
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type at 37°C is sufficient to enable cloning of the
prp3+ gene by complementation of the ts- growth
phenotype.
The prp3 mutant was transformed with an S.
pombe genomic DNA library (a gift from Paul
Young, Queens University, Canada), and rapidly
growing transformants (ts+) were selected at 37°C.
Of the 14 ts+ transformants obtained, six grew con-
sistently well after a second challenge at 37°C and
were dependent on the transforming plasmid for
growth at the restrictive temperature. Plasmid DNA
was isolated from the six ts+ yeast clones and used to
transform Escherichia coli. Bacterial transformants
were obtained for four of the six ts+ clones. All of the
plasmids recovered from the bacterial transformants
had an identical 8.7-kilobase-pair (kb) HindIII insert.
One of these plasmids was characterized further.
The plasmid clone was reintroduced into prp3 to
confirm that it cures the ts- growth defect. Three
fragments of the 8.7-kb clone were subcloned into
yeast vectors and used to transform prp3. None of
these subclones cured the ts- defect, indicating that
the fragments tested did not contain the complete
gene. I am currently constructing new overlapping
subclones, which will be tested in prp3. As men-
tioned in the previous section, one of our new
mutants, ts426, appears to be an allele of prp3 (prp3 -
2). Consistent with this result, the prp3+ clone is able
to cure the ts- growth defect in prp3-2. The prp3-2
mutation causes a more severe impairment to growth
and splicing than the original prp3-1 mutation. In the
future, in addition to characterizing the prp3+ gene,
we would like to sequence the prp3- genes of prp3-1
and prp3-2 to determine the mutations in these al-
leles. This information may give us an insight into
the function of the prp+ gene product.
A Mutant Defective in mRNA
3' -end Formation
D. Frendewey [in collaboration with T. Humphrey
and N. Proudfoot, Oxford University]
All mRNAs, with the exception of certain histone
mRNAs of higher eukaryotes, have a stretch of
adenosines at their 3' ends that is essential for the
stability of the mRNAs and may be a signal for trans-
port out of the nucleus. The polyadenosine (poly[A])
tract is not encoded in the DNA but is added post-
transcriptionally. In mammals, the mechanism of
mRNA 3 ' -end formation has been described with a
fair degree of biochemical detail. Although the con-
nection between 3' processing and termination of
transcription is poorly understood, it is clear that the
nascent pre-mRNA (perhaps still tethered to the tran-
scription complex) is cleaved a short distance
downstream from a nearly invariant AAUAAA signal
and immediately polyadenylated. The AAUAAA is
essential for both cleavage and polyadenylation. A
second conserved feature in mammalian pre-mRNAs
is a stretch of RNA rich in G and U immediately
downstream from the poly(A) site. The GU stretch is
not required for 3' -end formation in vitro but im-
proves efficiency in vivo. A factor that binds to the
AAUAAA and functions in both cleavage and
polyadenylation has been identified. Additional
proteins that participate in the cleavage reaction and
the poly(A) polymerase itself have been purified
from mammalian nuclear extracts. Although the U11
snRNP has been implicated in mRNA 3 ' -end forma-
tion, solid evidence in support of snRNP involvement
has not yet been obtained.
Very little is known about mRNA 3' -end forma-
tion in yeast. Poly(A) tails are found on the 3 ' ends
of Saccharomyces cerevisiae and S. pombe mRNAs,
but the mechanism by which this polyadenylation is
achieved is poorly understood. Sequences required
for mRNA 3 ' -end formation have been identified for
some S. cerevisiae pre-mRNAs; however, no clear
signal is apparent. If conserved primary sequence ele-
ments are involved in the polyadenylation of yeast
pre-mRNAs, then their features are much more
degenerate than those of mammals. The AAUAAA
sequence is often found near the 3 ' ends of yeast
mRNAs, but there is no evidence that it is required
for polyadenylation. Essentially nothing is known
about the cellular factors that participate in mRNA
3 ' maturation in yeast.
Our interest in mRNA 3 ' -end formation orig-
inates with an observation we made while screening
for pre-mRNA splicing mutants. One of the strains in
our ts- collection (ts39) produced an apparently
normal 13-tubulin mRNA at the restrictive tempera-
ture, but it also accumulated a [3-tubulin 'transcript
that was larger than the unspliced pre-mRNA
(Potashkin et al., EMBO J. 8: 551 [1989]). The ts39
mutant showed no pre-mRNA splicing defect, so the
aberrant transcript was probably extended at either its
5' end or its 3' end. In collaboration with Tim
Humphrey, a student in Nick Proudfoot's laboratory
at Oxford, we have recently begun to reinvestigate
ts39. To confirm the original observation, a Northern
blot analysis was performed for the ura4+ mRNA.
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This RNA is transcribed from an intronless gene. As
we observed for 13-tubulin mRNA, an aberrantly large
ura4+ transcript was seen at 37°C; only normal size
ura4+ mRNA was detected at 23°C. A closer analysis
of the 3 ' end of the ura4+ mRNA in ts39 indicated
that RNA with the correct 3 ' end was formed at
37°C, but there was a significant accumulation of
RNA that was extended beyond the normal poly(A)
site. We are currently attempting to map the precise
3' end of the aberrant ura4+ transcript produced in
ts39. Primer extension experiments reveal no dif-
ference in the 5 ' end of the ura4+ mRNA between
23°C and 37°C. These results strongly suggest that
ts39 suffers from a partial impairment in mRNA 3 ' -
end formation at 37°C. This is the first mutant of this
type in S. pombe. Several mutants that exhibit defects
in mRNA 3 ' -end formation have been described for
S. cerevisiae, but their characterization is not yet
complete.
We have transformed ts39 with an S. pombe
genomic library and selected transformants that grow
at 37°C. We isolated six ts+ transformants that were
dependent on the transforming plasmid for growth at
the restrictive temperature. So far, we have been able
to recover plasmid in E. coli from one of the is+
transformants. This plasmid has a 5.8-kb insert and is
able to cure the ts- defect upon reintroduction into
ts39. Since none of the factors identified as part of
the pre-mRNA cleavage and polyadenylation appara-
tus have been completely characterized, the cloning
and sequencing of the gene effected in ts39 would be
an important advance in our understanding of the
types of gene products that are required for mRNA
3' -end formation.
S. Pombe snRNP Proteins
M. Ghee, D. Frendewey [in collaboration with
D. Spector and A. Krainer, Cold Spring
Harbor Laboratory]
One of our long-term goals is the biochemical char-
acterization of the cellular components involved in
pre-mRNA splicing in fission yeast. In the absence of
a homologous in vitro pre-mRNA splicing system for
S. pombe, we have resorted to the genetic strategy de-
scribed in the previous sections to identify and char-
acterize gene products essential for pre-mRNA splic-
ing. However, one set of known splicing factors is
available for direct biochemical analysis: the small
nuclear ribonucleoprotein particles (snRNPs). The
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Ul, U2, U4/6, and U5 snRNPs are constituents of the
spliceosome and are required for pre-mRNA splicing.
Each snRNP consists of an snRNA (two in the case
of the U4/6 snRNP) complexed with a set of proteins.
Six core proteins are common to all of the splice-
osomal snRNPs, and, in addition, one or more
proteins specific to each of the individual snRNPs
have been identified. Due to their great abundance in
vertebrate nuclei and the availability of powerful im-
munochemical reagents, a large amount of informa-
tion has been gathered about vertebrate snRNP
proteins. The snRNPs have been purified, and their
protein components have been cataloged. The genes
for several of the snRNP proteins have been cloned
and sequenced, and a crystal structure for one has
been determined.
In contrast, very little is known about snRNP
proteins and snRNP structure in yeast. The major
snRNAs have been identified and sequenced, but
only a few snRNP-specific proteins have been char-
acterized. Yeast homologs of the core snRNP
proteins have not yet been found. The main impedi-
ment has been that in S. cerevisiae (the yeast in
which pre-mRNA splicing has been most thoroughly
studied), the snRNPs are more than 1000-fold less
abundant than in higher eukaryotic cells. An addi-
tional technical difficulty has been that most of the
antibodies that were used so effectively for the study
of vertebrate snRNPs do not react with the S.
cerevisiae counterparts. Both of these drawbacks are
partially overcome in the fission yeast system. First,
the cellular snRNP concentration in S. pombe is
10-100 times higher than that in S. cerevisiae. Sec-
ond, some of the common human snRNP antisera ef-
ficiently select the homologous snRNPs in S. pombe.
We have therefore begun a biochemical investigation
of the snRNP proteins in fission yeast.
Patients suffering from connective tissue diseases
often produce antibodies to snRNPs. One of the most
common of these antisera, anti-Sm, reacts with
epitopes on the core snRNP proteins; thus, anti-Sm
antibodies recognize all of the spliceosomal snRNPs.
We obtained a potent anti-Sm serum from E.
DeRobertis (University of California, Los Angeles)
and used it to immunoprecipitate snRNPs from S.
pombe whole-cell extracts. The protein was removed
from the immunoprecipitates, and the RNA was frac-
tionated on an acrylamide gel and blotted to a nylon
membrane. The Northern blot was then probed with
oligonucleotides complementary to the major
snRNAs. This experiment showed that the human
anti-Sm antibodies recognized the Ul, U2, U4/6, and
U5 snRNPs from S. pombe. No signals were ob-
served with probes for U3 RNA, a nucleolar snRNA
whose snRNP does not have the Sm-reactive core
proteins, or K RNA, the RNA subunit of the
nucleoplasmic tRNA processing enzyme RNase P.
Judy Potashkin and David Spector (Molecular
Genetics of Eukaryotic Cells Section) had previously
obtained evidence by immunoelectron microscopy
that another patient antisera known as anti-A protein
recognizes snRNPs in S. pombe nuclei. Anti-A
protein sera react with the Ul snRNP-specific A
protein and usually also recognize the closely related
B' protein of the U2 snRNP. In collaboration with
David Spector, we performed an immunoprecipita-
tion experiment with a number of anti-A protein sera.
Most of these sera efficiently selected the S. pombe
UI snRNP and one also reacted weakly with the U2
snRNP. The U3, U4, U5, U6, and K RNAs were not
detected on the blot of the anti-A protein im-
munoprecipitate. The results of the immunoprecipita-
tion with the anti-Sm and anti-A protein sera indicate
that S. pombe has homologs of the core proteins and
the UI A protein or the U2 B' protein that are
antigenically similar to their vertebrate counterparts.
We may now be able to use the human antisera to
characterize further the structure and function of the
S. pombe snRNPs and to eventually clone the genes
that encode these proteins in fission yeast.
All of the U snRNAs, with the exception of U6,
have an unusual and characteristic trimethyl-
guanosine (m3G) 5 ' "cap." Adrian Krainer (Tumor
Viruses Section) has produced a monoclonal anti-
body against this cap structure, which we previously
showed could select the Ul, U2, U3, U4/6, and U5
snRNPs from S. pombe. To look more directly at the
fission yeast snRNP proteins, we immunoselected
snRNPs from an S. pombe whole-cell extract with the
anti-m3G antibody. For comparison, the selection
was also performed on an equivalent amount of S.
cerevisiae whole-cell extract and a small amount of
HeLa nuclear extract. The proteins that bound to the
antibody were analyzed by SDS-polyacrylamide gel
electrophoresis, followed by silver staining. We ob-
tained a simple pattern of 10-15 protein bands for S.
pombe that was remarkably like the human snRNP
protein set. For example, bands similar in size to the
human D, E, F, and G core proteins were seen in S.
pombe. We have preliminary evidence from Western
blotting experiments that a single protein from an S.
pombe whole-cell extract reacts with anti-A protein
antibodies. This protein is slightly larger than the hu-
man A protein control on the same blot and may cor-
respond to a prominent band at the same position in
the S. pombe sample from the anti-m3G immunosel-
ection experiment. We have not absolutely identified
any of the S. pombe proteins selected by the anti-m3G
antibody, but the resemblance to the human pattern
and Western blotting results are encouraging. To il-
lustrate the advantage of fission yeast for this type of
investigation, the immunoselection of the S. cer-
evisiae snRNPs produced a protein pattern that was
too faint to be interpreted.
As mentioned above, the U6 RNA does not have
an m3G cap. Its 5' end has a simple methyles-
terification of the gamma phosphate on the 5' - termi-
nal guanosine triphosphate residue (MeGTP). Ram
Reddy's group at the Baylor College of Medicine has
generated an antibody against the MeGTP cap and
sent it to us to determine if S. pombe U6 RNA has the
same 5' terminus. The anti-MeGTP antibody im-
munoprecipitated only a small percentage of the total
U6 RNA in an S. pombe whole-cell extract. The
antibody is equally ineffective against mammalian
nuclear extracts. The reason for this poor per-
formance could be the antibody's low titer or the
MeGTP cap might be masked in the U4/6 snRNP.
Our results indicate that the latter explanation may
account, at least in part, for the low immunoprecipita-
tion efficiency. When anti-MeGTP immunoprecipi-
tates from S. pombe extracts were assayed by North-
ern blotting, we observed a weak U6 signal, but, sur-
prisingly, U6's snRNP partner, U4 RNA, was not
detected. An even more unexpected result was that
U2 RNA was immunoprecipitated by anti-MeGTP in
amounts approximately equal to that seen for U6
RNA. Alan Weiner's group at Yale has recently
demonstrated a base-paired interaction between the
5 ' end of U2 and the 3 ' end of U6 in HeLa nuclear
extracts. If our immunoprecipitations detected such
an interaction in S. pombe extracts, then the MeGTP
cap must be more accessible to the antibody in the
U2/U6 complex than in the U4/6 snRNP. At the com-
pletion of the pre-mRNA splicing reaction, the intron
lariat is released in an RNP with the U2, U6, and U5
RNAs. The U2/U6 interaction may be a remnant of
this complex and represent an intermediate in splice-
osome recycling.
Cloning of the snml- Gene
M. Gillespie, D. Frendewey
In previous Annual Reports, we described the isola-
tion and characterization of an interesting ts- mutant,
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which we named snml because it expresses a defect
in snRNA maintenance. A single recessive mutation
in snml causes a two- to tenfold reduction in the
steady-state levels of the Ul, U2, U4, U5, and U6
snRNAs and the RNase P RNA subunit. In addition,
3 ' -extended U2 and U4 RNAs and unspliced U6
RNA accumulate at the restrictive temperature. This
mutant phenotype implies that the snm1+ gene pro-
duct plays a central role in the correct and efficient
synthesis of a family of snRNAs. In last year's An-
nual Report, we briefly described our initial attempts
to clone the snm1+ gene. This project has continued
to be a major part of our effort, and our progress in
the last year is outlined below.
The snml mutant exhibits a "leaky" ts- growth
phenotype; it continues to grow at about one half the
wild-type rate after a shift from 23°C to 37°C. For
this reason, when we transformed snml with an S.
pombe genomic library and selected for growth at
37°C, many transformants appeared on the plates;
200 transformants were transferred to a fresh plate
and immediately challenged again at 37°C. Of these
200, 2 grew after this second selection. To confirm
these results, snml was transformed with the
genomic library again in a second independent exper-
iment. This time, 4 ts+ clones out of 200 original
transformants were obtained after the second selec-
tion. The six ts+ transformants all required the trans-
forming plasmid for growth at 37°C. Plasmids were
isolated from the yeast clones and recovered in E.
coli.
Five classes of bacterial clones were obtained,
having yeast DNA inserts ranging in size from 3.6 kb
to 10.3 kb. One class appeared to represent a rear-
rangement of the plasmid in that the intact vector was
not seen. Four of the five classes of clones (including
the rearranged plasmids) contained 3.2- and 0.4-kb
HindIll fragments, suggesting that the snm1+ gene
was on one or both of these pieces of DNA. Two of
the classes of clones that contained the common frag-
ments were used to transform snml and were shown
to cure the is- defect. Subsequently, a 4.3-kb Pstl
fragment from one of the larger clones was shown to
complement the snml- mutation. The Pstl subclone
contains a 3.2-kb HindIll fragment. Further analysis
has demonstrated that a 2.2-kb HindIII-Ndel subclone
is sufficient to transform snml to rapid growth at
37°C. The sequencing of this clone is nearly com-
plete, but we have not yet assigned an open reading
frame. Genetic and molecular examination of this
clone is continuing in order to confirm that it does
contain the snm1+ gene.
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U6 RNA Transcription in
S. pombe
M. Gillespie, D. Frendewey
In last year's Annual Report, we presented the results
of our analysis of the U6 RNA genes from the three
known species of Schizosaccharomyces and their
variants (Frendewey et al., Nucleic Acids Res. 18:
2025 [1990]). All of the fission yeast U6 genes were
found to have introns. The sequences of the introns
were different in each of the species, except for the
bases at the 5 ' and 3' splice sites and putative bran-
chpoints. However, we also noticed an unexpected
region of sequence conservation just upstream of the
expected branchpoint. The 11 conserved bases fit the
consensus for the B-box RNA polymerase Ili (pol
III) promoter element found in tRNA genes. This sur-
prising result suggested that conventional pol III
promoter elements might serve as transcription sig-
nals for U6 RNA synthesis in fission yeast. It is now
known that transcription of the S. cerevisiae U6 RNA
requires a B box at an unusual position in the 3' flank
(Brow and Guthrie, Genes Dev. 4: 1345 [1990]).
During the past year, we have begun experiments to
define the sequences required for U6 transcription in
S. pombe and, specifically, to test whether the con-
served B-box similarity is essential.
Our initial strategy to investigate U6 transcription
was to create a series of deletions in the U6 gene and
then to test their expression in vivo and in vitro. To
facilitate identification in vivo, each construct was
"marked" with a short stretch of foreign DNA placed
in the middle of exon 2. This was accomplished by
amplifying two fragments of the S. pombe U6 gene
by the polymerase chain reaction (PCR) and then
cloning them into the pBSM13 vector in such a way
that the sequences between the BamHI and Sad sites
of the plasmid's polylinker interrupted exon 2. One
of the U6 fragments included 102 by of 5 ' flank
(-102), exon 1, the intron, and about half of exon 2;
the second consisted of the 3' half of exon 2 and 155
by of 3' flank. This marked U6 gene (SpU6FL+) was
subcloned into a yeast vector and used to transform
wild-type S. pombe. Primer extension analysis of
RNA from the transformants showed that SpU6FL+
was efficiently expressed, with transcription initiating
at the wild-type start site. Both pre-U6 RNA and
spliced product were detected in an apparently wild-
type ratio. These results demonstrate that as little as
102 by of 5' flank is sufficient for accurate and effi-
cient expression of the U6 gene in vivo. We have also
made a marked wild-type U6 gene (SpU6-2+) having
1500 by of 5 ' flank (a gift from T. Tani and Y. Oh-
shima, Kyushu University, Japan). However, we have
based our mutant constructs on SpU6FL+. We made
a series of five deletions from -102 in the 5 ' flank to
position 22 in exon 1. We also deleted the intron
from SpU6FL+ and from some of the 5 ' deletion
mutants. The structures of the mutant genes were
confirmed by sequencing.
We first tested the U6 deletion mutations in vitro.
Since our attempts to make an S. pombe extract that
accurately and efficiently transcribes pol III genes
were unsuccessful, we resorted to two heterologous
pol III systems. It had been reported that the S.
pombe U6 gene is transcribed in an extract from
HeLa cells (Kleinschmidt et al., J. Mol. Biol. 211: 7
[1990]). However, when we tested SpU6-2+ and
SpU6FL+ in a HeLa nuclear extract (a gift from S.
Lobo and N. Hernandez, Cold Spring Harbor
Laboratory), our results indicated that transcription
initiated incorrectly at several sites greater than 50 by
upstream of the normal starting point. We therefore
switched to an S. cerevisiae whole-cell extract (a gift
from I. Willis, Albert Einstein College of Medicine).
Both SpU6-2+ and SpU6FL+ were accurately tran-
scribed in this extract. We then assayed the transcrip-
tion of each of the mutant U6 constructs. A deletion
that left 78 by of 5' flank was transcribed as efficient-
ly as SpU6-2+ and SpU6FL+ (1500 by and 102 by of
5 ' flank, respectively). The transcription efficiency
for a mutant that retains 52 by of 5' flank was slight-
ly lower than for SpU6-2+ and SpU6FL+. However,
when the presumptive TATA box at -25 was re-
placed with the vector sequence, transcription ef-
ficiency was reduced and a new start site was
detected a few bases upstream of the true initiation
point. Deletion/replacement of the complete 5 ' flank
(SpU6A4 +) reduced the amount of transcription fur-
ther but appeared to restore the normal start site. A
deletion of the 5 ' flank and the first 21 by of exon 1
(SpU6A5+) abolished transcription.
The in vivo expression of the 51+ and 52+ con-
structs (78 and 52 by of 5 ' flank, respectively)
mimicked the in vitro results. However, deletion of
the TATA box (53+, 21 by of 5 ' flank) was more
deleterious in vivo than in vitro. The 53+ mutant pro-
duced only a very small amount of incorrectly in-
itiated transcript in vivo. The 54+ and 55+ deletions
were not expressed at all in S. pombe cells. The
SpU6A5+ deletion/replacement creates three point
mutations in a sequence of 11 bases that matches the
consensus for the A-box pol III promoter element. If
these same three base changes are introduced into
SpU6FL+, they have as severe an effect on transcrip-
tion as the SpU6A5+ deletion. This result implicates
the A box as an essential promoter element in the S.
pombe U6 gene. Removal of the intron from
SpU6FL+ resulted in a severe reduction in transcrip-
tion efficiency; a very small amount of correctly in-
itiated transcript was detected. This result is con-
sistent with the hypothesis that the intron contains a
B-box promoter element. However, a point mutation
in the B box has little or no effect on transcription ef-
ficiency in vitro. The same mutation in the B box of a
tRNA gene prevents transcription.
We have subcloned our U6 mutants into a yeast
vector and tested their expression in vivo following
transformation of a wild-type S. pombe strain. As
stated above, SpU6FL+ (102 by of 5' flank) was very
efficiently expressed in vivo. Removal of the intron
and the point mutation in the B box, in contrast to the
in vitro results, had a similarly negative effect in
vivo: both of these mutant templates produced barely
detectable amounts of U6 transcript.
Our experiments with the U6 gene deletions have
pointed to a requirement for sequences in the 5'
flank, the first exon, and the intron for accurate and
efficient transcription. The results to date allow us to
make the following preliminary conclusions: (1) 78
by of 5 ' flank is sufficient for accurate and efficient
transcription; (2) an element between -78 and -52 is
required for optimal expression; (3) the TATA box at
-25 appears to be important for precise initiation; (4)
the A-box similarity in exon 1 appears to be essential;
and (5) the intron contains a sequence, most likely
the B-box similarity, that is required for transcription.
These results indicate that U6 RNA transcription in S.
pombe is significantly different from the situation in
vertebrates, where transcription is controlled by ele-
ments that lie solely in the 5 ' -flanking sequence.
PUBLICATIONS
Frendewey, D., I. Barta, M. Gillespie, and J. Potashkin.
1990. Schizosaccharomyces U6 genes have a se-
quence within their introns that matches the B box con-
sensus of tRNA internal promoters. Nucleic Acids Res.
18:2025 -2032.
Potashkin, J. and D. Frendewey. 1990. A mutation in a
single gene of Schizosaccharomyces pombe affects the
expression of several snRNAs and causes defects in
RNA processing. EMBO J. 9: 525-534.
167
PLANT GENETICS
V. Sundaresan
R. Martienssen
T. Peterson
S. Allen
P. Athma
J. Colasanti
A. Duseff
E. Grotewold
C.-D. Han
Identification of Transposition
Factors of the Robertson's
Mutator System
Z.-Y. Zhao, V. Sundaresan
A. Jahrsdoerfer
Z.-Y. Zhao
The family of transposable elements known as the
Mu transposable elements constitute the Robertson's
Mutator system, an unusually active transposon sys-
tem in maize that generates new mutations at fre-
quencies of 50-fold over background. The mechan-
ism of transposition of these elements is believed to
be replicative, but the elements or genes encoding the
transcription factors or transposase are presently un-
known. We have identified specific binding sites for
maize nuclear proteins on the termini of the Mul ele-
ment. One of the binding proteins is positively corre-
lated with Mu activity, and the other is at the same
level in both active and inactive lines. In the latter
case, the binding site is a hexamer sequence motif
(CGGT/GAA) that is also repeated in the essential
subterminal region of elements of the Ac /Ds family.
These binding proteins are candidates for transposi-
tion factors required for Mu transposition: The first
factor is Mu-specific and the other factor is a more
general host factor that may be involved in the
transposition of other elements as well. Recently, evi-
dence that the same factor also binds to the ends of
the Ac element has been obtained in Dr. Star linger's
laboratory at Koln (P. Star linger, pers. comm.). Noth-
ing is known about host factors that are required for
transposition of plant transposons, and our identifica-
tion of such factors in nuclear protein extracts should
lead to their eventual cloning and characterization.
Splicing of the Mu/ Transposable
Element Generates a Functional
Bronze Gene with a Novel Intron
V. Sundaresan, A. Doseff
We have previously isolated several "changes in
state" of a Mul insertion at the Bronze (Bz) locus
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(CSHL Annual Report 1989). Changes in state (orig-
inally observed by Dr. B. McClintock) are heritable
changes in patterns of ex-pression of a transposable
element at a locus. The Mul insertion at Bronze that
we have used in our studies is called bzMum9 and
was originally isolated by Robertson. This insertion
results in kernels that are colored bronze, with purple
spots. The background bronze color is due to in-
activation of the Bz gene by the Mul element, and the
purple spots are due to excisions of the Mul element
that restore Bz function. One of the changes in state
that we have isolated leads to normal phenotypic ex-
pression of the Bz gene, i.e., kernels that are com-
pletely purple in color. We have found that this
change in state is associated with the deletion of half
of the Mul element. Analysis of the RNA from these
kernels shows that the remainder of the Mul element
is spliced out from the Bz transcript using donor and
acceptor sites that are present within Mul. Therefore,
this change in state results in a functional Bz gene
with a novel intron. Interestingly, the Mul element it-
self is not normally transcribed at detectable levels,
so that the intron is probably not utilized unless in-
serted into a gene. Thus, the Mul transposable ele-
ment acts as a portable intron that participates in the
evolution of the transcription units of the maize
genome, in this case by generating a new Bz gene
with two introns.
Somatic Excision Activity of the
Mu/ Element
A. Doseff, V. Sundaresan
Mu elements differ from other transposons in that
there is no apparent correlation between excision and
forward transposition, i.e., the rate of new integra-
tions is very high, whereas germinal excision events
are very rare. It is presumed that unlike other plant
transposons, Mu elements transpose replicatively. Al-
though the rates of germinal excision of the Mu ele-
ments is very low, the rates of somatic excision are
quite high. It is therefore of interest to see if the
empty sites left by excision of Mu somatically resem-
ble that of the animal transposable elements such as
the P elements or Tel, whose genetic behavior is
closer to that of Mu. We have studied the somatic ex-
cision of a Mul element at Bz by analyzing DNA
from somatic tissues and sectors and find that it
leaves the same types of footprints that are character-
istic of other plant transposons and not those of the
animal transposons. This result suggests that a com-
mon mechanism is involved in the excision of all
plant transposons. Interestingly, we also found that
the Mul element also promotes intrachromosomal
recombination, i.e., crossovers and conversions of
short stretches of DNA near the excised site. Such
footprints have not been previously observed with
plant transposons, but we think that they might be
quite general. Interchromosomal gene conversion of
extensive stretches of DNA promoted by tran-
sposable element excision has been observed with the
P elements of Drosophila (Engels et al., Cell 62:
515 [1990]), but intrachromosomal conversion events
were not examined in their study. It is possible that
the latter types of conversion events promoted by Mu
transposable elements might not be limited to the Mu
system, but might be of general importance to the
evolution of complex genomes.
Control of Cell Division in
Higher Plants
J. Colasanti, V. Sundaresan
This research is aimed toward elucidation of the me-
chanisms of cell division in plants. The control of cell
division in animals and yeasts has been shown to be
regulated by a complex of proteins, with the central
role played by a protein kinase that is a homolog of
the cdc2 gene of Schizosaccharomyces pombe (and
the cdc28 gene of Saccharomyces cerevisiae). We
have recently cloned and characterized maize
homologs of the cdc2 kinase genes. We find, by the
isolation of two different but closely related cDNA
clones, cdc2ZmA and cdc2ZmB, that there are at least
two cdc2 genes in maize. Southern blot hybridization
using maize DNA suggests the possibility that there
may be up to four maize cdc2 genes. The expression
of these genes in different tissues is correlated with
the state of proliferation of the tissue, as well as the
amount of cdc2-specific histone H1 kinase activity
measured using pl3suel beads. One of the maize cdc2
genes, when introduced into the yeast S. pombe,
caused severe inhibition in growth of the yeast cells,
suggesting that the maize cdc2 gene interacts im-
properly with some of the other cell-division proteins
in S. pombe (e.g., cyclins) and that there might be im-
portant differences in the plant cdc2 protein that are
responsible for this result (see below). At the amino
acid level, the maize cdc2 protein is 65% identical to
both yeast and animal proteins. We have been able to
demonstrate functionality of the maize protein in S.
cerevisiae by its ability to complement a cdc28 muta-
tion in this yeast. We have also expressed the maize
gene in vitro and have shown that we can synthesize
a 34-kD protein that interacts specifically with the
yeast sucl protein. More recently, we have generated
antibodies specific to the maize cdc2 protein, and we
will use these to study the intracellular localization of
the kinase during cell division in mitotic and meiotic
cells.
Effects of the Maize cdc2 Protein
in Yeast Cells
J. Colasanti, V. Sundaresan
Definitive proof that a maize cdc2 cDNA clone en-
codes a functional p34cdc2 kinase lies in its ability to
complement either the cdc2 mutation of S. pombe or
the cdc28 mutation of S. cerevisiae. Expression of the
maize cdc2ZmA clone under the control of the con-
stitutive ADH promoter of S. pombe yielded micro-
colonies that could not be propagated. Viable trans-
formants were obtained when the cdc2 gene was
cloned under the control of the inducible thiA
promoter of S. pombe under conditions where expres-
sion was repressed. Expression of the maize cdc2
protein, however, resulted in cell death after approxi-
mately six cell doublings. Lethality of maize cdc2 ex-
pression could be partially alleviated in S. pombe
cells in which the endogenous cdc2 protein was over-
expressed. This suggests that the maize p34cdc2
kinase may interfere specifically with the yeast cell
cycle machinery, possibly by interacting and se-
questering other components required for cell divi-
sion.
Expression of maize cdc2 protein was not lethal
in S. cerevisiae. In three cdc28 alleles tested, only
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one, 28-1N, was complemented by expression of the
maize cdc2 protein. This allele is defective at the
G2/M transition of the cell cycle, whereas the others
are defective at the Gt /S transition referred to as
"START." These preliminary results suggest that the
maize protein encoded by cdc2ZmA can interact suc-
cessfully with the cell cycle components required for
the initiation of mitosis, but not for traversion of the
"START" point of the cell cycle. One possibility is
that the latter function may be provided by a separate
maize cdc2 gene. Experiments are under way to char-
acterize this phenomenon further.
Transposon Tagging of Gibberellin
Biosynthesis Genes in Maize
J. Colasanti, V. Sundaresan
The gibberellins are plant growth substances that
mediate various aspects of plant growth and develop-
ment. Mutants of maize that are defective at different
points in the gibberellin biosynthesis pathway are
characterized by short stature (dwarfs) and aberrant
floral development. We have taken advantage of the
well-characterized transposable element system of
maize to tag GA biosynthesis genes to facilitate their
eventual cloning and characterization.
We reported last year the isolation of a new Mu-
induced suppressible dwarf allele. In this case, a Mu
transposable element appears to have inserted itself
into a gene that catalyzes synthesis of gibberellic acid
(GA), resulting in a dwarf phenotype. This allele is
unique, however, in that the appearance of the dwarf
phenotype is correlated with the activity of the Mu
element; i.e., when Mu is "active," the plants are
dwarf and when Mu is inactive, the plants appear to
be wild type. Activity of Mu is correlated with the
state of methylation as determined by Hinfl digest-
ion. This type of suppressible Mu-induced phenotype
was first reported for the hcf106 gene by Martienssen
et al. (EMBO J. 8: 1633 [1989]). Plants that are
homozygous for the Mu-induced lesion all appear as
dwarfs initially; however, as they grow, some attain
larger stature and eventually appear normal, whereas
others remain as dwarfs or are intermediate in height.
We interpret this observation to be the result of
somatic inactivation of the Mu element during plant
development. This would result in sectors of plant tis-
sue in which the cells are able to produce the wild-
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type enzyme and therefore synthesize the diffusible
GA that would mediate normal growth. Plants that
have large somatic sectors, due to Mu inactivation
early in development, would produce more GA and
appear nearly wild type in height and flower develop-
ment, whereas plants with very small sectors of GA-
producing tissues will remain as dwarfs. We are fur-
ther characterizing this allele with the aim of event-
ually isolating the gene tagged by Mu.
The anther ear (anl) allele is GA-defective muta-
tion in maize that is characterized by aberrant floral
development, i.e., male anthers appear on the female
flower (the ear) of the plant. In addition, the plants
are semi-dwarf and grow to approximately 50% of
normal height. The lesion has been characterized
biochemically as a defect early in the GA bio-
synthesis pathway. The An1 gene is closely linked to
the Bz2 gene; the latter is required for anthocyanin
pigment production in the aleurone of the kernel and
the plant. An allele of Bz2, bz2-m2, contains a Ds ele-
ment, a defective form of the Activator (Ac) element
first characterized by Barbara McClintock. In the
presence of Ac, the Ds element is able to transpose
from its location in the Bz2 gene and move elsewhere
in the genome. This transposition results in a mutable
phenotype characterized by purple spots on the
kernels and occasional fully purple revertant kernels.
The Ac /Ds elements have a predisposition to move to
linked sites in the genome, therefore increasing the
chances of the Ds element at Bz2 inserting into the
An1 gene. We have taken advantage of this proximity
to isolate a new and mutation that resulted from the
insertion of the Ds element into the An1 gene, thus
facilitating the eventual isolation of this gene by
transposon tagging.
Molecular Analysis of Nuclear
Mutations Affecting
Chloroplast Development
R. Martienssen, C.-D. Han, A. Jahrsdoerfer
Chloroplast biogenesis is a complex process in higher
plants, requiring the coordination of plastid and cel-
lular differentiation during leaf development. Al-
though structural genes have been characterized for
many of the more abundant chloroplast proteins (both
nucleus- and plastid-encoded), genes that regulate
chloroplast development have not been widely
studied at the molecular level. We are taking a genet-
ic approach to understanding the role of nuclear
genes in chloroplast and leaf development by study-
ing the maize mutants hcf106 and iojap.
HCF106: A MUTATION AFFECTING
CHLOROPLAST MEMBRANE ORGANIZATION
The thylakoid membrane system is one of the best-
studied morphological features of the mature chlor-
oplast. This internal membrane system has a highly
organized structure comprising stacked and un-
stacked lamellae, with each accommodating a charac-
teristic set of membrane proteins. However, the me-
chanisms by which these membranes are organized
and the protein complexes assembled are poorly un-
derstood, particularly in higher plants. As we de-
scribed in last year's Annual Report, the nonphoto-
synthetic, seedling lethal mutant of maize, hcf106,
has a recessive nuclear mutation that prevents the
normal assembly of photosynthetic electron transport
complexes and causes aberrant thylakoid membrane
organization. Consequent reductions in chloroplast
pigment levels result in pale green leaves that
fluoresce under UV illumination in the dark (high
chlorophyll fluorescence). This mutation arose in a
Robertson's Mutator line, and a molecular clone of
the locus was obtained using the transposon Mul as a
tag. A 1.2-kb transcript that hybridized to the cloned
locus was identified on Northern blots, and genetic
analysis showed that it encoded the hcf106 gene pro-
duct (Martienssen et al., EMBO J. 8: 1633 [1989]).
We have now cloned and sequenced full-length
cDNA clones of this transcript, and a 243-amino-acid
open reading frame corresponding to the hcf106 gene
product has been identified. This encodes a protein
without global homology with any protein sequence
from the Genbank database, but the sequence does
contain a putative ATP-binding motif, a potential
chloroplast transit peptide, and a membrane spanning
domain. We have expressed TrpE::hcf706 fusion
proteins in Escherichia coli, and antibodies have
been raised. In preliminary experiments, these anti-
bodies have been used on Western blots of leaf
proteins from membrane and soluble fractions. A
membrane protein of approximately 30 kD is detec-
ted with our antibody in wild-type leaves, but not in
mutant leaves. We are currently trying to obtain
higher-affinity antibodies for immunocytochemistry.
The 1.2-kb hcf106 transcript accumulates in the
light to levels five- to tenfold higher than in the dark,
reaching a peak at around 6 hours after light ex-
posure. However, it is also found at low levels in the
root and cob, so that the hcf706 gene product may
have a general role in the biogenesis of both
amyloplasts and chloroplasts. The RACE protocol for
the rapid amplification of cDNA ends was used to
isolate full-length cDNA clones, but additional clones
made by conventional methods were also obtained
from A. Barkan (University of California, Berkeley).
These clones include a second, distantly related se-
quence that appears to be the product of a low-
stringency cognate gene. We have found that the
hcf106 mutation is nonlethal in some inbred back-
grounds of maize, and sequences specific to the cog-
nate gene appear to cosegregate with the nonlethality
factor. It is thus possible that some alleles of the cog-
nate gene can provide a level of duplicate function in
hcf106 mutants. Recombinant inbred lines have been
used to map the hcf106 gene to chromosome 2, close
to the endosperm marker floury. This marker will be
used to follow the mutant hcf106 allele for sub-
sequent genetic analysis.
10JAP: A VARIEGATED MUTANT OF MAIZE
Maize plants homozygous for the recessive mutation
iojap have variegated leaves and transmit defective
plastids through their female gametes. Since the work
of Jenkins (J. Hered. 25: 467 [1924]) and of Rhoades
(Proc. Natl. Acad. Sci. 29: 327 [1943]), the iojap
gene has been thought to have a fundamental role in
the interaction of nuclear and plastid compartments
during the development of the maize leaf. In particu-
lar, the pattern of leaf variegation in mutant plants
suggests that defective plastids may have failed to
respond to positional signals that coordinate cellular
and plastid development in the leaf. Embryos with
maternally inherited defective plastids also arise at
specific positions on the ear, rather than in clonal
groups.
A transposon-tagged allele of iojap was obtained
by C.-D. Han and E.H. Coe at the University of Mis-
souri using the transposable element Robertson's
Mutator, and a Mul element was found to coseg-
regate with the new ij-mum] allele (Han and Coe,
Maize Newsletter 64: 46 [1990]). In collaboration
with Coe, we have now obtained a molecular clone of
this Mu] element. DNA flanking the Mul element
hybridizes to a 1.3-kb transcript found in wild-type
seedlings, but reduced in abundance and altered in
mobility in seedlings homozygous for the original
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iojap allele. Two rare germinal revertants of this al-
lele, isolated by Coe, have suffered genomic rear-
rangements that can be detected by Southern
hybridization using this probe. We conclude that this
clone is likely to be a part of the iojap locus. In the
coming year, we hope to characterize the molecular
role of the iojap gene product in coordinating
chloroplast biogenesis with leaf development.
Suppression of Mu-induced
Mutations
R. Martienssen, A. Jahrsdoerfer
As we reported last year, the hcf106 mutation is
phenotypically suppressed when Mu transposons in
the genome lose activity; i.e., hcf106 homozygotes
adopt a wild-type phenotype despite the continued
presence of the Mu] transposon at the locus. Loss of
Mu activity and phenotypic suppression of hcf106 are
both reversible and are associated with DNA
methylation of the Mu transposon family. Phenotypic
suppression of hcf106, then, provides a marker for
DNA modification of Mu transposable elements.
Suppression of the mutant phenotype is accompanied
by accumulation of mRNA transcripts from the
hcf106 locus, despite the insertion of a Mul element
into the untranslated leader of the hcf106 gene, close
to the start of transcription. In contrast, mutant see-
dlings have no detectable transcript (Martienssen et
al. 1989). In collaboration with A. Barkan (Univer-
sity of California at Berkeley), we showed that sup-
pression of the hcf106 phenotype is mediated by an
outward reading promoter near the end of Mul that
substitutes for the normal hcf106 promoter when Mu
is inactive (A. Barkan and R. Martienssen, Proc.
Natl. Acad. Sci. [1991] in press). In the last year, the
phenotypes caused by several other Mu]- induced
mutations have been shown to respond to Mu activity
in a similar fashion. Those that have been cloned
have a Mul element close to the start of transcription,
as is the case with hcf106 (P. Chomet, S. Hake, D.
McCarty, pers. comm.).
In some families, hcf106 homozygotes were ob-
served that had large, phenotypically wild-type sec-
tors superimposed on pale green, mutant leaves.
DNA isolated from these sectors contained modified
Mul elements, including the one at the hcf106 locus
(Martienssen et al., Genes Dev. 4: 331 [1990]). The
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pattern of stripes suggested that clonal switching
events associated with DNA modification had oc-
curred in cells near the tip of the apical meristem, so
that more, and larger, sectors were observed in suc-
cessive leaves until, in the upper leaves, the entire
plant was phenotypically wild type. This resulted in a
gradient of transposon inactivity (and methylation)
up the plant. We have now shown that a second sup-
pressible mutation, a dominant Lesion-mimic, is coor-
dinately regulated in these sectors; i.e., plants that are
doubly mutant have sectors that are suppressed for
both phenotypes together. This suggests that a factor
influencing suppression must operate in trans to sup-
press both unlinked mutations. In crosses between
sectored and unsectored plants, the "sectored"
phenotype appears to segregate among the progeny,
so that a single dominant factor may be responsible
for this somatic variegation. In collaboration with V.
Sundaresan (Cold Spring Harbor Laboratory), we are
pursuing the hypothesis that this factor might encode
a protein that binds Mu termini (Z.-Y. Zhao and V.
Sundaresan, CSHL Annual Report 1990). We are
also in the process of constructing double and triple
mutants for seedling, plant, and kernel markers
whose phenotypes depend on Mu activity. This
should help to reveal the developmental and genetic
basis of the sectored patterns observed.
Molecular and Genetic Analysis
of the Maize P Locus
S. Allan, P. Athma, E. Grotewold, T. Peterson
Our research concerns the question of how gene ex-
pression is controlled during development in higher
eukaryotes. Toward this end, we are continuing our
analysis of the maize P gene, which is required for
flavonoid pigmentation of specific floral parts in
maize. The P gene is an excellent model system for
this study, in part because of its potential for incisive
genetic analysis. We have made significant progress
in the past year in defining the structure and function
of P.
ELUCIDATING THE COMPLEX
TRANSCRIPTIONAL PATTERN OF P
Since one major aim of our work is to understand
how P expression is controlled, we needed exact in-
formation on the gene structure, especially the loca-
tion of the 5 ' start sites. Previous attempts to isolate
full-length cDNA clones from conventional cDNA li-
braries were unsuccessful, probably due to a region
of strong secondary structure in the P message that
inhibited the progression of reverse transcriptase.
Therefore, we analyzed the P gene transcripts by
primer extension, RNase protection, and SI mapping
experiments, as well as conventional and polymerase
chain reaction (PCR)-derived cDNA cloning. The
results showed that P produces at least two alterna-
tively spliced messages and that all of the messages
are initiated at the same point (Fig. 1) (Grotewold et
al., Proc. Nall. Acad. Sci. [19911 in press).
REGULATORY FUNCTION OF THE P GENE
The sequence of the P transcripts showed an amino-
terminal region that has significant homology (40%)
with the DNA-binding domain of the vertebrate Myb
oncoprotein. Myb is a DNA-binding protein that can
activate transcription from promoters containing the
Myb-binding site. In mammalian cells, Myb is a
regulator of cell growth and differentiation, primarily
in hematopoietic cells. Our results indicate that
studies of P function could provide an important
complement to research on Myb in mammalian sys-
tems. One of the P transcripts encodes a protein with
a negatively charged domain that has the structural
features of a transcriptional activating domain. This
finding supports our previous hypothesis that P is a
transcriptional regulator. A functional test of this
hypothesis came from Northern blot analysis of RNA
from structural genes in the pigment biosynthetic
pathway. RNA transcripts from the maize genes C2
and A1, which encode chalcone synthase and
flavonol/flavonoid reductase, respectively, are pres-
ent in tissues that have a functional P gene but absent
from plants in which P is deleted. Additionally, we
have isolated cDNA clones encoding maize chalcone
isomerase, which catalyzes another step in pigment
biosynthesis. Like C2 and A I , the chalcone isomerase
message is also dependent on a functional P allele.
Thus, the hypothesis that P is a transcriptional reg-
ulator is supported not only by sequence homology,
but also by direct measurement of transcript ac-
cumulation from three target genes.
ANALYSIS OF THE CHANGE IN STATE ALLELE
P-OVOV
The P-ovov allele, which produces orange variegated
pericarp and cob glumes, resulted from a short-range
transposition of Ac to a new site in the P locus. It has
been suspected for some time that new alleles of
genes carrying transposon insertions could arise from
intragenic transpositions, but this is the first pub-
lished example confirmed at the molecular level. This
paper was published recently in Genetics (Peterson
1990). Since the Ac element preferentially transposes
to nearby sites, the P-ovov allele has been an ex-
cellent source of new mutant alleles carrying Ac at
diverse sites in the P locus.
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FIGURE 1 Structure of P gene transcripts. (Top) Map of the P locus, with restric-
tions sites for EcoRI (E) and Sall (S) indicated. The cross-hatched boxes indicate
a 5.2-kb direct repeat, and the stippled boxes indicate a 1.2-kb direct repeat se-
quence. The triangle containing the arrow marks the site of insertion and transcrip-
tional orientation of the transposable element Ac in the P-ovov-1114 allele; in P-vv,
the Ac element is inserted 161 by 3' of the site in P-ovov-1114, in the opposite
orientation.
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FIGURE 2 Structures of the P-ovov-1114 and P-ww-d alleles. The map at the top shows the
P-ovov-1114 genomic region with EcoRl sites. The two hatched boxes indicate the two 5.2-
kb direct repeats on either side of Ac; the smaller repeats are not shown. The map at the
bottom shows the structure of a typical P-ww-d allele with a 17-kb deletion, including 4.5 kb
of Ac and 12.5 kb of the P locus.
DIRECT REPEAT RECOMBINATION INDUCED BY
THE TRANSPOSON AC
The P gene has the unusual feature that the tran-
scribed region is flanked by two long repeats of 5.2
kb (Fig. 1); the function of these repeats, if any, is
unknown. During the course of our genetic experi-
ments, we found that P alleles that carry the
transposable element Ac inserted between the repeat
sequences produce a high frequency of null alleles.
We analyzed the structure of 51 null alleles and
found that all but 4 carried a large common deletion
that removed the Ac element, the P transcribed
region, and one copy of the flanking direct repeat se-
quences (Fig. 2). Since P alleles that do not have Ac
inserted are very stable, we conclude that the Ac in-
sertion induces recombination between the repeats.
This represents a previously unknown activity of Ac
(Athma and Peterson, Genetics [1991] in press).
We thank Michael Persans for assistance in vari-
ous aspects of this work.
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G1 AND G2 CELL CYCLE CONTROL
IN SACCHAROMYCES CEREVISIAE
B. Futcher B. Elliott M. Linskens G. Tokiwa
I Fitch N. Nash M. Tyers
Our main interest continues to be the regulation of
START in Saccharomyces cerevisiae. In particular,
we are interested in the mechanism that tethers divi-
sion to growth. To this end, we have studied two
mutations that provide a Wee phenotype and alter the
normal relationship between division and growth.
One of these mutations, WHIZ -1, was in a cyclin-like
gene now known as CLN3. The encoded protein was
the first member of a growing set of cyclin-like
proteins that regulate the G1 /S transition. In the past
year, we have found that Cln3 has a very short half-
life, is somehow affected by a ubiquitin-conjugating
enzyme, and is associated with a protein kinase ac-
tivity. The other mutation, whi3, appears to be in a
gene encoding an RNA-binding protein of unknown
function.
Our interest in CLN3 has led us to examine in a
more general way the role of various cyclins. In the
last year, we have found four B-type mitotic cyclins
in S. cerevisiae and possibly an A-type cyclin. When
added to the three previously known G1 cyclins
(Clnl, 2, and 3), this gives S. cerevisiae by far the
largest repertoire of known cyclins of any organism.
These different cyclins may confer different pro-
perties on their respective kinase complexes; work in
this area is continuing. There is preliminary evidence
that other organisms have a similarly wide array of
different cyclins doing different jobs.
Biochemistry of Cln3
M. Tyers, G. Tokiwa, B. Futcher
The Clnl, Cln2, and Cln3 proteins of S. cerevisiae
help regulate START, the Gi/S transition. Over-
expression or hyperactivation of these proteins ad-
vances START, shortening Gt and decreasing cell
size, whereas deletion of one or two of the genes
delays START. Deletion of all three genes causes a
lethal Gi arrest (Richardson et al., Cell 59: 1127
[1989]). These three proteins are related to each other
and distantly related to the mitotic cyclins. We be-
lieve that Clnl, 2, and 3 are "Gt cyclins" and regulate
START by a mechanism similar to that by which the
mitotic cyclins regulate mitosis.
CLN3 mRNA has a very short half-life of just a
few minutes. The protein has a similar very short
half-life (Fig. 1). Whereas mitotic cyclins are com-
pletely destroyed at one point in the cell cycle, but
are otherwise stable, the Cln3 protein appears to be
continuously turned over. The original WHIZ -1 (also
known as CLN3-1) mutation identifying the gene is
dominant. The molecular lesion is a stop codon that
removes the last third of the protein; this third con-
tains PEST regions, which may be signals for
proteolysis. The truncated, Cln3-1 protein is relative-
ly abundant, and it turns over very slowly (Fig. 1),
suggesting that the indestructibility of this protein
causes the mutant phenotype.
If CLN3-1 is transcribed from the GALL pro-
moter, and then transcription (and, in fact, all Cln3-1
synthesis) is stopped by the addition of glucose, the
cell's store of Cln3-1 protein is sufficient to drive it
through several cell cycles. In this situation, the
Cln3-1 protein is clearly not oscillating in abundance
through the cycle (it is still not clear whether the
abundance of the wild-type protein oscillates). Sur-
prisingly, a cell that is deleted for CLNI and CLN2,
and lives only because it contains the CLN3-1 gene,
is reasonably healthy (although Wee and otherwise
abnormal). Thus, oscillation of a Gt cyclin is not es-
sential for viability.
As expected for a cyclin-like molecule, Cln3 is
associated with a protein kinase activity (Fig. 2A).
The protein kinase activity will phosphorylate histone
H1, Cln3, and an unidentified protein of 45 kD that is
coprecipitated by anti -Cln3 antibodies. The Cdc28
polypeptide is present in anti-C1n3 immunoprecip-
itates, and thus we believe that Cdc28 is responsible
for at least some of the kinase activity. However,
only an extremely tiny fraction of the Cdc28 protein
in the cell is Cln3-associated. CLN3-1 mutant cells
have 50-100 times as much Cln3-1-associated kinase
activity as do CLN3 cells.
If the Cln3-associated kinase complex is treated
with a phosphatase, and then the phosphatase is
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FIGURE 1 Induction and decay of Cln3. Cells containing a Lerner-epitope-tagged version'of
Cln3 or Cln3-1 expressed from the GAL 1 promoter were grown in YEP + raffinose and then
induced with galactose. The number of hours of galactose induction is shown above each
lane. To examine turnover, Cin3 or Cln3-1 expression was induced for 4 hr, glucose was
then added to 2% to stop transcription, and samples were harvested after 0.3, 0.7, or 1.3 hr.
Lysates from 2 x 109 cells were immunoprecipitated with 0.5 pl of 12CA5 ascites fluid, elec-
trophoresed, and transferred to nitrocellulose. The filter was probed with a 1:2000 dilution of
12CA5 ascites fluid followed by 125l- labeled goat anti-mouse IgG, and then auto-
radiographed. Cln3 and Cin3-1 are indicated, as well as the IgG heavy (H) and light (L)
chains. Molecular mass (kD) is shown to the right.
washed away, the kinase activity is destroyed. This is
also true of the Cln3-1-associated kinase. In contrast,
when the same experiment is done with the mitotic
(Clb-associated) form of the Cdc28 kinase, the kinase
activity is increased. We believe that some protein in
the Cln3 kinase complex must be phosphorylated for
the kinase to be active. We cannot tell whether the
relevant phosphate(s) is on Cln3, on Cdc28, or else-
where. Cln3 and Cln3-1 appear to have only one
major phosphopeptide in common (containing phos-
phothreonine); this peptide is a good candidate for
the region where the regulatory phosphorylation oc-
curs.
Cln3 metabolism is dramatically affected by the
cdc34 mutation. cdc34 mutants are temperature-
sensitive lethal cdc mutants. At 36°C, they arrest with
buds (i.e., after START), but before initiation of
DNA synthesis. Cdc34 is a ubiquitin-conjugating en-
zyme, and so is presumably involved in protein
degradation. In a cdc34 mutant at the permissive
temperature, most of the Cln protein is in a highly
phosphorylated form, whereas only a few percent of
the Cln3 protein in a CDC34 strain is in this form.
However, the total amount of Cln3 protein does not
change very much (perhaps twofold). Strikingly, the
176
Cln3-associated kinase activity goes up 50-100-fold
in the cdc34 background at the permissive tempera-
ture (Fig. 2B). Therefore, we speculate that the
Cdc34 protein is somehow involved in degradation of
the phosphorylated form of Cln3, and it is this
phosphorylated form that is the active form. Con-
sistent with this hypothesis, the cdc34 mutation does
not affect the kinase activity associated with the in-
destructible Cln3-1 mutant protein (Fig. 2B). The
results of phosphatase experiments discussed above
are also consistent with this hypothesis.
CLN3-1 mutants are resistant to a-factor arrest.
We imagined that a-factor caused arrest by inducing
degradation of the wild-type protein but that the trun-
cated, mutant protein would be resistant to degrada-
tion. Surprisingly, we find that a-factor-arrested
wild-type cells still contain normal levels of the Cln3
protein. Even more surprisingly, these arrested cells
still contain normal levels of Cln3-associated histone
H1 kinase activity. There is strong genetic evidence
that a-factor does somehow inactivate Cln3, but this
inactivation does not seem to be caused by degrada-
tion or by destroying the kinase activity. Perhaps the
kinase activity in cc-factor-arrested cells has been
qualitatively changed.
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FIGURE 2 Cln3 has an associated kinase activity. (A) Cells containing a Lerner-epitope-tagged
version of Cln3 expressed from the GAL1 promoter were grown in YEP raffinose and then either in-
duced (1st, 3rd, and 4th lanes) or not induced (2nd lane, "raffinose") with galactose. Material was
precipitated from cell lysates with protein-A beads alone (lane 1), or 12CA5 ascites fluid (lane 2), or
12CA5 ascites fluid plus an excess of a competing epitope peptide (lane 3), or 12CA5 ascites fluid
(lane 4). lmmunoprecipitates were incubated with histone H1 and [y-32F]ATP in kinase buffer, and
the reaction products were electrophoresed and autoradiographed. (B) cdc34 mutation increases
Cln3-associated kinase activity. In a cdc34 mutant strain at the permissive temperature, the Cln3-
associated kinase is about 50-fold more active than in a CDC34 wild-type strain (compare lanes 2
and 4). In contrast, the Cln3-1-associated kinase is about equally high in both cdc34 and CDC34
strains (compare lanes 6 and 8).
G1 and Other Cyclins of
Schizosaccharomyces pombe
and Humans
T. Connolly, I. Fitch, M. Caligiuri, K. Galactionov,
B. Futcher, D. Beach, Y. Xiong
Cyclin-like molecules functioning in G., phase have
so far been identified only in S. cerevisiae. However,
they may occur in other organisms as well. To find
such molecules, we have constructed a strain deleted
for clnl and cln2 and that has CLN3 transcribed from
the GAL1 promoter. This strain is viable in the
presence of galactose, but dead in the absence of
galactose or in the presence of glucose. L. Guarente
and co-workers and M. Wigler, J. Colicelli, and co-
workers have supplied us with Schizosaccharomyces
pombe and human cDNA expression libraries in S.
cerevisiae vectors. We have transformed the clnl
cln2 GAL1-CLN3 strain with these libraries and have
selected for growth in the presence of glucose.
Several dozen transformants have been recovered. In
each case, the transforming vector contained a cyclin
homolog. From S. pombe, we obtained the cdc13*-
encoded B-type mitotic cyclin and two previously
unidentified cdc13+ homologs. In addition, we have
recovered a good homolog of S. cerevisiae CLN3,
and we hope that this may be an S. pombe Gt cyclin.
From human cells, we have recovered two B-type
mitotic cyclins, BI and B2, and also an interesting
cyclin-like molecule that does not seem to be a mem-
ber of any of the previously defined classes of
cyclins. As yet, there is no evidence that these new
CLN homologs function in Gt phase in S. pombe or
human cells.
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Identification of Four Mitotic
Cyclins of S. cerevisiae
I. Fitch, B. Futcher [in collaboration with U. Surana,
H. Robitsch, C. Price, T.Schuster, and
Kim Nasmyth, IMP, Vienna]
If Clnl, Cln2, and C1n3 really represent a new class
of "G1 cyclins" (as opposed to being "misplaced"
mitotic cyclins), then S. cerevisiae should possess
one or more mitotic cyclins as well as its Gt cyclins.
We have therefore searched for mitotic cyclins by the
polymerase chain reaction (PCR). Three such cyclin
homologs were identified, which we named CLB1,
CLB3, and CLB4 (for CycLin B-type). While the
PCR experiments were under way, our collaborators
in Vienna identified seven different high-copy-
number suppressors of an exceptional allele of cdc28
called cdc28-1N. cdc28-1N is defective only in a
G2/M function, whereas most alleles of cdc28 are
defective in both a Gt function and a G2/M function.
Since it seemed possible that high-copy-number
mitotic cyclins might suppress cdc28-IN, the CLBI,
CLB3, and CLB4 PCR fragments were hybridized to
each of the seven groups of high-copy-number sup-
pressors. CLB1 and CLB4 were found among the sup-
pressors. In addition, CLB1 hybridized weakly to a
third suppressor. Sequencing showed that this third
suppressor was also a B-cyclin homolog, which we
now call CLB2 (Fig. 3).
CDC13 MTTRALTRQHLLANTLGNNDENHPSNHIARAKSSLHSSENSLVNGKKATVSSTNVPKKRHALDDV
CLB1 MSRSLLV-ENSRTINSNEEKGVNESQYILQKRNVPRTILGNVTNNANILQEISMNREIGMKNFSK
CLB2 MSNPIENTENSQNTSSSRFLRNVQRLALNNVTNTTFQKSNANNPALTNFKSTLNSVEREGSRIPQ
CDC13 SNFHN KE GVPLASENTNVRHTTASVSTRA ALEEKSIIP-ATDD
CLB1 LNNF FPLKDDVSRADDFTSSFNDSRQ-GVKQEVLNNKENIPEYGYS
CLB2 FTRESVSRSTAAQEEKRTLKENGIQLP-KNNLLDDKENQDPSSQQFGALTSIKEGRAELP-ANIS
CDC13 EPASKKRRQPSVFN SSVPSLPQHLSTKSHSVSTHGVDAFHKDQATIPXKLKKDVDERV
CLB1 EQEKQQCSNDDSFHTN STALSCNRLITSENKSISTOMEWQKKIMREDSKERRPISTLVEQ
CLB2 LQESSSAKEIIQHDPLKGVGSSTEVVHNSVENEKLEPARSQLQVRNTESETDSGKERPISTIVEQ
CDC13 VSKDIPKIATRDSVESP--ESQDWDDLDAEDWADPLMVSEYVVDIFEYLNELEIETMPSPTYMDRQ
CLB2 ELPERFKVCDENGK----EEYEKEDLDAEDVNDPFMVSEYVNDIFEYLHQLEVITLPKKEDLYQH
CDC13 KELAWKMRGILTDWLIEVESRFRILPETLFLAVNIIDRFLSLRVCSLMKLQLVGIAALFIASKYE
CLB1 KNIKQN-RDILVNWIIKIHNEFGLLPETLYLAINIMDRFLCEEVVQLNALQLVGTSCLFIASKYE
CLB2 RNIHQN-Rp/LVNWLVKIHNKFGLLPETLYLAINIMDRFLGKELVQLDELQLVGTSCLF/ASKYE
CLB3 PELRNSIRSILIDWIVQVHEICFQLLPETLYLCINIIDRYLCICEVVPVNKFOLVGAASLFIAARYE
CLB4 VELTWFERRIMIDWLVQLEFRFRLLPETLYITINIVDRFLSKKTVILNRFQLVGVSALFIAAXFE
CDC13 EVMCPSVQNFVYMADGGYDEEEILQAERYILRVLEFNLAYPNPMNFLAR/SKADFYDIQTRTVAK
CLB1 EIYSPSIKHFAYETDGACSVEDIKEGERFILEKLDFQISFANPAWFLRRISKADDYDEaRTLAK
CLB2 EVYSPSIICHFASETDGACTEDEIKEGEITILKTLKFNLNYPNPMNFLRRISKADDYDIQSATLAK
CLB3 E/NCPIIK2FyyMSENCXSANDLLDAERTILNGLEFELGWPGPMSFLRA/SKADDYEHDTRTLAX
CLB4 EINCPILD2LyYMLENTXTBSDIIRAEQYMTDTLEFEIGWPGPWPFLAR/SKADDYDFEPRTLAK
CDC13 YLVEIGLLDHELLPYPPSQQCAAANYLAREIELGRGPWNRNLVEYSG-YEEYOLISVVKKMINYLQ
CLB1 FLMEISIVDFKFIGILPSLCASAAMPLSRKMLGKGTWDGNLISYSGGYTKAKLYPVCQLLMDYLV
CLB2 FLLEISLVDFRFIGILPSLCARANKFMSRKMIGKGKWDGNLIHYSGGYTKEELAPVCHM/MDYLV
CLB3 XLLESIIMDHRLVSAUSWLAAGAXPLSKIILGQEQWSIALN/YYSN-YTQE2ILPIATIIL
CLB4 XLIETTIVERKLVAAAPSWLAAGAXPLSRTILGSNDWa,KIV_FYSG-YTSSQIIPLASLIL
CDC13 KPVQHEAFFKKYASKKFNKASLFVRDWYKENSIPLGDDADEDYTFHKQKRIQHDNKDEEW
CLB1 GSTIHDEFLKKYQSARFLKASIISIEWALKVRANGYDIMTLSE
CLB2 SPIVHDEFHRICYQSRPFMRASIISVOWALKVRICNGYDIMTLEIE
FIGURE 3 Alignment of the S. pombe cdc13*-encoded cyclin with the complete
amino acid sequence of CLB1 and CLB2, and part of CLB3 and CLB4. Residues
shown in bold are identical in two of three cyclins, or three of five cyclins, as ap-
propriate. Underlined residues distinguish the CLB1/CLB2 pair from the
CLB3/CLB4 pair. Also underlined is the 'destruction box," a region found in the
amino-terminal region of most cyclins, and thought to be a signal for ubiquitin-
mediated degradation.
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CLB1 and CLB2 are a very closely related pair of
genes, and CLB3 and CLB4 form a second pair (Fig.
3). Disruptions of CLB1 or CLB2 alone have very
little phenotype, but a double clbl clb2 disruption is
lethal, and dies in mitosis (at a stage where spindles
have formed, but have not elongated) at about the
same stage as cdc28-IN mutants arrest. As yet, CLB3
and CLB4 have not been disrupted. CLB1 and CLB2
transcription is cell-cycle-regulated and peaks in
G2/M (Fig. 4). Several lines of evidence suggest that
CLB1 and CLB2 perform a qualitatively different
function than CLB3 and CLB4.
The whi3 Mutation
R. Nash
Like CLN3-1, whi3 causes cells to divide at ab-
normally small sizes. Unlike CLN3-1, whi3 is reces-
sive, suggesting that WHI3 inhibits or delays commit-
ment to division. The mutation was induced using a
G418R-marked Ty transposable element. The mutant
gene and flanking DNA were then cloned using the
G418R marker, and the wild-type gene was cloned
shortly thereafter. Sequencing showed that WHI3 has
an open reading frame of 661 amino acids. The pre-
FIGURE 4 CLB1 and CLB2 are transcription-
ally cell-cycle-regulated. Cells were arrested in
Gi with a-factor and then released, and
samples were withdrawn at a 10-min interval.
Northern blots were analyzed with CLB1- and
CLB2-specific probes. The graph (bottom)
shows the percentage of cells with fully formed
mitotic spindles following release.
CLB1 RNA
CLB2 RNA
dicted protein includes a domain found in a family of
RNA-binding proteins. Some preliminary evidence
suggests that whi3 may affect expression of CLN3
posttranscriptionally. Sequencing also showed that
the original mutation was indeed caused by insertion
of a Ty element into the open reading frame.
Targeted disruption of the WHI3 locus produced
the same Wee phenotype as the original Ty-induced
mutation. Integration of one copy of WHI3 at the
ura3 locus in a whi3 strain reverts the mutant
phenotype. Several copies of WHI3 appear to cause a
very large cell size and make the strain very sick.
Thus, as for CLN3, the effect of WHI3 on the critical
size for commitment may be dose-dependent. In sum-
mary, we think that Whi3 is an RNA-binding protein
that acts at START to inhibit commitment to divi-
sion. It could do this by, for instance, down-reg-
ulating translation of Clnl, Cln2, and/or Cln3.
The Stress and Quiescence
Response of S. cerevisiae
B. Elliott
In S. cerevisiae, the RAS/cAMP pathway can regulate
the physiological state of the cell in response to nutri-
amigo Weeemmee
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tional cues. However, when the RAS/cAMP signaling
pathway is destroyed, cells still respond appropriately
to nutritional cues (Cameron et al., Cell 53: 555
[1988]). Thus, there is at least one signaling pathway
in addition to the RAS/cAMP pathway. To identify
this pathway, we have used a strain lacking a
RAS/cAMP pathway and looked for mutations that
prevent appropriate nutritional responses. Several
such mutations have been found. Different mutations
affect different aspects of the normal nutritional
response. These genes are in the process of being
identified.
Effects of SV40 T-antigen
Expression in S. cerevisiae
M. Linskens
Eukaryotic cells have a control ensuring that DNA is
replicated once and once only. The mechanism of this
control is wholly unknown. However, the mechanism
can be overcome: In CV-1 monkey cells, SV40 T
antigen can cause multiple rounds of initiation of
DNA synthesis from an SV40 origin. We are inter-
ested in the mechanism of once and once-only con-
trol, and since yeast is a powerful model system, we
asked whether T antigen could
overreplication in yeast.
Yeast were transformed with a 2-micron circle-
based plasmid carrying SV40 T antigen under the
control of the GAL1 promoter, and an ARS centro-
mere plasmid carrying the SV40 origin. When the T
antigen was turned on, there was at best a very slight
increase in the copy number of the origin plasmid, so
it appears that overreplication did not occur. How-
ever, expression of T antigen caused some un-
expected but striking effects. A small proportion
(2-5%) of the cells in an expressing population
permanently arrested with extremely long buds.
Different cdc mutant strains were transformed
with the T-antigen expression plasmid. cdc34 mutant
cells were very strongly affected even at the permis-
sive temperature. The T-antigen-induced phenotype
was seen in about 25% of the cells. Expression of the
protein was assayed using an anti-T-antigen antibody
provided by B. Stillman (Tumor Viruses Section).
Wild-type cells expressed only very small amounts of
T antigen, perhaps accounting for the low penetrance.
This T antigen appears to have a short half-life.
cdc34 cells at the permissive temperature contained
much larger amounts of T antigen. As noted above,
CDC34 encodes a ubiquitin-conjugating enzyme, and
so is presumably involved in protein turnover. We
have no idea why T antigen is toxic, but we believe
that the Cdc34 protein participates in the degradation
of T antigen. When Cdc34 activity is reduced, T
antigen accumulates to toxic levels in a greater pro-
portion of the cells.
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TRANSCRIPTION AND CELL CYCLE REGULATION IN YEAST
K.T. Arndt C. Devlin M.J. Fernandez-Sarabia A. Sutton
C. Di Como F. Lin T. Zhong
A. Doseff M. Luke
In almost all aspects of basic cellular processes, the
yeast Saccharomyces cerevisiae has been found to be
very similar to higher eukaryotic cells. For this rea-
son, and the ease of manipulation and the powerful
genetic approaches available with yeast, we are using
yeast in our laboratory to study transcriptional regula-
tion and cell cycle control.
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Transcriptional Regulation
of the HIS4 Gene
C. Devlin
Our ultimate goal is to understand completely the
regulation of the yeast HIS4 gene and to use HIS4
regulation as a model for the transcriptional regula-
tion of other systems. The HIS4 gene is under com-
plex transcriptional control. Two independent sys-
tems activate HIS4 transcription: basal control and
general amino acid control. In general amino acid
control, starvation for any one or more amino acids
causes an increase in the levels of the GCN4 protein.
The GCN4 protein binds to the sequence TGACTC,
repeated five times in the HIS4 promoter, to activate
HIS4 transcription. GCN4 binds one of these H!S4
elements, repeat sequence C, much more tightly than
the others, and most (>80%) of the GCN4-dependent
activation of HIS4 transcription is due to repeat se-
quence C. We are using defective GCN4 derivatives
to obtain mutations in the general transcription ma-
chinery (see below).
The basal level control activates HIS4 transcrip-
tion in the absence of amino acid starvation. In addi-
tion, either phosphate or adenine starvation will cause
a further increase in the already high basal levels of
HIS4 transcription. Activation of the basal level tran-
scription of HIS4 requires two trans-acting proteins,
encoded by the BAS1 and BAS2 genes. Mutations in
BAS2 cause a phosphate requirement (BAS2 is the
same gene as PHO2), and mutations in either BAST
or BAS2 cause an adenine requirement. Thus, in
yeast, the phosphate, purine, and histidine pathways
are coregulated. Analysis of the metabolites in these
pathways shows the biological rational for the co-
regulation.
BAS1 contains an amino-terminal region similar
to that of Myb proteins, and BAS2 contains a homeo
box. The Myb domain is the DNA-binding domain
for BAS1, and the homeo box region is the DNA-
binding domain for BAS2. The Myb motif was first
identified in the v-myb gene of avian myeloblastosis
virus. Cellular homologs of v-myb were then found in
all vertebrates. In addition, Myb-type proteins have
been found in Drosophila and corn (C1). The Myb
motif contains three repeats of a sequence whose
most striking feature is three regularly spaced tryp-
tophans. The binding sites of these factors to the
HIS4 promoter are shown in Figure 1.
Basel level transcription of the HIS4 gene re-
quires both BAS1 and BAS2. Either protein alone,
even when overexpressed, can only poorly activate
HIS4 transcription (at 1/100th the level of when both
BAS1 and BAS2 are present). Since BAS1 and BAS2
do not bind cooperatively to the HIS4 promoter, the
nature of the requirement for both BAS1 and BAS2
for basal level HIS4 transcription remains to be
determined. In addition to activation of HIS4 tran-
scription, BAS2 is required to activate the transcrip-
tion of the secreted acid phosphatases (the major
secreted acid phosphatase is encoded by the PHO5
gene). However, BAS1 has no role in the activation
of the transcription of the secreted acid phosphatases.
In the next year, we would like to determine if BAS2
requires a second DNA-binding protein (to take the
place of BAS1) for activation of the secreted acid
phosphatases.
BAS1, BAS2, and GCN4 are the three activation
proteins for HIS4 transcription. In strains deleted for
all three proteins, HIS4 transcription is extremely low
and the strains are His-. However, as measured by
gel-shift assays using total yeast extracts, these three
activator proteins represent only a very small fraction
of the binding activity to the HIS4 promoter. The
major HIS4 promoter-binding activity is due to the
RAP1 protein, which binds to the HIS4 promoter as
shown in Figure 1. In the absence of GCN4, BAS1,
and BAS2, YNF1 is not able to activate HIS4 tran-
scription. In addition, the binding sites for YNF1 and
GCN4 overlap; GCN4 binds much tighter to the mid-
dle repeat element than to the other four repeat ele-
ments, and most GCN4-dependent transcription oc-
FIGURE 1 The HIS4 promoter and its binding factors.
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curs through the middle repeat sequence. In vitro
DNA-binding studies show that GCN4 and YNFI
bind completely to their respective sites.
We have determined that YNF1 is the same
protein as RAP1. RAP1 (which is probably the same
as GRF1-TUF) is an abundant DNA-binding protein
in yeast that binds to silencers, telomeres, and the
promoters of many of the genes encoding ribosomal
proteins and glycolytic enzymes. In addition, most of
the RAP1 protein is found associated with the nuclear
matrix or scaffold. The binding of RAP1 to the HIS4
promoter is somewhat unexpected, since it was
believed that RAP1 by itself is a transcriptional ac-
tivation protein. In the context of the HIS4 promoter,
RAP1 cannot activate transcription by itself, since a
strain lacking GCN4, BAS1, and BAS2 has extreme-
ly low levels of HIS4 transcription. We have prepared
a set of isogenic strains that differ only by point
mutations in the chromosomal HIS4 promoter. These
mutations eliminate building of RAP1, GCN4, or
both proteins. Using these strains, we have found that
RAPT is required for BAS1/BAS2-dependent activa-
tion of HIS4 Basel level transcription. The RAP1-
binding site overlaps with the single high affinity
HIS4 GCN4-binding site. Even though RAPT and
GCN4 bind competitively, RAP1 is required for (1)
steady-state levels of GCN4-dependent
HIS4 transcription under nonstarvation conditions
and (2) the rapid increases in GCN4-dependent
steady-state HIS4 mRNA levels following amino acid
starvation. The presence of the RAP1-binding site in
the HIS4 promoter causes a dramatic increase in the
micrococcal nuclease sensitivity of two adjacent
regions within HIS4 chromatin: one region contains
the high-affinity GCN4-binding site and the other
region contains the BAS1- and BAS2-binding sites.
These results suggest that RAP1 functions at HIS4 by
increasing the accessibility of GCN4, BAS1, and
BAS2 to their respective binding sites when these
sites are present within chromatin.
A Genetic Selection for General
Transcription Factors
C. Devlin
When the levels of HIS4 transcription are quantitated
by assaying the levels of P-galactosidase from a
HIS4-lacZ fusion, a wild-type strain gives about 400
units of activity, whereas a strain containing deletions
182
of the GCN4, BAS1, and BAS2 genes gives less than
one unit of activity. As a result, a strain deleted for
the three activators of H1S4 transcription is His'. We
have reverted this strain to His with the assumption
that mutations in genes encoding general transcrip-
tional factors could result in increased HIS4 tran-
scription. This reversion analysis has identified five
suppressor genes that permit HIS4 transcription in the
absence of GCN4, BAS1, and BAS2. We have
termed these suppressors sit genes for suppressors of
initiation of transcription. These suppressor genes en-
code factors that affect the transcription of many
diverse genes. Two of the suppressors, SIT] and
SIT2, are encoded by RPB1 and RPB2, the genes for
the two largest subunits of RNA polymerase II. All
strains containing suppressor mutations in RPBI and
RPB2 have reduced transcription of the INO1 gene
and an inositol requirement. Mutations in SIT3 or
high-copy-number SIT3 increase HIS4 transcription
in the absence of GCN4, BAS1, and BAS2. SIT3 is
the only suppressor that suppresses when the wild-
type gene is present in high copy number. The in-
crease in HIS4 transcription by high-copy-number
SIT3 or by sit3 alleles is largely independent of the
HIS4 TATA sequence. We sequenced the SIT3 gene
and found that it is identical to GCR1, a gene pre-
as being required for high-level
transcription of almost all glycolytic enzymes (whose
combined mRNAs constitute over 50% of the mRNA
in a yeast cell).
The SIT4 protein is over 50% identical to the
catalytic subunit of bovine type-2A protein phos-
phatase. The analysis of SIT4 is discussed below. We
have recently identified a new sit complementation
group that we call sit5. DNA sequence analysis of the
SITS clone and genetic analysis have shown that sit5
mutations are mutations in the histone H2At gene.
Experiments with the sit5 mutations show the follow-
ing: (1) At permissive temperatures, the sit5 muta-
tions cause a slow growth defect (doubling time of
about 5 hr). This was surprising because deletion of
the histone H2At gene causes only a slight to moder-
ate growth defect. (2) The sits mutations cause a
rapid (within 2 hr) and reversible temperature-
sensitive growth defect at 38.4°C. At the non-
permissive temperature, the cells arrest with about
50% large budded cells. Again, this result is surpris-
ing since deletion of the histone H2A1 gene does not
result in temperature sensitivity. (3) Deletion or over-
production of the histone 2A-2B dimer does not pro-
mote HIS4 transcription in the absence of GCN4,
BAS1, and BAS2. This lack of suppression of the ab-
sence of GCN4, BAS1, and BAS2 is in contrast to
the ability of altered histone 2A and 2B gene dosage
to suppress Ty element insertion into the HIS4
promoter. (4) That the sit5 mutants require RAP1 to
promote transcription of HIS4 suggests that H2At
may interact with RAP1. In the future, we will
determine if sits mutations alter the nucleosome
positioning at the HIS4 promoter and at other
chromosomal locations. We will also determine the
sequence alteration(s) in the two sit5 alleles to see if
both alleles alter a specific region of the H2A1
protein. This information may be useful for experi-
ments to investigate specific interactions between
RAP1 and H2At.
Progression from G1 to S Phase
Requires the SIT4 Protein
Phosphatase
A. Sutton
Regulation of the cell cycle, most importantly the de-
cision of whether or not to initiate a new cycle, is a
major determinant of cell proliferation. For the yeast
Saccharomyces, cells that are nutritionally starved
(such as by limiting an essential nutrient in the
growth medium) or cells in a saturated culture arrest
in Gt. Cells that have arrested at this point in G1 are
in a physiological state distinct from Gt cells in ac-
tively growing cultures. In general, cells initiate a
new cycle only when they will be able to complete
the entire cycle.
Much of what is known about regulation of the
cell cycle comes from strains containing conditional
mutations that arrest in Gi at the nonpermissive
temperature. Strains containing cdc19, cdc25, or
cdc35 (adenylate cyclase) arrest in GI at what seems
to be close to the nutritional arrest point (unbudded
uninucleate Gt cells with no spindle pole satellites).
Conditional mutations in the CDC28 gene, which en-
codes a protein kinase, cause arrest in Gt as un-
budded uninucleate Gt cells containing spindle poles
with a satellite structure. This Gt arrest point in
cdc28 mutants has been operationally defined as
START. Supposedly, if a normal cell passes START,
it is committed to completion of the cycle.
The SIT4 protein phosphatase was originally
identified in S. cerevisiae by mutations (sit4) that re-
store transcription to the HIS4 gene in the absence of
GCN4, BAS1, and BAS2. GCN4, BAS1, and BAS2
are trans-acting DNA-binding factors that are
normally required for HIS4 transcription. These sit4
mutations cause alterations in the transcription of
many diverse genes in addition to HIS4. Strains con-
taining transcriptional suppressor sit4 mutations grow
very slowly, are temperature-sensitive for growth,
and do not grow on nonfermentable carbon sources.
The SIT4 gene encodes a predicted protein of 35.5
kD that is 55% identical to the catalytic subunit of
mammalian type-2A PPases and 40% identical to the
catalytic subunit of mammalian type-1 PPases.
When strains containing the sit4 mutations are
shifted to the nonpermissive temperature, 85-90% of
the cells give a first cycle arrest as large unbudded
uninucleate cells with a single microtubule organiz-
ing center. Arrested sit4 cells have a 1n DNA content
as determined by flow cytometry analysis. Electron
microscopic analysis of serial sections of these ar-
rested cells shows a single unduplicated spindle pole
body. Although we could not determine if the single
spindle pole body had formed a satellite structure,
reciprocal shift experiments showed that strains con-
taining temperature-sensitive mutations in sit4 arrest
late in Gt at or very close to START.
SIT4 associates with two high-molecular-weight
phosphoproteins. For immunoprecipitation analysis,
the SIT4 protein was tagged with a nine-amino-acid
epitope for which a high-affinity monoclonal
antibody is available (12CA5). Two proteins, with
apparent molecular weights of 155,000 and 190,000,
specifically coimmunoprecipitate with SIT4. Im-
munoprecipitation of extracts prepared from cells
labeled with [32P]orthophosphate shows that both
p155 and p190 are phosphorylated in vivo. In con-
trast, SIT4 is not detectably phosphorylated in vivo.
Western analysis of extracts prepared from cells syn-
chronized by either a-factor or centrifugal elutriation
shows that the steady-state levels of SIT4 do not vary
in the cell cycle. In contrast, the association of SIT4
with p155 and p190 is regulated in the cell cycle. To
obtain uniformly labeled cells from different stages
of the cell cycle, yeast cells containing the epitope-
tagged SIT4 protein were grown in the presence of
[35S]methionine and then subjected to centrifugal
elutriation. Extracts were prepared from fractions
containing cells at different stages of the cell cycle.
Immunoprecipitation of SIT4 from extracts prepared
from cells in the later stages of the cell cycle contain
both p155 and p190. In contrast, p155 and p190 are
not detectable when SIT4 is immunoprecipitated
from extracts prepared from Gt cells. At about the
time of the GI to S phase transition, SIT4 abruptly as-
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sociates with p155 and p190. We are currently using
a variety of genetic approaches to identify the genes
that encode p155 and p190 (see below).
SSD1: A Polymorphic Gene That in
Some Forms Can Permit Strains with
a Deletion of SIT4 to Live
A. Sutton
A deletion of the SIT4 gene in laboratory strain W303
is lethal, and it is in this strain background that our
analysis of the role of SIT4 in the cell cycle was
carried out. Surprisingly, we have found that a dele-
tion of SIT4 in about one half of our laboratory
strains is not lethal, although the cells grow extreme-
ly slowly. Genetic analysis showed that the ability to
grow very slowly in the absence of SIT4 segregates
as a single genetic locus, unlinked to SIT4. We have
cloned the gene that allows life in the absence of
SIT4 and term this gene SSD1 (suppressor of SIT4
deletion). Although the function of SSD1 is not cur-
rently known, a variety of data implicate SSD1 in G,
control. First, the SSD1 gene has been independently
isolated in two other laboratories, one as a suppressor
of mutations that result in increased kinase activity of
the RAS/cAMP pathway and another as a suppressor
of an as yet unidentified (not sit4) mutation that
causes a block in the G, to S transition. Second, we
have found that strains containing a deletion of SSD1
have a Whi phenotype and are hypersensitive to caf-
feine. Interestingly, SSD1 has significant homology
with the S. pombe dis3 gene. Cold-sensitive muta-
tions in dis3 cause mitotic arrest and result in similar
phenotypes to mutations in dis2. The dis2 gene en-
codes a type-1 phosphatase. One model for the func-
tion of SSD1 is that it is a positive regulatory factor
for SIT4 or a related phosphatase that targets the
phosphatase to its substrate at a precise point in the
cell cycle. The possibility that SSD1 coimmuno-
precipitates with SIT4 is currently under investiga-
tion.
Isolation and Characterization of
Suppressors of Mutations in SIT4
A. Sutton
We are also investigating the role of SIT4 in progres-
sion from G, into S phase using genetic approaches.
184
Hopefully, these approaches will identify substrates
of SIT4 or regulators of SIT4 activity. One approach
to SIT4 function is to obtain second-site suppressors
of the temperature-sensitive-arrest phenotype of sit4
strains. This analysis has identified three different
complementation groups, which we call stsl through
sts3. At permissive temperatures, stsl mutants (in a
wild-type SIT4 background) have an unusual mor-
phology; cells are rod-shaped rather than round and
form multiple buds. Furthermore, like strains contain-
ing certain mutations in the RAS/cAMP pathway,
diploid strains containing the stsl mutation sporulate
on rich medium. Although the stsl mutation results in
temperature resistance in sit4 strains, strains contain-
ing stsl in a wild-type SIT4 background are tem-
perature-sensitive. Like stsl mutants, strains contain-
ing sts2 mutations grow slowly; however, the mor-
phology of these cells appears to be normal. Inter-
estingly, the presence of the sts2 mutations results in
the failure to germinate. The STS1 gene has recently
been cloned and sequence analysis is in progress.
Hopefully, the STS genes have identified important
G, control proteins that relate to SIT4 function. This
possibility will be determined by biochemical and ge-
netic analyses.
Serine/Threonine Protein
Phosphatases in S. cerevisiae
F. Lin
Recent studies have shown that protein phosphatases,
like protein kinases, play important and specific roles
in cellular regulation, including cell cycle control.
Four types of serine/threonine protein phosphatases,
PP1, PP2A, PP2B, and PP2C, are known from
biochemical analysis of mammalian cells. These
phosphatases were grouped into these classes by sub-
strate specificities, sensitivity to various inhibitors,
and cation requirements. The catalytic subunits of
PP1- and PP2A-type phosphatases are highly similar
and share about 50% sequence identity. S. cerevisiae
has a single PP1 phosphatase, two PP2A phos-
phatases, and the SIT4 phosphatase. Genetic analysis
shows that the two PP2A phosphatases have largely
overlapping functions. Deletion of either one of the
PP2A genes is viable but deletion of both genes
causes lethality. In addition, the PP1 and SIT4
phosphatases each provides essential functions for
yeast. A number of experiments implicate PP1
phosphatase in mitosis and glycogen regulation, SIT4
in transcription and Gi/S phase control, and PP2A in
regulation of activation of the CDC28 /cdc2 kinase.
However, each of these phosphatases probably has
many functions, some of which have yet to be identi-
fied.
Our focus is to investigate how these protein
phosphatases function in cellular regulation, especial-
ly on cell cycle control. Immunoprecipitation analysis
shows that PP1 interacts with at least eight proteins.
Experiments using mammalian cells show that a
major active form of PP1 is particulate and that the
association of the catalytic subunit with different
targeting subunits determines the in vivo specificity
of PP1. It is possible that PP1 of S. cerevisiae has
similar characteristics. Several different approaches
are in progress to define those PP1-targeting subunits
that are required for chromosome disjoining in
metaphase and regulation of glycogen synthesis.
Similar experiments are in progress with the two
yeast PP2A phosphatases. In addition, we are prepar-
ing hybrid proteins among PP1, SIT4, and PP2A
catalytic subunits to define which regions of each of
these very similar proteins confer uniqueness and
subunit association.
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ARABIDOPSIS SIGNAL TRANSDUCTION
AND FLOWER DEVELOPMENT
H. Ma H. Huang
A. Tag le
The research in our laboratory includes two areas of
plant biology, both of which are based on the work
that one us (H.M.) did with Dr. Martin Yanofsky,
when both were postdoctoral fellows in Dr. Elliot
Meyerowitz's laboratory at the California Institute of
Technology. The first area of research is a study of G
protein functions in plant signal transduction, starting
with isolated gene(s) coding for G protein subunits.
The second area is an analysis of genes involved in
flower morphogenesis; specifically, genes potentially
encoding transcription factors were isolated, and their
functions are now being tested using different ap-
proaches.
Plant cells respond to a large number of external
and internal stimuli, such as light, gravity, microbes,
and hormones. Little is known about the molecular
mechanisms of plant signal transduction pathways for
these responses. One approach to the understanding
of plant signaling processes is to study homologs of
proteins known to play important roles in signal
transduction in animals and simple eukaryotes, such
as G proteins. G proteins are members of a specific
family of guanine-nucleotide-binding regulatory pro-
teins that participate in a variety of eukaryotic signal-
ing processes, from yeasts to humans. These hetero-
trimeric proteins (a, (3, and y subunits) are associated
with the cytoplasmic side of cell membranes and
transmit signals from transmembrane receptors to ef-
fector proteins. These effector proteins in turn pro-
duce, often through a cascade of reactions, changes in
cellular metabolism. G protein a subunits bind
guanine nucleotides and have GTPase activity.
We believe that G proteins play important roles in
the signal transduction processes of plants, as they do
in other eukaryotic organisms. As a first step in test-
ing this hypothesis, we set out to isolate genes encod-
ing G proteins from Arabidopsis thaliana. To begin
with, we chose the genes coding for the a-subunits
because of their highly conserved short stretches of
amino acid sequences. Using polymerase chain reac-
tion (PCR) amplification and degenerate oligonucleo-
tides, a gene (GPA1) was isolated from A. thaliana
that encodes a G protein a subunit (Ma et al., Proc.
Natl. Acad. Sci. 87: 3821 [1990]). We are currently
characterizing GPA1 in several ways, attempting to
establish association of GPA1 with particular plant
signaling pathway(s). In addition, we are continuing
to look for other G protein genes in Arabidopsis.
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Expression of GPA1
Under Heterologous
Promoters
H. Ma, A. Tag le
Many G protein genes are known to be expressed in
specific cell types. Although GPAI is expressed in
several organs, flowers, stems, and leaves, all of
these share common cell types, for example, photo-
synthetic cells. It is possible that GPAI expression is
not constitutive, but rather in a subset of cells in these
organs. Although we will test this directly by per-
forming more detailed analysis of the GPAI expres-
sion pattern, we would also like to mis-express GPAI
under the control of heterologous promoters, e.g., the
cauliflower mosaic virus (CaMV) 35S and heat-
shock promoters (HSPs), to obtain clues about its
function. The constitutive CaMV 35S promoter will
direct increased GPAI expression in many cell types.
The elevated level of the GPAI gene product may
produce visible phenotypes. To achieve inducible ex-
pression, we would like to use HSPs. Constructs
fusing 35S and HSP to GPAI cDNA were made, and
they have been used in Agrobacterium-mediated
plant DNA transformations.
We are in the process of generating transgenic
plants, which will then first be analyzed for visible
phenotypes.
Construction and Analysis of
Mutant Alleles of GPA1
H. Huang, H. Ma
To test the function of GPAI, it would be very useful
to obtain mutations in the GPA1 gene. It is technical-
ly impractical to obtain chromosomal recessive muta-
tions in Arabidopsis, starting with a cloned gene.
However, for the G protein a-subunit, conserved
residues exist that can be altered and thus can lead to
dominant mutations. We have designed mutant
oligonucleotides and have generated four mutations
using PCR amplification and a GPAI cDNA. These
mutant gpal alleles have now been fused to 35S and
HSP and are in the process of being fused to the na-
tive GPAI promoter. We will soon introduce these
constructs into plants by transformation, and the
phenotypes of the transgenic plants will then be ex-
amined.
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In Search of New G Protein
Genes
H. Huang, H. Ma
We believe that Arabidopsis, like most other charac-
terized eukaryotes, has more than one gene coding
for the G protein a-subunit. We are using two ap-
proaches to isolate additional G protein genes. PCR
amplification was chosen as the main approach in or-
der to isolate as diverse a group of sequences as pos-
sible. We have performed a preliminary experiment,
and the sequences amplified include both GPAI and
additional sequences, some resembling G protein se-
quences. We will repeat the PCR experiment, and
then use new G-protein-like sequences as probes to
isolate cDNA and genomic clones. Low-stringency
hybridization was chosen as the second approach in
order to isolate sequences similar to GPAI. This ap-
proach is better for genes that are more homologous
to GPA1.
Floral Genes Potentially Encoding
Transcription Factors
H. Ma, A. Tagle
Flower morphogenesis is a complex developmental
process. Although flower development has been
studied for many years, very little is known about the
molecular machinery that controls the cellular differ-
entiation in developing flowers. In recent years, A.
thaliana has been used increasingly for plant mol-
ecular and genetic studies, and a number of Arab-
idopsis floral homeotic mutants have been character-
ized. Phenotypes of several homeotic mutants indi-
cate that they alter floral organ identities. One exam-
ple is AGAMOUS (AG). Previous genetic studies
(Bowman et al., Plant Cell 1 37 [1989]) indicate that
homozygous ag mutant plants produce double flow-
ers. Similar to wild-type flowers, ag mutant flowers
have four sepals, and four normal petals develop in
the outer two whorls (sets of similar floral organs);
on the other hand, ag mutant flowers have six addi-
tional petals occupying the third whorl, which are
stamens in the wild type. In addition, a new flower
appears in the position occupied in wild type by the
ovary. The pattern of four sepals surrounding ten (4 +
6) petals repeats until the whole flower has about 70
organs. The AG gene has been recently cloned
(Yanofsky et al., Nature 346: 35 [1990]), and DNA
sequence analysis indicates that it encodes a protein
that shares striking similarity in its amino-terminal
portion with the DNA-binding domains of transcrip-
tion factors from humans (SRF) and yeast (MCM1),
suggesting that the AG protein is a transcription fac-
tor.
To coordinate the formation of floral organs at the
proper time and location, the process of flower devel-
opment is likely to require more regulatory genes
than those dozen or so genes defined by mutations. In
an effort to gain further understanding of Arabidopsis
flower development, six new genes were isolated that
share substantial sequence similarity with AG, in-
cluding the DNA-binding motif and additional amino
acid sequences (Ma et al., Genes Dev. 5: 484
[1991]). They were designated AGL1 through AGL6
for AG-Like. Five of the new genes were found to be
preferentially expressed in flowers, and one of them
is also expressed in stems and leaves. In situ RNA
hybridizations showed that AGLI and AGL2 are ex-
pressed in specific floral organs. We are continuing
the characterization of the AG and AGL genes.
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INITIATION AND TERMINATION OF TRANSCRIPTION IN
HUMAN SNRNA GENES AND HIV-1
N. Hernandez M. Cockerill R. Ratnasabapathy
S. 'fill M. Sheldon
L. Johal M.L. Sullivan
S. Lobo
SMALL NUCLEAR RNA GENES
The human small nuclear RNA (snRNA) genes U2
and U6 are part of a growing family of genes that
share two characteristics: They have similar tran-
scriptional control elements, and they encode short
RNA molecules whose roles, in the cases where they
are known, are in the processing of other RNA
molecules. Therefore, by analogy to messenger
(m)RNAs and transfer (t)RNAs, whose names refer
to their function, we refer to the RNAs encoded by
this gene family as "processor RNAs" or "pRNAs,"
and to the genes as the "pRNA genes." Table 1 lists
the vertebrate pRNA genes that have been cloned to
date. Surprisingly, as indicated in Table 1, some of
the pRNA genes (e.g., the U2 snRNA gene) are tran-
scribed by RNA polymerase II, whereas others (e.g.,
the U6 snRNA gene) are transcribed by RNA poly-
merase III. As a result, the RNA polymerase II and
III pRNA promoters are more similar to each other
than to either the RNA polymerase II mRNA-type
promoters or the gene internal RNA polymerase III
promoters of tRNA and 5S genes.
The structures of the RNA polymerase II and III
pRNA promoters are shown in Figure 1. The RNA
polymerase II pRNA promoters consist of a proximal
element and an enhancer characterized by the
presence of an octamer motif. In addition, a "3 'box"
located 3' of the gene directs termination of tran-
scription. Remarkably, the 3 ' box is recognized as a
termination signal only when transcription is initiated
at RNA polymerase II pRNA promoters, suggesting
that these promoters direct the formation of transcrip-
tion complexes that are different from those directed
by mRNA promoters. The RNA polymerase III
pRNA promoters are nearly identical to the RNA
polymerase II pRNA promoters. They also contain a
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TABLE 1 Cloned pRNA Genes with an Octamer/PSE Promoter Structure
Genes
RNA
polymerase Organisms Function of the RNP RNA length'
U1 II H, M, R, C, X mRNA splicing 164
U2 II H, M, R, C, X mRNA splicing 187-188
U3 II H, R rRNA processing 214-217
U4 II H, C mRNA splicing 141-145
U5 II X mRNA splicing 116
U11 II? H polyadenylation? 135
HSUR1 II? Hs unknown 143
HSUR2 II? Hs unknown 115
HSUR3 II? Hs unknown 76
HSUR4 II? Hs unknown 106
HSUR5 II? Hs unknown 115
U6 III H, M, X mRNA splicing 106-107
7SK III H unknown 330-332
H1 Ill H tRNA 5' processing 341-344
MRP/Th III H, M RNA primer cleavag
in mitochondrial DNA
synthesis
265-275
hY1 H unknown 111-112
hY3 H unknown 100-101
H, human, M, mouse; R, rat, C, chicken; X, Xenopus; Hs, herpesvirus saimiri.
The lengths indicated do not include the cap.
proximal element and an enhancer with an octamer
motif. In fact, both of these elements have been
shown to be interchangeable between RNA poly-
merase II and III pRNA promoters. However, the
RNA polymerase III pRNA promoters also contain
an A/T box, which is reminiscent of the TATA box
of mRNA promoters. Surprisingly, in the human U6
gene, the A/T box is a dominant element that
ATGCAAAT
or
ATTTGCAT
Pol
DSE
-220
determines the RNA polymerase III specificity of the
promoter. When the A/T box is mutated, the U6 pro-
moter switches to RNA polymerase II, whereas
the A/T box is introduced into the U2 promoter, the
U2 promoter becomes a predominantly RNA poly-
merase III promoter. Thus, the U2 and U6 genes con-
stitute an ideal model system to study the mechan-
isms for RNA polymerase selection by promoter se-
TCACCNTNANT,NNAAAGAT, GTTN1-4 AANA1NAGA
3' BOXPSE
-45
GOCTTTATAATA
Pol I-->TTT TT
A/T BOX
I
-220
-50 -25
FIGURE 1 Structures of the RNA polymerase II and III pRNA promoters.
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quences. In addition, the RNA polymerase II pRNA
genes represent rare examples where the site of
termination by RNA polymerase II is known and
where the cis-acting elements required for the reac-
tion have been characterized in detail. Both of these
characteristics make the RNA polymerase II and III
pRNA genes attractive transcription units to study
transcriptional mechanisms.
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
Expression of the human immunodeficiency virus
type-1 (HIV-1) promoter is regulated by a complex
combination of cellular and viral factors. These in-
clude Tat, a potent viral trans-activator that functions
at least in part by increasing the amounts of HIV-1
mRNAs at the level of transcription. Tat affects both
initiation and elongation of transcription, although
some assays detect only the effect on elongation. Tat
is unusual in that it acts through an RNA element, the
trans-activation response (TAR) element, encoded by
sequences downstream from the HIV-1 initiation site,
between nucleotides +18 and +44. The TAR element
corresponds to the upper half of a buldged stem-and-
loop structure that extends from nucleotide +1 to
+59.
In transfection experiments, constructs that con-
tain the HIV-1 promoter and downstream sequences
to position +80 direct the synthesis of a large amount
of short transcripts that encompass the secondary
structure from +1 to +59. In the presence of Tat, the
number of short transcripts diminishes, and the num-
ber of long transcripts extending through the entire
HIV-1 transcription unit increases. A few years ago,
this observation prompted the suggestion that Tat
functions as an antiterminator that overcomes a block
to transcription elongation located around position
+59. However, in other experimental systems, the
number of short transcripts derived from the HIV-1
promoter in the absence of Tat is low, and coexpres-
sion of Tat does not decrease the number of short
transcripts but only increases the number of RNA
molecules extending through the entire transcription
unit, suggesting that in this case, Tat acts mainly on
initiation rather than elongation of transcription. In
addition, there is clearly no universal termination site
around position +60, because deletion of this region
or its insertion into other transcription units does not
have any positive or negative effect on gene expres-
sion as measured by chloramphenicol acetyltrans-
ferase (CAT) assays. We are interested in determin-
ing the mechanisms of short transcript formation, the
role of the short transcripts, and the link, if any, be-
tween short transcript formation and trans-activation
by Tat.
Factors Involved in Transcription
of the Human U6 Gene
S. Lobo, M. Cockerill, S. 'fill, M. Sullivan,
N. Hernandez
In the past few years, the cis-acting elements
responsible for transcription of the human U2 gene
by RNA polymerase II and the human U6 gene by
RNA polymerase III have been precisely defined. We
are now in the process of identifying and purifying
the trans-acting factors involved in transcription of
the U6 gene by RNA polymerase III. A crude nuclear
Dignam extract was fractionated over a P11 column
into four fractions: TFIIIA (flow-through), TFIIIB
(350 mM KC1), TFIIIC (600 mM KCI), and TFIID (1
M KCI). The TFIIIA fraction contains a factor that
binds to the internal promoter element of the 5S gene,
the TFIIIB fraction is required for transcription of
every RNA polymerase III gene tested to date, and
the TFIIIC factors bind to the internal B and A boxes
of tRNA-type genes, as well as to the TFIIIA -5S
gene complex. The TFIID fraction is required for
transcription of mRNA encoding genes by RNA
polymerase II and contains a 38-kD TATA-box-
binding factor referred to as TFIID. In yeast, TFIIIB
is a key transcription factor for 5S and tRNA gene
transcription by RNA polymerase III. TFIIB is
thought to allow promoter recognition by RNA
polymerase III, whereas TFIIIA and TFIIIC are as-
sembly factors whose only role is to promote binding
of TFIIIB to the DNA.
We found that the TFIIIA fraction stimulated, but
was not essential for, U6 transcription. U6 transcrip-
tion could be reconstituted by a combination of either
the TFIIIB and TFIIIC fractions or the TFIIIB and
TFIID fractions. Consequently, in later experiments,
we eluted the column with 350 mM KCl and with 1 M
KC1 to obtain a TFIIIB fraction and a TFIIIC/TFIID
fraction. The activity required for U6 transcription in
the TFIIIC/TFIID fraction seemed to consist of a
single factor, because it doted in a single peak from
several chromatography columns. We therefore
tested whether it might correspond to the cloned 38-
kD TATA-box-binding factor TFIID by substituting
human TFIID made in Escherichia coli for the
TFIIIC/TFIID fraction. Whereas the TFIIIB fraction
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alone did not sustain U6 transcription, addition of in-
creasing amounts of bacterially produced human
TFIID resulted in increasing levels of U6 transcrip-
tion. This transcription was dependent on the A/T
box, was directed by RNA polymerase III, and was
initiated at precisely the same site as U6 transcription
in vivo. These results demonstrate that the cloned
TFIID polypeptide is capable of directing in vitro
transcription of the U6 gene by RNA polymerase III
and suggest that it may play the same role in vivo.
Figure 2 shows a hypothetical cartoon of the hu-
man U2 and U6 transcription complexes. We imagine
that the minimal U2 transcription complex consists of
Oct-1, one or several factors binding to the proximal
element, and RNA polymerase II, which may contact
the U2 promoter downstream from the proximal ele-
ment with relaxed sequence specificity. In the wild-
type promoter, Spl also binds to the enhancer, but the
Spl-binding site can be replaced by a binding site for
another factor, indicating that Spl per se is not an es-
sential component of the U2 transcription complex.
The minimal U6 transcription complex may contain
similar if not identical enhancer and proximal ele-
ment binding proteins. However, downstream from
the proximal element, the A/T box binds the TFIID
38-kD protein. TFIID is shown interacting with the
proximal element binding factor, because the distance
between the proximal element and the A/T box is
strictly conserved in the human RNA polymerase III
pRNA genes. Furthermore, increasing the spacing be-
tween the proximal element and the A/T box is
detrimental for RNA polymerase III transcription
both in the Xenopus U6 promoter and in plant snRNA
promoters. Perhaps in combination, the TFIID
protein and the proximal element binding factor(s)
create a surface that can bind TFIIIB and mediate its
interaction with the DNA, thus defining the U6
promoter as an RNA polymerase III promoter. As il-
lustrated in the last panel of Figure 2, in other RNA
polymerase III promoters such as tRNA promoters,
this role may be played by the TFIIIC factors, which
bind the B and A internal promoter elements.
The observation that TFIID can direct U6 tran-
scription by RNA polymerase III raises the question
of whether it is also involved in transcription of other
RNA polymerase III genes. Several RNA polymerase
III genes contain A/T-rich regions in their 5 ' -flank-
ing sequences that are required for efficient transcrip-
tion. In addition, we have shown by Western blots
that the TFIIIC fraction contains the TFIID 38-kD
polypeptide. The TFIIIC fraction can be further
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FIGURE 2 Hypothetical cartoon of the human U2 and U6
transcription complexes.
divided into two fractions, TFIIIC1 and TFIIIC2, that
are both required for transcription of tRNA-type
genes by RNA polymerase III. TFIIIC2 has been
purified to five polypetides that may all be required
for activity, but the active components of the TFIIIC1
fraction have not been identified and may well in-
clude TFIID.
We will now pursue several questions. We will
determine whether the TFIID domains required for
RNA polymerase III transcription are identical to
those required for RNA polymerase II transcription.
We are also pursuing the purification of the factors
required for U6 transcription present in the TFIIIB
fraction.
Formation of Short RNAs by
the HIV-1 LTR
R. Ratnasabapathy, M. Sheldon, L. Johal, N. Hernandez
In the human RNA polymerase II snRNA genes,
termination of transcription is dependent on tran-
scription initiating at an snRNA promoter. To
determine the sequence requirements for formation of
short transcripts, we generated several constructs in
which either the HIV-1 promoter sequences or the se-
quences downstream from the transcriptional start
site were replaced by foreign sequences. Formation
of short transcripts was monitored in transient trans-
fection experiments.
PROMOTER SEQUENCES ARE NOT REQUIRED
FOR THE FORMATION OF SHORT TRANSCRIPTS
NOR FOR TAT TRANS-ACTIVATION
To determine the mechanisms of short transcript
formation in the HIV-1 long terminal repeat (LTR),
we first examined whether short transcript formation
was dependent on promoter sequences. We ex-
changed the HIV-1 promoter for a variety of other
promoters, including two promoters from mRNA en-
coding genes, the U2 promoter and the U6 promoter.
All of these constructs directed the synthesis of a
large amount of short transcripts in the absence of
Tat. In the presence of Tat, the number of short tran-
scripts was diminished, whereas the number of long
transcripts was greatly increased. The sole exception
was the construct containing the U6 promoter, whose
expression was not affected by Tat. These experi-
ments showed that several different RNA polymerase
II promoters can be trans-activated by Tat and that
short transcript formation is not dependent on pro-
moter sequences
THE HIV-1 SEQUENCES FROM -5 to +82 CONTAIN
AN INDUCER OF SHORT TRANSCRIPTS
We then replaced the HIV-1 sequences downstream
from the HIV-1 promoter (from -5 to +82) by foreign
sequences. In these constructs, no short transcripts
were formed as expected, but surprisingly, the num-
ber of long transcripts was not increased. Thus, in the
absence of the HIV-1 sequences from -5 to +82, the
total number of transcripts, short and long, derived
from the HIV-1 promoter and other promoters was
much lower than that in the presence of the -5 to +82
HIV-1 sequences. This suggested that these se-
quences contained an activator of transcription. To
demonstrate this directly, we performed run-on ex-
periments and showed that indeed this region could
activate transcription from different RNA polymerase
II promoters and even from the U6 RNA polymerase
III promoter. Thus, the -5 to +82 HIV-1 sequences
contain an unusual element: In its presence, the total
transcriptional activity of different promoters is
greatly increased, but all of the additional RNA
molecules resulting from this increase in transcription
are short. We therefore refer to this element as 1ST,
for inducer of short transcripts.
TAT CAN CHANGE ELONGATION PROPERTIES
OF AN ELONGATION COMPLEX
As mentioned in the introduction, the U2 snRNA
promoter directs the formation of peculiar transcrip-
tion complexes that are incapable of efficient elonga-
tion and terminate transcription at "3 ' boxes." To
determine whether Tat could affect elongation of
transcription, we tested the effects of Tat on tran-
scription from the U2 promoter. We generated a con-
struct that contained the U2 promoter followed by
HIV-1 sequences from -5 to +82, which include the
sequences encoding the TAR element. Just down-
stream from the HIV-1 sequences, we inserted a
3' box and further downstream, a polyadenylation
site. Thus, this construct contained three 3 ' -end
formation signals in a row: the putative signal for
formation of short transcripts, a 3' box, and a
polyadenylation site. In the absence of Tat, this con-
struct generated short transcripts as well as transcripts
that terminated at the 3' box. In the presence of Tat,
the number of short transcripts was reduced as ex-
pected, but the number of transcripts ending at the
3' box was not increased. Instead, a large number of
RNA molecules polyadenylated at the downstream
site were generated. Thus, in the presence of Tat, the
transcription complexes derived from the U2
promoter were capable of reading through a 3 ' box.
This suggests that Tat modifies the transcription com-
plexes derived from the U2 promoter and renders
them equivalent to transcription complexes derived
from mRNA promoters.
The discovery of the IST element and the obser-
vation that Tat can modify the elongation properties
of the U2 transcription complex suggest that the
HIV-1 promoter is capable of directing the formation
of two types of transcription complexes: one depen-
dent on IST and incapable of efficient elongation, and
the other dependent on TAR and Tat and capable of
efficient elongation. Perhaps because the total num-
ber of initiation events that can occur at the promoter
is limited, the effect of Tat can be perceived as an ef-
fect on transcription elongation or transcription initia-
tion, depending on the levels of IST activity: If IST
activity in the absence of Tat is high, Tat trans-
activation results in elongation-efficient transcription
complexes displacing some of the IST-directed tran-
scription complexes at the promoter, thus an apparent
effect on transcription elongation. If 1ST activity in
the absence of Tat is low, Tat trans-activation results
in an increase in the total number of transcription
complexes fired by the HIV-1 promoter, thus an ef-
fect on transcription initiation.
What is the role of 1ST, and what is the role of
short transcripts in HIV-1-infected cells? Because
Tat acts through an RNA target (TAR) encoded
downstream from the HIV-1 promoter, the HIV-1
promoter must be transcriptionally active to generate
TAR and be responsive to Tat. Perhaps the function
of IST is to generate the target for Tat trans-
activation in the absence of any viral gene expres-
sion. If this were the case, the ability of the HIV-1
LTR to generate short transcripts would allow an
otherwise silent and perhaps defective (Tat-) provirus
to respond to Tat provided by another provirus.
Alternatively, very high expression of short tran-
scripts might down-regulate Tat trans-activation. In-
deed, it has been shown that overexpression of TAR
sequences renders cells resistant to HIV-1 replication.
Thus, the short transcripts may be involved in
regulating the switch from latent to productive infec-
tion. The production of short transcripts may thus
define an intermediate stage between a completely
silent provirus and an actively expressed provirus.
Precise Mapping of the IST Element
in the HIV-1 LTR
M. Sheldon, R. Ratnasabapathy, N. Hernandez
1ST is located between positions -5 and +82 relative
to the start site of transcription in the HIV-1 LTR.
IST can be described as having two activities: On the
one hand, it activates transcription and, on the other
hand, it directs premature 3 ' -end formation of the
RNA molecules resulting from this activation of tran-
scription. The simplest model is that IST consists of a
single sequence element that activates the formation
of transcription complexes that, like the UI and U2
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transcription complexes, are not capable of efficient
elongation. The short transcripts would then represent
the final products of random termination, followed by
exonucleolytic degradation to the base of the stable
stem-and-loop structure that folds the first 59
nucleotides of the RNA. However, it is also possible
that IST consists of two distinct sequence elements,
an activator of transcription and a 3 ' -end formation
signal. These could be two DNA elements, a DNA
element and an RNA element, or even two RNA ele-
ments. Localizing the IST element is complicated by
the fact that mutations downstream from the start site
of transcription alter the sequence of the RNA and
thus may change its stability. In particular, the stem-
and-loop structure that folds the first 60 nucleotides
of the HIV-1 mRNAs may be required for stabiliza-
tion of the short transcripts.
To determine the precise location of the IST ele-
ment, we have generated a series of mutations in the
-5 to +82 region that maintain the base-paring in the
RNA secondary structure. We are in the process of
analyzing both steady-state RNA and nascent RNA
derived from these mutated constructs. This analysis
should define the exact nature and location of the IST
element.
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TELOMERASE AND TELOMERE LENGTH
C.W. Greider A.A. Avilion S. Kaplan
L.A. Harrington K.R. Prowse
We are studying the enzyme telomerase from
Tetrahymena in order to understand how telomeres
replicate and maintain their length. Telomerase
recognizes the 3' end of telomeric G-strand se-
quences and adds tandem repeats of the Tetrahymena
telomeric sequence, d(TTGGGG), in an apparently
template-independent manner. Thus, net lengthening
of telomeres allows telomere length to be maintained
since conventional replication would lead to loss of
sequences from chromosome ends at each round of
replication. Telomerase is a ribonucleoprotein com-
plex (RNP). We and other investigators have shown
that the essential RNA component provides the
template for the d(TTGGGG) repeats that the en-
zyme synthesizes.
TELOMERASE IS PROCESSIVE
We are pursuing the biochemical characterization of
this unusual DNA polymerase. Using primer chal-
lenge experiments, we have shown that telomerase
acts processively; i.e., once telomerase is bound to a
primer, many base pairs of d(TTGGGG) will be
synthesized before the enzyme dissociates. Telo-
merase was reacted in the presence of excess primer
under standard reaction conditions (1 um [32P]dGTP,
100 t,tm dTTP, 1 p.m Mg++, 10 um Tris, pH 8.0) for 5
minutes, and the reaction was then diluted 30-fold
into unlabeled dGTP, 100 pm dTTP, and a large ex-
cess of competitor primer d(TTGGGG)3 oligonu-
cleotide. The reaction was then allowed to proceed
for 5, 10, 15, 20, 30, 40, 60, or 90 minutes, and the
labeled products were run on an alkaline agarose gel
(Fig. 1). The increase in length of the products, even
after dilution into excess competitor oligonucleotide,
indicates that telomerase is processive.
Processivity is the probability that the enzyme
will dissociate from a given primer that is being
elongated. We define the processivity of telomerase
as the number of nucleotides synthesized when half
of the telomerase bound to primers has dissociated.
This value can be determined directly from the distri-
bution of labeled products in the alkaline agarose gel
(Fig. 1). We quantitated the distribution of counts in
the gel using the Phosphor-Imager (Molecular
Dynamics) and found that telomerase will synthesize
520 by before half of the enzyme has dissociated.
The average rate of primer elongation is about 80
nucleotides per minute. When compared to other
"conventional" polymerases, telomerase is a slow but
very processive enzyme.
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FIGURE 1 How processive is telomerase? Telomerase was
reacted for 3 min in the presence of 1321,1cIGTP, dTTP, and
excess primer d(TTGGGG)4 oligonucleotide. A portion was
stopped to determine the length obtained in the initial reac-
tion (lane 2), and a portion was diluted 30-fold into a mixture
containing unlabeled dGTP, dTTP, and excess primer
d(TTGGGG)4 oligonucleotide. The reaction was allowed to
proceed, and aliquots were removed after 5, 10, 15, 20, 30,
40, 60, and 90 min total reaction time (lanes 3- 1 0). A portion
of the initial reaction was allowed to proceed for 90 min
without dilution (lane //). The markers are the 1-kb ladder
from BRL (lanes 1 and 12). The 60-min sample was lost in
loading the gel (lane 9). The products were electrophoresed
on an alkaline agarose gel.
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Since the Tetrahymena telomerase acts pro-
cessively to synthesize, on average, 520 by before
dissociating, and the RNA template contains only 9
by of CAACCCCAA, there must be a translocation
step in the elongation mechanism. Telomerase reac-
tion products show a characteristic "pausing" pattern
on sequencing gels. To define at what position within
the repeat the translocation occurs, the banding pat-
tern produced by telomerase in vitro was analyzed.
Since the concentration of dTTP affects the pattern
produced, a titration of dTTP was carried out. To as-
sign sequence to the in vitro pattern, d(GGGGTT)3
was elongated in the presence of [35S]dGTP and
dideoxyTTP (ddTTP). Since ddTTP will be in-
corporated and cause chain termination, this experi-
ment defined the position of the first four added dGs
and a single ddT. Using this reaction as a reference,
the sequence added in the reactions using [35S]dGTP
and dTTP could be assigned (Fig. 2). The strong
TTGG5514 -3.-
,TTGGGG13
dTTP
ddTTP .01 01 1 10 100 1000
=WV
FIGURE 2 Pausing pattern. Telomerase was reacted under
standard conditions using [35S]dGTP, d(GGGGTT)3, and
various concentrations of unlabeled dTTP. The concentra-
tion of dTTP is shown above each lane. In lane 2, only
ddTTP was added to determine the sequence of the paus-
ing pattern. In lane 1, 32P-labeled 18-base d(TTGGGG)3
and 24-base d(TTGGGG)4 were run as markers.
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pause in the banding pattern that appears every six
bases occurs after addition of the first G residue
within the d(TTGGGG) repeat. The pause at this
position suggests that the entire 5 ' -CAACCCCAA-
3 ' RNA template is copied to the 5 ' -most C residue
and then translocation occurs. The pause after the ad-
dition of the first G residue would result if transloca-
tion were a slow step.
TELOMERASE PRIMER RECOGNITION
To gain a detailed understanding of the telomerase
enzyme mechanism, we asked whether d(TTGGGG)n
repeats are required at the 3' end of primer oligo-
nucleotides for recognition and elongation by telo-
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FIGURE 3 Telomerase elongation of telomeric and non-
telomeric olignucleotide substrates. Test oligonucleotides
are indicated above their respective two lanes. The left lane
in each set indicates the gel-purified, 5' 32P-end-labeled
oligonucleotide as a size marker for input primer. The right
lane represents oligonucleotide that has been incubated
with telomerase for 1 hr under standard reaction conditions.
The sequences of the oligonucleotides are shown in Fig. 4.
omerase. Earlier experiments showed that telomeric
sequence oligonucleotides are elongated and non-
telomeric oligonucleotides are not. Various oligo-
nucleotides containing different lengths of non-
telomeric sequence (pBR322 plasmid sequence) were
synthesized and tested for the ability to prime
d(TTGGGG)n addition in vitro. The results are
shown in Figure 3 and summarized in Figure 4. At
least two repeats of d(TTGGGG) are required at the
5 ' end of the primer oligonucleotide for recognition
and elongation by telomerase. However, the sequence
d(TTGGGGTTGGGG) can be followed by up to 24
bases of nontelomeric sequence on the 3' end and
still be elongated.
The results in Figures 3 and 4 also show that oli-
gonucleotides that have d(TTGGGG), or d(GGGG)
at their 3 ' end can be elongated. Since there is only
one short stretch of dG residues, these oligonu-
cleotides cannot form intramolecular G-G base-
paired structures. Structures containing G-G Hoog-
steen base pairs, or "G quartet" interactions, have
been postulated to play a role in recognition by
telomerase. Substitution of dG by deoxyinosine in
telomeric oligonucleotides renders them unable to
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form any intramolecular structures but does not affect
their ability to be elongated by telomerase (Hen-
derson et al., Biochemistry 29: 732 [1990]). These
results, in conjunction with our finding that
telomerase can efficiently elongate oligonucleotides
with only one or less than one d(TTGGGG) repeat at
the 3 ' end, suggest that such secondary structures are
not required for telomerase recognition.
It is possible that elongation of oligonucleotides
with nontelomeric 3 ' ends was due to exonucleolytic
degradation of telomeric sequences and subsequent
elongation. The results in Figure 3 suggested that this
was not the case, since the telomerase banding pat-
tern began above the position of the input primer
oligonucleotide. As a further control to show that
nontelomeric sequences were indeed retained on sub-
strate oligonucleotides, the primers in Figure 4 were
reacted with telomerase in the presence of radioac-
tively labeled dTTP and dideoxy GTP (ddGTP).
These end-labeled oligonucleotides were then sub-
jected to the dC-specific Maxam-Gilbert sequencing
reaction; 3 ' -end-labeled cleavage products of the ex-
pected lengths were observed, indicating that the
nontelomeric sequences were retained at the 3' end
Oligonucleotide
I TIGGGGTIGGGGTTGGGGTT-GGGG I
AGCCACTATCGACTACGCGATCAT
AGCCACTATCGACTACGCACOGGG I
AGCCACTATCGACTACGCITTGGGGI
AGCCACTATCGAITTGGGGTTGGGGI
AGccAcliTGGGGTIGGGGTTGGGGI
ITTGGGGITATCGACTACGCGATCAT
ITTGGGGTTGICAGCTACGCGATCAT
ITTGGGGTTGGGG ICTACGCGATCAT
I GGGGTTGGGGTTICTACGCGATCAT
ITTGGGGTTGGGGTTGGGGI
rriGGGG-FrGGGG I
ITTGGGGTTGGGG I
GATCAT
TATCGACTACGCGATCAT
Elongation
+ \ -
AGCCACTATCGACTACGCGATCAT
FIGURE 4 Sequences and names of telomeric and nontelomeric oligonucleotides.
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after telomerase elongation. These results confirmed
that telomerase was able to recognize and elongate
oligonucleotides that contained up to 24 bases of
nontelomeric sequence at the 3' end. Thus, hybridiza-
tion of the telomerase RNA to the 3 ' sequence of a
telomeric oligonucleotide is not required for primer
elongation. The primer recognition site of telomerase
may be functionally distinct from the site of addition
of d(TTGGGG). The ability of telomerase to elongate
nontelomeric sequence substrates suggests how this
enzyme might function in healing broken chromo-
somes and in new telomere formation in ciliates.
TELOMERES AND AGING
In addition to telomerase biochemistry, we are inter-
ested in how telomere length is maintained in vivo. In
a collaborative effort, we have found that as primary
human fibroblasts divide and undergo senescence in
culture, telomeric sequences are lost from
chromosome ends. The limited replicative capacity of
primary fibroblasts was well documented by Hayflick
and others in the 1960s (Hayflick et al., Exp. Cell.
Res. 25: 585 [1961]); however, the mechanism that
limits cellular life span is not yet known. Our data
suggest that telomere shortening may play some role
in cellular senescence. We have recently shown that
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telomere shortening occurs in vivo as well as in vitro.
Primary fibroblasts from older individuals have
shorter telomeres than those from younger individu-
als. Human sperm telomeres are several kilobases
longer than somatic cell telomeres (Cooke et al., Cold
Spring Harbor Symp. Quant. Biol. 51: 213 [1986]).
This, together with the telomere reduction seen with
age, suggests a simple model for telomere shortening:
Human telomerase is active only in the germ line
where telomeres are lengthened, and then telomerase
is shut off in the soma. The net loss of telomeric se-
quences may then occur in somatic tissue through in-
complete replication at each round of division. Ex-
periments are currently under way to determine
whether telomerase activity is present in the primary
fibroblasts where telomere shortening has been well
documented.
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STRUCTURE AND COMPUTATION
This section includes five laboratories interested in the detailed structural
properties of proteins and computational biology. It includes the laboratories of
Drs. Jim Pflugrath and John Anderson, who are interested in macromolecular
crystallography, and Dr. Rich Roberts, whose group has had a long-standing in-
terest in restriction enzymes and their associated methylases. Dr. Jeff Kuret
studies protein kinases, and his group has established a close collaboration with
Dr. Pflugrath's laboratory. The most recent addition to this section is Dr. Tom
Marr, who joined us in 1989 having been the lead designer of the GENBANK
Database at Los Alamos National Laboratory. Dr. Marr is building a group
devoted to computational biology, with particular emphasis on database applica-
tions. He is currently interacting extensively with Dr. David Beach's group to pro-
vide database support for the Schizosaccharomyces pombe genome mapping
project.
NUCLEIC ACID CHEMISTRY
R.J. Roberts A. Dubey
J. Earl-Hughes
S. Klein
S. Klimasauskas
C.-L. Lin
D. Macelis
C. Marcincuk
S. Mi
M. Miyahara
Purification and Characterization
of the Mspl Methylase
A. Dubey, M. Miyahara
The Mspl restriction-modification system recognizes
the sequence 5 ' -CCGG-3 ' . The complete system
has previously been cloned and sequenced (Lin et al.,
Nucleic Acids Res. 17: 3001 [19891). The methylase
gene has been further subcloned, placed downstream
from the pTac promoter in a pUC119 derivative, and
overexpressed in Escherichia coli strain RRI (B.
Mollet and R.J. Roberts, unpubl.). This recombinant
strain overproduces the MspI methylase to high
levels, causing aggregation of the protein to form in-
clusion bodies. These inclusion bodies are temper-
ature-sensitive. They are formed when the cells are
grown at 37°C but are not produced at 30°C. The ex-
tent of soluble protein present does not seem to vary
significantly at either temperature.
G. Otto
J. Posfai
D. Roberts
M. Wallace
Abundant proteins with apparent molecular
masses of 40 kD and 51 kD are present in the over-
expressing strain. Amino-terminal sequence analysis
of these two proteins shows that the 40-kD protein is
a truncated form of the MspI methylase, missing ex-
actly 40 amino acids from the amino terminus. The
new amino terminus is a methionine residue cor-
responding to the second AUG in the reading frame.
It is not known whether the carboxyl terminus is also
truncated. As confirmed by immuno-Western blot
analysis, it is the 51-kD species that is the bona fide
methylase, since only this form is present in the
original Moraxella species from which the gene was
cloned. Interestingly, polyclonal antibodies raised
against the Mspl methylase cross-react with m5C-
methylases of several other restriction-modification
systems. This is consistent with the existence of a
fundamental structural similarity among this family
of proteins.
A scheme has been developed to purify the Mspl
methylase to homogeneity from this overexpression
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system. This purification scheme includes treatment
of the cell lysate with protamine sulfate to remove
nucleic acids, followed by chromatography on
phosphocellulose and FPLC columns: Mono S and
Mono Q. Approximately 0.8 mg of pure protein per
gram of cells (wet weight) could be recovered.
While characterizing Mspl methylase-DNA inter-
actions, it was found that the enzyme can form a
stable complex with DNA, as judged from mobility
shift assays, either in the presence or in the absence
of the cofactor S-adenosylmethionine or its analog
sinefungin. A detailed functional and structural char-
acterization of this enzyme is under way. Crystalliza-
tion is being attempted in collaboration with Drs. X.
Cheng and J. Pflugrath (Macromolecular Crystal-
lography).
Additional studies have been aimed at preparing
mutants of the Mspl methylase that will be useful in
delineating the functions of the conserved regions
within all m5C-cytosine methylases. The main goal is
to find temperature-sensitive mutants that are defi-
cient in their ability to release from the DNA after in-
itial covalent bond formation. Such mutants would be
invaluable if our crystallization attempts are success-
ful.
Comparative Methods of
Sequence Analysis
G Otto
We are continuing our work on probabilistic methods
of comparative sequence analysis. The major focus is
on the comparison of protein sequences sharing a
common function. The goal of these comparisons is
to define significant sequence patterns that correlate
with and are predictive of function. In this context,
functions are taken to be specific ligand-binding ac-
tivities. The elements of the derived patterns are often
structurally relevant, tending to be those amino acids
in close contact with the bound ligand. There is a
large element of phylogenetic analysis in these meth-
ods. It has become clear that the best representation
of sequence similarities predictive of function is ac-
tually a phylogenetic tree of related sequence pat-
terns. A single, maximally inclusive pattern is just the
root of this larger tree. Beyond the pragmatic goal of
predicting protein function, it will be interesting to
examine the set of these pattern trees for similarities
198
that might reflect the evolution of protein diversity.
Our work on comparative methods involves a
number of mathematical issues. We departed from
standard comparative techniques by defining the
measure of similarity as the probability that an op-
timal alignment of sequences is due just to the ran-
dom matching between unrelated sequences. We pro-
posed a basic, empirical test that any probabilistic
measure must satisfy. An estimator of these probabil-
ities for pairwise comparisons was developed that
satisfied the test quite well. This measure has been
incorporated into a program for the comparison of
one sequence with a database. This measure has been
generalized to the case of multiple sequence com-
parisons, providing an estimate of the probability of a
given multiple alignment occurring among a random
set of proteins.
We have also developed a probabilistic measure
for the matching of consensus patterns with protein
sequences and have written a program that searches a
database for pattern matches of varying qualities.
However, many new developments are required for
this approach to achieve its full power.
The sheer volume of sequence data and the addi-
tional structure imposed on these data by biological
theory and experiments has generated considerable
interest among mathematicians and computer scien-
tists. It is also recognized that the measure of se-
quence similarity arises in many fields and is of gen-
eral scientific interest. We are beginning collabora-
tions with a number of these mathematical scientists
with the aim of developing a coherent interdisci-
plinary effort in the New York area.
Architecture of Cytosine-m5C
Methylases
S. Klimasauskas
One goal of our work is to identify the protein
domain(s) responsible for sequence-specific recogni-
tion of DNA by m5C-methylases. The experimental
approach is to construct hybrids between two
methylases that recognize different sequences. These
experiments employ the HpaII (recognition sequence:
5 ' -CmeCGG-3 ' ) and Hhal (recognition sequence:
5' -GmeCGC-3 ' ) DNA methylases that form part of
their respective restriction-modification systems. A
plasmid was constructed with the two methylase
genes in tandem and arranged in the same orientation
relative to transcription. The polymerase chain reac-
tion (PCR) was used to construct exact deletions
from the plasmid containing both methylase genes
such that the amino terminus of one methylase be-
comes joined to the corresponding carboxyl terminus
of the second methylase. These constructions take ad-
vantage of the conserved sequence motifs that are
present within the cytosine methylases so that the
boundaries in the hybrids are defined by the sequence
motifs. In each case, the overall architecture of the
methylase is maintained.
We have tested several constructs for their ability
to methylate plasmid DNAs in vivo as well as their
ability to induce an Mcr response using appropriate
tester strains. The majority of the hybrids tested were
able to induce an Mcr response in vivo, and yet no
methylation was detectable as judged from the
sensitivity of the plasmid DNAs to the corresponding
restriction enzymes. However, one hybrid that con-
tains the amino-terminal sequence of the HpaII
methylase up to the amino-terminal boundary of the
variable region, joined to a complementary fragment
containing the complete variable region and carboxyl
terminus of the Hhal methylase, is active in vivo.
This hybrid induces a strong Mcr response and leads
to partial methylation of the plasmid DNA. The
methylation induced by this hybrid gives low but
noticeable partial protection against the action of the
Hhal restriction enzyme but is completely sensitive
to cleavage by the Hpall restriction enzyme. The
plasmid encoding the hybrid methylase, like that en-
coding the parent Hhal methylase, is restricted by
McrB and is insensitive to McrA. These results show
that the new hybrid methylase has the specificity of
Hhal, as expected if the variable region encodes the
DNA recognition domain.
To increase the level of DNA methylation in vivo
and to obtain manageable amounts of proteins for in
vitro studies, we have overproduced the hybrid
proteins by subcloning corresponding constructs into
a pUHE25-2 vector that utilizes a T7-promoter-
driven lad-repressible expression system. Upon in-
duction, it leads to the synthesis of the hybrid
proteins in amounts above 10% of total soluble
proteins in the cell. In the case of the active hybrid
methylase described above, overexpression results in
an almost complete protection of the plasmid DNA in
vivo against the action of R. Hhal and no detectable
protection against RHpall. We have also prepared a
correponding overexpressing clone carrying the gene
for the wild-type HpaII methylase. This appears to be
a promising source of the methylase for large-scale
purification and protein crystallization experiments.
These experiments demonstrate that the tegion
responsible for sequence specificity in the monospe-
cific methylases lies in the carboxy-terminal half of
the molecule. To define the DNA recognition domain
more precisely as well as to obtain insight into the
flexibility with which active hybrids can be obtained,
we have prepared a series of reciprocal constructs
using the amino terminus of the Hhal methylase and
the carboxyl terminus of the HpaII methylase. We
have also prepared hybrids in which the variable
region, between conserved motifs VIII and IX, from
one methylase has been replaced exactly by the vari-
able region from a second methylase. These deriva-
tives have been made by using a different approach.
PCR-generated fragments containing the appropriate
portions of the genes to be fused are made in vitro
such that small overlaps are present that allow fusion
during the PCR. The resulting gene is cloned into
pUHE25-2 through appropriate restriction enzyme
sites. The level and specificity of methylase activity
of these hybrids are now under investigation using
the above techniques.
A New Method for the Analysis
of Global Sequence Similarities
J. Postai, R.J. Roberts
Similarity between protein sequences may reveal
structural, functional, or evolutionary relationships.
We have developed a new computer tool that helps to
discover and analyze similarities among multiple se-
quences. Most of the commonly used methods of se-
quence comparisons yield some numerical values
(such as the percentage of identities of aligned se-
quences or distances between sequences embedded
into a sequence space) that are intended to character-
ize the relationship between sequences. These values
are very limited in their scope. They cannot fully de-
scribe complex sequence relationships, nor can they
easily reveal how similarity changes along the se-
quences. The visualization of similarities by a dot
matrix is a method that can give a more full picture of
sequence relationships, but the method is not ap-
plicable for the comparison of multiple sequences.
The concept of our new approach is similar to that of
the dot matrix method in that common sequence fea-
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tures are presented to a human investigator who can
then manipulate visual representations of sequences.
The method is based on algorithms that we have
developed previously to detect regions of local
similarity among families of proteins. First, we ex-
plore the common elements of the sequence family
under analysis. We usually determine the set of
quasi-common amino acid triplets present in the fam-
ily of proteins under consideration. However, other
common sequence features, such as dipeptides or
segments with Dayhoff scores over a predetermined
threshold, can also be used in the analysis. We count
the number of common elements tied to every se-
quence position. The distribution of these common
elements, along the sequences, are then displayed on
the computer screen using bar graphs or histograms.
Horizontal lines represent the sequences and the
vertical bars show the number of common elements
at each position within the sequence (Fig. 1). Peaks
within the distribution represent the sites where con-
served regions are likely to be located. Segments that
lack common elements are likely to represent the
unique regions of each sequence. Sequences that
show few common elements are probably not true
members of the sequence family being investigated
and can be excluded from the further phases of analy-
sis.
Sequence segments where the dominant peaks of
the graphs occur can be delineated by the user, and
unique colors can be assigned to the sequence ele-
PHI3T
RHOUS
SPRI
HHAI
HPAII
HAEIII
ECORII
DCM
MSPI
DDEI
SINI
BSURI
BSPRI
. I
. .
.
IL 111.11.L.11.11. ..i
FIGURE 1 Sequences of several m5C-methylases are represented by horizontal lines, and vertical
bars indicate the number of common sequence elements present at each position within the se-
quence. The header contains the tools for manipulating the image. Six conserved blocks are identified
here. The order of the blocks is the same in all the sequences, and the distances between the blocks
have obvious regularity. A variable region in the carboxy-terminal half of the sequences is apparent,
and unique amino-terminal arms can be seen in some of the sequences.
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ments (triplets) represented. All sequence elements
contained within them are then repainted with the as-
signed color. This includes every occurrence of the
element throughout the sequence. If, for example, a
particular position matches to three common ele-
ments, two of which occur in a region assigned red,
and one in blue, the corresponding bar is painted red
up to the two thirds of its height, and the remaining
part will be painted blue. Identically colored seg-
ments indicate conserved regions. The heights of the
histograms give quantitative information about the
level of sequence conservation. Missing or swapped
colored segments point to deletions or to shuffled
domains. Elements that appear as common by chance
are effectively filtered out, because they either
remain noncolored or occur in segments where many
other colors also appear. The resulting image is easily
interpreted and can allow the investigator to gain
deep insight into the organization of the analyzed se-
quences. Importantly, the investigator can gain an un-
derstanding of the common elements present within
the whole family of sequences by a single glance at
the screen. This is very difficult to accomplish by
most conventional methods for multiple sequence
comparison.
An extensive set of image-manipulation tools are
integrated into the program to facilitate the creation
of color images and to boost their descriptive value.
Mouse-controlled buttons, menus, scrollbars, sliders,
etc., initiate the actions required by the investigator.
Preset palettes, color cycling, and foreground/back-
ground color flipping can help in the creation of
bright images. Subwindows allow the user to exam-
ine individual sequence blocks that are aligned on
selected colors and allow the display of the actual
common elements that led to the original peak.
This sequence analysis tool has been developed
for Sun workstations that have color monitors. The
programs are written in C, and the user interface (but-
tons, sliders, menus, mouse, etc.) and screen manipu-
lation take advantage of the Sun View library. Several
print options are available for Postscript printers.
Isolation of Mutants of Integration
Host Factor
D. Roberts
Integration host factor (IHF) is a site-specific DNA-
binding protein in E. coli that has been shown to play
a role both in regulation of gene expression and in
site-specific recombination. It is a heterodimer com-
posed of two homologous subunits, IHF-a and IHF-
13, each about 100 amino acids long. IHF binds DNA
by contacts in the minor groove (Craig and Nash,
Cell 39: 707 [1984]; Yang and Nash, Cell 57: 869
[1989]). Binding of IHF to DNA causes the DNA to
bend (Robertson and Nash, J. Biol. Chem. 263: 3554
[1988]; Prentki et al., EMBO J. 6: 2479 [1987]; Sten-
zel et al., Cell 49: 709 [1987]). We are interested in
learning more about the structure and function of
IHF, and as a first step, we have isolated new mutants
of IHF.
After mutagenesis of plasmids containing either
IHF-a or IHF-13, we isolated about 80 mutants of
IHF. These mutants were tested for IHF function in
five different genetic assays, involving five different
IHF-binding sites. Since IHF is homologous to the
bacterial histone-like protein HU, and the crystal
structure of HU has been determined (Tanaka et al.,
Nature 310: 376 [1984]; White et al., Proteins 5: 281
[1989]), the effects of the mutations can be inter-
preted with reference to the structure of HU. Of par-
ticular interest were 13 mutations that were defective
in some in vivo assays and functional in others. Five
of these mutations mapped to the putative DNA-
binding arm, and three of the mutations mapped to
the third a-helix. It has been proposed that the third
a-helix could make additional contacts with DNA to
facilitate or stabilize DNA bending, although this has
not been proven. Currently, work is continuing with
the mutants to measure directly the effects on DNA-
binding and site specificity. In addition, more
mutants are being generated. Three types of changes
are being made by site-specific mutagenesis. First,
mutations were found in the DNA-binding arm of
IHF-a but not IHF-(3. The same amino acid changes
are being made in IHF-13 to see if a similar phenotype
is observed. Second, additional mutations are being
made in the third a-helix to try to determine the role
of this region. Finally, since only the heterodimer
functions in vivo, hybrids are being made between
IHF-a and IHF-(3 to map the essential regions and to
understand the possible differential role of each sub-
unit.
Restriction Endonucleases
J. Earle-Hughes, S. Klein, D. Macelis, R.J. Roberts
The collection of type II restriction endonucleases
continues to grow, and more than 1700 enzymes have
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now been characterized; 172 different specificities
are known. During the last year, we have character-
ized 25 new enzymes as part of a continuing col-
laboration with I. Schildkraut and D. Comb (New
England BioLabs). Among these are several valuable
new specificities, including Pad from Pseudomonas
alcaligenes, which recognizes the octanucleotide se-
quence TTAATTAA. This brings the total number of
enzymes recognizing octanucleotide sequences to six.
These enzymes are especially useful for genome
mapping.
During the last year, much effort has gone into
the maintenance of the restriction enzyme database.
The ORACLE database management system is prov-
ing inadequate for many of our purposes, and a new
implementation under SYBASE is being written.
This will greatly increase the scope and utility of the
database and is expected to be on-line during the first
half of 1991. We have continued to expand our ser-
vice role to the molecular biology community by
providing specialized reports from the database that
will feed various computer programs. The user com-
munity continues to grow, and their needs will be
more adequately met from the SYBASE version of
the database.
PUBLICATIONS
Card, C.O., G.G Wilson, K. Weule, J. Hasapes, A. Kiss, and
R.J. Roberts 1990. Cloning and characterization of
the Hpall methylase gene. Nucleic Acids Res. 18:
1377-83.
Nelson, J.M., S.M. Miceli, M.P. Lechevalier, and R.J.
Roberts. 1990. Feel, a new type II restriction endo-
nuclease that recognizes the octanucleotide sequence
5' GGCCGGCC 3 ' . Nucleic Acids Res. 18: 2061-
2064.
Roberts, R.J. 1990. Restriction enzymes and their iso-
schizomers. Nucleic Acids Res. 18: (Suppl.)
2331-2365.
In Press, Submitted, and In Preparation
Dubey, A., B. Mollet, and R.J. Roberts. 1991. The purifica-
tion and characterization of the Mspl methylase. (In
preparation.)
Klimasauskas, S. and R.J. Roberts. 1991. Hybrid cytosine
methylases. (In preparation.)
Posfai J. and R.J. Roberts. 1991. Finding errors in DNA se-
quences. (Submitted.)
Roberts, R.J. 1991. Restriction enzymes and their iso-
schizomers. Nucleic Acids Res. 19: (in press).
Roberts, R.J. 1991. The Human Genome Project: A public
policy perspective. (In press.)
MACROMOLECULAR CRYSTALLOGRAPHY
J. Anderson
J.W. Pflugrath
E. Chang
X. Cheng
C.K. Cheung
F.-C. Chuan
R. Hsu
C.-S. Hung
J. Keller
C.-L. Lin
The primary goal of the Macromolecular Crystal-
lography group-to determine the structures of
biologically important proteins and nucleic acids to
atomic resolution to better understand their func-
tions-drew closer to realization in 1990. The year
saw significant progress in two projects: one on the
cAMP-dependent protein kinase from yeast and an-
other on the Pvull restriction endonuclease. More
details can be found in the individual sections below.
These developments have helped us to expand the
scientific personnel in our group significantly.
Several new researchers joined the laboratory in
1990, and several more are expected in 1991. We
therefore expect that in the coming months and years,
the group will become increasingly productive in our
investigations of the structures of kinases, DNA-
202
T. Malone
D. Milano
T. Sellati
binding proteins, oncogene products, and other mac-
romolecules.
Our studies are designed to benefit from and to
complement the genetic and biochemical experiments
performed by our own group and by other groups at
the laboratory and elsewhere. Together with these
data, the crystallographic structures we determine
will help us to understand the roles the macro-
molecules play in the normal day-to-day lives of
cells, as well as in afflictions such as cancer, AIDS,
and Alzheimer's disease.
We require well-formed crystals of the macro-
molecule being investigated. To grow crystals of a
useful size (>0.3 mm on a side), we need several mil-
ligrams of the highly purified macromolecule. This
does not guarantee that crystals can be produced, but
it is the minimal prerequisite before attempting to
crystallize the molecule. A major part of our
laboratory and time is devoted to producing and
purifying to crystallographic homogeneity the
proteins we are studying. When a suitable crystal is
obtained, it is placed in an intense X-ray beam small-
er than a pencil lead. The X-ray beams diffracted by
the crystal are measured on our area detector. We
must quantitate tens of thousands of these diffracted
beams from several dozen different crystals.
Fortunately, these experiments are computer control-
led, with much of the software written in-house. Only
after all the data are collected can we begin to con-
struct a three-dimensional model of the macro-
molecule-all the atoms and bonds-with the aid of
computer graphic tools.
Structural Studies of Pvull
Endonuclease and Its
Interaction with DNA
J. Anderson, F.-C. Chuan, J. Keller [in collaboration
with I. Schildkraut, New England BioLabs, and
R.M. Blumenthal, Medical College of Ohio]
We have cocrystallized the restriction endonuclease
from Proteus vulgaris, R.Pvull, with oligonucleotides
carrying its recognition sequence 5 ' -CAGCTG-3 ' .
The best crystals form with the 13-base-pair double-
stranded oligonucleotide shown in Figure 1. These
crystals are space group P23212, with unit cell
dimensions a = 95 A, b = 85 A, c = 48 A, and they
diffract to at least 2.8-A resolution. A screened
precession photograph of one plane of the diffraction
pattern is shown in Figure 2.
We have collected data sets from native cocrys-
tals and from isomorphous cocrystals grown with
TGACCAGCTGGTC native
CTGGTCGACCAGT
TGACCAGCTGGUC derivative 1
CUGGTCGACCAGT
UGACCAGCTGGTC derivative 2
CTGGTCGACCAGU
FIGURE 1 Sequences of the native and two derivative
oligonucleotides used in RPvull cocrystallization. The
recognition sequence is underlined. The single-base over-
hangs serve to stabilize the interactions between adjacent
protein-DNA complexes in the crystals. In the two derivative
sequences, U = 5-iododeoxyuridine.
FIGURE 2 µ = 15° precession photograph of the hOl
plane of the diffraction pattern of RPvull-DNA cocrystals.
The resolution at the edge of the circular region is 3.0 A. For
this picture, Cu Ka radiation of wavelength 1.5418 A was
used. Exposure was for 20 hr at 18°C. The crystal to film
distance was 100 mm.
heavy atom derivative-1 oligo (see Fig. 1). Isomor-
phous derivative crystals are necessary in order to
compute phases for the data. We are currently charac-
terizing cocrystals grown with derivative-2 oligo; the
preliminary indication is that these are also isomor-
phous. The heavy atoms for both derivatives are in-
troduced by covalent modification of the oligo, sub-
stituting an iodine atom for the methyl group of
thymine at certain positions in the sequence (see Fig.
1). This simplifies the task of locating the iodine
atoms, and hence of calculating the phases, because
we expect the conformation of the DNA in the crystal
to be similar to the well-known structure of B-DNA.
Once phases are determined, we will calculate an
electron density map and begin building a model of
the complex.
A more complete understanding of the enzymol-
ogy of RPvuII will require the structure of the un-
bound protein. Although we are now concentrating
on the crystals of the protein-DNA complex, we in-
tend to pursue the structure of free R.PvuII as well.
We have crystals of RPvuIl in the absence of DNA
that diffract to better than 2.5 A. We will prepare
heavy atom derivatives of these crystals in the con-
ventional way by soaking the crystals in various
heavy atom solutions. If the structure of the complex
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proceeds quickly enough, we may be able to use a
model of R-Pvull derived from it to calculate phases
for the unbound protein data, eliminating the need for
derivatization. Once structures for the complex and
the free protein are in hand, it should be relatively
easy to determine corresponding structures for
mutant proteins and DNAs given to us by our col-
laborators, using difference Fourier analysis. This set
of structures will provide much information about the
structure and enzymatic activity of R.PvuII.
Structural Studies of AP-1 Proteins
C.K. Cheung, F.-C. Chuan, J. Keller, E. Chang,
J. Anderson [in collaboration with T. Curran,
Roche Institute]
The protein products of the proto-oncogenes c-fos,
c-jun, and a number of related genes form a major
component of eukaryotic transcription factor AP-1
activity. Heterodimers of Fos-related and Jun-related
proteins, and homodimers of Jun-related proteins,
bind to DNA at AP-1 sites (5 ' -TGACTCA-3 ' ) in
the promoters of many genes. Once bound, they can
activate or repress transcription, depending on the
composition of the dimer and the context within
which it binds DNA. We have overexpressed Jun-
and Fos-related antigen FRA1 proteins from rat in
Escherichia coli in order to carry out X-ray crystal-
lographic studies of them and their complexes with
DNA.
We have purified the Jun protein to 98% homo-
geneity by using the following protocol. Full-length
Jun is found in the pellet of the bacterial lysate. The
pellet is dissolved in 6 ivt urea, and chromatography
on heparin-Sepharose is carried out in the presence of
6 M urea. After concentration of the protein in 6 M
urea to about 10 mg/ml, the urea concentration is
lowered to 0.6 M by diluting 0.1 ml into 1 ml of a
binding buffer containing an oligonucleotide bearing
an AP-1 site. Under these conditions, the protein
renatures and forms complexes with the oligo. This
mixture is then subjected to native polyacrylamide
gel electrophoresis. Jun-oligo complexes are located
by UV shadowing over fluorescent thin-layer chro-
matography plates and then excised from the gel.
Elution from the gel slice yields approximately 1 mg
of pure Jun. In analytical gel-shift assays, this
purified Jun binds DNA containing AP-1 sites, in-
cluding sites from the metallothionein promoter and
from the human immunodeficiency virus type-1
(HIV-1) long terminal repeat.
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Crystallization trials have been carried out with
purified Jun, so far without success. One reason for
this may be that the solubility of the protein is limited
to 1-2 mg/ml in the absence of urea; much higher
concentrations are usually required for crystalliza-
tion. It is also possible that the conformation of the
free protein is unstable or improperly renatured. Jun
homodimers undergo a conformational change in the
presence of DNA containing AP-1 sites (Patel et al.,
Nature 347: 572 (19901), and the resulting conforma-
tion may be more stable. Consistent with this, we
have found that renaturation and concentration of Jun
in the presence of plasmid DNA carrying AP-1 sites
permits protein concentrations of 10 mg/ml or higher
to be attained, compared to 1-2 mg/ml without DNA.
We believe that similar results will be achieved using
AP-1-site-containing oligos, a prediction that we are
about to test. If so, we will immediately set up
cocrystallization attempts with the Jun-oligo com-
plexes.
We are developing a purification procedure for
the bacterially produced FRA1 protein and will at-
tempt to prepare and characterize heterodimers of
FRA1 and Jun and complexes of the heterodimers
and AP-1 oligos. We will then attempt to crystallize
the complexes. Determination of these heterodimer
structures and Jun homodimer structures will help us
to understand the role that these proteins play in
normal cellular regulation and the role that altered
versions of them play in oncogenesis.
Yeast cAMP-dependent
Protein Kinase
J. W. Pflugrath, T. Malone, X. Cheng, J. Kuret,
A. O'Connor
Protein kinases are important and conserved com-
ponents of many regulatory pathways because they
can integrate several input signals and coordinate a
response through the phosphorylation of a limited
number of substrate proteins. The three-dimensional
crystal structure of the cAMP-dependent protein
kinase will allow us to define the structural basis of
enzyme/substrate recognition and to assess the im-
plications of this information for the protein kinase
family in general.
We have crystallized the cAMP-dependent
protein kinase catalytic subunit from Saccharomyces
cerevisiae. The kinase catalytic subunit crystallizes in
space group P6522 with cell dimensions a = b =
61 A, c = 320 A. We have grown crystals as large as
0.6 x 0.6 x 1.5 mm that have diffracted to 2.2-A
resolution at the National Synchrotron Light Source.
We have collected partial X-ray diffraction data
in our laboratory with a FAST area detector and
rotating anode generator by rotating the crystals for
40° around the a axis with c* initially oriented
toward the beam at a crystal-to-detector distance of
70 mm. Initial screening in this way yielded a data set
from p-chloromercuriphenyl sulfonate (PCMBS)-
soaked crystals that showed a single mercury site in
both isomorphous difference Patterson maps and
anomalous Patterson maps. This derivative with its
anomalous scattering constitutes the basis of our ap-
proach to solving the phase problem. To obtain com-
plete data sets with reflections separated along 1 when
c* is oriented near the plane of the detector, we
would need to use better optics with a relatively long
crystal-to-detector distance of 320 mm with Cu Ka
radiation.
To overcome the limitations of our laboratory X-
ray source, we used the facilities at beamline X12C at
the Brookhaven National Laboratory National Syn-
chrotron Light Source with the assistance of Dr.
Robert Sweet. The optics and intense tunable radia-
tion of XI2C allowed us to use a wavelength of 0.95
A and a crystal-to-detector distance of 360 mm to
separate the reflections, minimize air absorption, and
enhance the anomalous signal from the mercury
atoms. More than 37,000 measurements from four
kinase crystals soaked in PCMBS resulted in 9,613
unique reflections between 20 A and 2.5 A with an
overall Rmerge of 6.1%. The data are 92% complete
between 20 A and 2.8 A, and 93.5% complete in the
3.0-2.8-A shell. Representative Harker sections of
the anomalous Patterson map shown in Figure 3
clearly reveal the mercury site that had been found in
a previous isomorphous difference Patterson map.
Single isomorphous replacement with anomalous
scattering refinement gave us a trial set of phases that
were then used to calculate a 3.2-A resolution elec-
tron density map, a portion of which is shown in Fig-
ure 4. Regions of the map could be interpreted as a
helices. Experiments are under way to improve the
interpretability of the map.
Structural Studies of S10013
R. Hsu, T. Malone, J. Kuret, J.W. Pflugrath
fin collaboration with D. Marshak, Cold
Spring Harbor Laboratory]
Predominant among water-soluble brain proteins is
S10013, an acidic 10.5-kD protein that contains the se-
quence requirements necessary to form two EF hand
calcium-binding loops. Besides postulated calcium
signal mediation function, S10013 binds zinc very
tightly and has been implicated as a neurite extension
factor. In both Alzheimer's disease and Down's
syndrome, elevated levels of S10013 have been
detected [Marshak et al., Neurobiol. Aging [1991] in
press). We are expending considerable effort to
determine the three-dimensional structure of S100f3
so that we can better understand the relationships
among the many functions of this protein.
S100(3 was initially purified from bovine brain
extracts that typically yielded 50 mg of protein in 5
days. Rough purity estimates from silver-stained
SDS-PAGE revealed both monomeric S10013 migrat-
ing as expected at about 10 kD and dimeric S10013 as
a 1% contaminant. Crystals that diffracted X-rays to
3.5-A resolution were grown in the tetragonal space
group P41212 (or its enantiomorph) with unit cell a =
b = 64 A, c = 49 A via the hanging drop microvapor
, . . ' ,.-'7,:- ,', ono--,---, -
,--, _._._-_,,, .,,,..NoY ,,... . 41- -,-,, -
FIGURE 3 Harker sections (w = 1/6, w = 1/3, w = 1/2; u down 0 to 1, v across 0 to 1) contoured in intervals of standard
deviations except the zero-contour level. Solid lines denote positive levels, and dashed lines denote negative levels.
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diffusion technique in the presence of calcium and
polyethylene glycol 400. When first set up in the
hanging drops, the protein precipitated; crystals ap-
peared only after 5-7 days.
Crystal analysis of bovine S100(3 was not
pursued. First, crystallization experiments did not
yield routinely reproducible crystals. Second, bovine
brain extracts were oftentimes unwieldy and the
purification was labor-intensive. Third, and most im-
portant, sequence analysis of the purified S10013
revealed significant contamination by the associated
protein S100a. Because of similarities in the proper-
ties (molecular weight, amino acid sequence, func-
tion) of the two proteins, we found it very difficult to
purify them separately from brain extracts.
To overcome the above problems with bovine-
brain-derived protein, we decided to overexpress
S10013 in bacteria where other 5100 proteins were not
present. Beginning with the cDNA for rat 510013
(supplied by D. Marshak), we used the polymerase
chain reaction to obtain the S100(3 gene flanked by
useful restriction sites; the resulting fragment was
ligated to a T7 expression vector in E. coli. When a
late log phase bacterial culture growing at 37°C is in-
duced with isopropyl -13-n-thiogalactoside, harvested,
and lysed, 510013 amounts to about 40% of the total
soluble protein. The purification scheme consists of
ammonium sulfate precipitation, a 2-chloro-10-(3-
aminopropyl)phenothiazine affinity column, and a
MonoQ ion-exchange column. We now obtain 15-20
mg of pure S10013 from 1 liter of cells in 3 days free
from S100a contamination-a major improvement
over the brain preparations. Amino-terminal se-
quence analysis confirmed the sequence as that of rat
510013, and the removal of the initiator methionine in
25% of the 510013. We await activity analyses to as-
certain the effect of overexpression in a bacterial sys-
tem and the lack of amino-terminal acetylation,
which is normally present in mammalian 510013.
Crystallization trials of the recombinant 510013
showed that any combination of polyethylene glycol
and calcium resulted in rapid and excessive precipita-
tion of the protein. Although crystals could be ob-
tained under conditions similar to those used for
bovine S100(3, the excessive precipitation led us to
consider other conditions. Further experiments
eventually provided crystals that grow as three-
dimensional rectangular columns 0.6 to 0.8 mm long
in about 1 day, without any hint of our previous pre-
cipitation problems. These crystals do not diffract
very well, and thus we will continue to experiment
with the crystallization conditions.
FIGURE 4 Stereoplot of a portion of the electron density map calculated from 3.2-A resolu-
tion SIR-AS phases showing residues 182-197 of TPK1A with sequence KSIDVVWSF-
GILIYEML.
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PROTEIN KINASE STRUCTURE AND FUNCTION
J. Kuret D. Adelman
A. Desai
T. Mitcheson
A. O'Connor
During 1990, this laboratory saw the arrival of three
talented young investigators: Arshad Desai from Cal-
ifornia State University at Hayward, Thomas Mitch-
eson from Eton College in England, and David Adel-
man from Commack High School right here on Long
Island. After joining the "firm" of Kuret & O'Connor,
all three began work on protein kinases to learn more
about this important family of regulatory molecules.
In an effort to determine the common three-dimen-
sional structure that kinases adopt, and the implica-
tions of this structure for selective recognition of
protein substrates and catalysis of the phosphotrans-
ferase reaction, Arshad applied his energy (mostly
nocturnal) to the study of TPK1, the Saccharomyces
cerevisiae homolog of the cAMP-dependent protein
kinase (cAMPdPK) catalytic subunit. This kinase,
along with its isozymes, regulates the ability of that
organism to grow. Meanwhile, David, as part of Cold
Spring Harbor Laboratory's Partners for the Future
program, addressed the biological function of casein
kinase I, an enzyme found in all eukaryotic cells in
which it has been sought. It is unrelated to casein
kinase II, which is described elsewhere in this
volume. Late in the year, Tom also began work on
this enzyme, adding enthusiasm and a keen under-
standing of tea and its uses. Our progress in combin-
ing the techniques of X-ray crystallography and
molecular genetics in the study of protein kinases is
described below.
Yeast Casein Kinase I
J. Kuret, D. Adelman, T. Mitcheson, A. O'Connor
As the name implies, casein kinases are enzymes that
phosphorylate casein (an acidic, heavily phosphory-
lated family of proteins found normally in milk) effi-
ciently. Although casein is an unlikely target for
casein kinases in living cells, it is a useful and sur-
prisingly specific tool in the isolation, assay, and
characterization of these enzymes because few of the
many protein kinases cloned or purified are capable
of phosphorylating it. Two classes of casein kinases
termed casein kinase I (CK-I) and casein kinase II
(CK-II) are recognized in eukaryotic cells. Although
progress is being made on CK-II (described by Dan
Marshak in the Tumor Viruses Section), the structure,
intracellular location, and biological function of CK-I
have been a complete mystery. Our goal is to dis-
cover the biological role of CK-I using the yeast S.
cerevisiae as a model system.
Last year, we purified a novel form of CK-I from
yeast using classical methods and described some of
its biochemical properties in solution. Like the en-
zyme isolated from mammalian and other sources,
the yeast enzyme is a monomer with a very alkaline
isoelectric point. After purifying large quantities of
yeast CK-I, we partially proteolyzed the enzyme with
trypsin and chymotrypsin, separated the resulting
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TABLE 1 Comparison among Carboxy-terminal
Regions of Yeast Casein Kinase-I and Low-
molecular-weight GTP-binding Proteins
Locus
YPT1
SEC4 (YPT2)
ypt3
SASI
SAS2
CKII
Species Sequence
Sc TGGGCC
Sc SKSNCC
Sp SSSQCC
Dd KKKACC
Dd KKNTCC
Sc SKLGCC
Sc = Saccharomyces cereyisiae; Sp = Schizosaccharomyces
pombe; Dd = Dictyostelium discoideum
peptide fragments by gel electrophoresis, isolated the
products by blotting them onto membranes, and final-
ly subjected them to automated Edman degradation
(performed by the Protein Chemistry Core facility).
The internal amino acid sequence information we ob-
tained as a result was used to design an oligo-
nucleotide probe suitable for screening a yeast cDNA
library we had prepared earlier in bacteriophage X.
Thus, we obtained the full-length clone of yeast CK-
I.
Examination of yeast CK-I primary structure
reveals some interesting features. The sequence be-
gins with about 80 hydrophilic amino acid residues,
followed by a canonical protein kinase domain. This
is followed by a long stretch of hydrophilic residues
that are predicted to be highly flexible in the folded
CC
s'
protein. Finally, the protein chain terminates with a
short, hydrophobic sequence. Closer inspection of the
hydrophobic carboxyl terminus reveals a striking
homology with members of the low-molecular-
weight GTP-binding protein family (Table 1). In
these proteins, the sequence is associated with lipid
modification and intracellular membrane localization.
Thus, we predict that a hydrophobic, lipoprotein
"tail" anchors the CK-I protein kinase domain to in-
tracellular membranes via a hydrophilic and flexible
"tether" (Fig. 1). This organization is undoubtedly
important for facilitating access of CK-I to physio-
logical substrate proteins. In the coming year, we
hope to test this hypothesis by identifying the nature
of the posttranslational lipid modification and the
consequences of that modification for CK-I localiza-
tion. In addition, we plan to employ the genetic tools
available in yeast to obtain the first indications of the
biological function of CK-I.
Yeast cAMP-dependent
Protein Kinase
J. Kuret, A. Desai, A. O'Connor [in collaboration with
J. Pflugrath and X. Cheng, Cold Spring Harbor Laboratory]
Despite clear amino acid sequence homology among
members of the eukaryotic family of protein kinases,
catalytic core
hydrophilic tether
lipid anchor
internal membrane
FIGURE 1 Proposed model of yeast CK-I structure.
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and the probable existence of a common enzymatic
mechanism of phosphoryl transfer, each protein
kinase possesses a unique (although potentially over-
lapping) recognition selectivity for protein substrates.
For the handful of kinases studied in detail, the
ability of a protein to serve as a substrate is
determined by the amino acid sequence surrounding
its phosphorylatable hydroxy amino acid (i.e., serine,
threonine, or tyrosine), with the location and spacing
of charged amino acids being especially important.
Because we wish to understand the overall folding
pattern of eukaryotic protein kinases and to identify
the structural features of kinases that are involved in
catalysis, regulation, and substrate selectivity, we in-
itiated a crystallographic study of the well-character-
ized cAMPdPK catalytic subunit from yeast, TPK1.
We chose this enzyme for study because (1) its gene
has been cloned (by Mike Wigler's laboratory), (2)
mutant proteins with altered catalytic properties can
be obtained through genetic screens in yeast, (3) it
can be overexpressed in a soluble form in yeast, and
(4) it retains the well-characterized structural and ki-
netic features of the mammalian enzyme. Thus, the
yeast system allows us to study protein kinase en-
zymology with diverse techniques.
Last year, we reported the overexpression, puri-
fication, and crystallization of a truncated version of
TPK1, termed TPK1A. The crystals grow to more
than 1 mm in length, are hexagonal dipyramids in
shape (Fig. 2), and diffract beyond 2.8-A resolution.
Our efforts this year have been directed toward ob-
FIGURE 2 Crystals of TPK1A.
taming heavy atom derivatives of our crystals so that
we can solve the structure of TPK1A by multiple
isomorphous replacement. The method involves har-
vesting a fresh crystal, soaking it in a dilute solution
of heavy metal ions such as mercury or platinum, and
assaying for their incorporation by inspection of the
soaked crystal's X-ray diffraction pattern. A Patter-
son map showing the successful derivitization of
TPK1A with a mercury compound can be found in
the preceding section of this report (Macromolecular
Crystallography). The map is dominated by families
of concentric circles marking the position of electron-
dense mercury atoms.
We are pursuing two principal strategies to obtain
the additional derivatives needed to solve the struc-
ture of TPK1A. The first is to continue soaking crys-
tals in different heavy atom solutions in the hope of
finding a new compound that binds to a novel site.
The second is to reengineer TPK1A to provide addi-
tional heavy-atom-binding sites. This is accom-
plished by modifying the cysteine content of the
protein through site-directed mutagenesis, crystalliz-
ing the resulting mutant, and soaking it in heavy atom
solutions as described above. Because the bond be-
tween mercury and the sulfhydryl group of cysteine
is essentially covalent, cysteines are efficient heavy
atom binders. By the end of 1990, we had prepared
more than one dozen such mutants. In the coming
year, we plan to analyze these mutants and to create
still more to obtain our necessary derivatives.
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COMPUTATIONAL MOLECULAR BIOLOGY
T. Marr D. Lombardi
This is a new discipline in molecular biology that
merges the arts and crafts of scientific computing
with the arts and crafts of molecular biology. Com-
putational Molecular Biology is not unlike other dis-
ciplines that arose quite naturally in molecular biol-
ogy, such as nucleic acid chemistry and the bio-
physics of protein crystallography. The two primary
goals of our group are (1) to establish a strong pro-
gram in basic research in computational molecular
biology, with an initial focus on the development of
mathematical methods for constructing molecular
maps of DNA and new methods for the retrieval,
analysis, display, and manipulation of molecular se-
quence data, and (2) to enhance and develop com-
puter technologies that help the Laboratory maintain
its research excellence.
A Comprehensive Computing
Environment for Molecular
Biology and Genetics
T. Marr
In collaboration, with Andrew Reiner, a computer
scientist and consultant to the Jackson Laboratory,
design work has progressed on a new computer sys-
tem architecture for retrieval, analysis, and display of
molecular biology and genetic data. It is based on a
new type of software technology known as object-
oriented technology. Funding for this effort begins in
May of 1991, at which time Andy will be joining the
computational biology group as a research computer
scientist. Our goals are listed below.
1. Design and implement a system architecture for
the management, analysis, and display of
molecular genetics information and augment this
environment to support the creation of new man-
agement, analysis, and display techniques, and the
enhancement or retargeting of existing ones.
2. Develop a database environment that is com-
munity-driven and investigator-maintained. In
other words, this environment will support the in-
210
novative investigator who is not fortunate enough
to have institutional access to the expensive
resources (i.e., qualified people) that traditionally
have been necessary to develop a readily acces-
sible research resource.
3. Develop an infrastructure to support the transfer
of research findings from mathematicians and
computational scientists into mainstream biologi-
cal research.
A Computerized Laboratory
Information Management System
for Molecular Biologists
D. Lombardi, T. Marr [in collaboration with D. Beach,
Cold Spring Harbor Laboratory]
This project is aimed at computerization of most of
the day-to-day operations of information collection
and management of the laboratory of David Beach
(Genetics Section). We expect to use this system as a
general model for many experimental molecular biol-
ogy laboratories. Our first goal is to get a fully func-
tional system going in the Beach laboratory, and then
we will expand the system to include other laboratory
operations at Cold Spring Harbor and elsewhere, for
example, with collaborators at other locations. This
system includes an intuitive graphical interface for
data entry and retrieval. The system is now at the
prototype and testing phase and includes provision
for managing the fission yeast strain collection, clone
tracking, probe tracking, monoclonal and polyclonal
antibodies, proteins, and molecular sequences. The
system runs in client-server mode over the Lab-
oratory's local area network and is implemented in a
relational database management system, Sybase, run-
ning on a Sun/Unix server, with Macintosh com-
puters running the Claris/Hypercard and Sy-base/-
DBlib software. This way, users can use the highly
"user-friendly" Macintosh as the interface into the
system, with the complexity of powerful, but "user-
unfriendly" Unix workstations "hidden" from them.
The central database can be accessed simultaneously
from several locations with the Beach laboratory.
Committees and Workshops
T. Marr
This was a busy year in terms of national scientific
research service activities. I was invited by the Direc-
tor of the National Institutes of Health (NIH) to be a
member of the first chartered research review com-
mittee for the National Center for Human Genome
Research. This committee is responsible for the
scientific review of research and training grant
proposals for the National Institutes of Health Human
Genome activities. The first year of review of pro-
posed National Institutes of Health Genome Centers
was particularly demanding. I site-visited and re-
ported on five of the nine proposed Centers, as well
as serving on the Genome Center Parent Committee
and the Large-Scale DNA Sequencing study section.
It is important, for long-term success of this emerging
major national scientific effort, to get limited dollars
into the hands of the groups qualified best to tackle
the new-to-biology multidisciplinary nature of the
human genome program.
I also served on the National Academy of Science
committee "DNA Technology in the Forensic Sci-
ences." This committee examined and has written a
report on the underlying scientific principles and the
societal impact of the use of "DNA fingerprinting" in
court cases involving violent crimes against members
of our society. This report is scheduled for release in
the spring of 1991.
At the Banbury Center, I was coorganizer of a
workshop entitled "Issues in Training Computational
and Mathematical Biologists." This workshop was
sponsored by the National Science Foundation and
was aimed at examining how to meet the current and
future need for computational and mathematical
biologists. These scientists are needed to work on
new classes of problems in biology that require sub-
stantial cross-disciplinary skills, such as global
warming, human genome, neuroscience, and struc-
tural biology.
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NEUROSCIENCE
Neuroscience at Cold Spring Habor Laboratory has focused on the role of growth
factors in the differentiation and aging of neuronal cells. For some years, the re-
search has primarily centered on a glial-derived protein, S100(3, that acts as a
neurotrophic factor for embryonic cerebral cortical neurons. Abnormal levels of
this protein have been seen in Alzheimer's disease, in proximity to the amyloid
plaques that are characteristic of this degeneration. We are also pursuing the
role of this factor in Down's syndrome, a developmental neurological disease in-
volving chromosome-21 abnormalities. This year, our research has taken us into
the realm of protein kinases, as we probe the mechanisms of action of growth
factors of the nervous system, and as we try to understand the molecular basis of
neuronal differentiation. As we look forward to the new Neuroscience Center at
Cold Spring Harbor, our studies continue to probe the fundamentals of growth
and differentiation of neurons, particularly pertaining to human neurological dis-
eases.
NEURONAL GROWTH AND DIFFERENTIATION
D.R. Marshak E. Azmitia S. Pesce
Y.-S. Bae A. Wilson
N. Chester
During the last 5 years, the work in our laboratory re-
lated to neuroscience has centered on the outgrowth
of processes, or neurites, from embryonic neurons in
cell culture. This system serves as a model for the de-
velopment of neurons in vivo, by allowing us to iso-
late and characterize a neurite extension factor. We
have characterized the structure and function of the
factor, and we have developed reagents to permit
analysis of brain tissue taken on autopsy from
patients with several neurological diseases. Newer
studies involve other growth factors of the nervous
system, including a substrate-attachment factor that is
homologous to the family of fibroblast growth factors
(FGFs). Our long-term projects aim at discovering
the mechanisms of action of neuronal growth factors,
including changes in signal transduction pathways,
such as protein kinases, that stem from neuronal
growth.
Role of S10013 in Neurological
Diseases
D.R. Marshak, S. Pence [in collaboration with
W.S.T. Griffin, University of Arkansas]
A significant segment of the population over 65 years
of age is afflicted with Alzheimer's disease (AD), a
neurodegenerative process that results in memory
loss and progressive dementia. The hallmarks of AD
neuropathology are prevalent in temporal lobe struc-
tures, such as the hippocampal formation, that have
been associated with learning and memory. These
neuropathological symptoms include abnormal num-
bers of neurons that contain neurofibrillary tangles,
extracellular plaques with (3-amyloid cores, and reac-
tive astrocytes. A puzzling feature of plaque pathol-
ogy is the presence of enlarged neurites encircling the
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(3-amyloid deposits. The presence of soluble neuro-
trophic factors could give rise to inappropriate
growth of neurites. In support of this idea, we have
shown that the levels of a neurotrophic factor, the
protein S10013, and its encoding mRNA are elevated
in AD, but not control, brain temporal lobe. More-
over, AD temporal lobe extracts had more S100(3-
specific neurotrophic activity than similar extracts
from age-matched controls. We have suggested that
elevated levels of S100(3 contribute to the cellular
neuropathology in AD.
Down's syndrome (DS) is a developmental dis-
order arising from extra copies of all or part of hu-
man chromosome 21, either by trisomy, partial
duplication, or translocation. In addition to mental
retardation, DS patients that live to middle age in-
variably develop a degenerative neurological disorder
that is indistinguishable from AD. This is further sup-
ported by the findings that genes related to AD reside
on chromosome 21, although distinct from the DS
regions. Because the gene for S10013 is located on
chromosome 21 near the telomere of the long arm,
we tested samples of DS autopsy brain for S10013
levels. It appears that immunoreactive levels of
sloop are elevated in DS early in life, reaching
fivefold over normal levels at 3 months and decreas-
ing to normal levels by 9 months. This correlation
holds for both frontal and parietal cortex in 21 normal
and DS samples. We are trying to obtain tissue from
DS patients of other ages, including middle age,
elderly, and fetal, in an attempt to identify the critical
time of S10013 elevation in human brain develop-
ment.
Molecular Cloning and
Expression of S10013
D.R. Marshak, A. Wilson, N. Chester
The coding region of the cDNA clone was isolated as
a 916-bp BamHI fragment and subcloned into pBS+.
Restriction maps of this construct indicated that the
insert was oriented with the 5 ' end of the com-
plementary strand under control of the T3 promoter.
Synthesis of RNA probes using the T3 polymerase
resulted in positive slot blots and Northern blots of
brain RNA. These RNA probes have been very useful
in quantitating mRNA levels in AD and DS autopsy
brain samples. In addition, A. Wilson has probed pri-
mary human fibroblast extracts of RNA to determine
if the age of the cells in culture was related to S10013
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expression. C. Greider (Genetics Section) and col-
leagues previously described the phenomenon of
telomere shortening in aging fibroblasts. Because the
gene for S10013 is very close to the telomere of the
long arm of chromosome 21, we considered that the
telomeric shortening might affect S10013 gene expres-
sion. In preliminary experiments, little S10013 could
be detected in fibroblasts at either early or late stages
in culture. However, this project is ongoing and
promises to provide unique information concerning
the relationship between a telomere and a nearby
single-copy gene in the human genome.
Transgenic mice are being constructed through a
collaboration with Dr. Charles Epstein (University of
California, San Francisco). These mice may provide
an animal model for DS. We are also investigating
trisomy-10 mice (with Dr. Charles Epstein, UCSF)
that have an extra copy of the S100(3 gene and severe
neurological defects. Present experiments revolve
around the construction of expression plasmids that
utilize tissue-specific promoters for specific popula-
tions of cells in the brain.
The cDNA probe has also been used in col-
laboration with Dr. Kathleen Gardiner (Eleanor
Roosevelt Institute, Denver) to confirm the localiza-
tion of the gene and continue fine-structure mapping
of chromosome 21. Further mapping has been done
in collaboration with J. Korenberg (Cedars Sinai
Medical Center, Los Angeles). Patients have been
studied that have selected symptoms of DS, but who
have a circular fragment of additional chromosome
21, rather than a full trisomy 21. We are attempting
to investigate the question of whether these circular
chromosomes still contain the S10013 gene or if
recombination has occurred proximal to the gene. In
either case, these results will allow us to study the
contribution of the S10013 gene dosage to DS in hu-
mans.
Role of S100b In Vivo
E. Azmitia, D.R. Marshak, S. Pesce [in collaboration
with P. Whitaker, SUNY Stony Brook]
We have begun to examine the role of S100(3 in vivo
using the rat model system. The findings of Drs.
Whitaker and Azmitia indicate that serotonergic
neurons of the brain stem that innervate the hip-
pocampus appear to respond to S10013 as a
neurotrophic factor. This, combined with our findings
of increased S10013 in temporal lobe areas including
the hippocampus, suggests that S100(3 may play a
key role in the normal development of contacts be-
tween serotonergic neurons of the Raphe nuclei and
neurons of the hippocampus. Abnormal levels of
S10013 either during development (as in DS) or in
aging (as in AD) may lead to errors or lesions in
these connections. We have demonstrated that sero-
tonergic agonists can specifically release S10013 from
glial cells that surround the neurons of the hip-
pocampus, indicating that the neurotransmitter com-
pound itself might regulate the relase of the
neurotrophic factor in the developing brain. Further
studies indicate that chemical lesion of the connec-
tions between the brain stem and the hippocampus
results in up-regulation of serotonin receptors and
sensitivity to S10013 release by serotonergic agonists.
Injection of radioactively labeled S10013 into the hip-
pocampus indicates that much of the S10013 released
is associated with hippocampal neurons. Further
studies are in progress to map the pathways and
pharmacology of S10013 action in vivo that may
reveal some of the characteristics of S100(3 function
in normal brains and in diseased states.
Structural Analysis of Neurite
Extension Factor
D.R. Marshak [in collaboration with J. Pflugrath,
Cold Spring Harbor Laboratory]
Further analyses of the three-dimensional structure of
the S100(3 monomer and dimer are being accom-
plished by solving the X-ray crystal structure. In col-
laboration with Dr. Jim Pflugrath (Structure Section),
we have grown crystals of S100(3 suitable for X-ray
analysis. These crystals diffract to 2.5 A and have the
P21 space group. These crystals were difficult to
reproduce consistently, so we turned to recombinant
S100I3 for large quantities of protein. The cDNA
clone was inserted into a T7 expression system for
large-scale expression in Escherichia coli. Material
expressed in these bacteria can be purified to appar-
ent homogeneity in a few days, and crystals have
been grown from this fresh, recombinant material.
Dimensions of the crystals are larger than those from
the bovine brain material, and the space group and
unit cell appear to be different. These crystals will be
used to solve the complete structure of S10013 in the
coming year.
We have also succeeded in synthesizing the
protein chemically using solid-phase methods on an
automated instrument. The protein has 91 amino
acids and took approximately 4 weeks to synthesize
after several initial failures. Purification and charac-
terization of the product are now under way. Pre-
liminary results indicate that the synthetic product is
biologically active and can be promoted to form
dimers in vitro. We would like to compare the three-
dimensional structures of the native, synthetic, and
dimerized forms of S100[3.
Regulation of Brain Protein
Kinases
Y.-S. Bae, D.R. Marshak
The action of growth factors in the nervous system
has been implicated in the onset of symptoms of
neurological disease, such as AD. We have begun to
study the regulation of the signal transduction sys-
tems that are stimulated by growth factors in the
brain. In particular, we have purified casein kinase II
(CK-II) from bovine brain to examine the stimulation
and repression of the activity. Brain CK-II appears to
have an endogenous inhibitor as well as compounds
that can activate the enzyme. Our current research
focuses on the isolation and characterization of
molecules that regulate this kinase. CK-II is impor-
tant to transcriptional control, and it is possible that
alterations in CK-II levels or activity is associated
with degeneration of neurons. In other studies, we
have analyzed the protein kinase p34cdc2 in cells that
can become neurons in culture, rat PC12 cells. Upon
treatment with the nerve growth factor (NGF), these
cells differentiate into sympathetic, peripheral neur-
ons in culture. This appears to be accompanied by
changes in the expression of p34cdc2 and in its ac-
tivity as a protein kinase. One potential target of
phosphorylation, tyrosine hydroxylase, has been
studied. In vitro, p34cdc2 can phosphorylate tyrosine
hydroxylase, and the site and consequences of this
phosphorylation are under investigation.
Analysis of a Neurotrophic Heparin
Binding Growth Factor
D.R. Marshak [in collaboration with W.H. Burgess,
American Red Cross Research Center, Maryland]
During the past year, we have been fortunate to be in-
volved in the analysis of several proteins related to
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growth in human physiology. In collaboration with a
group at the American Red Cross Research Center in
Maryland, we characterized a new type of neuro-
trophic factor, HB-GAM. This small protein is
homologous to the family of fibroblast growth factors
(FGFs), but contains a high proportion of lysyl
residues. This highly basic protein was isolated from
bovine brain at neutral pH, and the complete se-
quence of the protein was determined by chemical
analysis and by plasma desorption mass spec-
trometry. In biological assays, the protein does not
appear to be active as a fibroblast or endothelial cell
mitogen, but it is highly active in neurotrophic as-
says. In particular, when HB-GAM is coated onto the
surface of cell culture matrix, the factor promotes
neurite outgrowth from chick cortical neurons. As a
soluble factor, HB-GAM does not significantly pro-
mote extension above that done as an attachment fac-
tor. These results suggest that this FGF family mem-
ber may act as a neurite outgrowth factor by sub-
stratum attachment, working in concert with soluble
growth factors in the brain.
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CSH LABORATORY JUNIOR FELLOWS
In 1986, Cold Spring Harbor Laboratory began a new program to encourage in-
dependent research by outstanding young scientists who, during their graduate
studies, displayed exceptional promise of becoming leading scientists of the fu-
ture. The purpose of this program is to provide an opportunity for each Fellow to
work independently at the Laboratory for a period of up to 3 years on projects of
his/her choice. The Fellow is provided with a salary, research support, and tech-
nical assistance so that they can accomplish their goals free from other distrac-
tions. The interaction among research groups at the Laboratory and the program
of courses and meetings on diverse topics in molecular biology contribute to a
research environment that is ideal for innovative science by these Fellows.
Two previous Cold Spring Harbor Fellows, Dr. Adrian Krainer (1987) and Dr.
Carol Greider (1988), are currently members of the scientific staff at the
Laboratory. The most recent Fellow, Dr. Eric Richards, joined us in 1989 from
Fred Ausubel's laboratory at the Massachusetts General Hospital. Dr. Richards is
studying the molecular biology of the centromeres and telomeres of the plant
Arabidopsis thaliana.
E.J. Richards
Molecular Chromosome Studies
in Arabidopsis thaliana
E.J. Richards, A. Vongs, S. Chao
We are currently pursuing three related projects by
investigating different aspects of plant molecular
chromosome structure and genome organization us-
ing Arabidopsis thaliana as a model system. The con-
tinuing projects concern the characterization of geno-
mic DNA organization at centromeric and telomeric
regions of plant chromosomes. In a recently initiated
project, we are looking at a different aspect of
genome organization: the role of DNA methylation.
CHARACTERIZATION OF TELOMERIC DNA
FROM A. THALIANA
Plants possess G-rich simple-sequence repeats at
their chromosome ends similar to those originally de-
scribed in unicellular eukaryotes (Richards and
Ausubel, Cell 53: 127 [1988]). Since the establish-
ment of the ubiquity of telomeric repeats, much of
the focus in the telomere field has turned to the
genomic regions that lie just proximal to the G-rich
repeats. Such telomere-associated sequences are
commonly composed of repeated DNA sequences
that exhibit variability in terms of DNA structure and
chromosome distribution (see, e.g., Horowitz et al.,
MoL Cell. Biol. 4: 2509 [1984]; Brown et al., Cell
63: 119 [1990]). We are currently characterizing
telomere-associated sequences present on eight
A. thaliana telomere clones recently isolated by se-
lection for plant DNA fragments that function as
telomeres on yeast artificial chromosome (YAC) vec-
tors.
We have analyzed one of these clones in detail.
As expected, the clone contains a block of
[TTTAGGG] corresponding to the most distal
chromosome end. Numerous variant repeats are also
found, particularly TTAAGGG, at the centromere-
proximal edge of the terminal simple-sequence block,
indicating that telomeric repeats diverge as one
moves away from the chromosome end. The region
adjacent to the telomeric repeat block corresponds to
single-copy DNA in the Landsberg strain of
A. thaliana from which the clone was derived. A
domain of the characterized flanking sequence also
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cross-hybridizes to an additional telomere-flanking
region in a different A. thaliana strain, Columbia. As
noted above, such variable distribution of telomere-
associated sequences is also found in fungi and mam-
mals and is thought to arise by recombination be-
tween nonhomologous chromosome ends.
Through analyses such as these, we hope to com-
plete the molecular description of the chromosome
ends and provide useful landmarks for the chromo-
some ends on the physical and genetic map.
CHARACTERIZATION OF CENTROMERIC DNA
FROM A. THALIANA
We are interested in identifying and characterizing
the DNA sequences required for centromere function
as a first step toward understanding how centromeres
work. At present, functional centromeric DNA se-
quences have been identified in only two systems,
Saccharomyces cerevisiae and Schizosaccharomyces
pombe. The picture that emerges from centromere
studies in the yeasts is rather confusing; the budding
yeast centromeres are quite small (120 bp) and do not
resemble the large (50-100 kb) arrays of repetitive
DNAs that make up S. pombe centromere regions
(Clarke, Trends Genet. 6: 150 [1990]). Although it is
generally thought that the S. pombe centromeres may
provide a simple model for the larger, more struc-
turally complex centromeres of higher eukaryotes, we
have decided to begin characterizing a higher eukar-
yotic centromere directly.
Our approach to isolating A. thaliana centromeric
DNA is similar to that first used to clone yeast
centromeres: begin with molecular markers that
flank a centromere and walk across the gap. The
centromere of A. thaliana chromosome 1 is the best
target, since it is the most precisely mapped, and
several genetic and restriction-fragment-length
polymorphism (RFLP) markers are closely linked to
this centromere.
Our current picture of the cenl region, shown at
the bottom of Figure 1, is based on RFLP analysis of
centromeric
heterochroma tin
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FIGURE 1 Cytological (Schweizer et al., Arabid. Inf. Serv. 25: 27 [1987]) and genetic (Koornneef, Genetic Maps, Cold Spring
Harbor Laboratory Press [1978]) maps of A. thaliana chromosome 1. The approximate position of cent relative to classical
genetic markers was determined by Koornneef (Genetics 62: 33 [1983]) by analyzing crosses between marked strains and
telotrisomic plants carrying the telocentric chromosome derivatives. The correlation between the classical genetic map and
the RFLP map (Nam et al., The Plant Cell 1: 699 [1989]) is indicated by the dashed lines. Our present refinement of the map
is shown at the bottom of the figure.
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segregating F2 populations of an interstrain cross,
where one parent carries an additional telocentric
chromosome 1 derivative (Tr1A Landsberg x disomic
Columbia). Distortion of RFLP allele ratios in F2 in-
dicates that the marker in question is located on the A
arm of the chromosome and, consequently, to the
"left" of the centromere as drawn in Figure 1. At
present, we have placed the gap-b and pAtT12 RFLP
markers to the "right" of the centromere on the B
arm, since alleles of these loci segregated normally.
We are currently determining the position of the
other known markers in the region in order to find a
useful molecular probe that flanks cenl on the A arm.
Flanking markers will then be used to construct
large-scale primary restriction maps of the region,
providing a low-resolution picture of the size and
DNA organization at the centromere. Such informa-
tion will supply a foundation for the next phase: iso-
lation of centromeric sequences in YAC vectors and
functional analysis of these sequences.
DNA HYPOMETHYLATION MUTANTS
In parallel with its small genome size, A. thaliana has
extremely low levels of methylcytosine (approxima-
tely 5%) for an angiosperm (Leutwiler, Mol. Gen.
Genet. 194: 15 [1984]). Most of the methylated
residues are sequestered into the highly repeated
DNA fraction (e.g., rDNA and satellite repeats)
thought to be localized in heterochromatic regions of
the chromosomes. To assess the role DNA methyla-
tion plays in chromosome structure and mechanics
(e.g., heterochromatization and segregation), we have
begun a collaboration with Rob Martienssen (Genet-
ics Section) to characterize A. thaliana mutants with
reduced levels of cytosine methylation.
At present, three hypomethylation mutants have
been recovered from M2 populations of EMS-muta-
genized seed by screening for plants that have satel-
lite arrays susceptible to digestion by methylation-
sensitive endonucleases. Both satellite arrays and
rDNA are hypomethylated in the mutants, but
methylation at some single-copy sequences is un-
affected. Supporting this observation, biochemical
analysis of global methylcytosine levels indicates that
the mutants still contain appreciable quantities of
methylcytosine (20% of wild type in the most
hypomethylated mutant). No morphological pheno-
type has yet been associated with hypomethylation.
We are currently investigating whether the
hypomethylation mutants have any defects in
chromosome ultrastructure or behavior. In addition,
we plan to look for possible effects of hypomethyla-
tion on rDNA transcription, expression of "silenced"
ectopic insertions, and transposition in order to
evaluate the role DNA methylation plays in these
general processes.
In Press, Submitted, and In Preparation
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characterization of telomere-associated sequences from
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Richards, E.J., W.D.B. Loos, J. Giraudat, H.M. Goodman,
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55th COLD SPRING HARBOR SYMPOSIUM
ON QUANTITATIVE BIOLOGY
The Brain
May 30-June 6, 1990
ARRANGED BY
James D. Watson, Cold Spring Harbor Laboratory
Eric D. Kandel, Columbia University College of Physicians & Surgeons
Charles Stevens, Yale University
Terrance Sejnowski, Salk Institute
281 participants
Over 280 outstanding scientists from research centers in Europe, the Far East,
and the United States gathered at Cold Spring Harbor to present their latest
ideas and data on the central question in neurobiology: How does the brain
work? The program included 105 speakers who explored such fundamental pro-
cesses as vision, olfaction, learning, memory, and motor control. These
scientists, acknowledged leaders from such diverse areas in neurobiology as
molecular neurobiology, systems neurobiology, and brain function modeling are
attempting to solve similar problems with different approaches. The meeting pro-
vided an opportunity to illustrate how these different approaches complement
and reinforce each other.
J.D. Watson, E. Watson, L.A. Hazen, F. Crick
Opening presentations by Shosaku Numa, Martin Raff, Sten Grillner, Will
Newsome, and Marcus Raichle outlined the themes of the symposium. One of
the highlights of the meeting was the Dorcas Cummings Lecture "How Do We
See Things? " given by Francis Crick of the Salk Institute. An excellent summary
talk of the meeting was given by Michael Stryker of the University of California,
San Francisco. The conference resulted in productive scientific exchange and
was a fine way to begin the congressionally proclaimed "Decade of the Brain."
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H Damasio, T.J. Sejnowski, C. Gilbert J. Byrne, C F. Stevens
C. Shatz, F. Bonhoeffer, C. Blakemore, M. Raff, P Patterson
The meeting was supported in part by the National Institute of Mental Health
(an Institute of the Alcohol, Drug Abuse, and Mental Health Administration); the
National Cancer Institute, the National Institute of Child Health and Human Devel-
opment, and the National Institute of Neurological Disorders and Stroke (all divi-
sions of the National Institutes of Health); the U.S. Department of Energy; and the
National Science Foundation.
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PROGRAM
Welcome: J.D. Watson
Opening Remarks
Chairman: W.M. Cowan, Howard Hughes Medical Institute, Bethesda
Synaptic Mechanisms
Chairman: P. Andersen, University of Oslo
Vision
Chairmen: D.H. Hubei, Harvard Medical School
T.N. Wiese], Rockefeller University
Learning and Memory
Chairman: S. Benzer, California Institute of Technology
Ion Channels
Chairman: L. Jan, University of California, San Francisco
Cognitive Neuroscience: Attention
Chairman: F. Crick, Salk Institute
Cell Adhesion and Recognition
Chairman: G.M. Edelman, Rockefeller University
Motion Detection, Stereopsis, and Neural Codes
Chairman: R.H. Wurtz, National Eye Institute, National Institutes of Health
Cognitive Neuroscience: Memory
Chairman: P.S. Goldman-Rakic, Yale University School of Medicine
Synaptic Plasticity
Chairman: T.V.P. Bliss, National Institutes for Medical Research
Dorcas Cummings Lecture
Speaker: F. Crick, Salk Institute
Motor Control
Chairman: E. Bizzi, Massachusetts Institute of Technology
Snyapse Formation and Fine Tuning
Chairman: J.P. Changeux, Institut Pasteur
Remodelling
Chairman: C.J. Shatz, Stanford University School of Medicine
Control of Cell Identity
Chairman: T.M. Jessell, Columbia University College of Physicians & Surgeons
Sensory Processing
Chairman: H.R. Horvitz, Massachusetts Institute of Technology
Cognitive Neuroscience: Perception
Chairman: V.B. Mountcastle, Johns Hopkins University School of Medicine
Summary: M.P. Stryker, University of California, San Francisco
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MEETINGS
Genome Mapping and Sequencing
May 2-May 6, 1990
ARRANGED BY
Charles Cantor, Human Genome Center, Lawrence Berkeley Laboratory
Maynard Olson, Washington University School of Medicine
Richard Roberts, Cold Spring Harbor Laboratory
300 participants
The 1990 meeting on Genome Mapping and Sequencing was the third in what
appears destined to become a continuing series. The meeting focused on the
current techniques for genome mapping and sequencing and highlighted some
of the systems in which great progress is being made. Throughout both the for-
mal presentations and the posters sessions, it was clear that the polymerase
chain reaction (PCR) is playing a dominant role in almost all aspects of the field.
The use of sequenced tagged sites (STSs) as landmarks for physical mapping
studies is becoming popular and will greatly facilitate information exchange be-
tween mapping laboratories. Yeast artificial chromosomes (YACs) are proving
very popular as vectors for the isolation and characterization of large pieces of
DNA. Nowhere was this more apparent than in the mapping of the Caenorhab-
ditis elegans genome, which is currently the most advanced of all mapping
projects. The map progresses at great pace, and plans are already being made
for an assault on its complete sequence.
K. lsono, M. Kroger R. Roberts, C. Cantor, M. Olson
Although no dramatic new methods for DNA sequencing have appeared,
several technical advances were announced. Magnetic beads, in combination
with the biotin/streptavidin system, can be used to separate DNA strands after
PCR and can facilitate template preparation. This method is particularly well-
suited for automation. The need for increasingly automated procedures was em-
phasized during a whole session devoted to the subject. The need is especially
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obvious for DNA sequencing, and it was gratifying to learn of improvements in
the current sequencing machines and their associated computer software. Final-
ly, a new strategy for reducing the cost of large-scale sequencing, based upon li-
braries of short oligonucleotide primers, was proposed and is being tested.
Two clear lessons emerged from the meeting. The first relates to the para-
mount importance of oligonucleotides as reagents for both mapping and se-
quencing. If easier and cheaper methods for their production can be devised,
this could have a dramatic impact on the cost of the human genome project.
Second, if PCR, or some alternative technique, could be extended to allow the
routine amplification of 50- to 100-kb stretches of DNA, novel strategies for map-
ping and sequencing will become possible. These, in turn, could markedly affect
both the time-scale and the cost of many genome projects.
The meeting was supported in part by the National Center for Human
Genome Research, a division of the National Institutes of Health.
PROGRAM
Genome Organization
Chairman: K. Davies, John Radcliffe Hospital, Oxford
Large DNA Cloning Methods
Chairman: W. Bodmer, Imperial Cancer Research Fund
ALU-PCR and Other Methods
Chairman: M. Olson, Washington University School of Medicine
Informatics
Chairman: C. Cantor, Human Genome Center, Lawrence Berkeley Laboratory
Polymorphisms and Linkage Maps
Chairman: A.-M. Frischauf, Imperial Cancer Research Fund
Sequencing
Chairman: K. Isom Kobe University
Automation
Chairman: R. Roberts, Cold Spring Harbor Laboratory
Large-scale Mapping Projects
Chairman: S. Naylor, University of Texas, San Antonio
Function and Evolution of RAS Proteins
C. Petit, A. Ballabio
May 9-May 13, 1990
ARRANGED BY
David Botstein, Genentech, Inc.
James Feramisco, University of California, San Diego
Michael Wigler, Cold Spring Harbor Laboratory
162 participants
A meeting was held on the subject of the family of low-molecular-weight
GTP/GDP-binding proteins that are among the most highly conserved proteins in
eukaryotes. Their biological role, biochemical functions, regulation, structure,
and evolution were discussed. The known members of this superfamily have
grown in the past decade, from the two oncogenic RAS genes first discovered in
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retroviruses, to over thirty members. The charter members of the family, i.e., the
genes most homologous to the oncogenic RAS genes, are involved in signal
transduction pathways that control cell growth, proliferation, and differentiation.
More diverse members of the family are involved in disparate cellular functions,
such as vesicular trafficking, organization of the cytoskeleton, and determination
of cellular polarity. Several general themes are emerging. These proteins are
acted on by families of proteins that regulate guanine nucleotide exchange, and
there may be proteins that block guanine nucleotide exchange. Families of
proteins that specifically enhance guanine nucleotide hydrolysis, known as
GAPs, have been identified. Evidence was presented that GAPs both regulate
and mediate RAS action. Novel forms of carboxy-terminal covalent modifications
target these proteins to specific subcellular compartments, and considerable
progress has been made in elucidating these pathways. The function of the on-
cogenic RAS proteins still remains a mystery. This meeting was supported in
part by the National Science Foundation and the National Cancer Institute, a divi-
sion of the National Institutes of Health.
D. Stacey, T. Pawson D. Gallwitz, C Der, E Racker
M. Wig ler, J. Feramisco
228
PROGRAM
Mediators of RAS Activity
Chairman: F. McCormick, Cetus Corporation
Control of RAS. I
Chairman: D.W. Stacey, Cleveland Clinic Foundation
RAS Superfamily Structure and Function. I
Chairman: D. Botstein, Genentech, Inc.
Processing of RAS
Chairman: D. Gallwitz, Max-Planck Institut
Control of RAS. II
Chairman: S. Powers, Robert Wood Johnson Medical School
Cell Biology of RAS
Chairman: M. Perucho, California Institute of Biological Research
RAS Superfamily-Structure and Function. II
Chairman: P. Novick, Yale University School of Medicine
RNA Processing
May 16-May 20, 1990
ARRANGED BY
Anita Hopper, Pennsylvania State University
James Manley, Columbia University
Olke Uhlenbeck, University of Colorado, Boulder
445 participants
The field of RNA processing concerns all the cellular mechanisms that convert
the primary transcripts into functional RNAs and their subsequent degradation.
This field has undergone explosive growth in the past several years, resulting in a
very large meeting and a long waiting list. The award of the 1989 Nobel Prize in
Chemistry to two long-standing participants of this meeting added to this interest.
The 5-day meeting includes seven sessions of ten, short presentations each and
more than 240 posters in three poster sessions. A very broad range of disciplines
were represented, including structural biologists, biochemists, and molecular
and cellular biologists.
A major focus of the meeting was RNA splicing. Considerable data was pre-
sented defining the more than 50 basic components of the reaction by genetic
and biochemical methods. Through the use of mutants and partial reactions, a
preliminary definition of the reaction pathway has been achieved. A good deal of
attention has focused on the large number of ways that different organisms have
adapted the splicing pathway either to prepare special RNAs, as in trans-
splicing, or as a means to regulate gene expression, as in alternate splicing. An-
other area that received a lot of attention was the relation of RNA structure to its
function. This theme pervaded many sessions and underscored the continued
difficulties of understanding RNA structure. Several papers on catalytic mechan-
isms of enzymatic reactions involving RNA provided a view of the future. A final
session was devoted to the newly emerging field of RNA editing. The major
puzzle of determining the origin of the information for this reaction appears to be
solved and work can now focus on establishing a mechanism.
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The meeting was supported in part by the National Institute of General Medi-
cal Sciences (a division of the National Institutes of Health) and the National
Science Foundation.
E Brody, M Rosbash, M. Wickens, J. Abelson, C. Guthrie 0. Uhlenbeck, A. Hopper, J. Manley
PROGRAM
Mechanism of Splicing
Chairman: M. Rosbash, Brandeis University
Catalytic RNAs
Chairman: T. Cech, University of Colorado, Boulder
Ribonucleoprotein Particles
Chairman: C. Guthrie, University of California, San Francisco
Stable RNAs
Chairman: C. Greer, University of California, Irvine
3' Processing and Nuclear Export
Chairman: M. Edmonds, University of Pittsburgh
Regulation of mRNA Splicing
Chairman: B. Nadal-Ginard, Harvard Medical School
Editing, Modification, and Turnover
Chairman: K. Stuart, Seattle Biomedical Research Institute
RNA Tumor Viruses
May 23-May 27, 1990
ARRANGED BY
Paul Jolicoeur, Clinical Research Institute of Montreal
Maxine Linial, Fred Hutchinson Cancer Research Center
435 participants
Papers were presented at the 1990 RNA Tumor Virus meeting that covered all
aspects of retrovirus replication and pathogenesis. As in the previous few years,
about half of the meeting involved discussion of human immunodeficiency
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viruses (HIV), human T-cell leukemia viruses (HTLV), and animal models for
these. Some of the highlights included isolation and characterization of several
retroviral receptors, a new model for the function of the HIV TAT protein, and new
insights into virus assembly. The Abstract bookcover highlighted a novel mutant
of D-type Mason-Pfizer monkey virus that assembles like a C-type virus. Prog-
ress continues to be made in the study of retroviral integration. This year an in
vitro integration system using only purified murine leukemia virus integrase was
reported. Much attention was focused on the pathogenesis of lentiviruses, in-
cluding results from the simian and feline animal models.
Reverse transcriptase took center stage in a special session that com-
memorated the 20th anniversary of the discovery of this remarkable enzyme.
Both Drs. Temin and Baltimore were on hand to present overviews of the dis-
covery and importance of reverse transcriptase as well as recent data from their
laboratories.
P. Jolicoeur, H. Fan, N. Rosenberg
PROGRAM
Receptors/Glycoproteins
Chairmen: E. Hunter, University of Alabama, Birmingham
J. Sodroski, Dana-Farber Cancer Institute
Integration/Endogenous Viruses
Chairmen: A.M. Skalka, Fox Chase Cancer Center
R. Craigie, National Institutes of Health
Reverse Transcription
Chairmen: J. Coffin, Tufts University School of Medicine
S. Goff, Columbia University
231
I. Dotau, R. Craigie M. Kotler, A. Skalka
Celebration of the 20th Anniversary of the Discovery of Reverse Transcriptase
Speakers: H. Temin, McArdle Laboratory for Cancer Research, University of Wisconsin
D. Baltimore, Whitehead Institute for Biomedical Research
Transcription/trans-Activation (TAT)
Chairmen: G. Pavlakis, NCI Frederick Cancer Research Facility
H.J. Kung, Case Western Reserve University
Pathogenesis/Latency
Chairmen: H. Fan, University of California, Irvine
N. Rosenberg, Tufts University Medical School
Structural Proteins and Processing/Assembly
Chairmen: V. Vogt, Cornell University
R. Swanstrom, University of North Carolina
Transformation/Proliferation
Chairmen: H. Robinson, University of Massachusetts Medical Center
A. Rein, NCI Frederick Cancer Research Facility
Transcription (TAX)/Posttranscriptional Regulation
Chairmen: C. Rosen, Roche Institute of Molecular Biology
K. Beeman, Johns Hopkins University
SV40, Polyoma, and Adenoviruses
August 15-August 19, 1990
ARRANGED BY
Michael Botchan, University of California, Berkeley
Terri Grodzicker, Cold Spring Harbor Laboratory
David Livingston, Dana-Farber Cancer Institute
323 participants
The Tumor Virus meeting on SV40 virus, polyoma virus, and adenoviruses was at-
tended by over 300 scientists who met to discuss their latest work. The DNA
tumor viruses continue to serve as model systems to study mechanisms of
replication, transformation, transcription, and RNA processing.
Much of the emphasis in the meeting was placed on the interaction of cellular
and virus-encoded proteins as they affect key points of cell and gene regulation.
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Thus, investigations on the interaction of adenovirus El proteins and/or SV40
large T antigen with the retinoblastoma (RB) susceptibility gene product, p53
protein(s), and cyclin A were discussed. The role of protein modifications of viral
regulatory proteins by different kinases and phosphatases was also the subject
of some attention. The analysis of interactions of polyoma middle T antigen with
cellular tyrosine kinases and the role of such complexes in the transformation
process were also discussed. Much research continues to focus on the purifica-
tion and analysis of cellular proteins that are concerned with viral DNA replication
and the use of in vitro replication systems to dissect different steps in the replica-
tion process. The analysis of transcriptional regulation of viral promoters and en-
hancers continued to produce a variety of interesting results. Several cellular
transcription factors have been purified, the corresponding genes have been
M. Green, C. Cole S. Courtneidge, T. Roberts
cloned, and the interactions of the factors with viral regulatory proteins have been
studied, using in vivo and in vitro transcription systems. Talks were also given on
RNA splicing, control of poly(A)-site usage, translational control, the role of viral
proteins in cell-cycle regulation, cell-cycle-specific protein modifications, and the
role of different viral proteins in the host's immune response.
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PROGRAM
Transcription. I: Adenoviruses
Chairman: A. Berk, University of California, Los Angeles
Protein Complexes
Chairman: S. Courtneidge, European Molecular Biology Laboratory, Heidelberg
Replication. I
Chairman: B. Stillman, Cold Spring Harbor Laboratory
Transcription. II: SV40 and Polyoma
Chairman: M. Green, Harvard University
Transformation. I: Adenoviruses
Chairman: P. Hearing, State University of New York, Stony Brook
Posttranscriptional Regulation
Chairman: J. Nevins, Duke University Medical Center
Replication. II.
Chairman: E. Fanning, Institute for Biochemistry, Munich
Transformation. II: SV40 and Polyoma
Chairman: D. Livingston, Dana-Farber Cancer Institute
Molecular Genetics of Bacteria and Phages
August 21-August 26, 1990
ARRANGED BY
Lucia Rothman-Denes, University of Chicago
Miriam Susskind, University of Southern California
Andrew Wright, Tufts Medical School
301 participants
The 1990 meeting on Molecular Genetics of Bacteria and Phages attracted over
300 participants, who presented 220 talks and posters. A common thread was
the critical involvement of specific protein-DNA, protein-protein, protein-RNA, and
RNA-RNA interactions in a variety of fundamental genetic processes, including
gene regulation, DNA replication and packaging, recombination, and the mobility
of transposons and introns. A spectacular presentation was the direct visualiza-
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tion of DNA loops formed between RNA polymerase bound to a nitrogen-
regulated promoter and an activator protein bound to an enhancer sequence 390
by upstream. A session was devoted to the role of small, abundant DNA-binding
proteins that are involved in an ever-increasing variety of cellular processes. The
session on protein structure included several demonstrations of the mysterious
and amazing ability of certain heat-shock ("chaperonin") proteins to help other
proteins perform and an elegant study of the structural requirements for zipping a
leucine zipper.
PROGRAM
Role of Abundant, Small DNA-binding Proteins
Chairman: N. Craig, University of California, San Francisco
DNA Replication and Packaging
Chairman: G. Mosig, Vanderbilt University
RNA Polymerase and Promoter Interactions
Chairman: G. Gussin, University of Iowa
Transcription Activation
Chairman: S. Adhya, National Institutes of Health
Transcription Antitermination Global Control
Chairman: J. Roberts, Cornell University
Posttranscriptional Control
Chairman: D. Wulff, State University of New York, Albany
Hard Times and Development
Chairman: P. Youngman, University of Pennsylvania
Membranes: Transport, Secretion, and Signaling
Chairman: S. Gottesman, National Institutes of Health
Protein Structure and Chaperonins
Chairman: R. Sauer, Massachusetts Institute of Technology
Recombination
Chairman: R. Wiesberg, National Institutes of Health
Mouse Molecular Genetics
August 29-September 2, 1990
ARRANGED BY
Douglas Hanahan, University of California, San Francisco
Richard Palmiter, University of Washington, Seattle
Erwin Wagner, Institute of Molecular Pathology, Vienna
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381 participants
The third annual Mouse Molecular Genetics meeting represented a milestone in
the development of the field. The organizers invited only eight senior scientists to
serve as session chairpersons, and yet more than 400 people chose to attend
the meeting, resulting in over 100 short talks and 50 posters, which were present-
ed during eight sessions and two poster sessions. Whereas the first two meetings
justifiably emphasized the diverse biological possibilities afforded by transgenic
mice produced via embryo microinjection, this meeting revealed wider horizons.
One of these was the undeniable arrival of embryonic stem cells as a practical
vehicle for introducing site-directed integrations that alter or simply knock out the
function of endogenous chromosomal genes. Another was the remarkable con-
vergence of classical mouse genetics with the new genetics of cloned genes and
transgenic technology. There was also continuing progress with the candidate
gene approach toward the control of development, using both traditional mice
and their transgenic compatriots. In addition, transgenic mice continue to bear
fruit in studies on control of gene regulation and on mechanisms of
tumorigenesis, as well as in generating models of disease conditions.
Although it is impossible to review this remarkably diverse meeting succinctly,
a few highlights bear mention. The search for the testes-determining gene has
now reached fruition in the identification of a gene (Sry) encoding a putative
DNA-binding protein that is transiently expressed during male embryogenesis
and deleted in certain XY female mice. Classical genetics and molecular cloning
provided access to the Sry gene, and it is clear that transgenic mice will now al-
low a convincing test of this gene as the necessary and sufficient component of
the Y chromosome for the determination of male sexuality.
The capability to knock out specific endogenous genes in embryonic stem
cells was demonstrated in a number of talks reporting mice homozygous for
genes disrupted by homologous integration. Eleven homozygous knockouts
were described, with another half dozen clearly in the pipeline. The knockout of
the GATA-1 erythroid-specific transcription factor resulted in the failure of
erythroid cells to develop, and the lack of an intact Wint-1 gene produced mice
with major disruptions in their cerebellum. Remarkably, the absence of an intact
c-src gene did not obviate prenatal development, but rather produced viable
pups with defects in bone development and immune function, similar to a dis-
ease condition called osteopetrosis. Taken together with the knockout of 132
microglobulin, which results in mice lacking class I major histocompatibility com-
plex and CD8+ T cells, it becomes evident that this technology will have a major
impact in testing the biological roles (and necessity) of specific genes whose
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functions have been postulated from indirect experiments, such as their expres-
sion patterns during development.
It was gratifying to see the continuing convergence of classical and molecular
genetics. Several mouse mutants have now been identified as cloned genes.
The most long awaited was the steel mutation, which has been found to be in a
gene encoding a mast cell growth factor that is the ligand for the c-kit receptor
that is encoded by a gene disrupted in a mutation called W Another
spontaneous mouse mutant showing both immunological and bone defects is the
osteopetrotic mouse, and the op mutation has now been found to reside in the
gene that encodes the macrophage growth factor M-CSF. It is provocative that
the op/op mutation, which results in an absence of the secreted M-CSF, has a
phenotype remarkably similar to that arising in mice lacking the c-src protein
kinase, suggesting that both play important and possibly interconnected roles in
bone development. In another causality proof, the Snell dwarf mutation, which is
characterized by a failure to develop pituitary somatotrophs and lactotrophs, has
been shown to result from a deletion of the gene encoding the Pit-1 pituitary-
specific transcription factor, confirming that a cell-type-specific DNA-binding
protein identified by biochemical techniques is necessary for the function of
these cell types.
These and other examples throughout this meeting illustrate the breadth and
biological possibilities afforded in both the traditional and the new transgenic
techniques, as well as their convergence into an experimental mammalian sys-
tem that will prove to be the genetic system of the 1990s.
The meeting was supported in part by the National Institute of Child Health
and Human Development, the National Institute of Neurological Disorders and
Stroke, and the National Institute of Diabetes, Digestive and Kidney Diseases (all
divisions of the National Institutes of Health) and the National Science Foundation
(Genetics Program).
J. DeMayo, A. McLaren
PROGRAM
Gene Expression during Development and Germ Cells
Chairman: A. McLaren, University College, London
Functional Analysis of Development (Dominant Transgenes)
Chairman: K. Paigen, Jackson Laboratory
V. Price, L. Pevny, F. Conlon, T. DeChiara
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Functional Analysis of Development (Dominant Transgenes: Tumorigenesis)
Chairman: R. Brinster, University of Pennsylvania, School of Veterinary Medicine
Functional Analysis of Development (Gain-of-function: Disease Models)
Chairman: A. Berns, The Netherlands Cancer Institute
Developmental Mutants (Loss-of-function: Homologous Recombination)
Chairman: N. Jenkins, ABL-Basic Research Program, Frederick, Maryland
Developmental Mutants (Loss-of-function: Insertional Mutations and Imprinting)
Chairman: D. Solter, Wistar Institute
Developmental Mutants (Loss-of-function: Spontaneously or Environmentally Induced)
Chairman: S Waelsch, Albert Einstein College of Medicine
Regulation of Gene Expression (cis-Acting Elements)
Chairman: V. Chapman, Roswell Park Memorial Institute
Origins of Human Cancer
September 4-10, 1990
ARRANGED BY
Joan Brugge, University of Pennsylvania School of Medicine
Thomas Curran, Roche Institute of Molecular Biology
Ed Harlow, Cold Spring Harbor Laboratory
Frank McCormick, Cetus Corporation
317 participants
The second meeting on Origins of Human Cancer, which took place 14 years
after the original landmark meeting, was a testament to the power of molecular
genetics in probing the mechanisms involved in carcinogenesis. Since the first
meeting on this subject, there has been a virtual explosion of information relating
to the identification and characterization of the oncogenes associated with known
tumorigenic viruses, and the identification of these oncogenes as the homologs
of normal chromosomal genes (proto-oncogenes). Several of these proto-
oncogenes have been shown to be mutated or rearranged in human tumors, and
H. Bourne, A. Mahowald, J. Brugge
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the natural functions of some of the proto-oncogene products have been identi-
fied. Yet other genes have been found to suppress the development of tumors
(suppressor genes); loss or mutation of the suppressor genes or inactivation of
the function of their protein products by association with viral transforming
proteins represents an important stage in the etiology of this disease.
The meeting included a mixture of sessions dealing with mechanisms un-
derlying normal cellular growth control and oncogenic transformation (including
comparisons of the biological and biochemical activities of the proteins encoded
by proto-oncogenes and their oncogenic counterparts) with sessions that dealt
with model tumor paradigms (i.e., leukemia, breast, colon, lung, cervix, and liver).
In each tumor system, there was a discussion of the epidemiology of the disease,
the associated chromosomal abnormalities, and the multistage processes in-
volved in the development of the neoplasia. Throughout all the sessions, sig-
nificant new findings were presented, and certainly the density of new information
introduced at this meeting was a reflection of the impressive pace at which this
research is moving.
The meeting was supported in part by the National Cancer Institute, a division
of the National Institutes of Health.
PROGRAM
Welcome: J.D. Watson
Growth Control
Chairman: I. Herskowitz, University of California, San Francisco
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Oncogenes. I: RAS/GAP
Chairman: H. Bourne, University of California, San Francisco
Carcinogenesis and Mutagenesis
Chairman: C. Barrett, National Institute of Environmental Health Sciences
Epidemiology
Chairman: J. Fraumeni, National Institutes of Health
Tumor Suppressor Genes
Chairman: E. Stanbridge, University of California, Irvine
Carcinomas. I: Colon
Chairman: B. Vogelstein, Johns Hopkins University
Oncogenes. II: Signal Transduction
Chairman: J. Brugge, University of Pennsylvania School of Medicine
Carcinomas. II: Breast
Chairman: A. Harris, Imperial Cancer Research Fund, Oxford
Oncogenes. III: Transcription
Chairman: P. Sharp, Massachusetts Institute of Technology
Carcinomas. III: Cervix and Liver
Chairman: H. zur Hausen, Deutsches Krebsforschungszentrum, Heidelberg
Regulation of Hematopoiesis
Chairman: D. Baltimore, Rockefeller University
Carcinomas. IV: Lung
Chairman: J. Minna, National Institutes of Health
Leukemia
Chairman: P. Nowell, University of Pennsylvania
Tumor Development
Chairman: P. Leder, Harvard Medical School
New Approaches to Therapy
Chairman: E. Frei, Dana-Farber Cancer Institute
Modern Approaches to New Vaccines including
Prevention of AIDS
September 12-16, 1990
ARRANGED BY
Fred Brown, Wellcome Biotechnology, Ltd.
Robert Chanock, NIAID, National Institutes of Health
Harold Ginsberg, Columbia University College of Physicians & Surgeons
Richard Lerner, Research Institute of Scripps Clinic
198 participants
The eighth annual meeting on Modern Approaches to New Vaccines provided an
opportunity for basic scientists and clinical investigators to exchange their latest
research observations and broaden their perspective of the many interactive
components of experimental immunoprophylaxis, such as immunology, virology,
bacteriology, parasitology, epidemiology, molecular pathogenesis, clinical in-
fectious diseases, and clinical trials.
Many important advances in various interrelated fields of investigation were
reported. For example, cloning of viral-antigen (influenza A virus hemagglutinin)-
specific murine immunoglobulin Fab fragments from a combinatorial expression
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library was described for the first time. Noteworthy also was the report of suc-
cessful intracellular immunization using a parvovirus (adeno-associated virus) -
based antisense vector to transduce intracellular resistance to human im-
munodeficiency virus (HIV) or human herpes virus. Despite a number of previous
failures to induce a neutralizing antibody response with picornavirus outer capsid
proteins expressed by a recombinant vector, success was reported for hepatitis
A virus capsid proteins expressed by a baculovirus recombinant. In addition, two
examples were presented of a new strategy to increase the immunogenicity of a
viral antigen by altering its intracellular pathway and ultimate site of localization.
Rotavirus VP7 outer capsid protein and dengue virus envelope glycoprotein that
were modified so that they were displayed on the surface of infected cells, rather
than being retained intracellularly, each exhibited a striking increase in im-
munogenicity.
This meeting was supported in part by the Rockefeller Foundation.
PROGRAM
AIDS. I
Chairman: H. Ginsberg, Columbia University College of Physicians & Surgeons
Immunology. I
Chairman: R. Lerner, Research Institute of Scripps Clinic
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Parasitology and Bacteriology
Chairman: J. Young, Molecular Vaccines, Inc.
Virology. II
Chairman: F. Brown, Wellcome Biotechnology, Ltd.
AIDS. II
Chairman: P. Nara, NCI, Frederick Cancer Research Facility
AIDS. III
Chairman: F. Ennis, University of Massachusetts Medical School
Virology. III
Chairman: A. Kapikian, National Institutes of Health
AIDS. IV and Virology. IV
Chairman: E. Norrby, Karolinska Institutet
Summary: E. Norrby, Karolinska Institutet
F. Ennis B. Murphy, J Esposito
Evolution: Molecules to Culture
September 24-27, 1990
ARRANGED BY
Richard Dawkins, Oxford University
Jared Diamond, University of California School of Medicine, Los Angeles
119 participants
The problem of similar structures arises in many fields, as when molecular
biologists compare structures of two proteins or when historical linguists com-
pare languages. The meeting on Evolution: Molecules to Culture considered the
relative contributions to similarity from common ancestry, convergence, borrow-
ing, and chance in six fields whose practitioners rarely communicate with each
other. The fields included molecular biology, functional morphology, animal be-
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J. Maynard Smith, P. Jenkins, R. Hickson, D Labuda
R. Sakai, G Lauder, J. Kiu
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havior, studies of sexual evolution, cultural anthropology, and linguistics. Among
the many highlights of the meeting was the realization that there is now an
emerging science of the comparative method to solve the problems that arise in
determining ancestral states and phylogenetic trees. Another highlight was the
recognition of the exciting prospect of the marriage between historical linguistics
and other fields, whereby statistical and mathematical models derived from other
areas could be applied to linguistic problems and whereby also human history
could be inferred from the degree of concordance between molecular and lin-
guistic characteristics of human populations.
The meeting was supported in part by the Alfred P. Sloan Foundation.
PROGRAM
Introduction: J. Diamond, University of California School of Medicine, Los Angeles
Molecular Evolution
Chairman: R. Doolittle, University of California, San Diego
Functional Morphology
Chairman: G.V. Lauder, University of California, Irvine
Comparative Method
Chairman: P. Harvey, Oxford University
Animal Behavior
Chairman: N.B. Davies, University of Cambridge
Sex and Sexual Selection
Chairman: L. Partridge, University of Edinburgh
Human Society
Chairman: P.V. Kirch, University of California, Berkeley
Linguistics
Chairman: A. Manaster Ramer, IBM Research and Wayne State University
Overview
Chairman: J. Diamond, University of California School of Medicine, Los Angeles
Speakers: J. Maynard Smith, University of Sussex
L.L. Cavalli-Sforza, Stanford University
E. Mayr, Harvard University
D. Hull, Northwestern University
R. Dawkins, University of Oxford
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Cell and Molecular Neurobiology of Aplysia
October 3-October 7, 1990
ARRANGED BY
Eric Kandel, Columbia University College of Physicians & Surgeons
Hersch Gerschenfeld, Ecole Normale Superieure
Leonard Kaczmarek, Yale University Medical School
Richard Scheller, Stanford University
Micha Spira, Hebrew University, Israel
84 participants
The second international meeting on Cell and Molecular Biology of Aplysia was
attended by 90 people from the United States, the Union of the Soviet Socialist
Republics, Europe, the Middle East, Canada, and Japan. Participants included a
number of investigators who work on related gastropod preparations, including
Bulla, Clione, Helix, Helisoma, Hermissenda, Lymnaea, Planorbis, and Tritonia.
All of these species share the property that originally made Aplysia so attrac-
tive-neurons with giant cell bodies. This feature, which allows neurons to be
identified as unique individuals that can be identified across preparations, was
originally valued because it allows one to work out neuronal wiring diagrams in
cellular detail. More recently, the large size of these neurons has also been im-
portant in facilitating biochemical and molecular biological studies.
There were 40 platform presentations and 33 posters. The presentations
were of high quality and included the first molecular characterization in Aplysia of
K* channels, a novel mechanism for processing peptides to target different pep-
tides to different terminals of the neuron, and the first analysis of operant con-
ditioning in Aplysia. A number of papers focused on the molecular mechanisms
that underlie the behavioral plasticity, defined as a change in the response of an
animal to a repeated, unchanging stimulus: those due to changes in motivational
state (e.g., hunger) and those due to experience (learning). Presentations ad-
dressed the biochemical mechanisms that generate the structural changes that
contribute to long-term behavioral plasticity; their relationship to mechanisms that
operate during development, the interactions of second messenger systems that
mediate behavioral plasticity at the cellular level, the functional implications of a
neuron having more than one synaptic transmitter, and the molecular mechan-
isms that cause changes in activity produced by a circadian rhythm-generating
neural network. The meeting concluded with a demonstration by Paul Forscher of
a new imaging method for studying growth-cone movement and a summary of
the proceedings by Irwin Levitan. The meeting proved a highly profitable forum
for the discussion of both new methods and findings emerging from studies re-
lated to the cellular and molecular biology of Aplysia.
The meeting was supported in part by the fidia Research Foundation.
PROGRAM
Welcome: H. Gerschenfeld, Ecole Normale Superieure
G.N. Orlovsky, Moscow State University
Cell Imaging and Neuronal Growth
Chairman: I. Levitan, Brandeis University
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Ion Channels and Channel Modulation
Chairman: J.S. Kehoe, Ecole Norma le Supdrieure
Peptides, Small Molecule Transmitters, and Synaptic Transmission
Chairman: L. Tauc, CNRS, Gif-sur-Yvette
Circadian Rhythm and Rhythmic Behavior
Chairman: J. Jack let, State University of New York, Albany
Neural Circuitry and Behavior
Chairman: I. Kupfermann, Columbia University
Nonassociative Learning
Chairman: C.H. Bailey, Columbia University
Associative Learning
Chairman: T.J. Carew, Yale University
Demonstration and Summary
Chairman: L. Kaczmarek, Yale University
Speakers: P. Forscher, Yale University
I. Levitan, Brandeis University
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DIRECTOR'S REPORT
Robertson House provides housing and dining accommodations at Banbury Center
The Banbury Center continues to play a special part in the Laboratory's meet-
ings program. Fourteen workshop-style meetings were held here in 1990, and
over 500 scientists attended them. In addition, there were three special meet-
ings for science journalists, congressional staff, and senior executives involved
in biotechnology. Bea To liver and Ellie Sidorenko in the Center's office and
Katya Davey at Robertson House once again coped wonderfully with the
pressures that always arise when dealing with a program of this nature-
cancellations, unusual requests, and meetings arranged at the last minute. The
1990 program at the Banbury Center seemed to be even more varied than
usual, so it is even more difficult to group the meetings into categories.
Molecular Genetics
Banbury continues to be a leading center for discussion meetings on human
molecular genetics, and there were four meetings on this theme in 1990. The
meetings ranged from discussions of methodology, through applications to par-
ticular diseases, to the societal implications of the powers of a genetic approach
to the ills that afflict human beings.
Although electrophoresis is used in every molecular biology laboratory to
separate DNA molecules, the technique as originally developed could not be
used for very large DNA molecules. In recent years, further developments have
led to systems that separate DNA fragments as large as intact yeast
chromosomes. Electrophoresis of Large DNA Molecules was concerned with
the theory and the practice of these techniques. In addition, the participants dis-
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cussed some of the novel techniques being developed for the physical analysis
of DNA. The most remarkable of these uses scanning tunneling microscopy to
"see" a DNA molecule directly.
The furthest extreme from analyzing individual DNA molecules is the study of
human genetics as revealed by the inheritance of genes in families. This has
proved to be an extremely powerful approach, as shown by the cloning of hu-
man disease genes such as that for cystic fibrosis. Genetic analysis of human
disorders that may result from the effects of several genes, acting independently
or together, and in which there is a strong environmental influence is much more
difficult. This was the subject of the meeting on the Genetics and Molecular Biol-
ogy of Complex Diseases. These diseases include autoimmune diseases such
as arthritis, alcoholism, and schizophrenia. The participants discussed general
approaches to the genetic analysis of these disorders and the progress, or lack
of it, in specific disorders.
Neurofibromatosis was one of the successes of cloning human disease
genes in 1990, and the Banbury Center meeting on Neurofibromatosis was held
at just the right time, in October. The gene for one form of neurofibromatosis had
been cloned in the Spring of 1990, and its similarity to genes known to be in-
volved in cancer was recognized just a few weeks prior to the meeting. The suc-
cess of research on neurofibromatosis is an example of what can be achieved
through a judicious combination of cooperation and competition and by the ef-
forts of a small foundation.
Increasingly, the results of the research laboratories' cloning of human dis-
ease genes are translated into practical, diagnostic applications. However, it is
becoming clear that DNA-based diagnosis may not be an unalloyed success.
The Impact of Human Molecular Genetics on Society considered the difficulties
that may arise when DNA diagnosis becomes possible for common, complex
genetic disorders. The issues discussed included how to decide when popula-
tion screening programs should be implemented and how an individual's ac-
cess to health care and insurance may be affected. The comments of the Euro-
pean geneticists, working in countries with national health care systems, were
particularly interesting, and there appear to be strong parallels with these same
issues in relation to AIDS.
A final meeting in this area dealt with Mapping the Genomes of Agriculturally
Important Animals. Although concerted efforts are being made to map and ana-
lyze the genomes of human beings, the fruit fly, a nematode worm, a bacterium,
and yeast, the same resources have yet to be applied to the genomes of
domesticated animals. The bovine genetic map is perhaps the best developed,
but even there the numbers of genes assigned to particular chromosomes is
very small. This meeting was intended as a planning meeting to discuss what
should be done to rectify this situation.
Plant Molecular Biology
Despite the obvious practical importance of studying the molecular biology of
plants, it has not been easy to find funding for meetings on this topic. So in
1990, a meeting on Recognition in Plant-Pathogen Interactions was included in
Banbury's Corporate Sponsor series of meetings. Plants have devised a variety
of means to deal with pathogens, but little is known of the molecular specificity
that determines the interaction between a plant -arind/potential pathogens. This
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meeting reviewed some of the best understood plant-pathogen interactions and
dealt particularly with progress toward cloning the genes involved. The ability to
manipulate the genes responsible for the resistance of plants to bacteria and
fungi could have far-reaching effects for agriculture.
Topics in Basic Research
Two meetings dealt with technical developments in molecular biology. It might
seem at first sight to be easy to derive the three-dimensional structure of a
protein from its amino acid sequence. In fact, it is still not possible to do this,
and participants in the meeting Computational Aspects of Protein Folding criti-
cally reviewed the approaches that have been devised. Among the topics dis-
cussed were methods based on free-energy calculations, molecular dynamics
studies, and knowledge-based approaches. The importance of the subject was
underscored by the large attendance of scientists from the Laboratory's corpo-
rate sponsors.
Monoclonal antibodies are among the most important tools available to
molecular biologists. Because of their specificity, monoclonal antibodies allow
very precise detection and purification of proteins. These antibodies are pro-
Banbury Meeting House
duced by cells growing in tissue culture, but over the past 2 years, methods
have been developed for using recombinant DNA techniques to produce
antibodies in bacteria. Vectors for Cloning the Immune Response reviewed the
present state of development of this field and looked forward to new develop-
ments in vectors and techniques that will speed up the move to creating
antibodies in vitro.
Cell death is usually thought of as the ultimate response of a cell to trauma,
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but so-called programmed cell death is a part of normal cell and tissue function-
ing. The phenomenon has been studied in a variety of cells, tissues, and
organisms and involves an interesting set of morphological and molecular
changes. Our meeting on Programmed Cell Death: Concepts and Mechanisms
was a first attempt at drawing these different interests together to determine the
degree to which common mechanisms may be involved.
One factor contributing to cell death may be the generation of free-oxygen
radicals. These are highly reactive and toxic to cells, and cells have evolved
methods for neutralizing these free radicals before they can do harm. The meet-
ing on Molecular Biology of Free-radical Scavenging Systems dealt with the
molecular mechanisms by which cells cope with oxidative stress. In addition,
there were discussions of some of the biomedical applications that might be de-
veloped for protecting cells.
Environmental Hazards
The primary focus of the first meetings at the Banbury Center was on "biological
risk assessments, especially of agents thought to act at the genetic level." The
first of the two 1990 meetings on environmental hazards continued this theme.
Molecular Mechanisms of Fiber Cytotoxicity and Carcinogenesis reviewed the
current research on the biological effects of asbestos and the extent to which
extrapolations can be made to the possible risks associated with man-made
substitutes for asbestos. The meeting was notable for the range of mechanisms
examined, including the disruption of cell division by fibers, their effects on
oxyradicals, and their role in inducing genetic changes.
The second of the year's meetings in this area was The Biological Basis for
Risk Assessment of Dioxins and Related Compounds. A meeting dealing with
the biological effects of dioxin was held at the Banbury Center in 1984. As its
title indicates, the 1990 meeting dealt with the impact of the results of biological
and epidemiological research on risk assessment and on regulations governing
environmental levels. There was much discussion about the biological basis for
the models that are used to estimate human exposure to dioxin. This is a highly
controversial subject, and it is to be hoped that the discussions that went on at
this meeting will lead to a resolution of some of the problems involved.
Sloan Foundation Workshops
The findings of biological research are having, or should have, an increasing
relevance to many aspects of society. The importance of a propdr interpretation
and implementation of those findings cannot be overemphasized. The aim of
these workshops is to provide two influential groups, congressional staff and
science journalists, with an opportunity to learn at first hand about some of this
research. The subject of the congressional staff meeting was Addiction. The
workshop covered an enormous range of topics, including an historical survey
of drug addiction and alcoholism in the United States, the pharmacology of ad-
diction, the relationship (if any) between "psychological" addiction (e.g., gam-
bling) and drug addiction. The meeting finished with a session debating whether
controlled legalization of drugs would alleviate or exacerbate the drug epidemic.
The science journalists' workshop dealt with an epidemic of another kind.
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Cancer rates are increasing in women, and the meeting on Women and Cancer
surveyed the latest research on the genetics of breast, cervical, and lung cancer
and how this research is being translated into diagnostic tests and treatments.
Some of this work is controversial, as for example, studies of the effectiveness of
screening tests for breast cancer. A particularly disturbing presentation showed
how the increase in women smoking parallels the increasing incidence of lung
cancer in women and how women are special targets for advertising.
The Baring Brothers/Cold Spring Harbor Laboratory Meeting
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Cancer is one area where genetic analysis at the molecular level has led to revo-
lutionary new insights, and it seemed to be just the right topic for our 1990
senior executives meeting. It was an outstanding meeting. A series of talks on
fundamental research on cancer dealt with oncogenes and the activities of their
protein products, control of the cell cycle, and genetic prognosis. These were
followed by presentations on metastasis, drug-resistance genes, and new
therapies for breast cancer. Cold Spring Harbor Laboratory has had a long in-
volvement with cancer research, and it was appropriate that the participants
spent an afternoon discussing research with some of the Laboratory's scientists.
Other Meetings
As in previous years, the Banbury Center has been used as a meeting center by
a small number of outside groups. The Esther A. and Joseph Klingenstein Fund
held their annual meeting of Klingenstein research fellows at the Center in April.
A participant in this year's meeting was Walter Gilbert, who speculated on what
the genome projects might mean for neurobiology research. All research in biol-
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ogy is coming to depend increasingly on mathematics and computers, not just
for analysis, but also for modeling. The National Science Foundation sponsored
a small workshop that discussed what might be done to develop training in
mathematical and computational skills for biologists. The Huntington Hospital
Board of Trustees and the Psychiatry Department of Mt. Sinai Medical School
also came to the Center.
Banbury Meeting House, rear view
Funding
Acknowledgments for financial support of meetings at the Banbury Center must
always begin with the members of the Laboratory's Corporate Sponsor Program.
In 1990, five meetings at the Banbury Center were supported by this program. It
is no exaggeration to say that the number and diversity of our meetings could
not be maintained without our Corporate Sponsors. Companies were also gener-
ous in their support of other meetings. Five companies interested in elec-
trophoresis techniques contributed to the Electrophoresis of Large DNA
Molecules meeting, and SmithKline Beecham sponsored the meeting on Vectors
for Cloning the Immune Response. The Chlorine Institute contributed to the
meeting on The Biological Basis for Risk Assessment of Dioxins and Related
Compounds. The Environmental Protection Agency helped fund two meetings,
and funding from the United States Department of Agriculture, the National
Science Foundation, and Granada BioSciences helped fund the meeting on
Mapping the Genomes of Agriculturally Important Animals. The Alfred P. Sloan
Foundation continues to fund the science journalists' and congressional staff
workshops. The Pew Charitable Trusts supported the meeting on The Impact of
Human Molecular Genetics on Society. A full listing of Banbury Center funds can
be found with the financial statements for the Laboratory.
We have received two major grants for meetings beginning in 1991. The Wil-
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liam Stamps Farish Fund has made the Center a three-year award for meetings
on the genetics of common polygenic diseases. This is undoubtedly where the
next major advances in human genetics will take place. The Banbury Center and
the DNA Learning Center have received a joint grant from the Department of En-
ergy for a series of workshops on genetics. The aim of the workshops will be to
provide information on human genetics for nonscientists involved in human
genome projects. We hope that the participants in the workshops will make use
of the information in their own special areas.
Banbury Center Books
Cold Spring Harbor Laboratory Press continues to produce an excellent series
of publications based on Banbury Center meetings. There were two further
books in the Banbury Report series, from meetings held in 1989. These were
Genetics and Biology of Alcoholism and Biology of Mammalian Germ Cell
Mutagenesis. The first of the new series of Current Communications in Cell &
Molecular Biology was published in early 1991. These books will still be based
on Banbury meetings but will now contain about ten selected reviews instead of
short abstracts of all presentations. They have more figures and references, and
the new format should result in books of lasting value. Electrophoresis of Large
DNA Molecules is the first in the new series, and it will be followed by books
based on other 1990 meetings. The Press also published a report of the meeting
on Mapping the Genomes of Agriculturally Important Animals.
Looking Forward to 1991
As is usual at the time this report is written, the program for the current year is
still being developed. However, it promises to be as stimulating and exciting as
in previous years. There will be meetings on basic research (adhesion molecule
receptors, receptors for viruses, and membrane proteins), molecular genetics
(Marfan disease, breast cancer, Escherichia coli genome, and AIDS), and social
issues in biological research. One of the most exciting developments, referred to
above, will be the first of the genetics workshops for individuals involved in
genome projects. In his 1981 Director's Report, Dr. Watson described the Ban-
bury Center program as being a most intellectually diverse smorgasbord" of
meetings. It is this variety of subjects and the outstanding quality of the
participants that makes the Banbury Center one of the most exciting meetings
centers in the world.
Jan A. Witkowski
Publications
Witkowski, J.A. 1990. [correspondence]. Carrel's Cultures. Science 247: 1385-1386.
Witkowski, J.A. 1990. The 51 most-cited articles in the Cold Spring Harbor Symposia on
Quantitative Biology. Current Contents 28, July 9 1990: 7-17.
Witkowski, J.A. 1990. The inherited character of cancer. Cancer Cells 2: 229-257.
Witkowski, J.A. 1990. Milestones in the development of DNA technology. In Forensic DNA
Technology (ed. M.A. Farley and J.J Harrington), pp. 1-23. Lewis Publishers, Inc.,
Michigan.
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MEETINGS
Sloan Foundation Congressional Workshop on Addiction
January 25-January 27
ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
M.J. Kreek, Rockefeller University, New York, New York: M. Eckardt, National Institute on Alcohol Abuse and Al-
Pharmacology and physiology of opiate addiction. coholism, Bethesda, Maryland: Alcohol as an addictive
N. Grunberg, Uniformed Services University of the Health substance.
Sciences, Bethesda, Maryland: Tobacco as an addictive S. Blume, South Oaks Hospital, Amityville, New York:
substance. Gambling as an addiction.
SESSION 2
T.R. Kosten, Yale University, New Haven, Connecticut: W. Comer, Bristol-Myers Squibb Company, New York, New
Treatments for drug addiction. York: Response of the pharmaceutical industry.
SESSION 3
D. Courtwright, University of North Florida, Jacksonville: New York: Legalization:Its potential impact on the streets.
Social and legislative origins of narcotic control. E.A. Nadelmann, Princeton University, New Jersey:
P. Reuter, RAND Corporation, Washington, D.C.: Comments on legalization.
Legalization issues: The current debate. A. Goldstein, Stanford University, California: Comments on
A. Hamid, John Jay College of Criminal Justice, New York, legalization.
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Mapping the Genomes of Agriculturally Important Animals
February 25-February 28
ARRANGED BY
C.J. Arntzen, Texas A&M University, College Station
N.L. First, University of Wisconsin, Madison
J.E. Womack, Texas A&M University, College Station
SESSION 1: Mammalian Gene Mapping: A Comparative Approach
Chairperson: C.J. Arntzen, Texas A&M University, College Station
D.E. Housman, Massachusetts Institute of Technology,
Cambridge: The human gene map: An overview of
strategies, status, and application.
D.L. Nelson, Baylor College of Medicine, Texas: Molecular
dissection of human X chromosome.
J.E. Womack, Texas A&M University, College Station:
Genomic conservation in humans, mice, and cattle.
L.C. Skow, Texas A&M University, College Station: The
mouse gene map: Implications for the genomes of
domestic animals.
V. McKusick, Johns Hopkins University, Baltimore,
Maryland: Discussion: Potential interrelationships with
human genome initiative.
SESSION 2: Potential Benefits of Animal Gene Maps to Agriculture
Chairperson: J. Lunney, Agricultural Research Service, USDA, Beltsville, Maryland
A.H. Paterson, E.I. du Pont de Nemours & Co., Inc., Wil-
mington, Delaware: Mapping QTL in tomato using genet-
ic linkage to DNA markers.
M. Soller, The Hebrew University of Jerusalem, Israel: Ex-
perimental designs and statistical analyses for mapping
QTL in animal populations.
A. Tea le, ILRAD, Nairobi, Kenya: Genes controlling disease
resistance as targets of bovine genome research.
L.A. Schuler, University of Wisconsin, Madison: The prolac-
tin gene family in cattle.
SESSION 3: Approaches to the Development of Animal Gene Maps
Chairperson: J.E. Womack, Texas A&M University, College Station
M.S. Georges, Genmark, Inc., Salt Lake City, Utah: Charac-
terization of highly polymorphic bovine markers.
H. Lewin, University of Illinois, Urbana: UFO -PCR: A strategy
for animal genome mapping.
R.L. White, Howard Hughes Medical Institute, University of
Utah Medical Center, Salt Lake City: New and emerging
technologies in linkage marker development: Parallel ap-
plication in humans and animals.
J. Hetzel, CSIRO, Queensland, Australia: International col-
laboration: Use of pedigreed reference families.
J. Hetzel, J. Womack, C. Arntzen
258
M. Soller A. Tea le, V. McKusick
SESSION 4: The Current Status of Gene Maps in Animals
Chairperson: H. Lewin, University of Illinois, Urbana
J.E. Womack, Texas A&M University, College Station: Cow.
L.B. Schook, University of Illinois, Urbana: Pig.
L.C. Skow, Texas A&M University, College Station: Horse.
SESSION 5: Discussion of Programs and Strategies
Chairperson: N.L. First, University of Wisconsin, Madison
J.E. Womack, Texas A&M University, College Station: USDA
Joint Committee on Animal Genome Mapping.
L.B. Schook, University of Illinois, Urbana: NC-150 Com-
mittee on the Application of Cellular and Molecular Biol-
ogy to Animal Science Research.
N.P. Clarke, Texas A&M University, College Station: National
J. Hetzel, CSIRO, Queensland, Australia: Sheep and goat.
R.M. Shuman, North Carolina State University, Raleigh:
Poultry.
initiatives in animal agriculture.
J. Hetzel, CSIRO, Queensland, Australia: International pro-
grams.
H. Mussman, US Department of Agriculture, Washington,
D.C.: Summary.
Electrophoresis of Large DNA Molecules: Theory, Practice,
and Future
March 5-March 8
ARRANGED BY
B. Birren, California Institute of Technology, Pasadena
E. Lai, University of North Carolina at Chapel Hill
SESSION 1: DNA Molecules and Gels
Chairperson: P. Serwer, University of Texas Health Science Center at San Antonio
F.H. Kirkpatrick, FMC BioProducts, Rockland, Maine: Over-
view of agarose gel properties.
B. Akerman, Chalmers University of Technology, Gothen-
burg, Sweden: Reorientational dynamics and mobility of
DNA during pulsed-field gel electrophoresis.
C. Bustamante, University of New Mexico, Albuquerque:
Observations of kinked configurations in DNA molecules
undergoing orthogonal field alternating gel elec-
trophoresis.
J.A. Schellman, University of Oregon, Eugene: Orientation
response and relaxation of DNA in agarose gels.
S. Smith, University of New Mexico, Albuquerque: Computer
simulation of individual DNA molecular motion during
pulsed-field gel electrophoresis.
J.M. Deutsch, University of California, Santa Cruz: Prediction
of electrophoresis experiments using computer simula-
tions.
G. Holzwarth, Wake Forest University, Winston-Salem, North
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C.R. Cantor, J.A. Witkowski, E. Lai C. Bustamante
Carolina: Acceleration of DNA during PFGE.
L.S. Lerman, Massachusetts Institute of Technology, Cam-
SESSION 2: Instrumentation
Chairperson: E. Lai, University of North Carolina at Chapel Hill
J. Noolandi, Xerox Research Center of Canada, Ontario: The
Xerox CAGE (computer-assisted gel electrophoresis)
system for pulsed-field gel electrophoresis of DNA.
J.R. Fassett, Beckman Instruments, Inc., Fullerton, Califor-
nia: The transverse alternating field system: New de-
signs.
S. Ferris, Bio-Rad Laboratories, Hercules, California:
Algorithm-optimized, multistate CHEF electrophoresis.
R. Blakesley, GIBCO/BRL, Life Technologies, Inc.,
E. Lai, L. Lerman
bridge: The interaction between DNA melting and its
electrophoretic mobility in polyacrylamide gels.
Gaithersburg, Maryland: Small DNA separations with a
PACE apparatus.
K. Kolb le, University of Oxford, United Kingdom:
ST/RIDE-An angle-variable 3D-PFGE system.
G.-J.B. van Ommen, Sylvius Laboratories, Leiden, The
Netherlands: Design and use of a simple space-saving
CHEF system driving four independent time-ramp pro-
grams.
SESSION 3: Electrophoresis
Chairperson: L.S. Lerman, Massachusetts Institute of Technology,
G.F. Carle, University of Nice, France: Field inversion gel
electrophoresis. B.
G. Chu, Stanford University Medical Center, California:
Separation of very large DNA with a variable angle CHEF C.
device.
P. Serwer, University of Texas Health Science Center at San S.
Antonio: New modes and effects of pulsed-field gel elec-
trophoresis. C.
E. Lai, University of North Carolina at Chapel Hill: Studies of
Cambridge
DNA migration made with the PACE system.
Birren, California Institute of Technology, Pasadena: Fac-
tors influencing pulsed-field migration of DNA.
Heller, University of Constance, Germany: Field inversion
gel electrophoresis with different pulse-time ramps.
Beverely, Harvard Medical School, Boston, Massachu-
setts: Circular DNA and pulsed-field gel electrophoresis.
R. Cantor, Lawrence Berkeley Laboratory, California: Ac-
celerating PFGE separations.
SESSION 4: Applications
Chairperson: C.R. Cantor, Lawrence Berkeley Laboratory, California
G.-J.B. van Ommen, Sylvius Laboratories, Leiden, The
Netherlands: Applications of PFGE and CHEF analysis to
disease study and YAC analysis.
C.L. Smith, University of Berkeley, California: Optimizing ap-
plications of PFGE electrophoresis.
H. Lehrach, Imperial Cancer Research Fund, London,
United Kingdom: Experimental approaches and results in
mapping large regions of mammalian genomes.
SESSION 5: The Future
Chairperson: B. Birren, California Institute of Technology, Pasadena
S. Williams, Cold Spring Harbor Laboratory, New York: Image analysis of gel patterns.
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A.S. Cohen, Northeastern University, Boston, Massachu-
setts: Restriction fragments and DNA sequencing using
open and gel high-performance capillary electrophoresis
(HPCE).
W. Efcavitch, Applied Biosystems, Inc., Foster City, Califor-
nia: Capillary gel electrophoresis.
C. Bustamante, University of New Mexico, Albuquerque:
STM studies of DNA.
Genetics and Molecular Biology of Complex Diseases
March 12-March 15
ARRANGED BY
A. Chakravarti, University of Pittsburgh, Pennsylvania
E.R. Lander, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: Genetics I: The Complexity of Inheritance
Chairperson: E.R. Lander, Whitehead Institute for Biomedical
J V. Neel, University of Michigan, Ann Arbor: The "bottom
up" approach to multifactorial inheritance: Some prob-
lems.
J.-M. Lalouel, University of Utah School of Medicine, Salt
Lake City: Genotypic versus phenotypic inference in
complex inheritance.
M.-C. King, University of California, Berkeley: Gene map-
ping of complex diseases, especially cancer (inherited
vs somatic alterations, choice of models, heterogeneity,
etc.).
Research, Cambridge, Massachusetts
C. Sapienza, Ludwig Institute for Cancer Research,
Montreal, Canada: Genetic models for penetrance and
expressivity.
E.H. Leiter, The Jackson Laboratory, Bar Harbor, Maine: The
role of environment in modulating the penetrance of
diabetogenic susceptibility genes in nonobese diabetic
(NOD) mice.
SESSION 2: Complex Diseases I: Cardiovascular and Psychiatric Diseases
Chairperson: A.G. Motulsky, University of Washington School of Medicine, Seattle
H.H. Hobbs, University of Texas Southwestern Medical Cen-
ter at Dallas: Evidence for an LDL-lowering gene in a
family with familial hypercholesterolemia.
S. Humphries, Charing Cross Sun ley Research Center,
London, United Kingdom: Strategies to identify func-
tionally important common polymorphisms in candidate
genes involved in atherosclerosis, thrombosis, and
coronary artery disease risk.
M. Baron, New York State Psychiatric Institute, New York,
New York: Genetic mapping of mental illness: Op-
portunities and pitfalls.
I.I. Gottesman, University of Virginia, Charlottesville:
Phenotypic confusion in the classification of
schizophrenics and their relatives for genetic analyses.
J.D. Rine, University of California, Berkeley: A possible con-
tribution of dogs to behavioral genetics of mammals.
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A. Chakravarti
SESSION 3: Genetics II: Genetic Tools
J.V. Neel, S. Beall
Chairperson: A. Chakravarti, University of Pittsburgh, Pennsylvania
G.J. Thomson, University of California, Berkeley: Mathemati- Cambridge, Massachusetts: Quantitative analysis of
cal techniques for molecular mapping of complex human polygenic traits.
genetic diseases. M. Lathrop, CEPH, Paris, France: Non-HLA genes in type I
N.J. Risch, Yale University School of Medicine, New Haven, diabetes.
Connecticut: Linkage strategies for genetically complex J.H. Edwards, University of Oxford, United Kingdom:
traits. Nucleus and cytoplasm. Two maps or one.
E.R. Lander, Whitehead Institute for Biomedical Research,
SESSION 4: Complex Diseases II: Cancer and Autoimmune Disorders
Chairperson: M.-C. King, University of California, Berkeley
A.G. Knudson, Institute for Cancer Research, Philadelphia,
Pennsylvania: Oncodemes and pathodemes.
M. Trucco, University of Pittsburgh, Pennsylvania: Suscep-
tibility markers for IDDM.
SESSION 5: Complex Diseases III: Congenital Defects
Chairperson: M.-C. King, University of California, Berkeley
D.H. Ledbetter, Baylor College of Medicine, Houston, Texas:
Molecular studies of contiguous gene deletion
syndromes.
A.A. Schinzel, Zurich Medical School, Switzerland: From the
SESSION 6: Genetics III
S. Beall, California Institute of Technology, Pasadena:
Strategies for determining the candidate genes involved
in etiology of multiple sclerosis.
visible chromosome aberration to the mutant gene: Anal-
ysis of complex diseases with combined cytogenetic and
molecular genetic techniques.
Chairperson: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
F. Smith, Mount Sinai School of Medicine, New York, New
York: Analysis of the acid p-glucosidase gene by PCR:
Heterogeneity of mutations in Gaucher's Disease.
C. Venter, National Institute of Neurological Disorders and
Stroke, Bethesda, Maryland: Large-scale automated
DNA sequencing of chromosome regions associated
with genetic diseases.
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G.A. Evans, Salk Institute, San Diego, California: Structure
and micropathology of human chromosome.
D.R. Cox, University of California, San Francisco: New ap-
proaches for mapping bipolar affective disease genes.
A.G. Motulsky, University of Washington School of Medicine,
Seattle: Summation.
Molecular Mechanism of Fiber Cytotoxicity
and Carcinogenesis
March 19-March 22
ARRANGED BY
W.R. Brinkley, University of Alabama at Birmingham
C.Harris, National Cancer Institute, Bethesda, Maryland
J.F. Lechner, National Cancer Institute, Bethesda, Maryland
SESSION 1: Background
W. Rom, New York University School of Medicine, New York,
New York: Epidemiology and chemoprevention.
S. Knuutila, University of Helsinki, Finland: Cytogenetics of
human mesothelioma.
J.E. Craighead, University of Vermont, Burlington: Animal
models.
J.F. Lechner, National Cancer Institute, Bethesda, Maryland:
In vitro models and effects of growth factors.
T.W. Hesterberg, Manville Corporation, Denver, Colorado:
Cytotoxic and cytogenetic effects of asbestos on human
bronchial epithelial cells: Chronic inhalation study with
refractile ceramic fibers in rats and hamsters-18-month
interim results.
SESSION 2: Growth Factors, Signal Transduction, and Cytoskeleton
W.R. Brinkley, University of Alabama at Birmingham: Over-
view.
M. Gilman, Cold Spring Harbor Laboratory, New York: In-
tracellular mediators of c-fos induction.
C.J. Molloy, National Cancer Institute, Bethesda, Maryland:
Oncogenes and signal transduction in malignancy.
D. Beach, Cold Spring Harbor Laboratory, New York: Genet-
ic control of the cell cycle.
J.G. Rheinwald, Dana-Farber Cancer Institute, Boston,
Massachusetts: The involvement of EGF, FGF, and a
novel autocrine mitogen in human mesothelial differentia-
tion and transformation.
SESSION 3: Mitotic Spindle Control and Aberrations
W.R. Brinkley, University of Alabama at Birmingham: The
centromere mitotic apparatus and aneuploidy.
C.L. Rieder, The Wadsworth Center, Albany, New York:
Mitotic spindle assembly and chromosome movement.
G. Sluder, Worcester Foundation for Experimental Biology,
Shrewsbury, Massachusetts: Biology of the centrisome:
Formation, function and reproduction.
J.C. Barrett, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina: Induc-
tion of chromosomal aberrations in rodent cells.
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SESSION 4: Molecular Mechanisms
C. Harris, National Cancer Institute, Bethesda, Maryland:
Overview.
B.T. Mossman, University of Vermont, Burlington: Role of
oxy-radicals in rodent cells.
J.D. Brain, Harvard University, Boston, Massachusetts: Role
of nonalveolar macrophages in lung injury.
M.-C. Jaurand, CHU Henri Mondor, France: Neoplastic
transformation of rodent cells by fibers.
T.F. Hei, Columbia University, New York, New York: Interac-
tive effects of fibers and radon in neoplastic transforma-
tion.
SESSION 5: Implications for Risk Assessment
R.O. McClellan, Chemical Industry Institute of Toxicology,
Research Triangle Park, North Carolina: Overview.
E.M. Johnson, Mount Sinai School of Medicine, New York,
New York: DNA transfection by fibers.
R.R. Reddel, Children's Medical Research Foundation,
Camperdown, Australia: Neoplastic transformation of hu-
man mesothelial cells by activated proto-oncogenes.
C. Walker, Chemical Industry Institute of Toxicology, Re-
search Triangle Park, North Carolina: Growth factor gene
expression in rat mesothelioma.
B.I. Gerwin, National Cancer Institute, Bethesda, Maryland:
Role of growth factors, oncogenes, and tumor suppres-
sor genes in human mesothelial cell carcinogenesis.
E. McConnell, Raleigh, North Carolina: Discussion leader.
Recognition in Plant-Pathogen Interactions
April 9-April 12
ARRANGED BY
S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston, Iowa
R.W. Michelmore, University of California, Davis
B. Staskawicz, University of California, Berkeley
SESSION 1: Interactions between Viruses and Plants
Chairperson: B. Staskawicz, University of California, Berkeley
D. Baulcombe, John Innes Institute, Norwich, United King-
dom: Identification of viral components that trigger
responses in the host plant: Examples from PVX, TRV,
and CMV.
R.N. Beachy, Washington University, St. Louis, Missouri:
SESSION 2: Interactions between Bacteria and Plants
Chairperson: B. Staskawicz, University of California, Berkeley
J. Leach, Kansas State University, Manhattan: Avirulence
genes from Xanthomonas campestris pv. oryzae, the
bacterial blight of rice pathogens.
N. Keen, University of California, Riverside: Characterization
of avirulence genes from Pseudomonas syringae pv.
tomato.
B. Staskawicz, University of California, Berkeley: Gene-for-
gene interactions specifying disease resistance in plant-
bacterial interactions.
J. Dangl, Max-DelbrOck-Laboratorium in der MPG, Koln,
Role of the TMV movement protein in host susceptibility.
J. Culver, University of California, Riverside: The role of the
tobacco mosaic virus coat protein in the induction of the
hypersensitive reaction.
Germany: Arabidopsis thaliana and Pseudomonas
syringae: Toward a simple pathosystem.
F. Ausubel, Massachusetts General Hospital, Boston: Pseu-
domonas induction of Arabidopsis thaliana phenylalanine
ammonia lyase and B-1,3-glucanase genes and the use
of "deletion cloning" to identify Pseudomonas avirulence
genes.
M.J. Daniels, John Innes Institute, Norwich, United King-
dom: Specificity in Xanthomonas-Arabidopsis interac-
tions.
SESSION 3: Interactions between Fungi and Plants: Potential Gene-for-Gene Interactions
Chairpersons: R.W. Michelmore, University of California, Davis, and S.P. Briggs, Pioneer Hi-Bred International, Inc.,
Johnston, Iowa
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B. Tyler, University of California, Davis: Molecular genetics
of Phytophthora megasperma.
P.J.G.M. de Wit, Wageningen Agricultural University, The
Netherlands: Cloning of a gene encoding a race-specific
elicitor from the tomato pathogen Cladosporium fulvum.
N.J. Talbot, University of East Anglia, Norwich, United King-
dom: Molecular genetic analysis of Cladosporium fulvum
race specificity.
J. Ellis, CSIRO, Canberra, Australia: Can Ac be used to tag
rust-resistance genes in flax?
J. Jones, John Innes Institute, Norwich, United Kingdom:
Strategies for the isolation of tomato genes for resistance
to leaf mold.
R.W. Michelmore, University of California, Davis: Molecular
markers in the analysis of lettuce downy mildew.
B. Valent, E.I. du Pont de Nemours & Company, Wilmington,
Delaware: Genes for cultivar specificity in the Rice Blast
fungus, Magnaporthe grisea.
J.E. Hamer, Purdue University, West Lafayette, Indiana:
Genome evolution, genetic mapping, and race-specific
interactions in Rice Blast disease.
S. Leong, University of Wisconsin, Madison: Toward the
cloning of genes controlling cultivar specificity in Mag-
naporthe grisea.
J. Bennetzen, Purdue University, West Lafayette, Indiana:
Fine-structure analysis of a maize disease-resistance
gene.
T. Pryor, CSIRO, Canberra, Australia: The Rpl gene com-
plex specifying rust resistance in maize.
S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston,
Iowa: Transposon-tagging the Hml locus in maize.
/.
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S. Briggs, R. Michelmore, A. Ellingboe
B. Staskawicz
SESSION 4: Interactions between Fungi and Plants Involving Toxins
Chairperson: S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston, Iowa
C.A. Bronson, Iowa State University, Ames: The genetics of J. Walton, Michigan State University, East Lansing: The
T-toxin synthesis in Cochliobolus heterostrophus. biochemistry of HC-toxin synthesis.
O.C. Yoder, Cornell University, Ithaca, New York: Specificity V. Macko, Cornell University, Ithaca,NewYork: Host- selective
in fungi-plant interactions. toxins as molecular determinants of plant disease.
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SESSION 5: Signal Transduction in Plants
Chairperson: S.P. Briggs, Pioneer Hi: ESred International, Inc., Johnston, Iowa
M.A. Lawton, Salk Institute for Biological Studies, San Diego, C.J. Lamb, Salk Institute for Biological Studies, San Diego,
California: Molecular analysis of plant protein kinase California: Integration of pathways for developmental and
genes. environmental regulation of plant genes.
Programmed Cell Death: Concepts and Mechanisms
April 16-April 19
ARRANGED BY
F.O. Cope, Ross Laboratories, Columbus, Ohio
D. G old ga ber, State University of New York at Stony Brook
L.D. Tomei, Ohio State University, Columbus
Definition and Incidence of Apoptosis: An Historical Perspective
J.F.R. Kerr, University of Queensland, Australia
SESSION 1: Radiobiology and Carcinogenesis
Chairperson: L.D. Tomei, Ohio State University, Columbus
R. Schulte-Hermann, Vienna University, Austria: Role of
apoptosis during carcinogenesis by nongenotoxic car-
cinogens.
T.R. Tritton, University of Vermont, Burlington: Cell death by
chemotherapy.
S.R. Umansky, USSR Academy of Sciences, Pushcino,
USSR: Radiation and glucocorticoid induced death of
lymphoid cells.
A. Columbano, Universita di Cagliari, Italy: Cell proliferation
and cell death in multistage chemical hepatocar-
cinogenesis.
K. Valerie, Virginia Commonwealth University, Richmond: In-
volvement of chromatin structure on radiation-induced
gene expression in human cells.
J. Hully, McArdle Laboratory for Cancer Research, Madison,
Wisconsin: Gap junctions and programmed cell death.
F.O. Cope, Ross Laboratories, Columbus, Ohio: Retinoid
receptor cell death in carcinogenesis.
SESSION 2: Developmental Biology
Chairperson: R.A. Lockshin, St. John's University, Jamaica, New York
R.A. Lockshin, St. John's University, Jamaica, New York:
Proteins synthesized during programmed cell death.
K.E. Alley, Ohio State University, Columbus: Cell death: A
developmental strategy for all stages.
A. Alles, University of North Carolina, Chapel Hill: Retinoic-
acid-induced cell death: Relationship to regions of pro-
grammed cell death in embryos.
J. Yuan, Massachusetts Institute of Technology, Cambridge:
Mechanisms of cell death in the nematode Caenorhab-
ditis elegans.
SESSION 3: Impact of Programmed Cell Death on Development of Clinical and Applied Concepts
Chairperson: F.O. Cope, Ross Laboratories, Columbus, Ohio
B. Szende, Semmelweis University Medical School,
Budapest, Hungary: The role of apoptosis in the regres-
sion of experimental mammary and pancreatic tumors
treated with luteinizing-hormone-releasing hormone
(LHRH) and somatostatin analogs.
J.T. Isaacs, Johns Hopkins Oncology Center, Baltimore,
Maryland: Programmed cell death of normal and malig-
nant prostatic cells.
R. Buttyan, Columbia University, New York, New York: The
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regressing prostate gland as a model to elucidate the
molecular pathway leading to programmed cell death.
L.E. Gerschenson, University of Colorado, Denver:
Hormones and growth factors regulation of programmed
cell death in rabbit uterine epithelium: Whole animal and
cell-culture studies.
P.H. Krammer, German Cancer Research Center, Heidel-
berg: A monoclonal-antibody-induced tumor regression
by induction of apoptosis.
SESSION 4: Immunology and Transplantation Biology
Chairperson: R.C. Duke, University of Colorado School of Medicine, Denver
D.J. McConkey, Dana-Farber Cancer Institute, Boston,
Massachusetts: Cellular signaling in thymocyte apop-
tosis.
R.C. Duke, University of Colorado School of Medicine, Den-
ver: Killer T cells possess the key to programmed cell
death.
D.R. Green, University of Alberta, Edmonton, Canada:
Activation-induced cell death in developing T cells and
T-cell hybridomas.
E.A. Copelan, Ohio State University Hospital, Columbus: Se-
lective eradication of malignant lymphoid cells from mar-
row using deoxycoformycin to initiate programmed cell
death.
L. Fesus, University Medical School of Debrecen, Hungary:
Transglutaminase-catalyzed cross-linking of proteins in
the program of physiological cell death.
Open discussion: Role of programmed cell death in immune
function.
Plenary discussion: Formation of an international organizing
committee for an International Conference on Apoptosis
in Biology and Experimental Medicine, 1991, and a com-
mittee on terminology.
SESSION 5: Biology of Differentiation and Aging
Chairperson: D. Goldgaber, State University of New York at Stony Brook
J.C. Barrett, National Institute of Environmental Health D. Goldgaber, State University of New York at Stony Brook:
Sciences, Research Triangle Park, North Carolina: Tumor Homeobox genes expression and aging.
suppressor genes: Role of cellular senescence and dif- Open discussion: How does apoptosis alter the prevailing
ferentiation. view of aging?
SESSION 6: Neurobiology
Chairperson: D. Goldgaber, State University of New York at Stony Brook
D.P. Martin, Washington University School of Medicine, St. P.B. Farel, University of North Carolina, Chapel Hill: Role of
Louis: Neuronal cell death caused by trophic factor the periphery in regulating naturally occurring death
deprivation. among spinal motoneurons.
P. Davies, Albert Einstein College of Medicine, New York, Open discussion: How has the concept of programmed cell
New York: Cell death in the developing human brain may death influenced neuropathology?
share features with Alzheimer's Disease.
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Vectors for Cloning the Immune Response
April 23-April 26
ARRANGED BY
R. Lerner, The Research Institute of Scripps Clinic, La Jolla, California
SESSION 1
Chairperson: W. Szybalski, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison
N.R. Klinman, Scripps Clinic and Research Foundation, La
Jolla, California: The rules that govern VH diversification.
M.G. Weigert, Fox Chase Cancer Center, Philadelphia,
Pennsylvania: Antibody repertoires in autoimmune mice.
G. Smith, G.P. Moore, M. Klinman
N.R. Klinman, Scripps Clinic and Research Foundation, La
Jolla, California: Repertoire expression in the memory B-
cell lineage.
1
M. Gefter, M. Scharff
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SESSION 2
Chairperson: H. Wigzell, Karolinska Institute, Stockholm, Sweden
J.A. Sorge, Stratagene, La Jolla, California: New tech-
nologies for expressing the immune repertoire.
W. Huse and A.S. Kang, The Research Institute of Scripps
Clinic, La Jolla, California: Generation of immunoglobulin
libraries in phage lambda.
D. Burton, Scripps Clinic and Research Foundation, La
SESSION 3
Jolla, California: Expression of a human antibody
repertoire in Escherichia coli using phage lambda.
M. Schulman, University of Toronto, Canada: Homologous
recombination between transferred and chromosomal
immunoglobulin genes: A low-tech method of genetic
engineering.
Chairperson: H. Wigzell, Karolinska Institute, Stockholm, Sweden
W. Szybalski, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: Bacteriophage lambda
vectors decorated with fusion protein.
A. Pluckthun, University of Munich, Martinsried, Germany:
Improving F, fragments by engineering for selection in E.
coli.
SESSION 4
D. J. Henner, Genentech, Inc., South San Francisco, Califor-
nia: Expression of Fab fragments in E. coli.
D. Filpula, Genex Corporation, Gaithersburg, Maryland: Pro-
duction of anti-fluorescein antigen-binding proteins.
Chairperson: E.A. Kabat, Columbia University, New York, New York
E. A. Kabat, Columbia University, New York, New York: The
repertoire of anti-a (1-6) dextrans.
K. Nickerson, Columbia University, New York, New York:
Cloning the antidextran repertoire.
G. Smith, University of Missouri, Columbia: Filamentous fu-
sion phage as vectors for antibody libraries.
F.D. Finkelman, Uniformed Services University of Health
Sciences School of Medicine, Bethesda, Maryland:
Polyclonal B-lymphocyte activation by anti-IgD antibody
and other methods.
V. Chaudhary, National Institutes of Health, Bethesda,
Maryland: Cloning of functional antibody variable
domains as single-chain immunotoxins.
Sloan Foundation Science Journalists
Workshop on Women and Cancer
April 29.-May 1
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ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
C. Prives, Columbia University, New York, New York: On-
cogenes and anti-oncogenes.
J. Cairns, Harvard School of Public Health, Boston, Massa-
chusetts: Epidemiology of cancer, 1990.
H.S. Smith, Brush Cancer Research Institute, San Francisco,
California: Oncogenes, chromosomal abnormalities, and
diagnosis in breast cancer.
A.B. Miller, University of Toronto, Ontario, Canada: Con-
troversial issues in breast cancer screening.
S. Swain, Lombardi Cancer Center, Washington, D.C.: Con-
troversial issues in treatment of breast cancer.
D. Mick los and M. Bloom, DNA Learning Center, Cold
Neurofibromatosis
S.
V.
P.
Spring Harbor Laboratory: Laboratory experiment: Bac-
terial transformation using an antibiotic-resistance gene.
Naylor, University of Texas Health Science Center, San
Antonio: Oncogenes, chromosomal abnormalities, and
diagnosis in lung cancer.
L. Ernster, University of California School of Medicine, San
Francisco: Lung cancer in women: Smoking and
cigarette advertising.
Howley, National Cancer Institute, Bethesda, Maryland:
Viruses and cervical cancer.
. Spiegel, Stanford University School of Medicine, Califor-
nia: Psychosocial intervention in treatment of cancer.
October 10-October 12
ARRANGED BY
F.S. Collins, University of Michigan Medical School, Ann Arbor
B.A. Ponder, Cambridge University, United Kingdom
B.R. Seizinger, Harvard Medical School, Boston, Massachusetts
SESSION 1: Introduction to the Clinical and Cell Biological Features of NF1/NF2
Chairperson: B.A. Ponder, Cambridge University, United Kingdom
S. Huson, Oxford University, United Kingdom: Clinical char- R. Martuza, Harvard Medical School, Boston, Massachu-
acteristics of NF1 and NF2. setts: Overview of cell types affected by NF1 and NF2.
SESSION 2: Cloning the NF1 Gene
Chairperson: F.S. Collins, University of Michigan Medical School, Ann Arbor
M.R. Wallace, University of Michigan Medical School, Ann P. O'Connell, University of Utah Medical Center, Salt Lake
Arbor: Identification and characterization of the NF1 City: Identification of the neurofibromatosis type-1 gene:
gene. Characterization of a gene within gene complex.
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SESSION 3: NF1, GAP, and IRA
Chairperson: D.E. Housman, Massachusetts Institute of Technology, Cambridge
K. Tanaka, University of Chicago, Illinois: Negative regula-
tion of RAS activity by a yeast homolog of GAP, IRA.
F. McCormick, Cetus Corporation, Emeryville, California:
The biochemical properties of the NF1 protein.
R.L. White, Howard Hughes Medical Institute, University of
Utah Medical Center, Salt Lake City: Mutation potential of
the NF1 gene.
SESSION 4: Recent Progress in Cloning the NF2 Gene
Chairperson: B.R. Seizinger, Harvard Medical School, Boston, Massachusetts
J. Gusella, Massachusetts General Hospital East, Charles-
town: Neurofibromatosis 2.
D.R. Cox, University of California, San Francisco: Fine-
structure mapping of the NF2 region of human
chromosome 22 by using radiation hybrids.
M. Nordenskjold, Karolinska Hospital, Stockholm, Sweden:
Deletion mapping of the tentative meningioma locus on
chromosome 22.
SESSION 5: Developmental Aspects of Neural Crest and Schwann Cells
Chairperson: D. Pleasure, Children's Hospital, Philadelphia, Pennsylvania
G.S. Ciment, Oregon Health Science University, Portland: Effects of protein growth factors on the development of
The melanocyte/Schwann cell progenitor: Effects of neural-crest-derived cells.
growth factors on commitment. M. Noble, Ludwig Institute, London, United Kingdom: Cel-
G. Lemke, The Salk Institute, San Diego, California: Tran- lular biological studies on glial division and differentia-
scriptional regulation of Schwann cell development. tion.
D. Pleasure, Children's Hospital, Philadelphia, Pennsylvania:
SESSION 6: Round Table Discussion of NF1/NF2 Tumorigenesis
SESSION 7: Models for the Road Ahead
Chairperson: D.R. Cox, University of California, San Francisco
F.S. Collins, University of Michigan Medical School, Ann Ar- North Carolina: Function of the retinoblastoma protein.
bor: Cystic fibrosis. T. Doetschman, University of Cincinnati, Ohio: Targeted
E.P. Hoffman, University of Pittsburgh, Pennsylvania: Life gene modification in the mouse germline.
after cloning: Recent advances in the muscular D.E. Housman, Massachusetts Institute of Technology,
dystrophies. Cambridge: Discussion: Where do we go from here?
J.M. Horowitz, Duke University Medical Center, Durham,
Biological Basis for Risk Assessment of Dioxins
and Related Compounds
October 21-October 24
ARRANGED BY
M.A. Gallo, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey
R.J. Scheuplein, Food and Drug Administration, Washington, D.C.
C.A. van der Heijden, National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands
Introduction and Goals of the Second Conference on Dioxins
J. A. Moore, Institute for Evaluating Health Risks, Irvine, California and A. Poland, McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison
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SESSION 1: Overview of the Adverse Health Effects of PCDDs and PCDFs
Chairperson: J.A. Moore, Institute for Evaluating Health Risks, Irvine, California
Animal Studies
R. Kociba, Dow Chemical Company, Midland, Michigan:
Summary and interpretation of chronic rodent bioassays
of TCDD.
W. Ray Brown, Research Pathology Services, Inc., New
Britan, Pennsylvania: Implications following the
reexamination of the slides from the chronic rat bioassay
of TCDD.
D. Neubert, Free University of Berlin, Germany: Reproduc-
tive toxicity of PCDDs and PCDFs in animal models.
L. Birnbaum, U.S. Environmental Protection Agency, Re-
search Triangle Park, North Carolina: Developmental
toxicity of TCDD and related compounds: Species
sensitivities and differences.
J.G. Vos, National Institute for Public Health and Environ-
mental Protection, Bilthoven, The Netherlands: Im-
munotoxicity of dioxin: Immune function and host
resistance.
Human Studies
P. Mocarelli, University Hospital, Milan, Italy: Effects of acute
and chronic exposure of humans to dioxins: A 9-year
follow-up to Seveso.
M.A. Fingerhut, National Institute for Occupational Safety
and Health, Cincinnati, Ohio: Studies of health effects
from occupational exposures to dioxins.
L.L. Needham, Toxicology Branch, Centers for Disease
Control, Atlanta, Georgia: Levels of TCDD in selected hu-
man populations.
Panel Discussion: Relevance of the animal studies to hu-
mans. Current state of the evidence supporting human
toxicity (carcinogenicity, reproductive and developmen-
tal effects, and immunotoxicity).
SESSION 2: Sources of Exposure to Dioxins and Tissue Levels in Animals and Humans
Chairperson: C. Rappe, University of Umea, Sweden
Environmental Sources of Exposure
C. Rappe, University of UrneA, Sweden: Primary sources of
PCDDs and PCDFs and human exposure via air and
water.
H. Beck, Max von Pettenkofer Institute, Berlin, Germany:
PCDD/PCDF levels in human milk and the problem of
breastfeeding.
P. Furst, Federal State Control Laboratory for Food and En-
vironmental Chemistry of North Rhine Westphalia,
Munich, Federal Republic of Germany: Body burden with
PCDD and PCDF from food.
P.M. Cook, U.S. Environmental Protection Agency, Duluth,
Minnesota: Bioaccumulation and toxicity of PCDDs,
PCDFs, and PCBs in aquatic ecosystems.
A. Schecter, State University of New York, Binghamton, New
York: Levels of PCDDs and related compounds in an-
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cient and modern human tissues: Exposed and general
populations.
Human Body Burden and Distribution in Tissue
C. Schlatter, Institute for Toxicology Technical High School
and University, Zurich, Switzerland: Pharmacokinetics of
PCDDs in humans.
V. Houk, Centers for Disease Control, Atlanta, Georgia:
Health effects of service in Viet Nam.
R.M.C. Thee len, National Institute of Public Health and En-
vironmental Protection, Bilthoven, The Netherlands:
Modeling of human exposure from relevant sources of
exposure.
M.E. Andersen, Chemical Industry Institute of Toxicology,
Research Triangle Park, North Carolina: Biological
determinants of the disposition of TCDD and related
compounds.
SESSION 3: Mechanism of Action
Chairperson: A. Poland, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison
Receptor Biochemistry
J.-A. Gustafsson, Huddinge University Hospital, Sweden:
Molecular biology and physiology of TCDD recep-
tor-DNA interactions.
T.A. Gasiewicz, University of Rochester School of Medicine,
New York: Different forms of the Ah receptor.
M.S. Denison, Michigan State University, East Lansing:
Species variation in Ah receptor transformation and DNA
binding.
Regulation of Gene Expression
J.P. Whitlock, Jr., Stanford University School of Medicine,
California: Genetic and molecular aspects of TCDD ac-
tion.
S.H. Safe, College of Veterinary Medicine, Texas A&M Uni-
versity, College Station: Regulation of growth factor and
hormone receptors.
W.F. Greenlee, Chemical Industry Institute of Toxicology,
Research Triangle Park, North Carolina: Isolation of novel
dioxin-responsive genes: Implications for
toxicity/carcinogenicity.
G. Lucier, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina: Tumor
promotion in liver.
S. Flodstrom, Karolinska Institute, Stockholm, Sweden:
Tumor-promoting activity of TCDD and related com-
pounds.
SESSION 4: Implications of Receptor-mediated Toxicity to Carcinogenic Risk Assessment
Chairperson: M.A. Gallo, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey
A. Poland, McArdle Laboratory for Cancer Research, Uni-
versity of Wisconsin, Madison: TCDD and related
aromatic hydrocarbons: Reexamination of the mechan-
ism of toxicity and carcinogenesis.
S.H. Safe, L.S. Birnbaum, T.A. Gasiewicz: Short reports from
the NIEHS Conference on Dioxin Risk Assessment.
(1) Survey of thresholdable dose response curves involv-
ing Ah-receptor-mediated responses.
(2) Survey of three papers on nuclear receptor response.
(3) Discussion of animal versus human sensitivity.
(4) Discussion of animal and human blood levels versus
response.
M.A. Gallo, UMDNJ-Robert Wood Johnson Medical School,
Piscataway, New Jersey: Can a threshold be credibly as-
sociated with the Ah receptor mechanism.
E. Silbergeld, University of Maryland Program in Toxicology,
Baltimore: Receptor-based models for risk assessment:
Application to TCDD.
Panel Discussion: Integration of mechanistic/dosimetry data
into human risk assessment.
The Impact of Human Molecular Genetics on Society
November 5-November 8
ARRANGED BY
C.T. Caskey, Baylor College of Medicine, Houston, Texas
P. Reilly, Shriver Center for Mental Retardation, Waltham, Massachusetts
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: Genetics and Society: Past, Present, and Future
Chairperson: C.T. Caskey, Baylor College of Medicine, Houston, Texas
P. Reilly, Shriver Center for Mental Retardation, Waltham, ture prospects for genetic testing of predisposition to
Massachusetts: Lessons from past experiences of polygenic disease.
society's involvement with genetics. M.W. Shaw, Evansville, Indiana: The human genome: Private
C.T. Caskey, Baylor College of Medicine, Houston, Texas: property or public domain?
Current studies of molecular diagnosis. Case study and discussion: Newborn and prenatal screen-
D. Botstein, Stanford University, California: Present and fu- ing.
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SESSION 2: Issues in Genetic Screening
Chairperson: J. Beckwith, Harvard Medical School, Boston,
F. Greenberg, Baylor College of Medicine, Houston, Texas:
Humanitarian issues raised by prenatal and neonatal
screening and diagnosis.
M. Angastiniotis, Archbishop Makarios Memorial Hospital,
Nicosia, Cyprus: Social or community responses to a na-
tional control program for Thalassemia.
Massachusetts
A. Chakravarti, University of Pittsburgh, Pennsylvania:
Strategies for screening large populations: CF as a
model.
N. Fost, University of Wisconsin Hospital, Madison: Ethical
issues in newborn and carrier screening for CF.
Case study and discussion: Carrier testing and screening.
III
SESSION 3: Genetic Testing: Health Care and Insurance
Chairpersons: J.A. Witkowski, Banbury Center, Cold Spring
Committee on Energy and Commerce, Washington, D.C.
T.H. Murray, Case Western Reserve University School of
Medicine, Cleveland, Ohio: Genetic testing in insurance:
Ethical issues.
J.M. Stein, The Prudential, Newark, New Jersey: Factors
determining the implementation of genetic testing for in-
surance purposes.
M.A. Rothstein, University of Houston, Texas: Genetic
screening in the workplace.
P. Harper, University of Wales College of Medicine, Cardiff,
United Kingdom: Huntington's disease: A model for ethi-
cal problems in testing children for late onset genetic
disorders.
Harbor Laboratory, New York, and L.M. Russell,
R.E. Pyeritz, The Johns Hopkins Hospital, Baltimore,
Maryland: Health-care and insurance problems of
families with genetic disease.
J. Levi, Washington, D.C.: Early experience of HIV testing as
a model.
R. Bachman, Kaiser-Permante Medical Center, Oakland,
California: High-tech health care: Hard choices in an
HMO.
Case study and discussion: Disclosure of genetic risk.
SESSION 4: Data Banks and DNA Banking
Chairperson: A. Chakravarti, University of Pittsburgh, Pennsylvania
G.J. Annas, Boston University Schools of Medicine & Public
Health, Massachusetts: Legal issues in DNA banking.
G.F. Vovis, Collaborative Research, Inc., Bedford, Massa-
chusetts: Commercial DNA banking.
P.R. Billings, Pacific Presbyterian Medical Center, San Fran-
cisco, California: Privacy issues and the human genome
projects.
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T. Marr, Cold Spring Harbor Laboratory, New York, and P.
Reilly, Shriver Center for Mental Retardation, Waltham,
Massachusetts: Data banks, DNA banking, and forensic
science.
Case study and discussion: DNA forensic/genetic data
banks.
Molecular Biology of Free-radical Scavenging Systems
November 11-November 14
ARRANGED BY
I. Fridovich, Duke University Medical Center, Durham, North Carolina
J.G. Scandalios, North Carolina State University, Raleigh
Introductory Remarks
J.G. Scandalios, North Carolina State University, Raleigh
SESSION 1: Prokaryotic Gene Regulation
Chairperson: K. Asada, Kyoto University, Japan
D. Touati, University of Paris, France: A double lock, imply-
ing two global regulatory systems, fur (ferric uptake
regulation) and arc (aerobic respiration control) shut off
anaerobic expression of MnSOD in Escherichia colt K12.
J.A. Fee, Los Alamos National Laboratory, New Mexico:
Role of the iron uptake locus (fur) in the regulation of
bacterial Sod genes.
H.M. Hassan, North Carolina State University, Raleigh:
Regulation of MnSOD in Escherichia coli: Role of DNA
topology.
P.C. Loewen, University of Manitoba, Winnipeg, Canada:
Regulation of katE and katFtranscription in Escherichia
coll.
C. Foyer, National Institute of Agronomic Research, Ver-
sailles, France: Effects of variations of the activity of
glutathione reductase on cellular glutathione contents
and metabolism in Escherichia coil and tobacco.
SESSION 21 Eukaryotic Gene Regulation
Chairperson: I. Fridovich, Duke University Medical Center, Durham, North Carolina
J.G. Scandalios, North Carolina State University, Raleigh: H. Ruis, University of Vienna, Austria: Differential control of
The antioxidant defense genes Cat and Sod of maize: synthesis of peroxisomal and a cytosolic catalase of Sac-
Structure and regulation. charomyces cerevisiae suggests different functions.
T. Asahi, Nagoya University, Japan: Catalase genes in the R.W. Skadsen, University of Wisconsin, Madison: Molecular
castor bean: Structure and regulation. mechanisms regulating Cat2 gene expression in the
J. P. Phillips, University of Guelph, Ontario, Canada: Genetic acutellum of maize seedlings.
analysis of free-radical scavenging systems in Drosoph- A.P. Autor, University of British Columbia, Vancouver, Cana-
ila. da: Regulation of MnSOD in eukaryotes.
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SESSION 3: Biomedical Approaches
Chairperson: S. Linn, University of California, Berkeley
L.W. Ober ley, University of Iowa, Iowa City: Role of
antioxidant enzymes in cancer.
G.H.W. Wong, Genentech, Inc., South San Francisco, Cali-
fornia: Relative protective effects of MnSOD, Cu/Zn SOD,
Ec-SOD against various cellular insults.
P.A. Cerutti, Swiss Institute for Experimental Cancer Re-
search, Lausanne, Switzerland: Genetic modulation of
antioxidant enzymes in mammalian cells.
J.V. Bannister, Cranfield Institute of Technology, Bed-
fordshire, United Kingdom: Biomedical aspects of the
application of recombinant SOD.
K. Matsushima, Frederick Cancer Research Facility,
Maryland: MnSOD modulates the sensitivity of tumor
cells tocytokine, radiation, and chemotherapy.
SESSION 4: Targets and Targeting
Chairperson: J.G. Scandalios, North Carolina State University, Raleigh
I. Fridovich, Duke University Medical Center, Durham, North gerprints of oxidative damage to DNA.
Carolina: Enzymatic targets for the superoxide radical. M. Nishimura, National Institute for Basic Biology, Okazaki,
P.B. Lazarow, Mount Sinai School of Medicine, New York: Japan: Biosynthesis, transport, and degradation of plant
Peroxisome biogenesis. microbody enzymes.
S. Linn, University of California, Berkeley: Mechanisms of R.S. Sohal, Southern Methodist University, Dallas, Texas:
damage to DNA by hydrogen peroxide. Relationship between generation of prooxidants and the
B. Halliwell, Kings College, London, United Kingdom: Fin- aging process.
SESSION 5: Structure, Function, and Evolution
Chairperson: H. Hassan, North Carolina State University, Raleigh
K. Asada, Kyoto University, Japan: Molecular mechanisms
of production and scavenging of active oxygen in
chloroplasts.
E.A. Havir, Connecticut Agricultural Experimental Station,
New Haven: Characterization of catalase isozymes with
enhanced peroxidatic activity in plants.
W. Stallings, The Monsanto Company, St. Louis, Missouri:
Fe and Mn SODs: Catalytic inferences from crystal struc-
tures.
R.E. Cannon, North Carolina State University, Raleigh: Struc-
ture and expression of the maize Cu/Zn Sod4 and Sod4A
cytosolic isozyme genes.
J. Kwiatowski, University of California, Irvine: Structure and
evolution of the Cu/Zn SOD in Diptera.
Computational Aspects of Protein Folding
December 3-December 6
ARRANGED BY
R.L. Jernigan, National Cancer Institute, Bethesda, Maryland
H.A. Scheraga, Cornell University, Ithaca, New York
SESSION 1: Potentials, Free Energies, and Methods
Chairperson: D.L. Beveridge, Wesleyan University, Middletown,
B. Honig, Columbia University, New York, New York: An
evaluation of energetic contributions to protein stability.
A.A. Rashin, Biosym Technologies Inc., Parsippany, New
Jersey: Electrostatics and the energetics of hydration in
proteins.
G.M. Crippen, University of Michigan, Ann Arbor: Protein
folding is a combinatorial contest between geometry and
energy.
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Connecticut
P.A. Kollman, University of California, San Francisco: Free-
energy calculations on macromolecules.
K.D. Gibson, Cornell University, Ithaca, New York: Recent
approaches to the multiple minimum problem in protein
folding.
H.A. Scheraga, Cornell University, Ithaca, New York:
Multiple-minima problem.
SESSION 2: Molecular Dynamics Simulations
Chairperson: P.A. Kollman, University of California, San Francisco
M. Karplus, Harvard University, Cambridge, Massachusetts:
Aspects of protein folding/stability.
W.L. Jorgensen, Yale University, New Haven, Connecticut: N.
Molecular dynamics simulations of peptide and protein
unfolding.
J. Hermans, University of North Carolina at Chapel Hill:
Molecular dynamics studies of peptide conformational A.
equilibria.
D.L. Beveridge, Wesleyan University, Middletown, Con-
SESSION 3: Models of Folding
Chairperson: H.A. Scheraga, Cornell University, Ithaca, New York
F.M. Richards, Yale University, New Haven, Connecticut: On
packing and cavities.
K.A. Dill, University of California, San Francisco: On the J.
origins of structure in globular proteins.
F.E. Cohen, University of California, San Francisco: The utili-
ty of simplified models in understanding protein structure. B.
R.L. Jernigan, National Cancer Institute, Bethesda,
Maryland: Characteristics of compact conformations.
J. Skolnick, Scripps Clinic and Research Foundation, La
necticut: Aspects of protein-folding accessible to
molecular dynamics simulation.
Go, Kyoto University, Japan: Description of protein
dynamics in terms of normal mode variables and its ap-
plication in the refinement of protein X-ray crystal-
lography.
Brunger, Howard Hughes Medical Institute, Yale Univer-
sity, New Haven, Connecticut: Simulation of helix-helix in-
teractions: Applications to leucine zippers.'
Jolla, California: Computer simulations of the folding of
plastocyanin.
Moult, Center for Advanced Research in Biotechnology,
Rockville, Maryland: Analysis of protein-folding path-
ways.
Robson, Proteus Molecular Design Limited, Cheshire,
United Kingdom: Folding proteins by the creation of new
conservation laws.
SESSION 4: Crystal Gazing and New Approaches
Chairperson: R.L. Jernigan, National Cancer Institute, Bethesda, Maryland
G.D. Fasman, Brandeis University, Waltham, Massachu- J.J. Wendoloski, E.I. du Pont de Nemours & Company, Wil-
setts: Prediction of protein conformation: Why have pre- mington, Delaware: Rebuilding proteins from limited
diction methods failed to give the correct structure? structural data.
S. Rackovsky, University of Rochester, New York: Quantita- S.J. Wodak, Free University of Brussels, Belgium:
tive classification of protein structures. Knowledge-based structure predictions: What are the
C.H. Chothia, M.R.C. Laboratory of Molecular Biology, Cam- limitations?
bridge, United Kingdom: Sequence determinants of S.H. Kim, University of California, Berkeley: Prediction of
protein folds. structural features by neural network.
SESSION 5: Model Building and Design
Chairperson: C.H. Chothia, M.R.C. Laboratory of Molecular
V.S. Madison, Hoffmann-La Roche, Inc., Nutley, New Jer-
sey: A beta-barrel model for ECGF.
0. Teleman, Lund University, Sweden: Peptide folding: An
attempt at a peptide catalyst, and the amino-terminal
EGF-homologous peptide from blood coagulation factor
X.
M.R. Pincus, State University of New York Health Science
Center, Syracuse: The chain build-up procedure in
protein folding: Peptide determinants of protein structure.
Biology, Cambridge, United Kingdom
G. Nernethy,Mount Sinai School of Medicine,New York,New
York: Interactions of local structures in protein folding.
F.R. Salemme, E.I. du Pont de Nemours & Company, Wil-
mington, Delaware: Statistical approaches to protein
reconstruction using substructure libraries.
H.R. Guy, National Cancer Institute, Bethesda, Maryland:
Modeling the structure of membrane channel proteins.
C. Sander, EMBL, Heidelberg, Germany: Protein design:
Theory and experiment.
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1990 PUBLICATIONS
General Books
Immunological Recognition
Symposia on Quantitative Biology 54
Vaccines 90
F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner (eds.)
Genetic Maps (5th edition)
S.J. O'Brien (ed.)
The Emergence of Bacterial Genetics
T.D. Brock
Mapping the Genomes of Agriculturally Important Animals
J.E. Womack (ed.)
CSHL Monograph Series
Oncogenes and the Molecular Origins of Cancer
R.A. Weinberg (ed.)
Stress Proteins in Biology and Medicine
R.I. Morimoto, A. Tissieres, and C. Georgopoulos (eds.)
DNA Topology and Its Biological Effects
N.R. Cozzarelli and J.C.Wang (eds.)
Banbury Report Series
Genetics and Biology of Alcoholism (Banbury Report 33)C.R. Cloninger and H. Begleiter (eds.)
Biology of Mammalian Germ Cell Mutagenesis (Banbury Report 34)J.W. Allen, B.A. Bridges, M.F. Lyon, M.J. Moses, and L.B. Russell (eds.)
Manuals
DNA Science: A First Course in Recombinant DNA TechnologyD.A. Micklos and G.A. Freyer
Methods in Yeast Genetics: A Laboratory Course ManualM.D. Rose, F. Winston, and P. Hieter
Journals
Genes & Development (Volume 4, numbers 1-12B)
Cancer Cells: A Monthly Review (Volume 2, numbers 1-12)
Other
CSHL Annual Report 1989
Abstract/program books for 12 CSHL meetings
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COLD SPRING HARBOR LABORATORY PRESS
To our great satisfaction, 1990, like its predecessor, was another notable year for
publishing at Cold Spring Harbor Laboratory. We ended the year with total
revenues in excess of $4.19 million, giving an operating margin before deprecia-
tion of over $480,000. Three factors contributed to this outcome: sustained sales
from our best-selling books, with Molecular Cloning being the most outstanding;
solid sales from the new 1990 titles, which were assisted by complimentary
reviews in prominent journals; and, for the first time, a major contribution to
revenues from our journal program.
Reviving a Respected Series and Breaking New Ground
In 1990, 12 books were published. This was a smaller number than in recent
years, but each was a substantial work. We have now reduced to a satisfactory
minimum our former dependence on the proceedings of meetings, particularly
those at the Banbury Center, whose extended abstracts accounted for well over
half of our output in the past five years. Three of the 1990 titles, on oncogenes,
stress (heat-shock) proteins, and DNA topoisomerases, revived the series of
Cold Spring Harbor Monographs begun in 1970. Oncogenes and the Molecular
Origins of Cancer was particularly popular, with sales of well over 1500 copies in
the year. Its editor, Robert Weinberg, clearly succeeded in his aim of producing a
book with broad appeal.
Space prevents individual mention of each title, but reference should be
made to the success of the fifth edition of Genetic Maps, edited by Stephen
O'Brien and produced for the first time in two editions, a cloth-bound com-
pendium and a series of six inexpensive paperbacks. The current interest in
genome sequencing helped to drive sales in 1990 past 2600 copies. It was
gratifying to see strong demand and admiring reviews for Michael Ashburner's
huge work, Drosophila, published in two parts at the end of 1989. We welcomed
also the appearance of DNA Science by David Micklos and Greg Freyer, a
textbook and lab manual aimed at students taking their first courses in molecular
biology, based largely on courses taught at the Laboratory's DNA Learning Cen-
ter. A handsome, two-color book, it triumphantly broke new ground for our pro-
duction staff. We and our copublishers, the Carolina Biological Supply Company,
were delighted when the first printing of 5000 copies rapidly sold out.
Underpinning our sales returns were our best-selling laboratory manuals. In
its second full year of publication, Antibodies surpassed 20,000 copies, and we
welcomed its authors Ed Harlow and David Lane back to Cold Spring Harbor in
November to celebrate that event. Molecular Cloning, by Joe Sambrook, Ed
Fritsch, and Tom Maniatis added 15,000 sales in 1990 to achieve in one year of
publication an extraordinary total of 50,000 copies. Its reputation as the bible of
the field seems still to be secure.
As usual, the book editorial and production staff, led by Nancy Ford, made
exceptional efforts to ensure that the design and accuracy of these books
matched both the authors' aspirations and their own customary high standards.
New technology provided invaluable assistance: 6 of the 12 books published
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Staff of the Editorial Production Department outside Urey Cottage. From right to left: Pat
Barker, Elaine Gaveglia, Lee Martin, Maryliz Dickerson, Marie Sullivan, Liz Ritcey, Dorothy
Brown, Nancy Ford, Jim Suddaby, Inez Sialiano, Annette Kirk, Mary Cozza, Pauline Tanen-
holz, Joan Ebert, Ralph Battey, Christy Kuret.
were typeset in-house, and the optical scanner bought last year quickly became
a mainstay. The equipment's success gave us the confidence to commit to com-
pleting our investment in independent typesetting next year, at a level of
sophistication adequate for all our needs, from books to journals to internal publi-
cations such as this Annual Report.
Establishing a New Voice
Our monthly review journal, Cancer Cells, completed its first full year of publica-
tion in September. It has had to jostle in a crowded marketplace, appearing just
as four other new journals were launched in cancer research, all with somewhat
similar aims. The field is in an optimistic phase, buoyed up by discoveries in
genetics and molecular biology in recent years, and the proliferation of new jour-
nals demonstrates a desire in the scientific community for new sources of the
best and most exciting work. This proliferation justifies the existence of Cancer
Cells, which recognizes the information overload and attempts to explain and in-
terpret advances for readers who lack either the time or the technical expertise to
keep up with the primary sources. In its first year, Cancer Cells established a
unique voice, a tribute to the editorial skills of Paula Kiberstis, who ensured that
the journal's coverage was broad and interesting and enhanced the submitted
commissioned manuscripts to high standards of clarity. In this task, she was
greatly helped by the appointment in October of Catriona Simpson as the jour-
nal's Assistant Editor. The journal's special qualities were acknowledged in a
prominent review of the year's new publications. Several editorial features proved
popular, particularly a digest of information about new oncogenes and a histori-
cal article, written by Jan Witkowski for the August/September issue, on the con-
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cept of cancer as a genetic disease. During the year, the circulation reached a
satisfactory level, and having established the journal's voice, the challenge now
is to ensure that it is loudly and widely heard.
Combining Excellence with Financial Success
In 1990, Genes & Development had another excellent year: 583 manuscripts
were offered for publication, and 204 (35%) were published in 13 issues. The
editorial standard remained strikingly high, which is a credit to its editors Terri
Grodzicker and Nicholas Hastie and to the uncompromising advice they received
from editorial board members and other reviewers. The issues were notable for
their editorial accuracy and production standards, and in mid-year, the journal
was awarded a printing industry prize, the Neographic Gold Award, in recogni-
tion of the graphic excellence of its design and its covers designed by Judy Cud-
dihy, the Managing Editor. The journal staff did an outstanding job under high
pressure throughout the year and was greatly assisted by the return to our ranks
of an experienced technical editor, Nadine Dumser.
Our sense that Genes & Development had advanced rapidly into the small,
select group of top-class journals was underlined by citation analysis, which
showed that even in 1988, its second year of publication and the most recent
year for which data are available, the journal was being cited at a rate higher
than any other journal of genetics or developmental biology. This impact was
reflected in an overall 22% increase in paid subscribers in 1990. Growth was par-
ticularly strong among libraries, which gave a healthy stimulus to the journal's
revenues. Income was boosted further by substantial increases in secondary
sources such as advertising, which rose by over 30% under the guidance of our
Staff of the Acquisition and Marketing Departments outside Carnegie Library. From left to
right: Catriona Simpson, Nancy Kuhle, John Inglis, Paula Kiberstis, Connie Hallaran, Nadine
Dumser, Terri Grodzicker, Lisa Sweeney, Judy Cuddihy.
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Advertising Manager, Nancy Kuhle, who joined us in February. Rising income
and prudent financial management ensured that, as predicted, the journal ended
the year with a surplus for the first time, bringing to an end the four-year period of
cumulative investment required from the Press and its partner, the Genetical
Society of Great Britain. For a journal with a professional staff, dedicated to rapid
publication and to quality, this rate of progress to profitability has been highly
satisfactory.
Improving Marketing and Customer Service
Our marketing activities remain centered on direct mail, display advertisements,
and sales at the larger scientific conferences. A concerted effort was made to
track down smaller meetings worldwide and send brochures which were often
created in-house. These activities, the production of three issues of our newslet-
ter the Notebook, the creation of the catalog and two short variations on it, and
the management of our bookstore in Grace Auditorium demanded much of the
marketing department staff, led by Charlaine Apsel. Our ever-expanding stock of
active titles continued to press the need for new and larger warehouse space.
The persistence of Guy Keyes, our Warehouse Manager, led eventually to the ac-
quisition of suitable premises in Plainview, about five miles from Cold Spring Har-
bor, in which the whole Customer Service department could be housed. Our
entire inventory, consisting of over 68,000 volumes plus a variety of other
materials, was moved to Plainview in September.
A further step in the improvement of our customer service was the purchase
in December of a new computer system for maintaining sales records, fulfilling
orders, and analyzing our customer data base. Breaking our former reliance on a
rented, shared system, the new computer's software was tailored to our specific
requirements. Its installation and the mounting of existing sales records required
extraordinary efforts from the staff involved. Nevertheless, all concerned recog-
nize that once it is functional and familiar, the new system will be quicker, more
cost-effective, and a powerful marketing tool.
Staff of the Business Operations Department outside the offices and warehouse at Plain-
view. From left to right: Elaine Gaveglia, Ann Felten, Jackie Matura, Guy Keyes, Charlaine
Apsel, Barbara Terry, Bill Dickerson, Penny Sheppard, John Flynn.
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Launching Three New Series and a Third Journal
A considerable variety and number of new publishing projects were initiated in
1990, most of which require time to mature. Four projects, however, will bear fruit
next year. In September, we completed negotiations with the Imperial Cancer Re-
search Fund for the rights to publish on its behalf the prestigious review series
Cancer Surveys. Three 300-page volumes, each containing invited reviews on a
single topic, will appear in 1991. Another new series for 1991 will be Current
Communications in Cell & Molecular Biology. These books range widely in sub-
ject and in some cases their preparation will be assisted by a Banbury Center
meeting on the topic. Jan Witkowski's participation with me in editing the series
has been invaluable. A third book series, Genome Analysis, edited by Kay
Davies and Shirley Tilghman, will begin early in 1991.
In December, we completed plans for the launch of a third journal in the com-
ing year. The polymerase chain reaction (PCR) has recently revolutionized biol-
ogy with its elegance and seemingly limitless application to DNA detection. Our
journal, PCR Methods and Applications, edited by Judy Cuddihy in association
with four academic scientists, will publish peer-reviewed research papers and
commissioned reviews on the principles and practice of PCR and other
amplification methods. The journal will be quarterly at first, appearing for the first
time in July. We have been fortunate to receive from Perkin-Elmer Cetus, the
leading PCR company, generous support for the journal in the form of a bulk sub-
scription purchase, guaranteed advertising and access to its customer database.
Although it is very early days for this project, the journal promises to be highly
regarded by a scientific community anxious to harness the power of this remark-
able technique.
Restructuring and Rationalizing Resources
During the year, it became clear that our investments in new technology and new
premises off the Laboratory grounds would permit us to rationalize resources and
restructure the management of the Press. This process took place in December,
and we prepared to enter the New Year reconfigured in four departments:
Editorial/Production, based in Urey Cottage and headed by Nancy Ford as
Managing Editor of the Press, responsible for both the book and journal pro-
grams; Business Operations, based at Plainview and managed by Charlaine Ap-
sel, responsible for customer service, sales, and financial reporting; a newly in-
dependent Marketing Department, based in Carnegie Library, for which a new
head is needed and which is responsible for marketing strategy and execution;
and Acquisition, based in Carnegie and headed by me, which is responsible for
the development of new publishing projects and the existing journals. The
restructuring affected a substantial proportion of our staff, who accepted the
changes with grace and adapted willingly. I am particularly grateful to the senior
staff of the Press, without whose support the restructuring would not have been
possible.
We ended 1990, therefore, on a note of real optimism, with satisfactory finan-
cial results, the immediate prospect of major benefits from new equipment and
improved organization, and the promise of publishing over 20 new books and fur-
ther expanding our journal program in 1991.
John R. Inglis
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Periodic studies conducted since 1959 show that general scientific illiteracy is a
persistent problem in the United States. Recent studies sponsored by the Nation-
al Science Foundation (NSF) suggest that only about 6% of Americans can be
considered functionally literate in scientific matters and that college graduates
are only marginally more literate.
Clearly, Americans have had enough difficulty understanding developments
in a postmodern world clouded by questions of nuclear fission/fusion and in-
creasingly controlled by devices crammed with computer microprocessors. Now,
the proliferation of gene-manipulation technology adds a new dimension to our
national science confusion. Indeed, a 1987 Office of Technology Assessment
survey found that 63% of Americans claim to have heard or read relatively little or
almost nothing about "genetic engineering" and 44% cannot give any meaningful
definition of the word. The NSF-sponsored studies show that only 10% of the
American public can explain what a molecule is, and only 22% can define DNA
correctly.
At the same time, we have a national research agenda to identify all of the ap-
proximately 100,000 different human genes, the Human Genome Project. The im-
pact of this work is already being felt. In September 1990, a 4-year-old girl suffer-
ing from a severe immune deficiency received an infusion of genetically altered
cells, in the first attempt to replace a defective gene with a normal one. Gene
therapy such as this promises the ultimate cure for the thousands of known ge-
netic diseases, and the molecular tracings of DNA fingerprints provide the
ultimate evidence in rape, murder, and paternity cases nationwide. These ac-
tivities also throw into sharp relief the potential risks of gene manipulation, the dif-
ficulties of fairly allocating resources for biological research, and the issues of
proper uses of and access to personal genetic profiles.
The good news is that 57% of Americans appear able to understand a simple
problem dealing with the inheritance of a genetic illness, suggesting that they
find this topic relevant to their personal lives. We also have a self-professed "edu-
cation president," and some two dozen bills to encourage science, math, and
engineering education were considered by Congress in 1990. In the contextof
this renewed sense of urgency, the social importance of the Human Genome Pro-
ject offers an opportunity to reorganize substantially biology and health education
to include new emphasis on human molecular genetics.
Ideal and Reality of Biology Education
Public education has long been viewed as a key enabler of democratic pluralism,
providing individuals with access to elements of cultural, political, and scientific
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literacy. If we take stock in this Madisonian concept of an informed citizenry that
participates in public decision making, DNA literacy must be considered an es-
sential element of precollege public education. In this view, science teachers,
who interface with a cross section of America's youth, constitute a major conduit
through which understanding of the uses and misuses of genetic technology can
flow broadly to society.
One assumes that children begin life with curiosity for the natural world. In-
deed, data from the 1986 National Assessment of Educational Progress (NAEP)
study show that the vast majority of American third graders both like their science
lessons (67%) and find them interesting (78%). However, there are many in-
dicators that this enthusiasm for science erodes dramatically with increased ex-
posure to formal science during junior and senior high school. The NAEP study
shows that whereas 67% of third graders believe that things learned in science
class will be useful in everyday life, only 54% of seventh graders and 49% of
eleventh graders see the practicality of their science studies. A recent study by
the International Association for the Evaluation of Educational Achievement found
that American fifth graders rank eighth in science achievement among their
peers in 14 developed and developing nations; however, advanced high school
seniors rank last in biology achievement among their international peers.
It is not that we don't have the chance to influence high school students to
pursue any native interest they may have in living things. Biology is the most fre-
quently studied science in high school and is taken by 90% of all American stu-
dents. In spite of, or perhaps because of, this exposure, only 6% of high school
students take an advanced course in biology, and only 3.7% of college freshmen
intend to major in the biological sciences.
All this suggests that it is the manner in which science is taught that causes
young people to become so disinterested in science. The NAEP study paints a
disturbing picture of the American precollege science classroom, where the "pre-
ponderance of class time [is] spent listening to teachers' lectures" and where
DNA Learning Center staff: (standing) David Mick los, Sandy Ordway, Margaret Henderson,
Mark Bloom, (seated) Susan Lauter, Amy Phillips
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there are "few opportunities to explore natural phenomena directly or engage in
discussions about the limited experiences that they did have." The scientific con-
tent in these classes "appears to be largely textbook- and workbook-driven,
reflecting little-or not at all-the recent technological advances in the domain of
science." Students interviewed in the NAEP study gave the following report on
their eleventh grade science classes:
79% listen to a lecture daily or several times per week.
54% read their textbooks daily or several times per week.
47% do not participate in experiments on at least a weekly basis.
41% had never written up experiments.
52% had never done an oral or written report.
39% had never read articles on science.
86% had never been on a field trip.
According to the NAEP study, more than one-third of eleventh grade science
teachers do not have access to a general purpose or specialized science
laboratory. Our conversations with high school biology teachers in a number of
states indicate that science departments typically have annual supply budgets
calculated at just several dollars per student and that capital equipment pur-
chases are limited to replacement of existing items. Many older high schools are
functioning with essentially the same basic set of equipment purchased with the
bond issue with which they were constructed during the "baby boom" of the
1950s-1960s.
Although the nature and practice of biology is forward looking, the burden of
evidence shows that teaching high school biology is reactionary. In many ways,
biology education has changed little from the days of our grandparents. Hands-
on laboratories are the exception, and rote memorization is the norm. This is in
large part because high school biology curricula have evolved in the twentieth
century essentially by cramming in more and more facts. Faced with the specter
of a standardized test that covers a vocabulary-driven syllabus, the teacher is
often constrained to spend his or her time lecturing on science facts. Meager
equipment/supply budgets and a lack of teaching laboratories preclude any but
the most simplistic laboratories, which reflect primarily the observational tradi-
tions of biology. Missing are meaningful experiments that reflect the quantitative
and biochemical basis of modern molecular genetics.
Publication of DNA Science
Since 1985, Cold Spring Harbor Laboratory has expended $2.5 million to infuse
genetic literacy through the public education system. The publication of DNA
Science: A First Course in Recombinant DNA Technology marked the culmination
of our effort to influence biology curricula at the advanced high school and be-
ginning college levels. The combined lab and text was coauthored by Dave
Mick los and Greg Freyer (now at Columbia University), with computer-generated
illustrations by Sue Lauter. We believe it is the first integrated learning program to
introduce novice biology students to the theory, practice, and applications of
DNA manipulation.
Unlike "super texts" that can only be sampled by even the most ambitious in-
structor or student, the 477-page DNA Science is designed to be read from
cover to cover. The eight text chapters are written in a semi-journalistic style and
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DNA Science was released in
October 1990, and by year's
end, plans were already made
for a second printing.
adopt an historical perspective to explain where DNA science has come from
and where it is going. Combining the unique perspectives of a research biologist
and a science writer, the topical treatment integrates up-to-the-minute examples
drawn directly from research literature. For these reasons, we believe the text is
suitable for introducing recombinant DNA in science and society courses.
Extensively tested by thousands of biology instructors nationwide, the ten
laboratory experiments cover the basic techniques of gene isolation and analy-
sis. The experiments engender systematic repetition to build student confidence
and mastery of techniques. Extensive preliminary notes for each experiment ex-
plain how to schedule and prepare them, and flow charts and icons make the
protocols easy to follow. A discussion section at the end of each experiment
reviews the laboratory in a rhetorical style, analyzing controls and showing both
ideal and "less-than-ideal" results. A final section suggests simple research
projects that extend the techniques learned in the laboratory and require few, if
any, additional reagents.
Truly a first course in recombinant DNA technology, the laboratory sequence
presupposes no prior experience on the part of instructor or student. Structured
to follow directly from an introduction to principles of biology, the experiments are
equally appropriate for the advanced high school student and the beginning col-
lege student. It can be used as the first course in a molecular biology sequence,
integrated as a genetics/DNA structure component of a general biology course,
or used as a unit within a microbiology or genetics course. Laboratories 3 and 5,
which illustrate methods to analyze DNA and to introduce genes into bacteria,
are recommended by the Educational Testing Service as part of the laboratory
curriculum for Advanced Placement (AP) students who take a college level biol-
ogy course.
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DNA Science is a copublication of Cold Spring Harbor Laboratory Press and
Carolina Biological Supply Company, which is one of the nation's oldest pur-
veyors of laboratory supplies and curriculum materials for biology teachers. The
laboratory course is completely supported by quality-assured Carolina products
to satisfy a range of teaching applications, from bulk reagents to reusable
reagent systems to single-use kits. Kits designed to introduce teachers to the AP
laboratories have quickly become among the company's largest sellers. Also
completed in 1990 was "Easy Gene Splicer," which is a simple kit that allows stu-
dents to construct safely and screen for small recombinant DNA molecules.
Renewed NSF Support for DNA Science Workshops
The 5-day DNA Science Workshop is our most well-known effort to update biol-
ogy teaching faculty. Through 1990, the DNA Learning Center staff have in-
structed 1,400 high school and college educators at 66 workshops in 27 states
and Canada, and allied programs in California, North Carolina, Wisconsin, and
Florida have used the curriculum as the basis for training an additional 700
teachers at 30 workshops.
The continued influence of the DNA Science Workshop was assured with the
renewal in 1990 of our core grant from the NSF. This three-year supportwill allow
us to teach 15 workshops, extending our coverage to the midwestern states in
1990 and to the deep south and southwestern states in 1991. Implementing
workshops nationwide is a complex task, involving liaison through numerous lo-
cal organizers, coordinating the travels of two Vector vans and six staff, and ship-
ping perishable reagents. However, this task has become sufficiently routine that
we intend to target the Rocky Mountain region for workshops in summer 1992.
Recognizing the educational value of the workshop experience, the State Uni-
versity of New York at Stony Brook offers a credit option to DNA Science Work-
shop participants nationwide. Teachers who complete both a workshop and a
follow-up are eligible for three graduate credits from the Continuing Education
Department. The University's Center for Biotechnology has sponsored a DNA
Science Workshop at Stony Brook each year since 1987. Travel support is also
provided for workshops held at distant sites.
We were honored when Howard Hughes Medical Institute (HHMI) Vice-
President Joe Perpich asked us to help establish a model genetics program in its
home area of Montgomery County, Maryland. The HHMI grantprovides $46,500
to the DNA Learning Center over three years to support teacher/student training
workshops and curriculum-enrichment activities. A coordinate grant was
awarded to the Montgomery County Public Schools Educational Foundation, Inc.,
for the implementation of the new curriculum. HHMI is respected as the largest
nongovernment contributor to medical research, and the Montgomery County
program is considered a test for wider support of precollege and public science
education in the next several years.
Measures of Success
Statistics derived from our student field-trip program and our hectic schedule of
teacher-enhancement activities (see list at back) give evidence that we have
been busy at our work to stimulate widespread DNA literacy. In 1990, DNA
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Learning Center staff logged 11,000 person-hours of contact with precollege stu-
dents and 25,000 person-hours of contact with teaching faculty.
However, funding agencies, particularly the NSF, have found that hard data
gauging the effects of faculty enhancement programs are difficult to attain.
Therefore, educators greeted with enthusiasm the results of a long-term study of
390 biology teachers trained at 22 DNA Science Workshops in 1987 through
1988. The report, "Retooling Biology Education for the Gene Age," was
coauthored by Dave Mick los and John Kruper.
Formerly a summer intern with the Vector Workshop program and now a post-
doctoral fellow at the University of Chicago, John was responsible for the
sophisticated computer analysis that included several types of multivariate
statistics. The data set for each teacher consisted of answers to surveys ad-
ministered at three time points: a 60-item presurvey completed at the beginning
of the summer workshop, a 95-item postsurvey completed at the end of the work-
shop, and an 87-item follow-up mail survey that was completed approximately 17
months after the workshop.
The analysis confirmed that participants in the DNA Science Workshop are a
rather select and highly professional group. Of ten, eight taught AP, honors biol-
ogy, or advanced biology electives. Seasoned teaching professionals, most had
taught at least 6 to 20 years, achieved a master's degree, and carried a full
teaching certification in biology or science. The typical respondent was likely a
member of several professional organizations and actively participated in
professional-development and curriculum-development activities. Many reported
regular participation in student-enrichment activities, including science field trips
(58%); science fairs and competitions (45%); after-school student research
(34%); and joint activities with research scientists (25%).
A majority of teachers appear to have made substantive changes in their
classroom behavior during the year after participation in the workshop. Two-
thirds or more of all respondents affirmed that they had in several ways in-
tegrated concepts from the workshop into their teaching. This included relating a
personal account of the making of a recombinant DNA molecule, giving new ex-
amples for topics already included on their teaching syllabi, and presenting new
topics not yet on their syllabi.
Significant numbers of teachers had attempted new laboratory techniques in
their classrooms in the school year after the workshop. Two-thirds had tried ex-
periments in bacteriology, which can be considered the entry into molecular
genetics. Thirty-five percent had implemented an AP-type lab on DNA trans-
formation, which requires no specialized equipment. Fewer (25%) had imple-
mented an AP-type lab on DNA restriction analysis, which requires an investment
in electrophoresis equipment. Based on a conservative estimate of 25 students
per lab (the median reported class size), the teachers in this study were
responsible for 5,775 student exposures to the AP labs on DNA transformation
and restriction analysis. Furthermore, a number had performed relatively sophisti-
cated experiments on DNA recombination (18%) and plasmid DNA isolation
(13%) that require a major investment in equipment and preparation time.
A number of respondents carried on networking activities to educate other
teaching professionals. More than one-third had made presentations about their
workshop experience to local teachers or school officials, while 7% had made a
presentation at a professional meeting. Most important, 18% had conducted a
laboratory demonstration for other educators, and 9% had led a teacher-training
workshop. Based on the assumption that each reported lab activity involved five
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Margaret Henderson discusses results of a DNA restriction analysis with high school
students in the 802000 Laboratory.
other teachers, we estimate conservatively that workshop participants
demonstrated or taught new lab techniques to 520 additional educators.
Half of all respondents attempted to secure funds with which to implement
new labs, typically approaching one or two sources. Fewer (29%) attempted to
secure donations of equipment or reagents from various sources, including uni-
versities, hospitals, and industry. Of those who tried, 64% were successful in
securing monetary or equipment gifts. Respondents reported receiving a total of
$507,000 in funding, including monetary donations of $381,000 and reagent
donations valued at $126,000. This was equivalent to $1,144 per participant,
which more than matched the average per-person training cost of $928. We be-
lieve this level of fund-raising success is unprecedented in the history of Amer-
ican biology education.
We judged that about 70% of teachers, although progressive, were primarily
adapting their new knowledge within the framework of the existing educational
system. In contrast to these "adaptors," true innovators had substantially
revamped their teaching style to make room for a considerable amount of new
experimentation in molecular genetics, including the suggested AP labs on bac-
terial transformation and DNA restriction analysis.
We used several statistical measures to highlight key attitudinal and behav-
ioral determinants that distinguish adaptors from innovators. Taken together, the
analysis emphasized that the innovative teacher is not a "lone wolf," but, rather, is
an active professional who operates within a social system. A teacher's involve-
ment with and positive evaluation of the "relevant others" within his/her work en-
vironment (students, parents, administrators, and other teachers) belongs to a
set of core evaluations and attitudes that are highly resistant to change and ap-
pear to be reliable predictors of innovative behavior. This "silent" background of
positive attitudes empowers the innovator to seek means to overcome difficult in-
frastructure constraints to innovation: insufficient lab time, space, and equipment.
A decreased reliance on textbooks and an ability to seek out information from pri-
mary sources allows the innovator to overcome the curriculum constraints of poor
texts and an overly ambitious syllabus.
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Ironic Situation in Freshman Biology
Five years ago, high school teachers had neither the training nor equipment for
hands-on experimentation with DNA. This situation has changed dramatically,
thanks to teacher-training institutes sponsored primarily by NSF, the incorpora-
tion of molecular genetics labs into AP biology, the unprecedented fund-raising
success of precollege biology teachers, and the availability of suitable teaching
kits from science suppliers. Extrapolating from the results of our study and
estimated sales of teaching kits, plus the actual numbers of students taught by
ourselves and others, we estimate from 50,000 to 70,000 student exposures per
year to the AP experiments on DNA transformation and restriction analysis in
American high schools.
This figure points up an ironic situation in American biology education. Ad-
vanced high school students perform DNA manipulation labs to fulfill a college
level biology curriculum; however, these labs are absent from the vast majority of
introductory college biology courses. Even at the largest and best of our univer-
sities, laboratory instruction on gene manipulation is confined mainly to upper-
level courses for biology majors. Thus, beginning college students who had been
excited by doing DNA experiments at the high school level are now frustrated to
learn that they will not likely work again with DNA until their junior or senior year.
One assumes, prima facie, that college biology professors are up-to-date on
advances in research biology; however, many American students are introduced
to biology by nonresearch teaching faculty. As with their high school counter-
parts, most of these individuals do not specialize in molecular biology and have
been out of school for a number of years. Molecular techniques have not effec-
tively filtered down through the collegiate education system, in part because of a
psychological schism between researchers and teachers that thwarts the flow of
laboratory innovation. This is a remnant of separation previously achieved by a
bicameral system of research universities and teacher-training colleges. Teach-
ing faculty may be reluctant to seek advice from research colleagues for fear of
appearing less "professional." The problem is especially acute at small institu-
tions or state colleges lacking active research programs.
Our experience suggests that college teaching faculty are eager to learn and
incorporate new laboratory teaching methods in molecular biology. A preliminary
study of college faculty we have trained at DNA Science Workshops showed that
they implement new laboratories at a significantly higher rate than do high school
teachers and that they carry on more networking activities. College biology de-
partments have infrastructures conducive to implementing new labs, and faculty
have easier access to funds for new equipment. College instructors reported ob-
taining an average of $4,700 in start-up funding for new labs, compared with
$1,200 per high school trainee.
The Forgotten Biology Teacher
The lack of laboratory teaching in molecular genetics in freshman biology is, in
part, another sorry legacy of Reaganomics. Precollege and college faculty alike
have long relied on faculty-enhancement programs funded by the NSF to keep
up with advances in research science and for instruction on implementing new
student labs. NSF funding for precollege and undergraduate programs was
greatly expanded after the launch of Sputnik and the attendant perception that
the United States was falling behind in the technology race. After peaking at $89
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million in 1968, NSF support for precollege and undergraduate programs (funded
through its Directorate for Science and Engineering Education [SEE]) declined in
the 1970s.
However, President Reagan added insult to injury during his first term in of-
fice. Budget cuts during the early 1980s essentially dismantled the SEE Direc-
torate, when total precollege and undergraduate funding fell to a pre-Sputnik
level of $3.82 million in 1982. This was a national disgrace and shows that even
the best efforts of this lead agency are not immune to the vagaries of our legisla-
tive process.
College biology teaching suffered most during this period, and funding for
undergraduate faculty enhancement programs was eliminated from 1982 to
1987. This coincided precisely with the isolation of the first human cancer genes,
the explosive development of the biotechnology industry, and the development of
key methods for analyzing human genes. It was a period during which research-
ers themselves had difficulty keeping apace with the flurry of discovery. Thus, the
lack of NSF enhancement programs during this critical time in effect put un-
dergraduate faculty nearly a decade behind in the meaningful transfer of genetic
technology to the college teaching laboratory.
Only in 1989 did NSF undergraduate funding regain a pre-Reagan funding
level of $28 million, with precollege funding reaching a record high of $104 mil-
lion. This new heyday of NSF funding for precollege science education appears
to be spurred by a growing perception that the United States is now losing the
technology race with Japan. The looming shadow of Gramm-Rudman-Hollings
notwithstanding, recent history suggests that we can't afford to entrust the
retraining of our biology teaching resource entirely with the federal government.
NSF Funding for a DNA Science 11 College Workshop
Against this backdrop, we were happy to receive word in December that the NSF
had approved funding for a two-year enhancement program for college faculty to
begin in 1991. The program will be administered by Assistant Director Mark
Dr. Greg Freyer, coauthor of DNA Science, assists college workshop participants with a
DNA hybridization experiment.
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Bloom, who developed a second series of 11 laboratories that articulate with and
extend the concepts in DNA Science. A bacterial system (Escherchia coli, plas-
mids, and bacteriophage X.) is used as a simple model to illustrate techniques for
constructing and screening gene libraries, including thetechniques of non-
radioactive hybridization and polymerase chain reaction.
The NSF-sponsored program will consist of a 10-day workshop and 2-day
follow-up program conducted at urban sites: Atlanta and San Francisco in 1991
and Boston and Baltimore in 1992. The labs will be further refined in manuscript
during the 1991 workshops. After incorporating feedback from the 1991 work-
shops, we hope to speed production work so that the laboratories can be formal-
ly published early in 1992 as DNA Science II: An Introduction to Methods of
Genome Analysis.
The success of the NSF proposal was, in large part, due to core support from
the Josiah Macy, Jr., Foundation, the J.M. Foundation, the Richard Lounsbery
Foundation, and the Banbury Fund, which allowed Mark and the high school in-
terns to do extensive preliminary lab work. Core support also allowed Mark to
field test the new lab program at a workshop held in July, which was attended by
24 college faculty from 19 metro-area institutions.
NSF Funding for the Exploring Human Genetics Workshop
Advanced high school teachers in the study mentioned above rated genetics
along with ecology as the biology topics "most important in preparing students
for adult life." Considering this perceived social and personal relevance of human
genetics, it is beginning to occur to many educators that introduction to human
genetics should, in fact, begin at the middle school level (grades 5-8). Making
best use of this window of opportunity may have two important effects. First, it
can inculcate basic tenets of scientific literacy that are essential for all children as
they grow into adulthood. Second, it may light en academic spark for science
that will survive into the college years.
Although human health is a prevalent middle school science topic, many
teachers emphasize drug and sex awareness rather than principles of science.
Human genetics at once not only builds on this traditional health emphasis of
middle school science, but also offers an entree to pure science. Genetics em-
phasizes science as a problem-solving venture involving the collecting, sharing,
and analyzing of data. It is also consistent with the across-curriculum approach
that incorporates science, math, and social studies and emphasizes the impact
of science and its practical applications.
Thus, we were happy to receive funding in the spring from the National
Science Foundation for a model program to train 336 middle school instructors in
New York and Maryland to teach a 15-20-hour unit, Exploring Human Genetics.
The process began in summer 1990 with a 4-day workshop to train 12 pairs of
lead teachers from school districts throughout New York State. In 1991, we will
have the difficult task of supporting and coordinating the activities of these
teachers as they lead "second-round" workshops for 12 pairs of additional
teachers in each of their local areas. The entire schedule of lead and second-
round workshops will be repeated in the state of Maryland, hopefully proving the
suitability of the program as a model for similar programs nationwide.
The workshop presupposes no specific experience in genetics, and it is
aimed at both 5th and 6th grade classroom teachers, as well as 7th and 8th
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David Mick los discusses a corn cross with middle school teachers in a pretest of the Explor-
ing Human Genetics Workshop.
grade life science teachers. Each participant is provided with a teaching kit con-
taining text and all necessary lab materials needed to initiate an experience-
based program at his or her school. Regular follow-up activities will further en-
courage implementation and networking between participants.
Continued Popularity of Local Programs
The Laboratory's current involvement in public education began with the estab-
lishment, in 1985, of a consortium of eight local school districts. This consortium,
the Curriculum Study, has grown over the years, reaching a new high of 27 dis-
tricts with the addition in 1990 of Garden City, Kings Park, and Roslyn. Cur-
riculum Study schools have served as a proving ground for both the DNA
Science and Exploring Human Genetics curricula, and their teachers frequently
form ad hoc committees to advise us on future projects. It is a tribute to the
enthusiasm with which local teachers adopted our ideas that, despite the lack of
a major biotechnology industry, the metropolitan New York area ranks along with
San Francisco as a national leader in advanced biology teaching at the high
school level.
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Curriculum Study schools receive reduced admission fees to DNA Learning
Center programs, spaces in student/teacher workshops, and equipment pur-
chase options. Students and teachers receive an insider's view of current biologi-
cal research through the "Great Moments in DNA Science" Lecture Series held
each spring. The 1990 lecturers and topics were the following:
William Gergits, Lifecodes Corporation. From Antelopes to Zebra Finches:
The A to Zs of Animal DNA Fingerprinting.
Carolyn Truncer, Health Science Center at the State University of New York,
Stony Brook. Clinical Applications of Genetic Technologies.
Robert Franza, Cold Spring Harbor Laboratory. DNA-binding Proteins and
Gene Function.
David Helfman, Cold Spring Harbor Laboratory. Protein Diversity through
Alternative RNA Splicing.
The laboratory field-trip program conducted in the Bio2000 Laboratory con-
tinues to operate at capacity, drawing both Curriculum Study members and
schools from throughout metropolitan New York. In 1990, 3,758 students and 270
teachers (180 classes) conducted the AP laboratories on DNA restriction analysis
and bacterial transformation. The field-trip program is subsidized by core grants
from the Esther A. and Joseph Klingenstein Fund, the Josiah Macy, Jr., Founda-
tion, the J.M. Foundation, Boehringer Mannheim Biochemicals, and United States
Biochemical Corporation.
Since the opening in September 1988 of the DNA Learning Center, 22,000
visitors have toured the exhibits housed here. The Search for Life: Genetic Tech-
nology in the Twentieth Century, on loan from the National Museum of American
History of the Smithsonian Institution, chronicles the study of heredity from Darwin
to DNA and confronts the visitor with the promise and concern of genetic technol-
ogy. DNA Detective, which opened in September 1989, examines the uses of
DNA fingerprinting in forensic and paternity law.
Exploring the Uses of Multimedia in Biology Education
During the last several decades, we have witnessed the virtual perfection of
several audiovisual technologies: television, video, computers, and random-
access laser disks. Taken alone, none has lived up to its potential as a teaching
tool. However, "multimedia" or "hypermedia" programs now offer the potential to
link these technologies into a flexible system that allows individuals to structure
their own learning experiences. With the help of our new Laboratory trustee Owen
Smith and senate majority leader Ralph Marino, we received a grant of $66,300
from the New York State Legislature to develop multimedia learning experiences
in human genetics.
Thus, at the end of 1990, Sue Lauter began to equip a multimedia develop-
ment laboratory. Her system is centered around a Macintosh Ilci computer, which
has adequate memory and processing speed to display various types of analog
and digital information, including video, photographs, artwork, sound, and text.
The information is accessed from CD-ROM and laser video disks, which have the
capability to store high-resolution images that are input from a scanner and video
camera/recorder. Authoring software, including a digital "paintbox," Hypercard,
and Macromind Director, allows Sue to merge the various media into a seamless,
interactive system. Our objective is to create open-ended learning experiences,
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in which students can actively explore a complex information field, that access
multiple analog and digital sources according to their preferences of information
use.
After pretesting with students from Curriculum Study schools, the multimedia
experiences will be offered as student field trips and will be incorporated into a
new public exhibit, Exploring the Human Genome. Because of its location and
specialization, the DNA Learning Center can never expect to draw significant
numbers of off-the-street visitors. However, it can influence widespread science
literacy by producing high-quality multimedia exhibitry for the use of other muse-
ums. Our in-house expertise in science interpretation and easy access to the
major figures in the world of molecular biology make the DNA Learning Center an
ideal interface between genetic science and society.
With assistance from the Albert and Mary Lasker Foundation, Sue is develop-
ing a new exhibit, Eye on the Prizes: Milestones in Molecular Genetics and Ge-
netic Medicine, highlighting recipients of the Nobel Prize and the Albert Lasker
Medical Research Award. Through a time line of prizewinners, the exhibit will
chronicle the development of modern genetics. We already have a small collec-
tion of Nobel Prizes, and the Lasker Foundation is donating one of its award
statuettes of the Winged Victory of Samothrace.
Doing Our Part for Soviet Glasnost
Steven Malloy, one of our student interns, combined his interests in Russian
studies and DNA to spark a collaboration between the DNA Learning Center and
the Shemyakin Institute of Bioorganic Chemistry (part of the of Soviet Academy of
Sciences). Through the New York State/Moscow Telecommunication
sponsored by the Copen Family Foundation, Steve contacted Moscow student
Nikita Skryabin, whose father is Vice-Director of the Academy's Engelhardt In-
Mark Bloom (left) and David Mick los (right) with Dimitri Debabov from the Engelhardt In-
stitute in front of Moscow State University during their visit to the Soviet Union in May.
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Laboratory Director James Watson (center) speaks with Soviet scientists (left to right) Leonid
Barsukov, Irina Severtsova, Niko lay Zvonok, and Dimitri Debabov during their visit to the
DNA Learning Center in August.
stitute of Molecular Biology. Discussion centered on the notion of creating a DNA
Science education program in Moscow modeled after the DNA Learning Center.
During a visit to the Soviet Union in May, Dave Mick los and Mark Bloom
reached an agreement with their counterparts from the Soviet Academy of
Sciences to initiate a joint education program. At that time, it was agreed that the
immediate objective was to set up a Moscow DNA Learning Center within the
Science-Education Center at the Shemyakin Institute. The Moscow DNA Learning
Center will adapt our successful DNA Science laboratories to suit the Soviet edu-
cational system. The DNA Learning Center agreed to seek donations from Amer-
ican and European manufacturers to equip and supply the Moscow Center. The
participating institutions further agreed to seek funding for a van to carry equip-
ment and reagents to schools in Moscow modeled after our Vector Mobile DNA
Laboratory.
Our trip to Moscow and Leningrad was a real eye-opener and pointed up the
potential impact of the proposed collaboration. In spite of a history of achieve-
ment and strong public support, Soviet biologists are suffering under perestroika.
Lack of hard currency makes it very difficult to pay for imported equipment and
reagents. All orders for supplies must go through the central bureaucracy, whose
already slow distribution system has been further stymied. If it is difficult to obtain
meat in Moscow, imagine the difficulty of obtaining a centrifuge. Even biologists
employed by the prestigious institutes of the Academy of Sciences have grown
used to waiting a full year for the arrival of even the most trivial reagent.
The shortfall of hard currency and supplies makes it difficult for researchers
to plan their experiments, but it makes it virtually impossible for undergraduate
students to obtain any practical experience with the tools of molecular biology.
There simply are not enough supplies and equipment to "waste" on students. The
science laboratories of the monolithic Moscow State University, the nation's
finest, look unchanged from the days of Stalin (except for the dust and the miss-
ing squares of parquet flooring). Few high schools appear to have anything com-
parable to a teaching laboratory. Clearly, rote learning reigns in the Soviet Union.
Our experiences in the Soviet Union made us realize that the implementation
of a DNA Learning Center-style program to put micropipets in the hands of Soviet
high school students would be truly revolutionary. We saw the real possibility that
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our ongoing collaboration might stimulate a general reform of biology education
in the Soviet Union similar to that which is occurring at the AP/college level in the
United States.
A delegation of four Soviet scientists from the Shemyakin and Engelhardt In-
stitutes visited New York in August to participate in a DNA Science Workshop at
the DNA Learning Center. During their visit, they met with American educators,
observed our teaching methods, and performed the DNA Science laboratories.
We traveled with the delegation to Washington, where we met with NSF Assistant
Directors Luther Williams and Mary Clutter to discuss our plans for collaboration.
We also finalized plans to conduct jointly a DNA Science Workshop at the
Shemyakin Institute in early 1991 to open the Moscow DNA Learning Center.
The Soviet scientists returned home carrying with them enough supplies and
equipment to begin implementing student experiments. The DNA Learning Cen-
ter had coordinated donations valued at $14,000 for the Moscow DNA Learning
Center: digital micropipets and a microcentrifuge from Eppendorf-Netheler-Hinz
GmgH of Germany (through arrangements by Brinkmann Instruments of West-
bury, New York); electrophoresis chambers, power supplies, and laboratory
manuals from Carolina Biological Supply Company of Burlington, North Carolina;
and a transilluminator/Polaroid camera system from Fotodyne, Inc., of New Berlin,
Wisconsin. Publications, reagents, and expendable supplies were provided by
Cold Spring Harbor Laboratory Press and the DNA Learning Center.
Charles A. Dana Award for Dave Mick los
On November 8th, director Dave Mick los was one of four individuals honored by
the Charles A. Dana Foundation for pioneering achievements in health and edu-
cation. The Dana Awards, given annually since 1986, are the only ones made ex-
clusively to recognize innovative ideas in health and disease prevention and are
among the largest awards for innovations in education. Recipients of the $50,000
David Mick los (far right) with other 1990 Dana Award winners (from left) John W. Farquhar,
M.D., Norbert Hirschhorn, M.D., and David P. Billington at the presentation banquet at the
Plaza Hotel.
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award are selected from nationwide nominations by a jury of leaders in health
and education.
David Mahoney, chairman of the Charles A. Dana Foundation, presented the
award to Dave for conceiving and directing a national scientific center's pioneer-
ing mission to carry the concepts and applications of the modern biological revo-
lution-and the protean potential of recombinant DNA technology-to future
biological scientists and all future citizens in the nation's schools."
David P. Billington, Professor of Civil Engineering and Operations Research at
Princeton University, received the other award in education; the recipients of the
health award were Norbert Hirschhorn, Vice-President of John Snow, Inc., and a
lecturer at Harvard Medical School, and John W. Farquhar, Professor of Disease
Prevention at Stanford University and Director of Stanford's Center for Research
in Disease Prevention. Past honorees have included Donald Henderson, for his
work in the eradication of smallpox, and F. Sherwood Rowland, for his research
and advocacy to prevent further depletion of the earth's ozone layer.
Staff Changes
Sandy Ordway ably stepped up to the hectic responsibilities as administrative
assistant, following the departure of Anne Zollo in June. Sandy needed no in-
struction on her new position. She had served as a volunteer to prepare for the
opening of the DNA Learning Center and had worked part-time on our evaluation
study and organizing special summer programs. Poised and polished, Sandy is a
wonder of organization. We all feel confident in her ability to orchestrate with
aplomb our many programs and collaborations.
After the departure of John LeGuyader for a position in the biotechnology de-
partment of the U.S. Patent Office, Margaret Henderson assumed the
responsibilities of Education Manager. A native of London, Ontario, Margaret has
an undergraduate degree in biology and a graduate degree in library science;
her husband Scott is a postdoctoral fellow in electron microscopy on the main
Sandy Ordway guides students through the Search for Life exhibit.
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Laboratory campus. She gamely stepped up to the demands of teaching six stu-
dent labs per week, getting rave reviews on her patience and providing an ex-
cellent role model for male and female students alike. Her library skills will be put
to use in a collaborative program with Biosis, the publisher of Biological Ab-
stracts, and in designing a proposed student research library.
Kelly Flynn continued to share some of the teaching duties in the Bio2000
Laboratory and also acted as editorial and photo researcher for DNA Science.
After contributing to the summer workshop program, Kelly entered the master's
program in genetic counseling at Sarah Lawrence University. While completing
her master of fine arts degree at Long Island University, Carrie Abel assisted Sue
Lauter with artwork for DNA Science, continuing on to a career in graphic design.
Interns, ranging from high school sophomores to graduate students, provide
critical assistance to our teaching staff. Amy Phillips, a senior at Huntington High
School, joined the staff in the spring and traveled with the Vector van this sum-
mer. Amy helped to develop two new educational kits to be marketed by Carolina
Biological Supply Company and supervised,newer interns Mark Staudinger and
Richard Chiang. Chat "Sol" Chen graduated from Rensselaer Polytechnic Institute
in June and reliably assisted the senior workshop instructors throughout the sum-
mer. He continues to keep us informed of his travels.
Publications
Bloom, M. Mapping and Sequencing the Human Genome. Cabisco Biotechnology Tips,
Vol. 1, No. 1. March, 1990.
Micklos, D. and G. Freyer. DNA Science: A First Course in Recombinant DNA Technology.
Carolina Biological Supply Company and Cold Spring Harbor Laboratory Press: New
York, 1990.
Micklos, D. DNA Science and Education. Carolina Tips 53, 1990.
Micklos, D. 'Preparing for the Gene Age.' Essay for the Fifth Annual Charles A. Dana
Awards for Pioneering Achievements in Health and Education, New York, 1990.
Micklos, D. and J. Kruper. Retooling Biology Education for the Gene Age: A Profile of In-
novative High School Science Teachers. Submitted.
Curriculum Study Membership 1989-1990
Cold Spring Harbor Central School District*
Commack Union Free School District
East Williston Union Free School District*
Garden City Union Free School District
Great Neck Public Schools*
Half Hollow Hills Central School District
Harborfields Central School District
Herricks Union Free School District*
Huntington Union Free School District
Island Trees Union Free School District
Jericho Union Free School District*
Kings Park Central School District
Lawrence Public Schools
Lindenhurst Public Schools
'Founding members
Locust Valley Central School District
Manhasset Public Schools
Northport-East Northport Union Free School District*
North Shore Central School District
Oyster Bay-East Norwich Central School District*
Plainedge Public Schools
Plainview-Old Bethpage Central School District
Portledge School
Port Washington Union Free School District
Roslyn Union Free School District
Sachem Central School District at Holbrook
South Huntington Union Free School District
Syosset Central School District*
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Sites of Major 4-8 Day Workshops 1985-1990
ALABAMA University of Alabama, Tuscaloosa 1987, 1988, 1989, 1990
ARIZONA Tuba City High School 1988
CALIFORNIA University of California, Davis 1986
CONNECTICUT Choate Rosemary Hall, Wallingford 1987
GEORGIA Fernbank, Inc., Atlanta 1989
HAWAII Kamehameha Secondary School, Honolulu 1990
ILLINOIS Argonne National Laboratory, Chicago 1986, 1987
INDIANA Butler University, Indianapolis 1987
IOWA Drake University, Des Moines 1987
KENTUCKY Murray State University 1988
LOUISIANA Jefferson Parish Public School, Harvey 1990
MANITOBA Red River Community College, Winnipeg 1989
MARYLAND Annapolis Senior High School 1989
McDonogh School, Baltimore 1988
Montgomery County Public Schools 1990
MASSACHUSETTS Beverly High School 1986
Dover-Sherborn High School, Dover 1989
Randolph High School 1988
Winsor School, Boston 1987
MICHIGAN Athens High School, Troy 1989
MISSISSIPPI Mississippi School for Math & Science, Columbus 1990
MISSOURI Washington University, St. Louis 1989
NEW HAMPSHIRE St. Paul's School, Concord 1986, 1987
NEW YORK Albany High School 1987
Bronx High School of Science 1987
Cold Spring Harbor High School 1985, 1987
DNA Learning Center, high school workshops 1988(3), 1989(2), 1990(2)
DNA Learning Center, college workshop 1990
DNA Learning Center, middle school workshop 1990
Huntington High School 1986
Irvington High School 1986
State University at Purchase 1989
State University at Stony Brook 1987, 1988, 1989, 1990
Wheatley School, Old Westbury 1985
NORTH CAROLINA North Carolina School of Science, Durham 1987
OHIO Case Western Reserve University, Cleveland 1990
Cleveland Clinic 1987(2)
North Westerville High School, Westerville 1990
PENNSYLVANIA Duquesne University, Pittsburgh 1988
Germantown Academy, Fort Washington 1988
SOUTH CAROLINA Medical University of South Carolina, Charleston 1988
University of South Carolina, Columbia 1988
TEXAS J.J. Pearce High School, Richardson 1990
VERMONT University of Vermont, Burlington 1989
VIRGINIA Jefferson School of Science, Alexandria 1987
Mathematics and Science Center, Richmond 1990
WEST VIRGINIA Bethany College 1989
WISCONSIN Marquette University, Milwaukee 1986, 1987
University of Wisconsin, Madison 1988, 1989
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1990 Workshops, Meetings, and Collaborations
January 6-7 Follow-up Workshop, National Science Foundation
Athens High School, Troy, Michigan
January 13-14 Follow-up Workshop, National Science Foundation
State University of New York at Purchase
January 17-18 Workshop, Cornell University, Ithaca, New York
January 20-21 Follow-up Workshop, National Science Foundation
Fernbank Science Center, Atlanta, Georgia
January 26 Banbury Workshop for Congressional Aides
DNA Learning Center, Cold Spring Harbor, New York
January 27-28 Follow-up Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
February 17-18 Follow-up Workshop, Red River Community College, Manitoba, Canada
March 3 Workshop, New York City Biology Teachers
DNA Learning Center, Cold Spring Harbor, New York
March 10 Workshop, Long Island Biological Association
DNA Learning Center, Cold Spring Harbor, New York
March 14 Follow-up Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
March 24 Follow-up Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
Workshop, New York Microscopical Society
DNA Learning Center, Cold Spring Harbor, New York
March 16-17 Workshop, Smith College, Northampton, Massachusetts
March 20-21 Conference, National Academy of Sciences, Washington, D.C.
April 6 Workshop, National Science Teachers Association Meeting, Atlanta, Georgia
May 5 Board of Trustees Meeting, Lunch
DNA Learning Center, Cold Spring Harbor, New York
May 5-19 Meetings, Soviet Academy of Sciences, Moscow and Leningrad, Soviet Union
May 12 Workshop, Long Island Biological Association
DNA Learning Center, Cold Spring Harbor, New York
May 17-18 Workshop, Macy Foundation
A. Philip Randolph High School, New York, New York
May 21-26 Workshop, Case Western Reserve, Cleveland, Ohio
June 11-15 Workshop, Macy Foundation, University of Alabama, Tuscaloosa, Alabama
June 13-15 Workshop, Pretest for Middle School Program
DNA Learning Center, Cold Spring Harbor, New York
June 18-22 Workshop, National Science Foundation
Mississippi School for Math and Science, Columbus, Mississippi
Workshop, National Science Foundation
Jefferson Parish Public Schools, Harvey, Louisiana
Workshop, Kamehameha Secondary School
Honolulu, Hawaii
Workshop, Republic of Singapore
June 25-29 Workshop, National Science Foundation
J.J. Pearce High School, Richardson, Texas
June 27 Workshop, Seminole Community College, Sanford, Florida
July 9-13 Workshop, Howard Hughes Medical Institute
Wheaton High School, Wheaton, Maryland
July 16-20 Workshop, National Science Foundation
Mathematics and Science Center, Richmond, Virginia
July 18-28 Workshop, College Faculty
DNA Learning Center, Cold Spring Harbor, New York
July 29-30 Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
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July 31 Workshop and Seminar, Florida Department of
Education Honors Science Symposium, Orlando, Florida
August 6-10 Workshop, National Science Foundation
Westerville North High School, Westerville, Ohio
August 13-19 Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
August 13-15 Conference, UNESCO
University of Maryland, College Park, Maryland
August 20-24 Workshop
State University of New York at Stony Brook
August 21 National Science Foundation Assistant Directors Meeting
Washington, D.C.,
August 27-31 Workshop, National Science Foundation Middle School Program
DNA Learning Center, Cold Spring Harbor, New York
September 29-30 Follow-up Workshop, National Science Foundation
Mississippi School for Math and Science, Columbus, Mississippi
October 6 Workshop, Ohio College Biology Teachers
Columbus, Ohio
October 10-11 Workshop, Board of Cooperative Education Services
State University of New York at Binghamton
October 13-14 Follow-up Workshop, Howard Hughes Medical Institute
Wheaton High School, Wheaton, Maryland
October 27-28 Follow-up Workshop, National Science Foundation
Mathematics and Science Center, Richmond, Virginia
November 1-3 Workshop, National Science Teachers Association Meeting
Long Beach, California
November 3-4 Follow-up Workshop, National Science Foundation
J.J. Pearce High School, Richardson, Texas
November 7-11 Seminar, National Association of Biology Teachers Meeting
Houston, Texas
November 14-17 Workshop, United States Biochemical
Cleveland, Ohio
November 29 Workshop, National Science Teachers Association Meeting
San Juan, Puerto Rico
November 30- Follow-up Workshop
December 1 Case Western Reserve, Cleveland, Ohio
December 8-9 Follow-up Workshop,
State University of New York at Stony Brook
Follow-up Workshop, National Science Foundation
Westerville North High School, Westerville, Ohio
December 10 Workshop, New York Association of Independent Schools
DNA Learning Center, Cold Spring Harbor, New York
December 14 Workshop, National Science Teachers Association Meeting
Washington, D.C.
December 15-16 Follow-up Workshop, Curriculum Study
DNA Learning Center, Cold Spring Harbor, New York
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The academic program at Cold Spring Harbor Laboratory now extends from the
beginning of April through the beginning of November, with hundreds of visiting
scientists taking part in the courses as students, instructors, and lecturers. The
first summer course given at the Laboratory was the famous "Phage Course,"
which began in 1945. This year, the Advanced Bacterial Genetics course, its suc-
cessor, celebrated their joint 45th anniversary. The Advanced Bacterial Genetics
course continues to be oversubscribed as are, in fact, all of the Lab's course of-
ferings. Two new courses were offered this summer: Advanced Drosophila
Genetics, taught by Gerry Rubin and Michael Ashburner, and Computational
Neuroscience: Learning and Memory, taught by Michael Jordan and Terrence
Sejnowski.
Nine 3-week laboratory courses in Molecular Genetics and Neurobiology (in-
structors and students are listed in the following pages) were held during the
summer in James, Jones, and Delbruck Laboratories. As is usually the case, the
course labs were open from nine in the morning until after midnight seven days a
week. Five 1- to 2-week lecture courses were held at the Banbury Center. In ad-
dition to the new lecture courses mentioned above, courses were offered in De-
velopmental Neurobiology, Genetic Approaches to Human Disease Using DNA
Markers, and Molecular Genetic Analysis of Diseases of the Nervous System.
The spring and fall courses, which started with a single course on X-ray Crys-
tallography in 1988, now seem settled into the Laboratory landscape. Four 2-
week courses cover Protein Purification and Characterization, Cloning and Analy-
sis of Large DNA Molecules, Molecular Genetics of Fission Yeast, and Macro-
molecular Crystallography and take place with the same mixture of intensity and
informality as the summer courses.
The courses are supported by, and would not be possible without, a series of
grants from federal and private sources. The summer Molecular Genetics
courses have been supported for many years by grants from the National In-
stitutes of Health and the National Science Foundation, and a grant from the Na-
tional Institute of Mental Health has supported several of the Neurobiology
courses. However, it has been a large education grant from the Howard Hughes
Medical Institute (HHMI) that has provided stable support for the neurobiology
program. Funds from HHMI to support new courses also allowed the Laboratory
to begin the series of spring and fall courses. As has been the case for several
years, the Grass Foundation provided funds for scholarships for students in
neurobiology courses.
The logistics of arranging for and dealing with the large number of scientists
who participate in the courses is handled with enormous goodwill and efficiency
by the staff in the Meetings Office: Barbara Ward, Maureen Berejka, Diane Tighe,
Karen Otto, Micki McBride, Marge Stellabotte, and Nancy Weeks.
While the various courses brought graduate students, postdoctoral fellows,
and faculty to the Laboratory, the Undergraduate Research Program (URP) con-
tinued to allow college students to spend the summer doing research in the
laboratories of staff scientists. This program, headed by Winship Herr, a Senior
Scientist at the Lab, allowed 18 students to work at Cold Spring Harbor this sum-
mer. Funds essential for the support of the URP Program were provided by the
Burroughs Wellcome Fund, Baring Brothers, Miles Inc./Bayer AG, the Cold
Spring Harbor Laboratory Robert H.P. Olney Fund, and Bio-Rad.
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Postgraduate Courses
The summer program of Postgraduate Courses at Cold Spring Harbor Laboratory
is aimed at meeting the special need for training in interdisciplinary subjects that
are either so new or so specialized that they are not adequately treated by uni-
versities. Our aim is to provide intensive study in the most recent developments
and techniques in these subjects and to prepare students to enter directly into
research in a particular area. To ensure up-to-date coverage of current research
work, we bring together a workshop staff from many laboratories around the
world and supplement this staff with a series of seminar speakers.
Cloning and Analysis of Large DNA Molecules
April 17-April 30
INSTRUCTORS
Gemmill, Robert, Ph.D., Eleanor Roosevelt Institute, Denver, Colorado
Klapholz, Sue, Ph.D., Stanford University, California
Sternberg, Nat, Ph.D., E.I. du Pont de Nemours & Company, Inc., Wilmington, Delaware
ASSISTANTS
Mendez, Michael, Eleanor Roosevelt Institute, Denver, Colorado
McGuigan, Terri, E.I. du Pont de Nemours & Company, Inc., Wilmington, Delaware
Williams, Reggie, Eleanor Roosevelt Institute, Denver, Colorado
This course covered the theory and practice of manipulating and cloning high-
molecular-weight DNA. Lectures and laboratory work dealt with the use of bac-
teriophage P1 and yeast artificial chromosome (YAC) cloning systems, the isola-
tion and manipulation of high-molecular-weight DNA from mammalian cells for
cloning (including the size selection of 200-300-kb DNA fragments), and the
analysis of high-molecular-weight DNA by pulsed-field gel (PFG) separation tech-
niques. P1 and YAC recombinant DNA molecules were produced, introduced
into cells (Escherichia coli and yeast, respectively), and reisolated after ap-
propriate clone selection and colony-screening procedures. Comparison of DNA
separation capabilities was made between the five major PFG techniques com-
monly in use. All aspects of Southern blot analysis of DNA were covered, includ-
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ing sample digestion with restriction enzymes, separation on pulsed-field gels,
Southern transfer, hybridization, and interpretation of results. Students gained
hands-on experience through participation in ongoing efforts to prepare physical
maps of portions of human chromosomes 3 and 12. Lectures by outside
speakers on topics of current interest supplemented the laboratory work.
PARTICIPANTS
Durkin, A., B.S., American Type Culture Collection, Rock-
ville, Maryland
Fey, G., Ph.D., Research Institute of Scripps Clinic, La Jolla,
California
Frey, B., Ph.D., Boehringer Mannheim GmbH, Penzberg,
Federal Republic of Germany
Hampikian, G., Ph.D., University of Connecticut, Storrs
Horowitz, M., Ph.D., Weizmann Institute, Israel
Kimura, S., Ph.D., Memorial Sloan-Kettering Cancer Center,
New York
King, T., Ph.D., Jackson Laboratory, Woods Hole, Massa-
chusetts
SEMINARS
Jesse, J., Bethesda Research Laboratories. High-efficiency
transformation of E. coli by electroporation.
Smith, S., University of New Mexico. Observation of DNA
molecular motions during electrophoresis.
Garza, D., Stanford University. YAC cloning the Drosophila
genome.
Burke, D., Princeton University. YAC cloning.
Hieter, P., Johns Hopkins University. Manipulation of large
Kitamura, Y., Ph.D., University of Tokyo, Japan
Mackie, S., Ph.D., University of Sheffield, England
Negrutiu, I., Ph.D., Institute of Molecular Biology, Belgium
Nimmo., E., M.S., St. Mary's Hospital, London, England
Pauletti, G., Ph.D., California Institute of Technology,
Pasadena
Rao, N., Ph.D., Eli Lilly & Company, Indianapolis, Indiana
Rijnkels, M., M.S., Gorleus Laboratory, Leiden, The Nether-
lands
Tribioli, C., Ph.D., Istituto di Genetica, Italy
Tsui, H., Ph.D., Toronto Western Hospital, Canada
DNA as yeast artificial chromosomes.
Roberts, R., Cold Spring Harbor Laboratory. Restriction
endonucleases.
Gardiner, K., Eleanor Roosevelt Institute. Physical mapping
and human chromosome 21.
McClelland, M., California Institute of Biological Research.
Rare cleavage specificities generated by methylation.
Protein Purification and Characterization
April 16-April 30
INSTRUCTORS
Marshak, Dan, Ph.D., Cold Spring Harbor Laboratory, New York
Erickson, Bruce, Ph.D., University of North Carolina, Chapel Hill
Kadonaga, James, Ph.D., University of California, San Diego
Smith, John, M.D., Ph.D , Harvard Medical School, Boston, Massachusetts
ASSISTANTS
Vasquez, Greg, University of North Carolina, Chapel Hill
Kerrigan, Leslie, University of California, San Diego
Lee, Fang-Jen S., Massachusetts General Hospital, Boston
This course was intended for scientists who are not familiar with the techniques of
protein isolation and characterization. Students learned the major techniques in
protein purification by actually performing four separate isolations: (1) a
regulatory protein from muscle tissue; (2) a fusion protein from Escherichia coil;
(3) a DNA-binding protein from nuclei of tissue culture cells; and (4) a chemically
synthesized peptide. A variety of chromatographic, electrophoretic, and bulk
312
fractionation techniques were employed including the following: ion exchange,
gel filtration, hydrophobic interaction, affinity-based adsorption, and im-
munoaffinity chromatography; polyacrylamide gel and two-dimensional gel elec-
trophoresis and electroblotting; precipitation by salt and pH; and high-
performance liquid chromatography analysis. Methods of protein characterization
were discussed, including amino acid analysis, protein sequencing, and mass
spectrometry. Emphasis was placed on methods of protein purification rather
than automated instrumental analysis. Guest lecturers discussed protein struc-
ture, modifications of proteins, and methodologies for protein purification. Ap-
plications of protein biochemistry to various areas of research in molecular biol-
ogy were discussed.
PARTICIPANTS
Bastiani, C., B.A., University of California, Davis
Bode, A., Ph.D., University of North Dakota, Grand Forks
Gahlmann, R., Ph.D., University of Southern California, Los
Angeles
Helm, B., Ph.D., University of Sheffield, England
Hocke, G., Ph.D., Research Institute of Scripps Clinic, La
Jolla, California
Khursheed, B., Ph.D., University of Chicago, Illinois
Lee, S.-K., M.S., University of Notre Dame, Indiana
Lissemore, J., Ph.D., Syracuse University, New York
SEMINARS
Rose, G., Hershey Medical, Pennsylvania State University.
Fundamentals of protein structure.
Smith, J., Harvard Medical School. Protein
purification-Basic methods.
Gierasch, L., University of Texas Southwestern Medical
Center. Spectroscopic techniques.
Pace, N., Texas A&M. Thermodynamics of protein folding.
Graves, D., Iowa State University. Modification of proteins.
Moremen, K., Massachusetts Institute of Technology.
Glycosylation of proteins.
Marshak, D., Cold Spring Harbor Laboratory. Mass spec-
trometry of proteins.
Lockhart, A., B.S., Birkbeck College, London, England
Luini, A., M.D., Mario Negri Institute, Italy
Macaulay, C., Ph.D., University of California, San Diego
Nepveu, A., Ph.D., Ludwig Institute, Montreal
Pintel, D., Ph.D., University of Missouri, Columbia
Samuelsson, E., M.S., Royal Institute of Technology,
Sweden
Stewart, V., Ph.D., Cornell University, Ithaca
Von Ka Im, L., Ph.D., University of California, Berkeley
Aebersold, R., University of British Columbia. Methods of mi-
croanalysis and transfer.
Dunbar, B., Baylor College of Medicine. Two-dimensional
gel electrophoresis.
Wilson, K., Applied Biosystems. High-performance separa-
tion methods.
Heckendorf, A., The Nest Group. High-performance liquid
chromatography column materials.
Erickson, B., University of North Carolina. Peptide synthesis.
Paterson, Y., University of Pennsylvania. Designing synthetic
antigens.
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Advanced Bacterial Genetics
June 8-June 28
INSTRUCTORS
Berget, Peter, Ph.D., Carnegie Mellon University, Pittsburgh, Pennsylvania
Maurer, Russell, Ph.D., Case Western Reserve University, Cleveland, Ohio
Weinstock, George, Ph.D., University of Texas, Houston
ASSISTANTS
Bianco, Piero, University of Texas, Houston
Heath, Joe Don, University of Texas, Houston
Slater, Steven, Case Western Reserve University, Cleveland, Ohio
AIDE
Karen, Marcia, Carnegie Mellon University, Pittsburgh, Pennsylvania
This laboratory course demonstrated genetic approaches that can be used to an-
alyze biological processes and their regulation, as well as detailed struc-
ture/function relationships of genes. Techniques that were covered included the
following: isolation, complementation, and mapping of mutations; use of
transposable genetic elements; construction of gene fusions; cloning of DNA;
restriction enzyme mapping; Southern blotting; macrorestriction mapping of
genomes by pulsed-field gel electrophoresis; and DNA sequencing. The course
consisted of a set of experiments incorporating most of these techniques and
was supplemented with lectures and discussions. The aim was to develop in stu-
dents the ability to design a successful genetic approach to any biological prob-
lem.
PARTICIPANTS
Bandopadhyay, A., M.S., Albert Einstein College of Medi-
cine, Bronx, New York
Barz, W., M.S., Max-Planck Institut, Martinsried, Federal Re-
public of Germany
Cohen-Fix, 0., M.S., Weiz.mann Institute, Israel
Fenwick, B., Ph.D., Kansas State University, Manhattan
Kohler, S., M.A., University of Wurzburg, Federal Republic of
Germany
Lantz, M., Ph.D., University of Alabama, Birmingham
Maslow, J., Ph.D., Boston Veteran's Administration Medical
Center, Massachusetts
Munoz, R., M.S., Rockefeller University, New York, New York
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Resnekov, 0., Ph.D., Karolinska Institute, Sweden Trucksis, M., Ph.D., Massachusetts General Hospital, Bos-
Rubin, L., M.D., Long Island Jewish Medical Center, New ton
York Versalovic, J., B.A., Baylor College of Medicine, Houston,
Schaefer, M., Ph.D., Texas A&M University, College Station Texas
Sirois, M., M.S., Laval University, Canada Wegrzyn, G., M.S., University of Gdansk, Poland
Spormann, A., Ph.D., University of Minnesota, Minneapolis
SEMINARS
Kaplan, S., University of Texas Medical School. The
wonders of photosynthetic bacteria.
Roth, J., University of Utah. Chromosome rearrangements.
Stewart, V., Cornell University. Nitrate regulation of
anaerobic respiration in Escherichia coli.
Taylor, R., University of Tennessee. Molecular genetics of
toxin coregulated genes in Vibrio cholera.
Maloy, S., University of Illinois. Genetic analysis of proline
transport in Salmonella.
Susskind, M., University of Southern California. How RNA
polymerase recognized promoters.
Molecular Embryology of the Mouse
June 8-June 28
INSTRUCTORS
Lovell-Badge, Robin, Ph.D., National Institute for Medical Research, London, England
McMahon, Andy, Ph.D., Roche Institute of Molecular Biology, Nutley, New Jersey
COINSTRUCTORS
Parada, Luis, National Cancer Institute, Frederick, Maryland
Rastan, Sohaila, Clinical Research Centre, Middlesex, England
ASSISTANT
Nichols, Jenny, ICRF Developmental Biology Unit, Oxford, England
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This course is designed for molecular biologists, biochemists, and cell biologists
interested in applying their expertise to the study of mouse embryonic develop-
ment. Lecture and laboratory components of the course emphasized both the
practical aspects of working with mouse embryos and the conceptual basis of
current embryonic research. The following procedures and their potential ap-
plications were described: isolation and culture of germ cells and pre-
implantation and postimplantation embryos, embryo transfer, establishment and
genetic manipulation of embryo-derived stem cell lines, germ-layer separation,
chimera formation, nuclear transplantation, microinjection of DNA into eggs,
retroviral infection of embryos, microinjection of cell lineage tracers, in situ
hybridization, and immunohistochemistry. Guest lecturers discussed current re-
search in the field.
PARTICIPANTS
Albano, R., M.S., National Institute for Medical Research,
London, England
Basler, K., Ph.D., University of Zurich, Switzerland
Charnay, P., Ph.D., Ecole Norma le Superieure, Paris, France
Dhawan, J., M.S., Boston University, Massachusetts
Elias-Arnanz, M., Ph.D., University of Murcia, Spain
Estreicher, A., Ph.D., State University of New York, Stony
Brook
Coate, A., Ph.D., St. Mary's Hospital, London, England
Himmelbauer, H., M.S., ICRF, London, England
SEMINARS
Ziomek, C., Worcester Foundation for Experimental Biology.
Preimplantation developments.
Beddington, R., ICRF Developmental Biology Unit.
Postimplantation development.
McLaren, A., MRC Mammalian Development Unit. Germ
cells.
. Sex determination I.
Rastan, S., MRC Clinical Research Centre. X-inactivation.
Lovell-Badge, R., National Institutes for Medical Research.
Sex determination II.
Hogan, B., Vanderbilt University. Extraembryonic mem-
branes.
. Role of TGF-0-related genes in organogenesis and
pattern formation in the mouse.
Lovell-Badge, R., National Institutes for Medical Research;
and
Robertson, L., Columbia University College of Physicians &
Surgeons. EC and ES cells.
. ES cells/gene disruption.
Wassarman, P., Roche Institute of Molecular Biology. Fertil-
ization.
Solter, D., Wistar Institute. Imprinting.
Rossant, J., Mount Sinai Hospital. Strategies for identifying
and mutating developmentally important genes.
Krumlauf, R., MRC National Institute for Medical Research.
Homeobox genes I (structure/regulation).
Wilkinson, D., MRC National Institute for Medical Research.
Segmentation in the nervous system.
Noden, D., New York State College of Veterinary Medicine.
Cell migration and tissue assembly during craniofacial de-
velopment.
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Lanahan, A., Ph.D., Johns Hopkirru Medical School, Balti-
more, Maryland
Ott, M. -O., Ph.D., Institute Pasteur, Paris, France
Rey-Campos, J., Ph.D., Institute Pasteur, Paris, France
Roe link, H., M.S., Stanford University, California
Sutherland, H., B.S., Western General Hospital, Edinburgh,
Scotland
Vasicek, T., Ph.D., Harvard Medical School, Boston, Massa-
chusetts
Krumlauf, R., MRC National Institute for Medical Research.
Homeobox genes II and discussion on segmentation in
vertebrates.
Rinchik, G., Oak Ridge National Laboratory. Genetic
resources.
Papaioannou, G., Tufts University. Chimeras in develop-
ment.
McMahon, A., Roche Institute of Molecular Biology. int
genes and cell interactions.
Parada, L., National Cancer Institute. Oncogenes and devel-
opment.
Bradley, A., Baylor College of Medicine. Homologous
recombination in ES cells.
Gearhart, J., Johns Hopkins School of Medicine. I.
Molecular analysis of postimplantation development; II.
YACs and development.
Strickland, S., State University of New York, Stony Brook.
Maternal RNA and the mouse cycle.
DePamphilis, M., Roche Institute of Molecular Biology. DNA
replication and gene expression in mouse oocytes and
preimplantation embryos.
Jessell, T., Columbia University College of Physicians &
Surgeons. Regional induction and axial formation in the
vertebrate nervous system.
McKay, R., Massachusetts Institute of Technology. Regula-
tion of cell number and type in the mammalian central ner-
vous system.
Bodine, D., National Institutes of Health. Hematopoiesis I.
Williams, D., Children's Hospital. Hematopoiesis II.
More, K., Frederick Cancer Research Facility. The analysis
of coat color mutations in the mouse.
Molecular Approaches to Ion Channel Function
and Expression
June 8-June 28
INSTRUCTORS
Goldin, Al, M.D., Ph.D., University of California, Irvine
Snutch, Terry, Ph.D., University of British Columbia, Vancouver, Canada
White, Michael, Ph.D., University of Pennsylvania, Philadelphia
ASSISTANT
Gilbert, Mary, University of British Columbia, Vancouver, Canada
Application of the techniques of molecular biology has provided novel ap-
proaches and a new level of sophistication in the examination of many
neurobiological problems. This intensive laboratory/lecture course is designed to
introduce students to the application of these techniques to the study of ion
channels. Students concentrated initially on basic aspects of this approach and
then proceeded to more integrated studies. The course dealt with the following
topics: mRNA isolation and handling; preparation of in vitro transcripts for ex-
pression and use as hybridization probes; Xenopus oocytes as an expression
system; characterization of newly expressed channels in oocytes using ligand
binding, affinity chromatography, voltage- and patch-clamping techniques; de-
sign and implementation of recording equipment; and monitoring levels of and
changes in channel expression using northern blot analysis.
PARTICIPANTS
Bassnett, S., Ph.D., Uniformed Services University,
Bethesda, Maryland
Duguay, F., B.S., Hospital for Sick Children, Toronto, Canada
Lievano, A., Ph.D., Roche Institute of Molecular Biology,
Nutley, New Jersey
Lummis, S., Ph.D., University of Cambridge, England
Li, W., M.S., Harvard University, Boston, Massachusetts
Maguire, G., Ph.D., University of California, Berkeley
Rossie, S., Ph.D., University of Arizona, Tucson
Ruben, P., Ph.D., University of Hawaii, Honolulu
Wheeler, S., B.S., Southampton University, England
Zupan, J., M.D., University of California, San Diego
SEMINARS
White, M., University of Pennsylvania. Biosynthesis and as-
sembly of the acetylcholine receptor.
Snutch, T., University of British Columbia. Ca" chan-
nels-It's a bit more complicated than T, N, and L.
Enyeart, J., Ohio State University. Ca++ channels in
secretory cells: Excitation-secretion coupling.
Goldin, A., University of California, Irvine. Structure/function
studies of Nar channels.
Margiotta, J., Mt. Sinai School of Medicine. Regulation of
neuronal acetylcholine receptor expression.
White, M., University of Pennsylvania. Cloning around with
neuropeptide receptors.
Claudio, T., Yale University. bS about the acetylcholine
receptor.
Fluharty, S., University of Pennsylvania. Molecular charac-
terization of neuronal angiotensin receptors.
MacKinnon, R., Harvard University. Searching for the con-
ductance pose in K+ channels.
Schwarz, T., Stanford University. Why waste your time with
Drosophila ?/What's where in K' channels.
Hess, P., Harvard University. Gating of cloned K' channels.
Mandel, G., State University of New York, Stony Brook. Con-
trol of Na' channel gene expression.
Levinson, R., University of Colorado. Role of nonprotein
domains in Na* channel function.
Dunn, R., McGill University. More on Na' channel struc-
ture/function relationships.
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Developmental Neurobiology
June 8-June 21
INSTRUCTORS
Goodman, Corey, Ph.D., University of California, Berkeley
Patterson, Paul, Ph. D., California Institute of Technology, Pasadena
This lecture course reviewed established principles and recent advances in de-
velopmental neurobiology. Major topics considered were: proliferation, migration,
and aggregation of nerve cells; factors influencing the differentiation of neurons;
trophic interactions in neural development; patterns, gradients, and compart-
ments; genetic programs for development; the guidance of axons to targets; and
the formation of synaptic connections. Particular emphasis was given to synapse
formation and to mechanisms underlying the specificity of this process. Finally,
the operation of developmental principles was examined in the context of the
mammalian visual system and in the development of learning and behavior.
PARTICIPANTS
Coles, H., B.A., Columbia University, New York, New York
Collazo, D., B.A., Harvard Medical School, Boston, Massa-
chusetts
Fur ley, A., Ph.D., Columbia University, New York, New York
Galli-Resta, L., Ph.D., Istituto di Neurofisiologia, Italy
Goda, Y., B.S., Stanford University, California
Groves, A., B.A., Ludwig Institute, London, England
Harper, S., B.S., St. George's Hospital, London, England
Hassinger, T., B.S., Colorado State University, Fort Collins
Hohn, A., M.A., Max-Planck Institute, Martinsried, Federal
Republic of Germany
Hume, C., Ph.D., Columbia University, New York, New York
Kasper, E., B.S., University of Oxford, England
Lans, D., B.A., University of California, Berkeley
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Lee, R., M.A., University of Colorado, Boulder
Montgomery, J., B.A., California Institute of Technology,
Pasadena
Nelson, B., Ph.D., University of Connecticut, Storrs
Okamoto, H., Ph.D., University of Michigan, Ann Arbor
Ramirez, R., B.S., University of Puerto Rico, Rio Piedras
Ramon-Cueto, A., M.D., Institute Cajal, Madrid, Spain
Ruiz i Altaba, A., Ph.D., Columbia University, New York, New
York
Schiffman, J., B.A., Thomas Jefferson University, Philadel-
phia, Pennsylvania
Seaver, E., B.S., University of Utah, Salt Lake City
Sehgal, R., B.A., University of California, San Francisco
SEMINARS
McConnell, S., Stanford University. Neurogenesis and
migration in the vertebrate central nervous system.
Sternberg, P., California Institute of Technology. Nematode
development.
Anderson, D., California Institute of Technology. Neural
crest differentiation.
Jessell, T., Columbia University. Axon guidance.
Landmesser, L., University of Connecticut. Neuromuscular
specificity.
Fraser, S., University of California, Irvine. Neuronal
specificity.
Sanes, J., Washington University. Synapse formation.
Frank, E., University of Pittsburgh. Synaptic specificity and
rearrangement.
Shatz, C., Stanford University. Central nervous system con-
nectivity and plasticity.
Breedlove, M., University of California, Berkeley. Hormones
and plasticity.
Kandel, E., Columbia University. Plasticity and learning.
Advanced Drosophila Genetics
June 23-July 6
INSTRUCTORS
Ashburner, Michael, Ph.D., University of Cambridge, England
Rubin, Gerald, Ph.D., University of California, Berkeley
This intensive seminar course provided an introduction to the theory and practice
of methods that are used to manipulate the Drosophila genome. It is suitable for
graduate students and researchers with some experience with Drosophila who
are interested in expanding their knowledge of the wide range of genetic tech-
niques now available for use with this organism. Topics covered included
chromosome mechanics, the design and execution of genetic screens, and
using transposable elements as genetic tools.
PARTICIPANTS
Cagan, R., Ph.D., University of California, Los Angeles
Carmena, M., M.S., Universidad Autonoma de Madrid,
Spain
Clark, H., B.S., University of California, Berkeley
Cook, K., M,S., University of Iowa, Iowa City
Grossniklaus, U., B.S., University of Basel, Switzerland
Harrison, S., Ph.D., MRC Laboratory of Molecular Biology,
England
Hart, M., M.S., St. Louis University, Missouri
Heck, M., Ph.D., Carnegie Institution of Washington
Huang, J., M.S., Brandeis University, Waltham, Massachu-
setts
Hultmark, D., Ph.D., University of Stockholm, Sweden
Knust, E., Ph.D., University of Koln, Germany
Louvi, A., B.S., University of Athens, Greece
Michelson, A., Ph.D., Harvard University, Cambridge, Mass-
achusetts
Nakano, Y., Ph.D., Imperial Cancer Research Fund, England
Nichols, R., Ph.D., University of Michigan, Ann Arbor
Parry, D., B.S., University of California, San Francisco
SEMINARS
Ashburner, M., University of Cambridge. Introduction to
Drosophila lab practice; biology; phylogeny.
. Chromosomes; cytogenetics; genetic behavior of
chromosomal aberrations; translocations, inversions, dele-
tions, duplications, etc.; balancers.
Screens; mutagenesis; genetic and cytogenetic
mapping; genetic characterization of mutations.
Hall, J., Brandeis University. Methods for mosaic analysis;
genetic analysis of behavior.
Greenspan, R., Roche Institute of Molecular Biology. Inter-
pretation of mosaic data; interpretation of epistatic inter-
actions (using neurogenesis as examples).
Lehmann, R., Whitehead Institute, Massachusetts Institute of
Technology. Genetic screens for mutations affecting em-
bryogenesis (including maternal affect mutations); meth-
ods for their analysis including injection and transplanta-
tion experiments.
Belote, J., Syracuse University. Genetic screens as ex-
Rio, D., Ph.D., Whitehead Institute, Cambridge, Massachu-
setts
Ronchi, E., Ph.D.,Rockefeller University, New York, New York
Wolk, A., M.S., Max-Planck Institute, Martinsried, Federal
Republic of Germany
Yee, G., B.A., Massachusetts Institute of Technology, Cam-
bridge
amplified by screens for loci affecting sex determination;
genes and pathways.
Hawley, S., Albert Einstein College of Medicine. Genetics of
meiosis-Methods of study and exploitation; distributive
pairing; predictive value of distributive models.
Glover, D., University of Dundee, Scotland. Genetic control
of cell cycle; meiosis.
Rubin, G., University of California, Berkeley. Genetic
screens for suppressors and enhancers.
Gelbart, W., Harvard University. Hobo elements-Discovery,
characterization, and use.
Engels, W., University of Wisconsin, Madison. Genetics of
PM hybrid dysgenesis and its control; genetic behavior of
P elements.
Spred ling, A., Carnegie Institution of Washington. P ele-
ments as genetic tools-Single P-element mutagenesis,
including enhancer trap screens; P-element-mediated
transformation.
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Molecular and Developmental Biology of Plants
July 2-July 22
INSTRUCTORS
Gruissem, Wilhelm, Ph.D., University of California, Berkeley
Maliga, Pal, Ph.D., Waksman Institute, Rutgers University, Piscataway, New Jersey
Varner, Joseph, Ph.D., Washington University, St. Louis, Missouri
ASSISTANTS
Benner, Michael, Ph.D., Waksman Institute, Rutgers University, Piscataway, New Jersey
Gibson, Susan, Ph.D., Michigan State University, East Lansing
Loos, William, Ph.D., Massachusetts General Hospital, Boston
Manzara, Thianda, Ph.D., University of California, Berkeley
Simmonds, Daina, Ph.D., Plant Research Center, Agriculture Canada, Ottawa
This course provided an intensive overview of current topics and techniques in
plant biology, with an emphasis on molecular and developmental biology and
genetics. It is designed for scientists with experience in molecular techniques
who are working with, or wish to work with, plant systems. The course consisted
of a rigorous lecture series, a hands-on laboratory, and informal discussions.
Guest speakers provided both an in-depth discussion of their work and an over-
view of their specialty. The laboratory covered established and novel techniques
in plant biology, including cell and tissue culture techniques, gene transfer tech-
niques, assays for transient gene expression, protein targeting, analysis of tran-
scription factors, in situ detection of RNA and protein, restriction-fragment-length
polymorphism mapping, genome mapping using yeast artificial chromosomes,
genetics of Arabidopsis thaliana and cytogenetics of Zea mays.
PARTICIPANTS
Ach, R., Ph.D., Yale University, New Haven, Connecticut
Bird, D., Ph.D., University of California, Riverside
Bouchez, D., Ph.D., Institut National de la Recherche
Agronomique, France
Feiler, H., M.A., University of Illinois, Chicago
Hershkovitz, M.S., Hebrew University of Jerusalem
Hobbie, L., Ph.D., Massachusetts Institute of Technology,
Cambridge
Loza-Tavera, H., M.S., Universidad Nacional Autonoma de
Mexico
Metzger, J., Ph.D., U.S. Dept. of Agriculture, Fargo, North
Dakota
Mishra, K., M.S.,Pioneer Hi-Bred International, Johnston, Iowa
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Norelli, J., Ph.D., Cornell University, Ithaca, New York
Pla, M., M.S., Conseil Superior d'Investigacions Cientifiques,
Barcelona, Spain
Riechmann, J., M.S., Universidad Autonoma de Madrid,
Spain
Shen, W.-H., Ph.D., Friedrich Miescher Institute, Basel, Swit-
zerland
Singh, A., Ph.D., Pennsylvania State University, Philadelphia
Stein, D., Ph.D., Mount Holyoke College, South Hadley,
Massachusetts
Vigil, E., Ph.D., U.S. Dept. of Agriculture, Beltsville, Maryland
SEMINARS
Nester, E., University of Washington. Agrobacterium biology
and applications.
Bizaro, D., Ohio State University. Molecular biology of gemi-
niviruses and geminivirus vectors.
Poethig, S., University of Pennsylvania. Developmental pat-
terns in plants.
Kao, T.-H., Pennsylvania State University. Self-
incompatibility during reproduction.
Klessig, D., Waksman Institute, Rutgers University.
Pathogenesis-related proteins in plants.
Walbot, V., Stanford University. The Mu transposable ele-
ment in maize.
Boynton, J., Duke University. Chlamydomonas organelle
genetics.
Vierstra, R., University of Wisconsin. Control of the level of
phytochrome.
Kondorosi, A., CNRS Institut des Sciences Vegeta les.
Rhizobium-plant symbiotic interactions.
Hanson, M., Cornell University. Molecular biology of plant
Molecular Cloning of Neural Genes
mitochondria-Cytoplasmic male sterility.
Nelson, T., Yale University. Ontogeny of C3 and C4 leaves.
Phillips, R., University of Minnesota. Genomic rearrange-
ments induced by tissue culture.
Beachy, R., Washington University. Plant RNA
viruses-Molecular biology and applications.
Ho, D., Washington University. Hormonal control of gene ex-
pression in barley.
Somerville, C., Michigan State University. Biochemical
genetics in Arabidopsis.
Star linger, P., University of Koln. Ac transposable element.
Hauge, B., Massachusetts General Hospital. The
Arabidopsis genome.
Keegstra, K., University of Wisconsin. Protein targeting in
plants.
Chua, N.-H., Rockefeller University. Control of tissue-
specific gene expression in plants.
Meyerowitz, E., California Institute of Technology. Genes
regulating flower development in Arabidopsis.
July 2-July 22
INSTRUCTORS
Chao, Moses, Ph.D., Cornell University Medical College, New York
Eberwine, Jim, Ph. D., University of Pennsylvania, Philadelphia
COINSTRUCTOR
Inman, Irene, Ph.D., Stanford University, California
ASSISTANTS
Patel, Ni la, Cornell University Medical College, New York
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This intensive laboratory/lecture course was intended to provide scientists with a
basic knowledge of the use of the techniques of molecular biology in examining
questions of neurobiological significance. Particular emphasis was placed on
using and discussing methods for circumventing the special problems posed in
the study of the nervous system; for example, examination of low-abundance
mRNAs in extremely heterogeneous cell populations.
The laboratory work included mRNA quantitation methods (e.g., nuclease
protection), preparation of hybridization probes, library construction (A. ZAP and
1ST procedure), plaque-screening techniques (probe hybridization and antibody
interaction), DNA sequencing, polymerase chain reaction amplification, RNA
amplification, and DNA-mediated gene transfer. A major portion of the course
was devoted to in situ hybridization and in situ transcription technologies. The
lecture series, presented by invited speakers, focused on emerging techniques
and how they may be applied to the study of the nervous system.
PARTICIPANTS
Barres, B., M D., University College, London, England
Berman, H., Ph.D., State University of New York, Buffalo
Bottenstein, J., Ph.D., Marine Biomedical Institute, Gal-
veston, Texas
Danoff, S., M.S., Johns Hopkins University, Baltimore,
Maryland
Gallagher, D., Ph.D., Yale University, New Haven, Con-
necticut
Hall, A., Ph.D., Case Western Reserve University, Cleveland,
Ohio
Kahoun, J., B.A., University of Wisconsin, Madison
Mc Morris, A., Ph.D., Wistar Institute, Philadelphia, Pennsyl-
vania
SEMINARS
Lemke, G., Salk Institute. Schwann cell gene expression.
Curran, T., Roche Institute. Oncogenes in the brain: fos, jun,
and the AP-1 binding site.
Hahn, B., University of Colorado. Functional validation of
genes expressed in the brain in perspective with develop-
mental and evolutionary aspects.
Potter, H., Harvard Medical School. Molecular biology of
Alzheimer's Disease.
Dixon, R., Merck. Mechanisms of desensitization of G-
Neurobiology of Drosophila
Milovanovic, S., M.D., Cornell University Medical College,
Ithaca, New York
Perrone Capano, C., Ph.D., Universita Deg li Studi di Napoli,
Italy
Peters, L., Ph.D , Jackson Laboratory, Woods Hole, Massa-
chusetts
Pierce, M., Ph.D., Northwestern University, Evanston, Illinois
Pinto, L., Ph.D., INSERM, Paris, France
Ruberg, M., Ph.D., INSERM, Paris, France
Schinstine, M., Ph.D., University of California, San Diego
Serbedzija, G., B.S., University of California, Irvine
protein-coupled receptors.
Amara, S., Yale University. Mechanisms of alternative splic-
ing for hnRNAs.
Gecko, C., Harvard University. Retroviruses in neurobiology.
Parada, L., Fredericksrin Cancer Center. trk oncogene ex-
pression in the nervous system.
Young, M., Rockefeller University. Molecular and cellular
studies of neurogenic genes in Drosophila.
July 2-July 22
INSTRUCTORS
Aldrich, Richard, Ph.D., Stanford University, California
Hartenstein, Volker, Ph.D., University of California, San Diego
Ready, Donald, Ph.D., Purdue University, West Lafayette, Indiana
ASSISTANT
Wolff, Tanya, Purdue University, West Lafayette, Indiana
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This laboratory/lecture course, intended for researchers at all levels who may
want to use Drosophila as an experimental system for studying neurobiology,
provided an introduction to current research in neuronal function and develop-
ment in Drosophila. The course began with a crash course in Drosophila genetics
and other techniques that make Drosophila research distinctive, such as
cytogenetics and DNA transformation. The main emphasis, however, was on
studies of the nervous system. The course covered basic electrophysiological
techniques, as applied to mutants with altered ion channels or sensory physiol-
ogy. In the development section, processes of neurogenesis and pathfinding
were examined. The course familiarized students with various preparations, in-
cluding the embryonic nervous system, imaginal discs, and adult nervous sys-
tem. It also reviewed the different approaches being used in attempts to unravel
the molecular basis of neural development.
PARTICIPANTS
Abrams, J., Ph.D., Massachusetts Institute of Technology,
Cambridge
Broadie, K., B.S., University of Cambridge, England
Crew, J., B.S., Carnegie Mellon University, Pittsburgh,
Pennsylvania
Cui, X., M.A., University of Illinois, Chicago
Hacohen, N., B.A., Stanford Medical School, California
Incardona, J., B.S., Case Western Reserve University,
Cleveland, Ohio
SEMINARS
Dickson, M., Roche Institute of Molecular Biology. Physiol-
ogy of campaniform sensilla and the control of flight.
Schwarz, T., Stanford University. Physiology and molecular
biology of Shaker.
Ganetzky, B., University of Wisconsin. Genetics and
molecular biology of ion channels.
Bate, M., University of Cambridge. Mesoderm and muscle
development.
Bodmer, R., University of California, San Francisco. Em-
bryonic development of the peripheral nervous system.
Thomas, J., Salk Institute. Neural pathfinding in the em-
bryonic central nervous system.
Taghert, P., Washington University. Development of the en-
teric nervous system.
Pulido, D., Ph.D., Squibb Institute for Medical Research,
Princeton, New Jersey
Schweisguth, F., Ph.D., Institut Jacques Monod, Paris,
France
Shibanaka, Y., Ph.D., Ciba-Geigy (Japan) Ltd.
Treisman, J., B.A., Rockefeller University, New York, New
York
Zhong, Y., M.S., University of Iowa, Iowa City
Doe, C., University of Illinois. Neurogenesis and the specifi-
cation of neural fates in the embryo.
Rubin, G., University of California, Berkeley. Molecular biol-
ogy of eye development.
Meinertzhagen, I., Dalhousie University. Visual pathways in
Drosophila.
Carlson, J., Yale University. Genetics of olfaction.
Tully, T., Brandeis University. Learning and memory in
Drosophila.
Campos-Ortega, J., Universitat zu KOIn. Neurogenic genes.
Truman, J., University of Washington. Postembryonic devel-
opment of the Drosophila nervous system.
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Computational Neuroscience: Learning and Memory
July 14-July 27
INSTRUCTORS
Jordan, Michael, Ph.D., Massachusetts Institute of Technology, Cambridge
Sejnowski, Terrence, Ph.D., Salk Institute, San Diego, California
ASSISTANTS
Bachrach, Jonathan, University of Massachusetts, Amherst
Viola, Paul, Massachusetts Institute of Technology, Cambridge
Wathey, Jack, Salk Institute, San Diego, California
This was an intensive laboratory and lecture course that examined computational
approaches to problems in learning and memory. Problems and techniques from
both neuroscience and cognitive science were covered, including learning pro-
cedures that have been developed recently for neural network models.
This course included a computer-based laboratory so that students could ac-
tively explore computational issues. Students were able to interact informally with
some of the leading researchers in the field. A strong grounding in mathematics
is important and previous exposure to neurobiology is essential for students.
PARTICIPANTS
Ahissar, E., ES., Hadassah Medical School, Israel
Brotchie, P., Ph.D., Massachusetts Institute of Technology,
Cambridge
Buxbaum, J., Ph.D., Rockefeller University, New York, New
York
Elliot, D., B.S., Massachusetts Institute of Technology, Cam-
bridge
Foldiak, P., M.S., University of Cambridge, England
Gullapalli, V., M.S., University of Massachusetts, Amherst
SEMINARS
Sejnowski, T., Salk Institute. Neuroscience overview.
Jordan, M., Massachusetts Institute of Technology. Com-
putation overview.
Byrne, J., University of Texas Medical School. Introduction
to invertebrate learning.
Brown, T., Yale University. Introduction to vertebrate learn-
ing.
Byrne, J., University of Texas Medical School. Synaptic
plasticity in Aplysia.
Lisberger, S., University of California School of Medicine. In
troduction to the oculomotor system.
Brown, T., Yale University. Synaptic plasticity in the hip-
pocampus.
Lisberger, S., University of California School of Medicine.
Learning in the VOR.
Donegan, N., Yale University. Introduction to conditioning.
Tesauro, G., IBM T.J. Watson Laboratories. Introduction to
models of conditioning.
Donegan, N., Yale University. Integrating biological and
psychological models of conditioning.
Sutton, R., GTE Laboratories. Temporal difference learning.
Linsker, R., IBM T.J.Watson Research Center. Introduction
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Hegde, V., M.S., University of Rochester, New York
Kapur, A., M.S., University of Wisconsin, Madison
Ringo, J., Ph.D., University of Rochester, New York
Rosen, D., B.A., Stanford University, California
Rubin, N., M.S., Hebrew University, Israel
Stern, J., B.S., Massachusetts Institute of Technology, Cam-
bridge
Worth, A., M.S., Boston University, Massachusetts
Ye, H., Ph.D., Institut de la communication Par lee, France
to the visual system.
Durbin, R., Stanford University. Optimization and cortical
maps.
Linsker, R., IBM T.J.Watson Research Center. Infomax and
receptive fields.
Durbin, R., Stanford University. Directed unsupervised
learning.
Moody, J., Yale University. Development of modularity.
Rumelhart, D., Stanford University. Introduction to super-
vised learning.
Sutton, R., GTE Laboratories. Reinforcement learning and
planning.
Rumelhart, D., Stanford University. Cognition and learning
systems.
LeCun, Y., AT&T Bell Laboratories. Learning as optimization.
Tesauro, G., IBM T.J. Watson Laboratories. Introduction to
motor learning.
Atkeson, C., Massachusetts Institute of Technology. Intro-
duction to motor learning.
. Associative motor memory.
Jordon, M., Massachusetts Institute of Technology. Learning
dynamical systems.
Le Cun, Y., AT&T Bell Laboratories. Learning on real-world larization and radial basis functions: Applications.
problems. Kearns, M., Massachusetts Institute of Technology. Intro-
Poggio, T., Massachusetts Institute of Technology. Theoreti- duction to learning theory and learning and natural prob-
cal framework for learning. lems.
Moody, J., Yale University. Strategies for efficient learning. Sejnowski, T., Salk Institute. General discussion.
Poggio, T., Massachusetts Institute of Technology. Regu-
Yeast Genetics
July 24-August 13
INSTRUCTORS
Hieter, Phil, Ph.D., Johns Hopkins University, Baltimore, Maryland
Mitchell, Aaron, Ph. D., Columbia University, New York, New York
Rose, Mark, Ph.D., Princeton University, New Jersey
Winston, Fred, Ph.D., Harvard Medical School, Boston, Massachusetts
ASSISTANTS
Floy, Kim, Johns Hopkins University, Baltimore, Maryland
Gansheroff, Lisa, Harvard Medical School, Boston, Massachusetts
Scidmore, Marci, Princeton University, New Jersey
The major laboratory techniques used in the genetic analysis of yeast were
studied, including the isolation and characterization of mutants, tetrad analysis,
complementation, and mitotic recombination. Micromanipulation used in tetrad
analysis were carried out by all students. Molecular genetic techniques, including
yeast transformation gene replacement, analysis of gene fusions, and electro-
fluorescence experiments were done to identify the nucleus, microtubules, and
other cellular components. Lectures on fundamental aspects of yeast genetics
were presented along with seminars given by outside speakers on topics of cur-
rent interest.
PARTICIPANTS
Altschuler, M., Ph.D., Williams College, Williamstown, Mass- Blanc, A., B.S., McGill University, Montreal, Canada
achusetts Brodsky, J., Ph.D., Harvard University, Cambridge, Massa-
Aspenstrom, P., B.S., University of Uppsala, Sweden chusetts
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Chang, A., Ph.D., Yale University, New Haven, Connecticut
Flaggs, G., B.S., Stanford Medical School, California
Greenleaf, A., Ph.D., Duke University, Durham, North Caro-
lina
Hwung, Y.-P., Ph.D., Baylor College of Medicine, Houston,
Texas
Kirkegaard, K., Ph.D., University of Colorado, Boulder
Nacht, M., B.S., University of Pennsylvania, Philadelphia
SEMINARS
Mitchell, A., Columbia University. Control of meiosis in yeast.
Hieter, P., Johns Hopkins Medical School. Chromosome
transmission fidelity in yeast.
Sherman, F., University of Rochester. Mutations that stabi-
lize yeast iso-1-cytochrome c.
Schekman, R., University of California, Berkeley. Control of
protein transport in yeast.
Rose, M., Princeton University. Microtubules, motors, mem-
branes, mating, and mitosis.
Johnson, S., University of California, San Francisco. Cell-
type control and transcriptional repression in yeast.
Fink, G., Whitehead Institute. Unusual genetic events in Sac-
charomyces.
Carlson, M., Columbia University. Glucose repression in
yeast.
Guarente, L., Massachusetts Institute of Technology.
Eukaryotic transcription: A conserved process from yeast
to man.
Padilla, C., B.S., University of New Mexico, Albuquerque
Pfaffle, P., Ph.D., University of Texas, Dallas
Rhoads, D., Ph.D., Kansas State University, Manhattan
Roth, S., Ph.D., National Institutes of Health, Bethesda,
Maryland
Stuart, F., B.S., University of Edinburgh, Scotland
Zhang, J., M.S., Mt. Sinai Medical Center, New York, New
York
Sternglanz, R., State University of New York, Stony Brook.
DNA topoisomerases.
Winston, F., Harvard Medical School. Analysis of transcrip-
tion mutants in yeast.
Petes, T., University of North Carolina. Homologous and
nonhomologous recombination in yeast.
Wigler, M., Cold Spring Harbor Laboratory. RAS control
pathways in yeast.
Botstein, D., Stanford University Medical School. Genetics of
cell biology in yeast.
Hinnebusch, A., National Institutes of Health. Translational
control of the transcriptional activator protein GCN4.
Broach, J., Princeton University. Switching and silencing.
Weinert, T., University of Arizona. Cell-cycle control and
checkpoints.
Silver, P., Princeton University. Import of proteins into the
yeast nucleus.
Advanced Molecular Cloning and Expression
of Eukaryotic Genes
July 24-August 13
INSTRUCTORS
Kingston, Robert, Ph.D., Harvard Medical School, Boston, Massachusetts
Myers, Richard, Ph.D., University of California, San Francisco
Rio, Donald, Ph.D., Whitehead Institute, Cambridge, Massachusetts
Robbins, Alan, Ph.D., E.I. du Pont de Nemours & Company, Inc., Wilmington, Delaware
ASSISTANTS
Hartzog, Grant, University of California, San Francisco
Louvi, Angeliki, University of Athens
This course focused on how to manipulate cloned eukaryotic genes to probe
questions on their structure, expression, and function. As a model system, we ex-
amined cis- and trans-acting components involved in the regulation of eukaryotic
gene expression. Students learned the theoretical and practical aspects of con-
structing genomic and cDNA libraries. Expression libraries from various
organisms were screened with recognition-site probes for specific DNA-binding
proteins. A variety of transfection techniques were used to introduce cloned DNA
molecules that have been manipulated in vitro into Drosophila.
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PARTICIPANTS
Bates, G., Ph.D., Imperial Cancer Research Fund, London,
England
Blanchard, K., Ph.D., Brigham & Women's Hospital, Boston,
Massachusetts
Buxton, J., B.S., St. Mary's Hospital, London, England
Clifford, J., B.S., M.D. Anderson Cancer Center, Houston,
Texas
Collinge, J., B.S., Clinical Research Center, England
Dmitrovsky, E., M.D., Memorial Sloan-Kettering Cancer Cen-
ter, New York, New York
Ho, S.-M., Ph.D., Tufts University, Medford, Massachusetts
Joost, H., Ph.D., Institute of Pharmacology, Gottingen, Fed-
eral Republic of Germany
Legay, C., Ph.D., Ecole Norma le Superieure, Paris, France
Lu, M., Ph.D., New York University, New York
Ma, A., M.D., Johns Hopkins University, Baltimore, Mary Ian,'
Poon, D., B.A., Vanderbilt University, Nashville, Tennessee
Shaw, L., B.S., Harvard Medical School, Boston, Massachu-
setts
Sirois, M., M.S., Laval University, Canada
Sokolowski, M., Ph.D., York University, Canada
Venter, H., M.S., University of Witwatersrand, South Africa
SEMINARS
Kingston, R., Massachusetts General Hospital. Transcription
factor interactions in chromatin.
Robbins, A., E.I. du Pont de Nemours & Company, Inc. Ef-
fect of brefeldin A on alphaherpesvirus membrane protein
glycosylation and virus egress.
Yamamoto, K., University of California, San Francisco. Posi-
tive and negative transcriptional regulation by the
glucocorticoid receptor.
Tjian, R., University of California, Berkeley. Species-specific
coactivators mediate transcriptional activation by
eukaryotic upstream regulators.
Myers, R., University of California, San Francisco. Regula-
tion of mammalian 0-globin gene expression.
Treisman, R., Imperial Cancer Research Fund, London. SRF
and the serum response element.
Johnson, S., University of California, San Francisco. Cell-
type control and transcriptional repression in yeast.
Stillman, B., Cold Spring Harbor Laboratory. Mechanism
and regulation of DNA regulation in human and yeast
cells.
Lehmann, R., Whitehead Institute, Massachusetts Institute of
Technology. Maternal control of pattern formation in
Drosophila.
Guarente, L., Massachusetts Institute of Technology.
Eukaryotic transcription: A conserved process from yeast
to man.
Levine, M., Columbia University. Transcriptional control of
Drosophila embryogenesis.
Baker, T., National Institutes of Health. Initiation of Es-
cherichia coli chromosomal replication: Role of transcrip-
tion and other factors that influence DNA structure.
Maniatis, T., Harvard University. Regulation of human 0-
interferon gene expression
Rio, D., Whitehead Institute, Massachusetts Institute of
Technology. Multiprotein complexes involved in transcrip-
tion by RNA polymerase II.
McKnight, S., Carnegie Institution of Washington. Mam-
malian transcription factors.
Botchan, M., University of California, Berkeley. Roles of a
transcription factor in viral DNA replication.
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Molecular Probes of the Nervous System
July 24-August 13
INSTRUCTORS
Carlson, Steve, PhD., University of Washington, Seattle
Evans, Christopher, Ph.D., Stanford University, California
Levitt, Pat, Ph.D., Medical College of Pennsylvania, Philadelphia
ASSISTANT
Hal [den, Gunnell, University of California, Berkeley
This course was designed for scientists from various disciplines who are inter-
ested in understanding the power and pitfalls of antibodies and nucleotide
probes as biochemical and anatomical reagents. A series of evening lectures ad-
dressed basic and advanced immunology concepts and the use of molecular
probes to investigate current issues in neurobiology. The primary emphasis of the
course was to acquire practical laboratory experience through daily exercises
using an extensive number of techniques, including generation and characteriza-
tion of monoclonal antibodies to synthetic peptides and complex neural antigens,
immunocytochemistry, in situ hybridization, immunoassays (enzyme-linked im-
munoadsorbent assay and radioimmune assay), affinity chromatography, and
western blot hybridization. Approaches that combine the use of molecular probes
were highlighted by performing expression library screening, oligonucleotide
synthesis, probe labeling, and exercises employing double-labeling strategies.
Participants also designed biological assays in tissue culture to demonstrate
functional relevance of specific molecules.
PARTICIPANTS
Diaz, R., M.S., Wisconsin Regional Primate Center, Madison
Durand, G., M.S., Albert Einstein College of Medicine,
Bronx, New York
Giddings, C., Ph.D., University of Texas, Dallas
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Henson, J., M.D., Memorial Sloan-Kettering Cancer Center,
New York, New York
Koester, S., B.A., Washington University School of Medicine,
St. Louis, Missouri
Krajcik, R., B.S., Wright State University, Dayton, Ohio
Kruger, C., B.S., University of Bremen, Federal Republic of
Germany
Matise, M., B.S., University of Pittsburgh, Pennsylvania
Pinkus, L., Ph.D., A.H. Robins Company, Richmond, Virginia
SEMINARS
Fleischman, J., Washington University Medical School. Im-
munoglobulins and superfamily.
Kurt-Jones, E., Brigham & Women's Hospital. T cells.
Wortis, H., Tufts University School of Medicine. B cells and
networks.
Alt, F., Columbia University College of Physicians &
Surgeons. Immunoglobulin gene rearrangement.
Helfman, D., Cold Spring Harbor Laboratory. Gene cloning
and differential RNA processing.
Pintar, J., Columbia University College of Physicians &
Surgeons. Gene expression in development.
Keller, F., Genentech, Inc. Adhesion molecules in invert.
Hockfield, S., Yale University School of Medicine. Activity-
Redondo, J., Ph.D., Universidad Nacional Autonoma de
Mexico
Sholl, S., Ph.D., Wisconsin Regional Primate Center,
Madison
Wu, W., B.S., University of Minnesota, Minneapolis
dependent molecular expression.
Bothwell, M., University of Washington. Growth factor recep-
tors in development.
Levitt, P., Pennsylvania Medical College. Specification of
cortex in development.
Pittman, R., University of Pennsylvania. Growth factor recep-
tors in development.
Evans, C., Stanford Medical School. Peptide processing
and expression.
Carlson, S., University of Washington. Proteoglycans as
synaptic components.
Maidment, N., Stanford University School of Medicine. In
vivo dialysis and brain function.
Genetic Approaches to Human Disease Using DNA Markers
July 30-August 5
INSTRUCTORS
Lander, Eric, Ph.D., Whitehead Institute and Massachusetts Institute of Technology,
Cambridge
Page, David, M.D., Whitehead Institute and Massachusetts Institute of Technology, Cam-
bridge
ASSISTANT
Jacob, Howard, Whitehead Institute, Cambridge, Massachusetts
It has recently become feasible to map genes underlying some human diseases
and traits, even when the molecular basis is unknown, by studying individuals
from natural populations and using DNA markers (such as restriction-fragment-
length polymorphisms). This intensive lecture course explored the possibilities
and difficulties of applying these methods to the study of various human diseases
and traits, including simply inherited disorders (e.g., cystic fibrosis), complex dis-
orders (e.g., heart disease or psychiatric conditions), inherited and spontaneous
cancers, and developmental abnormalities (e.g., sex determination). Understand-
ing such biological systems requires an interplay among transmission genetics
and cytogenetics in mammals, human population genetics, and molecular
biological techniques for analyzing large genomes. Accordingly, the course con-
centrated on ways to employ genetics to dissect complex biological problems in
natural populations. The course is intended for students with backgrounds in ei-
ther molecular biology, molecular genetics, or medical genetics interested in un-
dertaking research on particular diseases, traits, or physiological systems.
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PARTICIPANTS
Brink, P.A., M.D., Baylor College of Medicine, Houston,
Texas
Dermody, J., Ph.D., New Jersey Medical School, Newark
Eisenbarth, G., Ph.D., Jos lin Diabetes Center, Boston, Mass-
achusetts
Fechner, P., M.D., Johns Hopkins Hospital, Baltimore,
Maryland
Fidani, L., B.S., St. Mary's Hospital, London, England
Gnatt, A., M.S., Hebrew University of Jerusalem
Gore-Langton, R., Ph.D., University of Western Ontario, Can-
ada
Green, E., Ph.D., Washington University Medical School, St.
Louis, Missouri
Hastbacka, J., M.D., University of Helsinki, Finland
Kavuru, M., B.A., National.lnstitutes of Health, Bethesda,
Maryland
SEMINARS
Gilliam, C., Columbia University. Mapping neurological and
muscular disorders.
Tanzi, R., Harvard Medical School. Alzheimer's disease.
Housman, D., Massachusetts Institute of Technology. Can-
cer and recessive oncogenes.
King, M.-C., University of California, Berkeley. Breast can-
cer Segregation and linkage analysis.
Nussbaum, R., University of Pennsylvania. Fragile X
syndrome.
Puck, J., University of Pennsylvania. X inactivation and map-
ping of X-linked immunodeficiencies.
Lanser, M., M.D., University of California, San Francisco
Lehesjoki, A.-E., M.D., University of Helsinki, Finland
Lupski, J., Ph.D., Baylor College of Medicine, Houston,
Texas
Mirow, A., M.D., University of California, San Diego
Nevin, D., M.D., University of Wisconsin, Madison
Ngan, B., Ph.D., University of Toronto, Canada
Nimgaonkar, V., Ph.D., University of Pittsburgh, Pennsyl-
vania
Printz, M., Ph.D., University of California, San Diego
Romero, J., B.S., Boston University School of Medicine,
Massachusetts
Schalling, M., Ph.D., Karolinska Institute, Sweden
Whitehouse, W., Ph.D., John Radcliffe Hospital, Oxford,
England
Nicholls, R., University of Florida. Genomic imprinting.
Haines, J., Harvard Medical School. Linkage analysis meth-
ods (two lectures).
Chakravarti, A., University of Pittsburgh. 1. Epidemiology; 2.
Down's syndrome and centromere mapping.
Lincoln, S., Whitehead Institute. Linkage analysis.
Hobbs, H., University of Texas Southwestern Medical
School. Heart disease.
Page, D., Whitehead Institute and Massachusetts Institute of
Technology. Chromosomes.
Molecular Genetic Analysis of Diseases
of the Nervous System
August 7-August 13
INSTRUCTORS
Breakefield, Xandra, Ph.D., Massachusetts General Hospital and Harvard Medical
School, Boston
Evans, Glen, Ph.D., Salk Institute, San Diego, California
Gusella, James, Ph.D., Massachusetts General Hospital and Harvard Medical School,
Boston
This lecture course explored new techniques of molecular biology and neuro-
science being used to elucidate the molecular and cellular basis of neurologic
and psychiatric diseases in humans and in animal models. Many recently devel-
oped genetic methodologies provided the means to elucidate the action of dis-
ease genes and to manipulate and explore normal neural development and func-
tions. Areas covered included: linkage analysis and identification of disease
genes; action of one genes in development and tumor formation; gene transfer
into the nervous system using viral vectors; creation of animal models by
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homologous recombination and transgenes; specificity of neurotropic viruses;
gene families encoding receptors and ion channels; genes active in nerve
regeneration and cell death.
PARTICIPANTS
Brice, A., M.D., INSERM, Paris, France
Buxbaum, J., Ph.D., Rockefeller University, New York, New
York
Crawford, F., B.S., St. Mary's Hospital, London, England
Fotaki, M., Ph.D., Montreal General Hospital, Canada
Gasser, T., M.D., Ludwig Maximilian's University, Munich,
Federal Republic of Germany
Gates, H., Ph.D., University of Bristol, England
Gaughan, G., Ph.D., Oxford University, England
Hautamaa, D., Ph.D., University of Minnesota, Minneapolis
Kaye, E., M.D., Massachusetts General Hospital East,
Charlestown
Kowallis, G., M.D., St. Vincent's Hospital, New York
Lehesjoki, A.-E., M.S., University of Helsinki, Finland
Loring, J., Ph.D., GenPharm International, Mountain View,
California
Mathews, K., M.D., University of Iowa, Iowa City
McClatchey, A., Massachusetts General Hospital, Boston
McKee, M.A., M.D., Columbia Presbyterian Hospital, New
York, New York
Montag, D., M.D., Research Institute of Scripps Clinic, La
Jolla, California
Montal, M., Ph.D., University of California, San Diego
Orr-Urtreger, A., M.D., Weizmann Institute, Israel
Schalling, Ph.D., Karolinska Institute, Sweden
Teng, S., Ph.D., Massachusetts General Hospital, Boston
Waltman, S., M.A., Brown University, Providence, Rhode Is-
land
SEMINARS
Evans, G., Salk Institute. Strategies for scanning the human
genome: Human Genome Project.
Moyzis, R., Los Alamos National Laboratory. Repeat ele-
ments.
Gusella, J., Massachusetts General Hospital and Harvard
Medical School. Finding disease genes I: Linkage analy-
sis in Huntington's disease.
O'Connell, P., University of Utah Medical Center. Finding
disease genes I: Linkage analysis in neurofibromatosis
type I.
Brownstein, B., Washington University School of Medicine.
Finding disease genes II: Yeast artificial chromosomes as
cloning vehicles.
Ledbetter, D., Baylor College of Medicine. Contiguous gene
syndromes.
Hoffman, E., Children's Hospital. Characterization of disease
genes: Using genetics to define a dis-
ease-Duchenne/Becker muscular dystrophy.
MacLennan, D., University of Toronto. Malignant hyper-
thermia.
Gravel, R., McGill University. Mutational analysis:
Lysosomal storage diseases.
Wallace, D., Emory University. Mitochondrial defects.
Nussbaum, R., University of Pennsylvania Medical School.
Fragile X syndrome.
Breakefield, X., Massachusetts General Hospital and Har-
vard Medical School. MAO and its role in disease.
Jolicoeur, P., Institut de Recherches, Canada. Retroviral
neurotropism.
Benowitz, L., McLean Hospital. Genes in regeneration:
GAP43.
Brugge, J.S., University of Pennsylvania Medical School.
one genes in development and tumors: src and tyrosine
kinases in neuronal development.
Lee, W.-H., University of California School of Medicine, San
Diego. Role of tumor suppression genes in the develop-
ment of neoplasia.
Heineman, S., Salk Institute. Receptors: Glutamate receptor
family-Structure and function.
Oppenheim, R., Wake Forest University. Cell death in the
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nervous system.
Sutcliffe, G., Research Institute of Scripps Clinic.
Spontaneous mouse mutants-Identifying mouse disease
genes.
Milner, R., Research Institute of Scripps Clinic. Myelin
mutants.
Prusiner, S., University of California, San Francisco. Prions.
Mallet, J., Centre National de la Recherche Scientifique,
France. Catecholamine biosynthetic enzymes and their
regulation.
Beyreuther, K., Universitat Heidelberg, Federal Republic of
Germany. Amyloid transcriptions in Alzheimer's disease.
Macromolecular Crystallography
Isacson, 0., McLean Hospital. Grafting genetically modified
cells.
Rossant, J., Mt. Sinai Hospital Research Institute. Creating
mouse mutants: Homologous recombination.
Evans, G., Salk Institute. Transgenics.
Civelli, 0., Oregon Health Science University. Dopaminergic
receptors.
Caron, M., Duke University Center. Adrenergic receptors.
Stevens, J., University of California, Los Angeles. Gene
transfer with latent herpesvirus simplex.
Herrup, K., E.K. Shriver Center. Genetic modification to
study linkage in the developing nervous system.
October 11-October 24
INSTRUCTORS
Pflugrath, J.W., Ph.D., Cold Spring Harbor Laboratory, New York
McPherson, A., Ph.D., University of California, Riverside
Gilliland, G., Ph.D., Center for Advanced Research in Biotechnology, Rockville, Maryland
Furey, W., Ph.D., Veterans Administration Medical Center, Pittsburgh, Pennsylvania
ASSISTANT
Pechik, I., Center for Advanced Research in Biotechnology, Rockville, Maryland
Crystallography and X-ray diffraction yield a wealth of structural information un-
obtainable through other methods. This intensive laboratory/computational
course focused on the major techniques used to determine the three-dimensional
structures of macromolecules. It was designed for scientists with a working
knowledge of protein structure and function, but who were new to macro-
molecular crystallography. Topics covered included: protein purification, crystal-
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lization, crystal characterization, data collection (area detector methods), data
reduction, anomalous dispersion, phase determination, multiwavelength
anomalous diffraction, lane diffraction, molecular replacement and averaging,
electron density interpretation, structure refinement, molecular graphics, and
molecular dynamics. Participants learned through extensive hands-on experi-
ments, informal discussions, and lectures on current applications of these related
procedures given by outside speakers.
PARTICIPANTS
Air, G., Ph.D., University of Alabama, Birmingham
Berger, S., Ph.D., University of British Columbia, Canada
Clawson, D., M.S., Eli Lilly & Co., Indianapolis, Indiana
Cox, M., M.S., Burroughs Wellcome Company, Research
Triangle Park, North Carolina
Dencher, N., Ph.D., Hahn-Meitner Institut, Berlin, Federal
Republic of Germany
Diaz, D., M.S., Case Western Reserve University, Cleveland,
Ohio
Djebli, A., Ph.D., Case Western Reserve University,
Cleveland, Ohio
SEMINARS
Kuret, J., Cold Spring Harbor Laboratory. Protein purification
and characterization.
McPherson, A., University of California, Riverside. Crystal-
lization of macromolecules I.
Sweet, R., Brookhaven National Laboratory. Introduction to
crystallography.
. X ray sources and optics.
McPherson, A., University of California, Riverside. Crystal-
lization of macromolecules II.
Gilliland, G., National Institute of Standards and Technology.
Biological macromolecule crystallization database: A tool
for the development of crystallization strategies.
McPherson, A., University of California, Riverside. Introduc-
tion to Bragg's Law.
Aggarwal, A., Columbia University. Crystallization of nucleic
acids with proteins.
McPherson, A., University of California, Riverside.
Preliminary crystal characterization.
. Crystallographic symmetry and unit cells.
. Precession photography.
Pflugrath, J., Cold Spring Harbor Laboratory. Data collec-
tion: Area detector madness.
Herzberg, 0., University of Maryland. Structure and function
of p-lactamase.
McPherson, A., University of California, Riverside. Difference
pattersons.
Furey, W., Veteran's Administration Medical Center,
Pittsburgh. Multiple isomorphous replacement phase
refinement.
Sacchettini, J., Albert Einstein College of Medicine. Struc-
ture of rat intestinal fatty acid binding protein at 1.3 A
resolution.
Griffith, 0.H., Ph.D., University of Oregon, Eugene
Hallows, W., Ph.D., University of Rochester, New York
Kuo, C.-F., Ph.D., Research Institute of Scripps Clinic, La
Jolla, California
Lima, C., B.A., Northwestern University, Evanston, Illinois
Morals Cabral, J., B.S., University of Edinburgh, Scotland
Nunn, R., M.S., University of Sheffield, England
Sinclair, A., Ph.D., University of Leeds, England
Thorn, J., Ph.D., Northwestern University, Evanston, Illinois
Young, A., M.A., New York University, New York
Jones, T.A., University of Uppsala, Sweden. Map interpreta-
tion.
Furey, W., Veteran's Administration Medical Center,
Pittsburgh. Solvent flattening/phase combination.
Petsko, G., Brandeis University. Laue diffraction-Principles
and practice.
. Time-resolved studies of enzymes by Laue diffrac-
tion.
Hendrickson, W., Columbia University. Crystal structure of
ribonuclease H.
Horton, J., Columbia University. Multiwavelength anomalous
dispersion: Theory and practice.
Tronrud, D., University of Oregon. Structure refinement with
TNT.
Remington, S.J., University of Oregon. Molecular replace-
ment methods I.
. Molecular replacement methods II.
Gilliland, G., University of California, Riverside. Three-
dimensional structure of recombinant bovine chymosin at
2.3 A resolution.
Weis, W., Columbia University. X-PLOR: Macromolecular
structure refinement by simulated annealing.
Hog le, J., Research Institute of Scripps Clinic. Virus crystal-
lography.
Gilliland, G., National Institute of Standards and Technology.
Conformational flexibility of surface residues of bovine
RNAse A at 1 A resolution.
Clore, G.M., National Institutes of Health. Determination of
protein structure by two-dimensional, three-dimensional,
and four-dimensional nuclear magnetic resonance.
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Molecular Genetics of Fission Yeast
October 29-November 5
INSTRUCTORS
Fantes, Peter, Ph.D., University of Edinburgh, Scotland
Hyams, J., Ph.D., University College, London
McLeod, M., Ph.D., State University of New York, Brooklyn
ASSISTANTS
Alfa, Caroline, University College, London, England
Devoti, Jamie, State University of New York, Brooklyn
Warbrick, Emma, University of Edinburgh, Scotland
The fission yeast Schizosaccharomyces pombe is increasingly being used as a
model organism for the study of basic aspects of cell biology. This course intro-
duced the students to all aspects of fission yeast biology but with particular em-
phasis on genetic manipulation (both classical and with recombinant DNA) and
the use of the organism for the study of cell biology. Topics covered included
chemical mutagenesis and mutant analysis, transformation and gene replace-
ment techniques, isolation of nuclei, preparation of nuclear DNA, plasmid
recovery from yeast into bacteria, cell-cycle methods, cytology, and im-
munocytochemical techniques. In addition to hands-on experience, participants
had the opportunity to learn through informal group discussions and a lecture
series designed to complement the experimental section.
PARTICIPANTS
Alahari, S., M.S., Drexel University, Philadelphia, Pennsyl-
vania
Andrisani, O., Ph.D., Purdue University, West Lafayette, Indi-
ana
Basi, G., M.S., EMBL, Heidelberg, Federal Republic of
Germany
Beck, P., Ph.D., University of Texas Southwestern Medical
Center, Dallas
Dass, S., Ph.D., Michigan State University, East Lansing
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Daya, M., Ph.D., University of British Columbia, Canada
Dillon, P., Ph.D., Roche Institute of Molecular Biology, Nut-
ley, New Jersey
Grallert, B., Ph.D., L.K. University, Hungary
Lim, J., B.S., UMDNJ-Robert Wood Johnson Medical
School, New Jersey
Merrill, G., Ph.D., Oregon State University, Corvallis
Ottilie, S., Ph.D., Harvard University, Cambridge, Massachu-
setts
Robinson, J., B.A., California Institute of Technology,
Pasadena
Rowley, R., B.A., University of Utah, Salt Lake City
Toyamama, R., Ph.D., National Cancer Institute, National In-
stitutes of Health, Bethesda, Maryland
Wagner, P., Ph.D., Marie Curie Institute
Weil, T., Ph.D., Vanderbilt University, Nashville, Tennessee
SEMINARS
Yamamoto, M., University of Tokyo. Signal transduct on dur-
ing sexual development in S. pombe.
Young, P., Queen's University, Ontario. Genetics of ion
transport in S. pombe.
Wigler, M., Cold Spring Harbor Laboratory. Signal transduc-
tion pathways.
Klar, A., National Cancer Institute. Yeast yeast.
Chappell, T., Duke University Medical Center. The Golgi ap-
paratus of S. pombe.
Seminars
Cold Spring Harbor Seminars were initiated to provide a semiformal avenue for
communication between the various research groups at the Laboratory. They are
particularly useful for research personnel who have joined the Laboratory during
the summer. The seminars also afford a necessary opportunity for the graduate
students and postgraduate staff to develop their skills in defending, organizing,
and presenting their research. In addition to those listed below, seminars were
given by many others involved in research at this laboratory.
1990
January
David Goldfarb, University of Rochester, New York. Path-
ways in nuclear transport.
Alexander Titomirov, Institute of Molecular Biology, Union of
Soviet Socialist Republics Academy of Sciences, Mos-
cow. In vivo electroporation and stable transformation of
skin cells of mice.
William Earnshaw, Johns Hopkins School of Medicine, Balti-
more, Maryland. Structural domains of the vertebrate
centromere.
Heinz Saedler, Max-Planck Institute, Koln, Federal Republic
of Germany. En/Spm transposable element system of
maize.
Charles Sherr, St. Jude's Children's Research Hospital,
Memphis, Tennessee. c-FMS (CSF-1 receptor) proto-
oncogene.
,Jack Szostak, Massachusetts General Hospital, Boston.
Toward the design of a simple cell.
February
David Barford, Oxford University, England. Stereochemical
basis for the allosteric mechanism of glycogen
phosphorylase.
Kanna Visvanathan, ICRF, London, England. Introduction of
p-interferon expression. Reduced Oct-1 binding to the
TATA box and the adjacent negative element and NF-kB
activation.
Jonathan Gold, Memorial Sloan-Kettering Cancer Center,
New York, New York. AIDS: Epidemiological and clinical
update.
Aria Baniahmad, Max-Planck Institut, Martinsried, Federal
Republic of Germany. Are silencers negative enhancers?
March
Jonathan Pines, Salk Institute, San Diego, California. Mam-
malian cell-cycle cycling from B to A.
Gerry Klaus, National Institute for Medical Research,
London, England. Control of surface immunoglobulin
receptor signaling by G proteins.
Ryuji Kobayashi, Nagasaki University, Japan. Structural and
functional analysis of bacterial proteases.
Michael Green, Harvard University, Cambridge, Massachu-
setts. Mechanisms of viral and cellular transcription ac-
tivators.
April
Satoru Uzawa, Kyoto University, Japan. Fission yeast cuts*
gene couples chromosome disjunction with other cell
cycle events and has homology with budding yeast ESP1.
Jim Manley, Columbia University, New York, New York.
Analysis of transcription factors that control embryonic de-
velopment in Drosophila.
Jennifer Pietenpol, Vanderbilt University, Nashville, Ten-
nesee. TGF-p growth inhibitory pathway in keratinocytes.
Zachary Pitluk, Yale University, New Haven, Connecticut.
Regulation of the murine minute virus P4 promoter.
Julio Celis, University of Aarhus, Denmark. Comprehensive
two-dimensional gel human protein databases offer a
global approach to the study of gene regulation.
Paul Tempst, Harvard Medical School, Boston, Massachu-
setts. Protein microsequence analysis in modern biology:
Challenges and strategies.
Gisela Storz, Harvard Medical School and Massachusetts
General Hospital, Boston. Transcriptional regulator of
oxidative stress-inducible genes: Direct activation.
May
Ed Ziff, New York University School of Medicine, New York,
New York. Gene regulation by growth factors.
Robert Knowles, Memorial Sloan-Kettering Cancer Center,
New York, New York. More complexity in the HLA system.
Elizabeth Robertson, Columbia University, New York, New
York. Using embryonic skin cells to transfer mutations into
the mouse germ line.
Claude Desplan, Rockefeller University, New York, New
York. Transcriptional control during early Drosophila de-
velopment.
June
Louis Mahadevan, Oxford University, England. Chromatin-
associated signaling and induction and superinduction of
proto-oncogenes.
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Alan Harris, Yale University, New Haven, Connecticut. Cal-
pain I and calmodulin coordinately regulate fodrin, a multi-
functional protein of the actin-based cytoskeleton.
E.H. Coe, University of Missouri, Columbia. Toolkit of maize.
Adrian Bird, Institute of Molecular Pathology, Vienna,
Austria. Effect of DNA methylation on chromatin structure
and gene expression.
Ivan Raska, Institute of Experimental Medicine, Czecho-
slovak Academy of Sciences, Prague. Autoantibodies as
probes to study the ultrastructure of the cell nucleus.
August
Mike Palazzolo, California Institute of Technology,
Pasadena. Reverse Drosophila neurogenics.
Caroline Dean, John Innes Institute, U.K. Chromosome walk-
ing and transposon tagging in Aribidopsis to clone genes
involved in floral induction.
September
Eric Fearon, Johns Hopkins Oncology Center, Baltimore,
Maryland. Genetic alterations in colorectal tumor progres-
sion.
Scott Patterson, University of Queensland Equine Blood
Typing Research Laboratory, Australia. Methods of
protein identification following two-dimensional elec-
trophoresis.
October
Harold Vaessin, University of California, San Francisco.
Neuronal precursor formation in Drosophila.
Jim Howe, Yale University, New Haven, Connecticut.
Glutamate-receptor ion channels in rat cerebellar granule
cells.
William Tatnsey, University of Sydney, Australia. Analysis of
promoter elements in the human growth hormone gene
family.
Richard Carthew, University of California, Berkeley. seven in
absentia, a gene required for specification of R7 cell fate
in the Drosophila eye.
Maynard Olson, Washington University, St. Louis, Missouri.
Physical mapping of whole human chromosomes: What is
the best path forward?
Andrew Darrow, State University of New York, Stony Brook.
Tissue plasminogen activator (TPA) gene regulation upon
differentiation of F9 EC cells.
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Hiroyuki Nawa, Kyoto University, Japan. How does the
neuron decide which neurotransmitter to express?
November
Jim Van Etten, University of Nebraska, Lincoln. Virus-
infected eukaryotic green alga is the new source of modi-
fication and restriction enzymes.
Alex Toker, National Institute of Medical Research, Mill Hill,
London, England. Characterization of protein kinase C in-
hibitor proteins.
Pablo Scolnick, E.I. du Pont de Nemours and Co., Inc., Wil-
mington, Delaware. du Pont Arabidopsis project.
Richard Kramer, Columbia University College of Physicians
& Surgeons, New York, New York. New approaches to
studying intracellular signaling.
Roger Papke, Salk Institute, San Diego, California. Effects of
subunit composition on the single-channel properties of
rat neuronal nicotinic acetylcholine receptors.
Ron Davis, Baylor College of Medicine, Houston, Texas.
Dunce and other learning and memory mutants in
Drosophila.
Agiris Efstratiadis, Columbia University, New York, New
York. Parental imprinting in the insulin-like growth factor II
gene locus.
Rod MacKinnon, Harvard Medical School, Cambridge,
Massachusetts. Molecular physiology of potassium chan-
nels.
December
Robert Goldberg, University of California, Los Angeles. Cell-
specific gene regulation in higher plants and its applica-
tion to agriculture.
Conley Rieder, New York State Dept. of Health, Wadsworth
Center for Laboratories and Research, Albany, New York.
How chromosomes attach to the vertebrate spindle: Im-
plications for force production.
Masami Horikoshi, Rockefeller Foundation, New York, New
York. Analysis of the structure and function of the TATA
box binding factor TFIID.
Simon Bright, ICI Pharmaceuticals, England. Biotechnology
research at ICl/GARST seed company.
James Huettner, Harvard Medical School, Cambridge,
Massachusetts. Glutamate receptor channels in central
and peripheral neurons.
Richard Hynes, Massachusetts Institute of Technology,
Cambridge, Massachusetts. Genetic analyses of in-
tegrins.
Undergraduate Research
An important aspect of the summer program at the Laboratory is the participation
of college undergraduate students in active research projects under the supervi-
sion of full-time laboratory staff members. The program was initiated in 1959.
Since that year, 335 students have completed the course, and many have gone
on to creative careers in biological science.
The objectives of the program are to provide (1) a greater understanding of
the fundamental principles of biology; (2) an increased awareness of major prob-
lem areas under investigation; (3) a better understanding of the physical and in-
tellectual tools for modern research and the pertinence of this information to fu-
ture training; and (4) a personal acquaintance with research workers and centers
for study.
The following students, selected from over 145 applicants, took part in the
program, which was supported by the Burroughs Wellcome Fund, Baring
Brothers, Miles Inc./Bayer AG, Cold Spring Harbor Laboratory Robert H.P. Olney
Fund, and BioRad.
Benjamin Abella, Washington University
Research Advisor: Bruce Futcher/Carol Greider
Telomere structure in aging fibroblasts.
Luis Alvarez, University of California, Los Angeles
Research Advisor: Venkatesan Sundaresan
Mu-induced gene expression in maize.
Clare Baker, University of Cambridge
Research Advisor: Bruce Stillman
Investigation of a 13-kD single-stranded DNA-binding
protein from Saccharomyces cerevisiae.
Steven Chao, Harvard University
Research Advisor: Eric Richards
Cloning of TAS sequences of Arapidopsis thaliana by
complementation in YACs.
Matthew Cockerill, University of Cambridge
Research Advisor: Nouria Hernandez
A sensitive assay for U1 /U2 snRNA gene transcription
in vitro.
Arshad Desai, California State University, Los Angeles
Research Advisor: Jeff Kuret
Solution of the three-dimensional structure of a protein
kinase using site-specific mutagenesis to create sites for
isomorphous replacement.
Medeva Ghee, North Carolina State University
Research Advisor: David Frendewey
Analysis of snRNAs and snRNPs in fission yeast.
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Gilbert Henry, University of California, Los Angeles
Research Advisor: David Helfman
Isolation of the cDNAs encoding a putative Schizosac-
charomyces pombe tropomyosin and a novel actin-like
protein.
Chia-Suei Hung, Beloit College
Research Advisors: James Pflugrath/Thomas Marr
Purification and crystallization of proliferating cell nuclear
antigen.
David Immanuel, Wesleyan University
Research Advisor: Kim Arndt
Cloning of SDS1, a gene that suppresses a deletion of S/T4.
Michele Lozeron, University of Wisconsin, Madison
Research Advisor Thomas Peterson
Restriction mapping of the P Mosaic allele of maize.
Monn Monn Myat, Mount Holyoke College
Reseach Advisor: Adrian Krainer
Purification and characterization of U2 snRNP auxiliary
factor.
Stanford Peng, Stanford University
Research Advisor: David Spector
Eukaryotic RNA levels after heat shock.
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Urmas Saarma, Tartu University, Estonia, USSR
Research Advisor Arne Stenlund
Generation of an expression vector for the replication
protein El from bovine papillomavirus.
Angela Wilson, University of Wisconsin, Madison
Research Advisor: Daniel Marshak
Molecular analysis of the expression of neurotrophic
factor S10013.
John Yates, Glasgow University
Research Advisor: Dafna Bar-Sagi
Sequencing of PLA2 from muscle and liver, using
polymerase chain reaction and subcloning
techniques.
Ann Yonetani, University of Pennsylvania
Research Advisor: Gilbert Morris/Michael Mathews
Characterization of an Alu sequence transcribed from the
human proliferating cell nuclear antigen promoter.
Karen Zito, Indiana University
Research Advisor: Masafumi Tanaka/Winship Herr
Study of transcriptional activation by Oct-2, a lymphoid
octamer-binding protein.
Nature Study Program
The Nature Study Program gives elementary and secondary school students the
opportunity to acquire a greater knowledge and understanding of their environ-
ment. Through a series of specialized field courses, students can engage in such
introductory programs as Nature Detectives, Seashore Life, and Pebble Pups, as
well as more advanced programs such as Marine Biology and Nature Photog-
raphy.
During the summer of 1990 a total of 480 students participated in the Nature
Study Program. Most classes were held outdoors, when weather permitted, or at
the Uplands Farm Preserve, the headquarters of the Long Island Chapter of the
Nature Conservancy. The Laboratory has equipped and maintains class-
rooms/laboratories as well as a darkroom at Uplands Farm. This facility is used
as a base for the student's exploration of the local environment. Field classes are
held on Laboratory grounds, St. John's Preserve, Fire Island National Seashore,
Caumsett State Park, the Cold Spring Harbor Fish Hatchery and Aquarium, as
well as other local preserves and sanctuaries. Students in the Marine Biology
class participated in a whale watch aboard the Finback II, operated by the
Okeanos Ocean Research Foundation, Inc., Hampton Bays, New York.
In addition to the 4-week courses, the 2-day Adventure Education class took
students on an 18-mile bike hike to Caumsett State Park and a 12-mile canoe trip
on the Nissequogue River.
PROGRAM DIRECTOR
William M. Payoski, M.A., Adjunct Professor,
Nassau Community College
INSTRUCTORS
Cheryl Littman, B.A., science teacher, Northport School District
Michael Manfredonia, teaching candidate, Marist College
Maria Onfora, B.A., science teacher, West Babylon High School
Linda Payoski, B.A., science teacher, Uniondale High School
Marjorie Pizza, B.A., science teacher, Glen Cove School District
Donna Stokes, teaching candidate
Edward Tronolone, B.A., M.S., Principal, Locust Valley School District
COURSES
Nature Bugs
Nature Detectives
Advanced Nature Study
Ecology Explorers
Frogs, Flippers, and Fins
Pebble Pups
Bird Study
Frdsh Water Life
Seashore Life
Marine Biology
Nature Photography
Adventure Education
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FINANCIAL STATEMENT
BALANCE SHEET
year ended December 31, 1990
with comparative figures for year ended December 31, 1989
ASSETS
c...,
N
Operating Funds
Endowment &
Similar Funds
Land,
Building, &
Equipment Funds
Total All FundsUnrestricted
RestrictedUndesignated Designated 1990 1989
Cash and cash equivalents $2,710,250 650,000 804,086 11,854,697 7,294,160 23,313,193 30,717,964
Marketable securities 14,355 5,928,296 100,125 6,042,776 6,045,676
Accounts receivable:
Publications (less allowance for doubtful accounts
of $50,000 in 1990 and $95,000 in 1989) 729,472 - - - 729,472 1,884,531
Other 113,782 15,048 - - 128,830 528,905
Grants receivable - - 1,301,854 - - 1,301,854 2,024,479
Accrued interest receivable 16,982 - 256,444 - 273,426 153,978
Publications inventory 900,727 - - 900,727 617,542
Other assets, principally prepaid expenses 279,843 - 557,122 836,965 937,415
Investment in employee residences - - 1,084,424 1,084,424 853,524
Land, buildings, and equipment:
Land and improvements - - - 4,535,715 4,535,715 3,248,451
Buildings - 23,692,813 23,692,813 23,045,909
Furniture, fixtures, and equipment - 2,278,950 2,278,950 2,013,732
Laboratory equipment - - - 5,044,457 5,044,457 4,752,761
Library books and periodicals - 365,630 365,630 365,630
- - - - 35,917,565 35,917,565 33,426,483
Less accumulated depreciation and amortization - - 12,610,734 12,610,734 11,172,671
Land, buildings, and equipment, net - - - 23,306,831 23,306,831 22,253,812
Construction in progress 20,166,508 20,166,508 7,222,851
Total assets $4,765,411 650,000 2,120,988 18,039,437 52,509,170 78,085,006 73,240,677
LIABILITIES AND FUND BALANCES
Operating Funds
Endowment &
Similar Funds
Land,
Building, &
Equipment Funds
Total All FundsUnrestricted
RestrictedUndesignated Designated 1990 1989
Liabilities:
Accounts payable and accrued expenses $2,415,394 - - 776,642 3,192,036 3,002,980
Notes payable - - 964,869 964,869 1,063,857
Bonds payable - - - 20,000,000 20,000,000 20,000,000
Deferred revenue 697,470 2,120,988 - 2,818,458 3,153,137
Total liabilities 3,112,864 2,120,988 21,741,511 26,975,363 27,219,974
Fund balances:
Unrestricted-undesignated 1,652,547 - - - 1,652,547 1,238,405
Unrestricted-designated - 650,000 - - 650,000 400,000
Endowment and similar funds - - 18,039,437 - 18,039,437 15,263,933
Land, buildings, and equipment:
Expended - - - 28,222,713 28,222,713 17,424,570
Unexpended-Donor restricted - - - 1,460,522 1,460,522 10,843,739
Unexpended-Board authorized - - 1,084,424 1,084,424 850,056
Total fund balances 1,652,547 650,000 18,039,437 30,767,659 51,109,643 46,020,703
Total liabilities and fund balances $4,765,411 650,000 2,120,988 18,039,437 52,509,170 78,085,006 73,240,677
STATEMENT OF SUPPORT, REVENUE AND EXPENSES
AND CHANGES IN FUND BALANCES
year ended December 31, 1990
with comparative figures for year ended December 31, 1989
Operating Funds
Endowment &
Similar Funds
Land,
Building, &
Equipment Funds
Total All FundsUnrestricted
Undesignated Designated Restricted 1990 1989
Support and revenue:
4N
Public support $1,244,697 - 3,359,572 2,324,069 629,592 7,557,930 11,959,169
4=. Government grant awards - 10,250,777 - - 10,250,777 9,412,256
Indirect cost allowances 6,633,895 - - - 6,633,895 6,456,143
7,878,592 13,610,349 2,324,069 629,592 24,442,602 27,827,568
Other revenue:
Program fees 1,123,793 - - 1,123,793 1,298,031
Rental income 248,333 - - - 248,333 93,036
Publications 4,222,694 - - - - 4,222,694 4,449,690
Dining services 1,154,033 - - 1,154,033 1,336,698
Rooms and apartments 795,995 - - 795,995 774,769
Distribution from Robertson Funds 450,000 700,000 - - 1,150,000 976,800
Investment income 333,083 - 1,363,202 1,157,630 2,853,915 2,572,913
Miscellaneous 169,564 - - - - 169,564 262,109
Total other revenue 8,497,495 - 700,000 1,363,202 1,157,630 11,718,327 11,764,046
Total support and revenue 16,376,087 14,310,349. 3,687,271 1,787,222 36,160,929 39,591,614
Expenses:
Program services:
Research - - 11,348,636 - - 11,348,636 11,049,896
Summer programs 865,847 2,186,278 3,052,125 2,858,253
Publications 3,708,062 - - - - 3,708,062 3,934,216
Banbury Center conferences 178,424 321,518 - - 499,942 416,681
DNA Education Center programs 32,616 - 290,603 - - 323,219 349,586
Total program services 4,784,949 14,147,035 18,931,984 18,608,632
Supporting services:
Direct research support 609,502 - - - - 609,502 495,853
Library 388,221 - - 388,221 367,448
Operation and maintenance of plant 4,070,385 - - - - 4,070,385 3,706,217
General and administrative 2,832,903 - - 44,557 - 2,877,460 3,122,091
Dining services 1,296,009 - - - - 1,296,009 1,377,351
Interest - - 1,413,344 1,413,344 1,149,302
Total supporting services 9,197,020 44,557 1,413,344 10,654,921 10,218,262
Depreciation 1,485,084 1,485,084 1,399,409
Total expenses 13,981,969 - 14,147,035 44,557 2,898,428 31,071,989 30,226,303
Excess (deficiency) of support and
revenue over expenses before designation $2,394,118 163,314 3,642,714 (1,111,206) 5,088,940 9,365,311
Designation:
Funds designated for neuroscience
program (250,000) 250,000 - - -
Excess (deficiency) of support and
revenue over expenses and designation 2,144,118 250,000 163,314 3,642,714 (1,111,206) 5,088,940 9,365,311
Other changes in fund balances:
Capital expenditures (1,098,586) - (235,914) (1,426,000) 2,760,500 - -
Transfer to restricted funds - 72,600 (72,600) -
Transfer to endowment funds (631,390) - 631,390 - -
Net increase in fund balances 414,142 250,000 - 2,775,504 1,649,294 5,088,940 9,365,311
Fund balances at beginning of year 1,238,405 400,000 15,263,933 29,118,365 46,020,703 36,655,392
Fund balances at end of year $1,652,547 650,000 18,039,437 30,767,659 51,109,643 46,020,703
Copies of our complete, audited financial statements, certified by the independent auditing firm
of KPMG, Peat, Marwick & Co., are available upon request form the Comptroller, Cold Spring
Harbor Laboratory.
SOURCES OF REVENUE Federal Grants 44.2 %
YEAR ENDED DECEMBER 31, 1990
Endowments and Similar Funds 6.9 %
Foundation and Private
Contributions and Grants 16.9 %
Interest and Miscellaneous 4.6
Corporate Contributions
and Grants 6.5 %
Auxiliary Activities 20.9%
COMPARATIVE OPERATING HISTORY
1986-1990
(Dollars in Thousands)
1986 1987 1988 1989 1990
Income:
Main lab:
Grants & contracts $9,439 10,409 10,799 13,062 13,535
Indirect cost reimbursement 4,533 4,779 5,707 6,412 6,558
Other 2,572 2,727 3,205 4,034 3,976
ca
.r=.
CSH Press 1,357 1,556 1,641 4,450 4,223
en Banbury Center 963 982 976 1,012 1,120
DNA Learning Center 349 660 622 585
Total income 18,864 20,802 22,988 29,592 29,997
Expenses:
Main lab:
Grants & contracts 9,439 10,409 10,799 13,062 13,535
Operation & maintenance of plant 2,442 2,791 3,010 3,412 3,759
General & administrative 1,889 1,975 2,102 2,377 2,414
Other 2,124 2,633 3,049 3,165 2,973
CSH Press 1,060 1,311 1,719 3,934 3,708
Banbury Center 868 947 910 1,038 1,125
DNA Learning Center 260 590 635 615
Total expenses 17,822 20,326 22,179 27,623 28,129
Excess before depreciation and designation of funds 1,042 476 809 1,969 1,868
Depreciation (1,093) (1,127) (1,286) (1,399) (1,485)
Designation of funds - - (400) (250)(2)
Net operating excess (deficit) $ (51) (651) (477) 170 133
(1) The above amounts are presented on a combined basis for all funds for which Cold Spring Harbor prepares operating budgets.
(2) Funds designated to underwrite future direct and indirect expenses of the neuroscience program.
FINANCIAL SUPPORTOF TiHE LABORATORY

SOURCES OF SUPPORT
Cold Spring Harbor Laboratory is a nonprofit research and educational institution
chartered by the University of the State of New York. Less than half of its annual
support is derived from Federal grants and contracts. Contributions from the pri-
vate sector are tax exempt under the provisions of Section 501(c)(3) of the Inter-
nal Revenue Code. In addition, the Laboratory has been designated a "public
charity" and, therefore, may receive funds resulting from the termination of "pri-
vate foundations."
Over the years, the Laboratory has earned a reputation for innovative re-
search and high-level science education. By training young scientists in the latest
experimental techniques, it has helped spur the development of many research
fields, including tumor virology, cancer genes, gene regulation, movable genetic
elements, yeast genetics, and molecular neurobiology. This continual develop-
ment of new research programs and training courses requires substantial sup-
port from private sources.
Because its endowment is small and because government support is highly
competitive and the uses of research grants are restricted, the Laboratory
depends on annual contributions from the private sector; foundations, corpora-
tions, and individuals for its central institutional needs.
The Second Century Campaign seeks to raise $44M in capital funds by De-
cember 1991 for construction of new facilities, renovation of existing facilities,
and for staff and student endowment. This is the Laboratory's first public capital
campaign and it marks its Centennial.
METHODS OF CONTRIBUTING TO COLD SPRING HARBOR LABORATORY
Gifts of money can be made directly to Cold Spring Harbor Laboratory.
Securities You can generally deduct the full amount of the gift on your income tax return,
and, of course, you need pay no capital gains tax on the stock's appreciation.
We recommend any of the following methods:
(1) Have your broker sell the stock and remit the proceeds to Cold Spring Harbor
Laboratory.
(2) Deliver the stock certificates to your broker with instructions to him to open an ac-
count for Cold Spring Harbor Laboratory and hold the securities in that account
pending instructions from Cold Spring Harbor Laboratory.
(3) Send the unendorsed stock certificates directly to the Laboratory: Comptroller, Cold
Spring Harbor Laboratory, Box 100, Cold Spring Harbor, New York 11724. In a sepa-
rate envelope send an executed stock power.
Pooled Income Funds' Combine gifts from a number of donors in a pool for attractive in-
vestment and tax purposes.
Appreciated real estate or personal property Sizable tax benefits can result from
such donations; the Laboratory can use some in its program and can sell others.
Life insurance and charitable remainder trusts can be structured to suit the
donor's specific desires as to extent, timing, and tax needs.
Bequests Most wills probably need to be updated. Designating Cold Spring Harbor Labo-
ratory as beneficiary ensures that a bequest will be utilized as specified for continuing
good.
Conversion of private foundation to "public" status on termination This may be
done by creating a separate fund within Cold Spring Harbor Laboratory whereby the as-
sets of the private foundation are accounted for as a separate fund and used for the pur-
poses specified by the donor. Alternatively, the private foundation can be established as
a "supporting organization of Cold Spring Harbor Laboratory."
For additional information, please contact the Director of Development, Cold Spring Harbor
Laboratory, Box 100, Cold Spring Harbor, NY 11724, or call 516-367-8840.
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GRANTS
January 1, 1990-December 31, 1990
COLD SPRING HARBOR LABORATORY
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Projects Cancer Research Center, Dr. Mathews 1/87-12/91 $16,787,416
Cancer Center Support, Dr. Roberts 8/87 -7/95 8,823,360
PEBRA-HIV Grant, Dr. Herr 9/88 -8/91 3,672,816
Oncogene Program Project, Dr. Wigler 3/88 -2/93 4,869,923
Research Support Dr. Anderson 4/90 -3/93 176,000 *
Dr. Arndt 4/88 -3/93 1,288,964
Dr. Beach 12/84 -1/93 1,481,482
Dr. Beach 9/86 -8/94 3,032,957
Dr. Beach 7/88 -6/93 1,488,740
Dr. Beach 8/90 -7/93 1,287,507*
Dr. L. Field 4/87 -3/92 568,521
Dr. Franza 9/85 -11/94 1,497,483
Dr. Frendeway 4/87 -3/92 775,814
Dr. Futcher 4/88 -3/93 1,115,434
Dr. Garrels 1/85 -12/92 5,016,584
Dr. Gilman 9/87 -8/92 608,291
Dr. Greider 12/89 -11/94 1,130,019
Dr. Helfman 9/85 -3/94 2,109,264
Dr. Hernandez 7/87 -6/92 1,293,754
Dr. Krainer 7/89 -6/94 1,298,402
Dr. Kuret 7/89 -6/94 1,312,808
Dr. Marr 9/89 -9/90 126,428
Dr. Moran 3/88 -2/93 547,214
Dr. Peterson 4/88 -3/93 704,475
Dr. Pflugrath 4/88 -3/91 573,503
Dr. Rice 9/87 -8/90 528,037
Dr. Richards 7/90 -6/93 424,932*
Dr. Roberts 7/88 -6/93 1,598,876
Dr. Roberts 9/88 -8/91 446,241
Dr. Spector 4/90 -3/95 1,441,475*
Dr. Stillman 7/83 - 6/92 1,869,678
Dr. Wigler 7/85 -6/92 8,426,929
Dr. Wigler 8/90 -7/93 640,923*
Equipment Support Dr. Roberts 8/90 -7/91 37,583*
Dr. Spector 4/90 -4/91 180,000*
Fellowships Dr. Ballester 2/89 -1/92 63,996
Dr. Brill 8/89 -7/92 46,667
Dr. Connolly 1/90 -1/93 69,000*
Dr. Grueneberg 10/90 -9/93 69,000*
Dr. Kessler 8/88 -7/91 93,996
Dr. Otto 9/90 -8/93 100,500 *
Dr. Steinhelper 3/89 -2/92 77,254
Dr. Stern 11/88-11/91 63,996
Dr. Szymanski 11/90 -11/92 49,000*
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Grantor Program/Principal Investigator Duration of Grant Total Award
Training Support Institutional, Dr. Grodzicker 7/78 -4/94 2,364,146
Course Support Advanced Bacterial Genetics, Dr. Grodzicker 5/80 -4/93 559,540
Cancer Research Center Workshops,
Dr. Grodzicker
1/83 -3/92 1,010,057
Neurobiology Short-term Training,
Dr. Hockfield
5/82 -4/91 818,188
Meeting Support Cancer Cells-Origins of Human Cancer 1990 5,000*
Genome Mapping and Sequencing Conference 1990 -1993 78,040"
Mouse Molecular Genetics 1990 6,000*
Function and Evolution of RAS Protein 1990 2,000*
RNA Processing 1988 -1991 9,500
Symposium 1990 25,000"
NATIONAL SCIENCE FOUNDATION
Research Support Dr. Anderson 9/90 -8/93 315,000*
Dr. Herr 6/88 -5/91 240,000
Dr. Marr 7/90 -6/91 49,290*
Dr. Marshak 7/87 -12/90 190,000
Dr. Martienssen 7/89 -6/92 300,000
Dr. Richards 7/89 -6/90 95,000
Dr. Roberts 1/83 -5/90 640,000
Dr. Roberts 8/87 -7/92 63,106
Dr. Roberts 2/90 -2/93 210,000 *
Dr. Sundaresan 5/87 -4/91 360,000
Training Support Undergraduate Research Program, Dr. Herr 6/89 -5/90 42,000
Course Support Plant Molecular Biology, Dr. Grodzicker 8/86 -1/90 137,490
Meeting Support Molecular Neurobiology of Aplysia 1990 7,192*
Mouse Molecular Genetics 1990 5,000*
Function and Evolution of RAS Protein 1990 5,000*
Symposium 1990 10,000*
RNA Processing Conference 4/88 -3/91 30,000
DEPARTMENT OF ENERGY
Meeting Support Symposium 1990 10,000*
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Grantor Program/Principal Investigator Duration of Grant Total Award
NONFEDERAL GRANTS
Research Support
Aaron Diamond Foundation
American Cancer Society
Amersham International plc
Istituto Farmaco-
terapico Italiano (IFI)
Howard Hughes Medical
Institute
Japan Health Science
Foundation
J.N. Pew Jr. Charitable
Trust
Lucille P. Markey
Charitable Trust
Muscular Dystrophy
Association
Mellam Family Foundation
Richard Meltzer Fund
Fund for Cancer Research
(World Business Council)
Merck Sharp & Dohme
Research Laboratories
National Downs
Syndrome Society
New England Biolabs
Pew Memorial Trust
Pfizer, Inc.
Pioneer Hi-Bred
International, Inc.
Rita Allen Foundation
Samuel Freeman Charitable
Trust
Equipmnent Support
Fannie E. Rippe!
Fellowships
American Cancer Society
American Foundation for
Aids Research
Bristol-Myers Company
Bioseeds International
Damon Runyon-Walter
Winchell Cancer Fund
New Grants Awarded in 1990
Dr. Anderson
Dr. Bar-Sag i
Dr. Moran
Dr. Spector
Drs. Stillman, Gluzman,
Welch, Gilman, Institutional Award
Dr. Wig ler
Dr. Wig ler, Professorship
Dr. Gilman, Institutional Award
Dr. Harlow
Dr. Harlow
Neurobiology Support
Dr. Roberts
Plant Group Support
Neurobiology Support
(Neuroscience)
(Building Fund)
Dr. Mathews
Dr. Franza
Dr. Harlow
Dr. Harlow
Dr. Marshak
Dr. Roberts
Dr. Greider
Dr. Wig ler
Cooperative Research
Dr. Hernandez
Freeman Laboratory
of Cancer Cell Biology
Neurobiology Support
Dr. Conway
Dr. Ryan
Dr. Nefsky
Dr. Laspia
Fellowship Support
Plant Fellowship Support
Dr. Michaeli
Dr. Melendy
Dr. Walworth
Dr. Su
12/88 -11/91 200,000
7/89 -6/91 194,000
1/88 -12/90 90,500
7/87 -6/91 363,000
7/82 -6/90 300,000
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4/90 -3/91 10,000*
1986 -2012 1,333,333
7/90 -6/91 50,000*
11/86 -10/91 799,635
5/90 -4/91 100,000
1987 -1990 1,000,000
12/89 -2/90 31,700
4/87 -4/90 260,000
7/90 -6/96
2,000,000 *
2,000,000*
1/87 -6/90 100,718
12/88 -11/90 150,000
3/90 -2/91 16,667
3/90 -2/91 50,000*
7/90 -6/92 25,000 *
1990 10,000'
7/90 -6/94 200,000 *
1985 -1990 500,000
8/85 -4/91 2,500,000
10/89 -9/94 150,000
7/89 -6/94 1,000,000
10/89 -7/91 250,000
10/88 -9/91 63,000
7/88 -6/90 90,000
7/90 -6/93 69,000 *
7/89 -6/92 112,200
6/86 -5/91 500,000
7/88 -6/90 75,000
3/87 -2/90 69,000
1/89 -12/91 69,000
9/90 -8/93 84,000*
1/90 -12/90 22,000"
Grantor Program/Principal Investigator Duration of Grant Total Award
Anna Fuller Fund
Government of Canada
Helen Hay Whitney
Foundation
Irvington Institute
for Medical Research
Esther A. and Joseph
Klingenstein Fund, Inc.
Ladies Auxiliary to
the VFW
The Leukemia Society
of America
LIBA
Life Science Research
Merck Sharp & Dohme
.Research Laboratories
Muscular Dystrophy
Association
Andrew Seligson
Memorial Fellowships
Weizmann Institute of Science
Training Support
Baring Brothers & Co., Ltd.
Burroughs Wellcome
Foundation
Bio-Rad Laboratories
CSHL Centennial Fund
Grass Foundation
Miles, Inc.
Robert H.P. Olney
Memorial Fund
Course Support
Howard Hughes Medical
Institute
Meeting Support
Council for Tobacco
Research USA, Inc.
FIDIA Research
Foundation
Fondazione Sigma-Tau,
Foundation
Rockefeller Foundation
Rockefeller Foundation
Alfred P. Sloan
Foundation
Carl Zeiss, Inc.
New Grants Awarded in 1990
Dr. Bauer
Dr. Tyers
Dr. Tyers
Dr. Labrie
Dr. Ma
Dr. Giordano
Dr. Marshak
Dr. Yaciuk
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Dr. Das
Dr. Riabowol
Four Fellowships a Year
Dr. D. Roberts
Graduate Student Support
Dr. Lees-Miller
Dr. Kazzaz
Two Postdoctoral Fellows
(Cancer Research Support)
Dr. Gerst
Undergraduate Research Program
Undergraduate Research Program
CSHL Summer Undergraduate
Partners in the Future
Neurobiology Scholarship Support
CSHL Summer Undergraduate
Undergraduate Research Program
Neurobiology Courses
Role of Isoform
Diversity in Cytoskeletal
Function
Molecular
Neurobiology of Aplysia
Molecular
Neurobiology of Aplysia
Modern Approach
to New Vaccines (Publication Support)
Vaccines Conference
Evolution: From
Molecules to Culture
Role of Isoform
Diversity in Cytoskeletal
Function
1/90 -12/90
9/89 -8/90
9/90 -8/91
10/90 -9/91
4/90 -6/90
7/90 -6/93
7/87 -6/90
7/90 -6/91
7/89 -6/92
7/90 -6/93
1987 -1990
9/89 -8/93
12/88 -11/90
7/88 -6/89
1/90 -12/90
9/90 -8/91
9/89 -8/91
1990
1987 -1990
1990
10/90 -6/91
1980 -1990
1990
1989 -1990
21,000*
1,082
1,099*
1,300 *
5,750*
78,000 *
100,000
20,000*
76,140
93,960 *
300,000
105,000
30,000
51,000
25,000 *
70,000 *
57,000
26,625*
50,960
1, 000 *
27,500 *
166,670
4,803*
2,400
1987 -1990 1,000,000
7/90 -6/91
8/90 -12/90
8/90 -12/90
9/90 -8/91
1986 -1990
3/90 -2/91
1,000 "
5,000 *
5,000 *
20,000 *
45,000
30,000 *
7/90 -6/91 1,000 *
BANBURY CENTER
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
ENVIRONMENTAL PROTECTION AGENCY
Course Support Molecular Mechanisms
of Fiber Cytotoxicity
and Carcinogenesis
1990 20,000 *
Dioxin Meeting 1990 39,180 *
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES
Meeting Support Control of HIV Gene Expression 1990 25,432 *
Immunological Aspects of AIDS 1990 21,268"
NATIONAL SCIENCE FOUNDATION
Meeting Support Mapping the Genomes of Domestic Animals 1990 5,000*
OFFICE OF NAVAL RESEARCH
Course Support Computational Eye Movement Workshop 7/88 -6/91 87,125
U.S. DEPARTMENT OF AGRICULTURE
Course Support Mapping the Genomes of Domestic Animals 1990 5,000*
NONFEDERAL SUPPORT
Meeting Support
Abbott Laboratories Programmed Cell Death- 1990 500*
Concepts and Mechanisms
Alfred P. Sloan Foundation Journalist and Congressional 1990 -1992 150,000 *
Workshops
Alfred P. Sloan Foundation Molecular Clocks of Evolution 1990 3,000*
Beckman Instruments, Inc. Electrophoresis of Large DNA Molecules 1990 5,000*
Chlorine Institute Dioxin Meeting 1990 15,000*
CNS Research Programmed Cell Death- 1990 1,000*
Concepts and Mechanisms
FMC Corporation Electrophoresis of Large DNA Molecules 1990 5,000*
Granada Biosciences, Mapping the Genomes of 1990 3,000*
Inc. Domestic Animals
Hoefer Scientific Instruments Electrophoresis of Large DNA Molecules 1990 2,500*
Metropolitan Life Programmed Cell Death- 1990 10,000 *
Foundation Concepts and Mechanisms
Ohio State University Programmed Cell Death- 1990 7,000 *
Concepts and Mechanisms
Pew Charitable Trust New Human Molecular 1990 35,000*
Genetics-Impact on Society
Pharmacia Electrophoresis of Large DNA Molecules 1990 4,000 *
Risk Science Institute Molecular Mechanisms
of Fiber Cytotoxicity and
1990 3,000*
Carcinogenesis
Ross Laboratories Programmed Cell Death- 1990 2,500*
Concepts and Mechanisms
SmithKline Beecham Cloning the Antibody 1990 35,000*
Pharmaceuticals Repertoire
Thermal Insulation Molecular Mechanisms 1990 15,000*
Manufacturers of Fiber Cytotoxicity
Association and Carcinogenesis
William Stamps Meeting on Complex 1991 -1993 150,000*
Farish Fund Genetic Diseases
New Grants Awarded in 1990
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DNA LEARNING CENTER
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL SCIENCE
FOUNDATION
Teacher Enhancement Program
Teacher Enhancement Program
6/87 -11/90
3/90 -4/93
415,928
474,036 *
Teacher Enhancement Program 9/90 -6/93 252,614*
NONFEDERAL GRANTS
Howard Hughes DNA Science Workshop Program 5/90 -4/93 46,500'
Medical Institute
Josiah Macy, Jr., DNA Literacy Program 7/87 -6/90 490,850
Foundation
Josiah Macy, Jr., DNA Literacy Program 7/90 -6/91 98,905*
Foundation
The Banbury Fund Core Support 1990 30,000'
Brinkman Instruments, Inc. Core Support 1990 2,500*
The Esther and Joseph A. Core Support 1990 25,000
Klingenstein Fund, Inc.
North Carolina Biological Supply Co Core Support 1990 3,125
Nancy Van Vranken Core Support 1990 500*
Case Western Reserve University Vector Workshop 1990 11,075'
Center for Biotechnology, Vector Workshop 1990 10,500*
SUNY Stony Brook
Cornell University Vector Workshop 1990 1,550*
Jefferson Parish School District Vector Workshop 1990 2,000*
Louisiana
Kamehameha Schools, Hawaii Vector Workshop 1990 12,000
Richmond Mathematics & Vector Workshop 1990 2,000*
Science Center
Mississippi School for Vector Workshop 1990 1,550*
Math and Science
J.J. Pearce High School, Vector Workshop 1990 2,000*
Richardson, Texas
Ohio Academy of Science Vector Workshop 1990 2,000*
Smith College Vector Workshop 1990 1,550*
Commack School District Curriculum Study 1990 500
East Williston School District Curriculum Study 1990 500
Garden City School District Curriculum Study 1990 2,000*
Great Neck Public Schools Curriculum Study 1990 500
Half Hollow Hills School District Curriculum Study 1990 500
Harborfields School District Curriculum Study 1990 500
Herricks School District Curriculum Study 1990 500
Huntington School District Curriculum Study 1990 500
Island Trees School District Curriculum Study 1990 1,500
Jericho School District Curriculum Study 1990 500
Kings Park School District Curriculum Study 1990 2,000*
Lawrence School District Curriculum Study 1990 500
Lindenhurst School District Curriculum Study 1990 1,500
Locust Valley School District Curriculum Study 1990 500
Manhasset School District Curriculum Study 1990 500
Northport-East Northport School Curriculum Study 1990 500
District
North Shore School District Curriculum Study 1990 500
Oyster Bay-East Norwich Curriculum Study 1990 500
School District
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Grantor Program/Principal Investigator Duration of Grant Total Award
Plainview-Old Bethpage Curriculum Study 1990 500
School District
Plainedge School District Curriculum Study 1990 1,500
Port ledge School Curriculum Study 1990 500
Port Washington School District Curriculum Study 1990 500
Rosyln School District Curriculum Study 1990 2,000*
Sachem School District Curriculum Study 1990 500
South Huntington School District Curriculum Study 1990 1,500
Syosset School District Curriculum Study 1990 500
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ANNUAL CONTRIBUTIONS
Unrestricted
Long Island Biological Association (LIBA)
The Long Island Biological Association is the oldest supporting organization for
Cold Spring Harbor Laboratory. Over the years a most unique and productive
partnership has developed wherein LISA has become our "Friends of the
Laboratory" and accounts for the largest amount of unrestricted annual giving for
the Laboratory. (The detailed report of their activities appears later in this Annual
Report.)
Memorial Gifts
American Management Mrs. Frank Hohner
Systems, Inc. Mr. & Mrs. Richard Hollander
Mr. & Mrs. Lionel Bal Mr. Thomas Chase Homan
Baltic Linen Company, Inc. Mr. Jim Houlihan
Mrs. Eric Belmont Mr. Tony Hoyt
The Bibb Company Mr. Joseph T. Jones
Mr. & Mrs. Richard Blick Mr. & Mrs. Melvin P. Klein
Mr. & Mrs. Bruce R. Blovsky Mr. Robert B. Kraus
Ms. Joan B. Brady Ms. Timothea S. Larr
Ms. Lisa D. Casentini Mr. & Mrs. Richard B. Leather
Mr. & Mrs. Richard Charkow Mr. & Mrs. William E. Mahoney
Mr. William H. Chisholm Marine Midland Bank
Mr. & Mrs. P. Chisum, Jr. Mr. & Mrs. Markidis
Mr. Lawrence M. Clum Mr. Konrad Matthaei
Mr. & Mrs. Robert E. Cooper Mr. Robert R. McMillan
Mr. Jim Cronin Mr. & Mrs. Stephen Miller
Mr. & Mrs. Wayne A. Davidson Mr. George B. Munroe
Mr. & Mrs. Kurt E. Dreyfuss Nassau County Division
Dr. & Mrs. Lester Dubnick of Data Processing
Dr. & Mrs. Dennis Eryou Dr. & Mrs. James R. Nemeth
Mr. & Mrs. Joel M. Fairman Mr. Denis E. O'Connor
Mr. & Mrs. Raymond E. Fluddy Ms. Dixie Pasciucco
Mr. Richard L. Gelb Mr. & Mrs. Julius L. Pericola
Mr. & Mrs. Eugene M. Geddes Phelps Dodge Corporation
Mrs. J. Bardin Goodman Ms. Nancy L. Robinson
Ms. Ruth S. Greenberg Mr. & Mrs. Seymour Schlaefer
Mr. & Mrs. Howard Gross Mr. & Mrs. Gary Schweon
Mr. & Mrs. Homer Guinan Ms. Carole Smith
Mr. & Mrs. Raymond L. Hallaran Mrs. R. Brinkley Smithers
Harken, Inc. Dr. Abramo Virgilio
Mr. & Mrs. Stanley Himmelstein Ms. Ronni Wald
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In memory of
Agnes Alesi
Vincent Battista
Cathy Susan Bird
Mamie Botwick
Oliver T. Carpenter
Margaret Carroll
Garner Cline
Janet Cook Cotter
Patricia Crowe
Sophie E. Diaman
Clifford Fronapfel
Prudence Gaveglia
Nick Giammalvo
Arthur Greenberg
Herbert Hallaran
Frank Hohner
Sarah Kaufman
James Murray Kay
Lilly Kurfess
Harold Lerner
Per le Miller
Walter L. Ross II
Elizabeth Schneider
Summary of Annual Contributions
Unrestricted Annual Contributions
CSHL Associates (1/1/90-12/31/90) $200,137
LIBA Members (1/1/90-12/31/90) 64,225
General 17,951
Memorials 4,278
Restricted Annual Contributions
Miscellaneous 55,782
$286,591
$ 55,782
Total Annual Contributions $342,373
Frederica von Stade Concert Patrons
Mr. & Mrs. Harry A. Brooks
Mi. & Mrs. G. Morgan Browne, Jr.
Dr. & Mrs. Bayard D. Clarkson
Mr. & Mrs. John P. Cleary
Mrs. John K. Colgate
Mr. & Mrs. Robert L. Cummings
Mr. & Mrs. Theodore N. Danforth
Mr. & Mrs. Charles F. Dolan
Mr. & Mrs. E. Maxwell Geddes, Jr.
Mr. & Mrs. David A. George
Dr. & Mrs. Peter M. Guida
Mr. & Mrs. Henry U. Harris, Jr.
Mrs. Sinclair Hatch
Mr. & Mrs. Richard F. Hunnewell
Dr. & Mrs. Alan Kisner
Mr. & Mrs. Abraham Krasnoff
Mr. & Mrs. David L. Luke Ill
Mr. & Mrs. George Montgomery
Mr. & Mrs. Stephen V. Murphy
Dr. & Mrs. David B. Pall
Mrs. William Parsons, Jr.
Mr. & Mrs. Howard Phipps, Jr.
Mr. & Mrs. Willard C. Rapp ley, Jr.
Mrs. John M. Schiff
Mr. & Mrs. James F. Stebbins
Mr. & Mrs. Philip R. von Stade
Dr. & Mrs. James D. Watson
Mr. & Mrs. Taggart Whipple
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CORPORATE SPONSOR PROGRAM
Restricted
Once again, Cold Spring Harbor Laboratory is very pleased to acknowledge the
generosity of members of the Corporate Sponsor program. These companies,
with a special interest in biotechnology and a concern for fostering research in
molecular biology and genetics, contribute $18,500 each to underwrite the costs
of meetings held at Grace Auditorium and the Banbury Center. This support is
now essential for what we believe to be the most comprehensive series of meet-
ings on molecular biology available anywhere.
There were 12 large meetings held in Grace Auditorium, including the 55th
Cold Spring Harbor Laboratory Symposium on Quantitative Biology on "The
Brain," and five special meetings held at the Banbury Center. The latter included
"Electrophoresis of Large DNA Molecules: Theory, Practice and Future;"
"Genetics and Molecular Biology of Complex Diseases;" "Recognition in Plant-
Pathogen Interactions; Molecular Biology of Free Radical Scavenging Systems;"
and "Computational Predictions of Protein Structure." The benefits to sponsoring
companies include the waiver of all fees for eight representatives at our meet-
ings. Three of these meetings may be at the Banbury Center, where attendance
is otherwise only by invitation of the organizers. In addition, sponsors receive
gratis Cold Spring Harbor Laboratory and Banbury Center publications, including
the Laboratory's journals, Genes & Development and Cancer Cells.
We list 28 companies as members of the Corporate Sponsor program in
1990. This is a remarkable number, especially in the current economic climate. It
reflects the genuine contribution made by our meetings program to the research
activities of the scientists of member companies. However, the principal benefi-
ciaries are the over 5000 scientists from around the world who were able to
review data, generate ideas, and exchange gossip on some of the most exciting
topics in modern biology. We join with them in thanking our Corporate Sponsors.
Alafi Capital Company
American Cyanamid Company
AMGen, Inc.
Applied Biosystems, Inc.
Becton Dickinson and Company
Boehringer Mannheim Corporation
Bristol-Myers Squibb Company
Ciba-Geigy Corporation/Ciba-
Geigy Limited
Diagnostic Products Corporation
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Jan A. Witkowski
E.I. du Pont de Nemours & Company
Eastman Kodak Company
Genentech, Inc.
Genetics Institute
Hoffmann-La Roche, Inc.
Johnson & Johnson
Kyowa Hakko Kogyo Co., Ltd.
Life Technologies, Inc.
Eli Lilly and Company
Millipore Corporation
Monsanto Company
Pall Corporation
Perkin-Elmer Cetus Instruments
Pfizer, Inc.
Pharmacia, Inc.
Schering-Plough Corporation
SmithKline Beecham Pharmaceuticals
The Wellcome Research Laboratories,
Burroughs Wellcome Co.
Wyeth-Ayerst Research
SECOND CENTURY CAMPAIGN
January 1, 1986-December 31, 1990
Unrestricted Contributions
Anonymous 1
Anonymous 2
Anonymous 3
Mr. Amyas Ames
Mr. S. Reed Anthony
Mrs. Donald Arthur, Jr.
Mr. Edmund Bartlett
Bliss Fund
Mr. and Mrs. Allen L. Boorstein
Mrs. Leonie T. Brigham
Mr. G. Morgan Browne
Mr. and Mrs. Samuel Callaway
Mr. and Mrs. John Campbell
Mr. and Mrs. Ward Campbell
Mr. and Mrs. Peter Canna II
Chemical Bank
Dr. Bayard Clarkson
Mr. and Mrs. John Cleary
Mr. and Mrs. Miner D. Crary, Jr.
Mr. and Mrs. Arthur Crocker
Mr. Robert L. Cummings
Mr. and Mrs. Roderick H. Cushman
Mr. A. Neville Cutting
Mr. and Mrs. George W. Cutting, Jr.
Mr. Theodore N. Danforth
Mr. and Mrs. Norris Darrell, Jr.
Mr. and Mrs. Raymond deClairville
Mr. Charles Delafield
Mrs. David Deming
Mr. and Mrs. Donald Deming
Mr. and Mrs. Joseph P. Downer
Mr. and Mrs. James Eisenman
Mr. William Everdell
Mr. and Mrs. Harold L. Fates
Mr. and Mrs. Clarence Galston
Mr. and Mrs. Robert B. Gardner, Jr.
Mr. and Mrs. H. Bentley Glass
Mr. and Mrs. Edward Greenberg
Mr. C. Groel, Jr.
Mr. and Mrs. Henry U. Harris, Jr.
Mr. and Mrs. Sinclair Hatch
Mrs. Joseph H. Hazen
Mr. and Mrs. Morris Karpen
Mr. and Mrs. Albert Key
Mr. and Mrs. Townsend J. Knight
Mr. Abraham Krasnoff
Mr. Edward Lamont
Mrs. John H. Leib
Mr. and Mrs. George N. Lindsay
$7,260,186
Mr. and Mrs. John Livingston
Mr. David L. Luke, Ill
Lucille P. Markey Charitable Trust
Mr. and Mrs. Robert R. Maxfield
Mr. and Mrs. Edward McCann, II
Miss Diana Mcllvaine
Mr. and Mrs. Clarence Michalis
Mr. William H. Miller
Mr. and Mrs. William R. Miller
Mr. O.B. Miller
Milliken Foundation
Leo Model Foundation
Mr. and Mrs. Grinnell Morris
Dr. and Mrs. Larry Nathanson
Mr. and Mrs. Charles Noyes
Mr. and Mrs. George O'Neill
Mr. and Mrs. William H. Osborn, Jr.
Dr. and Mrs. David B. Pall
Mr. Edward L. Palmer
Mr. William Parsons, Sr.
Mrs. Francis T.P. Plimpton
Mr. and Mrs. F. Thomas Powers
Mrs. H. Irving Pratt
Mr. and Mrs. Richardson Pratt, Jr.
William and Maude Pritchard Charitable
Trust
Mr. Edward Pulling
Mr. James T. Pyle
Mrs. Curtis S. Read
Mr. and Mrs. John R. Reese
Dr. Frederic Richards
Mr. J. Wright Rumbough
Mr. and Mrs. Harvey E. Sampson
The Schiff Foundation
Mrs. Franz Schneider
Mr. H. Turner Slocum
Dr. George F. Sprague, Jr.
Seth Sprague Educational and Charitable
Trust
The Stebbins Fund
Mr. and Mrs. David S. Taylor
Mrs. Robert Tilney, Jr.
Mr. and Mrs. Philip R. von Stade
Mr. and Mrs. Colton Wagner
Dr. Jonathan Warner
Weinberg Foundation
Mr. Taggart Whipple
Mrs. Henry A. Wilmerding
Mr. Robert Winthrop
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Restricted Contributions $33,133,674
Endowment $ 5,162,226
Oliver and Lorraine Grace Director's Chair
Doubleday Professorship for Advance Cancer Research
Anonymous Professorship in Molecular Neuroscience
Garfield Undergraduate Internship
Libby Undergraduate Internship
Frederica von Stade Undergraduate Internship
Posy White Fund
Program $ 2,000.000
Howard Hughes Medical Institute
Facilities Development
Cancer Biology
Neuroscience Center
The Ache lis Foundation
Anonymous
George F. Baker Trust
Arnold and Mabel Beckman Foundation
The Bodman Foundation
Booth Ferris Foundation
The Ira W. De Camp Foundation
Dolan Family Foundation
Samuel Freeman Charitable Trust
Mary Livingston Griggs and Mary Griggs Burke Foundation
Howard Hughes Medical Institute
W.M. Keck Foundation
Esther and Joseph A. Klingenstein Fund, Inc.
The Kresge Foundation
Litchfield Charitable Trust
Lucille P. Markey Charitable Trust
James S. McDonnell Foundation
Nichols Foundation
Pew Charitable Trusts
Fannie E. Rippe! Foundation
Individual Contributors
Infrastructure
Boehringer Mannheim
Bristol-Myers Squibb
Burroughs Wellcome
E.I. DuPont
Hoffman-LaRoche
Merck and Company
Pall Corporation
Rorer Group
Schering Plough
SmithKline Beecham
Westvaco Corporation
Structural Biology
Lucille P. Markey Charitable Trust
Oliver and Lorraine Grace
Page Laboratory of Plant Genetics
Anonymous
Charles E. Culpeper Foundation
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$25,971,448
Ira W. De Camp Foundation
Morgan Guaranty Trust Company of New York
National Institutes of Health
National Science Foundation
Pioneer Hi-Bred International
William and Maude Pritchard Charitable Trust
Individual Contributors
Guest Facilities
Cabins
Alumni Cabin Contributors
Dr. Herbert Boyer
The Hyde-Watson Foundation
Dr. Thomas Maniatis
New England Biological Laboratories
Dr. Mark Ptashne
Visiting Scientist Guest House
Russell and Janet Doubleday Fund
DNA Learning Center
Banbury Fund #1
Banbury Fund #2
The Brinkmann Foundation
Mr. & Mrs. Henry U. Harris, Jr.
New York State
Total Second Century Campaign
Contributions $40,393,860
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SECOND CENTURY CAMPAIGN COMMITTEES
David L Luke III, Chairman
Steering Committee
Oliver R. Grace, Co-chairman
George W. Cutting, Jr., Co-chairman
Mrs. Sinclair Hatch, Co-chairman
Townsend J. Knight, Co-chairman
Taggart Whipple, Co-chairman
Leadership Gifts Committee
Oliver R. Grace, Chairman
G. Morgan Browne
Bayard D. Clarkson, M.D.
David L. Luke Ill
James D. Watson, Ph.D.
Taggart Whipple
Major Gifts Committee
Mrs. Sinclair Hatch, Chairman
Amyas Ames
Mrs. Harry A. Brooks
Robert L. Cummings
William Everdell
Mrs. Henry U. Harris, Jr.
Abraham Krasnoff
Laurie Landeau, V.M.D.
Dr. Cynthia MacKay
Mrs. George G. Montgomery, Jr.
H. Turner Slocum
Colton Wagner
Special Gifts Committee
George W. Cutting, Jr., Co-chairman
William H. Miller, Co-chairman
Mrs. Philip R. von Stade, Co-chairman
Mrs. Edward Greenberg, Co-chairman
Edmund Bartlett
David C. Clark
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H. Gray Colgrove
Arthur M. Crocker
Lawrence L. Davis
Mrs. Donald L. Deming
Joseph P. Downer
Charles J. Hubbard
Gordon Lamb
Edward Pulling
John R. Reese
J. Wright Rumbough, Jr.
Mrs. James F. Stebbins
Corporate Committee
David L. Luke Ill, Acting Chairman
G. Morgan Browne
Peter B. Cannell
Robert E. Cawthorn
William R. Miller
David B. Pall, Ph.D.
Douglas E. Rogers
James D. Watson, Ph.D.
Henry Wendt
Sigi Ziering, Ph.D.
Foundation Gifts Committee
Taggart Whipple, Chairman
Mrs. C. Payson Coleman
Robert Ebert, Ph.D.
James W. Fordyce
John Klingenstein
Clarence F. Michalis
William E. Murray
Planned Gifts Committee
Townsend J. Knight, Chairman
Maureen Augusciak
John Cleary
William J. Kramer
William Parsons, Sr.
Colton Wagner
LONG ISLAND
BIOLOGICAL
ASSOCIATION
Officers
George W. Cutting, Jr., Chairman
Mrs. Henry U. Harris, Vice-Chairman
Byam K. Stevens, Treasurer
Mrs. Bradford G. Weekes III, Secretary
G. Morgan Browne, Asst. Secretary/Treasurer
Directors
Mrs. Allen L. Boorstein
Mrs. Harry A. Brooks
John P. Cleary
Lawrence L. Davis
Mrs. Donald L. Deming
Joseph P. Downer
John R. Drexel IV
Lester Dubnick, Ph.D
Mrs. Duncan Elder
Mrs. E. Maxwell Geddes, Jr.
Mrs. Edward Greenberg
Mrs. Sinclair Hatch
Alan M. Kisner, M.D.
Gordon E. Lamb
Edward F. McCann
Mrs. Walter C. Meier
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Arthur C. Merrill
Larry Nathanson, M.D.
Mrs. Vincent Nesi
Douglas E. Rogers
James L. Spingarn
Seth A. Thayer
Mrs. Philip R. von Stade
James D. Watson, Ph.D.
THE LONG ISLAND BIOLOGICAL ASSOCIATION (LIBA)
and Its Relation to the Cold Spring Harbor Laboratory
Biological research at Cold Spring Harbor began in 1890 when the Brooklyn In-
stitute of Arts and Sciences was looking for a place to set up a summer
laboratory as the headquarters of its Department of Zoology. Representatives of
the Institute were invited by Eugene S. Blackford, at that time the Fish Com-
missioner of the State of New York, to inspect a site on Bungtown Road across
Northern Boulevard (25A) from the Fish Hatchery. The site was found to be ideal,
and so the original Laboratory was organized with Mr. Blackford as president of
the Board of Trustees. The land was leased from Mr. John D. Jones, whose family
since 1819 had operated various industries including shipbuilding, coopering,
and textile manufacture (later whaling, also) at the head of Cold Spring Harbor.
Bungtown Road, which runs through the Lab property, got its name from the fac-
tory that specialized in making bungs-or stoppers-for barrels.
In 1892 the Laboratory's land was leased for a dollar a year from the
Wawepex Society, which Mr. Jones had organized as a corporation for holding
real estate and for investing funds for the propagation of fishes and for scientific
research. In 1904 the Wawepex Society leased additional land to the Carnegie
Institution of Washington, which wanted to locate a Department of Experimental
Evolution in the Cold Spring Harbor area. Charies B. Davenport, who had been
directing the Laboratory since 1896, assumed the additional duties of director of
the Carnegie Institution's experimental station. Until 1934, Mr. Davenport lived in
the large Victorian house that still stands at the corner of Bungtown Road and
25A. Built in 1882 by John D. Jones, the house was renovated and repainted in
its original colors in 1979-80, when it was renamed Davenport House. Since 1934
it has served as a dormitory for Laboratory scientists.
The Long Island Biological Association was established in 1924 when the
Brooklyn Institute decided to discontinue its research at Cold Spring Harbor and
offered its laboratory to two universities. Fortunately, a local group of interested
neighbors decided to assume responsibility for the Lab, and thus LIBA came into
being. For 38 years LIBA actually operated the Laboratory in conjunction with the
Carnegie Institute, but in 1962 it seemed advisable for the Laboratory to be
reorganized as an independent unit. Therefore, the property on which it now
stands was conveyed to it by LIBA, which, however, still retains reversionary
rights. Today LIBA is one of eleven institutions participating in the support of the
Laboratory, each institution being represented on the Laboratory's Board of
Trustees.
LIBA has become an expanding group of "Friends of the Laboratory" who
help support it through annual contributions.
A large part of the Laboratory's resources is obtained from governmental,
corporate, and foundation sources as a result of grant applications which are
submitted by the individual scientists. Years ago, 85% of the funding came from
governmental agencies, but presently less than 50% comes from these sources.
Therefore the scientists must rely on an assortment of foundations, corporations,
Membership in LIBA requires a minimum annual contribution (tax deductible) of $25 to the Cold Spring Harbor Laboratory.
Further information can be obtained from the Long Island Biological Association, Box 100, Cold Spring Harbor, N.Y 11724, or
by telephoning the Laboratory at (516) 367-8840.
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and individuals for an increasing share of their support. The researchers com-
pete for grants in their specific areas of study. If an award is made, a portion of
the award is returned to the Laboratory in the form of indirect costs for overhead.
It is important to remember that these grants are highly competitive, and even if a
grant is given an outstanding score by scientific peers, the funding may not be
available.
LIBA sponsors the Laboratory's Annual Giving Program, which is its largest
source of unrestricted annual gifts. These gifts enable the Laboratory to respond
quickly to urgent or unexpected needs. Also, primarily through LIBA Fellowships
and funds to start up new laboratories, LIBA helps ensure that the Cold Spring
Harbor Laboratory continues to attract the best and brightest young scientists.
The affairs of LIBA are handled by a board of 28 directors who are elected to
office by the membership at an annual meeting. LIBA members are invited to
bring their friends to lectures and open houses at the Laboratory.
368
CHAIRMAN'S REPORT
The Long Island Biological Association's sponsorship of Annual Giving for the
Cold Spring Harbor Laboratory has completed its fourth year, and the un-
restricted funds that are provided are more important than ever before. Because
of the federal deficit, funding for biomedical research has become more difficult
to obtain, and even grants previously awarded to scientists have been cut
10-20%. The scientists here rely on LIBA members (contributors of $25 or more),
the Cold Spring Harbor Laboratory Associates (donors of $1000 and more), and
other private sources for a substantial portion of their support. Annual Giving
enables the Laboratory to respond more quickly to meet its challenges and par-
ticularly to fund bright young incoming scientists. As part of the appreciation for
their support, donors are afforded opportunities to meet many of the scientists
they help support and to increase their understanding of today's biology through
special LIBA events.
Events Sponsored by LIBA
Winter '90
Glasnost and dramatic political events during the Fall of 1989 prompted a panel
discussion by four of our visiting Soviet scientists and their wives at the LIBA An-
nual Meeting on January 21. Drs. Konstantin Galactionov, Salius Klimasauskas,
Mart and Ene Ustav, and Grigori and Natasha Yenikolopov discussed scientific
research, science education, and the daily routine in the Soviet Union. Of particu-
lar interest was the effect of all of the recent political changes on the availability
(or shortage) of supplies and laboratory equipment. Also of note, the Soviet
Union appears to have the same difficulty as the United States in attracting
young people into science. In both countries, a truck driver can earn more than a
scientist with a PhD. Underlying the discussions was a feeling that the objectives
of the republics were not necessarily acceptable to the central government, a
situation that became more and more apparent in the ensuing months.
"Getting Involved: An Artist's Reaction to Environmental Issues" was the title
of a centennial lecture by renowned photographer Robert G. Ketchum. Mr.
Ketchum is the curator of photography for the National Parks Foundation and the
author of several books, including The Tongass: Alaska's Vanishing Rain Forest.
The North Country, South Side, and Three Harbors Garden Clubs sponsored the
event on February 25 that inspired some of us to take a more active role in en-
vironmental concerns.
On March 4, LIBA members and friends were entertained by the New York
Virtuosi String Quartet featuring bassoonist Daniel Smith and harpsichordist
Elaine Comparone in a program entitled Music from Bach to Joplin. We are grate-
ful for the generous support of our patrons: Dr. and Mrs. Neil Battinelli, Drs. John
and Elaine Broome, Mrs. Joan E. Flint, Drs. Peter and Bernardita Luke, Dr. and
Mrs. Walter Meier, Mrs. Henry M. Minton, Mr. and Mrs. James J. Pirtle, Jr., Mr.
and Mrs. James E. Swiggett, and Mrs. George G. Walker.
Spring '90
In March and May, the Associates Program sponsored two DNA workshops at
the DNA Learning Center in Cold Spring Harbor on a new technique called
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John LeGuyader,
education manager
at the DNA Learning Center,
instructs LIBA members
during a hands-on workshop
with DNA experiments
polymerase chain reaction (PCR). This procedure enables scientists to amplify a
small sample of DNA one million times in less than two hours. PCR is becoming
widely used in DNA fingerprinting, mapping the human genome, genetics re-
search and diagnostics, and forensics.
Drug legalization was the subject of an Associates lecture given by United
States District Court Judge Robert W. Sweet on April 20 in Bush Lecture Hall. His
lecture entitled "Legalization of Certain Controlled Substances" stirred much
debate and these discussions continued during cocktails and supper in Black-
ford Hall immediately afterward.
55th Symposium
"The Brain" was the topic of Cold Spring Harbor Laboratory's 55th Symposium on
Quantitative Biology at the end of May. As in the past, the Dorcas Cummings
Memorial Lecture was held at the midpoint of the week-long meeting on Sunday,
June 3. LIBA members witnessed a reunion of the codiscoverers of the double-
helical structure of DNA when Dr. Watson introduced Dr. Francis N.C. Crick; Drs.
Watson and Crick shared the Nobel prize in 1962 for their discovery. Dr. Crick's
Francis Crick greets LIBA members after speaking at the Dorcas Cummings Memorial
Lecture
lecture entitled "How Do We See Things?" was delivered before a capacity crowd
in Grace Auditorium and was carried via closed-circuit TV to another "full house"
in Bush Lecture Hall across the street. Dr. Crick fascinated those present as he
related the latest efforts of scientists to understand how the brain recognizes and
interprets vision. Afterward, nearly 140 Symposium speakers and senior
scientists from the laboratory were entertained at 21 dinner parties held through-
out the community at the homes of LIBA members. This delightful tradition has
been carried on continuously for the past 36 years, and we owe its success dur-
ing the past few years to the tireless efforts of Joan Pesek and Edward Pulling.
We are grateful to this year's hosts:
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Auditorium to gather Symposium speakers
into dinner party groups
Mr. and Mrs. Loren Berry
Mr. and Mrs. John P. Cleary
Summer '90: Centennial Celebrations
Mr. and Mrs. Norris Darrell, Jr.
Mr. and Mrs. E. Maxwell Geddes, Jr.
Mr. and Mrs. Edward Greenberg
Mr. and Mrs. Henry U. Harris, Jr.
Mrs. Sinclair Hatch
Mr. and Mrs. Gordon E. Lamb
Mr. and Mrs. David L. Luke III
Dr. and Mrs. Walter C. Meier
Dr. and Mrs. Larry Nathanson
Mr. and Mrs. James J. Pirtle
Mrs. Francis T.P. Plimpton
Mr. and Mrs. Edward E. Post
Mr. and Mrs. James F. Stebbins
Mr. and Mrs. Byam K. Stevens, Jr.
Mr. and Mrs. John C. Stevenson
Mr. and Mrs. Seth A. Thayer
Mr. and Mrs. Martin Travis, Jr.
Mr. and Mrs. Robert P. Walton
Mr. and Mrs. Bradford Weekes III
Mr. and Mrs. Taggart Whipple
Tall ships, sea chantey singers, Grucci fireworks, brass bands, bagpipers, a re-
enactment of the first biology class on July 6, 1890, and an enormous barbecue
and birthday cake were some of the highlights of the birthday bash the
Laboratory held on July 14 to celebrate its Centennial. Over 1500 friends and
staff were present to celebrate 100 years of outstanding scientific achievements
and to usher in the Laboratory's second century of excellence.
In September, eminent evolutionist Dr. Richard Dawkins from the University of
Oxford spoke to LIBA members and community residents on Darwinizing with a
Vengeance. Dr. Dawkins has won numerous awards and honors for his books
The Blind Watchmaker and The Selfish Gene, which have been published in
numerous foreign translations, and for his work in evolutionary biology and animal
behavior. He stirred much debate in his stimulating and sometimes controversial
lecture.
Fall '90
On October 7, a reception was held for Associates on the terrace beside Bush
Lecture Hall. Attendees were able to meet many of the LIBA Fellows and to view
the plans for the renovation of Blackford Hall. Built in 1907 to house the kitchen
and dining facilities, it is one of the earliest examples of reinforced concrete con-
struction. With a capacity of 150, Blackford has been unable to meet the dining
needs of the Laboratory for many years. Only with the annual addition of tents on
the lawn, staggered dining shifts, and truly inventive food preparation by Jim
Hope and his staff has the Laboratory been able to feed its visiting scientists and
staff during the meetings season. The expansion and renovation planned over
the next three years will almost triple Blackford's capacity.
The final event of the Fall was a panel discussion on the Life Science Indus-
try. The panelists were Douglas E. Rogers of Baring Brothers, David Bonagura of
Ernst and Young, and John R. Drexel IV of Concord Capital Management; John
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Reese moderated. Topics covered included some of the problems facing small
biotech companies and the effect that the log jam" in the patent office was hav-
ing on United States competition with other countries.
LIBA Directors
At the Annual Meeting in January 1990, Jim Eisenman retired as Treasurer of
LIBA after 27 years of loyal and most effective service. Also retiring as Directors
were Arthur Crocker, Penny Chenery, and Lon Chaiken.
The Nominating Committee, comprised of Larry Davis, Chairman, and Direc-
tors Phyllis Weekes and John Cleary, nominated Jack Evans, Missy Geddes,
Alan Kisner, and Alec Thayer to succeed the outgoing Directors.
LIBA's Support
During the LIBA fiscal year ending September 30, 1990, Annual Giving contribu-
tions were received from 671 contributors totaling $284,214. Included in this total
were 139 Cold Spring Harbor Associates (contributors of $1000 or more).
This year's report reflects a far reaching and many faceted development ef-
fort, which would not have been possible without our small but most effective
staff of Konrad Matthaei, Joan Pesek, Claire Fairman, and Debra Mullen. The staff
relies on volunteer committees to expand the public's support and awareness of
the Laboratory.
For the past four years, LIBA has provided funds for postdoctoral fellows who
work under the guidance of senior laboratory scientists. This year, six awards
were made. The 1990 fellowship recipients are Young-Seuk Bae, Steven Bell,
Saulius Klimasauskas, Jacqueline Lees, Akila Mayeda, and Toshifumi Tsukahara.
In addition to the fellowship program, LIBA provides a New Investigator Start-up
Fund to a new staff member to purchase equipment or supplies or for salary sup-
port for an assistant. This year's recipient is Nicholas Tonks, who comes to us
from the Department of Biochemistry of the University of Washington. Dr. Tonks
received his PhD from the University of Dundee in 1984.
The Future
On July 14, 1990, Cold Spring Harbor Laboratory celebrated its Centennial and
ushered in its second century. We can look back on its many accomplishments
with pride. The Laboratory is now in an important transition stage. Gone is the
summer laboratory on the shore of Cold Spring Harbor and coming is a year-
round teaching institute. The first steps have been taken. The Arnold and Mabel
Beckman Neuroscience Center is nearing completion. The first scientists will
move into the building in March, and the dedication will take place in May. The
facility will include two teaching laboratories and six neuroscience laboratories to
enable year-round research and teaching.
What the future will hold will depend on many factors. However, as the
Laboratory enters its second century, there are many common links with its past.
Excellence in Leadership . .. from Charles B. Davenport to James D. Watson,
Cold Spring Harbor is simply unmatched.
Education . . the mission to stimulate scientific inquiry among students of all
ages.
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Basic Research ... the highest caliber of thinkers assembled in an environ-
ment that fosters the exchange of ideas.
Community Support ... awareness of the importance of the Laboratory to us
all, and a willingness to step forward to answer its call.
It is this community support that has led to the impending success of the Sec-
ond Century Campaign that has given the Laboratory the resources to enter its
next 100 years. It is also the continuance of this support through LIBA's sponsor-
ship of Annual Giving that will play an increasingly important role in the suc-
cesses of the future. Therefore, let us not rest too long to reflect on past success,
but broaden our support to ensure continued excellence.
George W. Cutting, Jr.. Chairman
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